FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Dominitz, JA Spiegel, B AF Dominitz, Jason A. Spiegel, Brennan TI On the Quality of Quality Metrics: Rethinking What Defines a Good Colonoscopy SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Editorial Material ID ADENOMA DETECTION RATE; SCREENING COLONOSCOPY; COLORECTAL-CANCER; WITHDRAWAL TIME; INTERVAL CANCER; DETECTION RATES; RISK; INDICATORS; POLYP AB The colonoscopy quality assurance movement has focused on a variety of process metrics, including the adenoma detection rate (ADR). However, the ADR only ascertains whether or not at least one adenoma is identified. Supplemental measures that quantify all neoplasia have been proposed. In this issue of the American Journal of Gastroenterology, Aniwan and colleagues performed tandem screening colonoscopies to determine the adenoma miss rate among high-ADR endoscopists. This permitted validation of supplemental colonoscopy quality metrics. This study highlights potential limitations of ADR and the need for further refinement of colonoscopy quality metrics, although logistic challenges abound. C1 [Dominitz, Jason A.] Univ Washington, VA Puget Sound Hlth Care Syst, Sch Med, Seattle, WA 98195 USA. [Spiegel, Brennan] Cedars Sinai Hlth Syst, CS CORE, Dept Hlth Serv Res, Los Angeles, CA USA. RP Dominitz, JA (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way 111 Gastro, Seattle, WA 98108 USA. EM jason.dominitz@va.gov NR 18 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD MAY PY 2016 VL 111 IS 5 BP 730 EP 732 DI 10.1038/ajg.2016.103 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DO2BH UT WOS:000377584000027 PM 27151122 ER PT J AU Shields, RK Clancy, CJ Press, EG Nguyen, MH AF Shields, Ryan K. Clancy, Cornelius J. Press, Ellen G. Nguyen, M. Hong TI Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID SEQUENCE TYPE 258; COMBINATION THERAPY; GENTAMICIN THERAPY; PEAK CONCENTRATION; INFECTIONS; COLISTIN; MORTALITY; DORIPENEM; STRAINS; TRACT AB Aminoglycoside treatment of carbapenem-resistant (CR) Klebsiella pneumoniae bacteremia was associated with a 70% rate (23/33) of 30-day survival. Successful treatment was associated with sources of bacteremia amenable to reliable aminoglycoside pharmacokinetics (P = 0.037), acute physiology and chronic health evaluation II (APACHE II) scores of <20 (P = 0.16), and nonfatal underlying diseases (P = 0.015). Success rates were 78% and 100% if >= 2 and all 3 factors were present, respectively. Clinicians may consider the use of aminoglycosides against CR K. pneumoniae bacteremia if strains are susceptible and the sources of infection are amenable to reliable pharmacokinetics. C1 [Shields, Ryan K.; Clancy, Cornelius J.; Press, Ellen G.; Nguyen, M. Hong] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Shields, Ryan K.; Clancy, Cornelius J.; Nguyen, M. Hong] Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Clancy, CJ (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.; Clancy, CJ (reprint author), Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA USA.; Clancy, CJ (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. EM cjc76@pitt.edu FU HHS \ NIH \ National Institute of Allergy and Infectious Diseases (NIAID) [K08AI114883, R21AI111037] FX This work, including the efforts of Ryan K. Shields, was funded by HHS vertical bar NIH vertical bar National Institute of Allergy and Infectious Diseases (NIAID) (K08AI114883). This work, including the efforts of Cornelius J. Clancy, was funded by HHS vertical bar NIH vertical bar National Institute of Allergy and Infectious Diseases (NIAID) (R21AI111037). NR 34 TC 2 Z9 2 U1 2 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD MAY PY 2016 VL 60 IS 5 BP 3187 EP 3192 DI 10.1128/AAC.02638-15 PG 6 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA DN4NX UT WOS:000377045600078 PM 26926642 ER PT J AU Buehrle, DJ Shields, RK Chen, L Hao, B Press, EG Alkrouk, A Potoski, BA Kreiswirth, BN Clancy, CJ Nguyen, MH AF Buehrle, Deanna J. Shields, Ryan K. Chen, Liang Hao, Binghua Press, Ellen G. Alkrouk, Ammar Potoski, Brian A. Kreiswirth, Barry N. Clancy, Cornelius J. Nguyen, M. Hong TI Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID BETA-LACTAM RESISTANCE; BLOOD-STREAM INFECTIONS; GRAM-NEGATIVE ORGANISMS; US MEDICAL-CENTERS; CARBAPENEM RESISTANCE; KLEBSIELLA-PNEUMONIAE; MEDITERRANEAN COUNTRIES; CXA-101 FR264205; MECHANISMS; ENTEROBACTERIACEAE AB We compared ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime, cefepime, and piperacillin-tazobactam MICs for 38 meropenem-resistant Pseudomonas aeruginosa isolates. No isolates harbored carbapenemases; 74% were oprD mutants. Ceftazidime-avibactam and ceftolozane-tazobactam were active against 92% of the isolates, including 80% that were resistant to all three beta-lactams. Forty-three percent of ceftazidime-avibactam-susceptible isolates and 6% of ceftolozane-tazobactam-susceptible isolates exhibited MICs at the respective breakpoints. Ceftolozane-tazobactam and ceftazidime-avibactam are therapeutic options for meropenem-resistant P. aeruginosa infections that should be used judiciously to preserve activity. C1 [Buehrle, Deanna J.; Potoski, Brian A.] Univ Pittsburgh, Dept Pharm & Therapeut, Pittsburgh, PA USA. [Shields, Ryan K.; Press, Ellen G.; Alkrouk, Ammar; Clancy, Cornelius J.; Nguyen, M. Hong] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Shields, Ryan K.; Hao, Binghua; Clancy, Cornelius J.; Nguyen, M. Hong] Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA USA. [Chen, Liang] Rutgers State Univ, Sch Med, Newark, NJ 07102 USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Clancy, CJ (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.; Clancy, CJ (reprint author), Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA USA.; Clancy, CJ (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. EM cjc76@pitt.edu FU HHS \ National Institutes of Health (NIH) [K08AI114883]; NIH [R21AI222037] FX This work, including the efforts of Ryan K Shields, was funded by HHS vertical bar National Institutes of Health (NIH) (K08AI114883). This work, including the efforts of Cornelius J. Clancy, was funded by NIH (R21AI222037). NR 25 TC 6 Z9 6 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD MAY PY 2016 VL 60 IS 5 BP 3227 EP 3231 DI 10.1128/AAC.02969-15 PG 5 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA DN4NX UT WOS:000377045600088 PM 26976862 ER PT J AU Moyer, CE Erickson, SL Fish, KN Thiels, E Penzes, P Sweet, RA AF Moyer, Caitlin E. Erickson, Susan L. Fish, Kenneth N. Thiels, Edda Penzes, Peter Sweet, Robert A. TI Developmental Trajectories of Auditory Cortex Synaptic Structures and Gap-Prepulse Inhibition of Acoustic Startle Between Early Adolescence and Young Adulthood in Mice SO CEREBRAL CORTEX LA English DT Article DE dendritic spines; GAD65; kalirin; spinophilin; VGluT1 ID DENDRITIC SPINE DENSITY; GLUTAMIC-ACID DECARBOXYLASE; MONKEY PREFRONTAL CORTEX; VISUAL-CORTEX; CEREBRAL-CORTEX; POSTNATAL-DEVELOPMENT; SOMATOSENSORY CORTEX; HEARING-LOSS; HOMEOSTATIC PLASTICITY; EXCITATORY SYNAPSES AB Cortical excitatory and inhibitory synapses are disrupted in schizophrenia, the symptoms of which often emerge during adolescence, when cortical excitatory synapses undergo pruning. In auditory cortex, a brain region implicated in schizophrenia, little is known about the development of excitatory and inhibitory synapses between early adolescence and young adulthood, and how these changes impact auditory cortex function. We used immunohistochemistry and quantitative fluorescence microscopy to quantify dendritic spines and GAD65-expressing inhibitory boutons in auditory cortex of early adolescent, late adolescent, and young adult mice. Numbers of spines decreased between early adolescence and young adulthood, during which time responses increased in an auditory cortex-dependent sensory task, silent gap-prepulse inhibition of the acoustic startle reflex (gap-PPI). Within-bouton GAD65 protein and GAD65-expressing bouton numbers decreased between late adolescence and young adulthood, a delay in onset relative to spine and gap-PPI changes. In mice lacking the spine protein kalirin, there were no significant changes in spine number, within-bouton GAD65 protein, or gap-PPI between adolescence and young adulthood. These results illustrate developmental changes in auditory cortex spines, inhibitory boutons, and auditory cortex function between adolescence and young adulthood, and provide insights into how disrupted adolescent neurodevelopment could contribute to auditory cortex synapse pathology and auditory impairments. C1 [Moyer, Caitlin E.; Fish, Kenneth N.; Thiels, Edda; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Ctr Neurosci, Pittsburgh, PA USA. [Moyer, Caitlin E.; Erickson, Susan L.; Fish, Kenneth N.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Translat Neurosci Program, Pittsburgh, PA USA. [Thiels, Edda] Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA USA. [Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA. [Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Sweet, RA (reprint author), Biomed Sci Tower,Rm W-1645,3811 OHara St, Pittsburgh, PA 15213 USA.; Sweet, RA (reprint author), Biomed Sci Tower,Rm W-1645,Lothrop & Terrace St, Pittsburgh, PA 15213 USA. EM sweetra@upmc.edu RI Penzes, Peter/L-3987-2016 OI Penzes, Peter/0000-0001-5449-1640 FU National Institute of Health [MH 096985, DA 027679, MH 071316, MH 097216, MH 071533] FX This work was supported by the National Institute of Health (MH 096985 to K.N.F., DA 027679 to E.T., MH 071316 and MH 097216 to P.P., and MH 071533 to R.A.S.). NR 81 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1047-3211 EI 1460-2199 J9 CEREB CORTEX JI Cereb. Cortex PD MAY PY 2016 VL 26 IS 5 BP 2115 EP 2126 DI 10.1093/cercor/bhv040 PG 12 WC Neurosciences SC Neurosciences & Neurology GA DO0LD UT WOS:000377469500023 PM 25759333 ER PT J AU Rocco, BR Sweet, RA Lewis, DA Fish, KN AF Rocco, Brad R. Sweet, Robert A. Lewis, David A. Fish, Kenneth N. TI GABA-Synthesizing Enzymes in Calbindin and Calretinin Neurons in Monkey Prefrontal Cortex SO CEREBRAL CORTEX LA English DT Article DE GAD65; GAD67; glutamic acid decarboxylase; somatostatin; vasoactive intestinal peptide ID GLUTAMIC-ACID DECARBOXYLASE; IMMUNOREACTIVE AXON TERMINALS; LOCAL CIRCUIT NEURONS; GENE-EXPRESSION; CEREBRAL-CORTEX; GABAERGIC NEURONS; MONOCLONAL-ANTIBODIES; CORTICAL INTERNEURONS; DENDRITIC INHIBITION; MICROARRAY ANALYSIS AB Non-overlapping groups of cortical gamma-aminobutyric acid-releasing (GABAergic) neurons are identifiable by the presence of calbindin (CB), calretinin (CR), or parvalbumin (PV). Boutons from PV neuron subtypes are also distinguishable by differences in protein levels of the GABA-synthesizing enzymes GAD65 and GAD67. Multilabel fluorescence microscopy was used to determine if this diversity extends to boutons of CB and CR neurons in monkey prefrontal cortex. CB and CR neurons gave rise to 3 subpopulations of GAD-containing boutons: GAD65+, GAD67+, and GAD65/GAD67+. Somatostatin and vasoactive intestinal peptide-expressing neurons, subtypes of CB and CR neurons, respectively, also gave rise to these distinct bouton subpopulations. At the transcript level, CB and CR neurons contained mRNA encoding GAD67-only or both GADS. Thus, the distinct subpopulations of CB/GAD+ and CR/GAD+ boutons arise from 2 unique subtypes of CB and CR neurons. The different CB and CR GAD-expressing neurons targeted the same projection neurons and neuronal structures immunoreactive for PV, CR, or CB. These findings suggest that GABA synthesis from CB/GAD67+ and CR/GAD67+ neurons would presumably be more vulnerable to disease-associated deficits in GAD67 expression, such as in schizophrenia, than neurons that also contain GAD65. C1 [Rocco, Brad R.; Sweet, Robert A.; Lewis, David A.; Fish, Kenneth N.] Univ Pittsburgh, Sch Med, Dept Psychiat, Biomed Sci Tower,Room W1651, Pittsburgh, PA 15213 USA. [Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Biomed Sci Tower,Room W1651, Pittsburgh, PA 15213 USA. [Lewis, David A.] Univ Pittsburgh, Sch Med, Dept Neurosci, Biomed Sci Tower,Room W1651, Pittsburgh, PA 15213 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, Educ & Clin Ctr MIRECC, VISN Mental Illness Res 4, Pittsburgh, PA 15213 USA. RP Fish, KN (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, Biomed Sci Tower,Room W1651, Pittsburgh, PA 15213 USA.; Fish, KN (reprint author), Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Biomed Sci Tower,Room W1651, Pittsburgh, PA USA. EM fishkn@upmc.edu OI Lewis, David/0000-0002-3225-6778 FU NSF [DGE-0549352]; NIMH [MH071533, MH051234, MH096985] FX This work was supported by the NSF (DGE-0549352 to B.R.R.) and NIMH (MH071533 to R.A.S.; MH051234 to D.A.L.; MH096985 to K.N.F.). NR 67 TC 2 Z9 2 U1 1 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1047-3211 EI 1460-2199 J9 CEREB CORTEX JI Cereb. Cortex PD MAY PY 2016 VL 26 IS 5 BP 2191 EP 2204 DI 10.1093/cercor/bhv051 PG 14 WC Neurosciences SC Neurosciences & Neurology GA DO0LD UT WOS:000377469500029 PM 25824535 ER PT J AU Gilley, RP Gonzalez-Juarbe, N Shenoy, AT Reyes, LF Dube, PH Restrepo, MI Orihuela, CJ AF Gilley, Ryan P. Gonzalez-Juarbe, Norberto Shenoy, Anukul T. Reyes, Luis F. Dube, Peter H. Restrepo, Marcos I. Orihuela, Carlos J. TI Infiltrated Macrophages Die of Pneumolysin-Mediated Necroptosis following Pneumococcal Myocardial Invasion SO INFECTION AND IMMUNITY LA English DT Article ID MIXED LINEAGE KINASE; STREPTOCOCCUS-PNEUMONIAE; INFLAMMATORY RESPONSE; CARDIOVASCULAR EVENTS; GENOME SEQUENCE; DOMAIN-LIKE; MORTALITY; NECROSIS; ASSOCIATION; RECEPTOR AB Streptococcus pneumoniae (the pneumococcus) is capable of invading the heart. Herein we observed that pneumococcal invasion of the myocardium occurred soon after development of bacteremia and was continuous thereafter. Using immunofluorescence microscopy (IFM), we observed that S. pneumoniae replication within the heart preceded visual signs of tissue damage in cardiac tissue sections stained with hematoxylin and eosin. Different S. pneumoniae strains caused distinct cardiac pathologies: strain TIGR4, a serotype 4 isolate, caused discrete pneumococcus-filled microscopic lesions (microlesions), whereas strain D39, a serotype 2 isolate, was, in most instances, detectable only using IFM and was associated with foci of cardiomyocyte hydropic degeneration and immune cell infiltration. Both strains efficiently invaded the myocardium, but cardiac damage was entirely dependent on the pore-forming toxin pneumolysin only for D39. Early microlesions caused by TIGR4 and microlesions formed by a TIGR4 pneumolysin-deficient mutant were infiltrated with CD11b(+) and Ly6G-positive neutrophils and CD11b(+) and F4/80positive (F4/80(+)) macrophages. We subsequently demonstrated that macrophages in TIGR4-infected hearts died as a result of pneumolysin-induced necroptosis. The effector of necroptosis, phosphorylated mixed-lineage kinase domain-like protein (MLKL), was detected in CD11b(+) and F4/80(+) cells associated with microlesions. Likewise, treatment of infected mice and THP-1 macrophages in vitro with the receptor-interacting protein 1 kinase (RIP1) inhibitor necrostatin-5 promoted the formation of purulent microlesions and blocked cell death, respectively. We conclude that pneumococci that have invaded the myocardium are an important cause of cardiac damage, pneumolysin contributes to cardiac damage in a bacterial strain-specific manner, and pneumolysin kills infiltrated macrophages via necroptosis, which alters the immune response. C1 [Gilley, Ryan P.; Gonzalez-Juarbe, Norberto; Shenoy, Anukul T.; Reyes, Luis F.; Dube, Peter H.; Orihuela, Carlos J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. [Gonzalez-Juarbe, Norberto; Shenoy, Anukul T.; Orihuela, Carlos J.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. [Reyes, Luis F.; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Dis & Crit Care Med, San Antonio, TX 78229 USA. [Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Div Pulm Dis & Crit Care Med, San Antonio, TX USA. RP Orihuela, CJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA.; Orihuela, CJ (reprint author), Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. EM corihuel@uab.edu FU HHS \ National Institutes of Health (NIH) [R01AI114800]; American Heart Association (AHA) [13IRG14560023] FX This work, including the efforts of Carlos J Orihuela, was funded by HHS vertical bar National Institutes of Health (NIH) (R01AI114800). This work, including the efforts of Carlos J Orihuela, was funded by American Heart Association (AHA) (13IRG14560023). NR 45 TC 2 Z9 3 U1 3 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 EI 1098-5522 J9 INFECT IMMUN JI Infect. Immun. PD MAY PY 2016 VL 84 IS 5 BP 1457 EP 1469 DI 10.1128/IAI.00007-16 PG 13 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DN5KT UT WOS:000377106600020 PM 26930705 ER PT J AU Fouad, NA Ghosh, A Chang, WH Figueiredo, C Bachhuber, T AF Fouad, Nadya A. Ghosh, Arpita Chang, Wen-hsin Figueiredo, Catia Bachhuber, Thomas TI Career Exploration Among College Students SO JOURNAL OF COLLEGE STUDENT DEVELOPMENT LA English DT Article ID PSYCHOMETRIC PROPERTIES; CONSTRUCTION C1 [Fouad, Nadya A.] Univ Wisconsin, Educ Psychol, Milwaukee, WI 53201 USA. [Ghosh, Arpita] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Womens Hlth, Madison, WI USA. [Ghosh, Arpita] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI USA. [Chang, Wen-hsin; Figueiredo, Catia] Univ Wisconsin, Counseling Psychol, Milwaukee, WI 53201 USA. [Bachhuber, Thomas] Univ Wisconsin, Career Dev Ctr, Milwaukee, WI 53201 USA. RP Fouad, NA (reprint author), Univ Wisconsin, Educ Psychol, Milwaukee, WI 53201 USA. FU Advanced Fellowship in Women's Health at the William S. Middleton Memorial Veterans Hospital, Madison, WI FX Research supported by the Advanced Fellowship in Women's Health at the William S. Middleton Memorial Veterans Hospital, Madison, WI. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. NR 18 TC 0 Z9 0 U1 3 U2 10 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 0897-5264 EI 1543-3382 J9 J COLL STUDENT DEV JI J. Coll. Stud. Dev. PD MAY PY 2016 VL 57 IS 4 BP 460 EP 464 PG 5 WC Education & Educational Research; Psychology, Applied SC Education & Educational Research; Psychology GA DN9TB UT WOS:000377422500008 ER PT J AU Matlock, DD Yamashita, TE Min, SJ Smith, AK Kelley, AS Fischer, SM AF Matlock, Daniel D. Yamashita, Traci E. Min, Sung-Joon Smith, Alexander K. Kelley, Amy S. Fischer, Stacy M. TI How US Doctors Die: A Cohort Study of Healthcare Use at the End of Life SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE end of life; hospice; physicians; Medicare ID TREATMENT INTENSITY; CANCER CARE; PHYSICIANS; PREFERENCES; GROWTH; TRENDS; COSTS AB ObjectivesTo compare healthcare use in the last months of life between physicians and nonphysicians in the United States. DesignA retrospective observational cohort study. SettingUnited States. ParticipantsFee-for-service Medicare beneficiaries: decedent physicians (n = 9,947) and a random sample of Medicare decedents (n = 192,006). MeasurementsMedicare Part A claims data from 2008 to 2010 were used to measure days in the hospital and proportion using hospice in the last 6 months of life as primary outcome measures adjusted for sociodemographic characteristics and regional variations in health care. ResultsInpatient hospital use in the last 6 months of life was no different between physicians and nonphysicians, although more physicians used hospice and for longer (using the hospital: odds ratio (OR) = 0.98, 95% confidence interval (CI) = 0.93-1.04; hospital days: mean difference 0.26, P = .14); dying in the hospital: OR = 0.99, 95% CI = 0.95-1.04; intensive care unit (ICU) or critical care unit (CCU) days: mean difference 0.35 more days for physicians, P < .001); using hospice: OR = 1.23, 95% CI = 1.18-1.29; number of days in hospice: mean difference 2.06, P < .001). ConclusionThis retrospective, observational study is subject to unmeasured confounders and variation in coding practices, but it provides preliminary evidence of actual use. U.S. physicians were more likely to use hospice and ICU- or CCU-level care. Hospitalization rates were similar. C1 [Matlock, Daniel D.] Univ Colorado, Div Geriatr, Sch Med, Acad Off 1,12631 E 17th Ave Campus Box B-179, Aurora, CO 80045 USA. [Yamashita, Traci E.] Univ Colorado, Undergrad Med Educ, Sch Med, Aurora, CO 80045 USA. [Min, Sung-Joon] Univ Colorado, Div Hlth Care Policy & Res, Sch Med, Aurora, CO 80045 USA. [Smith, Alexander K.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94143 USA. [Kelley, Amy S.] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Kelley, Amy S.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Fischer, Stacy M.] Univ Colorado, Div Gen Internal Med, Sch Med, Aurora, CO 80045 USA. RP Matlock, DD (reprint author), Univ Colorado, Div Geriatr, Sch Med, Acad Off 1,12631 E 17th Ave Campus Box B-179, Aurora, CO 80045 USA. EM daniel.matlock@ucdenver.edu FU Department of Medicine at the University of Colorado; National Institute on Aging [K23AG040696, K23AG028957, K23AG040772, K23AG040774]; American Federation for Aging Research FX This project was supported by the Department of Medicine at the University of Colorado. Drs. Matlock (K23AG040696), Fischer (K23AG028957), Smith (K23AG040772), and Kelley (K23AG040774) were all supported by the National Institute on Aging and the American Federation for Aging Research. NR 28 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 IS 5 BP 1061 EP 1067 DI 10.1111/jgs.14112 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DO1FD UT WOS:000377523000016 PM 27195936 ER PT J AU Rajagopalan, S Yoshikawa, TT AF Rajagopalan, Shobita Yoshikawa, Thomas T. TI Norovirus Infections in Long-Term Care Facilities SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE norovirus; aging; long-term care ID UNITED-STATES; ACUTE GASTROENTERITIS; HEALTH-CARE; EXCESS MORTALITY; RT-PCR; OUTBREAKS; CONTAMINATION; PREVENTION; GUIDELINE; DIAGNOSIS AB Noroviruses have emerged as one of the leading causes of viral gastroenteritis worldwide, affecting community-dwelling and institutionalized older adults. Recent global epidemics present a growing challenge to the healthcare system and to long-term care facilities. Noroviruses spread readily and rapidly through multiple routes (e.g., person-to-person contact, contact with contaminated surfaces, airborne dissemination of vomitus) and thus are able to sustain an epidemic efficiently and successfully. Although norovirus gastroenteritis is a short self-limited illness in healthy immunocompetent individuals, it can result in significant morbidity and mortality in vulnerable compromised persons such as frail elderly persons and older residents of nursing homes. Diagnosis is made by clinical assessment and confirmed primarily by stool evaluation using polymerase chain reaction. Treatment is confined to supportive measures. Public health prevention and control strategies provide guidance regarding surveillance and the necessary steps to curb the clinical effect and spread of norovirus infections in various settings, including long-term care. C1 [Rajagopalan, Shobita] Dept Publ Hlth, Los Angeles, CA USA. [Rajagopalan, Shobita] Charles R Drew Univ Med & Sci, 1621 E 120th St, Los Angeles, CA 90059 USA. [Yoshikawa, Thomas T.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Vet Affairs, Los Angeles, CA USA. [Yoshikawa, Thomas T.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Rajagopalan, S (reprint author), 123 W Manchester Blvd,Suite 220C, Inglewood, CA 90301 USA. EM srajagopalan@ph.lacounty.gov NR 43 TC 1 Z9 1 U1 5 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 IS 5 BP 1097 EP 1103 DI 10.1111/jgs.14085 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DO1FD UT WOS:000377523000022 PM 27225361 ER PT J AU Boockvar, KS Teresi, JA Inouye, SK AF Boockvar, Kenneth S. Teresi, Jeanne A. Inouye, Sharon K. TI Preliminary Data: An Adapted Hospital Elder Life Program to Prevent Delirium and Reduce Complications of Acute Illness in Long-Term Care Delivered by Certified Nursing Assistants SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE nursing homes; delirium; nosocomial infection; intervention ID MULTICOMPONENT INTERVENTION; HOME RESIDENTS; INDIVIDUALS; CONFUSION; SEVERITY; SYMPTOMS AB Nursing home (NH) residents have a high prevalence of delirium risk factors, experience two to four acute medical conditions (e.g., infections) each year, and have an incidence of delirium during these conditions similar to that of hospitalized older adults. Many NH residents with delirium do not return to their prior level of cognitive function. They are more likely to die, be hospitalized, and less likely to be discharged home than those without delirium. Research on the prevention or treatment of delirium in NHs is limited. This article describes the development and pilot testing of a multicomponent delirium prevention intervention in the NH setting adapted from the Hospital Elder Life Program (HELP-LTC). Activities to reduce the risk of delirium that were appropriate for functionally impaired NH residents were developed and delivered during treatment for and recovery from acute illness, a novel resident-targeting approach. Expertly trained certified nursing assistants (CNAs a total of 1.4 full-time equivalent (FTE) positions) visited residents throughout the facility and delivered the activities. The current study reports on incident delirium, delirium remission, cognitive and physical function change, hospitalization, and death associated with acute medical conditions as ascertained by a program coordinator. The integration and acceptance of the CNAs' activities by residents and staff are also reported on. Hospitalization and death were ascertained in a nonintervention comparison group. Findings support a test of the intervention in a controlled trial. The potential effect is great; there are approximately 1.4 million NH residents in the United States and an estimated 1 million with dementia or cognitive impairment, an important delirium risk factor. An intervention would be broadly adoptable if a reduction in healthcare costs through prevention of hospitalization offset the cost of the program's CNAs. C1 [Boockvar, Kenneth S.] New Jewish Home, New York, NY USA. [Boockvar, Kenneth S.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Boockvar, Kenneth S.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Teresi, Jeanne A.] Hebrew Home Riverdale, Div Res, Bronx, NY USA. [Teresi, Jeanne A.] Columbia Univ, New York State Psychiat Inst, Stroud Ctr, New York, NY USA. [Teresi, Jeanne A.] Weill Cornell Div Geriatr & Palliat Care, New York, NY USA. [Inouye, Sharon K.] Hebrew SeniorLife, Aging Brain Ctr, Boston, MA USA. [Inouye, Sharon K.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA. RP Boockvar, KS (reprint author), Jewish Home Lifecare, 120 West 106th St, New York, NY 10025 USA. EM kenneth.boockvar@mssm.edu OI Boockvar, Kenneth/0000-0003-1165-5558 FU Fan Fox and Leslie R. Samuels Foundation; National Institute on Aging [P30 AG028741, K07AG041835]; Jewish Home Lifecare Parkinson's Research Fund; HELP; Greenwall Foundation FX Financial support for the study was provided by the Fan Fox and Leslie R. Samuels Foundation, the National Institute on Aging (P30 AG028741; K07AG041835), the Jewish Home Lifecare Parkinson's Research Fund, and HELP. Dr. Boockvar is supported by the Greenwall Foundation. Dr. Inouye holds the Milton and Shirley F. Levy Family Chair. This work was supported with resources and the use of facilities at the James J. Peters Veterans Affairs Medical Center, Bronx, New York. The contents do not represent the views of the U.S. Department of Veterans Affairs or the U.S. government. NR 20 TC 0 Z9 0 U1 2 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 IS 5 BP 1108 EP 1113 DI 10.1111/jgs.14091 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DO1FD UT WOS:000377523000024 PM 27160212 ER PT J AU O'Kula, SS Gottesman, E Jones, S Signor, D Hung, WW Boockvar, KS AF O'Kula, Susanna S. Gottesman, Eve Jones, Shatice Signor, Daniel Hung, William W. Boockvar, Kenneth S. TI Transitional Care Outcomes in Older Spanish-English Bilingual Veterans SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter ID QUALITY C1 [O'Kula, Susanna S.; Hung, William W.; Boockvar, Kenneth S.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Gottesman, Eve; Jones, Shatice; Signor, Daniel; Hung, William W.; Boockvar, Kenneth S.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP O'Kula, SS (reprint author), Icahn Sch Med Mt Sinai, New York, NY 10029 USA. OI Boockvar, Kenneth/0000-0003-1165-5558 NR 8 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 IS 5 BP 1132 EP 1133 DI 10.1111/jgs.14116 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DO1FD UT WOS:000377523000029 PM 27225364 ER PT J AU Hawkins, EJ Malte, CA AF Hawkins, Eric J. Malte, Carol A. TI Prioritizing the reach and patient-centeredness of substance use-related care SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE LA English DT Editorial Material ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; ALCOHOL-USE DISORDERS; SMOKING-CESSATION; ADDICTION TREATMENT; COLLABORATIVE CARE; QUALITY CARE; HEALTH-CARE; FOLLOW-UP; MANAGEMENT C1 [Hawkins, Eric J.; Malte, Carol A.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev HSR&D Seattle Ctr Innovat Vet, Seattle, WA USA. [Hawkins, Eric J.; Malte, Carol A.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. [Hawkins, Eric J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Hawkins, EJ (reprint author), VA Puget Sound Hlth Care Syst, Seattle Div, S116ATC,1660 S Columbian Way, Seattle, WA 98108 USA. EM Eric.Hawkins@va.gov NR 37 TC 0 Z9 0 U1 5 U2 6 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0095-2990 EI 1097-9891 J9 AM J DRUG ALCOHOL AB JI Am. J. Drug Alcohol Abuse PD MAY PY 2016 VL 42 IS 3 BP 245 EP 249 DI 10.3109/00952990.2016.1147568 PG 5 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA DN5FB UT WOS:000377090800001 PM 27088963 ER PT J AU Folmer, RL AF Folmer, Robert L. TI Reply to: Psychometric properties of the Tinnitus Functional Index (TFI): Assessment in a UK research volunteer population SO HEARING RESEARCH LA English DT Letter C1 [Folmer, Robert L.] Natl Ctr Rehabil Auditory Res, Portland, OR USA. [Folmer, Robert L.] Med Ctr, Portland, OR USA. [Folmer, Robert L.] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA. [Folmer, Robert L.] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd NCRAR, Portland, OR 97239 USA. RP Folmer, RL (reprint author), Natl Ctr Rehabil Auditory Res, Portland, OR USA.; Folmer, RL (reprint author), Med Ctr, Portland, OR USA.; Folmer, RL (reprint author), Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA.; Folmer, RL (reprint author), Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd NCRAR, Portland, OR 97239 USA. EM Robert.Folmer@va.gov NR 3 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-5955 EI 1878-5891 J9 HEARING RES JI Hear. Res. PD MAY PY 2016 VL 335 BP 236 EP 236 DI 10.1016/j.heares.2016.02.011 PG 1 WC Audiology & Speech-Language Pathology; Neurosciences; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Neurosciences & Neurology; Otorhinolaryngology GA DM9VN UT WOS:000376713900023 PM 26900071 ER PT J AU Balbale, SN Etingen, B Malhiot, A Miskevics, S LaVela, SL AF Balbale, Salva N. Etingen, Bella Malhiot, Alex Miskevics, Scott LaVela, Sherri L. TI Perceptions of Chronic Illness Care Among Veterans With Multiple Chronic Conditions SO MILITARY MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; HEALTH-CARE; PATIENT ASSESSMENT; OLDER PERSONS; GUIDED CARE; QUALITY; MULTIMORBIDITY; COSTS; COMORBIDITY; OUTCOMES AB Objectives: Given the burden of multiple chronic conditions (MCCs) in the Veterans Affairs (VA) Health Care System, understanding perspectives of Veterans with MCC is essential to evaluate chronic care and ensure that care and quality improvement efforts align with patient needs. The purpose of this study was to use the Patient Assessment of Chronic Illness Care (PACIC) instrument to examine perceptions of chronic care among Veterans with MCC. Methods: We conducted a nation-wide, cross-sectional mailed survey. Study inclusion criteria were Veteran patients with MCC who receive care from eight VA facilities. The survey included questions on patient demographics, recent hospital or doctor visits, and the PACIC instrument. Chronic condition and health care utilization data were extracted from VA administrative databases. Results: The sample (n = 3,519) was mostly male; average age was 68.1 years. Mean PACIC summary score was 3.05 (standard deviation [SD] = 1.12). Respondents achieved higher scores (favorable perceptions) in the Delivery System Design and Patient Activation subscales, and lowest scores (unfavorable perceptions) in the Follow-up/Coordination subscale. Characteristics associated with higher scores included non-white race, recent VA doctor visit, and high school or less education. Conclusions: Perceptions of chronic care were high; however, quality improvements are needed to enhance care continuity and coordination. C1 [Balbale, Salva N.; Etingen, Bella; Malhiot, Alex; Miskevics, Scott; LaVela, Sherri L.] US Dept Vet Affairs, Ctr Evaluat Practices & Experiences Patient Ctr C, 5000 South 5th Ave,151H, Hines, IL 60141 USA. [Balbale, Salva N.; Etingen, Bella; Malhiot, Alex; Miskevics, Scott; LaVela, Sherri L.] Edward Hines Jr VA Hosp, Ctr Innovat Complex Chron Healthcare, 5000 South 5th Ave,151H, Hines, IL 60141 USA. [Balbale, Salva N.; LaVela, Sherri L.] Northwestern Univ, Feinberg Sch Med, Inst Publ Hlth & Med, Ctr Healthcare Studies, 633 North St Clair St, Chicago, IL 60611 USA. RP Balbale, SN (reprint author), US Dept Vet Affairs, Ctr Evaluat Practices & Experiences Patient Ctr C, 5000 South 5th Ave,151H, Hines, IL 60141 USA.; Balbale, SN (reprint author), Edward Hines Jr VA Hosp, Ctr Innovat Complex Chron Healthcare, 5000 South 5th Ave,151H, Hines, IL 60141 USA.; Balbale, SN (reprint author), Northwestern Univ, Feinberg Sch Med, Inst Publ Hlth & Med, Ctr Healthcare Studies, 633 North St Clair St, Chicago, IL 60611 USA. FU Department of VA, Office of Patient Centered Care & Cultural Transformation and Office of Research & Development, Health Services Research & Development, Quality Enhancement Research Initiative [PEC-13-002] FX This work was supported by the Department of VA, Office of Patient Centered Care & Cultural Transformation and Office of Research & Development, Health Services Research & Development, Quality Enhancement Research Initiative (PEC-13-002). NR 32 TC 0 Z9 0 U1 2 U2 2 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD MAY PY 2016 VL 181 IS 5 BP 439 EP 444 DI 10.7205/MILMED-D-15-00207 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DN5MZ UT WOS:000377114400009 PM 27136650 ER PT J AU Yan, GW AF Yan, Grace W. TI The Invisible Wound: Moral Injury and Its Impact on the Health of Operation Enduring Freedom/Operation Iraqi Freedom Veterans SO MILITARY MEDICINE LA English DT Article ID MAJOR DEPRESSIVE DISORDER; SERVICE MEMBERS; MENTAL-ILLNESS; WAR VETERANS; PTSD; CARE; SPIRITUALITY; AFGHANISTAN; DEPLOYMENT; SYMPTOMS AB Many veterans are now returning from Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) deployments with physical and mental health problems. However, there are few studies that examine the impact of moral injury on both physical and mental well-being. This study examines the impact of moral injury on self-reported general physical health, general mental health, post-traumatic stress disorder symptoms, and depression symptoms. Cross-sectional data were collected at as part of a pilot study at the New Jersey Veteran Affairs. 100 OEF/OIF veterans recruited at the New Jersey Veteran Affairs completed the paper questionnaire. We found that moral injury and combat experiences positively predicted post-traumatic stress disorder scores. Seeing the aftermath of battle and moral injury were negatively associated with mental well-being and positively associated with depression. Physical health status was negatively associated with depression. Spirituality and moral injury were negatively associated with physical health, whereas age was positively associated with physical health. Moral injury plays an important role in both physical and mental health outcomes for OEF/OIF veterans, but it is often not addressed in health care. These results underline the need for an approach to veterans' health care that includes discussion of existential and moral issues since they may impact health outcomes for many service members. C1 [Yan, Grace W.] US Dept Vet Affairs, Ctr Hlth & Wellness, 385 Tremont Ave,Bldg 17 MS11C, E Orange, NJ 07018 USA. RP Yan, GW (reprint author), US Dept Vet Affairs, Ctr Hlth & Wellness, 385 Tremont Ave,Bldg 17 MS11C, E Orange, NJ 07018 USA. FU Department of Veterans Affairs, Office of Patient-Centered Care and Cultural Transformation FX We would like to thank the faculty and staff of the War Related Illness and Injury Study Center at the New Jersey VA Health Care System for their support. We would also like to thank Dr. Ilysa Michelson and Rev. Thomas Malek-Jones for their comments and feedback on this manuscript. This study was supported by a grant from the Department of Veterans Affairs, Office of Patient-Centered Care and Cultural Transformation. NR 42 TC 0 Z9 0 U1 3 U2 8 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD MAY PY 2016 VL 181 IS 5 BP 451 EP 458 DI 10.7205/MILMED-D-15-00103 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA DN5MZ UT WOS:000377114400011 PM 27136652 ER PT J AU Pugh, MJ Jaramillo, CA Leung, KW Faverio, P Fleming, N Mortensen, E Amuan, ME Wang, CP Eapen, B Restrepo, M Morris, MJ AF Pugh, Mary Jo Jaramillo, Carlos A. Leung, Kar-wei Faverio, Paola Fleming, Nicholas Mortensen, Eric Amuan, Megan E. Wang, Chen-Pin Eapen, Blessen Restrepo, Marcos Morris, Michael J. TI Increasing Prevalence of Chronic Lung Disease in Veterans of the Wars in Iraq and Afghanistan SO MILITARY MEDICINE LA English DT Article ID US MILITARY PERSONNEL; OPERATION ENDURING FREEDOM; RESPIRATORY SYMPTOMS; PARTICULATE MATTER; SOUTHWEST ASIA; DEPLOYMENT; HEALTH; SOLDIERS; INJURY; PNEUMONIA AB Research from the wars in Afghanistan and Iraq have focused on traumatic brain injury (TBI) and mental health conditions; however, it is becoming clear that other health concerns, such as respiratory illnesses, warrant further scientific inquiry. Early reports from theater and postdeployment health assessments suggested an association with deployment-related exposures (e.g., sand, burn pits, chemical, etc.) and new-onset respiratory symptoms. We used data from Veterans Affairs medical encounters between fiscal years 2003 and 2011 to identify trends in chronic obstructive pulmonary disease, asthma, and interstitial lung disease in veterans. We used data from Veterans Affairs and Department of Defense sources to identify sociodemographic (age, sex, race), military (e.g., service branch, multiple deployments) and clinical characteristics (TBI, smoking) of individuals with and without chronic lung diseases. Generalized estimating equations found significant increases over time for chronic obstructive pulmonary disease and asthma in both unadjusted and adjusted analyses. Trends for interstitial lung disease were significant only in adjusted analyses. Age, smoking, and TBI were also significantly associated with chronic lung diseases; however, multiple deployments were not associated. Research is needed to identify which characteristics of deployment-related exposures are linked with chronic lung disease. C1 [Pugh, Mary Jo; Jaramillo, Carlos A.; Eapen, Blessen; Restrepo, Marcos] South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. [Pugh, Mary Jo; Jaramillo, Carlos A.; Leung, Kar-wei; Fleming, Nicholas; Wang, Chen-Pin; Eapen, Blessen; Restrepo, Marcos] Univ Texas Hlth Sci Ctr San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Faverio, Paola] Univ Milano Bicocca, AO San Gerardo, Clin Pneumol, Dept Hlth Sci, Via Pergolesi 22, Monza, Italy. [Mortensen, Eric] North Texas Vet Hlth Care Syst, 4500 South Lancaster Rd, Dallas, TX 75216 USA. [Amuan, Megan E.] Edith Nourse Rogers VA Med Ctr, 200 Springs Rd, Bedford, MA 01730 USA. [Morris, Michael J.] Uniformed Serv Univ Hlth Sci, Brooke Army Med Ctr, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA. RP Pugh, MJ (reprint author), South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.; Pugh, MJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. OI Pugh, Mary Jo/0000-0003-4196-7763; Mortensen, Eric/0000-0002-3880-5563 FU VA Health Services Research and Development Service [DHI 09-237] FX Data were obtained with the assistance of the VA Office of Environmental Epidemiology for the Operation Enduring Freedom/Operation Iraqi Freedom Roster file. This study was funded by the VA Health Services Research and Development Service (DHI 09-237). The content, of this article is solely the responsibility of the authors and does not necessarily reflect the official views of the Veterans' Health Administration or the Department of Defense. The funding organizations had no role in the design and conduct of die study; the collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript. This retrospective data study received approval including a waiver of informed consent and Health Insurance Portability and Accountability Act authorization by the institutional review boards of the University of Texas Health Science Center San Antonio and the Edith Nourse Rogers Memorial VA Hospital. NR 27 TC 0 Z9 0 U1 1 U2 2 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD MAY PY 2016 VL 181 IS 5 BP 476 EP 481 DI 10.7205/MILMED-D-15-00035 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DN5MZ UT WOS:000377114400015 PM 27136656 ER PT J AU Brill, AL Wisinski, JA Cadena, MT Thompson, MF Fenske, RJ Brar, HK Schaid, MD Pasker, RL Kimple, ME AF Brill, Allison L. Wisinski, Jaclyn A. Cadena, Mark T. Thompson, Mary F. Fenske, Rachel J. Brar, Harpreet K. Schaid, Michael D. Pasker, Renee L. Kimple, Michelle E. TI Synergy Between G alpha(z) Deficiency and GLP-1 Analog Treatment in Preserving Functional beta-Cell Mass in Experimental Diabetes SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID GLUCAGON-LIKE PEPTIDE-1; EPIDERMAL-GROWTH-FACTOR; COMBINATION THERAPY; RESTORES NORMOGLYCEMIA; INSULIN-SECRETION; GLUCOSE-TOLERANCE; HUMAN ISLETS; NOD MICE; APOPTOSIS; RATS AB A defining characteristic of type 1 diabetes mellitus ( T1DM) pathophysiology is pancreatic beta-cell death and dysfunction, resulting in insufficient insulin secretion to properly control blood glucose levels. Treatments that promote beta-cell replication and survival, thus reversing the loss of beta-cell mass, while also preserving beta-cell function, could lead to a real cure for T1DM. The alpha-subunit of the heterotrimeric G(z) protein, G alpha(z), is a tonic negative regulator of adenylate cyclase and downstream cAMP production. cAMP is one of a few identified signaling molecules that can simultaneously have a positive impact on pancreatic islet beta-cell proliferation, survival, and function. The purpose of our study was to determine whether mice lacking G alpha(z) might be protected, at least partially, from beta-cell loss and dysfunction after streptozotocin treatment. We also aimed to determine whether G alpha(z) might act in concert with an activator of the cAMP-stimulatory glucagon-like peptide 1 receptor, exendin-4 ( Ex4). Without Ex4 treatment, G alpha(z)-null mice still developed hyperglycemia, albeit delayed. The same finding held true for wild-type mice treated with Ex4. With Ex4 treatment, G alpha(z)-null mice were protected from developing severe hyperglycemia. Immunohistological studies performed on pancreas sections and in vitro apoptosis, cytotoxicity, and survival assays demonstrated a clear effect of G alpha(z) signaling on pancreatic beta-cell replication and death; beta-cell function was also improved in G alpha(z)-null islets. These data support our hypothesis that a combination of therapies targeting both stimulatory and inhibitory pathways will be more effective than either alone at protecting, preserving, and possibly regenerating beta-cell mass and function in T1DM. C1 [Brill, Allison L.; Wisinski, Jaclyn A.; Cadena, Mark T.; Thompson, Mary F.; Brar, Harpreet K.; Pasker, Renee L.; Kimple, Michelle E.] Univ Wisconsin, Dept Med, Div Endocrinol Diabet & Metab, Madison, WI 53705 USA. [Kimple, Michelle E.] Univ Wisconsin, Dept Cell & Regenerat Biol, Madison, WI 53705 USA. [Fenske, Rachel J.; Schaid, Michael D.; Kimple, Michelle E.] Univ Wisconsin, Interdisciplinary Grad Program Nutr Sci, Madison, WI 53705 USA. [Brill, Allison L.; Wisinski, Jaclyn A.; Cadena, Mark T.; Thompson, Mary F.; Fenske, Rachel J.; Brar, Harpreet K.; Schaid, Michael D.; Kimple, Michelle E.] William S Middleton Mem Vet Adm Med Ctr, Res Serv, Madison, WI 53705 USA. RP Kimple, ME (reprint author), Univ Wisconsin, Dept Med, Div Endocrinol, 4148 Univ Wisconsin Med Fdn Centennial Bldg, Madison, WI 53705 USA. EM mkimple@medicine.wisc.edu FU JDRF [17-2011-608]; National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases [R01 DK102598]; American Diabetes Association [1-14-BS-115]; University of Wisconsin-Madison; American Society of Pharmacology and Experimental Therapeutics FX This work was supported by the JDRF Grant 17-2011-608 (to M.E.K.), the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases Grant R01 DK102598 (to M.E.K.), the American Diabetes Association Grant 1-14-BS-115 (to M.E.K.), and the University of Wisconsin-Madison (M.E.K.). A.L.B. was funded in part through a Summer Undergraduate Research Fellowship from the American Society of Pharmacology and Experimental Therapeutics. M.T.C. was funded in part through a Minority Undergraduate Internship Award from the American Diabetes Association. H.K.B. was funded in part through a Hilldale Undergraduate/Faculty Research Award from the University of Wisconsin-Madison. This material is the result of work supported in part with the resources and use of facilities at the William S. Middleton Memorial Veterans Hospital, Madison, WI. NR 57 TC 1 Z9 1 U1 2 U2 2 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD MAY PY 2016 VL 30 IS 5 BP 543 EP 556 DI 10.1210/me.2015-1164 PG 14 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DN6TT UT WOS:000377209900006 PM 27049466 ER PT J AU Bramoweth, AD Renqvist, JG Germain, A Buysse, DJ Gentili, A Kochersberger, G Rodriguez, E Rossi, MI Weiner, DK AF Bramoweth, Adam D. Renqvist, Jenna G. Germain, Anne Buysse, Daniel J. Gentili, Angela Kochersberger, Gary Rodriguez, Eric Rossi, Michelle I. Weiner, Debra K. TI Deconstructing Chronic Low Back Pain in the Older Adult-Step by Step Evidence and Expert-Based Recommendations for Evaluation and Treatment: Part VII: Insomnia SO PAIN MEDICINE LA English DT Article DE Low Back Pain; Chronic Pain; Chronic Low Back Pain; Insomnia; Sleep Disorders; Elderly; Older Adults ID COGNITIVE-BEHAVIORAL THERAPY; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; SLEEP-ONSET; HEALTHY-VOLUNTEERS; SEVERITY INDEX; 6 MG; EFFICACY; ZOLPIDEM AB Objective. To present the seventh in a series of articles designed to deconstruct chronic low back pain ( CLBP) in older adults. This article focuses on insomnia and presents a treatment algorithm for managing insomnia in older adults, along with a representative clinical case. Methods.aEuro integral A modified Delphi process was used to develop the algorithm and supportive materials. A multidisciplinary expert panel representing expertise in health psychology and sleep medicine developed the algorithm and supporting documents that were subsequently refined through an iterative process of input from a primary care provider panel. Results.aEuro integral We present an illustrative clinical case and an algorithm to help guide the care of older adults with insomnia, an important contributor to CLBP and disability. Multicomponent cognitive behavioral therapy for insomnia (CBTI) and similar treatments (e.g., brief behavioral treatment for insomnia [BBTI]) are the recommended first-line treatment. Medications should be considered only if BBTI/CBTI is suboptimal or not effective and should be prescribed at the lowest effective dose for short periods of time (< 90 days). Conclusions.aEuro integral Insomnia is commonly comorbid with CLBP in older adults and should be routinely evaluated and treated because it is an important contributor to pain and disability. The algorithm presented was structured to assist primary care providers in planning treatment for older adults with CLBP and insomnia. C1 [Bramoweth, Adam D.; Renqvist, Jenna G.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. [Bramoweth, Adam D.; Germain, Anne; Buysse, Daniel J.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Gentili, Angela] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA. [Gentili, Angela] Virginia Commonwealth Univ Hlth Syst, Richmond, VA USA. [Kochersberger, Gary] VA Med Ctr, Canandaigua, NY USA. [Kochersberger, Gary] Univ Rochester, Div Geriatr, Rochester, NY 14627 USA. [Rossi, Michelle I.; Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Rodriguez, Eric; Rossi, Michelle I.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA 15213 USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA USA. RP Weiner, DK (reprint author), Pittsburgh Healthcare Syst, Univ Dr,Bldg 30,00GR, Pittsburgh, PA 15240 USA. EM debra.weiner@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service FX This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service. NR 73 TC 2 Z9 2 U1 4 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD MAY PY 2016 VL 17 IS 5 BP 851 EP 863 DI 10.1093/pm/pnw063 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA DM8ZW UT WOS:000376654000007 PM 27173512 ER PT J AU Jackson, JC Jutte, JE Hunter, CH Ciccolella, N Warrington, H Sevin, C Bienvenu, OJ AF Jackson, James C. Jutte, Jennifer E. Hunter, Cashuna Huddleston Ciccolella, Nancy Warrington, Hillary Sevin, Carla Bienvenu, Oscar J. TI Posttraumatic Stress Disorder (PTSD) After Critical Illness: A Conceptual Review of Distinct Clinical Issues and Their Implications SO REHABILITATION PSYCHOLOGY LA English DT Review DE critical care; posttraumatic stress disorders; intensive care units; psychosocial rehabilitation ID INTENSIVE-CARE-UNIT; ACUTE LUNG INJURY; QUALITY-OF-LIFE; RESPIRATORY-DISTRESS-SYNDROME; TRAUMATIC BRAIN-INJURY; PSYCHOLOGICAL DISTRESS; ILL PATIENTS; PHYSICAL REHABILITATION; MECHANICAL VENTILATION; PROLONGED EXPOSURE AB Purpose/Objective: Posttraumatic stress disorder (PTSD) that develops after critical care may be marked by a unique constellation of symptoms that differ, for example, from the symptoms that develop in response to more traditional traumas such as combat or assault. Research Method/Design: We describe ways in which symptoms of PTSD after critical illness can be clinically engaged, drawing from literature pointing to "best treatment" practices in other settings. And, we discuss the relevance of intensive care unit (ICU) related PTSD to rehabilitation psychologists and explain why rehabilitation psychologists are well suited to identify and treat ICU-related PTSD. Results: In this conceptual review, drawing from both empirical findings and theoretical models, we surmise that traumatized survivors of critical illness demonstrate 2 central clinical features-avoidance and reexperiencing. Conclusions/Implications: The potentially unique clinical profile of ICU-related PTSD likely requires unique assessment and treatment practices. These services may be best provided by providers with expertise in providing coordinated care, such as rehabilitation psychologists. Next steps should include empirical study to determine whether practices that are empirically supported in other settings may be translated to the ICU and post-ICU hospitalization for critical illness survivors. C1 [Jackson, James C.] Vanderbilt Univ, Sch Med, Div Allergy Pulm Crit Care Med, Ctr Hlth Serv Res, Nashville, TN 37232 USA. [Jackson, James C.] Vanderbilt Univ, Sch Med, Dept Psychiat, Nashville, TN 37232 USA. [Jackson, James C.] Vet Affairs Tennessee Valley Geriatr Res Educ & C, Nashville, TN USA. [Jutte, Jennifer E.] Univ Washington, Dept Rehabil Med, Sch Med, Harborview Med Ctr, Seattle, WA 98195 USA. [Hunter, Cashuna Huddleston] Houston Vet Affairs Med Ctr, Houston, TX USA. [Ciccolella, Nancy] Temple Univ, Dept Phys Med & Rehabil, Philadelphia, PA 19122 USA. [Warrington, Hillary] Baylor Univ, Dept Psychol, Waco, TX 76798 USA. [Sevin, Carla] Vanderbilt Univ, Sch Med, Div Allergy Pulm Crit Care Med, Nashville, TN 37232 USA. [Bienvenu, Oscar J.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21218 USA. RP Jackson, JC (reprint author), Vanderbilt Univ, Ctr Hlth Serv Res, 6100 Med Ctr East, Nashville, TN 37232 USA. EM james.c.jackson@vanderbilt.edu NR 87 TC 1 Z9 1 U1 4 U2 7 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0090-5550 EI 1939-1544 J9 REHABIL PSYCHOL JI Rehabil. Psychol. PD MAY PY 2016 VL 61 IS 2 BP 132 EP 140 DI 10.1037/rep0000085 PG 9 WC Psychology, Clinical; Rehabilitation SC Psychology; Rehabilitation GA DN2XS UT WOS:000376926900003 PM 27196856 ER PT J AU Wahl, ER Yazdany, J AF Wahl, Elizabeth R. Yazdany, Jinoos TI Challenges and Opportunities in Using Patient-reported Outcomes in Quality Measurement Rheumatology SO RHEUMATIC DISEASE CLINICS OF NORTH AMERICA LA English DT Article DE Patient-reported outcomes; Quality measures; Performance measures; Outcome measures; Health care quality; Rheumatology ID OF-CARE; HEALTH-CARE; CLINICAL-PRACTICE; EUMUSC.NET-PROJECT; INDICATOR SET; PERFORMANCE; ARTHRITIS; IMPROVEMENT; RECOMMENDATIONS; EUROPE AB Use of patient-reported outcome measures (PROs) in rheumatology research is widespread, but use of PRO data to evaluate the quality of.rheumatologic care delivered is less well established. This article reviews the use of PROs in assessing health care quality, and highlights challenges and opportunities specific to their use in rheumatology quality measurement. It first explores other countries' experiences collecting and evaluating national PRO data to assess quality of care. It describes the current use of PROs as quality measures in rheumatology, and frames an agenda for future work supporting development of meaningful quality measures based on PROs. C1 [Wahl, Elizabeth R.] San Francisco VA Med Ctr, Div Rheumatol, VA Qual Scholars Program, 4150 Clement St,Bldg 1,Room 207-1, San Francisco, CA 94121 USA. [Yazdany, Jinoos] Univ Calif San Francisco, Dept Internal Med, Div Rheumatol, 1001 Potrero Ave,Bldg SFGH 30,Room 3301,Box 0811, San Francisco, CA 94110 USA. RP Yazdany, J (reprint author), Univ Calif San Francisco, Dept Internal Med, Div Rheumatol, 1001 Potrero Ave,Bldg SFGH 30,Room 3301,Box 0811, San Francisco, CA 94110 USA. EM jinoos.yazdany@ucsf.edu FU NIAMS [K23 AR060259]; Russell/Engleman Rheumatology Research Center; Robert L. Kroc Endowed Chair in Rheumatic and Connective Tissue Diseases at the University of California, San Francisco; VA Quality Scholars Fellowship through the VA Office of Academic Affiliations FX J. Yazdany is supported by NIAMS K23 AR060259, the Russell/Engleman Rheumatology Research Center, and the Robert L. Kroc Endowed Chair in Rheumatic and Connective Tissue Diseases at the University of California, San Francisco. E. Wahl supported by a VA Quality Scholars Fellowship through the VA Office of Academic Affiliations. NR 35 TC 1 Z9 1 U1 2 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-857X EI 1558-3163 J9 RHEUM DIS CLIN N AM JI Rheum. Dis. Clin. North Am. PD MAY PY 2016 VL 42 IS 2 BP 363 EP + DI 10.1016/j.rdc.2016.01.008 PG 15 WC Rheumatology SC Rheumatology GA DN0YO UT WOS:000376793200013 PM 27133495 ER PT J AU Hirsch, J Generoso, JR Latoures, R Acar, Y Fidler, RL AF Hirsch, Jan Generoso, Jose R. Latoures, Renee Acar, Yahya Fidler, Richard L. TI Simulation Manikin Modifications for High-Fidelity Training of Advanced Airway Procedures SO A & A CASE REPORTS LA English DT Article ID INTUBATION AB Thoracic anesthesia procedures are challenging to master during anesthesia training. A Laerdal ALS Simulator (R) manikin was modified by adding a bronchial tree module to create fidelity to the fourth generation. After modification, placement of endotracheal tubes up to 8.0 mm is possible by direct laryngoscopy, video laryngoscopy, and fiberoptically; in addition, it allows fiberoptically guided insertion of endobronchial blockers. Insertion of left and right 35-Fr double-lumen tubes permits double-and single-lung ventilation with continuous positive airway pressure and positive end-expiratory pressure. This anatomical modification created a high-fidelity training tool for thoracic anesthesia that has been incorporated into educational curricula for anesthesia. C1 Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, Simulat Ctr, San Francisco, CA USA. RP Hirsch, J (reprint author), San Francisco VA Med Ctr, Anesthesia Serv, Mail 129,4150 Clement St, San Francisco, CA 94121 USA. EM jan.hirsch@ucsf.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2325-7237 J9 A A CASE REP JI A A Case Rep. PD MAY 1 PY 2016 VL 6 IS 9 BP 268 EP 271 DI 10.1213/XAA.0000000000000278 PG 4 WC Anesthesiology SC Anesthesiology GA DN0SZ UT WOS:000376776100002 PM 26752178 ER PT J AU Stall, R Matthews, DD Friedman, MR Kinsky, S Egan, JE Coulter, RWS Blosnich, JR Markovic, N AF Stall, Ron Matthews, Derrick D. Friedman, M. Reuel Kinsky, Suzanne Egan, James E. Coulter, Robert W. S. Blosnich, John R. Markovic, Nina TI The Continuing Development of Health Disparities Research on Lesbian, Gay, Bisexual, and Transgender Individuals SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material ID SEXUAL ORIENTATION; MENTAL-HEALTH C1 [Stall, Ron; Matthews, Derrick D.; Friedman, M. Reuel; Kinsky, Suzanne; Egan, James E.; Coulter, Robert W. S.; Blosnich, John R.; Markovic, Nina] Univ Pittsburgh, Grad Sch Publ Hlth, Ctr LGBT Hlth Res, 130 De Soto St, Pittsburgh, PA 15261 USA. [Stall, Ron; Kinsky, Suzanne; Egan, James E.; Coulter, Robert W. S.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA 15261 USA. [Matthews, Derrick D.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA. [Blosnich, John R.] US Dept Vet Affairs, VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Markovic, Nina] Univ Pittsburgh, Sch Dent Med, Dept Dent Publ Hlth, Pittsburgh, PA 15261 USA. RP Stall, R (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Ctr LGBT Hlth Res, 130 De Soto St, Pittsburgh, PA 15261 USA.; Stall, R (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Sci Dept Behav & Community Hlth Sci, 130 De Soto St, Pittsburgh, PA 15261 USA. EM rstall@pitt.edu OI Friedman, M. Reuel/0000-0001-6191-9799; Coulter, Robert/0000-0001-8350-0075 NR 9 TC 2 Z9 2 U1 0 U2 3 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAY PY 2016 VL 106 IS 5 BP 787 EP 789 DI 10.2105/AJPH.2016.303183 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DM2ME UT WOS:000376180100025 PM 27049415 ER PT J AU Ge, L Wu, YF Soleimani, M Khazalpour, M Takaba, K Tartibi, M Zhang, ZH Acevedo-Bolton, G Saloner, DA Wallace, AW Mishra, R Grossi, EA Guccione, JM Ratcliffe, MB AF Ge, Liang Wu, Yife Soleimani, Mehrdad Khazalpour, Michael Takaba, Kiyoaki Tartibi, Mehrzad Zhang, Zhihong Acevedo-Bolton, Gabriel Saloner, David A. Wallace, Arthur W. Mishra, Rakesh Grossi, Eugene A. Guccione, Julius M. Ratcliffe, Mark B. TI Moderate Ischemic Mitral Regurgitation After Posterolateral Myocardial Infarction in Sheep Alters Left Ventricular Shear but Not Normal Strain in the Infarct and Infarct Borderzone SO ANNALS OF THORACIC SURGERY LA English DT Article ID MATRIX METALLOPROTEINASE-2; TRANSMURAL STRAINS; SURGICAL-TREATMENT; OVINE MODEL; MR-IMAGES; ECHOCARDIOGRAPHY; DYSFUNCTION; INDUCTION; EXPANSION; OCCLUSION AB Background. Chronic ischemic mitral regurgitation (CIMR) is associated with poor outcome. Left ventricular (LV) strain after posterolateral myocardial infarction (MI) may drive LV remodeling. Although moderate CIMR has been previously shown to affect LV remodeling, the effect of CIMR on LV strain after posterolateral MI remains unknown. We tested the hypothesis that moderate CIMR alters LV strain after posterolateral MI. Methods. Posterolateral MI was created in 10 sheep. Cardiac magnetic resonance imaging with tags was performed 2 weeks before and 2, 8, and 16 weeks after MI. The left and right ventricular volumes were measured, and regurgitant volume indexed to body surface area (regurgitant volume index) was calculated as the difference between left ventricle and right ventricle stroke volumes divided by body surface area. Three-dimensional strain was calculated. Results. Circumferential strain (E-cc) and longitudinal strain (E-ll) were reduced in the infarct proper, MI borderzone, and remote myocardium 16 weeks after MI. In addition, radial circumferential (E-rc) and radial longitudinal (E-rl) shear strains were reduced in remote myocardium but increased in the infarct and borderzone 16 weeks after MI. Of all strain components, however, only E-rc was affected by regurgitant volume index (p = 0.0005). There was no statistically significant effect of regurgitant volume index on E-cc, E-ll, E-rl, or circumferential longitudinal shear strain (E-cl). Conclusions. Moderate CIMR alters radial circumferential shear strain after posterolateral MI in sheep. Further studies are needed to determine the effect of shear strain on myocyte hypertrophy and the effect of mitral repair on myocardial strain. (C) 2016 by The Society of Thoracic Surgeons C1 Univ Calif San Francisco, Dept Surg, San Francisco, CA USA. Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA USA. Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA USA. Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA. Vet Affairs Med Ctr, San Francisco, CA 94121 USA. NYU, Sch Med, Dept Cardiothorac Surg, New York, NY USA. RP Ratcliffe, MB (reprint author), San Francisco VA Med Ctr, Surg Serv 112, 4150 Clement St, San Francisco, CA 94121 USA. EM mark.ratcliffe@va.gov OI GROSSI, eugene/0000-0002-2066-7035 FU NIH [R01-HL-084431, R01-HL-077921] FX This study was supported by NIH grants R01-HL-084431 (Dr Ratcliffe) and R01-HL-077921 (Dr Guccione). NR 40 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD MAY PY 2016 VL 101 IS 5 BP 1691 EP 1699 DI 10.1016/j.athoracsur.2015.10.083 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA DL8CY UT WOS:000375868500027 PM 26857634 ER PT J AU Scott, GD Sauer, DA Woolf, KM Sukumar, MS Tieu, BH AF Scott, Gregory D. Sauer, David A. Woolf, Kirsten M. Sukumar, Mithran S. Tieu, Brandon H. TI Presumed Second Focus of Lung Immunoglobulin G4-Related Disease Found to be Adenocarcinoma SO ANNALS OF THORACIC SURGERY LA English DT Editorial Material ID IGG4-RELATED DISEASE AB We describe a patient presenting with bilateral radiologically similar lung lesions initially diagnosed as immunoglobulin (Ig) G4-related disease from biopsy of one lesion, but radiographic changes 6 months later prompted biopsy of the second lesion and showed adenocarcinoma. No case of lung IgG4-related disease and a distant lung malignancy has been previously reported. This is notable because lung IgG4-related disease often manifests in multiple thoracic locations but is diagnosed from a representative biopsy specimen. (C) 2016 by The Society of Thoracic Surgeons C1 Oregon Hlth & Sci Univ, MD PhD Program, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. Portland VA Med Ctr, Dept Pathol Lab, Portland, OR USA. Oregon Hlth & Sci Univ, Div Cardiothorac Surg, Portland, OR 97201 USA. RP Tieu, BH (reprint author), Cardiothorac Surg Div, Dept Surg, Mail Code L353,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM tieub@ohsu.edu NR 5 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD MAY PY 2016 VL 101 IS 5 BP 1965 EP 1967 DI 10.1016/j.athoracsur.2015.07.041 PG 4 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA DL8CY UT WOS:000375868500066 PM 27106428 ER PT J AU Perera, T George, MS Grammer, G Janicak, PG Pascual-Leone, A Wirecki, TS AF Perera, Tarique George, Mark S. Grammer, Geoffrey Janicak, Philip G. Pascual-Leone, Alvaro Wirecki, Theodore S. TI The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder SO BRAIN STIMULATION LA English DT Article DE Depression; TMS; Review; Guidelines ID TRANSCRANIAL MAGNETIC STIMULATION; SHAM-CONTROLLED TRIALS; TREATMENT-RESISTANT DEPRESSION; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; DOUBLE-BLIND; ELECTROCONVULSIVE-THERAPY; ANTIDEPRESSANT EFFICACY; OPEN-LABEL; RTMS AB Background: Prefrontal Transcranial Magnetic Stimulation (TMS) therapy repeated daily over 4-6 weeks (20-30 sessions) is US Food and Drug Administration (FDA) approved for treating Major Depressive Disorder in adults who have not responded to prior antidepressant medications. In 2011, leading TMS clinical providers and researchers created the Clinical TMS Society (cTMSs) (www.clinicaltmssociety.org, Greenwich, CT, USA), incorporated in 2013. Methods: This consensus review was written by cTMSs leaders, informed by membership polls, and approved by the governing board. It summarizes current evidence for the safety and efficacy of the use of TMS therapy for treating depression in routine clinical practice. Authors systematically reviewed the published TMS antidepressant therapy clinical trials. Studies were then assessed and graded on their strength of evidence using the Levels of Evidence framework published by the University of Oxford Centre for Evidence Based Medicine. The authors then summarize essentials for using TMS therapy in routine clinical practice settings derived from discussions and polls of cTMSs members. Finally, each summary clinical recommendation is presented with the substantiating peer-reviewed, published evidence supporting that recommendation. When the current published clinical trial evidence was insufficient or incomplete, expert opinion was included when sufficient consensus was available from experienced clinician users among the membership of the cTMSs, who were polled at the Annual Meetings in 2014 and 2015. Conclusions: Daily left prefrontal TMS has substantial evidence of efficacy and safety for treating the acute phase of depression in patients who are treatment resistant or intolerant. Following the clinical recommendations in this document should result in continued safe and effective use of this exciting new treatment modality. (C) 2016 The Authors. Published by Elsevier Inc. C1 [Perera, Tarique] Contemporary Care, Greenwich, CT USA. [George, Mark S.] Med Univ S Carolina, Dept Psychiat, Brain Stimulat Div, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Grammer, Geoffrey] TMS NeuroHlth, Mclean, VA USA. [Janicak, Philip G.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. [Pascual-Leone, Alvaro] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA 02215 USA. [Wirecki, Theodore S.] TMS Ctr Colorado, Denver, CO USA. RP George, MS (reprint author), Med Univ S Carolina, Dept Psychiat, Brain Stimulat Div, Charleston, SC 29425 USA.; George, MS (reprint author), Ralph H Johnson VA Med Ctr, Charleston, SC USA. EM georgem@musc.edu NR 71 TC 7 Z9 7 U1 8 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD MAY-JUN PY 2016 VL 9 IS 3 BP 336 EP 346 DI 10.1016/j.brs.2016.03.010 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DM6KQ UT WOS:000376461400004 PM 27090022 ER PT J AU Luetkemeyer, AF Firnhaber, C Kendall, MA Wu, XY Mazurek, GH Benator, DA Arduino, R Fernandez, M Guy, E Johnson, P Metchock, B Sattler, F Telzak, E Wang, YF Weiner, M Swindells, S Sanne, IM Havlir, DV Grinsztejn, B Alland, D AF Luetkemeyer, Anne F. Firnhaber, Cynthia Kendall, Michelle A. Wu, Xingye Mazurek, Gerald H. Benator, Debra A. Arduino, Roberto Fernandez, Michel Guy, Elizabeth Johnson, Pamela Metchock, Beverly Sattler, Fred Telzak, Edward Wang, Yun F. Weiner, Marc Swindells, Susan Sanne, Ian M. Havlir, Diane V. Grinsztejn, Beatriz Alland, David CA AIDS Clinical Trials Grp A5295 TB Trials Consortium Study 34 Team TI Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Xpert MTB/RIF; tuberculosis diagnosis; respiratory isolation; nontuberculous mycobacteria; HIV/tuberculosis coinfection ID DETECTING MYCOBACTERIUM-TUBERCULOSIS; UNITED-STATES; ASSAY AB Background. The Xpert MTB/RIF (Xpert) assay is a rapid nucleic acid amplification test widely used in settings of high tuberculosis prevalence to detect tuberculosis as well as rpoB mutations associated with rifampin resistance. Data are needed on the diagnostic performance of Xpert in lower-prevalence settings to inform appropriate use for both tuberculosis detection and the need for respiratory isolation. Methods. Xpert was compared to 2 sputum samples, each evaluated with acid-fast bacilli (AFB) smear and mycobacterial culture using liquid and solid culture media, from participants with suspected pulmonary tuberculosis from the United States, Brazil, and South Africa. Results. Of 992 participants enrolled with evaluable results, 22% had culture-confirmed tuberculosis. In 638 (64%) US participants, 1 Xpert result demonstrated sensitivity of 85.2% (96.7% in participants with AFB smear-positive [AFB(+)] sputum, 59.3% with AFB smear-negative [AFB(-)] sputum), specificity of 99.2%, negative predictive value (NPV) of 97.6%, and positive predictive value of 94.9%. Results did not differ between higher-and low-prevalence settings. A second Xpert assay increased overall sensitivity to 91.1% (100% if AFB(+), 71.4% if AFB(-)), with specificity of 98.9%. In US participants, a single negative Xpert result predicted the absence of AFB(+)/culture-positive tuberculosis with an NPV of 99.7%; NPV of 2 Xpert assays was 100%, suggesting a role in removing patients from airborne infection isolation. Xpert detected tuberculosis DNA and mutations associated with rifampin resistance in 5 of 7 participants with rifampin-resistant, culture-positive tuberculosis. Specificity for rifampin resistance was 99.5% and NPV was 98.9%. Conclusions. In the United States, Xpert testing performed comparably to 2 higher-tuberculosis-prevalence settings. These data support the use of Xpert in the initial evaluation of tuberculosis suspects and in algorithms assessing need for respiratory isolation. C1 [Luetkemeyer, Anne F.; Havlir, Diane V.] Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV Infect Dis & Global Med, Box 0874,Bldg 80,995 Potrero Ave, San Francisco, CA 94110 USA. [Firnhaber, Cynthia] Univ Witwatersrand, Fac Hlth Sci, Clin HIV Res Unit, Dept Internal Med, ZA-2050 Johannesburg, South Africa. [Firnhaber, Cynthia; Sanne, Ian M.] Right Care, Johannesburg, South Africa. [Kendall, Michelle A.; Wu, Xingye] Harvard Univ, TH Chan Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA. [Mazurek, Gerald H.; Metchock, Beverly] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Benator, Debra A.] Vet Affairs Med Ctr, Infect Dis Sect, 50 Irving St NW, Washington, DC 20422 USA. [Benator, Debra A.] George Washington Univ, Washington, DC USA. [Arduino, Roberto] Univ Texas Hlth Sci Ctr Houston, Div Infect Dis, Dept Internal Med, Houston, TX 77030 USA. [Fernandez, Michel] Univ N Texas, Hlth Sci Ctr, Tarrant Cty Hlth Dept, Ft Worth, TX USA. [Guy, Elizabeth] Baylor Coll Med, Ben Taub Gen Hosp, Sect Pulm Crit Care & Sleep Med, Houston, TX 77030 USA. [Johnson, Pamela] Cepheid, Sunnyvale, CA USA. [Sattler, Fred] Univ So Calif, Keck Sch Med, Div Infect Dis, Los Angeles, CA 90033 USA. [Telzak, Edward] Albert Einstein Coll Med, St Barnabus Hosp Hlth Syst, Bronx, NY 10467 USA. [Wang, Yun F.] Emory Univ, Sch Med, Grady Mem Hosp, Atlanta, GA USA. [Weiner, Marc] Univ Texas Hlth Sci Ctr San Antonio, Vet Adm Med Ctr, Dept Med, San Antonio, TX 78229 USA. [Swindells, Susan] Univ Nebraska Med Ctr, Internal Med Infect Dis, Lincoln, NE USA. [Sanne, Ian M.] Univ Witwatersrand, Fac Hlth Sci, Dept Internal Med, Johannesburg, South Africa. [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas Fiocruz, Dept Infect Dis, Rio De Janeiro, Brazil. [Alland, David] Rutgers New Jersey Med Sch, Div Infect Dis, Newark, NJ USA. RP Luetkemeyer, AF (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV Infect Dis & Global Med, Box 0874,Bldg 80,995 Potrero Ave, San Francisco, CA 94110 USA. EM annie.luetkemeyer@ucsf.edu RI Kendall, Michelle/B-7665-2016 OI Kendall, Michelle/0000-0001-9160-4544 FU National Institute of Allergy and Infectious Diseases through the ACTG [AI068634, U01AI068636, UM1 AI106701]; CDC through the TBTC; Division of Tuberculosis Elimination; National Center for HIV; Viral Hepatitis; STD; TB Prevention; National Institute of Mental Health; National Institute of Dental and Craniofacial Research FX This work was supported by the National Institute of Allergy and Infectious Diseases through the ACTG (grant numbers AI068634, U01AI068636, and UM1 AI106701); the CDC through the TBTC and the Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention; the National Institute of Mental Health, and the National Institute of Dental and Craniofacial Research. NR 15 TC 5 Z9 5 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 1 PY 2016 VL 62 IS 9 BP 1081 EP 1088 DI 10.1093/cid/ciw035 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DM5IO UT WOS:000376381800004 PM 26839383 ER PT J AU Ford, BK Ingersoll-Dayton, B Burgio, K AF Ford, Bryan Keith Ingersoll-Dayton, Berit Burgio, Kathryn TI Care Transition Experiences of Older Veterans and Their Caregivers SO HEALTH & SOCIAL WORK LA English DT Article DE caregiving; care transitions; health care; veterans ID FOLLOW-UP; QUALITY; INFORMATION; TECHNOLOGY; ELDERS AB This study's main objective was to examine care transition experiences of older veterans and their caregivers. Fifty patients age 65 years and older, discharged from a Veterans Affairs Medical Center hospital, completed the Care Transitions Measure-15 (TM) survey three to four weeks postdischarge. Seven patients and six caregivers participated in semistructured interviews. Overall, the quality of care transitions was rated as good; however, some items were indicated as problematic for veterans. Themes that emerged included agreeableness, frustration with complex information, caregiver education, and the timing and methods of information delivery. These findings have implications for all clinical staff working with veterans, and particularly for social workers facilitating care transitions for veterans and their caregivers. C1 [Ford, Bryan Keith] Birmingham VA Med Ctr, Mental Hlth Intens Case Management Program, 700 South 19th St, Birmingham, AL 35233 USA. [Ford, Bryan Keith; Burgio, Kathryn] Birmingham VA Med Ctr, GRECC, 700 South 19th St, Birmingham, AL 35233 USA. [Ingersoll-Dayton, Berit] Univ Michigan, Sch Social Work, Joint Doctoral Program Social Work & Social Sci, Ann Arbor, MI 48109 USA. RP Ford, BK (reprint author), Birmingham VA Med Ctr, Mental Hlth Intens Case Management Program, 700 South 19th St, Birmingham, AL 35233 USA.; Ford, BK (reprint author), Birmingham VA Med Ctr, GRECC, 700 South 19th St, Birmingham, AL 35233 USA. EM bryanford@uabmc.edu NR 40 TC 0 Z9 0 U1 3 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0360-7283 EI 1545-6854 J9 HEALTH SOC WORK JI Health Soc. Work PD MAY PY 2016 VL 41 IS 2 BP 129 EP 138 DI 10.1093/hsw/hlw009 PG 10 WC Social Work SC Social Work GA DM5PJ UT WOS:000376401800009 PM 27263203 ER PT J AU Hanson, L VandeVusse, L Jerme, M Abad, CL Safdar, N AF Hanson, Lisa VandeVusse, Leona Jerme, Martha Abad, Cybele L. Safdar, Nasia TI Probiotics for Treatment and Prevention of Urogenital Infections in Women: A Systematic Review SO JOURNAL OF MIDWIFERY & WOMENS HEALTH LA English DT Review DE probiotics; urogenital; infections; women's health; systematic review ID VULVO-VAGINAL CANDIDIASIS; LACTOBACILLUS-RHAMNOSUS GR-1; PLACEBO-CONTROLLED TRIAL; BACTERIAL VAGINOSIS; DOUBLE-BLIND; METRONIDAZOLE THERAPY; ORAL USE; VAGINITIS; TABLETS; ANTIBIOTICS AB Introduction: Probiotics are a complementary and integrative therapy useful in the treatment and prevention of urogenital infections in women. This study extends the work of researchers who systematically investigated the scientific literature on probiotics to prevent or treat urogenital infections. Methods: A systematic review was conducted to determine the efficacy of probiotics for prevention and/or treatment of urogenital infections in adult women from January 1, 2008, through June 30, 2015. We searched in CINAHL, MEDLINE, Cochrane Central Register of Controlled Trials, Web of Science, Dissertations and Theses, and Alt-HealthWatch. After removing duplicates and studies that did not meet inclusion criteria, 20 studies were reviewed. All included at least one species of Lactobacillus probiotic as an intervention for treatment or prevention of urogenital infections. Data extracted included samples, settings, study designs, intervention types, reported outcomes, follow-up periods, and results. We evaluated all randomized controlled trials for risk of bias and made quality appraisals on all studies. Results: Fourteen of the studies focused on bacterial vaginosis (BV), 3 on urinary tract infections (UTIs), 2 on vulvovaginal candidiasis, and one on human papillomavirus (HPV) as identified on Papanicolaou test. Studies were heterogeneous in terms of design, intervention, and outcomes. Four studies were of good quality, 9 of fair, and 7 poor. Probiotic interventions were effective for treatment and prevention of BV, prevention of recurrences of candidiasis and UTIs, and clearing HPV lesions. No study reported significant adverse events related to the probiotic intervention. Discussion: The quality of the studies in this systematic review varied. Although clinical practice recommendations were limited by the strength of evidence, probiotic interventions were effective in treatment and prevention of urogenital infections as alternatives or co-treatments. More good quality research is needed to strengthen the body of evidence needed for application by clinicians. (C) 2016 by the American College of Nurse-Midwives. C1 [Hanson, Lisa] Marquette Univ, Coll Nursing, Midwifery Program, Milwaukee, WI 53233 USA. [Hanson, Lisa] Aurora Midwifery & Wellness Ctr, Milwaukee, WI 53233 USA. [VandeVusse, Leona] Marquette Univ, Coll Nursing, Milwaukee, WI 53233 USA. [Jerme, Martha] Marquette Univ, Raynor Mem Lib, Milwaukee, WI 53233 USA. [Abad, Cybele L.] Univ Philippines, Philippine Gen Hosp, Manila, Philippines. [Safdar, Nasia] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med & Infect Dis, Madison, WI USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Res, Madison, WI 53705 USA. RP Hanson, L (reprint author), Marquette Univ, Coll Nursing, Nurse Midwifery Program, 530 N 16th St, Milwaukee, WI 53201 USA. EM lisa.hanson@mu.edu NR 45 TC 2 Z9 2 U1 5 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-9523 EI 1542-2011 J9 J MIDWIFERY WOM HEAL JI J. Midwifery Women Health PD MAY-JUN PY 2016 VL 61 IS 3 SI SI BP 339 EP 355 DI 10.1111/jmwh.12472 PG 17 WC Nursing SC Nursing GA DM7AC UT WOS:000376503200006 PM 27218592 ER PT J AU Garrido, MM Prigerson, HG Bao, YH Maciejewski, PK AF Garrido, Melissa M. Prigerson, Holly G. Bao, Yuhua Maciejewski, Paul K. TI Chemotherapy Use in the Months Before Death and Estimated Costs of Care in the Last Week of Life SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Chemotherapy; end of life; advanced cancer; costs of care; financial toxicity ID CANCER-PATIENTS END; OF-LIFE; CLINICAL ONCOLOGY; AMERICAN SOCIETY; MEDICARE BENEFICIARIES; PROSPECTIVE COHORT; ASSOCIATIONS; PREFERENCES; STATEMENT; TOXICITY AB Context. Considerable attention has been paid to the disproportionately high costs of care for patients nearing death, yet little is known about the costs associated with chemotherapy use among end-stage cancer patients. Objectives. To compare costs of care other than chemotherapy in the last week of life based on whether cancer patients were using chemotherapy in the months just before death. Methods. A total of 311 patients with advanced cancer who died between 2002 and 2008 were studied. Data included medical records, patient baseline surveys (median four months before death), and postmortem interviews of caregivers and clinicians. Costs of care were estimated based on reports of death site and services other than chemotherapy received in the week before death (e.g., resuscitation). We tested whether end-of-life (EOL) care preferences, do-not-resuscitate order completion, or EOL discussions accounted for relationships between chemotherapy use and estimated care costs. Results. Half (50.5%) of patients were receiving chemotherapy at baseline. Estimated EOL care costs for patients with baseline chemotherapy use (median = $2681) were significantly higher than for patients without baseline chemotherapy use (median = $1092) (P = 0.003). This relationship persisted after adjusting for sociodemographic and clinical characteristics in a generalized linear model (mean incremental cost = $2681, 95% confidence interval $611-$4751, P = 0.01). None of the psychosocial variables accounted for the relationship between chemotherapy use and estimated care costs. Conclusion. Chemotherapy for end-stage cancer patients is associated with higher estimated EOL care costs. Given evidence of limited benefit and potential harm of chemotherapy for end-stage cancer patients, the cost-effectiveness of such care is questioned and further study warranted. (C) 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved. C1 [Garrido, Melissa M.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Garrido, Melissa M.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Prigerson, Holly G.; Bao, Yuhua; Maciejewski, Paul K.] Weill Cornell Med Coll, New York, NY USA. RP Prigerson, HG (reprint author), Weill Cornell Med Coll, New York Presbyterian Hosp, Ctr Res End Life Care, 525 East 68th St,Box 39,1404 Baker Pavil, New York, NY 10065 USA. EM hgp2001@med.cornell.edu OI Garrido, Melissa/0000-0002-8986-3536 FU HSRD VA [CDP 12-255]; NCI NIH HHS [R01 CA106370, R35 CA197730, U54 CA156732]; NIA NIH HHS [P30 AG028741]; NIMH NIH HHS [R01 MH063892]; NIMHD NIH HHS [R01 MD007652] NR 42 TC 4 Z9 4 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD MAY PY 2016 VL 51 IS 5 BP 875 EP + DI 10.1016/j.jpainsymman.2015.12.323 PG 9 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DM7CJ UT WOS:000376510700014 PM 26899821 ER PT J AU Soban, LM Finley, EP Miltner, RS AF Soban, Lynn M. Finley, Erin P. Miltner, Rebecca S. TI Identifying Patterns in Implementation of Hospital Pressure Ulcer Prevention Programs A Multisite Qualitative Study SO JOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING LA English DT Article DE Nursing; Organization and delivery of care; Pressure ulcer prevention; Qualitative evaluation ID HEALTH-CARE AB PURPOSE: To describe the presence or absence of key components of hospital pressure ulcer (PU) prevention programs in 6 acute care hospitals. DESIGN: Multisite comparative case study. SUBJECTS AND SETTING: Using purposeful selection based on PU rates (high vs low) and hospital size, 6 hospitals within the Veterans Health Administration health care system were invited to participate. Key informant interviews (n = 48) were conducted in each of the 6 participating hospitals among individuals playing key roles in PU prevention: senior nursing leadership (n = 9), nurse manager (n = 7), wound care specialist (n = 6), frontline RNs (n = 26). METHODS: Qualitative data were collected during face-to-face, semistructured interviews. Interview protocols were tailored to each interviewee's role with a core set of common questions covering 3 major content areas: (1) practice environment (eg, policies and wound care specialists), (2) current prevention practices (eg, conduct of PU risk assessment and skin inspection), and (3) barriers to PU prevention. We conducted structured coding of 5 key components of PU prevention programs and cross-case analysis to identify patterns in operationalization and implementation of program components across hospitals based on facility size and PU rates (low vs high). RESULTS: All hospitals had implemented all PU prevention program components. Component operationalization varied considerably across hospitals. Wound care specialists were integral to the operationalization of the 4 other program components examined; however, staffing levels and work assignments of wound care specialists varied widely. Patterns emerged among hospitals with low and high PU rates with respect to wound care specialist staffing, data monitoring, and staff education. CONCLUSION: We found hospital-level variations in PU prevention programs. Wound care specialist staffing may represent a potential point of leverage in achieving other PU program components, particularly performance monitoring and staff education. C1 [Soban, Lynn M.] Cedars Sinai Med Ctr, Nursing Res & Dev, 8700 Beverly Blvd,Ste 2021, Los Angeles, CA 90048 USA. [Soban, Lynn M.] Vet Affairs Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implementat, North Hills, CA USA. [Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Miltner, Rebecca S.] Univ Alabama, Dept Family Community & Hlth Syst, Sch Nursing, Birmingham, W Midlands, England. RP Soban, LM (reprint author), Cedars Sinai Med Ctr, Nursing Res & Dev, 8700 Beverly Blvd,Ste 2021, Los Angeles, CA 90048 USA. EM lynn.soban@cshs.org OI Miltner, Rebecca/0000-0002-4653-0328; Finley, Erin/0000-0003-4497-7721 FU VA HSRD [NRI 10-124-2, CDA 06-301] FX This work was supported by VA HSR&D (Project # NRI 10-124-2). At the time of this work, Dr Soban was supported by a Career Development Award from the VA HSR&D Service (Project # CDA 06-301). NR 19 TC 1 Z9 1 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1071-5754 EI 1528-3976 J9 J WOUND OSTOMY CONT JI J. Wound Ostomy Cont. Nurs. PD MAY-JUN PY 2016 VL 43 IS 3 BP 248 EP 253 DI 10.1097/WON.0000000000000228 PG 6 WC Nursing SC Nursing GA DM6KL UT WOS:000376460800005 PM 27167318 ER PT J AU Park, LG Beatty, A Stafford, Z Whooley, MA AF Park, Linda G. Beatty, Alexis Stafford, Zoey Whooley, Mary A. TI Mobile Phone Interventions for the Secondary Prevention of Cardiovascular Disease SO PROGRESS IN CARDIOVASCULAR DISEASES LA English DT Review DE Cardiovascular disease; Mobile health; Text messaging; Mobile applications; Mobile phone; Systematic review ID RANDOMIZED CONTROLLED-TRIAL; CORONARY-HEART-DISEASE; IMPROVE MEDICATION ADHERENCE; TEXT MESSAGING INTERVENTION; CARDIAC REHABILITATION; FAILURE PATIENTS; PHYSICAL-ACTIVITY; SELF-MANAGEMENT; ARTERY-DISEASE; RISK REDUCTION AB Mobile health in the form of text messaging and mobile applications provides an innovative and effective approach to promote prevention and management of cardiovascular disease (CVD); however, the magnitude of these effects is unclear. Through a comprehensive search of databases from 2002-2016, we conducted a quantitative systematic review. The selected studies were critically evaluated to extract and summarize pertinent characteristics and outcomes. A large majority of studies (22 of 28, 79%) demonstrated text messaging, mobile applications, and telemonitoring via mobile phones were effective in improving outcomes. Some key factors associated with successful interventions included personalized messages with tailored advice, greater engagement (2-way text messaging, higher frequency of messages), and use of multiple modalities. Overall, text messaging appears more effective than smartphone-based interventions. Incorporating principles of behavioral activation will help promote and sustain healthy lifestyle behaviors in patients with CVD that result in improved clinical outcomes. (C) 2016 Elsevier Inc. All rights reserved. C1 [Park, Linda G.] Univ Calif San Francisco, Dept Community Hlth Syst, 2 Koret Way,Box 0608, San Francisco, CA 94143 USA. [Beatty, Alexis] Vet Affairs Puget Sound Med Ctr, Cardiol Sect, Seattle, WA USA. [Beatty, Alexis] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Stafford, Zoey] Univ Calif San Francisco, Dept Social & Behav Sci, San Francisco, CA 94143 USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Whooley, Mary A.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. RP Park, LG (reprint author), Univ Calif San Francisco, Dept Community Hlth Syst, 2 Koret Way,Box 0608, San Francisco, CA 94143 USA. EM Linda.Park@ucsf.edu; beattya@uw.edu; Zoey.Stafford@ucsf.edu; Mary.Whooley@ucsf.edu RI Emchi, Karma/Q-1952-2016 FU National Center for Advancing Translational Sciences of the NIH [KL2TR000143] FX Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the NIH under Award Number KL2TR000143. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. NR 54 TC 1 Z9 1 U1 4 U2 14 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0033-0620 EI 1873-1740 J9 PROG CARDIOVASC DIS JI Prog. Cardiovasc. Dis. PD MAY-JUN PY 2016 VL 58 IS 6 BP 639 EP 650 DI 10.1016/j.pcad.2016.03.002 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DM7PJ UT WOS:000376552200009 PM 27001245 ER PT J AU Horan, WP Jimenez, AM Lee, J Wynn, JK Eisenberger, NI Green, MF AF Horan, William P. Jimenez, Amy M. Lee, Junghee Wynn, Jonathan K. Eisenberger, Naomi I. Green, Michael F. TI Pain empathy in schizophrenia: an fMRI study SO SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE LA English DT Article DE empathy; schizophrenia; self-related processing; pain; affective empathy; social cognition ID PSYCHIATRIC RATING-SCALE; PERSPECTIVE-TAKING; SOCIAL-NEUROSCIENCE; EMOTION REGULATION; PREFRONTAL CORTEX; COGNITIVE EMPATHY; BRAIN ACTIVATION; SELF; METAANALYSIS; DYSFUNCTION AB Although it has been proposed that schizophrenia is characterized by impaired empathy, several recent studies found intact neural responses on tasks measuring the affective subdomain of empathy. This study further examined affective empathy in 21 schizophrenia outpatients and 21 healthy controls using a validated pain empathy paradigm with two components: (i) observing videos of people described as medical patients who were receiving a painful sound stimulation treatment; (ii) listening to the painful sounds (to create regions of interest). The observing videos component incorporated experimental manipulations of perspective taking (instructions to imagine 'Self' vs 'Other' experiencing pain) and cognitive appraisal (information about whether treatment was 'Effective' vs 'Not Effective'). When considering activation across experimental conditions, both groups showed similar dorsal anterior cingulate cortex (dACC) and anterior insula (AI) activation while merely observing others in pain. However, there were group differences associated with perspective taking: controls showed relatively greater dACC and AI activation for the Self vs Other contrast whereas patients showed relatively greater activation in these and additional regions for the Other vs Self contrast. Although patients demonstrated grossly intact neural activity while observing others in pain, they showed more subtle abnormalities when required to toggle between imagining themselves vs others experiencing pain. C1 [Horan, William P.; Jimenez, Amy M.; Lee, Junghee; Wynn, Jonathan K.; Green, Michael F.] VA Greater Angeles Healthcare Syst, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. [Horan, William P.; Jimenez, Amy M.; Lee, Junghee; Wynn, Jonathan K.; Eisenberger, Naomi I.; Green, Michael F.] Univ Calif Los Angeles, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. RP Horan, WP (reprint author), VA Greater Angeles Healthcare Syst, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.; Horan, WP (reprint author), Univ Calif Los Angeles, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM horan@ucla.edu RI Lee, Junghee/C-5226-2014 OI Lee, Junghee/0000-0001-9567-8700 FU VA Career Development Award; NIMH [MH065707, MH43292] FX Support for this study came from a VA Career Development Award (William P. Horan, PhD.) and NIMH Grants MH065707 and MH43292 (Michael F. Green, PhD). NR 68 TC 1 Z9 1 U1 5 U2 14 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1749-5016 EI 1749-5024 J9 SOC COGN AFFECT NEUR JI Soc. Cogn. Affect. Neurosci. PD MAY PY 2016 VL 11 IS 5 BP 783 EP 792 DI 10.1093/scan/nsw002 PG 10 WC Neurosciences; Psychology; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA DM9AH UT WOS:000376655100010 PM 26746181 ER PT J AU Schenning, KJ Murchison, CF Mattek, NC Silbert, LC Kaye, JA Quinn, JF AF Schenning, Katie J. Murchison, Charles F. Mattek, Nora C. Silbert, Lisa C. Kaye, Jeffrey A. Quinn, Joseph F. TI Surgery is associated with ventricular enlargement as well as cognitive and functional decline SO ALZHEIMERS & DEMENTIA LA English DT Article DE Epidemiology; Anesthesia; Surgery; Cognitive decline; Postoperative; Apolipoprotein E epsilon 4; Alzheimer's disease; Cohort study; Volumetric MRI ID ILLNESS RATING-SCALE; ALZHEIMERS-DISEASE; ANESTHESIA; DEMENTIA; DYSFUNCTION; POPULATION; PROGRESSION; IMPAIRMENT; RISK; OLD AB Introduction: In preclinical studies, surgery/anesthesia contribute to cognitive decline and enhance neuropathologic changes underlying Alzheimer's disease (AD). Nevertheless, the link between surgery, anesthesia, apolipoprotein E epsilon 4 (APOE epsilon 4), and AD remains unclear. Methods: We performed a retrospective cohort analysis of two prospective longitudinal aging studies. Mixed-effects statistical models were used to assess the relationship between surgical/anesthetic exposure, the APOE genotype, and rate of change in measures of cognition, function, and brain volumes. Results: The surgical group (n = 182) experienced a more rapid rate of deterioration compared with the nonsurgical group (n = 345) in several cognitive, functional, and brain magnetic resonance imaging measures. Furthermore, there was a significant synergistic effect of anesthesia/surgery exposure and presence of the APOE epsilon 4 allele in the decline of multiple cognitive and functional measures. Discussion: These data provide insight into the role of surgical exposure as a risk factor for cognitive and functional decline in older adults. (C) 2015 Alzheimer's Association. Published by Elsevier Inc. All rights reserved. C1 [Schenning, Katie J.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. [Murchison, Charles F.; Kaye, Jeffrey A.; Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Mattek, Nora C.; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Oregon Ctr Aging & Technol, Portland, OR 97201 USA. [Silbert, Lisa C.; Kaye, Jeffrey A.; Quinn, Joseph F.] Portland VA Med Ctr, Dept Neurol, Portland, OR USA. [Silbert, Lisa C.; Kaye, Jeffrey A.; Quinn, Joseph F.] Oregon Hlth & Sci Univ, Layton Aging & Alzheimers Dis Ctr, Portland, OR 97201 USA. RP Schenning, KJ (reprint author), Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. EM malcore@ohsu.edu OI Schenning, Katie/0000-0002-1784-0749 FU Agency for Healthcare Research and Quality [K12 HD 043488]; National Institutes of Health [P30AG024978, R01AG024059, P30AG008017, 1U10NS077350-01, R01AG036772, R01AG043398]; Merit Review Grant from U.S. Department of Veterans Affairs FX This study was funded in part by an Agency for Healthcare Research and Quality-funded BIRCWH K12 award (K12 HD 043488) and by grants from the National Institutes of Health (P30AG024978, R01AG024059, P30AG008017, 1U10NS077350-01, R01AG036772, and R01AG043398) and a Merit Review Grant from the U.S. Department of Veterans Affairs. The authors thank Kirk Hogan, for reviewing drafts of the article. NR 25 TC 6 Z9 6 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD MAY PY 2016 VL 12 IS 5 BP 590 EP 597 DI 10.1016/j.jalz.2015.10.004 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA DM0RT UT WOS:000376054200008 PM 26610898 ER PT J AU Mathews, R Fonarow, GC Li, S Peterson, ED Rumsfeld, JS Heidenreich, PA Roe, MT Oetgen, WJ Jollis, JG Cannon, CP de Lemos, JA Wang, TY AF Mathews, Robin Fonarow, Gregg C. Li, Shuang Peterson, Eric D. Rumsfeld, John S. Heidenreich, Paul A. Roe, Matthew T. Oetgen, William J. Jollis, James G. Cannon, Christopher P. de Lemos, James A. Wang, Tracy Y. CA Natl Cardiovasc Data Registry TI Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines SO AMERICAN HEART JOURNAL LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; MORTALITY-RATES; PROGRAM; ASSOCIATION; MANAGEMENT AB Background Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines (ACTION Registry-GWTG) was designed to measure and improve the treatment and outcomes of patients with acute myocardial infarction (AMI), yet it is unknown whether performance of Medicare Hospital Compare metrics and outcomes differ between hospitals participating versus those not participating in the registry. Methods Using 2007 to 2010 Hospital Compare data, we matched participating to nonparticipating hospitals based on teaching status, size, percutaneous coronary intervention capability, and baseline (2007) Hospital Compare AMI process measure performance/We used linear mixed modeling to compare 2010 Hospital Compare process measure adherence, 30-day risk-adjusted mortality, and readmission rates/We repeated these analyses after stratification according to baseline performance level. Results Compared with nonparticipating hospitals, those participating were larger (median 288 vs 139 beds, P < .0001), more often teaching hospitals (18.8% vs 6.3%, P < .0001), and more likely had interventional catheterization lab capabilities (85.7% vs 34.0%, P < .0001)/Among 502 matched pairs of participating and nonparticipating hospitals, we found high levels of process measure adherence in both 2007 and 2010, with minimal differences between them/Rates of 30-day mortality and readmission in 2010 were also similar between both groups/Results were consistent across strata of baseline performance level. Conclusions In this observational analysis, there were no significant differences in the performance of Hospital Compare process measures or outcomes between hospitals in Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines and other hospitals not in the registry/However, baseline performance on the Hospital Compare process measures was very high in both groups, suggesting the need for new quality improvement foci to further improve patient outcomes. C1 [Mathews, Robin; Li, Shuang; Peterson, Eric D.; Roe, Matthew T.; Jollis, James G.; Wang, Tracy Y.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Ahmanson UCLA Cardiomyopathy Ctr, Los Angeles, CA USA. [Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA. [Heidenreich, Paul A.] VA Palo Alto Hlth Syst, Palo Alto, CA USA. [Oetgen, William J.] Amer Coll Cardiol, Washington, DC USA. [Cannon, Christopher P.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [de Lemos, James A.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. RP Mathews, R (reprint author), Duke Univ, Med Ctr, 2400 Pratt St, Durham, NC 27705 USA. EM robin.mathews@duke.edu FU American College of Cardiology; American Heart Association; Eli Lilly Company; Janssen Pharmaceutical Products; Society of Thoracic Surgeons; KAI Pharmaceuticals; Sanofi-Aventis; AstraZeneca; Gilead; Lilly; Medicines Company; Canyon Pharmaceuticals; American College of Cardiology Foundation's NCDR; Society of Cardiovascular Patient Care; American College of Emergency Physicians; Society of Hospital Medicine FX Dr Peterson reports research funding from the American College of Cardiology, the American Heart Association, Eli Lilly & Company, Janssen Pharmaceutical Products, and the Society of Thoracic Surgeons (significant), and consulting for Merck & Co (modest), Boehringer Ingelheim, Genentech, Janssen Pharmaceutical Products, and Sanofi-Aventis (significant).; Dr Roe reports research funding from Eli Lilly & Company, KAI Pharmaceuticals, and Sanofi-Aventis; educational activities from Astra Zeneca and Janssen Pharmaceuticals (both modest); consulting for Bristol Myers Squibb, Eli Lilly & Company, Glaxo Smith Kline, and Regeneron (all modest) and Merck & Company, Janssen Pharmaceuticals, and Daiichi-Sankyo (all significant).; Dr Wang reports research funding from AstraZeneca, Gilead, Lilly, The Medicines Company, and Canyon Pharmaceuticals (all significant); educational activities or lectures (generates money for Duke) for AstraZeneca (modest); consulting (including CME) for Medco (modest) and American College of Cardiology (significant).; This research was supported by the American College of Cardiology Foundation's NCDR. The views expressed in this manuscript represent those of the author(s) and do not necessarily represent the official views of the NCDR or its associated professional societies identified at www.ncdr.com.; ACTION Registry-GWTG is an initiative of the American College of Cardiology Foundation and the American Heart Association, with partnering support from the Society of Cardiovascular Patient Care, the American College of Emergency Physicians, and the Society of Hospital Medicine. NR 19 TC 0 Z9 0 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD MAY PY 2016 VL 175 BP 1 EP 8 DI 10.1016/j.ahj.2016.01.008 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DL5CP UT WOS:000375655200002 PM 27179718 ER PT J AU Reed, BN Fox, ER Konig, M Jackevicius, CA Masoudi, FA Rabinstein, AA Page, RL AF Reed, Brent N. Fox, Erin R. Konig, Madeleine Jackevicius, Cynthia A. Masoudi, Frederick A. Rabinstein, Alejandro A. Page, Robert L., II TI The impact of drug shortages on patients with cardiovascular disease: causes, consequences, and a call to action SO AMERICAN HEART JOURNAL LA English DT Article ID HEALTH; CRISIS AB Shortages of cardiovascular drugs have become increasingly common, representing an ongoing public health crisis. Given few therapeutic alternatives to many of the drugs in short supply, these shortages also pose a major challenge for cardiovascular care professionals. Although changes in the regulatory environment have led to some improvements in recent years, problems involving manufacturing processes remain the most common underlying cause. Because of the complex nature of drug shortages, sustainable solutions to prevent and mitigate them will require collaboration between regulatory agencies, drug manufacturers, and other key stakeholder groups. In this report, we describe the scope of the cardiovascular drug shortage crisis in the United States, including its underlying causes and the efforts currently being made to address it. Furthermore, we provide specific recommendations for how cardiovascular care professionals can be involved in efforts to limit the impact of drug shortages on patient care as well as policy changes aimed at preventing and mitigating them. C1 [Reed, Brent N.] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA. [Fox, Erin R.] Univ Utah Hlth Care, Salt Lake City, UT USA. [Konig, Madeleine] Amer Heart Assoc, Dallas, TX USA. [Jackevicius, Cynthia A.] Western Univ Hlth Sci, Pomona, CA USA. [Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Jackevicius, Cynthia A.] Univ Toronto, Inst Clin Evaluat Sci, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Univ Hlth Network, Toronto, ON, Canada. [Masoudi, Frederick A.] Univ Colorado, Anschuts Med Campus, Aurora, CO USA. [Rabinstein, Alejandro A.] Mayo Clin, Rochester, MN USA. [Page, Robert L., II] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA. RP Reed, BN (reprint author), Univ Maryland, Sch Pharm, Dept Pharm Practice & Sci, BCPS AQ Cardiol, 20 N Pine St,Off S428, Baltimore, MD 21201 USA. EM breed@rx.umaryland.edu NR 41 TC 1 Z9 1 U1 1 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD MAY PY 2016 VL 175 BP 130 EP 141 DI 10.1016/j.ahj.2016.02.004 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DL5CP UT WOS:000375655200016 PM 27179732 ER PT J AU Lum, HD Sudore, RL AF Lum, Hillary D. Sudore, Rebecca L. TI Advance Care Planning and Goals of Care Communication in Older Adults with Cardiovascular Disease and Multi-Morbidity SO CLINICS IN GERIATRIC MEDICINE LA English DT Article DE Advance care planning; Goals of care; Patient-doctor relationship; Communication; Older adults; Cardiovascular disease; Multi-morbidity ID RANDOMIZED CONTROLLED-TRIAL; SURROGATE DECISION-MAKING; OF-LIFE CARE; HEART-FAILURE; ELDERLY-PATIENTS; HOSPITALIZED-PATIENTS; SERIOUS ILLNESS; DIRECTIVES; END; ASSOCIATION AB This article provides an approach to advance care planning (ACP) and goals of care communication in older adults with cardiovascular disease and multi-morbidity. The goal of ACP is to ensure that the medical care patients receive is aligned with their values and preferences. In this article, the authors outline common benefits and challenges to ACP for older adults with cardiovascular disease and multimorbidity. Recognizing that these patients experience diverse disease trajectories and receive care in multiple health care settings, the authors provide practical steps for multidisciplinary teams to integrate ACP into brief clinic encounters. C1 [Lum, Hillary D.] VA Eastern Colorado Geriatr Res Educ & Clin Ctr G, 1055 Clermont St, Denver, CO 80220 USA. [Lum, Hillary D.] Univ Colorado, Sch Med, Dept Med, Div Geriatr Med, 12631 East 17th Ave,B-179, Aurora, CO 80045 USA. [Sudore, Rebecca L.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med, Div Geriatr, SFVAMC 4150 Clement St 151R, San Francisco, CA 94121 USA. RP Lum, HD (reprint author), 12631 East 17th Ave,B-179, Aurora, CO 80045 USA. EM Hillary.Lum@ucdenver.edu FU National Palliative Care Research Center (NPCRC) FX The authors do not have commercial or financial conflicts of interest to disclose. This work was supported in by part by a Junior Faculty Career Development Award from the National Palliative Care Research Center (NPCRC). NR 38 TC 0 Z9 0 U1 4 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0690 EI 1879-8853 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD MAY PY 2016 VL 32 IS 2 BP 247 EP + DI 10.1016/j.cger.2016.01.011 PG 15 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA DM2XZ UT WOS:000376212700004 PM 27113144 ER PT J AU Hennig, S Svensson, EM Niebecker, R Fourie, PB Weiner, MH Bonora, S Peloquin, CA Gallicano, K Flexner, C Pym, A Vis, P Olliaro, PL McIlleron, H Karlsson, MO AF Hennig, Stefanie Svensson, Elin M. Niebecker, Ronald Fourie, P. Bernard Weiner, Marc H. Bonora, Stefano Peloquin, Charles A. Gallicano, Keith Flexner, Charles Pym, Alex Vis, Peter Olliaro, Piero L. McIlleron, Helen Karlsson, Mats O. TI Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article ID DIAGNOSED PULMONARY TUBERCULOSIS; ACQUIRED RIFAMYCIN RESISTANCE; EARLY BACTERICIDAL ACTIVITY; VIRUS-INFECTED PATIENTS; SPUTUM VIABLE COUNTS; HEALTHY-VOLUNTEERS; ANTIRETROVIRAL THERAPY; RIFAMPICIN; RITONAVIR; LOPINAVIR/RITONAVIR AB Extensive but fragmented data from existing studies were used to describe the drug-drug interaction between rifabutin and HIV PIs and predict doses achieving recommended therapeutic exposure for rifabutin in patients with HIV-associated TB, with concurrently administered PIs. Individual-level data from 13 published studies were pooled and a population analysis approach was used to develop a pharmacokinetic model for rifabutin, its main active metabolite 25-O-desacetyl rifabutin (des-rifabutin) and drug-drug interaction with PIs in healthy volunteers and patients who had HIV and TB (TB/HIV). Key parameters of rifabutin affected by drug-drug interaction in TB/HIV were clearance to routes other than des-rifabutin (reduced by 76%-100%), formation of the metabolite (increased by 224% in patients), volume of distribution (increased by 606%) and distribution to the peripheral compartment (reduced by 47%). For des-rifabutin, clearance was reduced by 35%-76% and volume of distribution increased by 67%-240% in TB/HIV. These changes resulted in overall increased exposure to rifabutin in TB/HIV patients by 210% because of the effects of PIs and 280% with ritonavir-boosted PIs. Given together with non-boosted or ritonavir-boosted PIs, rifabutin at 150 mg once daily results in similar or higher exposure compared with rifabutin at 300 mg once daily without concomitant PIs and may achieve peak concentrations within an acceptable therapeutic range. Although 300 mg of rifabutin every 3 days with boosted PI achieves an average equivalent exposure, intermittent doses of rifamycins are not supported by current guidelines. C1 [Hennig, Stefanie] Univ Queensland, Sch Pharm, Brisbane, Qld, Australia. [Hennig, Stefanie; Svensson, Elin M.; Niebecker, Ronald; Karlsson, Mats O.] Uppsala Univ, Dept Pharmaceut Biosci, Uppsala, Sweden. [Fourie, P. Bernard] Univ Pretoria, Dept Med Microbiol, ZA-0002 Pretoria, South Africa. [Weiner, Marc H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Weiner, Marc H.] Vet Adm Med Ctr, San Antonio, TX USA. [Bonora, Stefano] Univ Turin, Dept Med Sci, Unit Infect Dis, Turin, Italy. [Peloquin, Charles A.] Univ Florida, Coll Pharm, Gainesville, FL USA. [Peloquin, Charles A.] Univ Florida, Emerging Pathogens Inst, Gainesville, FL USA. [Gallicano, Keith] Novum Pharmaceut Res Serv, Murrieta, CA USA. [Flexner, Charles] Johns Hopkins Adult AIDS Clin Trials Unit, Div Clin Pharmacol, Baltimore, MD USA. [Pym, Alex] MRC, TB Res Unit, Durban, South Africa. [Pym, Alex] KwaZulu Natal Res Inst TB & HIV K RITH, Durban, South Africa. [Vis, Peter] Janssen Infect Dis BVBA, Beerse, Belgium. [Olliaro, Piero L.] WHO, Special Programme Res & Training Trop Dis TDR, CH-1211 Geneva, Switzerland. [McIlleron, Helen] Univ Cape Town, Dept Med, Div Clin Pharmacol, ZA-7925 Cape Town, South Africa. RP Hennig, S (reprint author), Univ Queensland, Pharm Australia Ctr Excellence, Sch Pharm, 20 Cornwall St, Woolloongabba, Qld 4102, Australia. EM s.hennig@uq.edu.au RI Hennig, Stefanie/E-4426-2011 OI Hennig, Stefanie/0000-0001-5972-3711; Pym, Alexander/0000-0002-6260-8180; McIlleron, Helen/0000-0002-0982-6226 FU Special Programme for Research and Training in Tropical Diseases (TDR) of the World Health Organization (WHO); National Research Foundation of South Africa [90729]; National Institute of Allergy and Infectious Diseases, National Institute of Mental Health (NIMH) [U01AI068636]; National Institute of Dental and Craniofacial Research (NIDCR); United States Government Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention; Centers for Disease Control and Prevention [AI69464]; Swedish Research Council [521-2011-3442]; Australian Centre of Pharmacometrics FX This project was supported by the Special Programme for Research and Training in Tropical Diseases (TDR) of the World Health Organization (WHO). H. M. was supported in part by the National Research Foundation of South Africa (Grant Number 90729). Support for one dataset37 that contributed data to this study received funding (Award Number U01AI068636) from the National Institute of Allergy and Infectious Diseases, National Institute of Mental Health (NIMH), and National Institute of Dental and Craniofacial Research (NIDCR); two other datasets contributing data were supported by the United States Government Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention. AIDS CTU Grant # AI69464, or the NCT (National Clinical Trials) number for ACTG 365, NCT00000877.; E. M. S. and M. O. K. were supported by the Swedish Research Council (Grant Number 521-2011-3442). The NONMEM license used was supported in part by the Australian Centre of Pharmacometrics. A portion of the computations was performed on resources provided by the Swedish National Infrastructure for Computing (SNIC) at UPPMAX. NR 75 TC 1 Z9 1 U1 5 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 EI 1460-2091 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD MAY PY 2016 VL 71 IS 5 BP 1330 EP 1340 DI 10.1093/jac/dkv470 PG 11 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA DM4BT UT WOS:000376291300027 PM 26832753 ER PT J AU Samantaray, S Das, A Matzelle, DC Yu, SP Wei, L Varma, A Ray, SK Banik, NL AF Samantaray, Supriti Das, Arabinda Matzelle, Denise C. Yu, Shan P. Wei, Ling Varma, Abhay Ray, Swapan K. Banik, Naren L. TI Administration of low dose estrogen attenuates persistent inflammation, promotes angiogenesis, and improves locomotor function following chronic spinal cord injury in rats SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE angiogenesis; axonal protection; chronic spinal cord injury; locomotor function; low dose estrogen; neuroprotection ID PRIMARY CORTICAL-NEURONS; APOPTOTIC CELL-DEATH; KAPPA-B ACTIVATION; CALPAIN INHIBITOR; SECONDARY INJURY; CONTROLLED-TRIAL; RECEPTOR-ALPHA; FIBROTIC SCAR; BRAIN-INJURY; BLOOD-FLOW AB Spinal cord injury (SCI) causes loss of neurological function and, depending upon the severity of injury, may lead to paralysis. Currently, no FDA-approved pharmacotherapy is available for SCI. High-dose methylprednisolone is widely used, but this treatment is controversial. We have previously shown that low doses of estrogen reduces inflammation, attenuates cell death, and protects axon and myelin in SCI rats, but its effectiveness in recovery of function is not known. Therefore, the goal of this study was to investigate whether low doses of estrogen in post-SCI would reduce inflammation, protect cells and axons, and improve locomotor function during the chronic phase of injury. Injury (40g.cm force) was induced at thoracic 10 in young adult male rats. Rats were treated with 10 or 100 mu g 17 beta-estradiol (estrogen) for 7days following SCI and compared with vehicle-treated injury and laminectomy (sham) controls. Histology (H&E staining), immunohistofluorescence, Doppler laser technique, and Western blotting were used to monitor tissue integrity, gliosis, blood flow, angiogenesis, the expression of angiogenic factors, axonal degeneration, and locomotor function (Basso, Beattie, and Bresnahan rating) following injury. To assess the progression of recovery, rats were sacrificed at 7, 14, or 42days post injury. A reduction in glial reactivity, attenuation of axonal and myelin damage, protection of cells, increased expression of angiogenic factors and microvessel growth, and improved locomotor function were found following estrogen treatment compared with vehicle-treated SCI rats. These results suggest that treatment with a very low dose of estrogen has significant therapeutic implications for the improvement of locomotor function in chronic SCI. C1 [Samantaray, Supriti; Das, Arabinda; Matzelle, Denise C.; Varma, Abhay; Banik, Naren L.] Med Univ S Carolina, Dept Neurol & Neurosurg, 96 Jonathan Lucas St, Charleston, SC 29425 USA. [Yu, Shan P.; Wei, Ling] Emory Univ, Sch Med, Dept Anesthesia, Atlanta, GA 30322 USA. [Ray, Swapan K.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA. [Banik, Naren L.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Banik, NL (reprint author), Med Univ S Carolina, Dept Neurol & Neurosurg, 96 Jonathan Lucas St, Charleston, SC 29425 USA.; Banik, NL (reprint author), Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. EM baniknl@musc.edu FU NIH [R01-NS31622, R01-NS45967]; Veterans Administration [1IOBX00126, 1IOBX002349]; South Carolina State Spinal Cord Research Fund [SCIRF-2015P-01, SCIRF-2015P-04, SCIRF-2015-I-01]; Department of Neurosurgery, MUSC; MUSC-CTSA program FX This work was supported in part by funding from NIH (R01-NS31622, R01-NS45967); Veterans Administration (1IOBX00126; 1IOBX002349); South Carolina State Spinal Cord Research Fund (SCIRF-2015P-01; SCIRF-2015P-04; SCIRF-2015-I-01); Department of Neurosurgery, MUSC; and MUSC-CTSA program. We also thank Dr. M. Kelly Guyton for her valuable contribution to this work. The authors declare no conflict of interest. NR 74 TC 4 Z9 4 U1 2 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3042 EI 1471-4159 J9 J NEUROCHEM JI J. Neurochem. PD MAY PY 2016 VL 137 IS 4 BP 604 EP 617 DI 10.1111/jnc.13610 PG 14 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA DL9YX UT WOS:000376000500011 PM 26998684 ER PT J AU Li, XF Shorter, D Kosten, TR AF Li, Xiaofan Shorter, Daryl Kosten, Thomas R. TI Buprenorphine Prescribing: To Expand or Not to Expand SO JOURNAL OF PSYCHIATRIC PRACTICE LA English DT Review DE buprenorphine; prescription opioids; abuse; diversion; regulation; policy ID EXTENDED-RELEASE OXYCODONE; PRESCRIPTION MONITORING PROGRAMS; SUBSTANCE-ABUSE TREATMENT; OFFICE-BASED TREATMENT; OPIOID DEPENDENCE; UNITED-STATES; NONMEDICAL USE; PRIMARY-CARE; MAINTENANCE THERAPY; TREATMENT-SEEKING AB As a result of the prescription opioid epidemic in the United States, there has been an increasing need for effective treatment interventions, both pharmacological and nonpharmacological. Buprenorphine has emerged as a critical component of the treatment of opioid use disorder, yet its adoption has not been without some concerns. This article first reviews the pharmacology, clinical use, and US legislative action related to buprenorphine, followed by a discussion of the misuse and diversion of buprenorphine in the United States as well as internationally. We then explore the impact of buprenorphine abuse as well as discussing strategies for its reduction, including changes in policy, prescription and pharmacy monitoring, and continuing medical education for guiding and improving clinical practice. C1 [Li, Xiaofan; Shorter, Daryl; Kosten, Thomas R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, 2002 Holcombe Blvd,Bldg 121,Off 121-137, Houston, TX 77030 USA. [Shorter, Daryl; Kosten, Thomas R.] Michael E DeBakey VA Med Ctr, Houston, TX USA. RP Shorter, D (reprint author), Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, 2002 Holcombe Blvd,Bldg 121,Off 121-137, Houston, TX 77030 USA.; Shorter, D (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Res Serv Line, 2002 Holcombe Blvd,Bldg 121,Off 121-137, Houston, TX 77030 USA. EM shorter@bcm.edu FU VA CSRD [I01BX007080]; NIH/NIDA [P50 DA018197] FX D.S. received support from VA CSR&D I01BX007080. T.R.K. received support from NIH/NIDA P50 DA018197. X.L. declares no conflicts of interest. NR 66 TC 1 Z9 1 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1527-4160 EI 1538-1145 J9 J PSYCHIATR PRACT JI J. Psychiatr. Pract. PD MAY PY 2016 VL 22 IS 3 BP 183 EP 192 DI 10.1097/PRA.0000000000000154 PG 10 WC Psychiatry SC Psychiatry GA DM0CM UT WOS:000376010200004 PM 27123798 ER PT J AU Chavez, LJ Williams, EC Lapham, GT Rubinsky, AD Kivlahan, DR Bradley, KA AF Chavez, Laura J. Williams, Emily C. Lapham, Gwen T. Rubinsky, Anna D. Kivlahan, Daniel R. Bradley, Katharine A. TI Changes in Patient-Reported Alcohol-Related Advice Following Veterans Health Administration Implementation of Brief Alcohol Interventions SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS LA English DT Article ID PRIMARY-CARE SETTINGS; AFFAIRS PRIMARY-CARE; SERVICES-TASK-FORCE; BEHAVIORAL-COUNSELING INTERVENTIONS; VA PRIMARY-CARE; FINANCIAL INCENTIVES; MEDICAL HOME; AUDIT-C; DRINKING; QUALITY AB Objective: Brief alcohol interventions are recommended for primary care patients who screen positive for alcohol misuse, but implementation is challenging. The U.S. Veterans Health Administration (Veterans Affairs [VA]) implemented brief interventions for patients with alcohol misuse in 2008, and rates of brief interventions documented in the electronic medical record increased from 24% to 78% (2008-2011). This study examined whether an independent measure of brief interventions-patient-reported alcohol-related advice-also increased among VA outpatients who screened positive for alcohol misuse on a mailed survey. Method: This retrospective cross-sectional study included VA outpatient respondents to the VA's Survey of Healthcare Experiences of Patients (SHEP; 2007-2011) who reported past-year alcohol use and answered a question about alcohol-related advice. Alcohol-related advice was defined as a report of past-year advice from a VA clinician to abstain from or reduce drinking. The adjusted prevalence of alcohol related advice among patients who screened positive for alcohol misuse (SHEP AUDIT-C >= 5) was estimated for each year. Results: Among patients with alcohol misuse (n = 61,843), the adjusted prevalence of alcohol-related advice increased from 40.4% (95% CI [39.3%, 41.5%]) in 2007 to 55.5% (95% CI [53.3%, 57.8%]) in 2011. Rates of alcohol related advice increased significantly each year except the last. Conclusions: The VA's efforts to implement brief interventions were associated with increased patient-reported alcohol-related advice over time, with a majority of patients with alcohol misuse reporting its receipt. Other systems considering similar approaches to implementation may benefit from collecting patient-reported measures of brief interventions for an additional perspective on implementation. C1 [Chavez, Laura J.; Williams, Emily C.; Lapham, Gwen T.; Rubinsky, Anna D.; Kivlahan, Daniel R.; Bradley, Katharine A.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1660 S Columbian Way S-152, Seattle, WA 98108 USA. [Williams, Emily C.; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Lapham, Gwen T.; Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA. [Rubinsky, Anna D.; Kivlahan, Daniel R.; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. [Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA. RP Chavez, LJ (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1660 S Columbian Way S-152, Seattle, WA 98108 USA. EM ljchavez@uw.edu FU Veteran's Affairs (VA) Substance Use Disorders Quality Enhancement Research Initiative (SUD QUERI); National Institutes of Health Agency for Healthcare Research and Quality (AHRQ) Dissertation Grant [NIH 1R36HS022800-01]; Career Development Award from VA Health Services Research Development [CDA 12-276]; Group Health Research Institute; VA's Seattle Center of Excellence for Substance Abuse Teaching and Education FX This study was supported by the Veteran's Affairs (VA) Substance Use Disorders Quality Enhancement Research Initiative (SUD QUERI). Dr. Chavez was supported by a National Institutes of Health Agency for Healthcare Research and Quality (AHRQ) Dissertation Grant (NIH 1R36HS022800-01). Dr. Williams is supported by a Career Development Award from VA Health Services Research & Development (CDA 12-276). Dr. Bradley's support for this project was from Group Health Research Institute and the VA's Seattle Center of Excellence for Substance Abuse Teaching and Education. Views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs, the University of Washington, or Group Health Research Institute. Laura J. Chavez, Emily C. Williams, Gwen T. Lapham, Anna D. Rubinsky, Daniel R. Kivlahan, and Katharine A. Bradley do not have any conflicts of interest to disclose. NR 51 TC 0 Z9 0 U1 2 U2 3 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 1937-1888 EI 1938-4114 J9 J STUD ALCOHOL DRUGS JI J. Stud. Alcohol Drugs PD MAY PY 2016 VL 77 IS 3 BP 500 EP 508 PG 9 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA DL9NH UT WOS:000375969500017 PM 27172583 ER PT J AU Cohen, NL Heinz, AJ Ilgen, M Bonn-Miller, MO AF Cohen, Nicole L. Heinz, Adrienne J. Ilgen, Mark Bonn-Miller, Marcel O. TI Pain, Cannabis Species, and Cannabis Use Disorders SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS LA English DT Article ID EXPERIENCES; EXTRACTS; MEMORY; THC AB Objective: The purpose of this study was to examine whether individuals who used medical cannabis for chronic pain were at increased risk for cannabis use problems compared with individuals who used medical cannabis for other reasons (e.g., anxiety, insomnia, and muscle spasms). An additional aim was to determine whether individuals who used cannabis for chronic pain, as well as those who reported greater within-group pain levels, demonstrated a species preference (i.e., sativa, indica, hybrids) and the extent to which species preference was associated with cannabis use problems. Method: Participants were 163 medical cannabis users (77% male), recruited from a medical marijuana dispensary in California, who completed assessments of medical cannabis use motives, history, preferences (species type), and problems, as well as current pain level. Results: Individuals who used cannabis to manage chronic pain experienced fewer cannabis use problems than those who did not use it for pain; among those who used it for pain, the average pain level in the past week was not associated with cannabis use problems. Furthermore, individuals who used cannabis for chronic pain were more likely to use indica over sativa. Preference for indica was associated with fewer cannabis use problems than preference for hybrid species. Conclusions: Individuals who use cannabis to manage chronic pain may be at a lower risk for cannabis use problems, relative to individuals who use it for other indications, potentially as a function of their species preference. C1 [Cohen, Nicole L.; Heinz, Adrienne J.; Bonn-Miller, Marcel O.] Vet Affairs Palo Alto Hlth Care Syst, Natl Ctr PTSD, 795 Willow Rd 152-MPD, Menlo Pk, CA 94025 USA. [Heinz, Adrienne J.; Bonn-Miller, Marcel O.] Vet Affairs Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Menlo Pk, CA 94025 USA. [Ilgen, Mark] Vet Affairs Ctr Clin Management Res, Ann Arbor, MI USA. [Ilgen, Mark] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Bonn-Miller, Marcel O.] Philadelphia VA Med Ctr, Ctr Excellence Subst Abuse Treatment & Educ, Philadelphia, PA USA. [Bonn-Miller, Marcel O.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Bonn-Miller, MO (reprint author), Vet Affairs Palo Alto Hlth Care Syst, Natl Ctr PTSD, 795 Willow Rd 152-MPD, Menlo Pk, CA 94025 USA. EM Marcel.Bonn-Miller@va.gov FU San Francisco Patient and Resource Center FX This work was supported by a donation to Marcel O. Bonn-Miller from the San Francisco Patient and Resource Center, and a Department of Veterans Affairs Rehabilitation Research and Development Career Development Award-2 awarded to Adrienne J. Heinz. The expressed views do not necessarily represent those of the Department of Veterans Affairs. NR 19 TC 1 Z9 1 U1 11 U2 17 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 1937-1888 EI 1938-4114 J9 J STUD ALCOHOL DRUGS JI J. Stud. Alcohol Drugs PD MAY PY 2016 VL 77 IS 3 BP 515 EP 520 PG 6 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA DL9NH UT WOS:000375969500019 PM 27172585 ER PT J AU Hsu, JJ Katz, R Chirinos, JA Jacobs, DR Duprez, DA Peralta, CA AF Hsu, Jeffrey J. Katz, Ronit Chirinos, Julio A. Jacobs, David R., Jr. Duprez, Daniel A. Peralta, Carmen A. TI Arterial wave reflections and kidney function decline among persons with preserved estimated glomerular filtration rate: the Multi-Ethnic Study of Atherosclerosis SO JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION LA English DT Article DE Arterial wave reflections; kidney function; reflection magnitude; pulse pressure amplification ID STAGE RENAL-DISEASE; ALL-CAUSE MORTALITY; CARDIOVASCULAR EVENTS; HYPERTENSIVE PATIENTS; AORTIC STIFFNESS; PULSE PRESSURE; BLOOD-PRESSURE; OLDER-ADULTS; VELOCITY; PROGRESSION AB Differences in arterial wave reflections have been associated with increased risk for heart failure and mortality. Whether these measures are also associated with kidney function decline is not well established. Reflection magnitude (RM, defined as the ratio of the backward wave [P-b] to that of the forward wave [P-f], augmentation index (AIx), and pulse pressure amplification (PPA) were derived from radial tonometry measures among 5232 participants free of cardiovascular disease who were enrolled in the Multiethnic Study of Atherosclerosis. Kidney function was estimated by creatinine and cystatin C measurements, as well as albumin-to-creatinine ratio. We evaluated the associations of P-b, P-f, RM, AIx, and PPA with annualized estimated glomerular filtration rate (eGFR) change and rapid kidney function decline over 5 years, using generalized linear mixed models and logistic regression, respectively. Of the study participants, 48% were male, mean age was 62 years, mean eGFR and median albumin-to-creatinine ratio at baseline were 84 mL/min/1.73 m(2) and 5.3 mg/g, respectively. In demographically adjusted models, both Pb and Pf had similarly strong associations with kidney function decline; compared to those in the lowest tertiles, the persons in the highest tertiles of P-b and P-f had a 1.01 and 0.99 mL/min/1.73 m(2)/year faster eGFR decline, respectively (P < .05). However, these associations were attenuated after adjustment for systolic blood pressure. We found no significant associations between RM, AIx, or PPA and kidney function decline. In conclusion, the reflected and forward wave components were similarly associated with kidney function decline, and these associations were explained by differences in systolic blood pressure. (C) 2016 American Society of Hypertension. All rights reserved. C1 [Hsu, Jeffrey J.; Peralta, Carmen A.] Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Katz, Ronit] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA. [Chirinos, Julio A.] Univ Penn, Dept Med, Div Cardiovasc, Perelman Sch Med, Philadelphia, PA 19104 USA. [Chirinos, Julio A.] Univ Ghent, Div Cardiol, B-9000 Ghent, Belgium. [Jacobs, David R., Jr.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA. [Duprez, Daniel A.] Univ Minnesota, Sch Med, Div Cardiol, Minneapolis, MN 55455 USA. RP Peralta, CA (reprint author), Univ Calif San Francisco, Gen Internal Med Sect, VA Med Ctr, 111A1,4150 Clement St, San Francisco, CA 94121 USA. EM Carmenalicia.peralta@ucsf.edu FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95169, R01-HL-098382]; National Insitute of Diabetes and Digestive and Kidney Diseases [R03DK095877]; National Institutes of Health [1R56HL124073-01A1, 1R01HL121510-01A1]; American Heart Association [5R21AG043802-02]; Robert Wood Johnson Harold Amos Award; National Institutes of Health; Veterans Affairs Administration; American College of Radiology Imaging Network; Bristol-Myers Squibb; Fukuda Denshi FX This research was supported by contracts N01-HC-95159 through N01-HC-95169, grant R01-HL-098382 from the National Heart, Lung, and Blood Institute, grant R03DK095877 from the National Insitute of Diabetes and Digestive and Kidney Diseases, grants 1R56HL124073-01A1 and 1R01HL121510-01A1 from the National Institutes of Health, and grant 5R21AG043802-02 from the American Heart Association. C.A. Peralta is supported by a Robert Wood Johnson Harold Amos Award. Dr. Chirinos receives research funding from the National Institutes of Health, Veterans Affairs Administration, the American College of Radiology Imaging Network, Bristol-Myers Squibb, and Fukuda Denshi. NR 35 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-1711 EI 1878-7436 J9 J AM SOC HYPERTENS JI J. Am. Soc. Hypertens. PD MAY PY 2016 VL 10 IS 5 BP 438 EP 446 DI 10.1016/j.jash.2016.02.014 PG 9 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DM3CF UT WOS:000376223700014 PM 27085205 ER PT J AU Townsend, RR Rosendorff, C Nichols, WW Edwards, DG Chirinos, JA Fernhall, B Cushman, WC AF Townsend, Raymond R. Rosendorff, Clive Nichols, Wilmer W. Edwards, David G. Chirinos, Julio A. Fernhall, Bo Cushman, William C. TI Comment on ASH position article on central blood pressure and waveform analysis Response SO JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION LA English DT Letter ID CARDIOVASCULAR EVENTS; ARTERY C1 [Townsend, Raymond R.; Chirinos, Julio A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Rosendorff, Clive] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Rosendorff, Clive] James J Peters VA Med Ctr, Bronx, NY USA. [Nichols, Wilmer W.] Univ Florida, Coll Med, Dept Med, Div Med, Gainesville, FL USA. [Nichols, Wilmer W.] Univ Florida, Div Cardiovasc Med, Gainesville, FL USA. [Edwards, David G.] Univ Delaware, Dept Kinesiol & Appl Physiol, Coll Hlth Sci, Newark, DE USA. [Fernhall, Bo] Univ Illinois, Coll Appl Hlth Sci, Chicago, IL USA. [Cushman, William C.] Univ Tennessee, Coll Med, Memphis, TN USA. [Cushman, William C.] Univ Tennessee, Vet Affairs Med Ctr, Memphis, TN USA. RP Townsend, RR (reprint author), Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-1711 EI 1878-7436 J9 J AM SOC HYPERTENS JI J. Am. Soc. Hypertens. PD MAY PY 2016 VL 10 IS 5 BP 470 EP 471 DI 10.1016/j.jash.2016.03.181 PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DM3CF UT WOS:000376223700019 PM 27085206 ER PT J AU Kluger, BM Herlofson, K Chou, KL Lou, JS Goetz, CG Lang, AE Weintraub, D Friedman, J AF Kluger, Benzi M. Herlofson, Karen Chou, Kelvin L. Lou, Jau-Shin Goetz, Christopher G. Lang, Anthony E. Weintraub, Daniel Friedman, Joseph TI Parkinson's disease-related fatigue: A case definition and recommendations for clinical research SO MOVEMENT DISORDERS LA English DT Review DE Parkinson's disease; fatigue; case definition; clinical research ID CANCER-RELATED FATIGUE; MULTIPLE-SCLEROSIS; MENTAL FATIGUE; PHYSICAL FATIGUE; MUSCLE FATIGUE; RATING-SCALES; IMPACT SCALE; DEPRESSION; MOTOR; MAGNETOENCEPHALOGRAPHY AB Fatigue is one of the most common and disabling symptoms in Parkinson's disease (PD). Since fatigue was first described as a common feature of PD 20 years ago, little progress has been made in understanding its causes or treatment. Importantly, PD patients attending the 2013 World Parkinson Congress voted fatigue as the leading symptom in need of further research. In response, the Parkinson Disease Foundation and ProjectSpark assembled an international team of experts to create recommendations for clinical research to advance this field. The working group identified several areas in which shared standards would improve research quality and foster progress including terminology, diagnostic criteria, and measurement. Terminology needs to (1) clearly distinguish fatigue from related phenomena (eg, sleepiness, apathy, depression); (2) differentiate subjective fatigue complaints from objective performance fatigability; and (3) specify domains affected by fatigue and causal factors. We propose diagnostic criteria for PD-related fatigue to guide participant selection for clinical trials and add rigor to mechanistic studies. Recommendations are made for measurement of subjective fatigue complaints, performance fatigability, and neurophysiologic changes. We also suggest areas in which future research is needed to address methodological issues and validate or optimize current practices. Many limitations in current PD-related fatigue research may be addressed by improving methodological standards, many of which are already being successfully applied in clinical fatigue research in other medical conditions (eg, cancer, multiple sclerosis). (c) 2016 International Parkinson and Movement Disorder Society C1 [Kluger, Benzi M.] Univ Colorado, Sch Med, Dept Neurol, Aurora, CO 80045 USA. [Herlofson, Karen] Sorlandet Hosp Arendal, Dept Neurol, Arendal, Norway. [Chou, Kelvin L.] Univ Michigan, Sch Med, Dept Neurol, Ann Arbor, MI USA. [Chou, Kelvin L.] Univ Michigan, Sch Med, Dept Neurosurg, Ann Arbor, MI USA. [Lou, Jau-Shin] Univ N Dakota, Sch Med & Hlth Sci, Dept Neurol, Dept Neurol,Sanford Hlth, Fargo, ND USA. [Goetz, Christopher G.] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA. [Lang, Anthony E.] Toronto Western Hosp, Morton & Gloria Shulman Movement Disorders Clin, Toronto, ON M5T 2S8, Canada. [Lang, Anthony E.] Toronto Western Hosp, Edmond J Safra Program Parkinsons Dis, Toronto, ON M5T 2S8, Canada. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis & Mental Illness Res Educ & Clin C, Philadelphia, PA USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, MIRECC, Philadelphia, PA USA. [Friedman, Joseph] Brown Univ, Butler Hosp, Alpert Med Sch, Providence, RI 02912 USA. RP Kluger, BM (reprint author), Univ Colorado, Dept Neurol, Mail Stop B-185,12631 East 17th Ave, Aurora, CO 80045 USA. EM benzi.kluger@ucdenver.edu FU NINDS NIH HHS [K02 NS080885, P50 NS091856] NR 61 TC 7 Z9 8 U1 5 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD MAY PY 2016 VL 31 IS 5 BP 625 EP 631 DI 10.1002/mds.26511 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA DL9CR UT WOS:000375939500005 PM 26879133 ER PT J AU Siu, AL Bibbins-Domingo, K Grossman, DC Baumann, LC Davidson, KW Ebell, M Garcia, FAR Gillman, M Herzstein, J Kemper, AR Krist, AH Kurth, AE Owens, DK Phillips, WR Phipps, MG Pignone, MP AF Siu, Albert L. Bibbins-Domingo, Kirsten Grossman, David C. Baumann, Linda Ciofu Davidson, Karina W. Ebell, Mark Garcia, Francisco A. R. Gillman, Matthew Herzstein, Jessica Kemper, Alex R. Krist, Alex H. Kurth, Ann E. Owens, Douglas K. Phillips, William R. Phipps, Maureen G. Pignone, Michael P. CA USPSTF TI Screening for Depression in Adults: US Preventive Services Task Force Recommendation Statement EDITORIAL COMMENT SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material C1 [Siu, Albert L.] Mt Sinai Sch Med, New York, NY USA. [Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Bibbins-Domingo, Kirsten] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Grossman, David C.] Grp Hlth Res Inst, Seattle, WA USA. [Baumann, Linda Ciofu] Univ Wisconsin, Madison, WI USA. [Davidson, Karina W.] Columbia Univ, New York, NY USA. [Ebell, Mark] Univ Georgia, Athens, GA 30602 USA. [Garcia, Francisco A. R.] Pima Cty Dept Hlth, Tucson, AZ USA. [Gillman, Matthew] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Gillman, Matthew] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Kemper, Alex R.] Duke Univ, Durham, NC USA. [Krist, Alex H.] Fairfax Family Practice, Fairfax, VA USA. [Krist, Alex H.] Virginia Commonwealth Univ, Richmond, VA USA. [Kurth, Ann E.] NYU, New York, NY USA. [Owens, Douglas K.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Owens, Douglas K.] Stanford Univ, Stanford, CA 94305 USA. [Phillips, William R.] Univ Washington, Seattle, WA 98195 USA. [Phipps, Maureen G.] Brown Univ, Providence, RI 02912 USA. [Pignone, Michael P.] Univ N Carolina, Chapel Hill, NC USA. RP Siu, AL (reprint author), Mt Sinai Sch Med, New York, NY USA.; Siu, AL (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7828 EI 1533-9866 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD MAY PY 2016 VL 71 IS 5 BP 283 EP 285 PG 3 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DM3VL UT WOS:000376274700011 ER PT J AU Ruzek, JI Eftekhari, A Rosen, CS Crowley, JJ Kuhn, E Foa, EB Hembree, EA Karlin, BE AF Ruzek, Josef I. Eftekhari, Afsoon Rosen, Craig S. Crowley, Jill J. Kuhn, Eric Foa, Edna B. Hembree, Elizabeth A. Karlin, Bradley E. TI Effects of a Comprehensive Training Program on Clinician Beliefs About and Intention to Use Prolonged Exposure Therapy for PTSD SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY LA English DT Article DE cognitive-behavioral; exposure therapy; Prolonged Exposure; PTSD; treatment ID POSTTRAUMATIC-STRESS-DISORDER; AFFAIRS-HEALTH-CARE; IMPLEMENTATION; DISSEMINATION; TRIAL; FRAMEWORK; TRENDS AB Objective: Evidence for treatment efficacy does not guarantee adoption in clinical practice. Attitudinal "buy-in" from clinicians is also important. This study examines evaluation data from a national training program in an evidence-based treatment for PTSD, Prolonged Exposure (PE) therapy, to assess changes in clinician beliefs related to the importance of specific treatment goals, PE outcome expectations, self-efficacy to deliver PE, perceived time and emotional burdens associated with delivering PE, and intentions to use PE. Method: Training included both an interactive workshop and posttraining telephone consultation. Participants were 943 licensed mental health clinicians who treated veterans with PTSD. They completed questionnaires before and after the workshop, and after consultation. Results: Results indicated that workshop participation was associated with significant increases in perceptions of the importance of helping patients improve by employing PE, expectations that patients would benefit from PE, and self-efficacy to deliver PE, and with reduced expectations of negative patient outcomes and concerns about distressing patients. The workshop alone had little impact on expected clinician emotional burden and no impact on anticipated time burden. Participation in ongoing case consultation was associated with additional increases in expected positive patient outcomes and clinician self-efficacy and further reductions in concerns about distressing patients and negative patient outcomes. Unlike the workshop, consultation was associated with decreased expectancies that PE would take too much time and would be emotionally burdensome to provide. Conclusion: Overall, the results suggest that the combination of workshop and ongoing consultation can significantly improve beliefs likely to affect treatment adoption. C1 [Ruzek, Josef I.; Eftekhari, Afsoon; Rosen, Craig S.; Crowley, Jill J.; Kuhn, Eric] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Disseminat & Training Div, 795 Willow Rd, Menlo Pk, CA 94025 USA. [Foa, Edna B.; Hembree, Elizabeth A.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Karlin, Bradley E.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, US Dept Vet Affairs,Mental Hlth Serv,Cent Off, Baltimore, MD 21218 USA. RP Ruzek, JI (reprint author), VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Disseminat & Training Div, 795 Willow Rd, Menlo Pk, CA 94025 USA. EM Josef.Ruzek@va.gov NR 33 TC 4 Z9 4 U1 3 U2 4 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1942-9681 EI 1942-969X J9 PSYCHOL TRAUMA-US JI Psychol. Trauma PD MAY PY 2016 VL 8 IS 3 BP 348 EP 355 DI 10.1037/tra0000004 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DM2VJ UT WOS:000376205900012 PM 26524541 ER PT J AU Gupta, PK Ramanan, B Grossman, L Gupta, H Fang, X MacTaggart, JN Lynch, TG Baxter, BT Pipinos, II AF Gupta, Prateek K. Ramanan, Bala Grossman, Leonid Gupta, Himani Fang, Xiang MacTaggart, Jason N. Lynch, Thomas G. Baxter, B. Timothy Pipinos, Iraklis I. TI Outcomes of Aortic Surgery for Abdominal Aortic Graft Infections SO VASCULAR AND ENDOVASCULAR SURGERY LA English DT Article DE aortic; graft; infection; resection ID VASCULAR SURGICAL-PROCEDURES; ANEURYSM REPAIR; RISK CALCULATOR; VOLUME; REPLACEMENT; VALIDATION; MANAGEMENT; REMOVAL AB Background: Literature on postoperative outcomes following aortic surgery for aortic graft infection (AGI) is limited by relatively small sample sizes, resulting in lack of national benchmarks for quality of care. We report in-hospital outcomes following abdominal aortic surgery for AGI and identify factors associated with postoperative complications using the Nationwide Inpatient Sample (NIS) database. Methods: Patients who underwent aortic graft resection for AGI were identified from the 2002 to 2008 NIS database, a multicenter database capturing 20% of all US admissions. Multivariable logistic regression analyses were performed. Results: Among 394 patients (men: 73.4%) who underwent abdominal aortic surgery for AGI, 53% of the admissions were emergent/urgent. A significant trend for decreasing number of abdominal aortic surgery for AGIs per year was observed (Pearson r correlation: -.96; P = .0006). Over the same time span, a significant correlation was also seen with decrease in open and increase in endovascular aortic aneurysm repairs in the NIS database. In-hospital rates of overall postoperative morbidity and mortality were 68.3% and 19.8%, respectively. In-hospital rates of postoperative respiratory failure, renal failure, and cardiac arrest were 35.5%, 14.2%, and 8.9%, respectively. Median length of stay was 26 days, with median hospital charges being US$184 162. On multivariable analysis, increase in age per year (odds ratio [OR] 1.07; 95% confidence interval [CI]: 1.03-1.12) was independently associated with postoperative morbidity, while higher hospital volume for this procedure was protective (OR: 0.71; 95% CI: 0.56-0.89). No preoperative factors were independently associated with postoperative mortality. Conclusion: Incidence of abdominal aortic surgery for AGI has progressively declined over the span of our study in association with decreased open and increased endovascular aortic aneurysm repairs. Aortic surgery for AGI is associated with very high morbidity and mortality rates along with prolonged lengths of stay and elevated hospital charges. The outcomes of operations for AGI are better in younger patients and higher volume hospitals. C1 [Gupta, Prateek K.] Univ Tennessee, Hlth Sci Ctr, Dept Surg, 1325 Eastmoreland Ave,Ste 310, Memphis, TN 38104 USA. [Gupta, Prateek K.] Methodist Le Bonheur Healthcare, Dept Surg, Memphis, TN USA. [Ramanan, Bala] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. [Grossman, Leonid; MacTaggart, Jason N.; Baxter, B. Timothy; Pipinos, Iraklis I.] Univ Nebraska Med Ctr, Dept Surg, Omaha, NE USA. [Gupta, Himani] William S Middleton Mem Vet Adm Med Ctr, Dept Med, Madison, WI USA. [Fang, Xiang] Creighton Univ, Biostat Core, Omaha, NE 68178 USA. [Lynch, Thomas G.] Vet Hlth Adm, Washington, DC USA. [Pipinos, Iraklis I.] VA Nebraska Western Iowa Hlth Care Syst, Dept Surg, Omaha, NE USA. RP Gupta, PK (reprint author), Univ Tennessee, Hlth Sci Ctr, Dept Surg, 1325 Eastmoreland Ave,Ste 310, Memphis, TN 38104 USA.; Gupta, PK (reprint author), Methodist Le Bonheur Healthcare, 1325 Eastmoreland Ave,Ste 310, Memphis, TN 38104 USA. EM pgupta5@uthsc.edu FU Charles and Mary Heider Fund for Excellence in Vascular Surgery; NIH [R01 AG034995] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part by the Charles and Mary Heider Fund for Excellence in Vascular Surgery and in part by the NIH grant R01 AG034995. NR 32 TC 0 Z9 0 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1538-5744 EI 1938-9116 J9 VASC ENDOVASC SURG JI Vasc. Endovasc. Surg. PD MAY PY 2016 VL 50 IS 4 BP 256 EP 260 DI 10.1177/1538574416637443 PG 5 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA DM3NO UT WOS:000376253400009 PM 27102873 ER PT J AU Jovanovich, A Chonchol, M Smits, G Ginde, A AF Jovanovich, Anna Chonchol, Michel Smits, Gerard Ginde, Adit TI FIBROBLAST GROWTH FACTOR 23 AND RISK OF INFECTION AMONG OLDER ADULTS SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Spring Clinical Meetings of the National-Kidney Foundation CY APR 27-MAY 01, 2016 CL Boston, MA SP Natl Kidney Fdn C1 [Jovanovich, Anna] Denver VA Med Ctr, Denver, CO USA. [Jovanovich, Anna; Chonchol, Michel; Smits, Gerard; Ginde, Adit] Univ Colorado, Sch Med, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAY PY 2016 VL 67 IS 5 MA 162 BP A59 EP A59 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA DK3WZ UT WOS:000374849400163 ER PT J AU Jovanovich, A Chonchol, M Smits, G Ginde, A AF Jovanovich, Anna Chonchol, Michel Smits, Gerard Ginde, Adit TI FALLS ARE NOT ASSOCIATED WITH FIBROBLAST GROWTH FACTOR 23 LEVELS AMONG OLDER ADULTS SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Spring Clinical Meetings of the National-Kidney Foundation CY APR 27-MAY 01, 2016 CL Boston, MA SP Natl Kidney Fdn C1 [Jovanovich, Anna] Denver VA Med Ctr, Denver, CO USA. [Jovanovich, Anna; Chonchol, Michel; Smits, Gerard; Ginde, Adit] Univ Colorado, Sch Med, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAY PY 2016 VL 67 IS 5 MA 161 BP A59 EP A59 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA DK3WZ UT WOS:000374849400162 ER PT J AU Crabbe, JC Schlumbohm, JP Hack, W Barkley-Levenson, AM Metten, P Lattal, KM AF Crabbe, John C. Schlumbohm, Jason P. Hack, Wyatt Barkley-Levenson, Amanda M. Metten, Pamela Lattal, K. Matthew TI Fear conditioning in mouse lines genetically selected for binge-like ethanol drinking SO ALCOHOL LA English DT Article DE Ethanol binge drinking; Conditioned fear; Selective breeding; Drinking in the dark; Mouse; Genetics ID POSTTRAUMATIC-STRESS-DISORDER; ANIMAL-MODEL; DBA/2 MICE; PTSD; GLUCOCORTICOIDS; INTOXICATION; EXTINCTION; AMYGDALA; C57BL/6; WOMEN AB The comorbidity of substance- and alcohol-use disorders (AUD) with other psychiatric conditions, especially those related to stress such as post-traumatic stress disorder (PTSD), is well-established. Binge-like intoxication is thought to be a crucial stage in the development of the chronic relapsing nature of the addictions, and self-medication through binge-like drinking is commonly seen in PTSD patients. We have selectively bred two separate High Drinking in the Dark (HDID-1 and HDID-2) mouse lines to reach high blood ethanol concentrations (BECs) after a 4-h period of access to 20% ethanol starting shortly after the onset of circadian dark. As an initial step toward the eventual goal of employing binge-prone HDID mice to study PTSD-like behavior including alcohol binge drinking, we sought first to determine their ability to acquire conditioned fear. We asked whether these mice acquired, generalized, or extinguished conditioned freezing to a greater or lesser extent than unselected control HS/Npt mice. In two experiments, we trained groups of 16 adult male mice in a standard conditioned fear protocol. Mice were tested for context-elicited freezing, and then, in a novel context, for cue-induced freezing. After extinction tests, renewal of conditioned fear was tested in the original context. Mice of all three genotypes showed typical fear responding. Context paired with shock elicited freezing behavior in a control experiment, but cue unpaired with shock did not. These studies indicate that fear learning per se does not appear to be influenced by genes causing predisposition to binge drinking, suggesting distinct neural mechanisms. However, HDID mice are shown to be a suitable model for studying the role of conditioned fear specifically in binge-like drinking. Published by Elsevier Inc. C1 [Crabbe, John C.; Schlumbohm, Jason P.; Hack, Wyatt; Barkley-Levenson, Amanda M.; Metten, Pamela] VA Portland Hlth Care Syst, Portland Alcohol Res Ctr, Portland, OR 97239 USA. [Crabbe, John C.; Schlumbohm, Jason P.; Hack, Wyatt; Barkley-Levenson, Amanda M.; Metten, Pamela; Lattal, K. Matthew] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. RP Crabbe, JC (reprint author), Portland VA Med Ctr, Res R&D 12, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM crabbe@ohsu.edu FU NIH-NIAAA [AA010760, AA013519, AA020245]; Department of Veterans Affairs [101BX000313]; Department of the Army/DoD-TATRC grant [10245005.05] FX These studies were supported by Grants AA010760, AA013519, and AA020245 from the NIH-NIAAA; by Grant #101BX000313 the Department of Veterans Affairs; and by the Department of the Army/DoD-TATRC grant 10245005.05. We thank Stephanie E. Spence and Lawrence C. Huang for maintaining the colonies and supplying the mice for these experiments. NR 34 TC 0 Z9 0 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-8329 EI 1873-6823 J9 ALCOHOL JI Alcohol PD MAY PY 2016 VL 52 BP 25 EP 32 DI 10.1016/j.alcohol.2016.01.004 PG 8 WC Substance Abuse; Pharmacology & Pharmacy; Toxicology SC Substance Abuse; Pharmacology & Pharmacy; Toxicology GA DL7JA UT WOS:000375815800003 PM 27139234 ER PT J AU Klaustermeyer, WB Choi, SH AF Klaustermeyer, William B. Choi, Soo H. TI A perspective on systemic corticosteroid therapy in severe bronchial asthma in adults SO ALLERGY AND ASTHMA PROCEEDINGS LA English DT Article ID SLOW RESPONSE; STEROID RESPONSIVENESS; ORAL CORTICOSTEROIDS; AIRWAY INFLAMMATION; VETERAN POPULATION; CIGARETTE-SMOKING; REFRACTORY ASTHMA; PULMONARY-DISEASE; DEPENDENT ASTHMA; EXACERBATIONS AB Background: Systemic corticosteroids have been used in the treatment of asthma since 1950 and are still required for the treatment of acute severe asthma and corticosteroid dependent asthma. Objective: To provide an updated overview of clinical considerations of systemic corticosteroids use in severe adult bronchial asthma. Methods: PubMed searches were undertaken of studies published between 1950 and 2015. Results: In this review the following concepts are discussed. 1) The onset of action of intravenous methylprednisone is 1-2 hours with a peak at 4-6 hours and duration of 12-30 hours. 2) Each patient should serve as their own control, using their best flow rates in the previous 6 months to 2 years. 3) The individual response to corticosteroid relates to the degree of obstruction at the time of onset of steroid treatment. 4) The pattern of response is variable but tends to be consistent for an individual patient. 5) In monitoring response to steroids frequent measures of peak expiratory flow rate and forced expiratory flow in 1 second are more useful than complete spirometric and lung mechanic tests measured less often. 6) In most cases oral steroids are as effective as parenteral regimens. 7) Patients usually respond in 3 days to 40 to 100 mg of methylprednisolone equivalent. 8) In corticosteroid resistant asthma consider compliance issues, allergen sensitivity, concomitant conditions, psychiatric factors and drug interactions. 9) Corticosteroid toxicity relates to the total lifetime dosage and serious side effects are usually not observed until a total dosage of 6.8 grams of prednisone equivalent. Conclusion: Until we have a better understanding of the mechanisms of action of glucocorticoids, we will continue to rely on currently available systemic corticosteroids in severe asthma. The intrapatient consistency as discussed in this review, should guide therapy. C1 [Klaustermeyer, William B.; Choi, Soo H.] Vet Affairs Greater Los Angeles Healthcare Syst U, Los Angeles, CA USA. RP Klaustermeyer, WB (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd 111R, Los Angeles, CA 90073 USA. EM william.klaustermeyer@va.gov NR 79 TC 2 Z9 2 U1 0 U2 3 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1088-5412 EI 1539-6304 J9 ALLERGY ASTHMA PROC JI Allergy Asthma Proc. PD MAY-JUN PY 2016 VL 37 IS 3 BP 192 EP 198 DI 10.2500/aap.2016.37.3941 PG 7 WC Allergy SC Allergy GA DL6AG UT WOS:000375718500005 PM 27178888 ER PT J AU Roose, SP Rutherford, BR Wall, MM Thase, ME AF Roose, Steven P. Rutherford, Bret R. Wall, Melanie M. Thase, Michael E. TI Practising evidence-based medicine in an era of high placebo response: number needed to treat reconsidered SO BRITISH JOURNAL OF PSYCHIATRY LA English DT Article ID LATE-LIFE DEPRESSION; ANTIDEPRESSANT EFFICACY; CLINICAL-SIGNIFICANCE; TRIALS; METAANALYSIS; PSYCHOTHERAPY; EXPECTANCY; FREQUENCY; CONTACT; THERAPY AB The number needed to treat (NNT) statistic was developed to facilitate the practice of evidence-based medicine. Placebo was assumed to be therapeutically inert when the NNT was originally conceived, but more recent data for conditions such as major depressive disorder (MDD) suggest that the placebo control condition can have considerable therapeutic effects. Complications arise because the NNT calculated from randomised controlled trials (RCTs) reflects a comparison between medication plus clinical management and placebo plus clinical management, whereas, in the clinical setting, physicians choose between prescribing open medication, observing a patient over time with a supportive approach, and doing nothing. Thus, NNTs derived from clinical trials are not directly relevant to clinical decision-making, because they are based on control conditions that do not exist in standard practice. Additional difficulties may arise when using NNTs to compare alternative treatments for MDD, such as medication and psychotherapy, since these comparisons require the control conditions upon which the respective NNTs are based to be similar.Whereas pill placebo conditions include intensive clinical management and elicit expectations of improvement, attention control conditions for psychotherapy research are less well developed. Often the effects of psychotherapy are gauged against a wait-list control condition, which has substantially fewer therapeutic components than a pill placebo control condition. To improve the clinical utility of NNTs for the treatment of MDD, we advocate effectiveness studies that include treatment conditions resembling actual clinical practice, rather than using placebo-controlled RCTs for this purpose. Until such studies are performed, the effect of bias in comparing NNTs across treatments can be controlled by ensuring that the RCT control conditions upon which the NNTs are based are comparable. C1 [Roose, Steven P.; Rutherford, Bret R.; Wall, Melanie M.] Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, 1051 Riverside Dr,Box 98, New York, NY 10032 USA. [Thase, Michael E.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Thase, Michael E.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA. RP Roose, SP (reprint author), Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, 1051 Riverside Dr,Box 98, New York, NY 10032 USA. EM spr2@cumc.columbia.edu FU National Institute of Mental Health [K23 MH085236, T32 MH015144] FX This work was supported by National Institute of Mental Health grants K23 MH085236 (BRR) and T32 MH015144 (SPR). NR 28 TC 1 Z9 1 U1 4 U2 4 PU ROYAL COLLEGE OF PSYCHIATRISTS PI LONDON PA BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON SW1X 8PG, ENGLAND SN 0007-1250 EI 1472-1465 J9 BRIT J PSYCHIAT JI Br. J. Psychiatry PD MAY PY 2016 VL 208 IS 5 BP 416 EP 420 DI 10.1192/bjp.bp.115.163261 PG 5 WC Psychiatry SC Psychiatry GA DL3DZ UT WOS:000375515700004 PM 27143006 ER PT J AU Armstrong, EJ Chhatriwalla, AK Szerlip, M Swaminathan, RV Patel, RAG AF Armstrong, Ehrin J. Chhatriwalla, Adnan K. Szerlip, Molly Swaminathan, Rajesh V. Patel, Rajan A. G. TI Late Breaking Trials of 2015 in Structural Heart Disease and Peripheral Artery Disease: Commentary Covering ACC, EuroPCR, SCAI, TCT, VIVA, ESC, and AHA SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article ID DRUG-COATED BALLOON; AORTIC-VALVE-REPLACEMENT; TRANSCATHETER; OUTCOMES; REGISTRY; THERAPY; SFA AB With the large number of late breaking clinical trials presented at major meetings, it is often difficult to stay current with advances in interventional cardiology. Therefore, the SCAI Publications Committee summarizes and provides editorial commentary on the most important structural heart and peripheral artery disease late-breaking trials from 2015. (C) 2016 Wiley Periodicals, Inc. C1 [Armstrong, Ehrin J.] Univ Colorado, Boulder, CO 80309 USA. [Armstrong, Ehrin J.] Denver VA Med Ctr, Denver, CO USA. [Chhatriwalla, Adnan K.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA. [Szerlip, Molly] Heart Hosp Baylor Plano, Plano, TX USA. [Swaminathan, Rajesh V.] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA. [Patel, Rajan A. G.] Ochsner Med Ctr, New Orleans, LA USA. RP Armstrong, EJ (reprint author), Univ Colorado, Sch Med, Div Cardiol, VA Eastern Colorado Healthcare Syst, Boulder, CO 80309 USA. EM ehrin.armstrong@gmail.com FU Edwards Lifesciences; Medtronic; St Jude Medical; Abbott Vascular FX EJA is a consultant for Abbott Vascular, Medtronic, Merck, Pfizer, and Spectranetics. AKC reports travel reimbursement from Edwards Lifesciences, Medtronic, St Jude Medical and Abbott Vascular. MS is a speaker for Edwards LifeSciences and Abbott Vascular. RVS has ownership of stock in Boston Scientific Corp. RP none. NR 14 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1522-1946 EI 1522-726X J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD MAY PY 2016 VL 87 IS 6 BP 1020 EP 1026 DI 10.1002/ccd.26473 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DL8MT UT WOS:000375896800008 PM 26947260 ER PT J AU Toledo, RA Qin, YJ Cheng, ZM Gao, Q Iwata, S Silva, GM Prasad, ML Ocal, IT Rao, S Aronin, N Barontini, M Bruder, J Reddick, RL Chen, YD Aguiar, RCT Dahia, PLM AF Toledo, Rodrigo A. Qin, Yuejuan Cheng, Zi-Ming Gao, Qing Iwata, Shintaro Silva, Gustavo M. Prasad, Manju L. Ocal, I. Tolgay Rao, Sarika Aronin, Neil Barontini, Marta Bruder, Jan Reddick, Robert L. Chen, Yidong Aguiar, Ricardo C. T. Dahia, Patricia L. M. TI Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas SO CLINICAL CANCER RESEARCH LA English DT Article ID GIANT-CELL TUMOR; PEDIATRIC GLIOBLASTOMA; RET PROTOONCOGENE; SOMATIC MUTATIONS; DRIVER MUTATIONS; HISTONE H3.3; CANCER; GERMLINE; FAMILY; SUSCEPTIBILITY AB Purpose: Pheochromocytomas and paragangliomas (PPGL) are genetically heterogeneous tumors of neural crest origin, but the molecular basis of most PPGLs is unknown. Experimental Design: We performed exome or transcriptome sequencing of 43 samples from 41 patients. Avalidation set of 136 PPGLs was used for amplicon-specific resequencing. In addition, a subset of these tumors was subjected to microarray-based transcription, protein expression, and histone methylation analysis by Western blotting or immunohistochemistry. In vitro analysis of mutants was performed in cell lines. Results: We detected mutations in chromatin-remodeling genes, including histone-methyltransferases, histone-demethylases, and histones in 11 samples from 8 patients (20%). In particular, we characterized a new cancer syndrome involving PPGLs and giant cell tumors of bone (GCT) caused by a postzygotic G34W mutation of the histone 3.3 gene, H3F3A. Furthermore, mutations in kinase genes were detected in samples from 15 patients (37%). Among those, a novel germline kinase domain mutation of MERTK detected in a patient with PPGL and medullary thyroid carcinoma was found to activate signaling downstream of this receptor. Recurrent germline and somatic mutations were also detected in MET, including a familial case and sporadic PPGLs. Importantly, in each of these three genes, mutations were also detected in the validation group. In addition, a somatic oncogenic hotspot FGFR1 mutation was found in a sporadic tumor. Conclusions: This study implicates chromatin-remodeling and kinase variants as frequent genetic events in PPGLs, many of which have no other known germline driver mutation. MERTK, MET, and H3F3A emerge as novel PPGL susceptibility genes. (C) 2015 AACR. C1 [Toledo, Rodrigo A.; Qin, Yuejuan; Cheng, Zi-Ming; Gao, Qing; Bruder, Jan; Aguiar, Ricardo C. T.; Dahia, Patricia L. M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr,MC 7880, San Antonio, TX 78229 USA. [Iwata, Shintaro] Chiba Canc Ctr, Dept Orthoped Surg, 666-2 Nitonacho, Chiba 2608717, Japan. [Silva, Gustavo M.] NYU, Dept Biol, Ctr Genom & Syst Biol, New York, NY 10003 USA. [Prasad, Manju L.] Yale Univ, Dept Pathol, New Haven, CT USA. [Ocal, I. Tolgay] Mayo Clin Arizona, Dept Lab Med & Pathol, Scottsdale, AZ USA. [Rao, Sarika; Aronin, Neil] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA. [Barontini, Marta] Ctr Endocrinol Invest CEDIE, Buenos Aires, DF, Argentina. [Reddick, Robert L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Chen, Yidong] Univ Texas Hlth Sci Ctr San Antonio, Dept Biostat, San Antonio, TX 78229 USA. [Aguiar, Ricardo C. T.] Audie Murphy VA Hosp, South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Dahia, Patricia L. M.] Univ Texas Hlth Sci Ctr San Antonio, CTRC, San Antonio, TX 78229 USA. RP Dahia, PLM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr,MC 7880, San Antonio, TX 78229 USA. EM Dahia@uthscsa.edu FU Max and Minnie Voelcker Fund; Greehey Children's Cancer Research Institute (GCCRI); National Council for Scientific and Technological Development (CNPq); UTHSCSA; NIH-NCI [P30 CA54174] FX This study was supported by grants from the Max and Minnie Voelcker Fund, and Greehey Children's Cancer Research Institute (GCCRI; to P.L.M. Dahia). R.A. Toledo was a recipient of a research fellowship from the National Council for Scientific and Technological Development (CNPq). The CTRC Pathology tumor bank and GCCRI Next Generation Sequencing core are supported by UTHSCSA, NIH-NCI P30 CA54174. NR 49 TC 5 Z9 5 U1 0 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD MAY 1 PY 2016 VL 22 IS 9 BP 2301 EP 2310 DI 10.1158/1078-0432.CCR-15-1841 PG 10 WC Oncology SC Oncology GA DL0NG UT WOS:000375329100026 PM 26700204 ER PT J AU Fleming, JN Taber, DJ Pilch, NA McGillicuddy, JW Srinivas, TR Baliga, PK Chavin, KD Bratton, CF AF Fleming, James N. Taber, David J. Pilch, Nicole A. McGillicuddy, John W. Srinivas, Titte R. Baliga, Prabhakar K. Chavin, Kenneth D. Bratton, Charles F. TI A randomized, prospective comparison of transition to sirolimus-based CNI-minimization or withdrawal in African American kidney transplant recipients SO CLINICAL TRANSPLANTATION LA English DT Article DE kidney; mammalian target of rapamycin; minimization; transplant; withdrawal ID RENAL-ALLOGRAFT SURVIVAL; MYCOPHENOLATE-MOFETIL; CALCINEURIN INHIBITORS; IMMUNOSUPPRESSION; REGIMENS; TACROLIMUS; OUTCOMES; COMBINATION; CONVERSION; TRIAL AB BackgroundThere is a lack of conclusive evidence to suggest if calcineurin inhibitor (CNI) withdrawal or minimization with sirolimus is the best strategy for African Americans. MethodsThis was a randomized, prospective, open-label, pilot study comparing the two mammalian target of rapamycin (mTOR) transition strategies in adult African Americans between six and 24 wk post-transplant. The primary outcome was a comparison of the eGFR at one yr after conversion. ResultsForty patients were randomized and analyzed in an intent-to-treat fashion. Median day of transition was day 96 (withdrawal) and 68 (minimization). Patients in the CNI-withdrawal group (n = 23) had significantly higher eGFR at one yr compared to the CNI-minimization group (n = 17, 73 vs. 56 mL/min, p = 0.03), as well as a significantly larger increase in eGFR from baseline (12 vs. 5 mL/min, p = 0.03). There were no differences in infections, acute rejection, death, or graft loss. Both regimens were constrained by disproportionately high discontinuation rates despite modest toxicity profiles. ConclusionIn spite of considerable withdrawal rate across both study arms, African American kidney transplant recipients who underwent early transition to a sirolimus-based CNI-withdrawal regimen had significantly better graft function at one yr compared to those transitioned to a sirolimus-based CNI-minimization regimen. Clinicaltrials.gov identifier: NCT01005706. C1 [Fleming, James N.; Pilch, Nicole A.] Med Univ S Carolina, Dept Pharm Serv, Charleston, SC 29425 USA. [Taber, David J.; McGillicuddy, John W.; Baliga, Prabhakar K.; Chavin, Kenneth D.; Bratton, Charles F.] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA. [Taber, David J.] Med Univ S Carolina, Ralph H Johnson VAMC, Dept Pharm, Charleston, SC 29425 USA. [Srinivas, Titte R.] Med Univ S Carolina, Dept Nephrol, Charleston, SC 29425 USA. RP Fleming, JN (reprint author), Med Univ S Carolina, Solid Organ Transplant, 150 Ashley Ave, Charleston, SC 29425 USA.; Fleming, JN (reprint author), South Carolina Coll Pharm, 150 Ashley Ave, Charleston, SC 29425 USA. EM fleminj@musc.edu FU Pfizer FX This study was funded by an unrestricted research grant from Pfizer. NR 20 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0902-0063 EI 1399-0012 J9 CLIN TRANSPLANT JI Clin. Transplant. PD MAY PY 2016 VL 30 IS 5 BP 528 EP 533 DI 10.1111/ctr.12718 PG 6 WC Surgery; Transplantation SC Surgery; Transplantation GA DL4LA UT WOS:000375606100006 PM 26914542 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Short article: Gastrointestinal bleeding in multiorgan failure SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY LA English DT Article DE endoscopic hemostasis; gastrointestinal bleeding; Markov chain; medical decision analysis; modeling AB Background and aimsGastrointestinal bleeding (GIB) may present as complication of multiorgan failure (MOF). The study aims to analyze the reasons for the limited success of hemostasis of GIB in MOF.MethodsUsing a Markov process, GIB is modeled as one of several complications associated with multiorgan breakdown to study how the reversal of GIB affects clinical outcome.ResultsAlthough endoscopic hemostasis can delay mortality in patients with severe systemic disease, its overall influence on survival is relatively small. In patients with a time-limited transition through an acute phase of increased mortality risk secondary to MOF, endoscopic hemostasis may substantially prolong survival in absolute terms. However, its relative contribution to overall survival still remains relatively small even in the scenario of transient risk only. The benefit of endoscopy is largest, if GIB is a major contributor to morbidity and mortality in comparison with all other disease complications.ConclusionBecause disease outcome in MOF is ultimately determined by other complications than GIB alone, the influence of endoscopic hemostasis on patient survival often remains disappointingly small. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved. C1 [Sonnenberg, Amnon] Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 7 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0954-691X EI 1473-5687 J9 EUR J GASTROEN HEPAT JI Eur. J. Gastroenterol. Hepatol. PD MAY PY 2016 VL 28 IS 5 BP 543 EP 545 DI 10.1097/MEG.0000000000000589 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DK2QP UT WOS:000374759800008 PM 26849464 ER PT J AU Cristancho, MA Thase, ME AF Cristancho, Mario A. Thase, Michael E. TI Critical appraisal of selegiline transdermal system for major depressive disorder SO EXPERT OPINION ON DRUG DELIVERY LA English DT Review DE Selegiline; Transdermal; Depression; Treatment ID HEALTHY-SUBJECTS; SHORT-TERM; INHIBITORS; EFFICACY; TRIALS; ANTIDEPRESSANTS; PHARMACOLOGY; METAANALYSIS; (-)DEPRENYL; SYMPTOMS AB Introduction: Although safer and easier to use antidepressants (ie.,SSRIs/SNRIs) have largely displaced MAOIs, these medications still have a role in difficult to treat conditions. Efforts to improve MAOIs benefit-risk profile resulted on the reversible MAOI and in the first antidepressant patch (selegiline transdermal delivery system-STS). The later had been available in the US since 2006. Thus a review on its safety profile and comparative efficacy is timely.Areas covered: This review provides an overview of STS's clinical pharmacology and summarizes what has been learned across nearly a decade of experience. Product labels and the search engine PubMed were used to obtain relevant information.Expert opinion: STS remains a unique treatment option. It is the only FDA-approved antidepressant for patients with significant problems ingesting, tolerating, or absorbing oral medications. It remains the only MAOI that can be initiated without dietary restrictions at a therapeutic dose and has a low incidence of side effects when compared to other MAOIs. STS also provides an interesting option for depressed patients suffering from Parkinson's disease. However these advantages are counterweighted by drawbacks including the need for wash-out periods and the lack of convincing data illustrating its utility for treatment of more severe, treatment refractory depression. C1 [Cristancho, Mario A.; Thase, Michael E.] Univ Penn, Dept Psychiat, Mood & Anxiety Disorders Treatment & Res Program, Perelman Sch Med, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Dept Psychiat, Philadelphia, PA USA. RP Thase, ME (reprint author), Univ Penn, Perelman Sch Med, Penn Behav Hlth, Psychiat, 3535 Market St 4th Floor, Philadelphia, PA 19104 USA. EM thase@mail.med.upenn.edu NR 27 TC 0 Z9 0 U1 3 U2 6 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1742-5247 EI 1744-7593 J9 EXPERT OPIN DRUG DEL JI Expert Opin. Drug Deliv. PD MAY PY 2016 VL 13 IS 5 BP 659 EP 665 DI 10.1517/17425247.2016.1140145 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DK1TA UT WOS:000374696000006 PM 26837935 ER PT J AU Sendelweck, MA Bell, E Anderson, AM Ashack, K Pindyck, T Townley, C Dellavalle, RP AF Sendelweck, Myra A. Bell, Eric Anderson, Amy Marie Ashack, Kurt Pindyck, Talia Townley, Cate Dellavalle, Robert P. TI Associations Between Indoor Tanning and Substance Use Among Colorado High School Students SO JAMA DERMATOLOGY LA English DT Letter ID UNITED-STATES C1 [Sendelweck, Myra A.] Univ Colorado, Sch Med, Aurora, CO USA. [Bell, Eric; Anderson, Amy Marie; Townley, Cate] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Ashack, Kurt] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA. [Pindyck, Talia] Univ Colorado, Colorado Sch Publ Hlth, Aurora, CO USA. [Dellavalle, Robert P.] Univ Colorado, Sch Med, Dept Dermatol, Aurora, CO USA. [Dellavalle, Robert P.] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. [Dellavalle, Robert P.] Denver Vet Affairs Med Ctr, Dermatol Serv, 1055 Clermont St,Mail Stop 165, Denver, CO 80220 USA. RP Dellavalle, RP (reprint author), Denver Vet Affairs Med Ctr, Dermatol Serv, 1055 Clermont St,Mail Stop 165, Denver, CO 80220 USA. EM robert.dellavalle@ucdenver.edu OI Bell, Eric/0000-0002-8187-7298 NR 6 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6068 EI 2168-6084 J9 JAMA DERMATOL JI JAMA Dermatol. PD MAY PY 2016 VL 152 IS 5 BP 575 EP 577 DI 10.1001/jamadermatol.2015.5663 PG 4 WC Dermatology SC Dermatology GA DL7BU UT WOS:000375795400023 PM 26791966 ER PT J AU Armstrong, AW Aldredge, L Yamauchi, PS AF Armstrong, April W. Aldredge, Lakshi Yamauchi, Paul S. TI Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners SO JOURNAL OF CUTANEOUS MEDICINE AND SURGERY LA English DT Review DE psoriasis; biologics; TNF inhibitor; cyclosporine; methotrexate ID SEVERE PLAQUE PSORIASIS; RHEUMATOID-ARTHRITIS; UNITED-STATES; MULTINATIONAL ASSESSMENT; PEDIATRIC PSORIASIS; MONOCLONAL-ANTIBODY; BIOLOGICS REGISTER; TOPICAL THERAPIES; ALPHA-INHIBITORS; CONTROLLED-TRIAL AB Psoriasis is a common inflammatory disease with significant comorbidities, whose management can be challenging given the variety of treatment options. It is critical for nurse practitioners, physician assistants, general practitioners, and dermatology trainees to have useful information about the treatment and monitoring of patients with psoriasis. Although certain aspects of care apply to all patients, each therapeutic agent has its own nuances in terms of assessments, dosing, and monitoring. The most appropriate treatment is based not only on disease severity but also on comorbid conditions and concomitant medications. These practitioners are vital in facilitating patient care by thorough understanding of systemic agents, selection criteria, dosing, and recommended monitoring. This article provides high-yield practical pearls on managing patients with moderate to severe psoriasis. It includes case-based discussions illustrating considerations for special populations, such as pregnant women, children, and patients with comorbidities (eg, human immunodeficiency virus infection, hepatitis C, hepatitis B, and history of malignancy). C1 [Armstrong, April W.] Univ Colorado Denver, Dept Dermatol, Aurora, CO USA. [Aldredge, Lakshi] Portland VA Med Ctr, Dept Dermatol, Portland, OR USA. [Yamauchi, Paul S.] Dermatol Inst & Skin Care Ctr, Santa Monica, CA USA. [Yamauchi, Paul S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Los Angeles, CA 90095 USA. [Armstrong, April W.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. RP Armstrong, AW (reprint author), Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. EM aprilarmstrong@post.harvard.edu FU AbbVie by Complete Publication Solutions, LLC (North Wales, PA, USA); AbbVie FX The author( s) disclosed receipt of the following financial support for the research, authorship, and/ or publication of this article: AbbVie funded development of the publication by Complete Publication Solutions, LLC (North Wales, PA, USA). AbbVie had no role in content development of the publication. All decisions regarding content were made by the authors. This support was funded by AbbVie. NR 67 TC 0 Z9 0 U1 2 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1203-4754 EI 1615-7109 J9 J CUTAN MED SURG JI J. Cutan. Med. Surg. PD MAY-JUN PY 2016 VL 20 IS 3 BP 196 EP 206 DI 10.1177/1203475415623508 PG 11 WC Dermatology SC Dermatology GA DJ8TK UT WOS:000374485900002 PM 26712930 ER PT J AU Gaither, JR Goulet, JL Becker, WC Crystal, S Edelman, EJ Gordon, K Kerns, RD Rimland, D Skanderson, M Justice, AC Fiellin, DA AF Gaither, Julie R. Goulet, Joseph L. Becker, William C. Crystal, Stephen Edelman, E. Jennifer Gordon, Kirsha Kerns, Robert D. Rimland, David Skanderson, Melissa Justice, Amy C. Fiellin, David A. TI The Association Between Receipt of Guideline-Concordant Long-Term Opioid Therapy and All-Cause Mortality SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE Opioid analgesics; practice guideline; quality of health care; mortality; pain ID CHRONIC NONCANCER PAIN; SUBSTANCE USE DISORDER; VETERANS AGING COHORT; CLINICAL GUIDELINES; OLDER-ADULTS; ANTIRETROVIRAL THERAPY; PRESCRIBING PRACTICES; UNINFECTED VETERANS; COMPARATIVE SAFETY; AMERICAN ACADEMY AB For patients receiving long-term opioid therapy (LtOT), the impact of guideline-concordant care on important clinical outcomes-notably mortality-is largely unknown, even among patients with a high comorbidity and mortality burden (e.g., HIV-infected patients). Our objective was to determine the association between receipt of guideline-concordant LtOT and 1-year all-cause mortality. Among HIV-infected and uninfected patients initiating LtOT between 2000 and 2010 through the Department of Veterans Affairs, we used Cox regression with time-updated covariates and propensity-score matched analyses to examine the association between receipt of guideline-concordant care and 1-year all-cause mortality. Of 17,044 patients initiating LtOT between 2000 and 2010, 1048 patients (6%) died during 1 year of follow-up. Patients receiving psychotherapeutic co-interventions (hazard ratio [HR] 0.62; 95% confidence interval [CI] 0.51-0.75; P < 0.001) or physical rehabilitative therapies (HR 0.81; 95% CI 0.67-0.98; P = 0.03) had a decreased risk of all-cause mortality compared to patients not receiving these services, whereas patients prescribed benzodiazepines concurrent with opioids had a higher risk of mortality (HR 1.39; 95% CI 1.12-1.66; P < 0.001). Among patients with a current substance use disorder (SUD), those receiving SUD treatment had a lower risk of mortality than untreated patients (HR 0.47; 95% CI 0.32-0.68; P = < 0.001). No association was found between all-cause mortality and primary care visits (HR 1.12; 95% CI 0.90-1.26; P = 0.32) or urine drug testing (HR 0.96; 95% CI 0.78-1.17; P = 0.67). Providers should use caution in initiating LtOT in conjunction with benzodiazepines and untreated SUDs. Patients receiving LtOT may benefit from multi-modal treatment that addresses chronic pain and its associated comorbidities across multiple disciplines. C1 [Gaither, Julie R.; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [Gaither, Julie R.; Goulet, Joseph L.; Becker, William C.; Gordon, Kirsha; Kerns, Robert D.; Justice, Amy C.] VA Connecticut Healthcare Syst, 950 Campbell Ave, West Haven, CT 06516 USA. [Gaither, Julie R.; Justice, Amy C.] Yale Univ, Sch Med, Yale Ctr Med Informat, New Haven, CT USA. [Gaither, Julie R.; Edelman, E. Jennifer; Fiellin, David A.] Yale Univ, Sch Publ Hlth, Ctr Interdisciplinary Res AIDS, New Haven, CT USA. [Goulet, Joseph L.; Kerns, Robert D.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Becker, William C.; Edelman, E. Jennifer; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Crystal, Stephen] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, 30 Coll Ave, New Brunswick, NJ 08903 USA. [Rimland, David] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA. [Rimland, David] Atlanta VA Med Ctr, Decatur, GA USA. [Skanderson, Melissa] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Gaither, JR (reprint author), VA Connecticut Healthcare Syst, 950 Campbell Ave, West Haven, CT 06516 USA. EM julie.gaither@yale.edu OI Justice, Amy/0000-0003-0139-5502; Fiellin, David/0000-0002-4006-010X; Goulet, Joseph/0000-0002-0842-804X FU National Institute on Drug Abuse [F31DA035567, K12DA033312]; National Institute on Alcohol Abuse and Alcoholism [U10AA013566, U01AA020790, U24AA020794]; National Institute of Mental Health [P30MH062294]; VA Health Services Research and Development Center of Innovation [CIN 13-047]; Agency for Healthcare Research and Quality [U19HS21112] FX Research reported in this paper was supported by grants from the National Institute on Drug Abuse (F31DA035567; K12DA033312), National Institute on Alcohol Abuse and Alcoholism (U10AA013566; U01AA020790; U24AA020794), National Institute of Mental Health (P30MH062294), VA Health Services Research and Development Center of Innovation (CIN 13-047), and the Agency for Healthcare Research and Quality (U19HS21112). These organizations had no role in the design, conduct, or reporting of this study. NR 67 TC 5 Z9 5 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 IS 5 BP 492 EP 501 DI 10.1007/s11606-015-3571-4 PG 10 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DJ8KO UT WOS:000374461400012 PM 26847447 ER PT J AU Radomski, TR Zhao, XH Thorpe, CT Thorpe, JM Good, CB Mor, MK Fine, MJ Gellad, WF AF Radomski, Thomas R. Zhao, Xinhua Thorpe, Carolyn T. Thorpe, Joshua M. Good, Chester B. Mor, Maria K. Fine, Michael J. Gellad, Walid F. TI VA and Medicare Utilization Among Dually Enrolled Veterans with Type 2 Diabetes: A Latent Class Analysis SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE utilization; diabetes; Veterans; Medicare; health services research ID AFFAIRS HEALTH-CARE; GLYCEMIC CONTROL; AMBULATORY-CARE; SYSTEM; SERVICES; MELLITUS; MEDICATIONS; PERFORMANCE; VALIDATION; MORTALITY AB Many Veterans treated within the VA Healthcare System (VA) are also enrolled in fee-for-service (FFS) Medicare and receive treatment outside the VA. Prior research has not accounted for the multiple ways that Veterans receive services across healthcare systems. We aimed to establish a typology of VA and Medicare utilization among dually enrolled Veterans with type 2 diabetes. This was a retrospective cohort. 316,775 community-dwelling Veterans age a parts per thousand yen 65 years with type 2 diabetes who were dually enrolled in the VA and FFS Medicare in 2008-2009. Using latent class analysis, we identified classes of Veterans based upon their probability of using VA and Medicare diabetes care services, including patient visits, laboratory tests, glucose test strips, and medications. We compared the amount of healthcare use between classes and identified factors associated with class membership using multinomial regression. We identified four distinct latent classes: class 1 (53.9 %) had high probabilities of VA use and low probabilities of Medicare use; classes 2 (17.2 %), 3 (21.8 %), and 4 (7.0 %) had high probabilities of VA and Medicare use, but differed in their Medicare services used. For example, Veterans in class 3 received test strips exclusively through Medicare, while Veterans in class 4 were reliant on Medicare for medications. Living a parts per thousand yen 40 miles from a VA predicted membership in classes 3 (OR 1.1, CI 1.06-1.15) and 4 (OR 1.11, CI 1.04-1.18), while Medicaid eligibility predicted membership in class 4 (OR 4.30, CI 4.10-4.51). Veterans with diabetes can be grouped into four distinct classes of dual health system use, representing a novel way to characterize how patients use multiple services across healthcare systems. This classification has applications for identifying patients facing differential risk from care fragmentation. C1 [Radomski, Thomas R.; Good, Chester B.; Fine, Michael J.; Gellad, Walid F.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Radomski, Thomas R.; Zhao, Xinhua; Thorpe, Carolyn T.; Thorpe, Joshua M.; Good, Chester B.; Mor, Maria K.; Fine, Michael J.; Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr 151C, Pittsburgh, PA 15240 USA. [Thorpe, Carolyn T.; Thorpe, Joshua M.; Good, Chester B.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA USA. [Good, Chester B.] US Dept Vet Affairs, Pharm Benefits Management Serv, Hines, IL USA. [Mor, Maria K.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA. RP Gellad, WF (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr 151C, Pittsburgh, PA 15240 USA. EM walid.gellad@va.gov FU U.S. Department of Veterans Affairs [CDA 09-207]; National Research Service Award from the Health Resources and Services Administration [T32HP22240]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, VA Information Resource Center [SDR 02-237, 98-004] FX This study was supported by a Career Development Award (CDA 09-207) from the U.S. Department of Veterans Affairs and a National Research Service Award from the Health Resources and Services Administration (T32HP22240). Support for VA/CMS data is provided by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, VA Information Resource Center (Project Numbers SDR 02-237 and 98-004). NR 39 TC 0 Z9 0 U1 3 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 IS 5 BP 524 EP 531 DI 10.1007/s11606-016-3631-4 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DJ8KO UT WOS:000374461400016 PM 26902242 ER PT J AU Breslau, ES Gorin, SS Edwards, HM Schonberg, MA Saiontz, N Walter, LC AF Breslau, Erica S. Gorin, Sherri Sheinfeld Edwards, Heather M. Schonberg, Mara A. Saiontz, Nicole Walter, Louise C. TI An Individualized Approach to Cancer Screening Decisions in Older Adults: A Multilevel Framework SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Review DE Individualized screening; Shared decisionmaking; Geriatric; Multilevel; Framework ID SERVICES TASK-FORCE; WOMEN AGED 80; PREVENTIVE SERVICES; COLORECTAL-CANCER; BREAST-CANCER; RECOMMENDATION STATEMENT; LIFE EXPECTANCY; CHRONIC ILLNESS; NATIONAL-SURVEY; HEALTH-CARE AB Guidelines for optimal cancer screening in older adults remain unclear, particularly for adults over the age of 75. While cancer screening in older adults may benefit some in good health, it may cause unnecessary burdens in others with limited life expectancy. Thus, a systematic approach to enable individualized cancer screening decisions in older adults is needed. We suggest a framework that guides such decisions through evidence-based approaches from multiple interactions, and that involves the patient, clinician, and healthcare system. An individualized approach considers differences in disease risk rather than the chronological age of the patient. This paper presents a comprehensive framework that depicts the independent and converging levels of influences on individualized cancer screening decisions in older adults. This Individualized Decisions for Screening (IDS) framework recognizes the reality of these interrelationships, including the tensions that arise when behaviors and outcomes are valued differently at the patient, clinician, and healthcare organization levels. Person-centered approaches are essential to advancing multilevel research of individualized cancer screening decisions among older adults. C1 [Breslau, Erica S.] NCI, Healthcare Delivery Res Program, Div Canc Control & Populat Sci, 9609 Med Ctr Dr, Rockville, MD 20850 USA. [Gorin, Sherri Sheinfeld] Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Frederick, MD USA. [Gorin, Sherri Sheinfeld] Herbert Irving Comprehens Canc Ctr, New York Phys Canc, New York, NY USA. [Edwards, Heather M.] Patient Ctr Outcomes Res Inst, Washington, DC USA. [Schonberg, Mara A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Gen Med & Primary Care, Boston, MA 02215 USA. [Saiontz, Nicole] NCI, Off Director, Div Canc Control & Populat Sci, Rockville, MD 20850 USA. [Walter, Louise C.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Walter, Louise C.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Breslau, ES (reprint author), NCI, Healthcare Delivery Res Program, Div Canc Control & Populat Sci, 9609 Med Ctr Dr, Rockville, MD 20850 USA. EM breslaue@mail.nih.gov FU National Cancer Institute, National Institutes of Health [HHSN261200800001E]; National Institute on Aging, National Institutes of Health [K24AG041180] FX Disclaimer for Drs. Edwards and Sheinfeld Gorin: This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E (HME). Dr. Walter was funded by the National Institute on Aging, National Institutes of Health under grant number K24AG041180. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products, or organizations imply endorsement by the U.S. government. NR 55 TC 0 Z9 0 U1 2 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 IS 5 BP 539 EP 547 DI 10.1007/s11606-016-3629-y PG 9 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DJ8KO UT WOS:000374461400024 PM 26941042 ER PT J AU Braithwaite, D Walter, LC Izano, M Kerlikowske, K AF Braithwaite, Dejana Walter, Louise C. Izano, Monika Kerlikowske, Karla TI Benefits and Harms of Screening Mammography by Comorbidity and Age: A Qualitative Synthesis of Observational Studies and Decision Analyses SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Review DE breast cancer screening; comorbidity; aging ID STAGE RENAL-DISEASE; BREAST-CANCER; OLDER WOMEN; COST-EFFECTIVENESS; LIFE EXPECTANCY; COMMUNITY PRACTICE; UNITED-STATES; ELDERLY-WOMEN; ADULTS; MODEL AB We conducted a systematic review to assess the quality and limitations of published studies examining benefits and harms of screening mammography in relation to comorbidity and age. We searched MEDLINE and EMBASE from January 1980 through June 2013 for studies that examined benefits or harms of screening mammography in women aged 65 years or older in relation to comorbidity. For each study, we extracted data regarding setting, design, quality, screening schedule, measure of comorbidity, and estimates of benefits and/or harms. We reviewed 1760 titles, identifying 7 articles that met the inclusion criteria: prospective cohort (two studies), retrospective cohort (two studies), and decision analyses (three studies). No randomized controlled trials were identified. At least one measure of life expectancy or reduction in the risk of breast cancer death as a marker of benefit was examined in four studies, whereas three studies addressed the harms of screening mammography, including false-positive results. Both cohort studies and decision analyses showed that screening benefits decreased with increasing age and comorbidity burden. The limited evidence currently available suggests that, apart from older women with severe comorbidity, women 65 and older may experience improvements in life expectancy from screening. Given the potential for harm, it is unclear whether the magnitude of the benefit is sufficient to warrant regular screening. Women, clinicians and policymakers should consider these factors in deciding whether continue screening. C1 [Braithwaite, Dejana; Izano, Monika; Kerlikowske, Karla] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Walter, Louise C.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. [Walter, Louise C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Izano, Monika] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Kerlikowske, Karla] Univ Calif San Francisco, Div Gen Internal Med, VA Med Ctr, San Francisco, CA 94143 USA. RP Braithwaite, D (reprint author), Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. EM DBraithwaite@epi.ucsf.edu FU American Cancer Society [121891-MRSG-12-007-01-CPHPS] FX This research was supported by grant no. 121891-MRSG-12-007-01-CPHPS from the American Cancer Society (to Dr. Braithwaite). We thank Min-Lin Fang, MLS, and Gloria Won, MLS, for their assistance with the literature search, and Jisu Shin for administrative assistance. We are also grateful to Iris Lansdorp-Vogelaar, PhD, for her helpful comments on an earlier version of this manuscript. NR 55 TC 2 Z9 2 U1 3 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 IS 5 BP 561 EP 572 DI 10.1007/s11606-015-3580-3 PG 12 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DJ8KO UT WOS:000374461400026 PM 26831305 ER PT J AU Braun, K Erickson, M Utech, A List, R Garcia, JM AF Braun, Katie Erickson, Megan Utech, Anne List, Riesa Garcia, Jose M. TI Evaluation of Veterans MOVE! Program for Weight Loss SO JOURNAL OF NUTRITION EDUCATION AND BEHAVIOR LA English DT Article DE weight management; obesity; nutrition education; veteran ID OBESITY; OVERWEIGHT; BURDEN; PREVALENCE; SUCCESS AB Objective: To evaluate the degree of weight loss in subjects enrolled in the Veterans Affairs weight management program (MOVE!). Design: Retrospective cohort design. Setting: Tertiary care US veterans hospital, July, 2007 to September, 2008, using a retrospective database. Participants: Adult veterans (n = 1,659), mostly men (85%). Intervention: Encounters with existing nutrition education classes were collected and outcomes were assessed. Main Outcome Measures: Primary outcome was weight change; the predictor was visits or encounters. Analysis: One-way ANOVA. Results: In this sample, >= 3 nutrition education encounters were associated with significantly more body weight loss compared with 1-2 encounters or no education (-1.62%, 0.2%, and -0.23%, respectively; P =.01). Conclusions and Implications: Three or more nutrition education encounters within the MOVE! weight management program at the Michael E. DeBakey Veterans Affairs Medical Center are associated with modest weight loss. Future prospective studies are needed to determine causality and confirm these findings. C1 [Braun, Katie; Utech, Anne] Michael E DeBakey VA Med Ctr, Nutr & Food Serv, Dept Vet Affairs, Houston, TX 77030 USA. [Braun, Katie; Erickson, Megan] Texas Womans Univ, Houston, TX USA. [List, Riesa] Edwards Hines Jr Vet Affairs Med Ctr, Nutr & Food Serv, Dept Vet Affairs, Hines, IL USA. [Garcia, Jose M.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Garcia, Jose M.] Univ Washington, Sch Med, Seattle, WA USA. [Garcia, Jose M.] Michael E DeBakey VA Med Ctr, Ctr Translat Res Inflammatory Dis, Houston, TX 77030 USA. [Garcia, Jose M.] Baylor Coll Med, Huffington Ctr Aging, Dept Med & Mol & Cell Biol, Houston, TX 77030 USA. RP Braun, K (reprint author), Michael E DeBakey VA Med Ctr, Nutr & Food Serv, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM Katie.Braun@va.gov FU Department of Veterans Affairs [I01-BX000507, I01 CX000174]; Department of Veterans Affairs (National Institute on Aging) [T32AG000183, AG040583]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development FX Dr Garcia received research support from the Department of Veterans Affairs (MERIT grants: I01-BX000507 and I01 CX000174 and National Institute on Aging T32AG000183 and AG040583). This material is based upon work supported (or supported in part) by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development. The views expressed here are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. The authors also acknowledge the following individuals for their technical and written contributions to the original works from which this project stems: Dr Charles Wright, Karen Moreland, Caroline Nelson, Rose Bush, John Radcliffe, and Mary Watson. The Institutional Review Boards at Baylor College of Medicine, the Michael E. DeBakey Veterans Affairs Medical Center, and Texas Woman's University approved this protocol. NR 20 TC 1 Z9 1 U1 3 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1499-4046 EI 1878-2620 J9 J NUTR EDUC BEHAV JI J. Nutr. Educ. Behav. PD MAY PY 2016 VL 48 IS 5 BP 299 EP + DI 10.1016/j.jneb.2016.02.012 PG 6 WC Education, Scientific Disciplines; Nutrition & Dietetics SC Education & Educational Research; Nutrition & Dietetics GA DL4DQ UT WOS:000375584100003 PM 27169639 ER PT J AU Ornstein, KA Aldridge, MD Mair, CA Gorges, R Siu, AL Kelley, AS AF Ornstein, Katherine A. Aldridge, Melissa D. Mair, Christine A. Gorges, Rebecca Siu, Albert L. Kelley, Amy S. TI Spousal Characteristics and Older Adults' Hospice Use: Understanding Disparities in End-of-Life Care SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID DECISION-MAKING; MENTAL-HEALTH; UNITED-STATES; ENROLLMENT; QUALITY; MEDICARE; CANCER; DEATH; ASSOCIATION; FAMILIES AB Background: Hospice use has been shown to benefit quality of life for patients with terminal illness and their families, with further evidence of cost savings for Medicare and other payers. While disparities in hospice use by patient diagnosis, race, and region are well documented and attention to the role of family members in end-of-life decision-making is increasing, the influence of spousal characteristics on the decision to use hospice is unknown. Objectives: To determine the association between spousal characteristics and hospice use. Design: We used data from the Health and Retirement Study (HRS), a prospective cohort study, linked to the Dartmouth Atlas of Health Care and Medicare claims. Setting: National study of 1567 decedents who were married or partnered at the time of death (2000-2011). Measures: Hospice use at least 1 day in the last year of life as measured via Medicare claims data. Spousal factors (e.g., education and health status) measured via survey. Results: In multivariate models controlling for patient factors and regional variation, spouses with lower educational attainment than their deceased spouse had decreased likelihood of hospice use (odds ratio [OR]=0.58; 95% confidence interval [CI]=0.40-0.82). Health of the spouse was not significantly associated with likelihood of decedent hospice use in adjusted models. C1 [Ornstein, Katherine A.; Aldridge, Melissa D.; Siu, Albert L.; Kelley, Amy S.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, Box 1070,One Gustave Levy Pl, New York, NY 10029 USA. [Ornstein, Katherine A.] Icahn Sch Med Mt Sinai, Inst Translat Epidemiol, New York, NY 10029 USA. [Siu, Albert L.; Kelley, Amy S.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Mair, Christine A.] Univ Maryland, Dept Sociol & Anthropol, Baltimore, MD 21201 USA. [Gorges, Rebecca] Univ Chicago, Harris Sch Publ Policy, Chicago, IL 60637 USA. RP Ornstein, KA (reprint author), Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, Box 1070,One Gustave Levy Pl, New York, NY 10029 USA. EM Katherine.ornstein@mssm.edu FU National Institute on Aging [K01AG047923] FX The research was supported by: National Institute on Aging K01AG047923 (Dr. Ornstein). NR 43 TC 0 Z9 0 U1 2 U2 7 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD MAY PY 2016 VL 19 IS 5 BP 509 EP 515 DI 10.1089/jpm.2015.0399 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DL8DZ UT WOS:000375871600011 PM 26991831 ER PT J AU Lam, CA Sherbourne, C Tang, LQ Belin, TR Williams, P Young-Brinn, A Miranda, J Wells, KB AF Lam, Christine A. Sherbourne, Cathy Tang, Lingqi Belin, Thomas R. Williams, Pluscedia Young-Brinn, Angela Miranda, Jeanne Wells, Kenneth B. TI The Impact of Community Engagement on Health, Social, and Utilization Outcomes in Depressed, Impoverished Populations: Secondary Findings from a Randomized Trial SO JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE LA English DT Article DE Depression; Health Care Disparities; Homelessness; Populations; Underserved; Social Determinants of Health ID FALSE DISCOVERY RATE; QUALITY IMPROVEMENT; COLLABORATIVE CARE; TREATING DEPRESSION; MINORITY WOMEN; SCREENING-TEST; DSM-IV; CLUSTER; LIFE; INTERVENTIONS AB Background: Disparities in depression care exist among the poor. Community Partners in Care (CPIC) compared a community coalition model with technical assistance to improve depression services in under-resourced communities. We examine effects on health, social, and utilization outcomes among the poor and, non-poor depressed, and poor subgroups. Methods: This study analyzed clients living above (n = 268) and below (n = 750) the federal-poverty level and, among the poor, 3 nonoverlapping subgroups: justice-involved (n = 158), homeless and not justice- involved (n = 298), and other poor (n = 294). Matched programs (n = 93) from health and community sectors were randomly assigned to community engagement and planning (CEP) or resources for services (RS). Primary outcomes were poor mental health-related quality of life and 8-item Patient Health Questionnaire scores, whereas community-prioritized and utilization outcomes were secondary. Effects were scrutinized using false discovery rate-adjusted P values to account for multiple comparisons. Results: In the impoverished group, CEP and RS clients of participating study programs did not differ in primary outcomes, but CEP more than RS improved mental wellness among the depressed poor (unadjusted P = .004) while providing suggestive evidence for other secondary outcomes. Within the poor subgroups, evidence favoring CEP was only suggestive but was strongest among justice-involved clients. Conclusions: A coalition approach to improving outcomes for low-income clients with depression, particularly those involved in the justice system, may offer additional benefits over standard technical assistance programs. C1 [Lam, Christine A.] Vet Adm Greater Los Angeles Healthcare Syst, Vet Adm Hlth Serv Res & Dev Ctr Study Healthcare, Sepulveda, CA USA. [Lam, Christine A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Belin, Thomas R.; Wells, Kenneth B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Lam, Christine A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Sherbourne, Cathy; Wells, Kenneth B.] RAND Corp, Santa Monica, CA USA. [Tang, Lingqi; Miranda, Jeanne; Wells, Kenneth B.] Univ Calif Los Angeles, Ctr Hlth Serv & Soc, Los Angeles, CA USA. [Belin, Thomas R.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Dept Biostat, Los Angeles, CA USA. [Wells, Kenneth B.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Williams, Pluscedia] Hlth African Amer Families II, Los Angeles, CA USA. [Williams, Pluscedia] Charles R Drew Univ Med & Sci, Dept Res, 1621 E 120th St, Los Angeles, CA 90059 USA. [Young-Brinn, Angela] JD Pacada Fdn, Los Angeles, CA USA. RP Lam, CA (reprint author), VA Greater Angeles Healthcare Syst, 11301 Wilshire Blvd 111G,Room 3233, Los Angeles, CA 90073 USA. EM christinealam@mednet.ucla.edu FU National Institute on Minority Health and Health Disparities [R01MH078853]; Patient-Centered Outcomes Research Institute [1845]; National Institute of Mental Health [R01MH078853, P30MH082760, P30MH068639]; Robert Wood Johnson Foundation [64244]; California Community Foundation [CMCH-12-97088]; National Library of Medicine [G08LM011058]; National Institutes of Health/National Center For Advancing Translational Science UCLA CTSI [UL1TR000124]; VA Quality Scholars program FX These analyses of Community Partners in Care data were supported by the National Institute on Minority Health and Health Disparities (grant no. R01MH078853; P.I.s JM, KBW) and the Patient-Centered Outcomes Research Institute (award no. 1845; P.I. KBW). The parent study was funded by the National Institute of Mental Health (award no. R01MH078853, P30MH082760, and P30MH068639); the Robert Wood Johnson Foundation (award no. 64244), the California Community Foundation (award no. CMCH-12-97088), the National Library of Medicine (award no. G08LM011058), and the National Institutes of Health/National Center For Advancing Translational Science UCLA CTSI (award no. UL1TR000124). CAL is supported by the VA Quality Scholars program. NR 50 TC 1 Z9 1 U1 8 U2 11 PU AMER BOARD FAMILY MEDICINE PI LEXINGTON PA 2228 YOUNG DR, LEXINGTON, KY 40505 USA SN 1557-2625 EI 1558-7118 J9 J AM BOARD FAM MED JI J. Am. Board Fam. Med. PD MAY-JUN PY 2016 VL 29 IS 3 BP 325 EP + DI 10.3122/jabfm.2016.03.150306 PG 20 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA DL6NT UT WOS:000375756600007 PM 27170790 ER PT J AU Arevalo-Flechas, LC Murray, A May, L Frausto, E Sanchez-Reilly, S Ross, J AF Arevalo-Flechas, L. C. Murray, A. May, L. Frausto, E. Sanchez-Reilly, S. Ross, J. TI The Fall: A Cultural and Linguistic Adaptation of a Fall Prevention Program for Community Dwelling Older Hispanics SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Arevalo-Flechas, L. C.; Sanchez-Reilly, S.; Ross, J.] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. [Arevalo-Flechas, L. C.; Murray, A.; May, L.; Frausto, E.; Sanchez-Reilly, S.; Ross, J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. FU University of Texas Patient Safety Medical Education Grant Award FX Supported By: University of Texas Patient Safety Medical Education Grant Award NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA C104 BP S186 EP S186 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800515 ER PT J AU Arevalo-Flechas, LC Noel, P Rottman-Sagebiel, R Cupples, N Conde, A Sanchez-Reilly, S Powers, B Espinoza, S AF Arevalo-Flechas, L. C. Noel, P. Rottman-Sagebiel, R. Cupples, N. Conde, A. Sanchez-Reilly, S. Powers, B. Espinoza, S. TI Presence of a Caregiver Associated with Increased Odds of Readmission in a Cohort of Older Adults Included in a Transitional Care Intervention SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Arevalo-Flechas, L. C.; Noel, P.; Rottman-Sagebiel, R.; Cupples, N.; Conde, A.; Sanchez-Reilly, S.; Powers, B.; Espinoza, S.] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. [Arevalo-Flechas, L. C.; Noel, P.; Rottman-Sagebiel, R.; Cupples, N.; Conde, A.; Sanchez-Reilly, S.; Powers, B.; Espinoza, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. FU Veterans Administration T21 Non-Institutional Long Term Care Initiative; Office of Rural Health FX Supported By: Veterans Administration T21 Non-Institutional Long Term Care Initiative and Office of Rural Health NR 0 TC 0 Z9 0 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA B149 BP S141 EP S141 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800386 ER PT J AU Arevalo-Flechas, LC Flores, BP Martinez, M Cleveland, L AF Arevalo-Flechas, L. C. Flores, B. P. Martinez, M. Cleveland, L. TI If they are taken away I will die: Hispanic Abuelas as custodial "caregivers" SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Arevalo-Flechas, L. C.] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. [Arevalo-Flechas, L. C.; Flores, B. P.; Martinez, M.; Cleveland, L.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. FU Center for Research to Advance Community Health (ReACH); University of Texas Health Science Center at San Antonio FX Center for Research to Advance Community Health (ReACH). The University of Texas Health Science Center at San Antonio NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA A112 BP S56 EP S57 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800156 ER PT J AU Binkley, C Davila, AE Sanchez-Reilly, S Lee, S AF Binkley, C. Davila, A. E. Sanchez-Reilly, S. Lee, S. TI Advance Care Planning among Homeless Older Adults: How Can We Facilitate the Process? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Binkley, C.; Davila, A. E.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, San Antonio, TX 78229 USA. [Davila, A. E.; Sanchez-Reilly, S.; Lee, S.] South Texas Vet Hlth Care Syst, GEC GRECC, San Antonio, TX USA. FU MSTAR/AFAR FX Supported By: MSTAR/AFAR NR 0 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA D26 BP S226 EP S226 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800629 ER PT J AU Blanchard, E Castle, S Ines, E Morey, M Deberry, J Humecky, T Obar, F Lee, CC AF Blanchard, E. Castle, S. Ines, E. Morey, M. Deberry, J. Humecky, T. Obar, F. Lee, C. C. TI Delivering a clinical exercise program to rural Veterans via clinical video telehealth SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Blanchard, E.; Castle, S.; Ines, E.; Humecky, T.; Obar, F.; Lee, C. C.] VA Greater Los Angeles, GRECC, Los Angeles, CA USA. [Castle, S.; Lee, C. C.] Univ Calif Los Angeles, David Geffen Sch Med, Internal Med Geriatr, Los Angeles, CA 90095 USA. [Morey, M.; Deberry, J.] VHA Durham, GRECC, Durham, NC USA. FU VA Office of Geriatrics and Extended Care Transformational Patient Centered Alternatives to Institutional Care program; VHA Office of Rural Health FX Supported By: 1) VA Office of Geriatrics and Extended Care Transformational Patient Centered Alternatives to Institutional Care program; 2) VHA Office of Rural Health NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA C167 BP S208 EP S208 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800578 ER PT J AU Bready, E Shi, Y Shu, Z Xue, X Kamat, A AF Bready, E. Shi, Y. Shu, Z. Xue, X. Kamat, A. TI Beta2-Adrenergic Receptor Activation In Vivo Induces Hepatic Steatosis in Rodents SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Bready, E.; Shi, Y.; Shu, Z.; Xue, X.; Kamat, A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Shi, Y.; Shu, Z.; Xue, X.; Kamat, A.] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. FU VA Merit Award [1I01BX001744]; Kronos Longevity Research Institute; AFAR/MSTAR FX Supported By: VA Merit Award (1I01BX001744), Kronos Longevity Research Institute, and AFAR/MSTAR NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA B131 BP S134 EP S134 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800368 ER PT J AU Brown, R Komaiko, K Fung, K Shi, Y Au-Yeung, A Jacob, R Steinman, M AF Brown, R. Komaiko, K. Fung, K. Shi, Y. Au-Yeung, A. Jacob, R. Steinman, M. TI Bringing functional status into a Big Data world: Validation of national Veterans Affairs functional status data SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Brown, R.; Komaiko, K.; Fung, K.; Shi, Y.; Au-Yeung, A.; Jacob, R.; Steinman, M.] UCSF, Div Geriatr, San Francisco VA Med Ctr, San Francisco, CA USA. FU National Center for Advancing Translational Sciences, National Institutes of Health through UCSF-Clinical and Translational Sciences Institute [KL2TR000143]; National Institute on Aging at the National Institutes of Health [K23AG045290, P30AG044281, K23AG030999, K24AG049057]; Tideswell at UCSF FX Supported By: 1. National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-Clinical and Translational Sciences Institute (KL2TR000143); 2. National Institute on Aging at the National Institutes of Health (K23AG045290, P30AG044281, K23AG030999, K24AG049057); 3. Tideswell at UCSF NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA B64 BP S109 EP S109 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800301 ER PT J AU Brown, R Ahalt, C Rivera, J Casadei, M Williams, B AF Brown, R. Ahalt, C. Rivera, J. Casadei, M. Williams, B. TI Good Cop, Better Cop: Evaluation of a Geriatrics Training Program for Police SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Brown, R.; Ahalt, C.; Rivera, J.; Casadei, M.; Williams, B.] UCSF Div Geriatr, San Francisco, CA USA. [Brown, R.] San Francisco VA Med Ctr, San Francisco, CA USA. FU Tideswell at UCSF; Jacob and Valeria Langeloth Foundation; National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-Clinical and Translational Sciences Institute [KL2TR000143]; National Institute on Aging at the National Institutes of Health [K23AG045290, P30AG044281] FX Supported By: 1. Tideswell at UCSF; 2. Jacob and Valeria Langeloth Foundation; 3. National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-Clinical and Translational Sciences Institute (KL2TR000143); 4. National Institute on Aging at the National Institutes of Health (K23AG045290, P30AG044281) NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA P8 BP S3 EP S3 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800009 ER PT J AU Burke, RE Whitfield, E Levy, C AF Burke, R. E. Whitfield, E. Levy, C. TI Improving transitions to post-acute care facilities SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Burke, R. E.; Whitfield, E.; Levy, C.] Denver VA Med Ctr, Denver, CO USA. FU Hartford Foundation/Jahnigen Center of Excellence at the University of Colorado FX Supported By: Drs. Burke and Whitfield were funded by the Hartford Foundation/Jahnigen Center of Excellence at the University of Colorado. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA C114 BP S189 EP S190 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800525 ER PT J AU Fathi, R Patel, K Houston, T Ritchie, C AF Fathi, R. Patel, K. Houston, T. Ritchie, C. TI Life-Space Assessment as a predictor of readmission and mobility in hospitalized older adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Fathi, R.; Patel, K.; Ritchie, C.] UCSF, Geriatr, San Francisco, CA USA. [Fathi, R.] San Francisco VA Med Ctr, Geriatr, San Francisco, CA USA. [Houston, T.] Univ Massachusetts, Sch Med, Worcester, MA USA. FU [1 R18 HS017786] FX Supported By: The project described was supported by grant number 1 R18 HS017786. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA A56 BP S37 EP S37 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800100 ER PT J AU Hagiwara, Y Lee, S Garza, G Huang, C Sanchez-Reilly, S AF Hagiwara, Y. Lee, S. Garza, G. Huang, C. Sanchez-Reilly, S. TI The Gateway to Geriatrics: Impact of an Innovative Early Exposure Geriatrics Curriculum For First Year College Students SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Lee, S.; Huang, C.; Sanchez-Reilly, S.] South Texas Vet Hlth Care Syst, GEC GRECC, San Antonio, TX USA. [Garza, G.] St Marys Univ, San Antonio, TX USA. [Hagiwara, Y.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. FU Hartford CoE Award, HRSA FX Supported By: Hartford CoE Award, HRSA NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA A71 BP S42 EP S42 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800115 ER PT J AU Hagiwara, Y Healy, J Ghannam, S Lee, S Sanchez-Reilly, S AF Hagiwara, Y. Healy, J. Ghannam, S. Lee, S. Sanchez-Reilly, S. TI The Family Meeting OSCE Assessment Tool: Development and Validation of a Novel Assessment Tool SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Hagiwara, Y.; Healy, J.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lee, S.; Sanchez-Reilly, S.] South Texas Vet Hlth Care Syst, GEC GRECC, San Antonio, TX USA. [Ghannam, S.] Univ Texas San Antonio, San Antonio, TX USA. FU Hartford CoE Award, HRSA FX Supported By: Hartford CoE Award, HRSA NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA A70 BP S41 EP S42 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800114 ER PT J AU Harris, J Hagiwara, Y Kasbarian, C Lee, S Ross, J AF Harris, J. Hagiwara, Y. Kasbarian, C. Lee, S. Ross, J. TI Geri-SAFE: An Educational Intervention to Aid Students in the Prevention & Assessment of Falls in the Elderly SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Harris, J.; Hagiwara, Y.; Kasbarian, C.; Lee, S.; Ross, J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Harris, J.; Hagiwara, Y.; Kasbarian, C.; Lee, S.; Ross, J.] South Texas Vet Hlth Care Syst, GEC GRECC, San Antonio, TX USA. FU MSTAR/AFAR; University of Texas System Patient Safety Medical Education Award FX Supported By: Supported by: MSTAR/AFAR and The University of Texas System Patient Safety Medical Education Award NR 0 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA B71 BP S111 EP S111 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800308 ER PT J AU Harrison, KL Smith, AK AF Harrison, K. L. Smith, A. K. TI Advance care planning in older adults: wide disparities, no difference by health SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Harrison, K. L.; Smith, A. K.] Univ Calif San Francisco, Geriatr, San Francisco, CA 94143 USA. [Harrison, K. L.; Smith, A. K.] San Francisco VA Med Ctr, San Francisco, CA USA. FU National Institute of Aging [T32-AG000212] FX Supported By: National Institute of Aging T32-AG000212 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA B79 BP S114 EP S114 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800316 ER PT J AU Hsu, A Gan, S Stijacic-Cenzer, I Lee, S AF Hsu, A. Gan, S. Stijacic-Cenzer, I. Lee, S. TI Glycemic control and functional status in residents of VA Community Living Centers (CLC) SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Hsu, A.; Stijacic-Cenzer, I.; Lee, S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hsu, A.; Gan, S.; Stijacic-Cenzer, I.; Lee, S.] San Francisco VA Med Ctr, San Francisco, CA USA. FU Beeson Career Development program from National Institute on Aging [K23AG040779]; American Federation of Aging Research FX Supported By: This work was supported with resources from and the use of facilities at the San Francisco VA Medical Center. S.J.L was supported by the Beeson Career Development program from the National Institute on Aging (K23AG040779) and the American Federation of Aging Research. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA C56 BP S169 EP S170 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800467 ER PT J AU Jang, M Davis, D Edes, T Makineni, R Kinosian, B AF Jang, M. Davis, D. Edes, T. Makineni, R. Kinosian, B. TI How Many Independence at Home Qualified (IAH-Q) Veterans do Home Based Primary Care (HBPC) Programs Think Need HBPC? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Jang, M.; Kinosian, B.] Philadelphia VAMC, GEC DAC, Philadelphia, PA USA. [Davis, D.; Edes, T.] US Dept Vet Affairs, Washington, DC USA. [Makineni, R.] Providence VAMC, GEC DAC, Providence, RI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA B109 BP S126 EP S126 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800346 ER PT J AU Joseph, M Higbea, A Thorpe, C Coley, K McGiveny, M Klatt, P Schleiden, L Zaharoff, J Cox-Vance, L Corbo, J Balestrino, V Sakely, H AF Joseph, M. Higbea, A. Thorpe, C. Coley, K. McGiveny, M. Klatt, P. Schleiden, L. Zaharoff, J. Cox-Vance, L. Corbo, J. Balestrino, V. Sakely, H. TI Surveys of older adult's medication-related self-efficacy and adherence: Pharmacist-led InterVentions On Transitions of Seniors (PIVOTS) SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Joseph, M.; Klatt, P.; Balestrino, V.; Sakely, H.] UPMC St Margaret, Pittsburgh, PA USA. [Thorpe, C.; Coley, K.; McGiveny, M.; Schleiden, L.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. [Thorpe, C.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Zaharoff, J.] Presbyterian Senior Care, Pittsburgh, PA USA. [Cox-Vance, L.] Chillicothe VA Med Ctr, Chillicothe, OH USA. [Higbea, A.] Texas Tech Univ, Sch Pharm, Lubbock, TX 79409 USA. [Corbo, J.] South Texas VA Hlth Syst, San Antonio, TX USA. FU ASHP Research and Education Foundation; Jewish Healthcare Foundation FX Supported By: ASHP Research and Education Foundation; Jewish Healthcare Foundation NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA D113 BP S257 EP S257 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800715 ER PT J AU Kennelty, KA Jensen, L Gehring, M Gilmore-Bykovskyi, A Roiland, R Hager, DR Kind, A AF Kennelty, K. A. Jensen, L. Gehring, M. Gilmore-Bykovskyi, A. Roiland, R. Hager, D. R. Kind, A. TI Development of the Preventing Opioid Theft and Ensuring Secure Transfer of Personal Health Information (PROTECT PHI) Intervention when Patients Transition from the Hospital to a Nursing Home SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Kennelty, K. A.; Jensen, L.; Gehring, M.; Gilmore-Bykovskyi, A.; Roiland, R.; Kind, A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Kennelty, K. A.; Gehring, M.; Gilmore-Bykovskyi, A.; Roiland, R.; Kind, A.] Univ Wisconsin, Madison, WI USA. [Hager, D. R.] UW Hlth, Madison, WI USA. FU National Institute on Aging Beeson Career Development Award [K23AG034551]; National Institute on Aging Beeson Career Development Award (National Institute on Aging); National Institute on Aging Beeson Career Development Award (American Federation for Aging Research); National Institute on Aging Beeson Career Development Award (John A. Hartford Foundation); National Institute on Aging Beeson Career Development Award (Atlantic Philanthropies); National Institute on Aging Beeson Career Development Award (Starr Foundation); National Institute on Aging [2P50AG033514-06]; University of Wisconsin School of Medicine and Public Health from the Wisconsin Partnership Program; Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research (UW ICTR), [1UL1RR025011] FX Supported By: This material is the result of work supported with resources at the William S. Middleton Memorial Veterans Hospital, Madison, WI. The contents do not represent views of the Dept. of Veterans Affairs or the United States Government. Dr. Kind was supported by a National Institute on Aging Beeson Career Development Award (K23AG034551 [PI Kind], National Institute on Aging, The American Federation for Aging Research, The John A. Hartford Foundation, The Atlantic Philanthropies and The Starr Foundation); National Institute on Aging 2P50AG033514-06. Dr. Kind's time was also partially supported by the University of Wisconsin School of Medicine and Public Health from the Wisconsin Partnership Program. Additional support was provided by the Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research (UW ICTR), grant 1UL1RR025011 from the Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources, National Institutes of Health. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA B146 BP S140 EP S140 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800383 ER PT J AU Kennelty, KA Gilmore-Bykovskyi, A Kind, A AF Kennelty, K. A. Gilmore-Bykovskyi, A. Kind, A. TI Absence of warfarin discharge communication components increases risk of 30-day rehospitalization and/or death in stroke and hip fracture patients discharged to sub-acute care SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Kennelty, K. A.; Gilmore-Bykovskyi, A.; Kind, A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Kennelty, K. A.; Gilmore-Bykovskyi, A.; Kind, A.] Univ Wisconsin, Madison, WI USA. FU National Institute on Aging Beeson Career Development Award [K23AG034551]; National Institute on Aging Beeson Career Development Award (National Institute on Aging, The American Federation for Aging Research); National Institute on Aging Beeson Career Development Award (The John A. Hartford Foundation); National Institute on Aging Beeson Career Development Award (The Atlantic Philanthropies); National Institute on Aging Beeson Career Development Award (Starr Foundation); National Institute on Aging [2P50AG033514-06]; University of Wisconsin School of Medicine and Public Health from the Wisconsin Partnership Program; Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research (UW ICTR) [1UL1RR025011] FX Supported By: This material is the result of work supported with resources at the William S. Middleton Memorial Veterans Hospital, Madison, WI. The contents do not represent views of the Dept. of Veterans Affairs or the United States Government. Dr. Kind was supported by a National Institute on Aging Beeson Career Development Award (K23AG034551 [PI Kind], National Institute on Aging, The American Federation for Aging Research, The John A. Hartford Foundation, The Atlantic Philanthropies and The Starr Foundation); National Institute on Aging 2P50AG033514-06. Dr. Kind's time was also partially supported by the University of Wisconsin School of Medicine and Public Health from the Wisconsin Partnership Program. Additional support was provided by the Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research (UW ICTR), grant 1UL1RR025011 from the Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources, National Institutes of Health. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA B81 BP S115 EP S115 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800318 ER PT J AU Lin, A Brook, J Grill, J Teng, E AF Lin, A. Brook, J. Grill, J. Teng, E. TI Participant-Informant Relationship Affects Quality of Life Ratings in Incipient and Clinical Alzheimer's Disease SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Lin, A.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Brook, J.] Univ Calif Los Angeles, David Geffen Sch Med, Med, Los Angeles, CA 90095 USA. [Grill, J.] UCI, Inst Memory Impairments & Neurol Disorders, Irvine, CA USA. [Teng, E.] Univ Calif Los Angeles, David Geffen Sch Med, Neurol, Los Angeles, CA 90095 USA. [Teng, E.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. FU National Institute on Aging [T35 AG026736, P50 AG16570]; Alzheimer's Disease Research Centers of California; Sidell-Kagan Foundation FX National Institute on Aging (T35 AG026736 [UCLA Medical Student Training in Aging Research Program], P50 AG16570 [UCLA Alzheimer's Disease Research Center]), Alzheimer's Disease Research Centers of California, and the Sidell-Kagan Foundation NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA B119 BP S130 EP S130 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800356 ER PT J AU Linden, J Stowers, KH Veeder, H Lee, S Sanchez-Reilly, S AF Linden, J. Stowers, K. H. Veeder, H. Lee, S. Sanchez-Reilly, S. TI Protecting our Vulnerable: Mistreatment in Palliative Care SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Linden, J.] Univ Hawaii Manoa, JABSOM, Honolulu, HI 96822 USA. [Stowers, K. H.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Veeder, H.] VITAS Hosp, San Antonio, TX USA. [Lee, S.; Sanchez-Reilly, S.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA D153 BP S271 EP S271 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800755 ER PT J AU Lum, H Jones, J Sudore, R Schwartz, R Levy, C Kutner, JD AF Lum, H. Jones, J. Sudore, R. Schwartz, R. Levy, C. Kutner, J. D. TI A Group Visit Intervention Improves Advance Care Planning Readiness, Conversations, and Documentation SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Lum, H.; Schwartz, R.; Levy, C.; Kutner, J. D.] Univ Colorado, Sch Med, Aurora, CO USA. [Lum, H.; Schwartz, R.] VA Eastern Colorado GRECC, Denver, CO USA. [Jones, J.] Univ Colorado, Coll Nursing, Aurora, CO USA. [Sudore, R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Sudore, R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. FU Colorado Health Foundation; University of Colorado Hospital/University of Colorado Denver/University Physicians, Inc. Primary Care Strategic Initiative Fund FX The Colorado Health Foundation; University of Colorado Hospital/University of Colorado Denver/University Physicians, Inc. Primary Care Strategic Initiative Fund NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA B100 BP S122 EP S123 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800337 ER PT J AU Mireles, C Murray, A Pagan-Ferrer, J Arevalo-Flechas, LC Ross, J AF Mireles, C. Murray, A. Pagan-Ferrer, J. Arevalo-Flechas, L. C. Ross, J. TI Determining the Efficacy of Clinical Novelas as a Teaching Tool for Fall Prevention in the Geriatric Population SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Mireles, C.; Murray, A.; Pagan-Ferrer, J.; Arevalo-Flechas, L. C.; Ross, J.] Univ Texas Hlth Sci Ctr San Antonio, Hlth Sci Ctr, San Antonio, TX 78229 USA. [Mireles, C.; Murray, A.; Pagan-Ferrer, J.; Arevalo-Flechas, L. C.; Ross, J.] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. FU University of Texas System Patient Safety Medical Education Award FX Supported By: University of Texas System Patient Safety Medical Education Award NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA C165 BP S207 EP S208 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800576 ER PT J AU Miura, L Onitsuka, J Srikantom, S Delmar, J Blehm, R AF Miura, L. Onitsuka, J. Srikantom, S. Delmar, J. Blehm, R. TI Preliminary Outcomes of a Fall Assessment Clinic SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Miura, L.; Onitsuka, J.; Srikantom, S.; Delmar, J.; Blehm, R.] Portland VA Med Ctr, Med, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA A178 BP S80 EP S80 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800222 ER PT J AU Nakano, C Chen, R Bell, C Robbins, J Ross, G Abbott, R Petrovitch, H Masaki, K AF Nakano, C. Chen, R. Bell, C. Robbins, J. Ross, G. Abbott, R. Petrovitch, H. Masaki, K. TI Dysphagia as a Predictor of All-Cause Mortality: The Honolulu-Asia Aging Study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Nakano, C.; Bell, C.; Ross, G.; Abbott, R.; Petrovitch, H.; Masaki, K.] Univ Hawaii, Geriatr Med, Honolulu, HI 96822 USA. [Chen, R.; Masaki, K.] Kuakini Med Ctr, Honolulu, HI USA. [Ross, G.; Petrovitch, H.] Vet Affairs Pacific Islands Hlth Care Syst, Honolulu, HI USA. [Abbott, R.] Shiga Univ Med Sci, Ctr Epidemiol Res Asia, Otsu, Shiga 52021, Japan. [Robbins, J.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Robbins, J.] Univ Wisconsin, Madison, WI USA. FU John A. Hartford Foundation Center of Excellence in Geriatrics; Department of Geriatric Medicine, University of Hawaii; John A. Burns School of Medicine, University of Hawaii; Kuakini Medical Center; National Institutes of Health (NIH) from National Institute on Aging [N01-AG-4-2149, U01 AG019349, R01AG027060, R01AG038707]; National Institutes of Health (NIH) from National Heart, Lung, and Blood Institute [N01-HC-05102]; Hawaii Community Foundation [2004-0463]; Office for Research and Development, Department of Veterans Affairs FX Supported By: This study was supported by the John A. Hartford Foundation Center of Excellence in Geriatrics, Department of Geriatric Medicine, John A. Burns School of Medicine, University of Hawaii; the Kuakini Medical Center; the National Institutes of Health (NIH) (Contract N01-AG-4-2149, Grants U01 AG019349, R01AG027060, and R01AG038707 from the National Institute on Aging, and Contract N01-HC-05102 from the National Heart, Lung, and Blood Institute); Hawaii Community Foundation grant 2004-0463; and the Office for Research and Development, Department of Veterans Affairs. The views expressed in this abstract do not necessarily represent those of the federal government. The funding sources had no role in the analysis. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA B63 BP S108 EP S108 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800300 ER PT J AU Niemiec, SS Halle, A Sarkisian, C AF Niemiec, S. Schepens Halle, A. Sarkisian, C. TI Knowledge and anxiety about aging and negative bias toward older adults in White and Asian occupational therapy students SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Niemiec, S. Schepens; Halle, A.] Univ So Calif, Div Occupat Sci & Occupat Therapy, Los Angeles, CA USA. [Sarkisian, C.] GRECC, VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Sarkisian, C.] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA 90095 USA. FU NIH--NCMRR [K12 HD055929]; NINDS; Midcareer Award in Patient-Oriented Community-Academic Partnered Aging Research [1K24AG047899-01] FX Supported By: Dr. Schepens Niemiec is supported by K12 HD055929 NIH--NCMRR and NINDS. Dr. Sarkisian is supported by 1K24AG047899-01 Midcareer Award in Patient-Oriented Community-Academic Partnered Aging Research. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA C79 BP S177 EP S178 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800490 ER PT J AU Nirkhe, S Rhea, EM Banks, WA AF Nirkhe, S. Rhea, E. M. Banks, W. A. TI Effects of Intranasal Insulin on Brain Insulin Signaling in an Aged Mouse Model of Alzheimer's Disease SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Nirkhe, S.; Rhea, E. M.; Banks, W. A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Nirkhe, S.] Univ Washington, Sch Med, Seattle, WA USA. [Rhea, E. M.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Banks, W. A.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. FU Medical Student Training in Aging Research Program, National Institute on Aging FX Supported By: Medical Student Training in Aging Research Program, National Institute on Aging NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA D122 BP S260 EP S260 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800724 ER PT J AU Obal, L Tubbesing, SA Vega, A Nelson, S Toy, S Brazier, J Bai, J Dhanani, S AF Obal, L. Tubbesing, S. A. Vega, A. Nelson, S. Toy, S. Brazier, J. Bai, J. Dhanani, S. TI Using Geographic Information Systems to Improve Practitioner Travel Efficiency in Home Based Primary Care SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Brazier, J.] VA Greater Angeles Healthcare Syst, Adm Med, Los Angeles, CA USA. [Tubbesing, S. A.] Univ Calif Los Angeles, David Geffen Sch Med, Internal Med Geriatr, Los Angeles, CA 90095 USA. [Dhanani, S.] VA Southern Oregon Rehabil Ctr & Clin, White City, OR USA. [Bai, J.] Vet Emergency Management Evaluat Ctr, Los Angeles, CA USA. [Toy, S.] VA Greater Angeles Healthcare Syst, Geriatr & Rehabil Care, Los Angeles, CA USA. [Nelson, S.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA. [Vega, A.] Univ Penn, NewCourtland Ctr Transit & Hlth, Philadelphia, PA 19104 USA. [Obal, L.; Tubbesing, S. A.] VA Greater Angeles Healthcare Syst, Geriatr & Extended Care, Los Angeles, CA USA. FU VA Office of Geriatrics and Extended Care FX Supported By: VA Office of Geriatrics and Extended Care NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA C117 BP S191 EP S191 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800528 ER PT J AU Pang, M Bartholomew, A Castle, S Lee, CC AF Pang, M. Bartholomew, A. Castle, S. Lee, C. C. TI Maintaining Diabetes Prevention Behaviors using a Social Cognitive Health Coaching Approach Within the Construct of GEROFIT SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Pang, M.; Bartholomew, A.; Castle, S.; Lee, C. C.] VA Greater Los Angeles, GRECC, Los Angeles, CA USA. [Castle, S.; Lee, C. C.] Univ Calif Los Angeles, David Geffen Sch Med, Internal Med Geriatr, Los Angeles, CA 90095 USA. FU VA Office of Geriatrics and Extended Care Transformative Non-Institutional Long Term Care Program; VHA Office of Rural Health FX Supported By: 1) VA Office of Geriatrics and Extended Care Transformative Non-Institutional Long Term Care Program; 2) VHA Office of Rural Health NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA D142 BP S267 EP S267 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800744 ER PT J AU Phibbs, C Intrator, O Kinosian, B Scott, W Dally, S Shay, K AF Phibbs, C. Intrator, O. Kinosian, B. Scott, W. Dally, S. Shay, K. TI Cost of Care for Veterans Receiving Primary Care in Patient Aligned Care Teams (PACT) vs. Geriatric PACT SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Phibbs, C.] Stanford Univ, Stanford, CA 94305 USA. [Phibbs, C.; Scott, W.; Dally, S.] VA Palo Alto Healthcare Syst, GECDAC & HERC, Palo Alto, CA USA. [Intrator, O.] Canandaigua VA Med Ctr, GECDAC, Canandaigua, NY USA. [Intrator, O.] Univ Rochester, Rochester, NY USA. [Kinosian, B.] Philadelphia VA Med Ctr, GECDAC, Philadelphia, PA USA. [Kinosian, B.] Univ Penn, Philadelphia, PA 19104 USA. [Shay, K.] Geriatr & Extended Care VA, Washington, DC USA. FU Veterans Affairs Office of Geriatrics and Extended Care Service FX Supported By: Veterans Affairs Office of Geriatrics and Extended Care Service NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA P17 BP S7 EP S7 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800018 ER PT J AU Ritchey, KC Olney, A Wojtowicz, M Howard, I Phelan, EA Matsumoto, AM AF Ritchey, K. C. Olney, A. Wojtowicz, M. Howard, I. Phelan, E. A. Matsumoto, A. M. TI The Relationship between Self-Report and Performance-Based Measures of Mobility in Persons with Osteoporosis SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Ritchey, K. C.; Wojtowicz, M.; Matsumoto, A. M.] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. [Ritchey, K. C.; Phelan, E. A.; Matsumoto, A. M.] Univ Washington, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Olney, A.; Howard, I.] VA Puget Sound Hlth Care Syst, RCS, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA C170 BP S209 EP S209 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800581 ER PT J AU Rodriguez, JC Alessi, C Martin, JL Hays, R Dzierzewski, J Col, N Patterson, E Jouldjian, S Josephson, K Song, Y Fung, CH AF Rodriguez, J. C. Alessi, C. Martin, J. L. Hays, R. Dzierzewski, J. Col, N. Patterson, E. Jouldjian, S. Josephson, K. Song, Y. Fung, C. H. TI Association Between Pain And Difficulty Setting Up Positive Airway Pressure Devices Among Older Adults With Sleep-Disordered Breathing SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Rodriguez, J. C.; Alessi, C.; Martin, J. L.; Hays, R.; Dzierzewski, J.; Fung, C. H.] Univ Calif Los Angeles, Med, Los Angeles, CA USA. [Rodriguez, J. C.; Alessi, C.; Martin, J. L.; Dzierzewski, J.; Jouldjian, S.; Josephson, K.; Song, Y.; Fung, C. H.] Vet Affairs Greater Los Angeles, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Col, N.] Univ New England, Main, ME USA. [Patterson, E.] Ohio State Univ, Columbus, OH 43210 USA. FU National Institute On Aging of the National Institutes of Health [K23AG045937]; Beeson Career Development in Aging Research Award Program; NIA; AFAR; John A. Hartford Foundation; Atlantic Philanthropies FX Supported By: Research reported in this publication was supported by the National Institute On Aging of the National Institutes of Health under Award Number K23AG045937 and The Beeson Career Development in Aging Research Award Program (supported by NIA, AFAR, The John A. Hartford Foundation, and The Atlantic Philanthropies). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Department of Veterans Affairs. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA D59 BP S238 EP S238 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800662 ER PT J AU Vandenberg, AE Vaughan, C Stevens, M Hastings, SN Powers, J Markland, AD Hwang, U Hung, W Echt, K AF Vandenberg, A. E. Vaughan, C. Stevens, M. Hastings, S. N. Powers, J. Markland, A. D. Hwang, U. Hung, W. Echt, K. TI Evaluating use of a clinical decision support tool to improve quality of geriatric prescribing in the ED SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Vandenberg, A. E.; Vaughan, C.; Stevens, M.; Echt, K.] Birmingham & Atlanta VAMC, GRECC, Atlanta, GA USA. [Vandenberg, A. E.; Vaughan, C.; Stevens, M.; Echt, K.] Emory Univ, Med, Atlanta, GA 30322 USA. [Hastings, S. N.] Durham VAMC, GRECC, Durham, NC USA. [Hastings, S. N.] Duke Univ, Med, Durham, NC USA. [Powers, J.] Tennessee Valley VAMC, GRECC, Nashville, TN USA. [Powers, J.] Vanderbilt Univ, Med, 221 Kirkland Hall, Nashville, TN 37235 USA. [Markland, A. D.] Birmingham & Atlanta VAMC, GRECC, Birmingham, AL USA. [Markland, A. D.] Univ Alabama Birmingham, Med, Birmingham, AL USA. [Hwang, U.; Hung, W.] James J Peters VAMC, GRECC, Bronx, NY USA. FU VA Office of Geriatrics and Extended Care; VA office of Rural Health; John A. Hartford Foundation; Emory University Department of Medicine FX Supported By: Funding provided by the VA Office of Geriatrics and Extended Care, VA office of Rural Health, John A. Hartford Foundation, and Emory University Department of Medicine NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA C109 BP S188 EP S188 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800520 ER PT J AU Zullo, AR Lee, Y Daiello, LA Mor, V Boscardin, W Steinman, M AF Zullo, A. R. Lee, Y. Daiello, L. A. Mor, V. Boscardin, W. Steinman, M. TI Effect of Beta Blocker Use on Daily Functioning, Rehospitalization, and Death After Myocardial Infarction Among Older Nursing Home Residents. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-Geriatrics-Society CY MAY 19-21, 2016 CL Long Beach, CA SP Amer Geriatr Soc C1 [Zullo, A. R.; Lee, Y.; Daiello, L. A.; Mor, V.] Brown Univ, Hlth Serv Policy & Practice, North Kingstown, RI USA. [Boscardin, W.; Steinman, M.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Boscardin, W.; Steinman, M.] San Francisco VA Med Ctr, San Francisco, CA USA. FU NIH [5R01HL111032-03]; AHRQ [5K12HS022998-02] FX Supported By: NIH (5R01HL111032-03) and AHRQ (5K12HS022998-02) NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2016 VL 64 SU 1 SI SI MA P25 BP S10 EP S10 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK2SD UT WOS:000374763800025 ER PT J AU Friedman, CP Donaldson, KM Vantsevich, AV AF Friedman, Charles P. Donaldson, Katherine M. Vantsevich, Anna V. TI Educating medical students in the era of ubiquitous information SO MEDICAL TEACHER LA English DT Article ID HEALTH-CARE; TECHNOLOGY; ERROR AB Health care around the world is going digital. This inexorable trend will result in: (1) routine documentation of care in digital form and emerging national infrastructures for sharing data that allow progress toward a learning health system; and (2) a biomedical knowledge cloud that is fully integrated into practice environments and accessible to both providers and consumers of healthcare. Concurrently, medical students will be complete digital natives who have literally grown up with the Internet and will enter practice early in the next decade when the projected changes in practice approach maturity. This essay describes three competencies linked to this evolving information environment(1) knowing what you do and don't know, (2) ability to ask a good question, and (3) skills in evaluating and weighing evidenceand suggests educational approaches to promote student mastery of each competency. Shifting medical education to address these competencies will call into question many current methods but may be essential to fully prepare trainees for optimal practice in the future. C1 [Friedman, Charles P.] Univ Michigan, Sch Med, Dept Learning Hlth Sci, Ann Arbor, MI 48109 USA. [Friedman, Charles P.] Univ Michigan, Sch Informat, Sch Publ Hlth, Ann Arbor, MI 48109 USA. [Donaldson, Katherine M.] Univ Chicago, NORC, Hlth Sci, Bethesda, MD USA. [Vantsevich, Anna V.] Mental Hlth Serv, San Francisco VA Med Ctr, San Francisco, CA USA. RP Friedman, CP (reprint author), Univ Michigan, Sch Med, 209 Victor Vaughan Bldg,SPC 2054, Ann Arbor, MI 48109 USA. EM cpfried@umich.edu NR 29 TC 0 Z9 0 U1 6 U2 10 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0142-159X EI 1466-187X J9 MED TEACH JI Med. Teach. PD MAY PY 2016 VL 38 IS 5 BP 504 EP 509 DI 10.3109/0142159X.2016.1150990 PG 6 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA DL7YD UT WOS:000375855400010 PM 27027546 ER PT J AU Duong, HA Le, KT Soulema, AL Yueh, RH Scheuner, MT Holick, MF Christensen, R Tajima, TL Leung, AM Mallya, SM AF Duong, Hannah A. Le, Karen T. Soulema, Albert L. Yueh, Ronald H. Scheuner, Maren T. Holick, Michael F. Christensen, Russell Tajima, Tracey L. Leung, Angela M. Mallya, Sanjay M. TI Gnathodiaphyseal dysplasia: report of a family with a novel mutation of the ANO5 gene SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY LA English DT Article ID FIBROOSSEOUS LESIONS; BONE; OSTEONECROSIS; PROTEIN; JAW AB Gnathodiaphyseal dysplasia (GDD) is a rare autosomal dominant disorder characterized by florid osseous dysplasia of the jaws, bone fragility, and diaphyseal cortical thickening and bowing of long bones. We present a family with previously undiagnosed GDD. The disorder was identified by the characteristic gnathic and skeletal manifestations in the father. Clinical and radiologic examination of the patient's son also revealed the characteristic features of GDD. Gene sequencing revealed a novel mutation (c. 1067 G>A, p. Cys356 Tyr) in the ANO5 gene, which is causative for GDD. This mutation was predicted to be detrimental by computational analyses and by structural modeling of the protein. The implications for recognition and management of this disease are discussed. C1 [Duong, Hannah A.; Mallya, Sanjay M.] Univ Calif Los Angeles, Sch Dent, Sect Oral & Maxillofacial Radiol, Los Angeles, CA 90024 USA. [Le, Karen T.; Leung, Angela M.] VA Greater Los Angeles Healthcare Syst, Div Endocrinol, Los Angeles, CA USA. [Le, Karen T.] Cedars Sinai Med Ctr, Div Endocrinol, Los Angeles, CA 90048 USA. [Soulema, Albert L.; Tajima, Tracey L.] VA Greater Los Angeles Healthcare Syst, Dept Dent, Los Angeles, CA USA. [Yueh, Ronald H.] VA Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Surg, Dent Serv, Sepulveda Campus, Los Angeles, CA USA. [Scheuner, Maren T.] VA Greater Los Angeles Healthcare Syst, Div Med Genet, Los Angeles, CA USA. [Scheuner, Maren T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Holick, Michael F.] Boston Univ, Sch Med, Sect Endocrinol Diabet & Nutr, Boston, MA 02118 USA. [Christensen, Russell] Univ Calif Los Angeles, Sch Dent, Sect Oral & Maxillofacial Pathol, Los Angeles, CA 90024 USA. [Leung, Angela M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol, Los Angeles, CA 90095 USA. RP Mallya, SM (reprint author), Univ Calif Los Angeles, Sch Dent, 53-068 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM Smallya@ucla.edu FU Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health [K23 HD068552] FX AML was supported, in part, by the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health under award number K23 HD068552. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 21 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2212-4403 EI 1528-395X J9 OR SURG OR MED OR PA JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. PD MAY PY 2016 VL 121 IS 5 BP E123 EP E128 DI 10.1016/j.oooo.2016.01.014 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA DL4LN UT WOS:000375608100005 PM 27068316 ER PT J AU Suri, P Pearson, AM Scherer, EA Zhao, WY Lurie, JD Morgan, TS Weinstein, JN AF Suri, Pradeep Pearson, Adam M. Scherer, Emily A. Zhao, Wenyan Lurie, Jon D. Morgan, Tamara S. Weinstein, James N. TI Recurrence of Pain After Usual Nonoperative Care for Symptomatic Lumbar Disk Herniation: Analysis of Data From the Spine Patient Outcomes Research Trial SO PM&R LA English DT Article ID LOW-BACK-PAIN; RISK-FACTORS; LONGITUDINAL ASSESSMENT; NONSURGICAL TREATMENT; GENERAL-POPULATION; SPORT; SCIATICA; COHORT; PREDICTORS; DISABILITY AB Objective: To determine risks and predictors of recurrent leg and low back pain (LBP) after unstructured, usual nonoperative care for subacute/chronic symptomatic lumbar disk herniation (LDH). Design: Secondary analysis of data from a concurrent randomized trial and observational cohort study. Setting: Thirteen outpatient spine practices. Participants: A total of 199 participants with resolution of leg pain and 142 participants with resolution of LBP from among 478 participants receiving usual nonoperative care for symptomatic LDH. Assessment of Risk Factors: Potential predictors of recurrence included time to initial symptom resolution, sociodemographics, clinical characteristics, work-related factors, imaging-detected herniation characteristics, and baseline pain bothersomeness. Main Outcome Measurements: Leg pain and LBP bothersomeness were assessed by the use of a 0-6 numerical scale at up to 4 years of follow-up. For individuals with initial resolution of leg pain, we defined recurrent leg pain as having leg pain, receiving lumbar epidural steroid injections, or undergoing lumbar surgery subsequent to initial leg pain resolution. We calculated cumulative risks of recurrence by using Kaplan-Meier survival plots and examined predictors of recurrence using Cox proportional hazards models. We used similar definitions for LBP recurrence. Results: One-and 3-year cumulative recurrence risks were 23% and 51% for leg pain, and 28% and 70% for LBP, respectively. Early leg pain resolution did not predict future leg pain recurrence. Complete leg pain resolution (adjusted hazard ratio [aHR] 0.47, 95% confidence interval [CI] 0.31-0.72) and posterolateral herniation location (aHR 0.61; 95% CI 0.39-0.97) predicted a lower risk of leg pain recurrence, and joint problems (aHR 1.89; 95% CI 1.16-3.05) and smoking (aHR 1.81; 95% CI 1.07-3.05) predicted a greater risk of leg pain recurrence. For participants with complete initial resolution of pain, recurrence risks at 1 and 3 years were 16% and 41% for leg pain and 24% and 59% for LBP, respectively. Conclusions: Recurrence of pain is common after unstructured, usual nonsurgical care for LDH. These risk estimates depend on the specific definitions applied, and the predictors identified require replication in future studies. C1 [Suri, Pradeep] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr ERIC, S-152 ERIC,1660 S Columbian Way, Seattle, WA USA. [Suri, Pradeep] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Pearson, Adam M.; Zhao, Wenyan] Dartmouth Hitchcock Med Ctr, Geisel Sch Med, Dept Orthopaed, Hanover, NH USA. [Scherer, Emily A.] Dartmouth Hitchcock Med Ctr, Geisel Sch Med, Dept Med, Hanover, NH USA. [Lurie, Jon D.] Dartmouth Hitchcock Med Ctr, Geisel Sch Med, Dartmouth Inst Hlth Policy & Clin Practice, Dept Med, Hanover, NH USA. [Morgan, Tamara S.; Weinstein, James N.] Dartmouth Hitchcock Med Ctr, Geisel Sch Med, Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH USA. RP Suri, P (reprint author), VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr ERIC, S-152 ERIC,1660 S Columbian Way, Seattle, WA USA.; Suri, P (reprint author), Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. EM pradeep.suri@va.gov FU National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [U01-AR45444]; Office of Research on Women's Health; National Institutes of Health; National Institute of Occupational Safety and Health; Centers for Disease Control and Prevention; NIAMS [P60-AR048094, P60-AR062799]; VA Puget Sound Health Care System FX Supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; U01-AR45444) and the Office of Research on Women's Health, the National Institutes of Health, and the National Institute of Occupational Safety and Health, the Centers for Disease Control and Prevention. The Multidisciplinary Clinical Research Center in Musculoskeletal Diseases is funded by NIAMS (P60-AR048094 and P60-AR062799). Dr. Suri's participation is this study was funded by VA Puget Sound Health Care System. The authors report no financial arrangements that may represent a possible conflict of interest with the work presented. NR 36 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 EI 1934-1563 J9 PM&R JI PM&R PD MAY PY 2016 VL 8 IS 5 BP 405 EP 414 DI 10.1016/j.pmrj.2015.10.016 PG 10 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA DL6LA UT WOS:000375749500002 PM 26548963 ER PT J AU Glaser, J Reeves, ST Stoll, WD Epperson, TI Hilbert, M Madan, A George, MS Borckardt, JJ AF Glaser, John Reeves, Scott T. Stoll, William David Epperson, Thomas I. Hilbert, Megan Madan, Alok George, Mark S. Borckardt, Jeffrey J. TI Motor/Prefrontal Transcranial Direct Current Stimulation (tDCS) Following Lumbar Surgery Reduces Postoperative Analgesia Use SO SPINE LA English DT Article DE back pain; brain stimulation; lumbar surgery; motor cortex; opioid use; pain; prefrontal cortex; transcranial direct current stimulation ID MOTOR CORTEX STIMULATION; CHRONIC NEUROPATHIC PAIN; SPINAL-CORD-INJURY; PREFRONTAL CORTEX; FIBROMYALGIA; RTMS; ELECTROACUPUNCTURE; REPLACEMENT; PERCEPTION; BRAIN AB Design. Randomized, controlled pilot trial. Objective. The present study is the first randomized, double-blind, sham-controlled pilot clinical trial of transcranial direct current stimulation (tDCS) for pain and patient-controlled analgesia (PCA) opioid usage among patients receiving spine surgery. Summary of Background Data. Lumbar spinal surgeries are common, and while pain is often a complaint that precedes surgical intervention, the procedures themselves are associated with considerable postoperative pain lasting days to weeks. Adequate postoperative pain control is an important factor in determining recovery and new analgesic strategies are needed that can be used adjunctively to existing strategies potentially to reduce reliance on opioid analgesia. Several novel brain stimulation technologies including tDCS are beginning to demonstrate promise as treatments for a variety of pain conditions. Methods. Twenty-seven patients undergoing lumbar spine procedures at Medical University of South Carolina were randomly assigned to receive four 20-minute sessions of real or sham tDCS during their postsurgical hospital stay. Patient-administered hydromorphone usage was tracked along with numeric rating scale pain ratings. Results. The effect of tDCS on the slope of the cumulative PCA curve was significant (P < 0.001) and tDCS was associated with a 23% reduction in PCA usage. In the real tDCS group a 31% reduction was observed in pain-at-its-least ratings from admission to discharge (P = 0.027), but no other changes in numeric rating scale pain ratings were significant in either group. Conclusion. The present pilot trial is the first study to demonstrate an opioid sparing effect of tDCS after spine surgical procedures. Although this was a small pilot trial in a heterogeneous sample of spinal surgery patients, a moderate effect-size was observed for tDCS, suggesting that future work in this area is warranted. C1 [Glaser, John] Med Univ S Carolina, Dept Orthoped Surg, Charleston, SC 29425 USA. [Reeves, Scott T.; Stoll, William David; Epperson, Thomas I.; Hilbert, Megan; Borckardt, Jeffrey J.] Med Univ S Carolina, Dept Anesthesia & Perioperat Med, Charleston, SC 29425 USA. [Madan, Alok] Menninger Clin, Houston, TX USA. [Madan, Alok] Baylor Coll Med, Houston, TX 77030 USA. [George, Mark S.; Borckardt, Jeffrey J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA. [George, Mark S.; Borckardt, Jeffrey J.] Ralph H Johnson VAMC, Charleston, SC USA. RP Borckardt, JJ (reprint author), Inst Psychiat MSC 861, 507 North,67 President St, Charleston, SC 29425 USA. EM borckard@musc.edu FU National Association for Spine Surgery (NASS) FX National Association for Spine Surgery (NASS) grant funds were received in support of this work. NR 30 TC 2 Z9 2 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0362-2436 EI 1528-1159 J9 SPINE JI SPINE PD MAY PY 2016 VL 41 IS 10 BP 835 EP 839 DI 10.1097/BRS.0000000000001525 PG 5 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA DL4RZ UT WOS:000375626200013 PM 26909844 ER PT J AU Callon, W Saha, S Korthuis, PT Wilson, IB Moore, RD Cohn, J Beach, MC AF Callon, Wynne Saha, Somnath Korthuis, P. Todd Wilson, Ira B. Moore, Richard D. Cohn, Jonathan Beach, Mary Catherine TI Which Clinician Questions Elicit Accurate Disclosure of Antiretroviral Non-adherence When Talking to Patients? SO AIDS AND BEHAVIOR LA English DT Article DE HIV/AIDS; Antiretrovirals; Adherence; Physician-patient communication ID HIV-INFECTED PATIENTS; MEDICATION ADHERENCE; SELF-REPORT; PROVIDER COMMUNICATION; THERAPY; CARE; INSTRUMENTS; BEHAVIOR; OUTCOMES; COHORT AB This study evaluated how clinicians assess antiretroviral (ARV) adherence in clinical encounters, and which questions elicit accurate responses. We conducted conversation analysis of audio-recorded encounters between 34 providers and 58 patients reporting ARV non-adherence in post-encounter interviews. Among 42 visits where adherence status was unknown by providers, 4 providers did not discuss ARVs (10 %), 6 discussed ARVs but did not elicit non-adherence disclosure (14 %), and 32 discussed ARVs which prompted disclosure (76 %). Questions were classified as: (1) clarification of medication ("Are you still taking the Combivir?"); (2) broad ("How's it going with your meds?"); (3) positively-framed ("Are you taking your medications regularly?"); (4) negatively-framed ("Have you missed any doses?"). Clinicians asked 75 ARV-related questions: 23 clarification, 12 broad, 17 positively-framed, and 23 negatively-framed. Negatively-framed questions were 3.8 times more likely to elicit accurate disclosure than all other question types (p < 0.0001). Providers can improve disclosure probability by asking directly about missed doses. C1 [Callon, Wynne; Moore, Richard D.; Beach, Mary Catherine] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Saha, Somnath] Portland VA Med Ctr, Portland, OR USA. [Saha, Somnath; Korthuis, P. Todd] Oregon Hlth & Sci Univ, Dept Med, Portland, OR USA. [Wilson, Ira B.] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, Providence, RI 02912 USA. [Cohn, Jonathan] Wayne State Univ, Dept Med, Detroit, MI 48202 USA. RP Callon, W (reprint author), Johns Hopkins Univ, Sch Med, Baltimore, MD USA. EM wcallon1@jhmi.edu FU Health Resources Service Administration; Agency for Healthcare Research and Quality [AHRQ 290-01-0012]; National Institute of Drug Abuse [K23 DA019809, K24 DA037804]; Department of Veterans Affairs FX This research was supported by a contract from the Health Resources Service Administration and the Agency for Healthcare Research and Quality (AHRQ 290-01-0012). In addition, Dr. Korthuis was supported by the National Institute of Drug Abuse (K23 DA019809). Dr. Saha was supported by the Department of Veterans Affairs, Dr. Beach was supported by the National Institute of Drug Abuse (K24 DA037804). None of the funders had a role in the design and conduct of this analysis, nor was it subject to their final approval. None of the authors have any relevant financial conflicts of interest. NR 29 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD MAY PY 2016 VL 20 IS 5 BP 1108 EP 1115 DI 10.1007/s10461-015-1231-7 PG 8 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA DK3XM UT WOS:000374850700017 PM 26499336 ER PT J AU Yaffe, K AF Yaffe, Kristine TI Moving Beyond Dualism to Advance Geriatric Neuropsychiatry SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Editorial Material ID DEPRESSION C1 [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Box 181,4150 Clement St, San Francisco, CA 94121 USA. RP Yaffe, K (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.; Yaffe, K (reprint author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.; Yaffe, K (reprint author), Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA.; Yaffe, K (reprint author), San Francisco VA Med Ctr, San Francisco, CA USA.; Yaffe, K (reprint author), Univ Calif San Francisco, Box 181,4150 Clement St, San Francisco, CA 94121 USA. EM kristine.yaffe@ucsf.edu NR 10 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAY PY 2016 VL 24 IS 5 BP 339 EP 341 DI 10.1016/j.jagp.2016.01.137 PG 3 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA DK6SF UT WOS:000375054800001 PM 27066734 ER PT J AU Epstein, AE Olshansky, B Naccarelli, GV Kennedy, JI Murphy, EJ Goldschlager, N AF Epstein, Andrew E. Olshansky, Brian Naccarelli, Gerald V. Kennedy, John I., Jr. Murphy, Elizabeth J. Goldschlager, Nora TI Practical Management Guide for Clinicians Who Treat Patients with Amiodarone SO AMERICAN JOURNAL OF MEDICINE LA English DT Review DE Adverse drug reactions; Amiodarone; Atrial fibrillation; Ventricular fibrillation; Ventricular tachycardia ID CONGESTIVE-HEART-FAILURE; ANTIARRHYTHMIC-DRUG-THERAPY; LEFT-VENTRICULAR DYSFUNCTION; ACUTE MYOCARDIAL-INFARCTION; ONSET ATRIAL-FIBRILLATION; SUDDEN CARDIAC DEATH; LOW-DOSE AMIODARONE; PULMONARY TOXICITY; RANDOMIZED-TRIAL; INTRAVENOUS AMIODARONE AB Amiodarone, an iodinated benzofuran derivative with Class I, II, III, and IV antiarrhythmic properties, is the most commonly used antiarrhythmic drug used to treat supraventricular and ventricular arrhythmias. Appropriate use of this drug, with its severe and potentially life-threatening adverse effects, requires an essential understanding of its risk-benefit properties in order to ensure safety. The objective of this review is to afford clinicians who treat patients receiving amiodarone an appropriate management strategy for its safe use. The authors of this consensus management guide have thoroughly reviewed and evaluated the existing literature on amiodarone and apply this information, along with the collective experience of the authors, in its development. Provided are management guides on the intravenous and oral dosing of amiodarone, appropriate outpatient follow-up of patients taking the drug, its recognized adverse effects, and recommendations on when to consult specialists to help in patient management. All clinicians must be cognizant of the appropriate use, follow-up, and adverse reactions of amiodarone. The responsibility incurred by those treating such patients cannot be overemphasized. Published by Elsevier Inc. C1 [Epstein, Andrew E.] Univ Penn, Dept Med, Electrophysiol Sect, Cardiovasc Div, Philadelphia, PA 19104 USA. [Olshansky, Brian] Mercy Hosp North Iowa, Mason City, PA USA. [Naccarelli, Gerald V.] Penn State Univ, Penn State Heart & Vasc Inst, Hershey, PA USA. [Kennedy, John I., Jr.] Univ Alabama Birmingham, Dept Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA. [Kennedy, John I., Jr.] Birmingham VA Med Ctr, Dept Med, Birmingham, AL USA. [Murphy, Elizabeth J.; Goldschlager, Nora] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Murphy, Elizabeth J.] San Francisco Gen Hosp, Dept Med, Div Endocrinol, San Francisco, CA 94110 USA. [Goldschlager, Nora] San Francisco Gen Hosp, Dept Med, Div Cardiol, San Francisco, CA 94110 USA. RP Epstein, AE (reprint author), Univ Penn, Cardiovasc Div, Electrophysiol Sect, 3400 Spruce St,9 Founders, Philadelphia, PA 19104 USA. EM andrew.epstein@uphs.upenn.edu NR 64 TC 7 Z9 7 U1 4 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 EI 1555-7162 J9 AM J MED JI Am. J. Med. PD MAY PY 2016 VL 129 IS 5 BP 468 EP 475 DI 10.1016/j.amjmed.2015.08.039 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA DK7YZ UT WOS:000375144600023 PM 26497904 ER PT J AU Brondfield, S Feingold, KR AF Brondfield, Sam Feingold, Kenneth R. TI Symptomatic Graves' Disease After Autoimmune Hypothyroidism SO AMERICAN JOURNAL OF MEDICINE LA English DT Letter C1 [Brondfield, Sam; Feingold, Kenneth R.] Univ Calif San Francisco, Dept Med, 505 Parnassus Ave,Rm 987, San Francisco, CA 94143 USA. [Brondfield, Sam; Feingold, Kenneth R.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. RP Brondfield, S (reprint author), Univ Calif San Francisco, Dept Med, 505 Parnassus Ave,Rm 987, San Francisco, CA 94143 USA. EM sam.brondfield@ucsf.edu NR 5 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 EI 1555-7162 J9 AM J MED JI Am. J. Med. PD MAY PY 2016 VL 129 IS 5 BP E19 EP E20 DI 10.1016/j.amjmed.2015.12.017 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DK7YZ UT WOS:000375144600008 PM 26772649 ER PT J AU Yarar-Fisher, C Bickel, CS Kelly, NA Stec, MJ Windham, ST McLain, AB Oster, RA Bamman, MM AF Yarar-Fisher, Ceren Bickel, C. Scott Kelly, Neil A. Stec, Michael J. Windham, Samuel T. McLain, Amie B. Oster, Robert A. Bamman, Marcas M. TI Heightened TWEAK-NF-kappa B signaling and inflammation-associated fibrosis in paralyzed muscles of men with chronic spinal cord injury SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE TNF-like weak inducer of apoptosis; nuclear factor kappa-light-chain-enhancer of activated B cells ID SKELETAL-MUSCLE; APOPTOSIS TWEAK; WEAK INDUCER; GLUCOSE-TOLERANCE; OLDER-ADULTS; ATROPHY; EXERCISE; MICE; INDIVIDUALS; ACTIVATION AB Individuals with long-standing spinal cord injury (SCI) often present with extreme muscle atrophy and impaired glucose metabolism at both the skeletal muscle and whole body level. Persistent inflammation and increased levels of proinflammatory cytokines in the skeletal muscle are potential contributors to dysregulation of glucose metabolism and atrophy; however, to date no study has assessed the effects of long-standing SCI on their expression or intracellular signaling in the paralyzed muscle. In the present study, we assessed the expression of genes (TNF alpha R, TNF alpha, IL-6R, IL-6, TWEAK, TWEAK R, atrogin-1, and MuRF1) and abundance of intracellular signaling proteins (TWEAK, TWEAK R, NF-kappa B, and p-p65/p-50/105) that are known to mediate inflammation and atrophy in skeletal muscle. In addition, based on the effects of muscle inflammation on promotion of skeletal muscle fibrosis, we assessed the degree of fibrosis between myofibers and fascicles in both groups. For further insight into the distribution and variability of muscle fiber size, we also analyzed the frequency distribution of SCI fiber size. Resting vastus lateralis (VL) muscle biopsy samples were taken from 11 men with long-standing SCI (approximate to 22 yr) and compared with VL samples from 11 able-bodied men of similar age. Our results demonstrated that chronic SCI muscle has heightened TNF alpha R and TWEAK R gene expression and NF-kappa B signaling (higher TWEAK R and phospho-NF-kappa B p65) and fibrosis, along with substantial myofiber size heterogeneity, compared with able-bodied individuals. Our data suggest that the TWEAK/TWEAK R/NF-kappa B signaling pathway may be an important mediator of chronic inflammation and fibrotic adaptation in SCI muscle. C1 [Yarar-Fisher, Ceren; McLain, Amie B.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL 35294 USA. [Kelly, Neil A.; Stec, Michael J.; Bamman, Marcas M.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294 USA. [Bickel, C. Scott] Univ Alabama Birmingham, Dept Phys Therapy, Birmingham, AL 35294 USA. [Windham, Samuel T.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA. [Oster, Robert A.; Bamman, Marcas M.] Univ Alabama Birmingham, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA. [Yarar-Fisher, Ceren; Bickel, C. Scott; Kelly, Neil A.; Stec, Michael J.; Windham, Samuel T.; McLain, Amie B.] Univ Alabama Birmingham, UAB Ctr Exercise Med, 966 McCallum Basic Hlth Sci Bldg, Birmingham, AL 35294 USA. [Bamman, Marcas M.] Birmingham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. RP Bamman, MM (reprint author), Univ Alabama Birmingham, UAB Ctr Exercise Med, 966 McCallum Basic Hlth Sci Bldg, Birmingham, AL 35294 USA. EM mbamman@uab.edu FU Veterans Affairs Merit Award; UAB Center for Exercise Medicine, Department of Physical Medicine and Rehabilitation [5T32-DK-62710]; UAB Center for Clinical and Translational Science [UL1-TR-000165] FX This work was supported by a Veterans Affairs Merit Award (M. M. Bamman), the UAB Center for Exercise Medicine, Department of Physical Medicine and Rehabilitation, 5T32-DK-62710, and the UAB Center for Clinical and Translational Science (UL1-TR-000165). NR 45 TC 3 Z9 4 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 EI 1522-1555 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD MAY 1 PY 2016 VL 310 IS 9 BP E754 EP E761 DI 10.1152/ajpendo.00240.2015 PG 8 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA DK9FC UT WOS:000375235200005 PM 26931128 ER PT J AU Leonpacher, AK Peters, ME Drye, LT Makino, KM Newell, JA Devanand, DP Frangakis, C Munro, CA Mintzer, JE Pollock, BG Rosenberg, PB Schneider, LS Shade, DM Weintraub, D Yesavage, J Lyketsos, CG Porsteinsson, AP AF Leonpacher, Anne K. Peters, Matthew E. Drye, Lea T. Makino, Kelly M. Newell, Jeffery A. Devanand, D. P. Frangakis, Constantine Munro, Cynthia A. Mintzer, Jacobo E. Pollock, Bruce G. Rosenberg, Paul B. Schneider, Lon S. Shade, David M. Weintraub, Daniel Yesavage, Jerome Lyketsos, Constantine G. Porsteinsson, Anton P. CA CitAD Res Grp TI Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID PLACEBO-CONTROLLED TRIALS; BEHAVIORAL DISTURBANCES; ANTIPSYCHOTIC-DRUGS; PSYCHOTIC SYMPTOMS; NURSING-HOMES; CACHE COUNTY; RISK-FACTORS; DISEASE; AGITATION; HEALTH AB Objective: Citalopram has been shown to improve agitation in patients with Alzheimer's disease. The authors evaluated whether other neuropsychiatric symptoms improve with citalopram treatment compared with placebo. Method: In this planned secondary analysis of the Citalopram for Agitation in Alzheimer's Disease study, the authors evaluated the effect of citalopram on the 12 neuropsychiatric symptom domains assessed by the Neuropsychiatric Inventory (NPI). They compared caregiver-reported NPI scores at week 9 in patients receiving citalopram(30 mg/day) or placebo with regard to both the presence or absence of individual neuropsychiatric symptoms and individual domain scores (reflecting severity) in participants who had symptoms at week 9. Results: At week 9, participants treated with citalopram were significantly less likely to be reported as showing delusions (odds ratio=0.40), anxiety (odds ratio=0.43), and irritability/lability (odds ratio=0.38). A comparison of median scores of participants with symptoms present at week 9 showed significant differences favoring citalopram for hallucinations and favoring placebo for sleep/nighttime behavior disorders. Conclusions: While dosage constraints must be considered because of citalopram's adverse effect profile, this agent's overall therapeutic effects in patients with Alzheimer's disease and agitation, in addition to efficacy for agitation/aggression, included reductions in the frequency of irritability, anxiety, and delusions; among patients who had these symptoms at week 9, they included a reduction in the severity of hallucinations but an increase in the severity of sleep/nighttime behavior disorders. C1 [Porsteinsson, Anton P.] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA. Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. Univ Rochester, Sch Med & Dent, Alzheimers Dis Care Res & Educ Program, Rochester, NY USA. Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. New York State Psychiat Inst & Hosp, Dept Psychiat, Div Geriatr Psychiat, New York, NY 10032 USA. Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA. Roper St Francis Healthcare, Clin Biotechnol Res Inst, Charleston, SC USA. Ralph H Johnson VA Med Ctr, Dept Psychiat, Charleston, SC USA. Ctr Addict & Mental Hlth, Campbell Inst, Toronto, ON, Canada. Univ Toronto, Dept Psychiat, Toronto, ON, Canada. Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA. Univ So Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90033 USA. Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Porsteinsson, AP (reprint author), Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA. EM anton_porsteinsson@urmc.rochester.edu FU National Institute on Aging (NIA); NIMH [R01AG031348]; NIH [P50-AG05142]; Avanir; NIA; Office of the Federal Public Defender; U.S. Attorney's Office; Avanir Pharmaceuticals; Transition Therapeutics; Insys Therapeutics; Takeda Global Research and Development Center; Pfizer; Genentech; Merck; Accera; Elan; Hoffmann-La Roche; Novartis; Baxter; Eli Lilly; Wyeth; Janssen Alzheimer Initiative; Alzheimer's Assocation; Functional Neuromodulation; Abbott; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Johnson Johnson; Lundbeck; Roche; AbbVie; ACImmune; Forest Laboratories; Forum; Merz; Orion; Otsuka; Servier; Takeda; Toyama/FujiFilm; Zinfandel; Michael J. Fox Foundation for Parkinson's Research; Department of Veterans Affairs; Avid Radiopharmaceuticals; Alzheimer's Disease Cooperative Study; International Parkinson; Movement Disorder Society; Associated Jewish Federation of Baltimore; Weinberg Foundation; Forest; Eisai; Ortho-McNeil; National Football League; Biogen; EnVivo; Genentech/Roche; Medivation; MerckPfizer; Toyama; Department of Defense FX Supported by National Institute on Aging (NIA) and NIMH grant R01AG031348, and in part by NIH grant P50-AG05142 (to University of Southern California and Dr. Schneider).; Dr. Devanand has received research support from Avanir and has served on scientific advisory boards for AbbVie, Astellas, and Lundbeck and as a consultant for Intracellular Therapies. Dr. Munro has received grant funding (to her institution) from NIA, NIH, and NIMH and has received payment for expert testimony from various law firms, from the Office of the Federal Public Defender, and from the U.S. Attorney's Office, as well as payment for lectures for Episcopal Ministries. Dr. Mintzer has received grant support from and served as a consultant for Avanir Pharmaceuticals, Transition Therapeutics, and Insys Therapeutics; he has received support for travel to meetings from NIA and NIMH; he has received grants (to his institution) from NIA, NIH, Takeda Global Research and Development Center, Pfizer, Genentech, Merck, Accera, Elan, Avanir, Hoffmann-La Roche, Novartis, Baxter, Eli Lilly, Wyeth, and Janssen Alzheimer Initiative; he has been employed by NeuroQuest and is founder of BioPharma Connex. Dr. Pollock has received a grant (to his institution) from NIA and NIMH; he has served on a board for Lundbeck Canada and as a consultant for Wyeth; and he has received travel and accommodation support from Lundbeck International Neuroscience Foundation. Dr. Rosenberg has received grant support from the Alzheimer's Assocation, Eli Lilly, Functional Neuromodulation, Merck, NIA, and Novartis; he has served as a consultant to AbbVie, Abide, Insys, Janssen, and Merck; and he has received travel support from Eli Lilly. Dr. Schneider has received grant and clinical trial support from Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Lundbeck, Merck, NIH, Novartis, Pfizer, and Roche and consultancy fees, including for data monitoring committees and adjudication committees, from Abbott, AbbVie, ACImmune, AstraZeneca, Baxter, Bristol-Myers Squibb, Elan, Eli Lilly, Forest Laboratories, Forum, GlaxoSmithKline, Johnson & Johnson, Lundbeck, Merck, Merz, Novartis, Orion, Otsuka, Pfizer, Roche, Servier, Takeda, Toyama/FujiFilm, and Zinfandel. Dr. Weintraub has received research funding or support from the Michael J. Fox Foundation for Parkinson's Research, NIH, Novartis, the Department of Veterans Affairs, Avid Radiopharmaceuticals, the Alzheimer's Disease Cooperative Study, and the International Parkinson and Movement Disorder Society; honoraria from AbbVie, Acadia, Biotie, Clintrex, Novartis, Teva Pharmaceuticals, UCB, and the CHDI Foundation; license fee payments from the University of Pennsylvania for the QUIP and QUIP-RS; royalties from Wolters Kluwer; and fees for legal consultation for a lawsuit related to antipsychotic prescribing in a patient with Parkinson's disease. Dr. Lyketsos has received grant support (for research or CME) from NIMH, NIA, the Associated Jewish Federation of Baltimore, the Weinberg Foundation, Forest, GlaxoSmithKline, Eisai, Pfizer, AstraZeneca, Eli Lilly, Ortho-McNeil, Bristol-Myers Squibb, Novartis, the National Football League, Elan, and Functional Neuromodulation; he has served as a consultant or adviser to AstraZeneca, GlaxoSmithKline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Eli Lilly, Pfizer, Genentech, Elan, the NFL Players Association, the NFL Benefits Office, Avanir, Zinfandel, Bristol-Myers Squibb, AbbVie, Janssen, Orion, Otsuka, and Astellas; and he has received honoraria or travel support from Pfizer, Forest, GlaxoSmithKline, and Health Monitor. Dr.; Porsteinsson has received grants (to his institution) from AstraZeneca, Avanir, Baxter, Biogen, Bristol-Myers Squibb, Eisai, Elan, EnVivo, Genentech/Roche, the Janssen Alzheimer Initiative, Medivation, Merck, Pfizer, Toyama, Transition Therapeutics, NIH, NIMH, NIA, and the Department of Defense; he has served as a consultant for Elan, the Janssen Alzheimer Initiative, Lundbeck, Pfizer, and TransTech Pharma; and he has been amember on data safety and monitoring boards for Quintiles, Functional Neuromodulation, and the New York State Psychiatric Institute, participated on a speakers bureau for Forest, and participated in the development of educational presentations for CME, Inc., and PVI. The other authors report no financial relationships with commercial interests. NR 38 TC 4 Z9 4 U1 7 U2 12 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X EI 1535-7228 J9 AM J PSYCHIAT JI Am. J. Psychiat. PD MAY PY 2016 VL 173 IS 5 BP 473 EP 480 DI 10.1176/appi.ajp.2016.15020248 PG 8 WC Psychiatry SC Psychiatry GA DK9ZS UT WOS:000375291500010 PM 27032628 ER PT J AU Kurzbard-Roach, N Lewis, M Chow, K Masih, S Modaressi, S AF Kurzbard-Roach, Nicole Lewis, Michael Chow, Kira Masih, Sulabh Modaressi, Shahla TI Stewart-Bluefarb syndrome SO APPLIED RADIOLOGY LA English DT Editorial Material C1 [Kurzbard-Roach, Nicole] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90024 USA. [Lewis, Michael] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Pathol, Los Angeles, CA USA. [Chow, Kira] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Radiol, Los Angeles, CA USA. [Masih, Sulabh; Modaressi, Shahla] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. RP Kurzbard-Roach, N (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90024 USA. NR 9 TC 0 Z9 0 U1 0 U2 0 PU ANDERSON PUBLISHING, INC PI SCOTCH PLAINS PA 180 GLENSIDE AVE, SCOTCH PLAINS, NJ 07076 USA SN 0160-9963 EI 1879-2898 J9 APPL RADIOL JI Appl. Radiol. PD MAY PY 2016 VL 45 IS 5 BP 42 EP 45 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DK9EK UT WOS:000375233400010 ER PT J AU Wells, JM Morrison, JB Bhatt, SP Nath, H Dransfield, MT AF Wells, J. Michael Morrison, Joshua B. Bhatt, Surya P. Nath, Hrudaya Dransfield, Mark T. TI Pulmonary Artery Enlargement Is Associated With Cardiac Injury During Severe Exacerbations of COPD SO CHEST LA English DT Article DE acute exacerbation of COPD; COPD; CT scan; enzymes (cardiology); pulmonary circulation ID CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; COMPUTED-TOMOGRAPHY; PROGNOSTIC-VALUE; TROPONIN-T; HYPERTENSION; MORTALITY; PREDICTORS; RISK; DYSFUNCTION AB BACKGROUND: Relative pulmonary arterial enlargement, defined by a pulmonary artery to aorta (PA/A) ratio > 1 on CT scanning, predicts hospitalization for acute exacerbations of COPD (AECOPD). However, it is unclear how AECOPD affect the PA/A ratio. We hypothesized that the PA/A ratio would increase at the time of AECOPD and that a ratio > 1 would be associated with worse clinical outcomes. METHODS: Patients discharged with an International Classification of Diseases, Ninth Revision, diagnosis of AECOPD from a single center over a 5-year period were identified. Patients were included who had a CT scan performed during the stable period prior to the index AECOPD episode as well as a CT scan at the time of hospitalization. A subset of patients also underwent postexacerbation CT scans. The pulmonary arterial diameter, ascending aortic diameter, and the PA/A ratio were measured on CT scans. Demographic data, comorbidities, troponin level, and hospital outcome data were analyzed. RESULTS: A total of 134 patients were included in the study. They had a mean age of 65 +/- 10 years, 47% were male, and 69% were white; overall, patients had a mean FEV1 of 47% +/- 19%. The PA/A ratio increased from baseline at the time of exacerbation (0.97 +/- 0.15 from 0.91 +/- 0.17; P < .001). Younger age and known pulmonary hypertension were independently associated with an exacerbation PA/A ratio > 1. Patients with PA/A ratio > 1 had higher troponin values. Those with a PA/A ratio > 1 and troponin levels > 0.01 ng/mL had increased acute respiratory failure, ICU admission, or inpatient mortality compared with those without both factors (P = .0028). The PA/A ratio returned to baseline values following AECOPD. CONCLUSIONS: The PA/A ratio increased at the time of severe AECOPD and a ratio > 1 predicted cardiac injury and a more severe hospital course. C1 [Wells, J. Michael; Morrison, Joshua B.; Bhatt, Surya P.; Dransfield, Mark T.] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care, Birmingham, AL USA. [Wells, J. Michael; Morrison, Joshua B.; Bhatt, Surya P.; Dransfield, Mark T.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Wells, J. Michael; Bhatt, Surya P.; Dransfield, Mark T.] Univ Alabama Birmingham, Lung Hlth Ctr, Birmingham, AL USA. [Nath, Hrudaya] Univ Alabama Birmingham, Dept Radiol, Div Cardiothorac Imaging, Birmingham, AL USA. [Wells, J. Michael; Dransfield, Mark T.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Wells, JM (reprint author), 1900 Univ Blvd,THT 422, Birmingham, AL 35294 USA. EM jmwells@uab.edu FU National Institutes of Health/National Heart, Lung, and Blood Institute [K08HL123940]; University of Alabama at Birmingham FX The funding for this study came from the National Institutes of Health/National Heart, Lung, and Blood Institute (K08HL123940) and the Walter B. Frommeyer Jr. Fellowship in Investigational Medicine from the University of Alabama at Birmingham (to Dr Wells). NR 47 TC 1 Z9 1 U1 0 U2 3 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD MAY PY 2016 VL 149 IS 5 BP 1197 EP 1204 DI 10.1378/chest.15-1504 PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DL2TH UT WOS:000375487600023 PM 26501747 ER PT J AU Ebert, N Delanaye, P Shlipak, M Jakob, O Martus, P Bartel, J Gaedeke, J van der Giet, M Schuchardt, M Cavalier, E Schaeffner, E AF Ebert, Natalie Delanaye, Pierre Shlipak, Michael Jakob, Olga Martus, Peter Bartel, Jan Gaedeke, Jens van der Giet, Markus Schuchardt, Mirjam Cavalier, Etienne Schaeffner, Elke TI Cystatin C standardization decreases assay variation and improves assessment of glomerular filtration rate SO CLINICA CHIMICA ACTA LA English DT Article DE Cystatin C; Renal biomarkers; Assay standardization; Glomerular filtration rate ID CHRONIC KIDNEY-DISEASE; SERUM CREATININE; MULTICENTRIC EVALUATION; RENAL-DISEASE; EQUATIONS; CALIBRATION; IMPACT; IMMUNOASSAY; VALIDATION; PREDICTION AB Background: Cystatin C is increasingly used in glomerular filtration rate (GFR) estimation equations. The dependence of cystatin C results upon the analytical method has been a major source of controversy. Methods: Cystatin C was measured with non-standardized turbidimetric Roche Generation 1 and standardized nephelometric Siemens assays in 3666 and additionally with standardized Roche Generation 2 and Siemens in 567 blood samples of the Berlin Initiative Study. Cystatin C-based GFR was assessed with CKD-EPIcys (Chronic Kidney Disease Epidemiology) and CAPA (Caucasian, Asian, Pediatric, Adult) equations and the impact of the assays on GFR estimation was determined. Equation performance compared to measured GFR was evaluated. Results: Concordance of Roche Gen2 and Siemens was high with median difference of 0.003 +/- 0.13 mg/L (limits of agreement: -0.12 to 0.12) and Passing Bablok correlation was essentially perfect. Roche Gen1 assay showed worse concordance with Siemens: median difference was 0.08 +/- 0.13 mg/L (limits of agreement: -0.18 to 034) and correlation was inferior. Mean difference (+/-SD) of estimated GFR(CKD-EPIcys) was 0 +/- 4 mL/min/1.73 m(2) for Gen2 and Siemens compared to -5 +/- 8 with Gen1. Performance of GFR estimating equations was not influenced by the choice of Siemens or Gen2 assays. Conclusions: Standardization of Roche Gen2 assay improved accuracy of cystatin C measurement compared to Siemens. It suggests only negligible method bias and results in equal performance of both assays when estimating GFR indicating that successful calibration has led to major progress in cystatin C analysis. (C) 2016 Elsevier B.V. All rights reserved. C1 [Ebert, Natalie; Schaeffner, Elke] Charite, Inst Publ Hlth, Campus Virchow,Seestr 73, D-13347 Berlin, Germany. [Delanaye, Pierre] Ctr Hosp Univ Sart Tilman, Div Nephrol, Liege, Belgium. [Shlipak, Michael] San Francisco VA Med Ctr, San Francisco, CA USA. [Shlipak, Michael] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Jakob, Olga] Charite, Inst Biostat & Clin Epidemiol, Berlin, Germany. [Martus, Peter] Univ Tubingen, Inst Clin Epidemiol & Med Biostat, Tubingen, Germany. [Bartel, Jan] Limbach Lab, Heidelberg, Germany. [Gaedeke, Jens] Charite, Div Nephrol, Campus Mitte, D-13347 Berlin, Germany. [van der Giet, Markus; Schuchardt, Mirjam] Charite, Div Nephrol, Campus Benjamin Franklin, D-13347 Berlin, Germany. [Cavalier, Etienne] Ctr Hosp Univ Sart Tilman, Dept Clin Chem, Liege, Belgium. RP Ebert, N (reprint author), Charite, Inst Publ Hlth, Campus Virchow,Seestr 73, D-13347 Berlin, Germany. EM natalie.ebert@charite.de OI Bartel, Jan/0000-0001-7602-7224 FU Kuratorium fur Dialyse und Nierentransplantation (KfH) Foundation of Preventive Medicine; Stiftung fur Pathobiochemie und Molelculare Diagnostik FX By the Kuratorium fur Dialyse und Nierentransplantation (KfH) Foundation of Preventive Medicine and the Stiftung fur Pathobiochemie und Molelculare Diagnostik. NR 35 TC 2 Z9 2 U1 3 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0009-8981 EI 1873-3492 J9 CLIN CHIM ACTA JI Clin. Chim. Acta PD MAY 1 PY 2016 VL 456 BP 115 EP 121 DI 10.1016/j.cca.2016.03.002 PG 7 WC Medical Laboratory Technology SC Medical Laboratory Technology GA DL0YG UT WOS:000375357900020 PM 26947968 ER PT J AU Acierno, R Gros, DF Ruggiero, KJ Hernandez-Tejada, BMA Knapp, RG Lejuez, CW Muzzy, W Frueh, CB Egede, LE Tuerk, PW AF Acierno, Ron Gros, Daniel F. Ruggiero, Kenneth J. Hernandez-Tejada, B. Melba A. Knapp, Rebecca G. Lejuez, Carl W. Muzzy, Wendy Frueh, Christopher B. Egede, Leonard E. Tuerk, Peter W. TI BEHAVIORAL ACTIVATION AND THERAPEUTIC EXPOSURE FOR POSTTRAUMATIC STRESS DISORDER: A NONINFERIORITY TRIAL OF TREATMENT DELIVERED IN PERSON VERSUS HOME-BASED TELEHEALTH SO DEPRESSION AND ANXIETY LA English DT Article DE PTSD; major depression; telehealth; telemedicine; telemental health; psychotherapy; home-based ID MENTAL-HEALTH PROBLEMS; PTSD; DEPRESSION; VETERANS; AFGHANISTAN; SERVICE; IRAQ; PSYCHOTHERAPY; TELEMEDICINE; MILITARY AB ObjectiveCombat veterans returning to society with impairing mental health conditions such as PTSD and major depression (MD) report significant barriers to care related to aspects of traditional psychotherapy service delivery (e.g., stigma, travel time, and cost). Hence, alternate treatment delivery methods are needed. Home-based telehealth (HBT) is one such option; however, this delivery mode has not been compared to in person, clinic-based care for PTSD in adequately powered trials. The present study was designed to compare relative noninferiority of evidence-based psychotherapies for PTSD and MD, specifically Behavioral Activation and Therapeutic Exposure (BA-TE), when delivered via HBT versus in person, in clinic delivery. MethodA repeated measures (i.e., baseline, posttreatment, 3-, 6-month follow-up) randomized controlled design powered for noninferiority analyses was used to compare PTSD and MD symptom improvement in response to BA-TE delivered via HBT versus in person, in clinic conditions. Participants were 232 veterans diagnosed with full criteria or predefined subthreshold PTSD. ResultsPTSD and MD symptom improvement following BA-TE delivered by HBT was comparable to that of BA-TE delivered in person at posttreatment and at 3- and 12-month follow-up. ConclusionEvidence-based psychotherapy for PTSD and depression can be safely and effectively delivered via HBT with clinical outcomes paralleling those of clinic-based care delivered in person. HBT, thereby, addresses barriers to care related to both logistics and stigma. C1 [Acierno, Ron; Gros, Daniel F.; Ruggiero, Kenneth J.; Hernandez-Tejada, B. Melba A.; Knapp, Rebecca G.; Muzzy, Wendy; Egede, Leonard E.; Tuerk, Peter W.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC 29401 USA. [Acierno, Ron; Ruggiero, Kenneth J.; Hernandez-Tejada, B. Melba A.; Muzzy, Wendy] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA. [Gros, Daniel F.; Knapp, Rebecca G.; Egede, Leonard E.; Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA. [Lejuez, Carl W.] Univ Maryland, Ctr Addict Personal & Emot Res, College Pk, MD 20742 USA. [Frueh, Christopher B.] Univ Hawaii, Dept Psychol, Hilo, HI 96720 USA. RP Acierno, R (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM acierno@musc.edu FU Department of Veteran Affairs Clinical Sciences Research and Development Career Development Award [CX000845] FX Several authors are core and affiliate members of the Ralph H. Johnson VAMC Center of Innovation (CIN 13-418; PI: Egede), the Health Equity and Rural Outreach Innovation Center (HEROIC). Dr. Gros is funded by Department of Veteran Affairs Clinical Sciences Research and Development Career Development Award CX000845 (PI: Gros). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. There are no conflicts of interest to disclose. There are no conflicts of interest for any of the authors. NR 27 TC 5 Z9 5 U1 3 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 EI 1520-6394 J9 DEPRESS ANXIETY JI Depress. Anxiety PD MAY PY 2016 VL 33 IS 5 BP 415 EP 423 DI 10.1002/da.22476 PG 9 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA DK8CM UT WOS:000375154800008 PM 26864655 ER PT J AU Nayak, BK Shanmugasundaram, K Friedrichs, WE Cavaglierii, RC Patel, M Barnes, J Block, K AF Nayak, Bijaya K. Shanmugasundaram, Karthigayan Friedrichs, William E. Cavaglierii, Rita C. Patel, Mandakini Barnes, Jeffrey Block, Karen TI HIF-1 Mediates Renal Fibrosis in OVE26 Type 1 Diabetic Mice SO DIABETES LA English DT Article ID HYPOXIA-INDUCIBLE FACTORS; RAT MESANGIAL CELLS; FACTOR-I; FACTOR 1-ALPHA; TGF-BETA; NEPHROPATHY; EXPRESSION; MECHANISMS; HIF-1-ALPHA; DISEASE AB Hypoxia-inducible factor (HIF)-1 mediates hypoxia- and chronic kidney disease-induced fibrotic events. Here, we assessed whether HIF-1 blockade attenuates the manifestations of diabetic nephropathy in a type 1 diabetic animal model, OVE26. YC-1 [3-(5-hydroxymethyl-2-furyl)-1-benzyl indazole], an HIF-1 inhibitor, reduced whole kidney glomerular hypertrophy, mesangial matrix expansion, extracellular matrix accumulation, and urinary albumin excretion as well as NOX4 protein expression and NADPH-dependent reactive oxygen species production, while blood glucose levels remained unchanged. The role of NOX oxidases in HIF-1-mediated extracellular matrix accumulation was explored in vitro using glomerular mesangial cells. Through a series of genetic silencing and adenoviral overexpression studies, we have defined GLUT1 as a critical downstream target of HIF-1 mediating high glucose-induced matrix expression through the NADPH oxidase isoform, NOX4. Together, our data suggest that pharmacological inhibition of HIF-1 may improve clinical manifestations of diabetic nephropathy. C1 [Nayak, Bijaya K.; Shanmugasundaram, Karthigayan; Friedrichs, William E.; Cavaglierii, Rita C.; Patel, Mandakini; Barnes, Jeffrey; Block, Karen] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Barnes, Jeffrey; Block, Karen] South Texas Vet Hlth Care Syst, Audie L Murphy Mem VA Hosp Div, San Antonio, TX USA. RP Block, K (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.; Block, K (reprint author), South Texas Vet Hlth Care Syst, Audie L Murphy Mem VA Hosp Div, San Antonio, TX USA. EM block@uthscsa.edu FU U.S. Department of Veterans Affairs Merit Award; JDRF; National Institute of Diabetes and Digestive and Kidney Diseases [DK-033665] FX This work was supported by the U.S. Department of Veterans Affairs Merit Award (grant to K.B.), a multi-project grant from JDRF (to K.B.), and the National Institute of Diabetes and Digestive and Kidney Diseases (DK-033665 to K.B.). NR 44 TC 4 Z9 4 U1 4 U2 8 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD MAY PY 2016 VL 65 IS 5 BP 1387 EP 1397 DI 10.2337/db15-0519 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DK6JA UT WOS:000375028000028 PM 26908870 ER PT J AU Maria, MMMS Baker, NL McRae-Clark, AL Prisciandaro, JJ Brady, KT AF Maria, M. M. Moran-Santa Baker, N. L. McRae-Clark, A. L. Prisciandaro, J. J. Brady, K. T. TI Effects of yohimbine and drug cues on impulsivity and attention in cocaine-dependent men and women and sex-matched controls SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Cocaine; Sex differences; Yohimbine; Executive control; Stress; Drug-cues ID COGNITIVE-BEHAVIORAL THERAPY; INDUCED REINSTATEMENT; INHIBITORY CONTROL; STRESS; INDIVIDUALS; ADDICTION; DEFICITS; SEEKING; USERS; ENHANCEMENT AB Background: Deficits in executive function have been associated with risk for relapse. Data from previous studies suggest that relapse may be triggered by stress and drug-paired cues and that there are significant sex differences in the magnitude of these responses. The aim of this study was to examine the impact of the pharmacological stressor and alpha-2 adrenergic receptor antagonist yohimbine and cocaine cues on executive function in cocaine-dependent men and women. Methods: In a double-blind placebo controlled cross-over study, cocaine-dependent men (n = 12), cocaine dependent women (n = 27), control men (n = 31) and control women (n=25) received either yohimbine or placebo prior to two cocaine cue exposure sessions. Participants performed the Connors' Continuous Performance Test II prior to medication/placebo administration and immediately after each cue exposure session Results: Healthy controls had a significant increase in commission errors under the yohimbine condition [RR (95% CI)=1.1 (1.0-1.3), chi(2)(1)=2.0, p = 0.050]. Cocaine-dependent individuals exhibited a significant decrease in omission errors under the yohimbine condition [RR (95% CI) = 0.6 (0.4-0.8), chi(2)(1)=8.6, p = 0.003]. Cocaine-dependent women had more omission errors as compared to cocaine-dependent men regardless of treatment [RR (95% CI)= 7.2 (3.6-14.7), chi(2)(1) =30.1, p<0.001]. Cocaine-dependent women exhibited a slower hit reaction time as compared to cocaine-dependent men [Female 354 +/- 13 vs. Male 415 +/- 14; t(89) = 2.6, p = 0.012]. Conclusions: These data add to a growing literature demonstrating significant sex differences in behaviors associated with relapse in cocaine-dependent individuals. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Maria, M. M. Moran-Santa; McRae-Clark, A. L.; Prisciandaro, J. J.; Brady, K. T.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA. [Baker, N. L.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Brady, K. T.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Maria, MMMS (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Addict Sci Div, 125 Doughty St, Charleston, SC 29425 USA. EM moranm@musc.edu FU Forest Pharmaceuticals FX Authors Moran-Santa Maria, Baker, and Prisciandaro declare no conflict of interest. Kathleen Brady lists: Consultant AstraZeneca Pharmaceuticals. Aimee McRae lists: Forest Pharmaceuticals medication provided for separate NIH grant. NR 44 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD MAY 1 PY 2016 VL 162 BP 56 EP 63 DI 10.1016/j.drugalcdep.2016.02.021 PG 8 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DK8GK UT WOS:000375165000007 ER PT J AU Saunders, GH Frederick, MT Silverman, SC Nielsen, C Laplante-Levesque, A AF Saunders, Gabrielle H. Frederick, Melissa T. Silverman, ShienPei C. Nielsen, Claus Laplante-Levesque, Ariane TI Description of Adults Seeking Hearing Help for the First Time According to Two Health Behavior Change Approaches: Transtheoretical Model (Stages of Change) and Health Belief Model SO EAR AND HEARING LA English DT Article DE Health behavior; Health care seeking behavior; Motivation; Patient acceptance of health care; Rehabilitation of hearing impaired ID OLDER-ADULTS; AID; IMPAIRMENT; ATTITUDES; ADOPTION; PEOPLE; STIGMA AB Objectives: Several models of health behavior change are commonly used in health psychology. This study applied the constructs delineated by two models-the transtheoretical model (in which readiness for health behavior change can be described with the stages of precontemplation, contemplation and action) and the health belief model (in which susceptibility, severity, benefits, barriers, self-efficacy, and cues to action are thought to determine likelihood of health behavior change)-to adults seeking hearing help for the first time. Design: One hundred eighty-two participants (mean age: 69.5 years) were recruited following an initial hearing assessment by an audiologist. Participants' mean four-frequency pure-tone average was 35.4 dB HL, with 25.8% having no hearing impairment, 50.5% having a slight impairment, and 23.1% having a moderate or severe impairment using the World Health Organization definition of hearing loss. Participants' hearing-related attitudes and beliefs toward hearing health behaviors were examined using the University of Rhode Island Change Assessment (URICA) and the health beliefs questionnaire (HBQ), which assess the constructs of the transtheoretical model and the health belief model, respectively. Participants also provided demographic information, and completed the hearing handicap inventory (HHI) to assess participation restrictions, and the psychosocial impact of hearing loss (PIHL) to assess the extent to which hearing impacts competence, self-esteem, and adaptability. Results: Degree of hearing impairment was associated with participation restrictions, perceived competence, self-esteem and adaptability, and attitudes and beliefs measured by the URICA and the HBQ. As degree of impairment increased, participation restrictions measured by the HHI, and impacts of hearing loss, as measured by the PIHL, increased. The majority of first-time help seekers in this study were in the action stage of change. Furthermore, relative to individuals with less hearing impairment, individuals with more hearing impairment were at more advanced stages of change as measured by the URICA (i.e., higher contemplation and action scores relative to their precontemplation score), and they perceived fewer barriers and more susceptibility, severity, benefits and cues to action as measured by the HBQ. Multiple regression analyses showed participation restrictions (HHI scores) to be a highly significant predictor of stages of change explaining 30% to 37% of the variance, as were duration of hearing difficulty, and perceived benefits, severity, self-efficacy and cues to action assessed by the HBQ. Conclusions: The main predictors of stages of change in first-time help seekers were reported participation restrictions and duration of hearing difficulty, with constructs from the health belief model also explaining some of the variance in stages of change scores. The transtheoretical model and the health belief model are valuable for understanding hearing health behaviors and can be applied when developing interventions to promote help seeking. C1 [Saunders, Gabrielle H.; Frederick, Melissa T.; Silverman, ShienPei C.] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR USA. [Saunders, Gabrielle H.] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA. [Nielsen, Claus; Laplante-Levesque, Ariane] Oticon AS, Eriksholm Res Ctr, Snekkersten, Denmark. [Laplante-Levesque, Ariane] Linkoping Univ, Dept Behav Sci & Learning, Linkoping, Sweden. RP Saunders, GH (reprint author), VA Portland Hlth Care Syst, Natl Ctr Rehabilitat Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM gabrielle.saunders@va.gov FU Oticon Foundation; VA Rehabilitation Research and Development Center of Excellence [C9230C] FX This study was supported financially by the Oticon Foundation, with additional support from a VA Rehabilitation Research and Development Center of Excellence award #C9230C. NR 39 TC 3 Z9 3 U1 7 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0196-0202 EI 1538-4667 J9 EAR HEARING JI Ear Hear. PD MAY-JUN PY 2016 VL 37 IS 3 BP 324 EP 333 DI 10.1097/AUD.0000000000000268 PG 10 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA DK8BM UT WOS:000375151900016 PM 26765286 ER PT J AU Freudenberg, C Jones, RA Livingston, G Goetsch, V Schaffner, A Buchanan, L AF Freudenberg, Cara Jones, Rebecca A. Livingston, Genvieve Goetsch, Virginia Schaffner, Angela Buchanan, Linda TI Effectiveness of individualized, integrative outpatient treatment for females with anorexia nervosa and bulimia nervosa SO EATING DISORDERS LA English DT Article ID COGNITIVE-BEHAVIORAL THERAPY; BINGE-EATING DISORDER; RANDOMIZED CONTROLLED-TRIALS; 3 PSYCHOLOGICAL TREATMENTS; NATURAL COURSE; PREDICTORS; INVENTORY; 5-YEAR; CARE AB The effectiveness of an individualized outpatient program was investigated in the treatment of bulimia nervosa (BN) and anorexia nervosa (AN). Participants included 151 females who received outpatient eating disorder treatment in the partial hospitalization program, the intensive outpatient program, or a combination of the two programs. Outcome measures included the Eating Disorder Inventory (EDI-2), Beck Depression Inventory (BDI-II), frequency of binge eating and purging, and mean body weight. Findings included significant increases in weight for the AN group, reductions in binge eating frequency for the BN group, and reductions in EDI-2 and BDI-II scores and purging frequency for both groups. This study provides preliminary support for the efficacy of a multimodal program for the treatment of both anorexia nervosa and bulimia nervosa. C1 [Freudenberg, Cara] Tennessee Valley Healthcare Syst, US Dept Vet Affairs, Murfreesboro, TN USA. [Jones, Rebecca A.; Livingston, Genvieve; Goetsch, Virginia] Argosy Univ, Georgia Sch Profess Psychol, 980 Hammond Dr, Atlanta, GA 30328 USA. [Schaffner, Angela] Richmont Grad Univ, Atlanta Ctr Eating Disorders, Atlanta, GA USA. [Schaffner, Angela] Richmont Grad Univ, Sch Counseling, Atlanta, GA USA. [Buchanan, Linda] Atlanta Ctr Eating Disorders, Atlanta, GA USA. RP Jones, RA (reprint author), Argosy Univ, Georgia Sch Profess Psychol, 980 Hammond Dr, Atlanta, GA 30328 USA. EM rjones@argosy.edu NR 60 TC 0 Z9 0 U1 6 U2 11 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1064-0266 EI 1532-530X J9 EAT DISORD JI Eat. Disord PD MAY-JUN PY 2016 VL 24 IS 3 BP 240 EP 254 DI 10.1080/10640266.2015.1090868 PG 15 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA DL3UE UT WOS:000375558100003 PM 26467107 ER PT J AU Santos, GM Coffin, P Santos, D Huffaker, S Matheson, T Euren, J DeMartini, A Rowe, C Hahn, JA Vlahov, D Vittinghoff, E Batki, SL AF Santos, Glenn-Milo Coffin, Phillip Santos, Deirdre Huffaker, Shannon Matheson, Tim Euren, Jason DeMartini, Anna Rowe, Christopher Hahn, Judith A. Vlahov, David Vittinghoff, Eric Batki, Steven L. TI Feasibility, Acceptability, and Tolerability of Targeted Naltrexone for Nondependent Methamphetamine-Using and Binge-Drinking Men Who Have Sex with Men SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE methamphetamine; alcohol; HIV; men who have sex with men; HIV prevention; pharmacotherapy ID HIV BEHAVIORAL SURVEILLANCE; RANDOMIZED CONTROLLED-TRIAL; MESSENGER-RNA EXPRESSION; MU-OPIOID RECEPTOR; SUBSTANCE USE; GAY MEN; RISK BEHAVIORS; DRUG-USE; AMPHETAMINE DEPENDENCE; TESTING BEHAVIORS AB Background: There are no effective pharmacologic strategies for nondependent methamphetamine (meth)-using and binge-drinking men who have sex with men (MSM) at high-risk for HIV. We sought to determine the feasibility of enrolling and retaining this population in a pharmacologic trial; the acceptability of pharmacotherapy study procedures; and the tolerability of targeted naltrexone versus placebo. Methods: Thirty meth-using and binge-drinking MSM were randomly assigned 1: 1 to 50 mg naltrexone or placebo for 8 weeks for targeted administration (ie, during craving or in anticipation of meth or alcohol use). Substance use counseling and behavioral assessments were conducted every 2 weeks. Medication use was measured using WisePill dispensers. Results: Trial completion was 93%; visit completion rate was 95%. Mean weekly number of medication pills taken was 2.1 and was similar between arms. Participant satisfaction rate was 96%. There were neither serious adverse events nor differences in adverse event rates between arms. In exploratory intention-to-treat analyses, there were no differences in meth use and drinking. Naltrexone participants had greater reductions in serodiscordant receptive anal intercourse [incident rate ratio (IRR) = 0.15; 95% CI = 0.05 to 0.42] and serodiscordant condomless receptive anal intercourse (IRR = 0.11; 95% CI = 0.03 to 0.37), compared with placebo. In subgroup analyses among frequent meth users, naltrexone participants had greater reductions in meth-using days (IRR = 0.78; 95% CI = 0.62 to 0.99). In as-treated analyses, frequent study medication users in the naltrexone arm had greater reductions in binge drinking days (IRR = 0.72; 95% CI = 0.54 to 0.97). Conclusions: Targeted naltrexone is a feasible, acceptable, and tolerable intervention strategy for nondependent meth-using and binge-drinking MSM. Naltrexone was associated with significant sexual risk reductions; and for some individuals, naltrexone was associated with meth and binge-drinking reductions. C1 [Santos, Glenn-Milo; Coffin, Phillip; Santos, Deirdre; Huffaker, Shannon; Matheson, Tim; Euren, Jason; DeMartini, Anna; Rowe, Christopher] San Francisco Dept Publ Hlth, Ctr Publ Hlth, Res Branch, San Francisco, CA USA. [Santos, Glenn-Milo; Vlahov, David] Univ Calif San Francisco, Sch Nursing, Dept Community Hlth Syst, San Francisco, CA 94143 USA. [Coffin, Phillip; Hahn, Judith A.] Univ Calif San Francisco, Sch Med, Div HIV AIDS, San Francisco, CA USA. [Hahn, Judith A.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA. [Vlahov, David; Vittinghoff, Eric] Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA USA. [Batki, Steven L.] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA 94143 USA. [Batki, Steven L.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Santos, GM (reprint author), Univ Calif San Francisco, San Francisco Dept Publ Hlth, San Francisco, CA 94107 USA. EM glenn-milo.santos@ucsf.edu FU National Institutes of Drug Abuse (NIDA) [R36DA035109]; [K24AA022586] FX This study was funded by the National Institutes of Drug Abuse (NIDA), grant number R36DA035109. JAH was funded by K24AA022586. NR 83 TC 0 Z9 0 U1 5 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAY 1 PY 2016 VL 72 IS 1 BP 21 EP 30 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DK6WY UT WOS:000375067600013 PM 26674372 ER PT J AU Bhattacharya, D Tseng, CH Tate, JP Lo Re, V Gibert, CL Butt, AA Brown, ST Lim, JK Rodriguez-Barradas, MC Rimland, D Kaufman, E Justice, AC Goetz, MB AF Bhattacharya, Debika Tseng, Chi-hong Tate, Janet P. Lo Re, Vincent, III Gibert, Cynthia L. Butt, Adeel A. Brown, Sheldon T. Lim, Joseph K. Rodriguez-Barradas, Maria C. Rimland, David Kaufman, Erica Justice, Amy C. Goetz, Matthew Bidwell TI Isolated Hepatitis B Core Antibody is Associated With Advanced Hepatic Fibrosis in HIV/HCV Infection But Not in HIV Infection Alone SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Letter ID SIMPLE NONINVASIVE INDEX; VIRUS INFECTION; LIVER-DISEASE; COINFECTION; PREVALENCE; COHORT; PREDICT; DNA C1 [Bhattacharya, Debika; Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Bhattacharya, Debika; Tseng, Chi-hong; Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Tate, Janet P.; Lim, Joseph K.; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Tate, Janet P.; Lim, Joseph K.; Justice, Amy C.] Yale Univ, Sch Med, New Haven, CT USA. [Lo Re, Vincent, III] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Lo Re, Vincent, III] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Gibert, Cynthia L.] Washington DC VA Med Ctr, Washington, DC USA. [Gibert, Cynthia L.] George Washington Univ, Med Ctr, Washington, DC 20037 USA. [Butt, Adeel A.] Hamad Healthcare Qual Inst, Doha, Qatar. [Butt, Adeel A.] Hamad Med Corp, Doha, Qatar. [Butt, Adeel A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Brown, Sheldon T.] James J Peters VA Med Ctr, Bronx, NY USA. [Rodriguez-Barradas, Maria C.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Houston, TX 77030 USA. [Rimland, David] Atlanta VA Med Ctr, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. [Kaufman, Erica] St Louis Univ, Sch Med, St Louis, MO USA. RP Bhattacharya, D (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.; Bhattacharya, D (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. FU NIAAA NIH HHS [U01 AA020790, U10 AA013566, U24 AA020794]; NIDDK NIH HHS [P30 DK034989] NR 17 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAY 1 PY 2016 VL 72 IS 1 BP E14 EP E17 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DK6WY UT WOS:000375067600005 PM 26829660 ER PT J AU Au, DH AF Au, David H. TI Screening for Chronic Obstructive Pulmonary Disease D Is the New F SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID COPD C1 [Au, David H.] VA Puget Sound Hlth Care Syst, Ctr Innovat Veteran Centered & Value Driven Care, 1660 S Columbian Way,MS 152, Seattle, WA 98101 USA. [Au, David H.] Univ Washington, Div Pulm & Crit Care Med, 1660 S Columbian Way,MS 152, Seattle, WA 98101 USA. RP Au, DH (reprint author), VA Puget Sound Hlth Care Syst, Ctr Innovat Veteran Centered & Value Driven Care, 1660 S Columbian Way,MS 152, Seattle, WA 98101 USA.; Au, DH (reprint author), Univ Washington, Div Pulm & Crit Care Med, 1660 S Columbian Way,MS 152, Seattle, WA 98101 USA. EM dau@uw.edu NR 6 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAY PY 2016 VL 176 IS 5 BP 601 EP 602 DI 10.1001/jamainternmed.2016.1115 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA DL0AC UT WOS:000375292500011 PM 27046674 ER PT J AU Keyhani, S Cheng, EM Naseri, A Halm, EA Williams, LS Johanning, J Madden, E Rofagha, S Woodbridge, A Abraham, A Ahn, R Saba, S Eilkhani, E Hebert, P Bravata, DM AF Keyhani, Salomeh Cheng, Eric M. Naseri, Ayman Halm, Ethan A. Williams, Linda S. Johanning, Jason Madden, Erin Rofagha, Soraya Woodbridge, Alexandra Abraham, Ann Ahn, Rosa Saba, Susan Eilkhani, Elnaz Hebert, Paul Bravata, Dawn M. TI Common Reasons That Asymptomatic Patients Who Are 65 Years and Older Receive Carotid Imaging SO JAMA INTERNAL MEDICINE LA English DT Article ID ENDARTERECTOMY; STROKE; STENOSIS; TRIAL; APPROPRIATENESS; PREVENTION AB IMPORTANCE National guidelines do not agree on the role of carotid screening in asymptomatic patients (ie, patients who have not had a stroke or transient ischemic attack). Recently, several physician organizations participating in the Choosing Wisely campaign have identified carotid imaging in selected asymptomatic populations as being of low value. However, the majority of patients who are evaluated for carotid stenosis and subsequently revascularized are asymptomatic. OBJECTIVE To better understand why asymptomatic patients who undergo revascularization receive initial carotid imaging. DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study of 4127 Veterans Health Administration patients 65 years and older undergoing carotid revascularization for asymptomatic carotid stenosis between 2005 and 2009. MAIN OUTCOMES AND MEASURES Indications for carotid ultrasounds were extracted using trained abstractors. Frequency of indications and appropriateness of initial carotid ultrasound imaging for patients within each rating category after the intervention were reported. RESULTS The mean (SD) age of this cohort of 4127 patients was 73.6 (5.9) years; 4014 (98.8%) were male. Overall, there were 5226 indications for 4063 carotid ultrasounds. The most common indications listed were carotid bruit (1578 [30.2% of indications]) and follow-up for carotid disease (stenosis/history of carotid disease) in patients who had previously documented carotid stenosis (1087 [20.8% of indications]). Multiple vascular risk factors were the next most common indication listed. Rates of appropriate, uncertain, and inappropriate imaging were 5.4%(227 indications), 83.4%(3387 indications), and 11.3%(458 indications), respectively. Among the most common inappropriate indications were dizziness/vertigo and syncope. Among the 4063 patients, 3373 (83.0%) received a carotid endarterectomy. Overall, 663 procedures were performed in patients 80 years and older. CONCLUSIONS AND RELEVANCE Carotid bruit and follow-up for carotid disease accounted for approximately half of all indications provided by physicians for carotid testing. Strong consideration should be given to improving the evidence base around carotid testing, especially around monitoring stenosis over long periods and evaluating carotid bruits. Targeting carotid ultrasound ordering with decision support tools may also be an important step in reducing use of low-value imaging. C1 [Keyhani, Salomeh; Naseri, Ayman; Madden, Erin; Rofagha, Soraya; Woodbridge, Alexandra; Abraham, Ann; Ahn, Rosa; Saba, Susan; Eilkhani, Elnaz] San Francisco VA Med Ctr, San Francisco, CA USA. [Keyhani, Salomeh; Rofagha, Soraya] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA. [Cheng, Eric M.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Neurol, Los Angeles, CA USA. [Cheng, Eric M.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Naseri, Ayman] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA. [Williams, Linda S.; Bravata, Dawn M.] Richard L Roudebush Vet Affairs Med Ctr, Ctr Excellence Implementing Evidence Based Practi, Vet Hlth Adm, Hlth Serv Res & Dev Serv, 1481 W 10th St, Indianapolis, IN 46202 USA. [Williams, Linda S.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN 46202 USA. [Bravata, Dawn M.] Indiana Univ Sch Med, Dept Internal Med, Indianapolis, IN 46202 USA. [Halm, Ethan A.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA. [Johanning, Jason] Univ Nebraska Med Ctr, Dept Surg, Omaha, NE USA. [Johanning, Jason] Omaha Vet Affairs Nebraska Western Iowa Hlth Care, Omaha, NE USA. [Hebert, Paul] Puget Sound Vet Affairs Med Ctr, Seattle, WA USA. [Hebert, Paul] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. RP Keyhani, S (reprint author), 4150 Clement St, San Francisco, CA 94121 USA. EM salomeh.keyhani@ucsf.edu FU National Institutes of Health/National Heart, Lung, and Blood Institute [RO1 HL114563-01A1] FX The project reported was supported by National Institutes of Health/National Heart, Lung, and Blood Institute grant RO1 HL114563-01A1. NR 16 TC 1 Z9 1 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAY PY 2016 VL 176 IS 5 BP 626 EP 633 DI 10.1001/jamainternmed.2016.0678 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA DL0AC UT WOS:000375292500016 PM 27088224 ER PT J AU Schonberg, MA Smith, AK AF Schonberg, Mara A. Smith, Alexander K. TI Discussing Long-term Prognosis in Primary Care Hard but Necessary SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID SURVIVAL; ADULTS C1 [Schonberg, Mara A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Gen Med & Primary Care, Boston, MA 02215 USA. [Smith, Alexander K.] Univ Calif San Francisco, Dept Med, Div Geriatr, 4150 Clement St,181G, San Francisco, CA 94121 USA. [Smith, Alexander K.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Smith, AK (reprint author), Univ Calif San Francisco, Dept Med, Div Geriatr, 4150 Clement St,181G, San Francisco, CA 94121 USA. EM aksmith@ucsf.edu FU NCI NIH HHS [R01 CA181357]; NIA NIH HHS [K23 AG040772] NR 10 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAY PY 2016 VL 176 IS 5 BP 678 EP 680 DI 10.1001/jamainternmed.2016.0972 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA DL0AC UT WOS:000375292500026 PM 27064576 ER PT J AU Weintraub, D Chiang, C Kim, HM Wilkinson, J Marras, C Stanislawski, B Mamikonyan, E Kales, HC AF Weintraub, Daniel Chiang, Claire Kim, Hyungjin Myra Wilkinson, Jayne Marras, Connie Stanislawski, Barbara Mamikonyan, Eugenia Kales, Helen C. TI Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease SO JAMA NEUROLOGY LA English DT Article ID OLDER-ADULTS; LEWY BODIES; DEMENTIA; MANAGEMENT; SYMPTOMS; PSYCHOSIS; MEDICATIONS; PATTERNS; DISORDER; FRACTURE AB IMPORTANCE As many as 60% of patients with Parkinson disease (PD) experience psychosis, 80% develop dementia, and the use of antipsychotics (APs) in the population with PD is common. The use of APs by patients with dementia in the general population is associated with increased mortality, but whether this risk extends to patients with PD remains unknown. OBJECTIVE To determine whether AP use in patients with PD is associated with increased mortality. DESIGN, SETTING, AND PARTICIPANTS This retrospective matched-cohort study used data from a Veterans Health Administration database from fiscal years 1999 to 2010 to examine the risk associated with AP use in a cohort of patients with idiopathic PD and recent stable physical health. The rates of 180-day mortality were compared in 7877 patients initiating AP therapy and 7877 patients who did not initiate AP therapy (matched for age +/- 2.5 years, sex, race, index year, presence and duration of dementia, PD duration, delirium, hospitalization, Charlson Comorbidity Index, and new nonpsychiatric medications). Data were analyzed from October 19, 2012, to September 21, 2015. MAIN OUTCOMES AND MEASURES Mortality rates at 180 days in those patients who initiated AP therapy compared with matched patients who did not use APs. Cox proportional hazards regression models were used with intent-to-treat (ITT) and exposure-only analyses. RESULTS The study population included 7877 matched pairs of patients with PD (65 women [0.8%] and 7812 men [99.2%] in each cohort; mean [SD] age, 76.3 [7.7] years for those who initiated AP therapy and 76.4 [7.6] years for those who did not). Antipsychotic use was associated with more than twice the hazard ratio (HR) of death compared with nonuse (ITT HR, 2.35; 95% CI, 2.08-2.66; P < .001). The HR was significantly higher for patients who used typical vs atypical APs (ITT HR, 1.54; 95% CI, 1.24-1.91; P < .001). Among the atypical APs used, HRs relative to nonuse of APs in descending order were 2.79 (95% CI, 1.97-3.96) for olanzapine, 2.46 (95% CI, 1.94-3.12) for risperidone, and 2.16 (95% CI, 1.88-2.48) for quetiapine fumarate. CONCLUSIONS AND RELEVANCE Use of APs is associated with a significantly increased mortality risk in patients with PD, after adjusting for measurable confounders. This finding highlights the need for cautious use of APs in patients with PD. Future studies should examine the role of nonpharmacologic strategies in managing psychosis in PD. In addition, new pharmacologic treatments that do not increase mortality in patients with neurodegenerative diseases need to be developed. C1 [Weintraub, Daniel; Wilkinson, Jayne] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. [Weintraub, Daniel; Wilkinson, Jayne; Mamikonyan, Eugenia] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19014 USA. [Weintraub, Daniel; Wilkinson, Jayne; Mamikonyan, Eugenia] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19014 USA. [Chiang, Claire; Kim, Hyungjin Myra; Stanislawski, Barbara; Kales, Helen C.] US Dept Vet Affairs, Hlth Serv Res & Dev, Ctr Clin Management Res, Ann Arbor, MI USA. [Kim, Hyungjin Myra] Univ Michigan, Ctr Stat Consultat & Res, Ann Arbor, MI 48109 USA. [Marras, Connie] Univ Toronto, Toronto Western Hosp, Edmond J Safra Program Parkinsons Dis, Morton & Gloria Shulman Movement Disorder Ctr, Toronto, ON M5T 2S8, Canada. [Kales, Helen C.] Vet Affairs Ann Arbor Healthcare Syst, Geriatr Res Educ & Clin Ctr, Ann Arbor, MI USA. [Kales, Helen C.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. RP Weintraub, D (reprint author), Univ Penn, Perelman Sch Med, 3615 Chestnut St,Ste 330, Philadelphia, PA 19014 USA. EM daniel.weintraub@uphs.upenn.edu FU Veterans Health Administration [IIR 12-144-2]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, VA Information Resource Center [SDR 02-237, 98-004] FX This study was supported by merit review award IIR 12-144-2 from the Veterans Health Administration. Support for the Veterans Administration and Centers for Medicare & Medicaid data is provided by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, VA Information Resource Center (project SDR 02-237 and 98-004). NR 34 TC 14 Z9 14 U1 3 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD MAY PY 2016 VL 73 IS 5 BP 535 EP 541 DI 10.1001/jamaneurol.2016.0031 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA DL2JW UT WOS:000375461900015 PM 26999262 ER PT J AU Yehuda, R Hoge, CW AF Yehuda, Rachel Hoge, Charles W. TI The Meaning of Evidence-Based Treatments for Veterans With Posttraumatic Stress Disorder SO JAMA PSYCHIATRY LA English DT Editorial Material ID PTSD C1 [Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Dept Psychiat, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. [Yehuda, Rachel] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Hoge, Charles W.] Walter Reed Army Inst Res, Silver Spring, MD USA. RP Yehuda, R (reprint author), James J Peters Vet Affairs Med Ctr, Dept Psychiat, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM rachel.yehuda@mssm.edu NR 7 TC 8 Z9 8 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD MAY PY 2016 VL 73 IS 5 BP 433 EP 434 DI 10.1001/jamapsychiatry.2015.2878 PG 2 WC Psychiatry SC Psychiatry GA DL2KD UT WOS:000375462600002 PM 26886229 ER PT J AU Sherva, R Wang, Q Kranzler, H Zhao, HY Koesterer, R Herman, A Farrer, LA Gelernter, J AF Sherva, Richard Wang, Qian Kranzler, Henry Zhao, Hongyu Koesterer, Ryan Herman, Aryeh Farrer, Lindsay A. Gelernter, Joel TI Genome-wide Association Study of Cannabis Dependence Severity, Novel Risk Variants, and Shared Genetic Risks SO JAMA PSYCHIATRY LA English DT Article ID PSYCHIATRIC-DISORDERS; NICOTINE DEPENDENCE; EUROPEAN-AMERICANS; AFRICAN-AMERICANS; LINKAGE ANALYSIS; DRUG-USE; SCHIZOPHRENIA; LOCI; SUSCEPTIBILITY; IDENTIFICATION AB IMPORTANCE Cannabis dependence (CAD) is a serious problem worldwide and is of growing importance in the United States because cannabis is increasingly available legally. Although genetic factors contribute substantially to CAD risk, at present no well-established specific genetic risk factors for CAD have been elucidated. OBJECTIVE To report findings for DSM-IV CAD criteria from association analyses performed in large cohorts of African American and European American participants from 3 studies of substance use disorder genetics. DESIGN, SETTING, AND PARTICIPANTS This genome-wide association study for DSM-IV CAD criterion count was performed in 3 independent substance dependence cohorts (the Yale-Penn Study, Study of Addiction: Genetics and Environment [SAGE], and International Consortium on the Genetics of Heroin Dependence [ICGHD]). A referral sample and volunteers recruited in the community and from substance abuse treatment centers included 6000 African American and 8754 European American participants, including some from small families. Participants from the Yale-Penn Study were recruited from 2000 to 2013. Data were collected for the SAGE trial from 1990 to 2007 and for the ICGHD from 2004 to 2009. Data were analyzed from January 2, 2013, to November 9, 2015. MAIN OUTCOMES AND MEASURES Criterion count for DSM-IV CAD. RESULTS Among the 14 754 participants, 7879 were male, 6875 were female, and the mean (SD) age was 39.2 (10.2) years. Three independent regions with genome-wide significant single-nucleotide polymorphism associations were identified, considering the largest possible sample. These included rs143244591 (beta = 0.54, P = 4.32 x 10(-10) for the meta-analysis) in novel antisense transcript RP11-206M11.7; rs146091982 (beta = 0.54, P = 1.33 x 10(-9) for the meta-analysis) in the solute carrier family 35 member G1 gene (SLC35G1); and rs77378271 (beta = 0.29, P = 2.13 x 10(-8) for the meta-analysis) in the CUB and Sushi multiple domains 1 gene (CSMD1). Also noted was evidence of genome-level pleiotropy between CAD and major depressive disorder and for an association with single-nucleotide polymorphisms in genes associated with schizophrenia risk. Several of the genes identified have functions related to neuronal calcium homeostasis or central nervous system development. CONCLUSIONS AND RELEVANCE These results are the first, to our knowledge, to identify specific CAD risk alleles and potential genetic factors contributing to the comorbidity of CAD with major depression and schizophrenia. C1 [Sherva, Richard; Koesterer, Ryan; Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Med, Sect Biomed Genet, Boston, MA 02118 USA. [Wang, Qian; Zhao, Hongyu] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT USA. [Kranzler, Henry] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Kranzler, Henry] Philadelphia VA Med Ctr, Vet Affairs VA Stars & Stripes Healthcare Network, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. [Zhao, Hongyu] Yale Univ, Sch Med, Dept Genet, West Haven, CT 06516 USA. [Zhao, Hongyu] Yale Univ, Sch Publ Hlth, Dept Biostat, New Haven, CT USA. [Zhao, Hongyu; Gelernter, Joel] VA Cooperat Studies Program Coordinating Ctr, West Haven, CT USA. [Herman, Aryeh; Gelernter, Joel] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA. [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Gelernter, Joel] Yale Univ, Sch Med, VA Connecticut Healthcare Ctr, Dept Psychiat, West Haven, CT 06516 USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA. RP Gelernter, J (reprint author), Yale Univ, Sch Med, Vet Affairs Connecticut Healthcare Ctr, Dept Psychiat, 116A2,950 Campbell Ave, West Haven, CT 06516 USA. EM joel.gelernter@yale.edu RI Wang, Qian/Q-4664-2016 OI Wang, Qian/0000-0002-5615-4506 FU National Institutes of Health (NIH) [RC2 DA028909, R01 DA12690, R01 DA12849, R01 DA18432, R01 AA11330, R01 AA017535]; Veterans Affairs Connecticut Healthcare Center; Philadelphia Veterans Affairs Mental Illness Research, Education and Clinical Center; NIH Genes, Environment and Health Initiative [U01 HG004422, U01HG004438]; Gene Environment Association Studies under the Genes, Environment and Health Initiative; National Institute on Alcohol Abuse and Alcoholism [HHSN268200782096C]; National Institute on Drug Abuse, NIH; NIH [HHSN268200782096C, U10 AA008401, P01 CA089392, R01 DA013423, HHSN268201100011I] FX This study was supported by grants RC2 DA028909, R01 DA12690, R01 DA12849, R01 DA18432, R01 AA11330, and R01 AA017535 from the National Institutes of Health (NIH), the Veterans Affairs Connecticut Healthcare Center, and the Philadelphia Veterans Affairs Mental Illness Research, Education and Clinical Center. Funding support for the Study of Addiction: Genetics and Environment (SAGE) was provided by grant U01 HG004422 from the NIH Genes, Environment and Health Initiative. SAGE is one of the genome-wide association studies funded as part of the Gene Environment Association Studies under the Genes, Environment and Health Initiative. The portion of the genotyping that was performed at the Johns Hopkins University Center for Inherited Disease Research was supported by grant U01HG004438 from the NIH Genes, Environment and Health Initiative, and by contract HHSN268200782096C (High Throughput Genotyping for Studying the Genetic Contributions to Human Disease) from the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Drug Abuse, NIH. Support for collection of datasets and samples was provided by grant U10 AA008401 (Collaborative Study on the Genetics of Alcoholism), grant P01 CA089392 (Collaborative Genetic Study of Nicotine Dependence), and grant R01 DA013423 (Family Study of Cocaine Dependence) from the NIH. The International Consortium on the Genetics of Heroin Dependence (principal investigator, Elliot Nelson, MD) was funded by HHSN268200782096C (NIH contract: High Throughput Genotyping for Studying the Genetic Contributions to Human Disease) and HHSN268201100011I (NIH contract: High Throughput Genotyping for Studying the Genetic Contributions to Human Disease). NR 50 TC 11 Z9 11 U1 1 U2 17 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD MAY PY 2016 VL 73 IS 5 BP 472 EP 480 DI 10.1001/jamapsychiatry.2016.0036 PG 9 WC Psychiatry SC Psychiatry GA DL2KD UT WOS:000375462600012 PM 27028160 ER PT J AU Kaup, AR Byers, AL Falvey, C Simonsick, EM Satterfield, S Ayonayon, HN Smagula, SF Rubin, SM Yaffe, K AF Kaup, Allison R. Byers, Amy L. Falvey, Cherie Simonsick, Eleanor M. Satterfield, Suzanne Ayonayon, Hilsa N. Smagula, Stephen F. Rubin, Susan M. Yaffe, Kristine TI Trajectories of Depressive Symptoms in Older Adults and Risk of Dementia SO JAMA PSYCHIATRY LA English DT Article ID MILD COGNITIVE IMPAIRMENT; LATE-LIFE DEPRESSION; ALZHEIMERS-DISEASE; BODY-COMPOSITION; PRIMARY-CARE; HEALTH ABC; DECLINE; WOMEN; ASSOCIATION; PREDICTORS AB IMPORTANCE Depression has been identified as a risk factor for dementia. However, most studies have measured depressive symptoms at only one time point, and older adults may show different patterns of depressive symptoms over time. OBJECTIVE To investigate the association between trajectories of depressive symptoms and risk of dementia in older adults. DESIGN, SETTING, AND PARTICIPANTS This was a prospective cohort investigation of black and white community-dwelling older adults in the Health, Aging, and Body Composition study. Participants were enrolled between May 1997 and June 1998 and followed up through 2001-2002. The dates of this analysis were September 2014 to December 2015. The setting was community research centers in Memphis, Tennessee, and Pittsburgh, Pennsylvania. Trajectories of depressive symptoms were assessed from baseline to year 5. Symptoms were measured with the Center for Epidemiologic Studies Depression Scale Short Form, and trajectories were calculated using latent class growth curve analysis. MAIN OUTCOMES AND MEASURES Incident dementia through year 11, determined by dementia medication use, hospital records, or significant cognitive decline (>= 1.5 SD race-specific decline on the Modified Mini-Mental State Examination). We examined the association between depressive symptom trajectories and dementia incidence using Cox proportional hazards regression models adjusted for demographics, health factors that differed between groups, and cognition during the depressive symptom assessment period (baseline to year 5). RESULTS The analytic cohort included 2488 black and white older adults with repeated depressive symptom assessments from baseline to year 5 who were free of dementia throughout that period. Their mean (SD) age at baseline was 74.0 (2.8) years, and 53.1% (n = 1322) were female. The following 3 depressive symptom trajectories were identified: consistently minimal symptoms (62.0% [n = 1542] of participants), moderate and increasing symptoms (32.2%[n = 801] of participants), and high and increasing symptoms (5.8% [n = 145] of participants). Compared with the consistently minimal trajectory, having a high and increasing depressive symptom trajectory was associated with significantly increased risk of dementia (fully adjusted hazard ratio, 1.94; 95% CI, 1.30-2.90), while the moderate and increasing trajectory was not associated with risk of dementia after full adjustment. Sensitivity analyses indicated that the high and increasing trajectory was associated with dementia incidence, while depressive symptoms at individual time points were not. CONCLUSIONS AND RELEVANCE Older adults with a longitudinal pattern of high and increasing depressive symptoms are at high risk for dementia. Individuals' trajectory of depressive symptoms may inform dementia risk more accurately than one-time assessment of depressive symptoms. C1 [Kaup, Allison R.; Byers, Amy L.] San Francisco VA Med Ctr, Res Serv, 4150 Clement St,Mail Code 116H, San Francisco, CA 94121 USA. [Kaup, Allison R.; Byers, Amy L.; Falvey, Cherie; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Simonsick, Eleanor M.] NIA, Intramural Res Program, Baltimore, MD 21224 USA. [Satterfield, Suzanne] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Memphis, TN USA. [Ayonayon, Hilsa N.; Rubin, Susan M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Smagula, Stephen F.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Kaup, AR (reprint author), San Francisco VA Med Ctr, Res Serv, 4150 Clement St,Mail Code 116H, San Francisco, CA 94121 USA. EM allison.kaup@ucsf.edu FU National Institute on Aging [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01-AG028050, K24AG031155]; National Institute for Nursing Research [R01-NR012459]; Intramural Research Program of the National Institute on Aging; US Department of Veterans Affairs, Rehabilitation Research and Development Service [1IK2RX001629]; National Institute of Mental Health [T32 MH019986]; Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment; Medical Research Service of the San Francisco Veterans Affairs Medical Center; Department of Veterans Affairs Sierra-Pacific Mental Illness Research, Education, and Clinical Center FX This research was supported by contracts N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106 from the National Institute on Aging; by grant R01-AG028050 from the National Institute on Aging; by grant R01-NR012459 from the National Institute for Nursing Research; and in part by the Intramural Research Program of the National Institute on Aging. The research described herein was also supported in part by Career Development Award 1IK2RX001629 from the US Department of Veterans Affairs, Rehabilitation Research and Development Service (Dr Kaup); by research training grant T32 MH019986 from the National Institute of Mental Health (Dr Smagula); by grant K24AG031155 from the National Institute on Aging (Dr Yaffe); and by the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment, the Medical Research Service of the San Francisco Veterans Affairs Medical Center, and the Department of Veterans Affairs Sierra-Pacific Mental Illness Research, Education, and Clinical Center. NR 35 TC 5 Z9 5 U1 3 U2 9 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD MAY PY 2016 VL 73 IS 5 BP 525 EP 531 DI 10.1001/jamapsychiatry.2016.0004 PG 7 WC Psychiatry SC Psychiatry GA DL2KD UT WOS:000375462600018 PM 26982217 ER PT J AU Horan, WP Wynn, JK Hajcak, G Altshuler, L Green, MF AF Horan, William P. Wynn, Jonathan K. Hajcak, Greg Altshuler, Lori Green, Michael F. TI Distinct Patterns of Dysfunctional Appetitive and Aversive Motivation in Bipolar Disorder Versus Schizophrenia: An Event-Related Potential Study SO JOURNAL OF ABNORMAL PSYCHOLOGY LA English DT Article DE schizophrenia; bipolar disorder; event-related potentials; psychological distance; motivation ID BEHAVIORAL ACTIVATION SYSTEM; RATING-SCALE; EMOTIONAL PICTURES; CORTICAL ACTIVITY; NEGATIVE EMOTION; REWARD; ANTICIPATION; IMPULSIVITY; DEPRESSION; SPECTRUM AB Schizophrenia and bipolar disorder are associated with different clinical profiles of disturbances in motivation, yet few studies have compared the neurophysiological correlates of such disturbances. Outpatients with schizophrenia (n = 34), or bipolar disorder I (n = 33), and healthy controls (n = 31) completed a task in which the late positive potential (LPP), an index of motivated attention, was assessed along motivational gradients determined by apparent distance from potential rewards or punishments. Sequences of cues signaling possible monetary gains or losses appeared to loom progressively closer to the viewer; a reaction time (RT) task after the final cue determined the outcome. Controls showed the expected pattern with LPPs for appetitive and aversive cues that were initially elevated, smaller during intermediate positions, and escalated just prior to the RT task. The clinical groups showed different patterns in the final positions just prior to the RT task: the bipolar group's LPPs to both types of cues peaked relatively early during looming sequences and subsequently decreased, whereas the schizophrenia group showed relatively small LPP escalations, particularly for aversive cues. These distinct patterns suggest that the temporal unfolding of attentional resource allocation for motivationally significant events may qualitatively differ between these disorders. C1 [Horan, William P.; Wynn, Jonathan K.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Horan, William P.; Wynn, Jonathan K.; Green, Michael F.] Univ Calif Los Angeles, Dept Psychiat, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90024 USA. [Hajcak, Greg] SUNY Stony Brook, Dept Psychol, Stony Brook, NY USA. [Altshuler, Lori] Univ Calif Los Angeles, Los Angeles, CA USA. RP Horan, WP (reprint author), Univ Calif Los Angeles, Dept Psychiat, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90024 USA.; Horan, WP (reprint author), VA Greater Los Angeles Healthcare Syst, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM horan@ucla.edu FU National Institute of Mental Health [MH091468, MH065707, MH43292]; Amgen; Forum FX Support for this study came from a National Institute of Mental Health Grants MH091468 (William P. Horan) and MH065707 and MH43292 (Michael F. Green). We thank Amanda Bender, Michelle Dolinsky, Crystal Gibson, Cory Tripp, and Katherine Weiner for assistance in data collection. Michael F. Green has been a consultant to AbbVie, DSP, Forum, and Takeda, and he is on the scientific advisory board of Mnemosyne. He has received research funds from Amgen and Forum. The rest of the authors report no biomedical financial interests or potential conflicts of interest. NR 57 TC 1 Z9 1 U1 1 U2 4 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0021-843X EI 1939-1846 J9 J ABNORM PSYCHOL JI J. Abnorm. Psychol. PD MAY PY 2016 VL 125 IS 4 BP 576 EP 587 DI 10.1037/abn0000142 PG 12 WC Psychology, Clinical; Psychology, Multidisciplinary SC Psychology GA DK8ZJ UT WOS:000375218300011 PM 26845261 ER PT J AU Chimote, AA Hajdu, P Kottyan, LC Harley, JB Yun, YH Conforti, L AF Chimote, Ameet A. Hajdu, Peter Kottyan, Leah C. Harley, John B. Yun, Yeoheung Conforti, Laura TI Nanovesicle-targeted Kv1.3 knockdown in memory T cells suppresses CD40L expression and memory phenotype SO JOURNAL OF AUTOIMMUNITY LA English DT Article DE Autoimmunity; T cell; Kv1.3 ion channel; CD40 ligand; Lipid nanoparticles; Ca2+ signaling ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; INFLAMMATORY-BOWEL-DISEASE; ION CHANNELS; MULTIPLE-SCLEROSIS; POTASSIUM CHANNELS; K+ CHANNELS; LYMPHOCYTES; ACTIVATION; CALCINEURIN AB Ca2+ signaling controls activation and effector functions of T lymphocytes. Ca2+ levels also regulate NFAT activation and CD40 ligand (CD40L) expression in T cells. CD40L in activated memory T cells binds to its cognate receptor, CD40, on other cell types resulting in the production of antibodies and pro inflammatory mediators. The CD40L/CD40 interaction is implicated in the pathogenesis of autoimmune disorders and CD40L is widely recognized as a therapeutic target. Ca2+ signaling in T cells is regulated by Kv1.3 channels. We have developed lipid nanoparticles that deliver Kv1.3 siRNAs (Kv1.3-NPs) selectively to CD45RO(+) memory T cells and reduce the activation-induced Ca2+ influx. Herein we report that Kv1.3-NPs reduced NFAT activation and CD40L expression exclusively in CD45RO(+) T cells. Furthermore, Kv1.3-NPs suppressed cytokine release and induced a phenotype switch of T cells from predominantly memory to naive. These findings indicate that Kv1.3-NPs operate as targeted immune suppressive agents with promising therapeutic potentials. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Chimote, Ameet A.; Hajdu, Peter; Conforti, Laura] Univ Cincinnati, Div Nephrol, Dept Internal Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA. [Kottyan, Leah C.; Harley, John B.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol, Cincinnati, OH 45267 USA. [Yun, Yeoheung] N Carolina Agr & Tech State Univ, Biol & Bioengn Dept, Greensboro, NC 27411 USA. [Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. RP Conforti, L (reprint author), Univ Cincinnati, Div Nephrol, Dept Internal Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA. EM Laura.Conforti@uc.edu RI Chimote, Ameet/R-5357-2016 OI Kottyan, Leah/0000-0003-3979-2220 FU NIH [R21AR060966, R01CA095286]; Dialysis Clinic, Inc. FX This project was funded in part by NIH grants R21AR060966, R01CA095286 and a research grant from Dialysis Clinic, Inc. to LC. All flow cytometry experiments were performed at the Research Flow Cytometry Core in the Division of Rheumatology at Cincinnati Children's Hospital Medical Center and Shriner's Hospital for Children Flow Cytometry Core, Cincinnati OH. We thank Dr. Heather Duncan for her assistance with IRB regulatory affairs and Dr. Giovanni Pauletti for making the Zetasizer Nano ZS instrument available to us. We are also grateful to Dr. Judith Heiny and Dr. Christy Holland for the use of the lyophilizer. All authors discussed the results and commented on the manuscript. NR 42 TC 1 Z9 1 U1 2 U2 6 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0896-8411 EI 1095-9157 J9 J AUTOIMMUN JI J. Autoimmun. PD MAY PY 2016 VL 69 BP 86 EP 93 DI 10.1016/j.jaut.2016.03.004 PG 8 WC Immunology SC Immunology GA DK4WB UT WOS:000374919900009 PM 26994905 ER PT J AU Schopfer, DW Priano, S Allsup, K Helfrich, CD Ho, PM Rumsfeld, JS Forman, DE Whooley, MA AF Schopfer, David W. Priano, Susan Allsup, Kelly Helfrich, Christian D. Ho, P. Michael Rumsfeld, John S. Forman, Daniel E. Whooley, Mary A. TI Factors Associated With Utilization of Cardiac Rehabilitation Among Patients With Ischemic Heart Disease in the Veterans Health Administration A QUALITATIVE STUDY SO JOURNAL OF CARDIOPULMONARY REHABILITATION AND PREVENTION LA English DT Article DE cardiac rehabilitation; program delivery; qualitative; utilization ID CORONARY-ARTERY-DISEASE; MYOCARDIAL-INFARCTION; EXERCISE; CARE; PREDICTORS; PREVENTION; CARDIOLOGY; MORTALITY; PROGRAM; SYSTEM AB BACKGROUND: Cardiac rehabilitation (CR) programs reduce morbidity and mortality in patients with ischemic heart disease but are vastly underutilized in the United States, including the Veterans Health Administration (VA) Healthcare System. Numerous barriers affecting utilization have been identified in other health care systems, but the specific factors affecting Veterans are unknown. We sought to identify barriers and facilitators associated with utilization of CR in VA facilities. METHODS: We performed a qualitative study of 56 VA patients, providers, and CR program managers at 30 VA facilities across the United States. We conducted semistructured interviews with key informants to explore their attitudes and knowledge toward CR. Interviews were conducted until thematic saturation occurred. Analyses using grounded theory to identify key themes were conducted using the qualitative data analysis package ATLAS.ti. RESULTS: We identified 6 themes as barriers and 5 as facilitators. The most common barriers to participation in CR were patient transportation issues (68%), lack of patient willingness to participate (41%), and no access to a nearby VA hospital with a CR program (30%). The most common facilitators were involvement of a dedicated provider or "clinical champion" (50%), provider knowledge of or experience with CR (48%), and patient desire for additional medical support (32%). CONCLUSIONS: Our findings suggest that addressing access issues and educating and activating providers on CR may increase utilization of CR programs. Targeting these specific factors may improve utilization of CR programs. C1 [Schopfer, David W.; Whooley, Mary A.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Schopfer, David W.; Whooley, Mary A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Priano, Susan] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. [Allsup, Kelly; Forman, Daniel E.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Helfrich, Christian D.] Vet Affairs Puget Sound Healthcare Syst, Northwest Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. [Ho, P. Michael; Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Div Cardiol, Denver, CO USA. [Ho, P. Michael; Rumsfeld, John S.] Univ Colorado, Hlth Sci Ctr, Div Cardiol, Dept Med, Denver, CO 80262 USA. [Forman, Daniel E.] Univ Pittsburgh, Med Ctr, Geriatr Cardiol Sect, Pittsburgh, PA USA. [Forman, Daniel E.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Schopfer, DW (reprint author), 4150 Clement St 111A1, San Francisco, CA 94121 USA. EM david.schopfer@gmail.com OI Schopfer, David/0000-0002-7244-9857 FU Department of Veterans Affairs (Health Services Research RRP) [12-232]; National Center for Advancing Translational Sciences of the NIH [KL2TR000143] FX This study was supported by a grant from the Department of Veterans Affairs (Health Services & Research RRP #12-232). Dr Schopfer is supported by the National Center for Advancing Translational Sciences of the NIH under Award Number KL2TR000143. NR 38 TC 2 Z9 2 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-7501 EI 1932-751X J9 J CARDIOPULM REHABIL JI J. Cardiopulm. Rehabil. Prev. PD MAY-JUN PY 2016 VL 36 IS 3 BP 167 EP 173 DI 10.1097/HCR.0000000000000166 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DK7QH UT WOS:000375120300003 PM 27115074 ER PT J AU Lee, J Fei, P Packard, RRS Kang, H Xu, H Baek, KI Jen, N Chen, JJ Yen, H Kuo, CCJ Chi, NC Ho, CM Li, RS Hsiai, TK AF Lee, Juhyun Fei, Peng Packard, Rene R. Sevag Kang, Hanul Xu, Hao Baek, Kyung In Jen, Nelson Chen, Junjie Yen, Hilary Kuo, C-C Jay Chi, Neil C. Ho, Chih-Ming Li, Rongsong Hsiai, Tzung K. TI 4-Dimensional light-sheet microscopy to elucidate shear stress modulation of cardiac trabeculation SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID VENTRICULAR NONCOMPACTION CARDIOMYOPATHY; ZEBRAFISH HEART; IN-VIVO; MESENCHYMAL TRANSITION; BLOOD-VESSELS; NADPH OXIDASE; NOTCH; EMBRYOS; FORCE; PROLIFERATION AB Hemodynamic shear forces are intimately linked with cardiac development, during which trabeculae form a network of branching outgrowths from the myocardium. Mutations that alter Notch signaling also result in trabeculation defects. Here, we assessed whether shear stress modulates trabeculation to influence contractile function. Specifically, we acquired 4D (3D + time) images with light sheets by selective plane illumination microscopy (SPIM) for rapid scanning and deep axial penetration during zebrafish morphogenesis. Reduction of blood viscosity via gata1a morpholino oligonucleotides (MO) reduced shear stress, resulting in downregulation of Notch signaling and attenuation of trabeculation. Arrest of cardiomyocyte contraction either by troponin T type 2a (tnnt2a) MO or in weak atrium(m58) (wea) mutants resulted in reduced shear stress and downregulation of Notch signaling and trabeculation. Integrating 4D SPIM imaging with synchronization algorithm demonstrated that coinjection of neuregulin1 mRNA with gata1 MO rescued trabeculation to restore contractile function in association with upregulation of Notch-related genes. Crossbreeding of Tg(flk:mCherry) fish, which allows visualization of the vascular system with the Tg(tp1:gfp) Notch reporter line, revealed that shear stress-mediated Notch activation localizes to the endocardium. Deleting endocardium via the cloche(sk4) mutants downregulated Notch signaling, resulting in nontrabeculated ventricle. Subjecting endothelial cells to pulsatile flow in the presence of the ADAM10 inhibitor corroborated shear stress-activated Notch signaling to modulate trabeculation. C1 [Lee, Juhyun; Baek, Kyung In; Jen, Nelson; Chen, Junjie; Yen, Hilary; Hsiai, Tzung K.] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA USA. [Fei, Peng] Huazhong Univ Sci & Technol, Sch Opt & Elect Informat, Wuhan 430074, Peoples R China. [Fei, Peng; Ho, Chih-Ming] Univ Calif Los Angeles, Dept Mech Engn, Los Angeles, CA USA. [Packard, Rene R. Sevag; Kang, Hanul; Li, Rongsong; Hsiai, Tzung K.] Univ Calif Los Angeles, Dept Med, Div Cardiol, Los Angeles, CA 90024 USA. [Kang, Hanul; Li, Rongsong; Hsiai, Tzung K.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Cardiol, Los Angeles, CA USA. [Xu, Hao; Kuo, C-C Jay] Univ So Calif, Dept Elect Engn, Los Angeles, CA 90089 USA. [Chi, Neil C.] UCSD, Dept Med, Inst Genom Med, La Jolla, CA USA. [Hsiai, Tzung K.] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA USA. RP Hsiai, TK (reprint author), Univ Calif Los Angeles, Dept Med Cardiol & Bioengn, 10833 Le Conte,CHS 17-054, Los Angeles, CA 90095 USA. EM thsiai@mednet.ucla.edu OI Packard, Rene/0000-0002-8520-5843 FU NIH [HL118650, HL083015, HD069305, HL111437, HL129727, T32HL007895]; American Heart Association [15PRE21400019] FX The authors would like to express gratitude to William Talbot from Stanford University for providing the human Nrg1 plasmid and to Deborah Yelon from UCSD for providing the wea mutants. In addition, the authors also thank David Traver at UCSD and Nathan Lawson at the University of Massachusetts Medical School (Worcester, Massachusetts, USA) for generously providing the Tg(tp1:gfp) line. This study was supported by grants NIH HL118650 (to T.K. Hsiai), HL083015 (to T.K. Hsiai), HD069305 (to N.C. Chi and T.K. Hsiai.), HL111437 (to T.K. Hsiai and N.C. Chi), HL129727 (to T.K. Hsiai), T32HL007895 (to R.R. Sevag Packard), and American Heart Association Pre-Doctoral Fellowship 15PRE21400019 (to J. Lee). NR 71 TC 3 Z9 3 U1 1 U2 10 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD MAY PY 2016 VL 126 IS 5 BP 1679 EP 1690 DI 10.1172/JCI83496 PG 12 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DK8MX UT WOS:000375182100010 PM 27018592 ER PT J AU Szkudlinska, MA von Frankenberg, AD Utzschneider, KM AF Szkudlinska, Magdalena A. von Frankenberg, Anize D. Utzschneider, Kristina M. TI The antioxidant N-Acetylcysteine does not improve glucose tolerance or beta-cell function in type 2 diabetes SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Article DE N-Acetylcysteine; beta-cell function; Antioxidant; Oxidative stress; Supplement ID CHRONIC OXIDATIVE STRESS; ENDOTHELIAL ACTIVATION; TOXICITY; GLUTATHIONE; DYSFUNCTION; MECHANISM; MELLITUS; CYSTEINE AB Hyperglycemia induces oxidative stress and thereby may exacerbate beta-cell dysfunction in type 2 diabetes (T2DM). Notably, glutathione (GSH), synthesized from N-Acetylcysteine (NAC), neutralizes reactive oxygen species within cells and is low in individuals with diabetes. Aim: Determine if NAC supplementation improves beta-cell function and glucose tolerance by decreasing oxidative stress in T2DM. Methods: Thirteen subjects (6 M/7 F) with T2DM (duration: 0-13 years, median: 2 years), treated with diet/exercise alone (n = 7) or metformin (n = 6), underwent a 2-h oral glucose tolerance test (OGTT) at baseline, after 2 weeks supplementation with 600 mg NAC orally twice daily, and again after 2 weeks supplementation with 1200 mg NAC twice daily. The following measurements were made: fasting glucose and fructosamine for glycemic control, incremental AUC glucose (0-120 min) for glucose tolerance, and A insulin/Delta, glucose (0-30 min) for the early insulin response to glucose. Fasting erythrocyte GSH and GSSG (oxidized glutathione) levels, plasma thiobarbituric acid reactive substances (TBARS), and urine F2 alpha isoprostanes were measured to assess oxidative status. Results: Subjects were middle aged (mean +/- SEM: 53.9 +/- 32 years), obese (BMI 373 +/- 2.8 kg/m(2)), and relatively well-controlled (HbA1c 6.7 +/- 03%, 50 mmol/mol). Glycemic control, glucose tolerance, insulin release, and oxidative markers did not change with either dose of NAC. Conclusions: Based on the lack of any short-term benefit from NAC supplementation on markers of glucose metabolism, beta-cell response, and oxidative status, it is unlikely to be a valuable therapeutic approach for treatment of type 2 diabetes. Published by Elsevier Inc. C1 [Szkudlinska, Magdalena A.; Utzschneider, Kristina M.] VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Szkudlinska, Magdalena A.; Utzschneider, Kristina M.] Univ Washington, Seattle, WA 98195 USA. [von Frankenberg, Anize D.] Univ Fed Rio Grande do Sul, Sch Med, Postgrad Endocrinol Program, Porto Alegre, RS, Brazil. RP Szkudlinska, MA (reprint author), VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA USA.; Szkudlinska, MA (reprint author), Univ Washington, Seattle, WA 98195 USA. EM magda3@u.washington.edu; anize.frankenberg@gmail.com; kutzschn@u.washington.edu FU Department of Veteran Affairs; Diabetes Research Center [P30DK017047] FX We are grateful to the study participants for their contribution and time. This study was supported by funding and resources from the Department of Veteran Affairs and the Diabetes Research Center (P30DK017047). The NAC supplement was generously provided free of charge from Twin Labs. NR 25 TC 0 Z9 0 U1 3 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 EI 1873-460X J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD MAY-JUN PY 2016 VL 30 IS 4 BP 618 EP 622 DI 10.1016/j.jdiacomp.2016.02.003 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DK4UQ UT WOS:000374916200010 PM 26922582 ER PT J AU Lopes-Virella, MF Hunt, KJ Baker, NL Virella, G AF Lopes-Virella, Maria F. Hunt, Kelly J. Baker, Nathaniel L. Virella, Gabriel CA VADT Grp Investigators TI High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Article DE Nephropathy; Albuminuria; Modified LDL immune complexes; Modified LDL antibodies; AGE- LDL; MDA-LDL ID LOW-DENSITY-LIPOPROTEIN; GLYCATION END-PRODUCTS; EURODIAB PROSPECTIVE COMPLICATIONS; INTIMA-MEDIA THICKNESS; OXIDIZED LDL; CARDIOVASCULAR EVENTS; OXIDATIVE STRESS; GLYCEMIC CONTROL; MODIFIED FORMS; RISK-FACTORS AB Background: Circulating immune complexes (IC) containing modified forms of LDL (mLDL) are strongly pro-inflammatory and when present in high levels are associated with the development of diabetic complications. Objective: We investigated whether levels of oxidized LDL (oxLDL), malondialdehyde-LDL (MDA-LDL) and advanced glycation end products-LDL (AGE-LDL) as well as IgG and IgM antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL isolated from circulating IC were associated with progression to macroalbuminuria in type 2 diabetes (VADT cohort). Methods: Levels of mLDL in IC were measured in 905 patients, a median of two years after entry into the study. Participants were followed for an average of 3.7 years for renal outcomes. Generalized logistic regression models were used to quantify the association of increased levels of biomarkers and development of abnormal albuminuria. Normal, persistent micro-(ACR >= 30), incident micro-(ACR >= 30) and incident macroalbuminuria (ACR >= 300) were the outcomes of interest. Results and conclusions: Patients with macro (n = 78) or non-persistent microalbuminuria (n = 81) at baseline were excluded. Odds ratios for endpoints in relation to high versus low (defined using a median split) biomarker levels are found in Fig. 1. Our study demonstrates that high levels of AGE-LDL as well as of IgG antibodies (but not IgM antibodies) reacting with MDA-LDL lysine epitopes in circulating IC predict the development of macroalbuminuria in patients with type 2 diabetes. These data support the pathogenic role of modified LDL IgG antibodies but not the protective role of modified LDL IgM antibodies. Published by Elsevier Inc. C1 [Lopes-Virella, Maria F.] Med Univ S Carolina, Dept Med & Lab Serv, Charleston, SC 29425 USA. [Lopes-Virella, Maria F.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Hunt, Kelly J.; Baker, Nathaniel L.] Med Univ S Carolina, Dept Publ Hlth Serv, Charleston, SC 29425 USA. [Virella, Gabriel] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. RP Lopes-Virella, MF (reprint author), 114 Doughty St, Charleston, SC 29425 USA. EM virellam@musc.edu FU Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development; National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01-DK099177] FX This work was supported in part by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development. This work was also supported by a program project funded by the National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Grants R01-DK099177. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government. M. L.-V. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. NR 46 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 EI 1873-460X J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD MAY-JUN PY 2016 VL 30 IS 4 BP 693 EP 699 DI 10.1016/j.jdiacomp.2016.01.012 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DK4UQ UT WOS:000374916200021 PM 26861948 ER PT J AU Gallegos, AM Streltzov, NA Stecker, T AF Gallegos, Autumn M. Streltzov, Nicholas A. Stecker, Tracy TI Improving Treatment Engagement for Returning Operation Enduring Freedom and Operation Iraqi Freedom Veterans With Posttraumatic Stress Disorder, Depression, and Suicidal Ideation SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE OEF/OIF veterans; posttraumatic stress disorder; suicidal ideation; treatment engagement ID MENTAL-HEALTH TREATMENT; AFGHANISTAN; CARE; PREDICTORS; SERVICES; BARRIERS; SAMPLE; PTSD; RISK; WAR AB Posttraumatic stress disorder (PTSD) is associated with increased risk of suicidal ideation among veterans of Operation Enduring Freedom and Operation Iraqi Freedom. This report examined the effectiveness of a brief phone-based cognitive-behavioral intervention on treatment seeking among suicidal and nonsuicidal Operation Enduring Freedom and Operation Iraqi Freedom veterans who screened positive for PTSD. Participants were randomized to the intervention or control conditions. We found that suicidal participants, regardless of condition, were twice as likely to attend treatment as nonsuicidal participants. Participants assigned to the control condition who did not indicate suicidality at baseline were less likely to attend treatment at both the 1- and 6-month follow-up interviews. Qualitative findings of the suicidal participants indicated PTSD and depressive symptoms, low social support, and infrequent positive coping mechanisms. Our finding indicates the effectiveness of an intervention to motivate veterans with PTSD to initiate and remain in treatment. The intervention might be particularly useful prior to experiencing a psychological crisis. C1 [Gallegos, Autumn M.] Univ Rochester, Med Ctr, Dept Psychiat, 300 Crittenden Blvd, Rochester, NY 14642 USA. [Streltzov, Nicholas A.] Geisel Sch Med Dartmouth, Dartmouth Psychiat Res Ctr, Lebanon, NH USA. [Stecker, Tracy] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA. [Stecker, Tracy] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Gallegos, AM (reprint author), Univ Rochester, Med Ctr, Dept Psychiat, 300 Crittenden Blvd, Rochester, NY 14642 USA. EM autumn_gallegos@urmc.rochester.edu FU National Institute of Mental Health [R01 MH086939] FX This research was funded by grant R01 MH086939 from the National Institute of Mental Health. NR 26 TC 0 Z9 0 U1 1 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0022-3018 EI 1539-736X J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD MAY PY 2016 VL 204 IS 5 BP 339 EP 343 DI 10.1097/NMD.0000000000000489 PG 5 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DK4LL UT WOS:000374889700002 PM 26894313 ER PT J AU La Fountaine, MF Toda, M Testa, A Bauman, WA AF La Fountaine, Michael F. Toda, Michita Testa, Anthony Bauman, William A. TI Suppression of Serum Prolactin Levels after Sports Concussion with Prompt Resolution Upon Independent Clinical Assessment To Permit Return-to-Play SO JOURNAL OF NEUROTRAUMA LA English DT Article DE adult brain injury; head trauma; hypopituitarism ID TRAUMATIC BRAIN-INJURY; SLEEP; HYPOPITUITARISM; DYSFUNCTION; STATEMENT; SECRETION; HORMONE AB A significant outflow of neurotransmitters and metabolites with associated enhanced cortical excitation occurs after concussive head trauma. Cellular changes in the acute post-injury period cannot be observed directly in humans, and as such, require indirect evidence from systems sufficiently sensitive to central neuronal cellular excitation. Dopamine is a neurotransmitter with numerous targets in the central and peripheral nervous system. Changes to central dopaminergic tone result in reciprocal responses to the level of serum prolactin (PRL). Thus, a concussion may lead to abnormal dopaminergic tone, resulting in dynamic perturbations in the serum PRL concentration. To determine the effect of concussion on serum PRL concentrations, venipuncture was performed in the morning in four male intercollegiate athletes (age, 20 +/- 1 years; height, 71 +/- 5 inches; weight, 174 +/- 21 pounds) within 48 h of concussion and again at 7 and 14 days post-injury. Serum PRL concentrations for each visit were categorized by quartile within the normal range. In all athletes, serum PRL concentrations increased from the lower quartiles in samples obtained closer to the time of injury to the higher quartiles at 14 days post-injury. These serum PRL changes accompanied the resolution of symptoms and the clinical decision to permit return-to-play. It may be postulated that transient augmentation of central dopaminergic tone resulted in inhibition of PRL secretion early after concussion and that disinhibition of PRL release occurred when central dopaminergic tone subsequently returned to baseline levels. This novel observation provides evidence for dopaminergic dysfunction after concussion that may be tracked by determination of serum PRL levels. C1 [La Fountaine, Michael F.] Seton Hall Univ, Sch Hlth & Med Sci, 400 South Orange Ave, S Orange, NJ 07079 USA. [La Fountaine, Michael F.] Seton Hall Univ, Inst Adv Study Rehabil & Sports Sci, S Orange, NJ 07079 USA. [Testa, Anthony] Seton Hall Univ, Dept Athlet, S Orange, NJ 07079 USA. [La Fountaine, Michael F.; Bauman, William A.] James J Peters VA Med Ctr, VA Rehabil Res & Dev Natl Ctr Excellence Med Cons, Bronx, NY USA. [Toda, Michita] Univ Wisconsin, Dept Athlet, Madison, WI USA. [Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. RP La Fountaine, MF (reprint author), Seton Hall Univ, Sch Hlth & Med Sci, 400 South Orange Ave, S Orange, NJ 07079 USA. EM lafounmi@shu.edu NR 20 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD MAY 1 PY 2016 VL 33 IS 9 BP 904 EP 906 DI 10.1089/neu.2015.3968 PG 3 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA DK7SA UT WOS:000375124800012 PM 26159360 ER PT J AU Waltz, P Carchman, E Gomez, H Zuckerbraun, B AF Waltz, Paul Carchman, Evie Gomez, Hernando Zuckerbraun, Brian TI Sepsis results in an altered renal metabolic and osmolyte profile SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE Sepsis; CLP; Acute kidney injury; Metabolomics ID ACUTE KIDNEY INJURY; EPIDEMIOLOGY; MULTICENTER; DYSFUNCTION; UREA AB Background: Sepsis remains a major health-care burden and source of morbidity and mortality. Acute kidney injury and failure frequently accompanies severe sepsis and contributes to this burden. Despite a great deal of research, the exact mechanisms underlying renal failure in sepsis are poorly understood. This study aims to further understand metabolic changes in renal tissue during sepsis. Materials and methods: Experimental sepsis was induced by cecal ligation and puncture (CLP) in C57BL/6 mice. Serum and organs were harvested 8 h after CLP. Markers of renal function including serum creatinine, blood urea nitrogen, and cystatin C were measured. Whole kidneys were analyzed for a global biochemical profile via liquid chromatography/tandem mass spectrometry by Metabolon. Results: CLP induced renal injury as evidenced by elevated serum creatinine, blood urea nitrogen, and cystatin C. Global energetic profile in sepsis showed an increase in glycolytic intermediates with decreased flux through the tricarboxylic acid (TCA) cycle. Multiple inflammatory markers were elevated in response to CLP. Levels of osmotic regulators varied, with an overall increase in pinitol, urea, and taurine in response to CLP. Conclusions: CLP resulted in dramatic changes in the renal macromolecular milieu. There appears to be an increased dependence on glycolysis and diminished flush through the TCA cycle. In addition, changes in renal osmolytes including pinitol, urea, and taurine were observed, perhaps uncovering an additional change with implications on renal function during sepsis. Published by Elsevier Inc. C1 [Waltz, Paul; Carchman, Evie; Zuckerbraun, Brian] Univ Pittsburgh, Dept Surg, F1267PUH,200 Lothrop St, Pittsburgh, PA 15213 USA. [Gomez, Hernando] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA. [Zuckerbraun, Brian] VA Pittsburgh Healthcare Syst, Univ Dr C, Pittsburgh, PA USA. RP Zuckerbraun, B (reprint author), Univ Pittsburgh, Dept Surg, F1267PUH,200 Lothrop St, Pittsburgh, PA 15213 USA. EM zuckerbraunbs@upmc.edu FU NIH [GM113816] FX This work was funded by NIH grant GM113816. NR 14 TC 2 Z9 2 U1 2 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 EI 1095-8673 J9 J SURG RES JI J. Surg. Res. PD MAY 1 PY 2016 VL 202 IS 1 BP 8 EP 12 DI 10.1016/j.jss.2015.12.011 PG 5 WC Surgery SC Surgery GA DK5OR UT WOS:000374969800002 PM 27083942 ER PT J AU Veenstra, CM Vachani, A Ciunci, CA Zafar, HM Epstein, AI Paulson, EC AF Veenstra, Christine M. Vachani, Anil Ciunci, Christine A. Zafar, Hanna M. Epstein, Andrew I. Paulson, E. Carter TI Trends in the Use of F-18-Fluorodeoxyglucose PET Imaging in Surveillance of Non-Small-Cell Lung and Colorectal Cancer SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol DE Positron emission tomographic imaging; surveillance; colorectal cancer; non-small-cell lung cancer; Choosing Wisely; FDG-PET ID MEDICARE BENEFICIARIES; FOLLOW-UP; CLINICAL ONCOLOGY; AMERICAN SOCIETY; TOMOGRAPHY AB Purpose: Surveillance PET after curative-intent treatment of non small-cell lung cancer (NSCLC) or colorectal cancer (CRC) is not clearly supported by available evidence or the Choosing Wisely campaign. However, the frequency of PET imaging during the surveillance period is relatively unknown. Methods: Using Surveillance, Epidemiology, and End Results Medicare data, 65,748 patients aged 66 years or older who were diagnosed with stage I to IIIA NSCLC or stage I to III CRC from 2001 through 2009 and who underwent surgical resection were identified. Trends in "any PET" or "PET-only" use 6 to 18 months postoperatively were assessed. Results: Any PET use more than doubled over the study period. Eleven percent of patients with NSCLC and 4% of those with CRC diagnosed in 2001 received any PET, compared with 25% of patients with NSCLC and 13% of those with CRC in 2009 (P < .001 for both). Higher stage disease was correlated with higher PET utilization and faster growth in use over the study period. PET-only use also increased over the study period, especially in higher stage disease. Fewer than 2% of patients diagnosed with stage IIIA NSCLC in 2001 received PET only, compared with 15% of patients diagnosed in 2009 (P = .014). Similarly, 1% of patients diagnosed with stage III CRC in 2001 received PET only, compared with 8% of patients diagnosed in 2009 (P < .001). Conclusions: PET utilization during the surveillance period increased between 2001 and 2009. Further research is needed to determine the factors driving use of surveillance PET and to examine relationships between PET and patient outcomes. C1 [Veenstra, Christine M.] Univ Michigan, Dept Internal Med, North Ingalls Bldg,3A22,300 North Ingalls, Ann Arbor, MI 48109 USA. [Veenstra, Christine M.] Univ Michigan, Inst Healthcare Policy & Innovat, North Ingalls Bldg,3A22,300 North Ingalls, Ann Arbor, MI 48109 USA. [Vachani, Anil; Ciunci, Christine A.; Epstein, Andrew I.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Zafar, Hanna M.] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. [Zafar, Hanna M.; Epstein, Andrew I.; Paulson, E. Carter] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Vachani, Anil; Epstein, Andrew I.; Paulson, E. Carter] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Paulson, E. Carter] Univ Penn, Div Colon & Rectal Surg, Philadelphia, PA 19104 USA. RP Veenstra, CM (reprint author), Univ Michigan, North Ingalls Bldg,3A22,300 North Ingalls, Ann Arbor, MI 48109 USA. EM cveenstr@med.umich.edu FU NCI NIH HHS [P30 CA016520] NR 13 TC 1 Z9 1 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD MAY PY 2016 VL 13 IS 5 BP 491 EP 496 DI 10.1016/j.jacr.2015.11.016 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DL0YE UT WOS:000375357700004 PM 26774883 ER PT J AU Berian, JR Paruch, JL Cohen, ME Merkow, RP Dahlke, AR Ko, CY Bilimoria, KY AF Berian, Julia R. Paruch, Jennifer L. Cohen, Mark E. Merkow, Ryan P. Dahlke, Allison R. Ko, Clifford Y. Bilimoria, Karl Y. TI Does Performance Vary Within the Same Hospital When Separately Examining Different Patient Subgroups? SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID QUALITY IMPROVEMENT PROGRAM; BODY-MASS INDEX; SURGICAL QUALITY; AMERICAN-COLLEGE; SURGERY; OUTCOMES; CANCER; RISK; MORTALITY; NSQIP AB BACKGROUND: Surgical quality programs, such as the American College of Surgeons NSQIP, provide reports based on specialty or procedure, with patients aggregated together. It is unknown whether hospital performance differs by patient subgroup (eg cancer vs noncancer patients), masking opportunities for improvement. Our objectives were to determine whether performance differs within a given hospital for 6 contrasting patient subgroups and to identify the percentage of hospitals with greater than chance differences in performance. STUDY DESIGN: Using the American College of Surgeons NSQIP data, adults undergoing lung resection, esophagectomy, hepatectomy, pancreatectomy, colectomy, and proctectomy (2005 through 2012) were divided into 6 contrasting subgroups (elderly vs nonelderly, white vs nonwhite, obese vs nonobese, renal insufficiency vs normal renal function, cancer vs noncancer, emergency vs nonemergency). The main end point was serious morbidity or mortality. Observed to expected ratios were constructed using hierarchical models and compared using paired t-tests (eg observed to expected for cancer cases compared with noncancer). Variation in performance differences was assessed using a randomization test and z-tests for proportions. RESULTS: From 433 hospitals, 221,518 patients were included. Overall quality differed for elderly vs nonelderly, renal insufficiency vs normal renal function patients, cancer vs noncancer, and emergency vs nonemergency (p < 0.05). Variation in within-hospital performance differences exceeded chance expectations for renal insufficiency vs normal renal function in 31.1% of hospitals, cancer vs noncancer in 40.8%, and emergency vs nonemergency patients in 55.4% (p < 0.001). CONCLUSIONS: Hospital performance within a given hospital varies by patient subgroup. Quality programs can consider separate reports for these subgroups to identify opportunities for quality improvement. (C) 2016 by the American College of Surgeons. Published by Elsevier Inc. All rights reserved. C1 [Berian, Julia R.; Paruch, Jennifer L.; Cohen, Mark E.; Merkow, Ryan P.; Ko, Clifford Y.; Bilimoria, Karl Y.] Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA. [Berian, Julia R.; Paruch, Jennifer L.; Merkow, Ryan P.] Univ Chicago, Med Ctr, Dept Surg, Chicago, IL 60637 USA. [Berian, Julia R.; Merkow, Ryan P.; Dahlke, Allison R.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Surg Outcomes & Qual Improvement, Dept Surg, Chicago, IL 60611 USA. [Berian, Julia R.; Merkow, Ryan P.; Dahlke, Allison R.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Northwestern Inst Comparat Effectiveness Res Onco, Chicago, IL 60611 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. RP Berian, JR (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA. EM jberian@facs.org FU Agency for Healthcare Research and Quality [R21 HS21857-01]; American Cancer Society [280521]; American College of Surgeons Clinical Scholars in Residence Program, University of Chicago Medical Center, Northwestern University; John A Hartford Foundation; American College of Surgeons, the University of Chicago, Northwestern University; Genentech FX This work was supported in part by the Agency for Healthcare Research and Quality (R21 HS21857-01; Principal Investigator: Dr Bilimoria) and American Cancer Society (280521; Principal Investigator: Dr Bilimoria). Dr Berian's fellowship position at the American College of Surgeons as a Clinical Scholar in Residence is supported by the American College of Surgeons Clinical Scholars in Residence Program, University of Chicago Medical Center, Northwestern University, and a grant from the John A Hartford Foundation. Dr Paruch's American College of Surgeons Clinical Scholars in Residence fellowship was supported by the American College of Surgeons, the University of Chicago, Northwestern University, and an unrestricted educational grant from Genentech, which had no input on the selection of the recipient, research topic, research direction, or the content of any resulting report, presentation, or publication. NR 27 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD MAY PY 2016 VL 222 IS 5 BP 790 EP + DI 10.1016/j.jamcollsurg.2016.01.057 PG 9 WC Surgery SC Surgery GA DK7UD UT WOS:000375130300012 PM 27016904 ER PT J AU Sharath, SE Kougias, P Pisimisis, G Barshes, NR AF Sharath, Sherene E. Kougias, Panos Pisimisis, George Barshes, Neal R. TI The impact of clinical, psychological, behavioral, social, and environmental factors on self-perceived symptom severity in a male cohort with intermittent claudication SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID PERIPHERAL ARTERIAL-DISEASE; WALKING IMPAIRMENT QUESTIONNAIRE; ANKLE-BRACHIAL INDEX; QUALITY-OF-LIFE; LOW-BACK-PAIN; PHYSICAL-ACTIVITY; D PERSONALITY; EXERCISE; VALIDATION; THERAPY AB Objective: To understand the relationship between self-perceived severity of intermittent claudication and various associated nonclinical factors, we examined how correlates in domains of physical activity (ie, clinical, psychological, behavioral, social, and environmental factors) relate to exertional limb symptoms. Methods: A survey was administered to individuals with intermittent claudication during their initial outpatient assessment. The subjects' self-reported exertional limb symptom severity and classic -versus -atypical claudication classification was based on the Walking Impairment Questionnaire (WIQ) and San Diego Claudication Questionnaire (SDCQ), respectively. We evaluated psychosocial and environmental factors, osteoarthritis symptoms, health, behaviors, and beliefs. Logistic and linear regressions identified factors with a strong independent association with total WIQ scores and the SDCQs. Results: A cohort of 102 subjects (99.0% male) was enrolled in the study. The median age was 65 years with a median ankle -brachial index of 0.69. Forty-three subjects (43%) had "typical" claudication per SDCQs. Individuals with atypical claudication were more likely to report higher Aberdeen Clinical Back Pain Questionnaire scores (odds ratio, 1.04; P = .04) and no depressive symptoms (odds ratio, 8.30; P = .03). Exertional limb symptom severity among the entire cohort was significantly associated with increasing osteoarthritis symptoms (P <001), age (P = .02), a reserved personality (P = .008), and the belief that an exercise regimen would not improve symptoms (P = .005), self -perceived levels of boredom (P = .002), and the belief that exercise (P = .002) was the best way to improve symptoms were associated with decreased symptom severity. When restricted to those with atypical pain, significant factors associated with increasing exertional symptom severity included age greater than 60 years (P = .005), osteoarthritis (P = .02), alcohol use (P = .01), belief that exercise would not improve walking (P = .03), and difficulty walking around the neighborhood (P = .02). When restricted to those with classic claudication, significant factors associated with increasing exertional limb symptom severity included frequent pain or aching in the calves while walking or sitting (P = .03 [walking]; P = .01 [sitting]) and occasional morning joint stiffness (P = .007). Exertional limb symptom severity was also associated with high limitations at home (P = .003) and a belief that exercise would not improve walking (P = .005) among those with classic claudication. Conclusions: Symptom severity and type of pain are associated with a number of nonclinical factors. A multidomain approach, as indicated by the models above, would benefit the continuum of care for intermittent claudication, where management is integrated and coordinated among multiple lines of care. C1 [Sharath, Sherene E.] Michael E DeBakey VA Med Ctr, Hlth Serv & Res Dev, Houston, TX USA. [Kougias, Panos; Pisimisis, George; Barshes, Neal R.] Baylor Coll Med, Michael E DeBakey Dept Surg, Div Vasc Surg & Endovasc Therapy, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd OCL 112, Houston, TX 77030 USA. RP Barshes, NR (reprint author), Baylor Coll Med, Michael E DeBakey Dept Surg, Div Vasc Surg & Endovasc Therapy, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd OCL 112, Houston, TX 77030 USA. EM nbarshes@bcm.tmc.edu NR 38 TC 0 Z9 0 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD MAY PY 2016 VL 63 IS 5 BP 1296 EP U483 DI 10.1016/j.jvs.2015.11.040 PG 13 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA DK8YN UT WOS:000375216000025 PM 26821592 ER PT J AU Ankri-Eliahoo, G Weitz, K Cox, TC Tang, GL AF Ankri-Eliahoo, Galit Weitz, Kevin Cox, Timothy C. Tang, Gale L. TI p27(kip1) Knockout enhances collateralization in response to hindlimb ischemia SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID MUSCLE-CELL MIGRATION; SINGLE NUCLEOTIDE POLYMORPHISM; MATRIX METALLOPROTEINASES; THERAPEUTIC ANGIOGENESIS; PROLIFERATION; CONTRACTION; INHIBITORS; GROWTH; MMP-9; CYCLE AB Objective: The natural response to arterial occlusive disease is enlargement of collaterals; however, the molecular factors that control collateralization are not well understood. The gene p27(Kipl) (p27) affects human response to arterial injury. Previous studies have shown that overexpression of p27 inhibits vascular endothelial and vascular smooth muscle cell (VSMC) proliferation and angiogenesis. To test the hypothesis that knockout of p27 would improve collateralization in reaction to ischemia, we performed in vivo and in vitro experiments using p27 knockout (p27(-/-)) and wild-type (wt) mice. Methods: Hindlimb ischemia was induced by left femoral artery ligation in p27(-/-) and wt (C57BL/6) female mice. The mice underwent weekly laser Doppler perfusion imaging of the footpads until sacrifice on postoperative day 28 followed by microcomputed tomography scanning of both hindlimbs VSMCs were isolated from p27 /and wt mice and used in migration and gel contraction assays in the absence and presence of the nonspecific matrix metalloproteinase (M1VIP) inhibitor BB94. MMP-2 and MMP-9 messenger RNA (mRNA) expression was measured by quantitative reverse transcription-polymerase chain reaction in p27 /and wt VSMCs. Results: p27 /mice reperfused more effectively than wt mice by laser Doppler starting from day 7 (ischemic/nonischemic ratio, 0.33 +/- 0.02 vs 0.25 +/- 0.02; P<.05) and continuing through day 28 (0.45 +/- 0.04 vs +/- 0.31 0.04; P<.05). The gracilis collateral diameter was similar for the nonischemic hindlimbs of the p27 /and wt mice, and this collateral pathway increased similarly after ischemia as assessed by microcomputed tomography. However, the p27 /mice significantly enlarged a novel collateral pathway that bridged directly between the femoral artery proximal to the ligation site and the saphenous or popliteal artery distal to the ligation site more than wt mice (158 18.3 vs 82 22 m; P<.001). p27 /VSMCs migrated more (79% 5% vs 56% 6%; P<.05) and caused more gel contraction (18% 5% of the initial area vs 43% 4%; P<.05) than wt cells. Migration and collagen contraction were abolished in p27 /and wt cells by MMP inhibition. p27 /cells expressed significantly more MMP-2 mRNA than wt cells did. Conclusions: Knockout of p27 enhances arterial collateralization in response to hindlimb ischemia through enlargement of a new collateral pathway. In vitro, knockout of p27 increases collagen gel contraction in addition to stimulating VSMC migration. We speculate that p27 may affect collateralization through its role in regulating MMP-2 expression. (J Vasc Surg 2016;63:1351-9.) Clinical Relevance: Atherosclerosis is the leading cause of mortality and morbidity in the United States. _ENREF_2 The adaptive response to the progressive occlusion of arteries is collateralization (arteriogenesis). As many patients with severe atherosclerosis are not good candidates for angioplasty or surgical bypass, therapies directed toward improving collateralization are needed. The molecular pathways controlling collateralization, however, are not well understood. The human response to arterial injury is affected by a genetic polymorphism in the gene CDKNIB (p27K'P1 or p27). We demonstrate that knockout of p27 improves collateralization. Study of the molecular partners of p27 will identify therapeutic candidates to enhance this process for patients. C1 [Ankri-Eliahoo, Galit; Weitz, Kevin; Tang, Gale L.] Univ Washington, Div Vasc Surg, Seattle, WA 98195 USA. [Cox, Timothy C.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Cox, Timothy C.] Seattle Childrens Res Inst, Ctr Dev Biol & Regenerat Med, Seattle, WA USA. [Tang, Gale L.] VA Puget Sound Hlth Care Syst, Dept Surg, Div Vasc Surg, Seattle, WA USA. RP Tang, GL (reprint author), Univ Washington, Dept Surg, Div Vasc Surg, Surg Serv 112, 1660 S Columbian Way, Seattle, WA 98108 USA. EM gtang@uw.edu FU University of Washington Royalty Research Fund FX This work was supported with the facilities and resources of the VA Puget Sound Health Care System, the Seattle Institute for Biomedical and Clinical Research, the University of Washington Royalty Research Fund, the Vascular Cures Foundation, and the Laurel Foundation. NR 29 TC 0 Z9 0 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD MAY PY 2016 VL 63 IS 5 BP 1351 EP 1359 DI 10.1016/j.jvs.2015.12.047 PG 9 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA DK8YN UT WOS:000375216000032 PM 25701497 ER PT J AU Zaidi, M Iqbal, J AF Zaidi, Mone Iqbal, Jameel TI Closing the loop on the bone-resorbing osteoclast SO NATURE MEDICINE LA English DT Editorial Material AB A new study shows in mice that tumor necrosis factor (TNF) superfamily member 11 (TNFSF11, also known as RANKL), which stimulates osteoclasts to remove bone, binds to the G-protein-coupled receptor LGR4 to prevent excessive bone removal. In mouse models of osteoporosis, a recombinant LGR4 ectodomain reduces bone loss. C1 [Zaidi, Mone] Icahn Sch Med Mt Sinai, Mt Sinai Bone Program, New York, NY 10029 USA. [Iqbal, Jameel] Los Angeles VA Med Ctr, Dept Pathol, Los Angeles, CA USA. RP Zaidi, M (reprint author), Icahn Sch Med Mt Sinai, Mt Sinai Bone Program, New York, NY 10029 USA. EM Mone.zaidi@mssm.edu NR 12 TC 1 Z9 1 U1 5 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 EI 1546-170X J9 NAT MED JI Nat. Med. PD MAY PY 2016 VL 22 IS 5 BP 460 EP 461 PG 2 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA DL3DI UT WOS:000375514000006 PM 27149217 ER PT J AU Amini, A Jasem, J Jones, BL Robin, TP McDermott, JD Bhatia, S Raben, D Jimeno, A Bowles, DW Karam, SD AF Amini, Arya Jasem, Jagar Jones, Bernard L. Robin, Tyler P. McDermott, Jessica D. Bhatia, Shilpa Raben, David Jimeno, Antonio Bowles, Daniel W. Karam, Sana D. TI Predictors of overall survival in human papillomavirus-associated oropharyngeal cancer using the National Cancer Data Base SO ORAL ONCOLOGY LA English DT Article DE Human papillomavirus (HPV); National Cancer Data Base (NCDB); Oropharynx cancer; Survival outcomes; Chemoradiation; Head and neck squamous cell carcinoma ID SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; DISTANT METASTASIS; REGIONAL CONTROL; DE-ESCALATION; LYMPH-NODES; NECK-CANCER; HIGH-RISK; RADIOTHERAPY; CHEMOTHERAPY AB Objectives: This study identifies clinical characteristics associated with HPV-positive oropharynx squamous cell carcinoma (OPSCC) and evaluates predictors of overall survival (OS) in HPV-positive patients undergoing definitive treatment within the National Cancer Data Base (NCDB). Material and methods: The NCDB was queried for patients P18 years old with OPSCC and known HPV status who underwent definitive treatment: surgery, radiation (RT), chemotherapy-RT (CRT), surgery + RT, surgery + CRT (S-CRT). Cox proportional hazards model was used for multivariate analysis (MVA) to evaluate predictors of OS by HPV status. Results: 3952 patients were included: 2454 (62%) were HPV-positive. Median follow up was 23.7 months (range, 1.0-54.5). Unadjusted 2-year OS rates for HPV-positive vs. negative were 93.1% vs. 77.8% (p < 0.001) with an adjusted hazard ratio of 0.44 (95% CI, 0.36-0.53; p < 0.001). MVA identified multimodality treatment including CRT (HR, 0.42; p = 0.024) and S-RT (HR, 0.30; p = 0.024), but not S-CRT (HR, 0.51; p = 0.086), as predictors for improved OS in HPV-positive stage III-IVB disease. Multimodality treatment including S-CRT was associated with longer OS in HPV-negative OPSCC. Nodal stage was poorly associated with OS in HPV-positive cancers. The presence of positive margins and/or extracapsular extension was associated with worse OS in HPV-negative (HR, 2.11; p = 0.008) but not HPV positive OPSCC (HR, 1.61; p = 0.154). Conclusion: The established demographic and clinical features of HPV-positive OPSCC were corroborated in the NCDB. Population analysis suggests that AJCC staging is poorly associated with OS in HPV-positive cancer, and traditional high-risk features may be less impactful. Bimodality therapy appears beneficial in HPV-positive HNSCC. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Amini, Arya; Jones, Bernard L.; Robin, Tyler P.; Bhatia, Shilpa; Raben, David; Karam, Sana D.] Univ Colorado, Sch Med, Dept Radiat Oncol, 1665 Aurora Court,Room 1032, Aurora, CO 80045 USA. [Jasem, Jagar] Univ Colorado, Sch Med, Dept Med, Aurora, CO 80045 USA. [McDermott, Jessica D.; Bowles, Daniel W.] Eastern Colorado Hlth Care Syst, Denver Vet Affairs Med Ctr, Denver, CO USA. [McDermott, Jessica D.; Jimeno, Antonio; Bowles, Daniel W.] Univ Colorado, Sch Med, Dept Med, Div Med Oncol, Aurora, CO 80045 USA. RP Karam, SD (reprint author), Univ Colorado, Sch Med, Dept Radiat Oncol, 1665 Aurora Court,Room 1032, Aurora, CO 80045 USA. EM arya.amini@ucdenver.edu; sana.karam@ucdenver.edu OI Jones, Bernard/0000-0001-7169-559X NR 31 TC 6 Z9 6 U1 2 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1368-8375 EI 1879-0593 J9 ORAL ONCOL JI Oral Oncol. PD MAY PY 2016 VL 56 BP 1 EP 7 DI 10.1016/j.oraloncology.2016.02.011 PG 7 WC Oncology; Dentistry, Oral Surgery & Medicine SC Oncology; Dentistry, Oral Surgery & Medicine GA DK3VF UT WOS:000374844800008 PM 27086480 ER PT J AU Melton, DW Lei, XF Gelfond, JAL Shireman, PK AF Melton, David W. Lei, XiuFen Gelfond, Jonathan A. L. Shireman, Paula K. TI Dynamic macrophage polarization-specific miRNA patterns reveal increased soluble VEGF receptor 1 by miR-125a-5p inhibition SO PHYSIOLOGICAL GENOMICS LA English DT Article DE microRNAs; temporal; M1; M2a; M2c; VEGF ID ENDOTHELIAL GROWTH-FACTOR; TUMOR-ASSOCIATED MACROPHAGES; IN-VIVO; INFLAMMATORY RESPONSE; ACTIVATED MACROPHAGES; HUMAN MONOCYTES; EXPRESSION; MICRORNAS; ANGIOGENESIS; FLT-1 AB Dynamic, epigenetic mechanisms can regulate macrophage phenotypes following exposure to different stimulating conditions and environments. However, temporal patterns of microRNAs (miRNAs or miRs) across multiple macrophage polarization phenotypes have not been defined. We determined miRNA expression in bone marrow-derived murine macrophages over multiple time points (0.5, 1, 3, 24 h) following exposure to cytokines and/or LPS. We hypothesized that dynamic changes in miRNAs regulate macrophage phenotypes. Changes in macrophage polarization markers were detected as early as 0.5 and as late as 24 h; however, robust responses for most markers occurred within 3 h. In parallel, many polarization-specific miRNAs were also changed by 3 h and expressed divergent patterns between M1 and M2a conditions, with increased expression in M1 (miR-155, 199a-3p, 214-3p, 455-3p, and 125a) or M2a (miR-511 and 449a). Specifically, miR-125a-5p exhibited divergent patterns: increased at 12-24 h in M1 macrophages and decreasing trend in M2a. VEGF in the culture media of macrophages was dependent upon the polarization state, with greatly diminished VEGF in M2a compared with M1 macrophage culture media despite similar VEGF in cell lysates. Inhibition of miR-125a-5p in media-only controls (MO) and M1 macrophages greatly increased expression and secretion of soluble VEGF receptor-1 (sVEGFR1) leading to diminished VEGF in the culture media, partially converting MO and M1 into an M2a phenotype. Thus, the divergent expression patterns of polarization-specific miRNAs led to the identification and demonstrated the regulation of a specific macrophage polarization phenotype, sVEGFR1 by inhibition of miR-125a-5p. C1 [Melton, David W.; Lei, XiuFen; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, 7703 Floyd Curl Dr,MC 7741, San Antonio, TX 78229 USA. [Gelfond, Jonathan A. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Melton, David W.; Gelfond, Jonathan A. L.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Melton, David W.; Lei, XiuFen; Shireman, Paula K.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Shireman, PK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, 7703 Floyd Curl Dr,MC 7741, San Antonio, TX 78229 USA. EM shireman@uthscsa.edu FU National Heart, Lung, and Blood Institute Grants [HL-074236, HL-110743]; Veterans Administration Merit Review [1I01BX001186]; Institute for the Integration of Medicine and Science [UL1 TR001120] FX This study was supported in part by National Heart, Lung, and Blood Institute Grants HL-074236 and HL-110743, the Veterans Administration Merit Review (1I01BX001186), and the Institute for the Integration of Medicine and Science, UL1 TR001120. NR 88 TC 2 Z9 2 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1094-8341 EI 1531-2267 J9 PHYSIOL GENOMICS JI Physiol. Genomics PD MAY 1 PY 2016 VL 48 IS 5 BP 345 EP 360 DI 10.1152/physiolgenomics.00098.2015 PG 16 WC Cell Biology; Genetics & Heredity; Physiology SC Cell Biology; Genetics & Heredity; Physiology GA DK7SS UT WOS:000375126600003 PM 26884460 ER PT J AU Halpin, DMG Vogelmeier, C Pieper, MP Metzdorf, N Richard, F Anzueto, A AF Halpin, David M. G. Vogelmeier, Claus Pieper, Michael P. Metzdorf, Norbert Richard, Frank Anzueto, Antonio TI Effect of tiotropium on COPD exacerbations: A systematic review SO RESPIRATORY MEDICINE LA English DT Review DE Anticholinergic; Antimuscarinic; COPD; Long-acting muscarinic antagonist ID OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED-TRIAL; HEALTH OUTCOMES; PARALLEL-GROUP; LUNG-FUNCTION; UPLIFT TRIAL; EFFICACY; SAFETY; SALMETEROL; BRONCHODILATOR AB Background: Exacerbation frequency is related to disease progression, quality of life, and prognosis in COPD. Earlier diagnosis, along with interventions aimed at preventing exacerbations and delaying progression, may help reduce the global burden of disease. Long-acting inhaled bronchodilators are effective at maintaining symptom relief and are recommended as first-choice therapy for more symptomatic patients and those at risk of exacerbation. Methods: As prevention of exacerbations is a priority goal in COPD management and a number of different long-acting bronchodilators are available, we conducted a systematic review of exacerbation data from randomized controlled trials (published January 2000 to May 2014) comparing the effect of tiotropium versus placebo and/or other maintenance therapies. Results: Exacerbations were a primary endpoint in 12 publications (five studies: four comparing tiotropium with placebo; one with active comparator) and a secondary endpoint in 17 publications (seven studies: six comparing tiotropium with placebo; one with active comparator). Overall, tiotropium was associated with a longer time to first exacerbation event and fewer exacerbations (including severe exacerbations/hospitalizations) compared with placebo and long-acting beta(2)-agonists. Tiotropium also showed similar efficacy to glycopyrronium and a fixed long-acting muscarinic antagonist/long-acting beta(2)-agonist combination (glycopyrronium/indacaterol), although not all studies were powered to demonstrate differences in exacerbation outcomes. Exacerbation outcomes were comparable with both formulations of tiotropium (HandiHaler (R) 18 mu g/Respimat (R) 5 mu g). Conclusions: The results of this comprehensive systematic review demonstrate tiotropium is beneficial in reducing exacerbation risk versus placebo or other maintenance treatments. (C) 2016 The Authors. Published by Elsevier Ltd. C1 [Halpin, David M. G.] Univ Exeter, Sch Med, Royal Devon & Exeter Hosp, Exeter, Devon, England. [Vogelmeier, Claus] Univ Marburg, Univ Med Ctr Giessen & Marburg, German Ctr Lung Res, Dept Med Pulm & Crit Care Med, Marburg, Germany. [Pieper, Michael P.] Boehringer Ingelheim Pharma GmbH & Co KG, Resp Dis Res, Biberach, Germany. [Metzdorf, Norbert; Richard, Frank] Boehringer Ingelheim Pharma GmbH Co KG, Ingelheim, Germany. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Pulm Dis, Crit Care Med, San Antonio, TX 78229 USA. [Anzueto, Antonio] Audie L Murphy Mem Vet Hosp Div, South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Halpin, DMG (reprint author), Royal Devon & Exeter Hosp, Dept Resp Med, Barrack Rd, Exeter EX2 5DW, Devon, England. EM d.halpin@nhs.net OI Richard, Frank/0000-0003-1027-3814 FU Boehringer Ingelheim FX Writing assistance was provided by Leigh Prevost and Natalie Dennis from PAREXEL, which was funded by Boehringer Ingelheim. NR 53 TC 0 Z9 1 U1 3 U2 3 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0954-6111 EI 1532-3064 J9 RESP MED JI Respir. Med. PD MAY PY 2016 VL 114 BP 1 EP 8 DI 10.1016/j.rmed.2016.02.012 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System SC Cardiovascular System & Cardiology; Respiratory System GA DK8WJ UT WOS:000375209000001 PM 27109805 ER PT J AU Schure, MB Borson, S Nguyen, HQ Trittschuh, EH Thielke, SM Pike, KC Adams, SG Fan, VS AF Schure, Mark B. Borson, Soo Nguyen, Huong Q. Trittschuh, Emily H. Thielke, Stephen M. Pike, Kenneth C. Adams, Sandra G. Fan, Vincent S. TI Associations of cognition with physical functioning and health-related quality of life among COPD patients SO RESPIRATORY MEDICINE LA English DT Article DE Cognition; COPD; Physical functioning; Quality of life; Physical activity; Affective symptoms; Motor strength ID OBSTRUCTIVE PULMONARY-DISEASE; OLDER MEXICAN-AMERICANS; CONSTRUCT-VALIDITY; SURVEY SF-36; PART-B; IMPAIRMENT; TRAIL; FRAILTY; PHENOTYPE; OUTCOMES AB Background: Neurocognitive impairment has been described in COPD patients, but little is known about its relationship with physical functioning and health-related quality of life (HRQL) in this chronically ill patient group. Methods: 301 stable COPD patients completed the Trail Making Test (TMT-A: psychomotor speed and TMT-B: executive control); 198 patients completed the Memory Impairment Screen (MIS). Standardization of TMT-A and TMT-B scores to a normative population yielded classifications of normal, borderline, or impaired cognitive status. Using multivariable regression, we examined the relationship between the TMT-A, TMT-B, and MIS with physical functioning (physical activity, 6-min walk test, and grip strength) and health-related quality of life (HRQL) measured with the Chronic Respiratory Questionnaire and the SF-36. Results: Nearly 30% of patients had either borderline or impaired cognition on the TMT-A or TMT-B. Adjusted models indicated that those with either borderline or impaired cognitive functioning had weaker grip strength (TMT-A borderline: beta = -2.9, P < 0.05; TMT-B borderline: beta = -3.0, P < 0.05; TMT-B impaired: beta = -2.5, P < 0.05) and lower scores on the mental health component summary score (MCS-SF-36 HRQOL) measure (TMT-A impaired: beta = -4.7, P < 0.01). No adjusted significant associations were found for other physical functioning measures or the other HRQL measures. Impaired memory showed a significant association only with the MCS scale. Conclusions: Cognitive function was not associated with most standard indicators of physical function or most measures of HRQL in COPD patients. Both TMT-A and TMT-B were associated with weaker grip strength, and the TMT-A and MIS with poorer mental health. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Schure, Mark B.] Montana State Univ, Dept Hlth & Human Dev, POB 173540, Bozeman, MT 59717 USA. [Borson, Soo; Trittschuh, Emily H.; Thielke, Stephen M.] Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Box 356560, Seattle, WA 98195 USA. [Nguyen, Huong Q.] Kaiser Permanente So Calif, 100 S Los Robies, Pasadena, CA 91101 USA. [Nguyen, Huong Q.; Thielke, Stephen M.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA. [Pike, Kenneth C.] Univ Washington, Off Nursing Res, 1959 NE Pacific St, Seattle, WA 98195 USA. [Adams, Sandra G.] Univ Texas Hlth Sci Ctr San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Adams, Sandra G.] South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. [Fan, Vincent S.] Ctr Innovat VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1660 S Columbian Way, Seattle, WA 98108 USA. [Fan, Vincent S.] Univ Washington, Dept Med, 1959 NE Pacific St, Seattle, WA 98195 USA. RP Schure, MB (reprint author), 305 Herrick Hall,POB 173540, Bozeman, MT 59717 USA. EM mark.schure@montana.edu FU National Heart, Lung, and Blood Institute (NHLBI) [R01HL093146] FX This grant was funded by grant R01HL093146 from the National Heart, Lung, and Blood Institute (NHLBI). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the VA. NR 47 TC 0 Z9 0 U1 4 U2 5 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0954-6111 EI 1532-3064 J9 RESP MED JI Respir. Med. PD MAY PY 2016 VL 114 BP 46 EP 52 DI 10.1016/j.rmed.2016.03.005 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System SC Cardiovascular System & Cardiology; Respiratory System GA DK8WJ UT WOS:000375209000006 PM 27109810 ER PT J AU Ponce, AN Aosved, AC Cornish, JAE AF Ponce, Allison N. Aosved, Allison C. Cornish, Jennifer A. Erickson TI Parental Leave During Internship and Postdoctoral Psychology Training: APPIC Guidelines Revisited SO TRAINING AND EDUCATION IN PROFESSIONAL PSYCHOLOGY LA English DT Article DE parental leave; maternity leave; paternity leave; psychology; training ID MATERNITY LEAVE; HEALTH; CHILD AB This article introduces the updated Association of Psychology Postdoctoral and Internship Centers' (APPIC) APPIC Guidelines for Parental Leave During Internship and Postdoctoral Training and provides recommendations for addressing the complex issue of supporting parental leave during the course of a doctoral internship or postdoctoral training year. C1 [Ponce, Allison N.] Yale Univ, Sch Med, Dept Psychiat, 34 Pk St, New Haven, CT 06519 USA. [Aosved, Allison C.] VA Puget Sound, Amer Lake Div, Tacoma, WA USA. [Cornish, Jennifer A. Erickson] Univ Denver, Clin Training & Internship Consortium, Grad Sch Profess Psychol, Denver, CO 80208 USA. RP Ponce, AN (reprint author), Yale Univ, Sch Med, Dept Psychiat, 34 Pk St, New Haven, CT 06519 USA. EM allison.ponce@yale.edu NR 18 TC 1 Z9 1 U1 0 U2 1 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1931-3918 EI 1931-3926 J9 TRAIN EDUC PROF PSYC JI Train. Educ. Prof. Psychol. PD MAY PY 2016 VL 10 IS 2 BP 71 EP 77 DI 10.1037/tep0000109 PG 7 WC Psychology, Educational SC Psychology GA DK3DL UT WOS:000374796200002 ER PT J AU Abdul-Ghani, M Del Prato, S Chilton, R DeFronzo, RA AF Abdul-Ghani, Muhammad Del Prato, Stefano Chilton, Robert DeFronzo, Ralph A. TI SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study SO DIABETES CARE LA English DT Article ID TYPE-2 DIABETES-MELLITUS; RANDOMIZED CONTROLLED-TRIAL; PIOGLITAZONE CLINICAL-TRIAL; INSULIN SENSITIVITY; GLYCEMIC CONTROL; GLUCOSE CONTROL; BLOOD-PRESSURE; MICROVASCULAR OUTCOMES; MYOCARDIAL-INFARCTION; MACROVASCULAR EVENTS AB Although cardiovascular (CV) mortality is the principal cause of death in individuals with type 2 diabetes (T2DM), reduction of plasma glucose concentration has little effect on CV disease (CVD) risk. Thus, novel strategies to reduce CVD risk in T2DM patients are needed. The recently published BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) study demonstrated that in T2DM patients with high CVD risk empagliflozin reduced the primary major adverse cardiac event end point (CV death, nonfatal myocardial infarction, nonfatal stroke) by 14%. This beneficial effect was driven by a 38% reduction in CV mortality with no significant decrease in nonfatal myocardial infarction or stroke. Empagliflozin also caused a 35% reduction in hospitalization for heart failure without affecting hospitalization for unstable angina. Although sodium-glucose cotransporter 2 inhibitors exert multiple metabolic benefits (decreases in HbA(1c), body weight, and blood pressure and an increase in HDL cholesterol), all of which could reduce CVD risk, it is unlikely that the reduction in CV mortality can be explained by empagliflozin's metabolic effects. More likely, hemodynamic effects, specifically reduced blood pressure and decreased extracellular volume, are responsible for the reduction in CV mortality and heart failure hospitalization. In this Perspective, we will discuss possible mechanisms for these beneficial effects of empagliflozin and their implications for the care of T2DM patients. C1 [Abdul-Ghani, Muhammad; DeFronzo, Ralph A.] Univ Texas San Antonio, Hlth Sci Ctr, Div Diabet, San Antonio, TX USA. [Abdul-Ghani, Muhammad] Hamad Gen Hosp, Diabet & Obes Clin Res Ctr, Dept Med, Doha, Qatar. [Del Prato, Stefano] Univ Pisa, Sch Med, Dept Clin & Expt Med, I-56100 Pisa, Italy. [Chilton, Robert] Univ Texas San Antonio, Div Cardiol, Hlth Sci Ctr, San Antonio, TX USA. [Chilton, Robert] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Abdul-Ghani, M; DeFronzo, RA (reprint author), Univ Texas San Antonio, Hlth Sci Ctr, Div Diabet, San Antonio, TX USA.; Abdul-Ghani, M (reprint author), Hamad Gen Hosp, Diabet & Obes Clin Res Ctr, Dept Med, Doha, Qatar. EM abdulghani@uthscsa.edu; albarado@uthscsa.edu RI Del Prato, Stefano/K-3405-2016 OI Del Prato, Stefano/0000-0002-5388-0270 FU Qatar Foundation [NPRP 4-248-3-076]; National Institutes of Health [R01 DK097554-01, 5R01DK24093]; South Texas Veterans Health Care System FX M.A.-G. receives grant support from the Qatar Foundation (NPRP 4-248-3-076). M.A.-G. (R01 DK097554-01) and R.A.D. (5R01DK24093) have received grant support from the National Institutes of Health. The salary of R.A.D. is partially supported by the South Texas Veterans Health Care System. NR 56 TC 26 Z9 26 U1 4 U2 7 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD MAY PY 2016 VL 39 IS 5 BP 717 EP 725 DI 10.2337/dc16-0041 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DK6MU UT WOS:000375039000012 PM 27208375 ER PT J AU Azad, N Bahn, GD Emanuele, NV Agrawal, L Ge, L Reda, D Klein, R Reaven, PD Hayward, R AF Azad, Nasrin Bahn, Gideon D. Emanuele, Nicholas V. Agrawal, Lily Ge, Ling Reda, Dominic Klein, Ronald Reaven, Peter D. Hayward, Rodney CA VADT Study Grp TI Association of Blood Glucose Control and Lipids With Diabetic Retinopathy in the Veterans Affairs Diabetes Trial (VADT) SO DIABETES CARE LA English DT Article ID RISK-FACTORS; SERUM-LIPIDS; HARD EXUDATE; COMPLICATIONS; PROGRESSION; MELLITUS; PREVALENCE; DIAGNOSIS; THERAPY AB OBJECTIVE This study examined whether lipids modify the relationship between intensive glucose control (INT) and diabetic retinopathy (DR). RESEARCH DESIGN AND METHODS The incidence and progression of DR were assessed in 858 of 1,791 participants with 7-field stereoscopic fundus photographs at baseline and 5 years later. RESULTS Odds of DR progression were lower by similar to 40% in those with baseline total cholesterol (TC) >= 200 mg/dL (P = 0.007), LDL-C >= 120 mg/dL (P < 0.02), or HDL-C >= 40 mg/dL (P < 0.007) in the INT arm versus standard glycemic treatment. Odds of DR progression were reduced by similar to 40% in those who had TC <= 140 mg/dL (P <= 0.024), triglycerides (TG) <= 120 mg/dL (P = 0.004), or HDL-C >= 45 mg/dL (P = 0.01) at the fifth year. Odds of DR progression were lower by similar to 40-50% with reductions of TC by >= 40 mg/dL (P < 0.0001), of LDL-C of >= 40 mg/dL (P < 0.004), and of TG by >= 60 mg/dL (P = 0.004) at the fifth year. Odds of DR progression increased by 80% with increases in TC of >= 20 mg/dL (P < 0.0001) and by 180% with increases in LDL-C by >= 60 mg/dL (P < 0.004). After adjusting for covariants, those with higher TC at baseline and lower TC during and at the fifth year and higher HDL-C throughout study had significantly decreased odds of DR progression in INT. CONCLUSIONS INT was associated with decreased odds of progression but not with onset of retinopathy in those with worse lipid levels at baseline and more improved lipid levels during the study. Higher HDL-C was consistently associated with better response to INT throughout the study. C1 [Azad, Nasrin; Emanuele, Nicholas V.; Agrawal, Lily] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Endocrinol Sect, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. [Bahn, Gideon D.; Ge, Ling; Reda, Dominic] Coordinating Ctr, Cooperat Studies Program, Hines, IL USA. [Klein, Ronald] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA. [Reaven, Peter D.] Carl T Hayden VA Med Ctr, Endocrinol Sect, Phoenix, AZ USA. [Hayward, Rodney] Ann Arbor VA Healthcare Syst, Ann Arbor, MI USA. RP Azad, N (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Endocrinol Sect, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. EM nasrin.azad@va.gov FU Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development; National Eye Institute; Sanofi; GlaxoSmithKline; Novo Nordisk; Roche; Kos Pharmaceuticals; Merck; Amylin FX The study was sponsored by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development. There was also generous support from the National Eye Institute.; Medications and financial support were provided by Sanofi, GlaxoSmithKline, Novo Nordisk, Roche, Kos Pharmaceuticals, Merck, and Amylin. These companies had no role in the design of the study, in the accrual or analysis of the data, or in the preparation or approval of the manuscript. NR 37 TC 0 Z9 0 U1 2 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD MAY PY 2016 VL 39 IS 5 BP 816 EP 822 DI 10.2337/dc15-1897 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DK6MU UT WOS:000375039000026 PM 27006510 ER PT J AU Baksh, SN Gellad, WF Alexander, GC AF Baksh, Sheriza N. Gellad, Walid F. Alexander, G. Caleb TI Maximizing the Post-Approval Safety of Flibanserin: A Role for Regulators, Clinicians, and Patients SO DRUG SAFETY LA English DT Article ID SEXUAL DESIRE DISORDER; PREMENOPAUSAL WOMEN EFFICACY AB In August 2015, the US Food and Drug Administration (FDA) made the controversial decision to approve flibanserin (Addyi((R))) for women experiencing hypoactive sexual desire disorder. A number of factors contributed to disagreements regarding the FDA's decision, including the product's two prior failed FDA reviews, the unmet need of women with this disorder, extensive advocacy and politicization surrounding the product's relevance to women and sexual health, the potential for widespread off-label use, and the product's tenuous risk/benefit profile. Despite that, attention now shifts to maximizing the safe use of the product, including the optimal means to avoid numerous drug-drug interactions as well as the concomitant use of alcohol, both of which potentiate the risks of dizziness, hypotension, and syncope. Although the FDA has implemented a comprehensive Risk Evaluation and Mitigation Strategies program to maximize the product's safe use, patients, clinicians, and regulators must exhibit heightened vigilance early in the product's post-market life. C1 [Baksh, Sheriza N.; Alexander, G. Caleb] Johns Hopkins Univ, Ctr Drug Safety & Effectiveness, Baltimore, MD 21205 USA. [Baksh, Sheriza N.; Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St W6035, Baltimore, MD 21205 USA. [Gellad, Walid F.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA 15261 USA. [Gellad, Walid F.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA 15261 USA. [Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15261 USA. [Alexander, G. Caleb] Johns Hopkins Med, Dept Med, Div Gen Internal Med, Baltimore, MD 21205 USA. RP Alexander, GC (reprint author), Johns Hopkins Univ, Ctr Drug Safety & Effectiveness, Baltimore, MD 21205 USA.; Alexander, GC (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St W6035, Baltimore, MD 21205 USA.; Alexander, GC (reprint author), Johns Hopkins Med, Dept Med, Div Gen Internal Med, Baltimore, MD 21205 USA. EM galexan9@jhmi.edu NR 21 TC 1 Z9 2 U1 0 U2 1 PU ADIS INT LTD PI NORTHCOTE PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND SN 0114-5916 EI 1179-1942 J9 DRUG SAFETY JI Drug Saf. PD MAY PY 2016 VL 39 IS 5 BP 375 EP 380 DI 10.1007/s40264-015-0389-2 PG 6 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy; Toxicology SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy; Toxicology GA DJ6NM UT WOS:000374330200002 PM 26798050 ER PT J AU Braley, TJ Boudreau, EA AF Braley, Tiffany J. Boudreau, Eilis Ann TI Sleep Disorders in Multiple Sclerosis SO CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS LA English DT Review DE Obstructive sleep apnea; Restless leg syndrome; Insomnia; Fatigue; Multiple sclerosis ID RESTLESS LEGS SYNDROME; QUALITY-OF-LIFE; COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; PERIODIC LIMB MOVEMENTS; FATIGUE IMPACT SCALE; HEART HEALTH; CLINICAL-PRACTICE; RISK-FACTOR; APNEA AB Recent studies suggest that individuals with multiple sclerosis (MS) are at increased risk for sleep disturbances and that sleep disturbances contribute to fatigue and other chronic symptoms in MS. Although fatigue occurs commonly in people with MS, this symptom is often attributed to MS-specific pathology. Consequently, sleep disorders are often unrecognized and untreated in this population. Timely diagnosis and treatment of sleep problems in MS offer a new opportunity to ameliorate some of the daytime fatigue experienced by patients with MS. To increase this opportunity, the practitioner should be comfortable performing basic screening for common sleep complaints among patients with MS. The objectives of this review are to summarize the latest relevant data on sleep disorders in MS and offer a helpful approach to the identification and workup of the most common sleep problems in this population. Unexplored research avenues and opportunities to address important questions at the interface of sleep and MS are also discussed. C1 [Braley, Tiffany J.] Univ Michigan, Dept Neurol, Multiple Sclerosis Ctr, 1500 E Med Ctr Dr,C728 Med Inn Bldg, Ann Arbor, MI USA. [Braley, Tiffany J.] Univ Michigan, Dept Neurol, Sleep Disorders Ctr, 1500 E Med Ctr Dr,C728 Med Inn Bldg, Ann Arbor, MI USA. [Boudreau, Eilis Ann] Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd L226, Portland, OR 97239 USA. [Boudreau, Eilis Ann] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, 3181 SW Sam Jackson Pk Rd L226, Portland, OR 97239 USA. [Boudreau, Eilis Ann] Portland VA Med Ctr, P3-ECOE,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. RP Boudreau, EA (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd L226, Portland, OR 97239 USA.; Boudreau, EA (reprint author), Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, 3181 SW Sam Jackson Pk Rd L226, Portland, OR 97239 USA.; Boudreau, EA (reprint author), Portland VA Med Ctr, P3-ECOE,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM tbraley@med.umich.edu; boudreau@ohsu.edu FU National Multiple Sclerosis Society; American Sleep Medicine Foundation; Michigan Translation and Commercialization (MTRAC) for Life Sciences Program; Biogen; Genzyme-Sanofi; Genentech-Roche FX Tiffany J. Braley receives grant support from the National Multiple Sclerosis Society, the American Sleep Medicine Foundation, and the Michigan Translation and Commercialization (MTRAC) for Life Sciences Program to conduct her research. She is principal investigator on a clinical trial that receives material support, but no financial support, from Biogen. She is site principal investigator for several industry-funded studies of MS immunotherapeutics at the University of Michigan (sponsors include Genzyme-Sanofi and Genentech-Roche) but receives no direct compensation for any of this work. NR 79 TC 4 Z9 4 U1 4 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1528-4042 EI 1534-6293 J9 CURR NEUROL NEUROSCI JI Curr. Neurol. Neurosci. Rep. PD MAY PY 2016 VL 16 IS 5 AR 50 DI 10.1007/s11910-016-0649-2 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DJ5NO UT WOS:000374255800009 PM 27068547 ER PT J AU Karimkhani, C Wanga, V Coffeng, LE Naghavi, P Dellavalle, RP Naghavi, M AF Karimkhani, Chante Wanga, Valentine Coffeng, Luc E. Naghavi, Paria Dellavalle, Robert P. Naghavi, Mohsen TI Global burden of cutaneous leishmaniasis: a cross-sectional analysis from the Global Burden of Disease Study 2013 SO LANCET INFECTIOUS DISEASES LA English DT Article ID LIFE YEARS DALYS; INFECTION; INJURIES; ISFAHAN; IRAN AB Background High-quality epidemiological studies evaluating the burden of cutaneous leishmaniasis worldwide are lacking. We compared the burden of cutaneous leishmaniasis in each country to the overall global burden and assessed the equality of cutaneous leishmaniasis burden across different countries and regions. Methods Data were extracted from scientific literature, hospital sources, country reports, and WHO sources on the prevalence of sequalae of both acute and chronic cutaneous leishmaniasis. Prevalence data were combined with a disability weight to yield years lived with disability. Disability-adjusted life-years (DALYs) are a sum of the years lived with disability and years of life lost (or mortality, assumed to be zero). We compared DALYs due to cutaneous leishmaniasis for 152 countries using standard Z score analysis with Bonferroni correction (p<0.003) and generation of Lorenz curves with a Gini coefficient. Findings In 2013, the global mean age-standardised DALYs for cutaneous leishmaniasis was 0.58 per 100 000 people. Nine countries had significantly greater DALYs from cutaneous leishmaniasis than the mean: Afghanistan (87.0), Sudan (20.2), Syria (9.2), Yemen (6.2), Iraq (6.0), Burkina Faso (4.8), Bolivia (4.6), Haiti (4.1), and Peru (4.0). The Gini coefficient was 0.89. Andean Latin America, North Africa and Middle East, western sub-Saharan Africa, and south Asia had the highest DALYs from cutaneous leishmaniasis. Among males, Palestine had the highest incidence rates (616.2 cases per 100 000 people) followed by Afghanistan (566.4), Syria (357.1), and Nicaragua (354.8). Among females, Afghanistan had the highest incidence rates (623.9) followed by Syria (406.3), Palestine (222.1), and Nicaragua (180.8). Similar proportions of males and females had cutaneous leishmaniasis in most countries with a high incidence. Interpretation The burden from cutaneous leishmaniasis mainly falls on countries in Africa and the Middle East. Global and national data on the burden of cutaneous leishmaniasis disease are pivotal to promote field studies and initiate behavioural change. C1 [Karimkhani, Chante] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA. [Wanga, Valentine; Coffeng, Luc E.; Naghavi, Paria; Naghavi, Mohsen] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA. [Coffeng, Luc E.] Erasmus MC Univ Med Ctr Rotterdam, Dept Publ Hlth, Ca Rotterdam, Netherlands. [Dellavalle, Robert P.] Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO USA. [Dellavalle, Robert P.] Eastern Colorado Hlth Care Syst, Dermatol Serv, US Dept Vet Affairs, Denver, CO USA. [Dellavalle, Robert P.] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. RP Karimkhani, C (reprint author), Univ Hosp Case Western Med Ctr, Dept Med, 408 W St Clair Ave,Unit 317, Cleveland, OH 44113 USA. EM ck2525@caa.columbia.edu OI Naghavi, Paria/0000-0002-8908-7952 FU Bill & Melinda Gates Foundation FX Bill & Melinda Gates Foundation. NR 31 TC 7 Z9 8 U1 5 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD MAY PY 2016 VL 16 IS 5 BP 584 EP 591 DI 10.1016/S1473-3099(16)00003-7 PG 8 WC Infectious Diseases SC Infectious Diseases GA DJ5TL UT WOS:000374272900029 PM 26879176 ER PT J AU Lo-Ciganic, WH Gellad, WF Gordon, AJ Cochran, G Zemaitis, MA Cathers, T Kelley, D Donohue, JM AF Lo-Ciganic, Wei-Hsuan Gellad, Walid F. Gordon, Adam J. Cochran, Gerald Zemaitis, Michael A. Cathers, Terri Kelley, David Donohue, Julie M. TI Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization SO ADDICTION LA English DT Article DE Buprenorphine; group-based trajectory models; Medicaid; opioid agonist therapy; Opioid use disorders; trajectories; treatment duration; treatment patterns ID OFFICE-BASED TREATMENT; PRESCRIPTION OPIOID DEPENDENCE; HEALTH-CARE-SYSTEM; MEDICATION-ADHERENCE; MAINTENANCE THERAPY; AGONIST TREATMENT; USE DISORDER; HOSPITALIZATION; METHADONE; NONADHERENCE AB Background and aimsUncertainty about optimal treatment duration for buprenorphine opioid agonist therapy may lead to substantial variation in provider and payer decision-making regarding treatment course. We aimed to identify distinct trajectories of buprenorphine use and examine outcomes associated with these trajectories to guide health system interventions regarding treatment length. DesignRetrospective cohort study. SettingUS Pennsylvania Medicaid. PatientsA total of 10945 enrollees aged 18-64years initiating buprenorphine treatment between 2007 and 2012. MeasurementsGroup-based trajectory models were used to identify trajectories based on monthly proportion of days covered with buprenorphine in the 12months post-treatment initiation. We used separate multivariable Cox proportional hazard models to examine associations between trajectories and time to first all-cause hospitalization and emergency department (ED) visit within 12months after the first-year treatment. FindingsSix trajectories [Bayesian information criterion (BIC)=-86246.70] were identified: 24.9% discontinued buprenorphine <3months, 18.7% discontinued between 3 and 5months, 12.4% discontinued between 5 and 8months, 13.3% discontinued >8months, 9.5% refilled intermittently and 21.2% refilled persistently for 12months. Persistent refill trajectories were associated with an 18% lower risk of all-cause hospitalizations [hazard ratio (HR)=0.82, 95% confidence interval (CI)=0.70-0.95] and 14% lower risk of ED visits (HR=0.86, 95% CI=0.78-0.95) in the subsequent year, compared with those discontinuing between 3 and 5months. ConclusionsSix distinct buprenorphine treatment trajectories were identified in this population-based low-income Medicaid cohort in Pennsylvania, USA. There appears to be an association between persistent use of buprenorphine for 12months and lower risk of all-cause hospitalizations/emergency department visits. C1 [Lo-Ciganic, Wei-Hsuan] Univ Arizona, Coll Pharm, Dept Pharm Practice & Sci, Drachman Hall,Room 307E,1295 N Martin Ave, Tucson, AZ 85719 USA. [Lo-Ciganic, Wei-Hsuan; Gellad, Walid F.; Gordon, Adam J.; Cochran, Gerald; Zemaitis, Michael A.; Donohue, Julie M.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Hlth Policy Inst, Pittsburgh, PA USA. [Gellad, Walid F.; Gordon, Adam J.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Gellad, Walid F.; Gordon, Adam J.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Cochran, Gerald] Univ Pittsburgh, Sch Social Work, Pittsburgh, PA 15260 USA. [Zemaitis, Michael A.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. [Cathers, Terri; Kelley, David] Penn Dept Human Serv, Harrisburg, PA USA. [Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA. RP Lo-Ciganic, WH (reprint author), Univ Arizona, Coll Pharm, Dept Pharm Practice & Sci, Drachman Hall,Room 307E,1295 N Martin Ave, Tucson, AZ 85719 USA. EM lociganic@pharmacy.arizona.edu OI Donohue, Julie/0000-0003-2418-6017 FU University of Pittsburgh Health Policy Institute, Center for Pharmaceutical Policy and Prescribing; Pennsylvania Department of Human Services; University of Pittsburgh; VA HSR&D Career Development Award FX We thank Dr. Bobby Jones for his assistance on performing group-based trajectory models. W.-H.L.-C. was funded by a post-doctoral fellowship through the University of Pittsburgh Health Policy Institute, Center for Pharmaceutical Policy and Prescribing. This work was supported in part by an intergovernmental agreement between the Pennsylvania Department of Human Services and the University of Pittsburgh. W.F.G. was supported by a VA HSR&D Career Development Award. NR 58 TC 2 Z9 2 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD MAY PY 2016 VL 111 IS 5 BP 892 EP 902 DI 10.1111/add.13270 PG 11 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DJ3HO UT WOS:000374095600019 PM 26662858 ER PT J AU Sidani, JE Shensa, A Shiffman, S Switzer, GE Primack, BA AF Sidani, J. E. Shensa, A. Shiffman, S. Switzer, G. E. Primack, B. A. TI Public health implications of waterpipe tobacco use in the United States warrant initial steps towards assessing dependence SO ADDICTION LA English DT Letter ID INTERMITTENT SMOKERS; PUFF TOPOGRAPHY; YOUNG-ADULTS; SMOKING; EXPOSURE C1 [Sidani, J. E.; Shensa, A.; Primack, B. A.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med,UPMC Montefiore Hosp, Pittsburgh, PA 15213 USA. [Sidani, J. E.; Shensa, A.; Primack, B. A.] Univ Pittsburgh, Ctr Res Media Technol & Hlth, Pittsburgh, PA USA. [Shiffman, S.] Pinney Associates, Pittsburgh, PA USA. [Switzer, G. E.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Switzer, G. E.] Univ Pittsburgh, Dept Med Psychiat Clin & Translat Sci, Pittsburgh, PA USA. [Primack, B. A.] Univ Pittsburgh, Sch Med, Dept Pediat, Div Adolescent Med, Pittsburgh, PA 15261 USA. RP Sidani, JE (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med,UPMC Montefiore Hosp, Pittsburgh, PA 15213 USA. FU NCI NIH HHS [R01 CA140150, R21 CA185767] NR 16 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD MAY PY 2016 VL 111 IS 5 BP 937 EP 938 DI 10.1111/add.13316 PG 2 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DJ3HO UT WOS:000374095600024 PM 26987303 ER PT J AU Ren, XY Tu, V Bischoff, D Weisgerber, DW Lewis, MS Yamaguchi, DT Miller, TA Harley, BAC Lee, JC AF Ren, Xiaoyan Tu, Victor Bischoff, David Weisgerber, Daniel W. Lewis, Michael S. Yamaguchi, Dean T. Miller, Timothy A. Harley, Brendan A. C. Lee, Justine C. TI Nanoparticulate mineralized collagen scaffolds induce in vivo bone regeneration independent of progenitor cell loading or exogenous growth factor stimulation SO BIOMATERIALS LA English DT Article DE Bone regeneration; Biomimetic material; Nanoparticulate mineralization ID MESENCHYMAL STEM-CELLS; OSTEOGENIC DIFFERENTIATION; MORPHOGENETIC PROTEINS; SIGNALING PATHWAYS; CROSS-LINKING; DEFECT MODEL; GAG SCAFFOLD; FAMILY; RHBMP-2; FUSION AB Current strategies for skeletal regeneration often require co-delivery of scaffold technologies, growth factors, and cellular material. However, isolation and expansion of stem cells can be time consuming, costly, and requires an additional procedure for harvest. Further, the introduction of supraphysiologic doses of growth factors may result in untoward clinical side effects, warranting pursuit of alternative methods for stimulating osteogenesis. In this work, we describe a nanoparticulate mineralized collagen glycosaminoglycan scaffold that induces healing of critical-sized rabbit cranial defects without addition of expanded stem cells or exogenous growth factors. We demonstrate that the mechanism of osteogenic induction corresponds to an increase in canonical BMP receptor signalling secondary to autogenous production of BMP-2 and -9 early and BMP-4 later during differentiation. Thus, nanoparticulate mineralized collagen glycosaminoglycan scaffolds may provide a novel growth factor-free and ex vivo progenitor cell culture-free implantable method for bone regeneration. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Ren, Xiaoyan; Tu, Victor; Miller, Timothy A.; Lee, Justine C.] Univ Calif Los Angeles, David Geffen Sch Med, Div Plast & Reconstruct Surg, 200 UCLA Med Plaza,Suite 465, Los Angeles, CA 90095 USA. [Ren, Xiaoyan; Tu, Victor; Miller, Timothy A.; Lee, Justine C.] Greater Los Angeles VA Healthcare Syst, Div Plast & Reconstruct Surg, Los Angeles, CA 90073 USA. [Ren, Xiaoyan; Tu, Victor; Bischoff, David; Yamaguchi, Dean T.; Lee, Justine C.] Greater Los Angeles VA Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. [Weisgerber, Daniel W.; Harley, Brendan A. C.] Univ Illinois, Inst Genom Biol, Dept Chem & Biomol Engn, Urbana, IL 61801 USA. [Lewis, Michael S.] Greater Los Angeles VA Healthcare Syst, Dept Pathol, Los Angeles, CA 90073 USA. RP Lee, JC (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Plast & Reconstruct Surg, 200 UCLA Med Plaza,Suite 465, Los Angeles, CA 90095 USA. EM justine@ucla.edu OI Harley, Brendan/0000-0001-5458-154X FU US Department of Veterans Affairs [IK2 BX002442-01A2, 1I01BX001367-01A2]; Aramont Foundation; Jean Perkins Foundation; National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health [R21 AR063331]; AO Foundation, Switzerland [S-14-54H]; National Science Foundation (NSF) IGERT: Training the Next Generation of Researchers in Cellular & Molecular Mechanics and BioNanotechnology [0965918] FX This work was supported by the US Department of Veterans Affairs under award numbers IK2 BX002442-01A2 (JCL) and 1I01BX001367-01A2 (TAM), the Aramont Foundation (TAM), and the Jean Perkins Foundation (JCL). Research reported in this publication was also supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award number R21 AR063331 (BACH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional support was provided by project number S-14-54H by AO Foundation, Switzerland (BACH). DWW was funded at UIUC from National Science Foundation (NSF) Grant 0965918 IGERT: Training the Next Generation of Researchers in Cellular & Molecular Mechanics and BioNanotechnology. NR 48 TC 3 Z9 3 U1 7 U2 39 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0142-9612 EI 1878-5905 J9 BIOMATERIALS JI Biomaterials PD MAY PY 2016 VL 89 BP 67 EP 78 DI 10.1016/j.biomaterials.2016.02.020 PG 12 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA DJ2YY UT WOS:000374072500006 PM 26950166 ER PT J AU Rugge, M Genta, RM Graham, DY Di Mario, F Coelho, LGV Kim, N Malfertheiner, P Sugano, K Tsukanov, V Correa, P AF Rugge, Massimo Genta, Robert M. Graham, David Y. Di Mario, Francesco Coelho, Luiz Gonzaga Vaz Kim, Nayoung Malfertheiner, Peter Sugano, Kentaro Tsukanov, Vladislav Correa, Pelayo TI Chronicles of a cancer foretold: 35 years of gastric cancer risk assessment SO GUT LA English DT Article ID HELICOBACTER-PYLORI INFECTION; CHRONIC ATROPHIC GASTRITIS; INTESTINAL METAPLASIA; EPITHELIAL-DYSPLASIA; PRECANCEROUS LESIONS; MAGNIFYING ENDOSCOPY; MALT LYMPHOMA; CLASSIFICATION; MANAGEMENT; OLGA C1 [Rugge, Massimo] Univ Padua, Dept Med DIMED, Pathol & Cytopathol Unit, Padua, Italy. [Rugge, Massimo] Tumor Registry Veneto Reg, Padua, Italy. [Genta, Robert M.] Miraca Life Sci Res Inst, Irving, TX USA. [Genta, Robert M.] Univ Texas Southwestern Med Sch, Dallas, TX USA. [Graham, David Y.] Michael E De Bakey Vet Affairs Med Ctr, Dept Med, Houston, TX USA. [Graham, David Y.] Baylor Coll Med, Houston, TX 77030 USA. [Di Mario, Francesco] Univ Parma, Dept Clin & Expt Med, I-43100 Parma, Italy. [Coelho, Luiz Gonzaga Vaz] Univ Fed Minas Gerais, Inst Alfa Gastroenterol, Belo Horizonte, MG, Brazil. [Kim, Nayoung] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Songnam, Gyeonggi Do, South Korea. [Malfertheiner, Peter] Univ Med Ctr Magdeburg, Otto Von Guericke Univ, Dept Gastroenterol Hepatol & Infect Dis, Magdeburg, Germany. [Sugano, Kentaro] Jichi Med Univ, Dept Med, Shimotsuke, Tochigi, Japan. [Tsukanov, Vladislav] Russian Acad Med Sci, State Sci Med Res Inst, Northern Problems Siberian Div, Krasnoyarsk, Russia. [Correa, Pelayo] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37235 USA. RP Rugge, M (reprint author), Univ Padua, Surg Pathol & Cytopathol Unit, Dept Med DIMED, Via A Gabelli 61, I-35121 Padua, Italy. EM massimo.rugge@unipd.it RI Rugge, Massimo/K-7525-2016; Tsukanov, Vladislav/E-6638-2015 FU Italian Association for Cancer Research (AIRC) [6421]; Healthy Stomach Initiative (HSI) FX This work was partly supported by a grant from the Italian Association for Cancer Research (AIRC Regional grant 2008 N. 6421). This study was conducted under the cooperative auspices of the Healthy Stomach Initiative (HSI). NR 50 TC 3 Z9 3 U1 1 U2 5 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 EI 1468-3288 J9 GUT JI Gut PD MAY PY 2016 VL 65 IS 5 BP 721 EP + DI 10.1136/gutjnl-2015-310846 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DJ3QA UT WOS:000374119400001 PM 26927528 ER PT J AU Nasti, TH Cochran, JB Tsuruta, Y Yusuf, N McKay, KM Athar, M Timares, L Elmets, CA AF Nasti, Tahseen H. Cochran, J. Barry Tsuruta, Yuko Yusuf, Nabiha McKay, Kristopher M. Athar, Mohammad Timares, Laura Elmets, Craig A. TI A murine model for the development of melanocytic nevi and their progression to melanoma SO MOLECULAR CARCINOGENESIS LA English DT Article DE carcinogenesis; melanocyte; nevi; Ras ID CELL-CYCLE ARREST; ULTRAVIOLET-RADIATION; CUTANEOUS MELANOMA; MALIGNANT-MELANOMA; TUMOR PROMOTION; KNOCKOUT MICE; GROWTH-FACTOR; MOUSE MODEL; IN-VIVO; SKIN AB Acquired melanocytic nevi are commonly found in sun exposed and unexposed human skin, but the potential for their transformation into invasive melanoma is not clear. Therefore, a mouse model of nevus initiation and progression was developed in C3H/HeN mice using a modified chemical carcinogenesis protocol. Nevi develop due to DNA damage initiated by dimethylbenz(a) anthracene (DMBA) followed by chronic promotion with 12-O-tetradecanoyl-phorbol-13-acetate (TPA). Dysplastic pigmented skin lesions appeared in 7-9wk with 100% penetrance. Nests of melanocytic cells appeared in a subset of skin draining lymph nodes (dLN) by 25wk, but not in age matched controls. Immunohistochemistry, real-time PCR, and flow cytometric analyses confirmed their melanocytic origin. Transformed cells were present in a subset of nevi and dLNs, which exhibited anchorage-independent growth, tumor development, and metastasis in nude mice. Approximately 50% of the cell lines contained H-Ras mutations and lost tumor suppressor p16(Ink4a) expression. While most studies of melanoma focus on tumor progression in transgenic mouse models where the mutations are present from birth, our model permits investigation of acquired mutations at the earliest stages of nevus initiation and promotion of nevus cell transformation. This robust nevus/melanoma model may prove useful for identifying genetic loci associated with nevus formation, novel oncogenic pathways, tumor targets for immune-prevention, screening therapeutics, and elucidating mechanisms of immune surveillance and immune evasion. (c) 2015 The Authors. Molecular Carcinogenesis, published by Wiley Periodicals, Inc. C1 [Nasti, Tahseen H.; Cochran, J. Barry; Tsuruta, Yuko; Yusuf, Nabiha; McKay, Kristopher M.; Athar, Mohammad; Timares, Laura; Elmets, Craig A.] Univ Alabama Birmingham, Sch Med, Dept Dermatol, Birmingham, AL USA. [Tsuruta, Yuko; Yusuf, Nabiha; Athar, Mohammad; Timares, Laura; Elmets, Craig A.] Univ Alabama Birmingham, Skin Dis Res Ctr, Sch Med, Birmingham, AL USA. [Yusuf, Nabiha; Timares, Laura; Elmets, Craig A.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Timares, L (reprint author), Univ Alabama Birmingham, Dept Dermatol, 1720 2nd Ave S, Birmingham, AL 35294 USA. FU UAB Skin Diseases Research Center Core [P30 AR05094]; NIH NCI [R01 CA138988]; Heflin Center Genomic Core and Cancer Center Core [P30CA13148-40]; UAB Comprehensive Flow Cytometry Core of the Rheumatic Diseases Core Center [P30AR048311, P30AI27667] FX Grant sponsor: UAB Skin Diseases Research Center Core; Grant number: P30 AR05094; Grant sponsor: NIH NCI; Grant number: R01 CA138988; Grant sponsor: Heflin Center Genomic Core and Cancer Center Core; Grant number: P30CA13148-40; Grant sponsor: UAB Comprehensive Flow Cytometry Core of the Rheumatic Diseases Core Center; Grant numbers: P30AR048311; P30AI27667 NR 58 TC 2 Z9 2 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0899-1987 EI 1098-2744 J9 MOL CARCINOGEN JI Mol. Carcinog. PD MAY PY 2016 VL 55 IS 5 BP 646 EP 658 DI 10.1002/mc.22310 PG 13 WC Biochemistry & Molecular Biology; Oncology SC Biochemistry & Molecular Biology; Oncology GA DJ3IA UT WOS:000374096800020 PM 25788145 ER PT J AU Gutzmer, K Ludwig-Barron, NT Wyatt, GE Hamilton, AB Stockman, JK AF Gutzmer, Kyle Ludwig-Barron, Natasha T. Wyatt, Gail E. Hamilton, Alison B. Stockman, Jamila K. TI "Come on Baby. You Know I Love You": African American Women's Experiences of Communication with Male Partners and Disclosure in the Context of Unwanted Sex SO ARCHIVES OF SEXUAL BEHAVIOR LA English DT Article DE Unwanted sex; Partner communication; Disclosure; African American women ID INTIMATE PARTNER; HELP-SEEKING; DATING PARTNERS; VIOLENCE; COERCION; HEALTH; ASSAULT; MEN; VICTIMIZATION; BEHAVIOR AB We examined African American women's experiences of communication with their male intimate partners a couple of hours before and after an incident of unwanted sex. We also examined women's experiences of disclosure following an incident of unwanted sex. Semi-structured qualitative interviews were conducted with a community-based sample of sexually active African American women (n = 19) reporting at least one incident of sexual coercion (i.e., being pressured into unwanted sex without consent) by an intimate male partner since the age of 18. Our analysis was guided by "the sexual division of power" from Connell's (1987) theory of gender and power. Data were analyzed inductively by examining the interviews for common themes in the following domains: communication before the unwanted sex, communication after the unwanted sex, and disclosure to others. Men pressured partners for unwanted sex through verbal and non-verbal tactics, ranging from pestering and blunt requests for sex to verbal bullying and violence. Many women responded by clearly saying no. However, many women also described eventually ceasing to resist their partners and engaging in unwanted sex. After the unwanted sex, men actively and passively avoided discussing the incident. Although many women discussed the unwanted sex with family and friends, less women disclosed to trained professionals. In some cases, women did not discuss the incident with anyone at all. These findings indicate that, when addressing sexual violence against women, there is a need to target men as well as the norms of masculinity that underpin physical and sexual violence against women. C1 [Gutzmer, Kyle] Univ Calif San Diego, Dept Family Med & Publ Hlth, 9500 Gilman Dr,MC 0507, La Jolla, CA 92093 USA. [Gutzmer, Kyle] San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA. [Ludwig-Barron, Natasha T.; Stockman, Jamila K.] Univ Calif San Diego, Dept Med, Div Global Publ Hlth, 9500 Gilman Dr,MC 0507, La Jolla, CA 92093 USA. [Wyatt, Gail E.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Hamilton, Alison B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Stockman, JK (reprint author), Univ Calif San Diego, Dept Med, Div Global Publ Hlth, 9500 Gilman Dr,MC 0507, La Jolla, CA 92093 USA. EM jstockman@ucsd.edu FU National Institute of Mental Health [R25MH080665, R25MH080664]; National Institute on Drug Abuse [K01DA031593]; National Institute on Minority Health and Health Disparities [L60MD003701]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [R01HD077891] FX We gratefully acknowledge the contributions of study participants and study staff to this research. This study was supported by the National Institute of Mental Health (Grant #R25MH080665 and Grant #R25MH080664), the National Institute on Drug Abuse (Grant #K01DA031593), the National Institute on Minority Health and Health Disparities (Grant#L60MD003701), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (Grant #R01HD077891). The views expressed are those of the authors and not necessarily those of the National Institutes of Health. NR 42 TC 0 Z9 0 U1 5 U2 11 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0004-0002 EI 1573-2800 J9 ARCH SEX BEHAV JI Arch. Sex. Behav. PD MAY PY 2016 VL 45 IS 4 BP 807 EP 819 DI 10.1007/s10508-015-0688-9 PG 13 WC Psychology, Clinical; Social Sciences, Interdisciplinary SC Psychology; Social Sciences - Other Topics GA DI6WH UT WOS:000373640400011 PM 26892099 ER PT J AU Guerrero-Berroa, E Ravona-Springer, R Heymann, A Schmeidler, J Hoffman, H Preiss, R Koifmann, K Greenbaum, L Levy, A Silverman, JM Leroith, D Sano, M Schnaider-Beeri, M AF Guerrero-Berroa, Elizabeth Ravona-Springer, Ramit Heymann, Anthony Schmeidler, James Hoffman, Hadas Preiss, Rachel Koifmann, Keren Greenbaum, Lior Levy, Andrew Silverman, Jeremy M. Leroith, Derek Sano, Mary Schnaider-Beeri, Michal TI Ethnicity/culture modulates the relationships of the haptoglobin (Hp) 1-1 phenotype with cognitive function in older individuals with type 2 diabetes SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE cognitive function; cognitive domains; diabetes; haptoglobin; ethnicity/culture; older adults ID SMALL VESSEL DISEASE; NEUROPSYCHOLOGICAL BATTERY; ALZHEIMERS-DISEASE; CARDIOVASCULAR-DISEASE; DEMENTIA; RISK; SUSCEPTIBILITY; CERAD; POLYMORPHISM; EDUCATION AB Objective: The haptoglobin (Hp) genotype has been associated with cognitive function in type 2 diabetes. Because ethnicity/culture has been associated with both cognitive function and Hp genotype frequencies, we examined whether it modulates the association of Hp with cognitive function. Methods: This cross-sectional study evaluated 787 cognitively normal older individuals (> 65 years of age) with type 2 diabetes participating in the Israel Diabetes and Cognitive Decline study. Interactions in two-way analyses of covariance compared Group (Non-Ashkenazi versus Ashkenazi Jews) on the associations of Hp phenotype (Hp 1-1 versus non-Hp 1-1) with five cognitive outcome measures. The primary control variables were age, gender, and education. Results: Compared with Ashkenazi Jews, non-Ashkenazi Jews with the Hp 1-1 phenotype had significantly poorer cognitive function than non-Hp 1-1 in the domains of Attention/Working Memory (p= 0.035) and Executive Function (p= 0.023), but not in Language/Semantic Categorization (p= 0.432), Episodic Memory (p= 0.268), or Overall Cognition (p= 0.082). After controlling for additional covariates (type 2 diabetes-related characteristics, cardiovascular risk factors, Mini-mental State Examination, and extent of depressive symptoms), Attention/Working Memory (p= 0.038) and Executive Function (p= 0.013) remained significant. Conclusions: Older individuals from specific ethnic/cultural backgrounds with the Hp 1-1 phenotype may benefit more from treatment targeted at decreasing or halting the detrimental effects of Hp 1-1 on the brain. Future studies should examine differential associations of Hp 1-1 and cognitive impairment, especially for groups with high prevalence of both, such as African-Americans and Hispanics. Copyright (C) 2015 John Wiley & Sons, Ltd. C1 [Guerrero-Berroa, Elizabeth; Schmeidler, James; Silverman, Jeremy M.; Sano, Mary; Schnaider-Beeri, Michal] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Guerrero-Berroa, Elizabeth; Silverman, Jeremy M.; Sano, Mary] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [Ravona-Springer, Ramit; Koifmann, Keren; Greenbaum, Lior; Schnaider-Beeri, Michal] Chaim Sheba Med Ctr, Joseph Sagol Neurosci Ctr, Ramat Gan, Israel. [Ravona-Springer, Ramit; Heymann, Anthony] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel. [Heymann, Anthony; Hoffman, Hadas; Preiss, Rachel] Maccabi Healthcare Serv, Tel Aviv, Israel. [Levy, Andrew] Technion Israel Inst Technol, Technion Fac Med, Haifa, Israel. [Leroith, Derek] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. RP Guerrero-Berroa, E (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.; Guerrero-Berroa, E (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. EM elizabeth.guerrero-berroa@mssm.edu FU NIA [R01 AG034087, P50 AG05138]; Helen Bader Foundation; Leroy Schecter Foundation; Irma T. Hirschl Scholar award; Alzheimer's Association [MNIRGD-14-321113] FX This study was supported by NIA grants R01 AG034087 to Dr. Beeri and P50 AG05138 to Dr. Sano; the Helen Bader Foundation, the Leroy Schecter Foundation, and the Irma T. Hirschl Scholar award to Dr. Beeri; and the Alzheimer's Association grant MNIRGD-14-321113 to Dr. Guerrero-Berroa. NR 45 TC 0 Z9 0 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-6230 EI 1099-1166 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD MAY PY 2016 VL 31 IS 5 BP 494 EP 501 DI 10.1002/gps.4354 PG 8 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA DI8RA UT WOS:000373767400006 PM 26388309 ER PT J AU Barnett, MD Williams, BR Tucker, RO AF Barnett, Michael D. Williams, Beverly R. Tucker, Rodney O. TI Sudden Advanced Illness: An Emerging Concept Among Palliative Care and Surgical Critical Care Physicians SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Article DE critical care; surgery; palliative care; prognostication; decision making; caregiver issues ID OF-LIFE CARE; INTENSIVE-CARE; UNIT; END; TRAUMA; SERVICES; ICU; PROJECT; MODELS AB Background: End-of-life discussions in critically-ill patients with acute surgical conditions may be rushed and occur earlier during hospitalization. This study explores the concept of sudden advanced illness (SAI) and its relevance to patients requiring Palliative and Surgical Critical Care. Methods: Semi-structured interviews were completed with 16 physicians, querying each about (1) definitional components, (2) illustrative cases, and (3) comfort with SAI. Analysis was done by grounded theory. Results: SAI was characterized as unforeseen, emerging abruptly and producing devastating injury, often in healthy, younger patients. There is (1) prognostic uncertainty, (2) loss of capacity, and (3) unprepared surrogate decision-making. Cases are emotionally-charged and often personal. Conclusion: The emerging concept of SAI is important for understanding how Palliative Care can enhance care for this subset of patients. C1 [Barnett, Michael D.; Williams, Beverly R.; Tucker, Rodney O.] Univ Alabama Birmingham, Ctr Palliat & Support Care, 1720 2nd Ave S,CH19 219, Birmingham, AL 35294 USA. [Barnett, Michael D.; Williams, Beverly R.; Tucker, Rodney O.] Univ Alabama Birmingham, Div Geriatr Gerontol & Palliat Care, Birmingham, AL USA. [Barnett, Michael D.] Univ Alabama Birmingham, Div Gen Pediat & Adolescent Med, Birmingham, AL USA. [Williams, Beverly R.] Birmingham VA Med Ctr, Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. RP Barnett, MD (reprint author), Univ Alabama Birmingham, Ctr Palliat & Support Care, 1720 2nd Ave S,CH19 219, Birmingham, AL 35294 USA. EM mbarnett@peds.uab.edu NR 23 TC 0 Z9 0 U1 2 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 EI 1938-2715 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD MAY PY 2016 VL 33 IS 4 BP 321 EP 326 DI 10.1177/1049909114565108 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DH6CX UT WOS:000372879700002 PM 25548391 ER PT J AU Hutt, E Whitfield, E Min, SJ Jones, J Weber, M Albright, K Levy, C O'Toole, T AF Hutt, Evelyn Whitfield, Emily Min, Sung-Joon Jones, Jacqueline Weber, Mary Albright, Karen Levy, Cari O'Toole, Thomas TI Challenges of Providing End-of-Life Care for Homeless Veterans SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Article DE veteran; palliative care; homelessness ID DEATH; ADULTS; BOSTON AB Objective: To describe challenges of caring for homeless veterans at end of life (EOL) as perceived by Veterans Affairs Medical Center (VAMC) homeless and EOL care staff. Design: E-mail survey. Setting/participants: Homelessness and EOL programs at VAMCs. Measurements: Programs and their ratings of personal, structural, and clinical care challenges were described statistically. Homelessness and EOL program responses were compared in unadjusted analyses and using multivariable models. Results: Of 152 VAMCs, 50 (33%) completed the survey. The VAMCs treated an average of 6.5 homeless veterans at EOL annually. Lack of appropriate housing was the most critical challenge. The EOL programs expressed somewhat more concern about lack of appropriate care site and care coordination than did homelessness programs. Conclusions: Personal, clinical, and structural challenges face care providers for veterans who are homeless at EOL. Deeper understanding of these challenges will require qualitative study of homeless veterans and care providers. C1 [Hutt, Evelyn; Whitfield, Emily; Levy, Cari] Denver Vet Affairs Med Ctr VAMC, Denver, CO USA. [Hutt, Evelyn; Whitfield, Emily; Min, Sung-Joon; Albright, Karen; Levy, Cari] Univ Colorado, Sch Med, Dept Med, Denver, CO USA. [Jones, Jacqueline; Weber, Mary] Univ Colorado, Coll Nursing, Denver, CO USA. [O'Toole, Thomas] Providence Vet Affairs Med Ctr, Providence, RI USA. [O'Toole, Thomas] Brown Univ, Alpert Med Sch, Dept Med, Providence, RI 02912 USA. RP Hutt, E (reprint author), Denver VA Med Ctr, Res, 1055 Clermont St,Mail Code A151, Denver, CO 80220 USA. EM evelyn.hutt@ucdenver.edu FU Department of Veterans Affairs [10-322] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The funding for this study was provided by Merit Award 10-322 from the Department of Veterans Affairs. The funding sources had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. NR 12 TC 0 Z9 0 U1 2 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 EI 1938-2715 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD MAY PY 2016 VL 33 IS 4 BP 381 EP 389 DI 10.1177/1049909115572992 PG 9 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DH6CX UT WOS:000372879700011 PM 25701660 ER PT J AU Egede, LE Bishu, KG Walker, RJ Dismuke, CE AF Egede, Leonard E. Bishu, Kinfe G. Walker, Rebekah J. Dismuke, Clara E. TI Impact of diagnosed depression on healthcare costs in adults with and without diabetes: United States, 2004-2011 SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Diabetes; Depression; Cost; Comorbidities; Expenditures ID COMORBID DEPRESSION; MEDICAL COSTS; PREVALENCE; COMPLICATIONS; EXPENDITURES; BURDEN; MODELS AB Objective: This study used the Medical Expenditures Panel Survey (MEPS) to estimate the cost of diabetes, depression, and comorbid diabetes and depression over 8 years. Methods: An 8-year pooled dataset was created using the household and medical provider components of MEPS. Medical expenditures were adjusted to a common 2014 dollar value. Analyses used responses of 147,095 individuals > 18 years of age for the years 2004-2011. The dependent variable in this study was total healthcare expenditure and the primary independent variables were diabetes and depression status. A two-part (probit/GLM) model was used to estimate the annual medical spending and marginal effects were calculated for incremental cost. Results: In the pooled sample, after adjusting for socio-demographic factors, comorbidities and time trend covariates, the incremental cost of depression only was $2654 (95% CI 2343-2966), diabetes was $2692 (95% CI 2338-3046), and both was $6037 (CI 95% 5243-6830) when compared to patients with none. Based on the unadjusted mean, annual average aggregate cost of depression only was estimated at $238.3 billion, diabetes only $150.1 billion and depression and diabetes together was $77.6 billion. Conclusion: Costs at both the individual and aggregate level are significant, with comorbid diagnoses resulting in higher incremental costs than the sum of the costs for each diagnosis alone. In addition, while the cost of depression increased over time, the cost of diabetes decreased over time, much due to decreased inpatient costs. This study highlights the tremendous cost savings possible through more aggressive screening, diagnosis, and treatment of depression. (C) 2016 Elsevier B.V. All rights reserved. C1 [Egede, Leonard E.; Bishu, Kinfe G.; Walker, Rebekah J.; Dismuke, Clara E.] Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Egede, Leonard E.; Bishu, Kinfe G.; Walker, Rebekah J.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Dept Med, Charleston, SC 29425 USA. [Egede, Leonard E.; Walker, Rebekah J.; Dismuke, Clara E.] Ralph H Johnson Vet Affairs Med Ctr, HEROIC, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280G, Charleston, SC 29425 USA. EM egedel@musc.edu FU National Institute of Diabetes and Digestive and Kidney Disease [K24DK093699-01] FX This study was supported by Grant K24DK093699-01 from The National Institute of Diabetes and Digestive and Kidney Disease (PI: Leonard Egede). NR 40 TC 2 Z9 2 U1 4 U2 18 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD MAY PY 2016 VL 195 BP 119 EP 126 DI 10.1016/j.jad.2016.02.011 PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DF3PP UT WOS:000371257400014 PM 26890289 ER PT J AU Morris, JN Howard, EP Steel, K Berg, K Tchalla, A Munankarmi, A David, D AF Morris, John N. Howard, Elizabeth P. Steel, Knight Berg, Katherine Tchalla, Achille Munankarmi, Amy David, Daniel TI Strategies to reduce the risk of falling: Cohort study analysis with 1-year follow-up in community dwelling older adults SO BMC GERIATRICS LA English DT Article DE Strategies to reduce risk of falls; Community-dwelling older adults; interRAI assessment ID RANDOMIZED CONTROLLED-TRIAL; PHYSICAL FUNCTION; ELDERLY-PEOPLE; VISUAL-ACUITY; REHABILITATION; HEALTH; ASSOCIATIONS; PREVENTION; POPULATION; PREDICTORS AB Background: According to the CDC, falls rank among the leading causes of accidental death in the United States, resulting in significant health care costs annually. In this paper we present information about everyday lifestyle decisions of the older adult that may help reduce the risk of falling. We pursued two lines of inquiry: first, we identify and then test known mutable fall risk factors and ask how the resolution of such problems correlates with changes in fall rates. Second, we identify a series of everyday lifestyle options that persons may follow and then ask, does such engagement (e.g., engagement in exercise programs) lessen the older adult's risk of falling and if it does, will the relationship hold as the count of risk factors increases? Methods: Using a secondary analysis of lifestyle choices and risk changes that may explain fall rates over one year, we drew on a data set of 13,623 community residing elders in independent housing sites from 24 US states. All older adults were assessed at baseline, and a subset assessed one year later (n = 4,563) using two interRAI tools: the interRAI Community Health Assessment and interRAI Wellness Assessment. Results: For the vast majority of risk measures, problem resolution is followed by lower rate of falls. This is true for physical measures such as doing housework, meal preparation, unsteady gait, transferring, and dressing the lower body. Similarly, this pattern is observed for clinical measures such as depression, memory, vision, dizziness, and fatigue. Among the older adults who had a falls risk at the baseline assessment, about 20 % improve, that is, they had a decreased falls rate when the problem risk improved. This outcome suggests that improvement of physical or clinical states potentially may result in a decreased falls rate. Additionally, physical exercise and cognitive activities are associated with a lower rate of falls. Conclusions: The resolution of risk problems and physical and cognitive lifestyle choices are related to lower fall rates in elders in the community. The results presented here point to specific areas, that when targeted, may reduce the risk of falls. In addition, when there is problem resolution for specific clinical conditions, a decreased risk for falls also may occur. C1 [Morris, John N.] Hebrew SeniorLife, Inst Aging Res, 1200 Ctr St, Boston, MA 02131 USA. [Howard, Elizabeth P.] Northeastern Univ, Sch Nursing, 360 Huntington Ave, Boston, MA 02115 USA. [Steel, Knight] Hackensack Univ, Med Ctr, 30 Prospect Ave, Hackensack, NJ 07601 USA. [Berg, Katherine] Univ Toronto, Dept Phys Therapy, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada. [Berg, Katherine] Univ Toronto, Rehabil Sci Inst, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada. [Tchalla, Achille] Univ Limoges, Dept Geriatr Med, IFR Geist 145, F-87025 Limoges, France. [Tchalla, Achille] CHU Limoges, EA HAVAE 6310, F-87025 Limoges, France. [Munankarmi, Amy] Northeastern Univ, 360 Huntington Ave, Boston, MA 02115 USA. [David, Daniel] San Francisco VA Med Ctr, VA Qual Scholar Geriatr Palliat & Extended Care S, San Francisco, CA 94121 USA. RP Howard, EP (reprint author), Northeastern Univ, Sch Nursing, 360 Huntington Ave, Boston, MA 02115 USA. EM e.howard@neu.edu FU COLLAGE FX Financial support was provided partially by COLLAGE with the remainder being self-supported. NR 51 TC 0 Z9 0 U1 9 U2 15 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2318 J9 BMC GERIATR JI BMC Geriatr. PD APR 29 PY 2016 VL 16 AR 92 DI 10.1186/s12877-016-0267-5 PG 10 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DK7IT UT WOS:000375099100001 PM 27129303 ER PT J AU Vergidis, P Clancy, CJ Shields, RK Park, SY Wildfeuer, BN Simmons, RL Nguyen, MH AF Vergidis, Pascalis Clancy, Cornelius J. Shields, Ryan K. Park, Seo Young Wildfeuer, Brett N. Simmons, Richard L. Nguyen, M. Hong TI Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment SO PLOS ONE LA English DT Article ID INTENSIVE-CARE-UNIT; INVASIVE CANDIDIASIS; ABDOMINAL CANDIDIASIS; SURGICAL-PATIENTS; NONCULTURE DIAGNOSTICS; RISK-FACTORS; PERITONITIS; INFECTIONS; MANAGEMENT; MORTALITY AB Intra-abdominal candidiasis (IAC) is poorly understood compared to candidemia. We described the clinical characteristics, microbiology, treatment and outcomes of IAC, and identified risk factors for mortality. We performed a retrospective study of adults diagnosed with IAC at our center in 2012-2013. Risk factors for mortality were evaluated using multivariable logistic regression. We identified 163 patients with IAC, compared to 161 with candidemia. Types of IAC were intra-abdominal abscesses (55%), secondary peritonitis (33%), primary peritonitis (5%), infected pancreatic necrosis (5%), and cholecystitis/cholangitis (3%). Eighty-three percent and 66% of secondary peritonitis and abscesses, respectively, stemmed from gastrointestinal (GI) tract sources. C. albicans (56%) and C. glabrata (24%) were the most common species. Bacterial co-infections and candidemia occurred in 67% and 6% of patients, respectively. Seventy-two percent of patients underwent an early source control intervention (within 5 days) and 72% received early antifungal treatment. 100-day mortality was 28%, and highest with primary (88%) or secondary (40%) peritonitis. Younger age, abscesses and early source control were independent predictors of survival. Younger age, abscesses and early antifungal treatment were independently associated with survival for IAC stemming from GI tract sources. Infectious diseases (ID) consultations were obtained in only 48% of patients. Consulted patients were significantly more likely to receive antifungal treatment. IAC is a common disease associated with heterogeneous manifestations, which result in poor outcomes. All patients should undergo source control interventions and receive antifungal treatment promptly. It is important for the ID community to become more engaged in treating IAC. C1 [Vergidis, Pascalis; Clancy, Cornelius J.; Shields, Ryan K.; Wildfeuer, Brett N.; Nguyen, M. Hong] Univ Pittsburgh, Sch Med, Dept Med, Div Infect Dis, Pittsburgh, PA 15213 USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Park, Seo Young] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Simmons, Richard L.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA. RP Vergidis, P (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Div Infect Dis, Pittsburgh, PA 15213 USA. EM vergidisp@upmc.edu FU National Institutes of Health (NIH) [R21AI107290]; National Center for Advancing Translational Sciences of the NIH [KL2TR000146]; NIH [K08AI114883] FX The study was supported, in part, by award R21AI107290 (M.H.N.) from the National Institutes of Health (NIH). P.V. is supported by the National Center for Advancing Translational Sciences of the NIH under Award Number KL2TR000146. R.K.S is supported by the NIH under award number K08AI114883. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 40 TC 4 Z9 4 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 28 PY 2016 VL 11 IS 4 AR e0153247 DI 10.1371/journal.pone.0153247 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DK8XE UT WOS:000375211700013 PM 27123857 ER PT J AU Reddy, AT Lakshmi, SP Muchumarri, RR Reddy, RC AF Reddy, Aravind T. Lakshmi, Sowmya P. Muchumarri, Ramamohan R. Reddy, Raju C. TI Nitrated Fatty Acids Reverse Cigarette Smoke-Induced Alveolar Macrophage Activation and Inhibit Protease Activity via Electrophilic S-Alkylation SO PLOS ONE LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; HUMAN CATHEPSIN-S; EPITHELIAL-CELLS; NITROLINOLEIC ACID; PPAR-GAMMA; INFLAMMATION; TRANSDUCTION; REPERFUSION; MECHANISMS; ISCHEMIA AB Nitrated fatty acids (NFAs), endogenous products of nonenzymatic reactions of NO-derived reactive nitrogen species with unsaturated fatty acids, exhibit substantial anti-inflammatory activities. They are both reversible electrophiles and peroxisome proliferator-activated receptor gamma (PPAR gamma) agonists, but the physiological implications of their electrophilic activity are poorly understood. We tested their effects on inflammatory and emphysema-related biomarkers in alveolar macrophages (AMs) of smoke-exposed mice. NFA (10-nitro-oleic acid or 12-nitrolinoleic acid) treatment downregulated expression and activity of the inflammatory transcription factor NF-kappa B while upregulating those of PPAR gamma. It also downregulated production of inflammatory cytokines and chemokines and of the protease cathepsin S (Cat S), a key mediator of emphysematous septal destruction. Cat S downregulation was accompanied by decreased AM elastolytic activity, a major mechanism of septal destruction. NFAs downregulated both Cat S expression and activity in AMs of wild-type mice, but only inhibited its activity in AMs of PPAR. knockout mice, pointing to a PPAR gamma-independent mechanism of enzyme inhibition. We hypothesized that this mechanism was electrophilic S-alkylation of target Cat S cysteines, and found that NFAs bind directly to Cat S following treatment of intact AMs and, as suggested by in silico modeling and calculation of relevant parameters, elicit S-alkylation of Cys25 when incubated with purified Cat S. These results demonstrate that NFAs' electrophilic activity, in addition to their role as PPAR. agonists, underlies their protective effects in chronic obstructive pulmonary disease (COPD) and support their therapeutic potential in this disease. C1 [Reddy, Aravind T.; Lakshmi, Sowmya P.; Muchumarri, Ramamohan R.; Reddy, Raju C.] Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA. [Reddy, Aravind T.; Lakshmi, Sowmya P.; Muchumarri, Ramamohan R.; Reddy, Raju C.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Reddy, RC (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA.; Reddy, RC (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. EM reddyrc@upmc.edu FU U.S. Department of Veterans Affairs; National Institutes of Health [HL093196] FX This work was supported by a Merit Review award from the U.S. Department of Veterans Affairs and National Institutes of Health grant HL093196 to RCR. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 28 TC 1 Z9 1 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 27 PY 2016 VL 11 IS 4 AR e0153336 DI 10.1371/journal.pone.0153336 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DK5QZ UT WOS:000374976200022 PM 27119365 ER PT J AU Kim, JE Scherzer, R Estrella, MM Ix, JH Shlipak, MG AF Kim, Julie E. Scherzer, Rebecca Estrella, Michelle M. Ix, Joachim H. Shlipak, Michael G. TI Tenofovir exposure alters associations of serum bicarbonate with chronic kidney disease risk in HIV-infected veterans SO AIDS LA English DT Article DE tenofovir; HIV; chronic kidney disease; bicarbonate ID ANTIRETROVIRAL THERAPY; COHORT; PROGRESSION; ACIDOSIS; OUTCOMES; HEALTH; CARE; CKD AB Objective: Among HIV-infected persons, tenofovir disoproxil fumarate (TDF) use is associated with higher risk of developing chronic kidney disease (CKD). Because lower serum bicarbonate concentrations may precede CKD onset, this study investigated the associations between TDF use and bicarbonate concentrations, and between bicarbonate with CKD risk among TDF users and nonusers. Methods: Retrospective cohort study of 16 070 HIV-infected US veterans who initiated antiretroviral therapy between 1997-2011. The association between TDF use with longitudinal bicarbonate concentrations and associations between bicarbonate with incident CKD stratified by TDF use (never, initial, and later user) were evaluated. Results: Compared with TDF users, never users had faster declines in bicarbonate concentrations: change in bicarbonate -0.11 mmol/l per year (95% confidence interval -0.16, -0.05), compared with -0.04 mmol/l per year (-0.06, 0.05) in initial users and -0.02 mmol/l per year (-0.05, 0.01) in later users. Low baseline bicarbonate (<22 mmol/l) was significantly associated with CKD risk among TDF never users (1.80; 1.21, 2.68), but not among TDF users (0.98; 0.69, 1.38). Similarly, declining bicarbonate concentrations were associated with higher CKD risk among never users (hazard ratio 1.67 per mmol/l; 1.34, 2.08), but not among TDF users (1.09; 0.98, 1.22). Interactions were highly significant for both analyses (P value = 0.001). Conclusion: Despite associations with nephrotoxicity, TDF use was associated with higher serum bicarbonate concentrations longitudinally. Additionally, TDF use obscured the strong associations of bicarbonate with CKD risk in HIV-infected persons. Therefore, the role of bicarbonate concentrations as a tool to monitor kidney health in HIV-infected persons may be limited in the setting of TDF use. C1 [Kim, Julie E.; Scherzer, Rebecca; Estrella, Michelle M.; Ix, Joachim H.; Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Shlipak, MG (reprint author), San Francisco VA Med Ctr, San Francisco, CA USA. EM michael.shlipak@ucsf.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [1K23DK081317]; American Heart Association [14EIA18560026]; National Institute of Aging [R01AG034853] FX R.S. received honorarium from Merck for participating in a Renal Expert Input Forum in June 2014; this honorarium was donated to NCIRE to support kidney research. M.E. was supported by grant 1K23DK081317 from the National Institute of Diabetes and Digestive and Kidney Diseases. J.I. was supported by an Established Investigator Award 14EIA18560026 from the American Heart Association. M.S. was supported by grant R01AG034853 from the National Institute of Aging. NR 25 TC 0 Z9 0 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD APR 24 PY 2016 VL 30 IS 7 BP 1049 EP 1057 DI 10.1097/QAD.0000000000001023 PG 9 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA DI1AW UT WOS:000373229400001 PM 26760455 ER PT J AU Krager, SC Prochazka, AV AF Krager, Steven C. Prochazka, Allan V. TI Review: In women 50 to 69 y of age at average risk, mammography screening reduces breast cancer mortality SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID FORCE RECOMMENDATION STATEMENT; TRIAL C1 [Krager, Steven C.; Prochazka, Allan V.] Denver VA Med Ctr, Denver, CO USA. RP Krager, SC (reprint author), Denver VA Med Ctr, Denver, CO USA. NR 7 TC 0 Z9 0 U1 3 U2 4 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 19 PY 2016 VL 164 IS 8 BP JC38 EP JC39 DI 10.7326/ACPJC-2016-164-8-038 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DJ5OH UT WOS:000374257900001 PM 27089086 ER PT J AU Prochazka, AV AF Prochazka, Allan V. TI Varenicline increased smoking cessation at 24 weeks in patients hospitalized with ACS and motivated to quit SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material C1 [Prochazka, Allan V.] Denver VA Med Ctr, Denver, CO USA. RP Prochazka, AV (reprint author), Denver VA Med Ctr, Denver, CO USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 19 PY 2016 VL 164 IS 8 BP JC43 EP JC43 DI 10.7326/ACPJC-2016-164-6-043 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA DJ5OH UT WOS:000374257900005 PM 27089093 ER PT J AU Baek, JI Kwon, SH Zuo, XF Choi, SY Kim, SH Lipschutz, JH AF Baek, Jeong-In Kwon, Sang-Ho Zuo, Xiaofeng Choi, Soo Young Kim, Seok-Hyung Lipschutz, Joshua H. TI Dynamin Binding Protein (Tuba) Deficiency Inhibits Ciliogenesis and Nephrogenesis in Vitro and in Vivo SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article DE CDC42; cilia; guanine nucleotide exchange factor (GEF); kidney; membrane trafficking ID NUCLEOTIDE EXCHANGE FACTORS; EPITHELIAL-CELLS; CDC42 GEF; ZEBRAFISH PRONEPHROS; PRIMARY CILIUM; FACIOGENITAL DYSPLASIA; INDUCED TUBULOGENESIS; EXTRACELLULAR-MATRIX; SPINDLE ORIENTATION; ACTIN CYTOSKELETON AB Dysfunction of renal primary cilia leads to polycystic kidney disease. We previously showed that the exocyst, a protein trafficking complex, is essential for ciliogenesis and regulated by multiple Rho and Rab family GTPases, such as Cdc42. Cdc42 deficiency resulted in a disruption of renal ciliogenesis and a polycystic kidney disease phenotype in zebrafish and mice. Here we investigate the role of Dynamin binding protein (also known as Tuba), a Cdc42-specific guanine nucleotide exchange factor, in ciliogenesis and nephrogenesis using Tuba knockdown Madin-Darby canine kidney cells and tuba knockdown in zebrafish. Tuba depletion resulted in an absence of cilia, with impaired apical polarization and inhibition of hepatocyte growth factor-induced tubulogenesis in Tuba knockdown Madin-Darby canine kidney cell cysts cultured in a collagen gel. In zebrafish, tuba was expressed in multiple ciliated organs, and, accordingly, tuba start and splice site morphants showed various ciliary mutant phenotypes in these organs. Co-injection of tuba and cdc42 morpholinos at low doses, which alone had no effect, resulted in genetic synergy and led to abnormal kidney development with highly disorganized pronephric duct cilia. Morpholinos targeting two other guanine nucleotide exchange factors not known to be in the Cdc42/ciliogenesis pathway and a scrambled control morpholino showed no phenotypic effect. Given the molecular nature of Cdc42 and Tuba, our data strongly suggest that tuba and cdc42 act in the same ciliogenesis pathway. Our study demonstrates that Tuba deficiency causes an abnormal renal ciliary and morphogenetic phenotype. Tuba most likely plays a critical role in ciliogenesis and nephrogenesis by regulating Cdc42 activity. C1 [Baek, Jeong-In; Kwon, Sang-Ho; Zuo, Xiaofeng; Choi, Soo Young; Kim, Seok-Hyung; Lipschutz, Joshua H.] Med Univ S Carolina, Dept Med, Clin Sci Bldg 829,96 Jonathan Lucas St, Charleston, SC 29425 USA. [Lipschutz, Joshua H.] Ralph H Johnson Vet Affairs Med Ctr, Dept Med, Charleston, SC 29401 USA. RP Lipschutz, JH (reprint author), Med Univ S Carolina, Dept Med, Clin Sci Bldg 829,96 Jonathan Lucas St, Charleston, SC 29425 USA. EM Lipschut@musc.edu FU Department of Veterans Affairs Merit Award [2I01BX000820]; National Institutes of Health [2P30DK074038]; PKD Foundation fellowship award FX This work was supported in part by Department of Veterans Affairs Merit Award 2I01BX000820 (to J. H. L.), National Institutes of Health Grant 2P30DK074038 (to J. H. L.), and a PKD Foundation fellowship award (to J. I. B.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 74 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD APR 15 PY 2016 VL 291 IS 16 BP 8632 EP 8643 DI 10.1074/jbc.M115.688663 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DK2VT UT WOS:000374773200026 PM 26895965 ER PT J AU Ferrario, CM VonCannon, J Jiao, Y Ahmad, S Bader, M Dell'Italia, LJ Groban, L Varagic, J AF Ferrario, Carlos M. VonCannon, Jessica Jiao, Yan Ahmad, Sarfaraz Bader, Michael Dell'Italia, Louis J. Groban, Leanne Varagic, Jasmina TI Cardiac angiotensin-(1-12) expression and systemic hypertension in rats expressing the human angiotensinogen gene SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE angiotensin converting enzyme inhibitors; angiotensin II; angiotensinogen; cardiac angiotensins; chymase; angiotensin-(1-12); renin ID CONVERTING ENZYME; HUMAN RENIN; BLOOD-PRESSURE; II GENERATION; CHYMASE; HEART; INTRACRINE; PROANGIOTENSIN-12; IDENTIFICATION; METABOLISM AB Angiotensin-(1-12) [ANG-(1-12)] is processed into ANG II by chymase in rodent and human heart tissue. Differences in the amino acid sequence of rat and human ANG-(1-12) render the human angiotensinogen (hAGT) protein refractory to cleavage by renin. We used transgenic rats harboring the hAGT gene [TGR(hAGT)L1623] to assess the non-renin-dependent effects of increased hAGT expression on heart function and arterial pressure. Compared with Sprague-Dawley (SD) control rats (n = 11), male homozygous TGR(hAGT)L1623 (n = 9) demonstrated sustained daytime and nighttime hypertension associated with no changes in heart rate but increased heart rate lability. Increased heart weight/tibial length ratio and echocardiographic indexes of cardiac hypertrophy were associated with modest reduction of systolic function in hAGT rats. Robust human ANG-(1-12) immunofluorescence within myocytes of TGR(hAGT) L1623 rats was associated with a fourfold increase in cardiac ANG II content. Chymase enzymatic activity, using the rat or human ANG-(1-12) as a substrate, was not different in the cardiac tissue of SD and hAGT rats. Since both cardiac angiotensin-converting enzyme (ACE) and ACE2 activities were not different among the two strains, the changes in cardiac structure and function, blood pressure, and left ventricular ANG II content might be a product of an increased cardiac expression of ANG II generated through a non-renin-dependent mechanism. The data also underscore the existence in the rat of alternate enzymes capable of acting on hAGT protein. Homozygous transgenic rats expressing the hAGT gene represent a novel tool to investigate the contribution of human relevant renin-independent cardiac ANG II formation and function. C1 [Ferrario, Carlos M.; VonCannon, Jessica; Jiao, Yan; Varagic, Jasmina] Wake Forest Sch Med, Dept Surg, Winston Salem, NC USA. [VonCannon, Jessica; Ahmad, Sarfaraz; Groban, Leanne; Varagic, Jasmina] Wake Forest Sch Med, Hypertens & Vasc Res Ctr, Winston Salem, NC USA. [Bader, Michael] Max Delbruck Ctr Mol Med MDC, Berlin, Germany. [Dell'Italia, Louis J.] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Dell'Italia, Louis J.] Birmingham Vet Affairs Med Ctr, Dept Vet Affairs, Birmingham, AL USA. [Groban, Leanne] Wake Forest Sch Med, Dept Anesthesiol, Winston Salem, NC USA. [Ferrario, Carlos M.; Varagic, Jasmina] Wake Forest Sch Med, Dept Med Nephrol, Winston Salem, NC USA. [Ferrario, Carlos M.; Varagic, Jasmina] Wake Forest Sch Med, Dept Physiol Pharmacol, Winston Salem, NC USA. RP Varagic, J (reprint author), Wake Forest Sch Med, Hypertens & Vasc Res Ctr, Div Surg Sci, Med Ctr Blvd, Winston Salem, NC 27157 USA. EM jvaragic@wakehealth.edu FU National Heart, Lung, and Blood Institute [P01-HL-051952]; Wake Forest University TSC-Reynolda Grant [U01079] FX This research was supported by National Heart, Lung, and Blood Institute Grant P01-HL-051952 (to C. M. Ferrario) and Wake Forest University TSC-Reynolda Grant U01079 (to J. Varagic). NR 39 TC 2 Z9 2 U1 2 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 EI 1522-1539 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD APR 15 PY 2016 VL 310 IS 8 BP H995 EP H1002 DI 10.1152/ajpheart.00833.2015 PG 8 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA DJ3IY UT WOS:000374099500005 PM 26873967 ER PT J AU Liu, H Rose, ME Culver, S Ma, XC Dixon, CE Graham, SH AF Liu, Hao Rose, Marie E. Culver, Sherman Ma, Xiecheng Dixon, C. Edward Graham, Steven H. TI Rosiglitazone attenuates inflammation and CA3 neuronal loss following traumatic brain injury in rats SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Traumatic brain injury; PPAR gamma; Inflammation; Rosiglitazone; Behavioral; Cell survival ID SPINAL-CORD-INJURY; PPAR-GAMMA; STROKE; AGONIST; DYSFUNCTION; MECHANISMS; THERAPIES; DEFICITS; TARGET; DAMAGE AB Rosiglitazone, a potent peroxisome proliferator-activated receptor (PPAR)-gamma agonist, has been shown to confer neuroprotective effects in stroke and spinal cord injury, but its role in the traumatic brain injury (TBI) is still controversial. Using a controlled cortical impact model in rats, the current study was designed to determine the effects of rosiglitazone treatment (6 mg/kg at 5 min, 6 h and 24 h post injury) upon inflammation and histological outcome at 21 d after TBI. In addition, the effects of rosiglitazone upon inflammatory cytokine transcription, vestibulomotor behavior and spatial memory function were determined at earlier time points (24 h, 1-5 d, 14-20 d post injury, respectively). Compared with the vehicle-treated group, rosiglitazone treatment suppressed production of TNF alpha at 24 h after TBI, attenuated activation of microglia/macrophages and increased survival of CA3 neurons but had no effect on lesion volume at 21 d after TBI. Rosiglitazone-treated animals had improved performance on beam balance testing, but there was no difference in spatial memory function as determined by Morris water maze. In summary, this study indicates that rosiglitazone treatment in the first 24 h after TBI has limited anti-inflammatory and neuroprotective effects in rat traumatic injury. Further study using an alternative dosage paradigm and more sensitive behavioral testing may be warranted. Published by Elsevier Inc. C1 [Liu, Hao; Rose, Marie E.; Culver, Sherman; Ma, Xiecheng; Dixon, C. Edward; Graham, Steven H.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Liu, Hao; Rose, Marie E.; Graham, Steven H.] Univ Pittsburgh, Dept Neurol, Sch Med, Pittsburgh, PA 15260 USA. [Culver, Sherman; Ma, Xiecheng; Dixon, C. Edward] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15216 USA. [Culver, Sherman; Ma, Xiecheng; Dixon, C. Edward] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15216 USA. RP Graham, SH (reprint author), VA Pittsburgh Healthcare Ctr Res, Geriatr Res Educ & Clin Ctr, Off Bldg 30,Mail Code 151, Pittsburgh, PA 15240 USA. EM Steven.Graham@va.gov FU Veteran's Affairs Rehabilitation Research and Development Merit Review Program Award [I01RX000310] FX This work was supported by the Veteran's Affairs Rehabilitation Research and Development Merit Review Program Award I01RX000310 (S.H.G.). NR 26 TC 2 Z9 2 U1 1 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X EI 1090-2104 J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD APR 15 PY 2016 VL 472 IS 4 BP 648 EP 655 DI 10.1016/j.bbrc.2016.03.003 PG 8 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA DI8LX UT WOS:000373753600013 PM 26947332 ER PT J AU Liu, SJ Nowakowski, TJ Pollen, AA Lui, JH Horlbeck, MA Attenello, FJ He, D Weissman, JS Kriegstein, AR Diaz, AA Lim, DA AF Liu, Siyuan John Nowakowski, Tomasz J. Pollen, Alex A. Lui, Jan H. Horlbeck, Max A. Attenello, Frank J. He, Daniel Weissman, Jonathan S. Kriegstein, Arnold R. Diaz, Aaron A. Lim, Daniel A. TI Single-cell analysis of long non-coding RNAs in the developing human neocortex SO GENOME BIOLOGY LA English DT Article DE lncRNA; Single-cell RNA-seq; Developing brain; CRISPRi ID EMBRYONIC STEM-CELLS; GENOME-WIDE ANALYSIS; CEREBRAL-CORTEX; MOUSE-BRAIN; IN-VIVO; REVEALS; GENE; EXPRESSION; SEQ; TRANSCRIPTOME AB Background: Long non-coding RNAs (lncRNAs) comprise a diverse class of transcripts that can regulate molecular and cellular processes in brain development and disease. LncRNAs exhibit cell type-and tissue-specific expression, but little is known about the expression and function of lncRNAs in the developing human brain. Furthermore, it has been unclear whether lncRNAs are highly expressed in subsets of cells within tissues, despite appearing lowly expressed in bulk populations. Results: We use strand-specific RNA-seq to deeply profile lncRNAs from polyadenylated and total RNA obtained from human neocortex at different stages of development, and we apply this reference to analyze the transcriptomes of single cells. While lncRNAs are generally detected at low levels in bulk tissues, single-cell transcriptomics of hundreds of neocortex cells reveal that many lncRNAs are abundantly expressed in individual cells and are cell type-specific. Notably, LOC646329 is a lncRNA enriched in single radial glia cells but is detected at low abundance in tissues. CRISPRi knockdown of LOC646329 indicates that this lncRNA regulates cell proliferation. Conclusion: The discrete and abundant expression of lncRNAs among individual cells has important implications for both their biological function and utility for distinguishing neural cell types. C1 [Liu, Siyuan John; Attenello, Frank J.; He, Daniel; Diaz, Aaron A.; Lim, Daniel A.] Univ Calif San Francisco, Dept Neurol Surg, Ray & Dagmar Dolby Regenerat Med Bldg, San Francisco, CA 94143 USA. [Liu, Siyuan John; Nowakowski, Tomasz J.; Pollen, Alex A.; Lui, Jan H.; Attenello, Frank J.; He, Daniel; Kriegstein, Arnold R.; Diaz, Aaron A.; Lim, Daniel A.] Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA 94143 USA. [Nowakowski, Tomasz J.; Pollen, Alex A.; Lui, Jan H.; Kriegstein, Arnold R.] Dept Neurol, San Francisco, CA 94143 USA. [Horlbeck, Max A.; Weissman, Jonathan S.] Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA. [Horlbeck, Max A.; Weissman, Jonathan S.] Howard Hughes Med Inst, San Francisco, CA 94143 USA. [Horlbeck, Max A.; Weissman, Jonathan S.] Calif Inst Quantitat Biomed Res, San Francisco, CA 94143 USA. [Horlbeck, Max A.; Weissman, Jonathan S.] Ctr RNA Syst Biol, San Francisco, CA 94143 USA. [Liu, Siyuan John; Nowakowski, Tomasz J.; Pollen, Alex A.; Lui, Jan H.; Horlbeck, Max A.; Attenello, Frank J.; He, Daniel; Weissman, Jonathan S.; Kriegstein, Arnold R.; Diaz, Aaron A.; Lim, Daniel A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Lim, Daniel A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Lui, Jan H.] Stanford Univ, Dept Biol, Stanford, CA 94305 USA. [Lui, Jan H.] Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA. RP Diaz, AA; Lim, DA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, Ray & Dagmar Dolby Regenerat Med Bldg, San Francisco, CA 94143 USA. EM Aaron.Diaz@ucsf.edu; Daniel.Lim@ucsf.edu FU VA [5I01 BX000252-06]; NIH [1R01NS091544-01A1, U01 MH105989, F30 NS092319-01]; NIH SPORE DRP; Shurl and Kay Curci Foundation; Hana Jabsheh Initiative; UCSF-CTSI [UL1 TR000004]; Damon Runyon Cancer Research Foundation [DRG-2166-13] FX This project was supported by VA 5I01 BX000252-06, NIH 1R01NS091544-01A1, NIH SPORE DRP, the Shurl and Kay Curci Foundation, and the Hana Jabsheh Initiative (to DAL), UCSF-CTSI UL1 TR000004 (to AAD), and NIH U01 MH105989 to ARK. SJL is supported by NIH F30 NS092319-01. AAP is supported by a Damon Runyon Cancer Research Foundation postdoctoral fellowship (DRG-2166-13). NR 59 TC 17 Z9 17 U1 3 U2 25 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1465-6906 EI 1474-760X J9 GENOME BIOL JI Genome Biol. PD APR 14 PY 2016 VL 17 AR 67 DI 10.1186/s13059-016-0932-1 PG 17 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA DJ5WK UT WOS:000374281300001 PM 27081004 ER PT J AU Aras, MA Teerlink, JR AF Aras, Mandar A. Teerlink, John R. TI Lung ultrasound: a 'B-line' to the prediction of decompensated heart failure SO EUROPEAN HEART JOURNAL LA English DT Editorial Material ID PULMONARY CONGESTION; REHOSPITALIZATION C1 [Aras, Mandar A.; Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Teerlink, John R.] San Francisco VA Med Ctr, Sect Cardiol, 111C Bldg 203,Room 2A-49,4150 Clement St, San Francisco, CA 94121 USA. RP Teerlink, JR (reprint author), San Francisco VA Med Ctr, Sect Cardiol, 111C Bldg 203,Room 2A-49,4150 Clement St, San Francisco, CA 94121 USA. EM john.teerlink@ucsf.edu NR 11 TC 4 Z9 4 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD APR 14 PY 2016 VL 37 IS 15 BP 1252 EP 1254 DI 10.1093/eurheartj/ehw094 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DJ1TC UT WOS:000373985800018 PM 27080198 ER PT J AU He, BK Nohara, K Park, N Park, YS Guillory, B Zhao, ZY Garcia, JM Koike, N Lee, CC Takahashi, JS Yoo, SH Chen, Z AF He, Baokun Nohara, Kazunari Park, Noheon Park, Yong-Sung Guillory, Bobby Zhao, Zhaoyang Garcia, Jose M. Koike, Nobuya Lee, Cheng Chi Takahashi, Joseph S. Yoo, Seung-Hee Chen, Zheng TI The Small Molecule Nobiletin Targets the Molecular Oscillator to Enhance Circadian Rhythms and Protect against Metabolic Syndrome SO CELL METABOLISM LA English DT Article ID ORPHAN NUCLEAR RECEPTOR; REV-ERB-ALPHA; HIGH-FAT DIET; INSULIN-RESISTANCE; ROR-ALPHA; CITRUS FLAVONOIDS; LIPID-METABOLISM; GENE-EXPRESSION; T-CELLS; CLOCK AB Dysregulation of circadian rhythms is associated with metabolic dysfunction, yet it is unclear whether enhancing clock function can ameliorate metabolic disorders. In an unbiased chemical screen using fibroblasts expressing PER2::Luc, we identified Nobiletin (NOB), a natural polymethoxylated flavone, as a clock amplitude-enhancing small molecule. When administered to diet-induced obese (DIO) mice, NOB strongly counteracted metabolic syndrome and augmented energy expenditure and locomotor activity in a Clock gene-dependent manner. In db/db mutant mice, the clock is also required for the mitigating effects of NOB on metabolic disorders. In DIO mouse liver, NOB enhanced clock protein levels and elicited pronounced gene expression remodeling. We identified retinoid acid receptor-related orphan receptors as direct targets of NOB, revealing a pharmacological intervention that enhances circadian rhythms to combat metabolic disease via the circadian gene network. C1 [He, Baokun; Nohara, Kazunari; Park, Yong-Sung; Zhao, Zhaoyang; Lee, Cheng Chi; Yoo, Seung-Hee; Chen, Zheng] Univ Texas Hlth Sci Ctr Houston, Dept Biochem & Mol Biol, 6431 Fannin St, Houston, TX 77030 USA. [Park, Noheon; Takahashi, Joseph S.] Univ Texas SW Med Ctr Dallas, Dept Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. [Guillory, Bobby; Garcia, Jose M.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Ctr Translat Res Inflammatory Dis, MCL,Div Endocrinol Diabet & Metab, Houston, TX 77030 USA. [Guillory, Bobby; Garcia, Jose M.] Baylor Coll Med, Huffington Ctr Aging, Dan L Duncan Canc Ctr, Dept Med & Mol & Cell Biol, Houston, TX 77030 USA. [Koike, Nobuya] Kyoto Prefectural Univ Med, Dept Physiol & Syst Biosci, Kyoto 6028566, Japan. [Takahashi, Joseph S.] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA. [Garcia, Jose M.] Univ Washington, VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, 1660 South Columbian Way S-182-GRECC, Seattle, WA 98108 USA. RP Chen, Z (reprint author), Univ Texas Hlth Sci Ctr Houston, Dept Biochem & Mol Biol, 6431 Fannin St, Houston, TX 77030 USA. EM zheng.chen.1@uth.tmc.edu OI Takahashi, Joseph/0000-0003-0384-8878 FU Welch Foundation [AU-1731]; American Heart Association [11SDG7600045]; NIH/National Institute on Aging [R01AG045828]; NIH/National Institute of General Medical Sciences [R01 GM114424]; Texas Medical Center Digestive Disease Center P/F Awards (National Institute of Diabetes and Digestive and Kidney Diseases) [P30-DK056338]; U.S.A. Department of Veterans Affairs [BX000507, CX000174]; NIH [AG040583, T32AG000183, NIH/DP1 OD000895]; JSPS [26293048]; Uehara Memorial Foundation FX We thank C. Lee for reagent; C. Stephan, E. Song, C. Ayoub, and T.M. Tran for technical support; and S. McKnight, C. Green, M. Bogdanov, G. Lee, D. Marshak, C. Wu, P. Griffin, R. Garcia-Ordonez, and G. Gloston for helpful advice and/or critical reading of the manuscript. This work is supported in part by The Welch Foundation (AU-1731), the American Heart Association (11SDG7600045), and the NIH/National Institute on Aging (R01AG045828) to Z.C., NIH/National Institute of General Medical Sciences (R01 GM114424) to S.-H.Y., Texas Medical Center Digestive Disease Center P/F Awards (National Institute of Diabetes and Digestive and Kidney Diseases Center Grant P30-DK056338) to S.-H.Y. and Z.C., U.S.A. Department of Veterans Affairs, BX000507 and CX000174; and NIH AG040583 to J.M.G., T32AG000183 to B.G., NIH/DP1 OD000895 to C.C.L., and JSPS KAKENHI (26293048) and the Uehara Memorial Foundation to N.K. J.S.T. is an Investigator in the Howard Hughes Medical Institute. NR 85 TC 15 Z9 15 U1 9 U2 15 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1550-4131 EI 1932-7420 J9 CELL METAB JI Cell Metab. PD APR 12 PY 2016 VL 23 IS 4 BP 610 EP 621 DI 10.1016/j.cmet.2016.03.007 PG 12 WC Cell Biology; Endocrinology & Metabolism SC Cell Biology; Endocrinology & Metabolism GA DJ3RL UT WOS:000374123200010 PM 27076076 ER PT J AU Garrido, MM AF Garrido, Melissa M. TI Covariate Adjustment and Propensity Score SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Garrido, Melissa M.] James J Peters VA Med Ctr, 130 W Kingsbridge Rd,4A-17J, Bronx, NY USA. RP Garrido, MM (reprint author), James J Peters VA Med Ctr, 130 W Kingsbridge Rd,4A-17J, Bronx, NY USA. EM melissa.garrido@mssm.edu NR 3 TC 0 Z9 0 U1 3 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 12 PY 2016 VL 315 IS 14 BP 1521 EP 1522 DI 10.1001/jama.2015.19081 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DJ0EE UT WOS:000373873800026 PM 27115275 ER PT J AU Inohara, T Kohsaka, S Miyata, H Ueda, I Maekawa, Y Fukuda, K Cohen, DJ Kennedy, KF Rumsfeld, JS Spertus, JA AF Inohara, Taku Kohsaka, Shun Miyata, Hiroaki Ueda, Ikuko Maekawa, Yuichiro Fukuda, Keiichi Cohen, David J. Kennedy, Kevin F. Rumsfeld, John S. Spertus, John A. TI Performance and Validation of the US NCDR Acute Kidney Injury Prediction Model in Japan SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE external validation; percutaneous coronary intervention; risk model; serum creatinine ID PERCUTANEOUS CORONARY INTERVENTION; CONTRAST-INDUCED NEPHROPATHY; RENAL-FAILURE; APPROPRIATENESS; DATABASE; OUTCOMES; REGISTRY AB BACKGROUND Stratifying patient risk for acute kidney injury (AKI) prior to percutaneous coronary intervention (PCI) can enable clinicians to tailor their approach to minimize AKI. The National Cardiovascular Data Registry (NCDR) CathPCI Registry recently developed 2 prediction models: for AKI and AKI requiring dialysis (AKI-D). OBJECTIVES This study sought to externally validate the NCDR AKI and AKI-D models in a Japanese population. Determining the generalizability of the U.S. model could support quality improvement efforts in Japan. METHODS The NCDR prediction models were applied to 11,041 consecutive patients in the Japanese multicenter PCI registry. AKI was defined as an absolute increase >= 0.3 mg/dL or a relative increase of 50% in serum creatinine, in accordance with the definition of AKI Network criteria; AKI-D was defined as initiation of dialysis after PCI. Discrimination and calibration of the NCDR models were tested in the Japanese cohort. If the model was perfectly calibrated, the slope and intercept would equal 1.0 and 0.0, respectively. RESULTS In the Japanese PCI cohort, AKI and AKI-D occurred in 10.5% and 1.5% of patients, respectively. The NCDR AKI prediction model showed good discrimination (c-statistic = 0.76) and calibration (slope = 0.93 and intercept = -0.10) in both acute and nonacute PCI. The AKI-D prediction model had good discrimination (c-statistic = 0.92), but while the calibration slope was good (1.04), the intercept was significantly underestimated (0.96). However, this was corrected with recalibration (slope = 1.04 and intercept = -0.087). CONCLUSIONS In a Japanese population, the NCDR AKI models validly predict post-procedural AKI and, with recalibration, AKI-D. Prospective use of these models to inform clinical decision making should be tested as a means of reducing AKI after PCI in Japan. (C) 2016 by the American College of Cardiology Foundation. C1 [Inohara, Taku; Kohsaka, Shun; Ueda, Ikuko; Maekawa, Yuichiro; Fukuda, Keiichi] Keio Univ, Sch Med, Dept Cardiol, Tokyo 1608582, Japan. [Inohara, Taku] Hiratsuka City Hosp, Dept Cardiol, Hiratsuka, Kanagawa, Japan. [Miyata, Hiroaki] Keio Univ, Sch Med, Dept Hlth Policy & Management, Tokyo 1608582, Japan. [Cohen, David J.; Kennedy, Kevin F.; Spertus, John A.] Univ Missouri, Sch Med, St Lukes Mid Amer Heart Inst, Kansas City, MO 64108 USA. [Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA. RP Kohsaka, S (reprint author), Keio Univ, Sch Med, Dept Cardiol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan. EM kohsaka@cpnet.med.keio.ac.jp RI Fukuda, Keiichi/L-3777-2013 OI Kohsaka, Shun/0000-0003-3779-2972 FU Japan Society for the Promotion of Science [25460630, 80571398]; Pfizer Health Research Foundation; Pfizer Japan, Inc.; Bayer Pharmaceutical Co., Ltd. FX The present study was funded by the Grants-in-Aid for Scientific Research from Japan Society for the Promotion of Science (Grant Nos. 25460630, 80571398) and Pfizer Health Research Foundation. The funders had no role in the conduct of the study; in the collection, management, analysis, and interpretation of the data; or in the preparation or approval of the manuscript. Dr. Kohsaka has received unrestricted research grants for the Department of Cardiology, Keio University School of Medicine, from Pfizer Japan, Inc. and Bayer Pharmaceutical Co., Ltd. Dr. Rumsfeld is the Chief Science Officer of the National Cardiovascular Data Registry. Dr. Spertus is the principal investigator of a contract from the American College of Cardiology Foundation to analyze the National Cardiovascular Data Registry data; and has an equity interest in Health Outcomes Sciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Peter A. McCullough, MD, served as Guest Editor for this paper. NR 26 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD APR 12 PY 2016 VL 67 IS 14 BP 1715 EP 1722 DI 10.1016/j.jacc.2016.01.049 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DI3LP UT WOS:000373400500009 PM 27056778 ER PT J AU Coronado-Montoya, S Levis, AW Kwakkenbos, L Steele, RJ Turner, EH Thombs, BD AF Coronado-Montoya, Stephanie Levis, Alexander W. Kwakkenbos, Linda Steele, Russell J. Turner, Erick H. Thombs, Brett D. TI Reporting of Positive Results in Randomized Controlled Trials of Mindfulness-Based Mental Health Interventions SO PLOS ONE LA English DT Article ID QUALITY-OF-LIFE; COGNITIVE THERAPY; STRESS REDUCTION; PUBLICATION BIAS; EXCESS SIGNIFICANCE; PRIMARY OUTCOMES; METAANALYSIS; DEPRESSION; ANXIETY; PREVENTION AB Background A large proportion of mindfulness-based therapy trials report statistically significant results, even in the context of very low statistical power. The objective of the present study was to characterize the reporting of "positive" results in randomized controlled trials of mindfulness-based therapy. We also assessed mindfulness-based therapy trial registrations for indications of possible reporting bias and reviewed recent systematic reviews and meta-analyses to determine whether reporting biases were identified. Methods CINAHL, Cochrane CENTRAL, EMBASE, ISI, MEDLINE, PsycInfo, and SCOPUS databases were searched for randomized controlled trials of mindfulness-based therapy. The number of positive trials was described and compared to the number that might be expected if mindfulness-based therapy were similarly effective compared to individual therapy for depression. Trial registries were searched for mindfulness-based therapy registrations. CINAHL, Cochrane CENTRAL, EMBASE, ISI, MEDLINE, PsycInfo, and SCOPUS were also searched for mindfulness-based therapy systematic reviews and meta-analyses. Results 108 (87%) of 124 published trials reported >= 1 positive outcome in the abstract, and 109 (88%) concluded that mindfulness-based therapy was effective, 1.6 times greater than the expected number of positive trials based on effect size d = 0.55 (expected number positive trials = 65.7). Of 21 trial registrations, 13 (62%) remained unpublished 30 months post-trial completion. No trial registrations adequately specified a single primary outcome measure with time of assessment. None of 36 systematic reviews and meta-analyses concluded that effect estimates were overestimated due to reporting biases. Conclusions The proportion of mindfulnessbased therapy trials with statistically significant results may overstate what would occur in practice. C1 [Coronado-Montoya, Stephanie; Levis, Alexander W.; Kwakkenbos, Linda; Steele, Russell J.; Thombs, Brett D.] McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada. [Coronado-Montoya, Stephanie; Kwakkenbos, Linda; Thombs, Brett D.] McGill Univ, Dept Psychiat, Montreal, PQ, Canada. [Steele, Russell J.; Thombs, Brett D.] McGill Univ, Dept Math & Stat, Montreal, PQ, Canada. [Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Turner, Erick H.] Portland VA Med Ctr, Dept Psychiat, Portland, OR USA. [Thombs, Brett D.] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada. [Thombs, Brett D.] McGill Univ, Dept Med, Montreal, PQ, Canada. [Thombs, Brett D.] McGill Univ, Dept Educ & Counselling Psychol, Montreal, PQ, Canada. [Thombs, Brett D.] McGill Univ, Dept Psychol, Montreal, PQ, Canada. [Thombs, Brett D.] McGill Univ, Sch Nursing, Montreal, PQ, Canada. RP Thombs, BD (reprint author), McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada.; Thombs, BD (reprint author), McGill Univ, Dept Psychiat, Montreal, PQ, Canada.; Thombs, BD (reprint author), McGill Univ, Dept Math & Stat, Montreal, PQ, Canada.; Thombs, BD (reprint author), McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada.; Thombs, BD (reprint author), McGill Univ, Dept Med, Montreal, PQ, Canada.; Thombs, BD (reprint author), McGill Univ, Dept Educ & Counselling Psychol, Montreal, PQ, Canada.; Thombs, BD (reprint author), McGill Univ, Dept Psychol, Montreal, PQ, Canada.; Thombs, BD (reprint author), McGill Univ, Sch Nursing, Montreal, PQ, Canada. EM brett.thombs@mcgill.ca RI Steele, Russell/G-6926-2017 NR 71 TC 2 Z9 2 U1 6 U2 25 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 8 PY 2016 VL 11 IS 4 AR e0153220 DI 10.1371/journal.pone.0153220 PG 18 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DI6JK UT WOS:000373604800022 PM 27058355 ER PT J AU Kozlenkov, A Wang, MH Roussos, P Rudchenko, S Barbu, M Bibikova, M Klotzle, B Dwork, AJ Zhang, B Hurd, YL Koonin, EV Wegner, M Dracheva, S AF Kozlenkov, Alexey Wang, Minghui Roussos, Panos Rudchenko, Sergei Barbu, Mihaela Bibikova, Marina Klotzle, Brandy Dwork, Andrew J. Zhang, Bin Hurd, Yasmin L. Koonin, Eugene V. Wegner, Michael Dracheva, Stella TI Substantial DNA methylation differences between two major neuronal subtypes in human brain SO NUCLEIC ACIDS RESEARCH LA English DT Article ID EMBRYONIC STEM-CELLS; HUMAN HOUSEKEEPING GENES; RETT-SYNDROME; GABAERGIC INTERNEURONS; EPIGENETIC MEMORY; PREFRONTAL CORTEX; SITE RESOLUTION; MECP2 BINDS; RNA-SEQ; SCHIZOPHRENIA AB The brain is built from a large number of cell types which have been historically classified using location, morphology and molecular markers. Recent research suggests an important role of epigenetics in shaping and maintaining cell identity in the brain. To elucidate the role of DNA methylation in neuronal differentiation, we developed a new protocol for separation of nuclei from the two major populations of human prefrontal cortex neurons-GABAergic interneurons and glutamatergic (GLU) projection neurons. Major differences between the neuronal subtypes were revealed in CpG, non-CpG and hydroxymethylation (hCpG). A dramatically greater number of undermethylated CpG sites in GLU versus GABA neurons were identified. These differences did not directly translate into differences in gene expression and did not stem from the differences in hCpG methylation, as more hCpG methylation was detected in GLU versus GABA neurons. Notably, a comparable number of undermethylated non-CpG sites were identified in GLU and GABA neurons, and non-CpG methylation was a better predictor of subtype-specific gene expression compared to CpG methylation. Regions that are differentially methylated in GABA and GLU neurons were significantly enriched for schizophrenia risk loci. Collectively, our findings suggest that functional differences between neuronal subtypes are linked to their epigenetic specification. C1 [Kozlenkov, Alexey; Roussos, Panos; Dracheva, Stella] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Kozlenkov, Alexey; Roussos, Panos; Hurd, Yasmin L.; Dracheva, Stella] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. [Kozlenkov, Alexey; Roussos, Panos; Hurd, Yasmin L.; Dracheva, Stella] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Wang, Minghui; Roussos, Panos; Zhang, Bin] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. [Rudchenko, Sergei; Barbu, Mihaela] Hosp Special Surg, New York, NY 10021 USA. [Bibikova, Marina; Klotzle, Brandy] Illumina Inc, San Diego, CA 92122 USA. [Dwork, Andrew J.] Columbia Univ, Dept Psychiat, New York, NY 10032 USA. [Koonin, Eugene V.] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA. [Wegner, Michael] Univ Erlangen Nurnberg, Emil Fischer Zentrum, Inst Biochem, D-91054 Erlangen, Germany. RP Dracheva, S (reprint author), James J Peters VA Med Ctr, Bronx, NY 10468 USA.; Dracheva, S (reprint author), Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA.; Dracheva, S (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. EM Stella.Dracheva@mssm.edu RI Roussos, Panos/J-7090-2013 OI Roussos, Panos/0000-0002-4640-6239 FU National Institute of Mental Health [R21MH103877]; U.S. Department of Veterans Affairs [BX001829]; U.S. Department of Health and Human Services; National Institute of Health FX National Institute of Mental Health [R21MH103877 that is a part of the PsychENCODE consortium to S.D.]; U.S. Department of Veterans Affairs [Merit Review Award BX001829 to S.D.]; Intramural funds of the U.S. Department of Health and Human Services to National Library of Medicine (to E.V.K.). Funding for open access charge: National Institute of Health. NR 96 TC 7 Z9 7 U1 4 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-1048 EI 1362-4962 J9 NUCLEIC ACIDS RES JI Nucleic Acids Res. PD APR 7 PY 2016 VL 44 IS 6 BP 2593 EP 2612 DI 10.1093/nar/gkv1304 PG 20 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DJ9YW UT WOS:000374570500020 PM 26612861 ER PT J AU Callahan, A Abeyruwan, SW Al-Ali, H Sakurai, K Ferguson, AR Popovich, PG Shah, NH Visser, U Bixby, JL Lemmon, VP AF Callahan, Alison Abeyruwan, Saminda W. Al-Ali, Hassan Sakurai, Kunie Ferguson, Adam R. Popovich, Phillip G. Shah, Nigam H. Visser, Ubbo Bixby, John L. Lemmon, Vance P. TI RegenBase: a knowledge base of spinal cord injury biology for translational research SO DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION LA English DT Article ID GROWTH-FACTOR RECEPTOR; KINASE INHIBITOR SELECTIVITY; THROUGHPUT SCREENING DATA; ACTIVATED PROTEIN-KINASE; BIOASSAY ONTOLOGY BAO; AXON REGENERATION; NEURITE OUTGROWTH; PHENOTYPE ONTOLOGY; GENOME DATABASE; DRUG TARGETS AB Spinal cord injury (SCI) research is a data-rich field that aims to identify the biological mechanisms resulting in loss of function and mobility after SCI, as well as develop therapies that promote recovery after injury. SCI experimental methods, data and domain knowledge are locked in the largely unstructured text of scientific publications, making large scale integration with existing bioinformatics resources and subsequent analysis infeasible. The lack of standard reporting for experiment variables and results also makes experiment replicability a significant challenge. To address these challenges, we have developed RegenBase, a knowledge base of SCI biology. RegenBase integrates curated literature-sourced facts and experimental details, raw assay data profiling the effect of compounds on enzyme activity and cell growth, and structured SCI domain knowledge in the form of the first ontology for SCI, using Semantic Web representation languages and frameworks. RegenBase uses consistent identifier schemes and data representations that enable automated linking among RegenBase statements and also to other biological databases and electronic resources. By querying RegenBase, we have identified novel biological hypotheses linking the effects of perturbagens to observed behavioral outcomes after SCI. RegenBase is publicly available for browsing, querying and download. C1 [Callahan, Alison; Shah, Nigam H.] Stanford Univ, Stanford Ctr Biomed Informat Res, Stanford, CA 94305 USA. [Abeyruwan, Saminda W.; Visser, Ubbo] Univ Miami, Dept Comp Sci, Coral Gables, FL 33146 USA. [Al-Ali, Hassan; Sakurai, Kunie; Bixby, John L.; Lemmon, Vance P.] Univ Miami, Miami Project Cure Paralysis, Sch Med, Miami, FL 33136 USA. [Ferguson, Adam R.] Univ Calif San Francisco, Dept Neurol Surg, Brain & Spinal Injury Ctr BASIC, San Francisco, CA 94143 USA. [Ferguson, Adam R.] San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Popovich, Phillip G.] Ohio State Univ, Ctr Brain & Spinal Cord Repair, Columbus, OH 43210 USA. [Popovich, Phillip G.] Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA. [Bixby, John L.; Lemmon, Vance P.] Univ Miami, Ctr Computat Sci, Coral Gables, FL 33146 USA. [Bixby, John L.] Univ Miami, Dept Cellular & Mol Pharmacol, Sch Med, Miami, FL 33136 USA. RP Lemmon, VP (reprint author), Univ Miami, Miami Project Cure Paralysis, Sch Med, Miami, FL 33136 USA.; Lemmon, VP (reprint author), Univ Miami, Ctr Computat Sci, Coral Gables, FL 33146 USA. EM vlemmon@miami.edu OI Lemmon, Vance/0000-0003-3550-7576 FU National Institute of Child Health and Human Development [HD057632]; National Institute of Neurological Disorders and Stroke [NS080145]; University of Miami Center for Computational Science; Miami Project to Cure Paralysis FX National Institute of Child Health and Human Development (HD057632); National Institute of Neurological Disorders and Stroke (NS080145); University of Miami Center for Computational Science and the Miami Project to Cure Paralysis. NR 73 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1758-0463 J9 DATABASE-OXFORD JI Database PD APR 7 PY 2016 AR baw040 DI 10.1093/database/baw040 PG 13 WC Mathematical & Computational Biology SC Mathematical & Computational Biology GA DJ3GZ UT WOS:000374094100001 ER PT J AU Tagge, I O'Connor, A Chaudhary, P Pollaro, J Berlow, Y Chalupsky, M Bourdette, D Woltjer, R Johnson, M Rooney, W AF Tagge, Ian O'Connor, Audrey Chaudhary, Priya Pollaro, Jim Berlow, Yosef Chalupsky, Megan Bourdette, Dennis Woltjer, Randy Johnson, Mac Rooney, William TI Spatio-Temporal Patterns of Demyelination and Remyelination in the Cuprizone Mouse Model SO PLOS ONE LA English DT Article ID CENTRAL-NERVOUS-SYSTEM; CORPUS-CALLOSUM; MAGNETIZATION-TRANSFER; SUBVENTRICULAR ZONE; MULTIPLE-SCLEROSIS; WHITE-MATTER; IN-VIVO; REGIONAL HETEROGENEITY; BRAIN; MRI AB Cuprizone administration in mice provides a reproducible model of demyelination and spontaneous remyelination, and has been useful in understanding important aspects of human disease, including multiple sclerosis. In this study, we apply high spatial resolution quantitative MRI techniques to establish the spatio-temporal patterns of acute demyelination in C57BL/6 mice after 6 weeks of cuprizone administration, and subsequent remyelination after 6 weeks of post-cuprizone recovery. MRI measurements were complemented with Black Gold II stain for myelin and immunohistochemical stains for associated tissue changes. Gene expression was evaluated using the Allen Gene Expression Atlas. Twenty-five C57BL/6 male mice were split into control and cuprizone groups; MRI data were obtained at baseline, after 6 weeks of cuprizone, and 6 weeks post-cuprizone. High-resolution (100 mu m isotropic) whole-brain coverage magnetization transfer ratio (MTR) parametric maps demonstrated concurrent caudal-to-rostral and medial-to-lateral gradients of MTR decrease within corpus callosum (CC) that correlated well with demyelination assessed histologically. Our results show that demyelination was not limited to the midsagittal line of the corpus callosum, and also that opposing gradients of demyelination occur in the lateral and medial CC. T-2-weighted MRI gray/white matter contrast was strong at baseline, weak after 6 weeks of cuprizone treatment, and returned to a limited extent after recovery. MTR decreases during demyelination were observed throughout the brain, most clearly in callosal white matter. Myelin damage and repair appear to be influenced by proximity to oligodendrocyte progenitor cell populations and exhibit an inverse correlation with myelin basic protein gene expression. These findings suggest that susceptibility to injury and ability to repair vary across the brain, and whole-brain analysis is necessary to accurately characterize this model. Whole-brain parametric mapping across time is essential for gaining a real understanding of disease processes in-vivo. MTR increases in healthy mice throughout adolescence and adulthood were observed, illustrating the need for appropriate age-matched controls. Elucidating the unique and site-specific demyelination in the cuprizone model may offer new insights into in mechanisms of both damage and repair in human demyelinating diseases. C1 [Tagge, Ian; O'Connor, Audrey; Pollaro, Jim; Berlow, Yosef; Rooney, William] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. [Tagge, Ian; Rooney, William] Oregon Hlth & Sci Univ, Biomed Engn, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. [Chaudhary, Priya; Bourdette, Dennis; Rooney, William] Oregon Hlth & Sci Univ, Neurol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. [Chalupsky, Megan; Woltjer, Randy] Oregon Hlth & Sci Univ, Pathol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. [Bourdette, Dennis] Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. [Johnson, Mac] Vertex Pharmaceut Inc, 50 Northern Ave, Boston, MA 02210 USA. RP Tagge, I; Rooney, W (reprint author), Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM taggei@ohsu.edu; rooneyw@ohsu.edu OI Tagge, Ian/0000-0002-5260-7117 FU Vertex Pharmaceuticals, Inc.; NIA [P30 AG008017] FX The primary funder, Vertex Pharmaceuticals, Inc., provided a grant to investigate MRI biomarkers of myelination which supported experimental costs and partial salary support for authors AO'C, JP, IT, and WR, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. MJ, on behalf of Vertex Pharmaceuticals, Inc., contributed to study design insofar as suggesting the use of cuprizone in mice to validate MRI biomarkers of myelin content in-vivo. The funders had no role in data acquisition, processing, or analysis. MJ reviewed the paper prior to submission and offered comments on presentation, but otherwise did not have a role in the decision to publish.; Evan Calkins, Danielle Galipeau, and David Clark provided excellent technical support in histological processing. We would like to express our thanks to the Advanced Light Microscopy Core (P30 NS061800) Facility at the Oregon Health & Science University. Immunohistochemical studies were performed in the laboratory of the Oregon Brain Bank and the Oregon Alzheimer's Disease Center (supported by NIA P30 AG008017). NR 60 TC 4 Z9 4 U1 3 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD APR 7 PY 2016 VL 11 IS 4 AR e0152480 DI 10.1371/journal.pone.0152480 PG 24 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DI6KO UT WOS:000373608000021 PM 27054832 ER PT J AU Garg, A Sharma, A Krishnamoorthy, P Bagae, S Mukherjee, D AF Garg, Aakash Sharma, Abhishek Krishnamoorthy, Parasuram Bagae, Solomon Mukherjee, Debabrata TI ROLE OF NIACIN IN CURRENT CLINICAL PRACTICE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROL TRIALS SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 65th Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC) CY APR 02-04, 2016 CL Chicago, IL SP Amer Coll Cardiol C1 [Garg, Aakash; Sharma, Abhishek; Krishnamoorthy, Parasuram; Bagae, Solomon; Mukherjee, Debabrata] James J Peters VA Hosp, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD APR 5 PY 2016 VL 67 IS 13 SU S MA 1271-383 BP 2025 EP 2025 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DK8PH UT WOS:000375188702871 ER PT J AU Psotka, M Schiller, N Whooley, M Mishra, R AF Psotka, Mitchell Schiller, Nelson Whooley, Mary Mishra, Rakesh TI ASSOCIATION OF FIVE-YEAR CHANGE IN N-TERMINAL FRAGMENT OF THE PROHORMONE BRAIN-TYPE NATRIURETIC PEPTIDE WITH CHANGE IN LEFT VENTRICULAR MASS AND INCIDENT HYPERTROPHY IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE: THE HEART AND SOUL STUDY SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 65th Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC) CY APR 02-04, 2016 CL Chicago, IL SP Amer Coll Cardiol C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD APR 5 PY 2016 VL 67 IS 13 SU S MA 1124M-09 BP 2084 EP 2084 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DK8PH UT WOS:000375188702930 ER PT J AU Valle, J Graham, L Thiruvoipati, T Armstrong, E Hawn, MT Maddox, T Bradley, S AF Valle, Javier Graham, Laura Thiruvoipati, Thejasvi Armstrong, Ehrin Hawn, Mary T. Maddox, Thomas Bradley, Steven TI IS PREOPERATIVE STRESS TESTING ASSOCIATED WITH 30-DAY POSTOPERATIVE MORTALITY IN PATIENTS PRIOR PCI UNDERGOING NONCARDIAC SURGERY: INSIGHTS FROM THE VETERANS AFFAIRS HEALTH CARE SYSTEM SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 65th Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC) CY APR 02-04, 2016 CL Chicago, IL SP Amer Coll Cardiol C1 Vet Affairs Eastern Colorado Hlth Care Syst, Denver, CO USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD APR 5 PY 2016 VL 67 IS 13 SU S MA 912-04 BP 2110 EP 2110 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DK8PH UT WOS:000375188702956 ER PT J AU Xu, RJ Wang, K Mileva, I Hannun, YA Obeid, LM Mao, CG AF Xu, Ruijuan Wang, Kai Mileva, Izolda Hannun, Yusuf A. Obeid, Lina M. Mao, Cungui TI Alkaline ceramidase 2 and its bioactive product sphingosine are novel regulators of the DNA damage response SO ONCOTARGET LA English DT Article DE ceramide; Golgi; p53; programmed cell death; reactive oxygen species ID RADIATION-INDUCED APOPTOSIS; INDUCED CELL-DEATH; CANCER-CELLS; MITOCHONDRIAL PATHWAY; CONFERS RESISTANCE; OXIDATIVE STRESS; UP-REGULATION; HELA-CELLS; ACID; SPHINGOSINE-1-PHOSPHATE AB Human cells respond to DNA damage by elevating sphingosine, a bioactive sphingolipid that induces programmed cell death (PCD) in response to various forms of stress, but its regulation and role in the DNA damage response remain obscure. Herein we demonstrate that DNA damage increases sphingosine levels in tumor cells by upregulating alkaline ceramidase 2 (ACER2) and that the upregulation of the ACER2/sphingosine pathway induces PCD in response to DNA damage by increasing the production of reactive oxygen species (ROS). Treatment with the DNA damaging agent doxorubicin increased both ACER2 expression and sphingosine levels in HCT116 cells in a dose-dependent manner. ACER2 overexpression increased sphingosine in HeLa cells whereas knocking down ACER2 inhibited the doxorubicin-induced increase in sphingosine in HCT116 cells, suggesting that DNA damage elevates sphingosine by upregulating ACER2. Knocking down ACER2 inhibited an increase in the apoptotic and necrotic cell population and the cleavage of poly ADP ribose polymerase (PARP) in HCT116 cells in response to doxorubicin as well as doxorubicin-induced release of lactate dehydrogenase (LDH) from these cells. Similar to treatment with doxorubicin, ACER2 overexpression induced an increase in the apoptotic and necrotic cell population and PARP cleavage in HeLa cells and LDH release from cells, suggesting that ACER2 upregulation mediates PCD in response to DNA damage through sphingosine. Mechanistic studies demonstrated that the upregulation of the ACER2/sphingosine pathway induces PCD by increasing ROS levels. Taken together, these results suggest that the ACER2/sphingosine pathway mediates PCD in response to DNA damage through ROS production. C1 [Xu, Ruijuan; Wang, Kai; Hannun, Yusuf A.; Obeid, Lina M.; Mao, Cungui] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA. [Xu, Ruijuan; Wang, Kai; Hannun, Yusuf A.; Obeid, Lina M.; Mao, Cungui] SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA. [Mileva, Izolda] SUNY Stony Brook, Lipid Core Facil, Stony Brook, NY 11794 USA. [Obeid, Lina M.] Ralph H Johnson Vet Adm Hosp, Stony Brook, NY 11794 USA. RP Mao, CG (reprint author), SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA.; Mao, CG (reprint author), SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA. EM cungui.mao@stonybrook.edu FU National Institutes of Health Grants [R01CA104834, R01CA163825, P20RR017677, P01CA097132] FX This work was supported, in whole or in part, by National Institutes of Health Grants R01CA104834 (to C.M.), R01CA163825 (to C.M), P20RR017677 (to L.M.O.), and P01CA097132 (to Y.A.H). NR 54 TC 2 Z9 3 U1 0 U2 2 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD APR 5 PY 2016 VL 7 IS 14 BP 18440 EP 18457 PG 18 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DL5TE UT WOS:000375699000091 PM 26943039 ER PT J AU Downs, JR O'Malley, PG AF Downs, John R. O'Malley, Patrick G. TI Management of Dyslipidemia for Cardiovascular Disease Risk Reduction RESPONSE SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 [Downs, John R.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [O'Malley, Patrick G.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. RP Downs, JR (reprint author), South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 4 TC 0 Z9 0 U1 2 U2 4 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 5 PY 2016 VL 164 IS 7 BP 509 EP 510 DI 10.7326/L15-0522 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DI6QP UT WOS:000373625300018 PM 27043985 ER PT J AU Weisbord, SD Palevsky, PM AF Weisbord, Steven D. Palevsky, Paul M. TI Prevention Strategies for Contrast-Induced Nephropathy SO ANNALS OF INTERNAL MEDICINE LA English DT Letter ID ASSOCIATION TASK-FORCE; PRACTICE GUIDELINES C1 [Weisbord, Steven D.; Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. OI Palevsky, Paul/0000-0002-7334-5400 NR 5 TC 0 Z9 0 U1 0 U2 1 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 5 PY 2016 VL 164 IS 7 BP 511 EP 511 DI 10.7326/L16-0098 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA DI6QP UT WOS:000373625300021 PM 27043990 ER PT J AU Siu, AL Bibbins-Domingo, K Grossman, DC Davidson, KW Epling, JW Garcia, FAR Gillman, M Kemper, AR Krist, AH Kurth, AE Landefeld, CS Mangione, CM Harper, DM Phillips, WR Phipps, MG Pignone, MP AF Siu, Albert L. Bibbins-Domingo, Kirsten Grossman, David C. Davidson, Karina W. Epling, John W., Jr. Garcia, Francisco A. R. Gillman, Matthew Kemper, Alex R. Krist, Alex H. Kurth, Ann E. Landefeld, C. Seth Mangione, Carol M. Harper, Diane M. Phillips, William R. Phipps, Maureen G. Pignone, Michael P. CA USPSTF TI Screening for Chronic Obstructive Pulmonary Disease US Preventive Services Task Force Recommendation Statement SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; SMOKING-CESSATION; COPD; QUESTIONNAIRE; SPIROMETRY; SMOKERS AB IMPORTANCE About 14% of US adults aged 40 to 79 years have chronic obstructive pulmonary disease (COPD), and it is the third leading cause of death in the United States. Persons with severe COPD are often unable to participate in normal physical activity due to deterioration of lung function. OBJECTIVE To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for COPD in asymptomatic adults. EVIDENCE REVIEW The USPSTF reviewed the evidence on whether screening for COPD in asymptomatic adults (those who do not recognize or report respiratory symptoms) improves health outcomes. The USPSTF reviewed the diagnostic accuracy of screening tools (including prescreening questionnaires and spirometry); whether screening for COPD improves the delivery and uptake of targeted preventive services, such as smoking cessation or relevant immunizations; and the possible harms of screening for and treatment of mild to moderate COPD. FINDINGS Similar to 2008, the USPSTF did not find evidence that screening for COPD in asymptomatic persons improves health-related quality of life, morbidity, or mortality. The USPSTF determined that early detection of COPD, before the development of symptoms, does not alter the course of the disease or improve patient outcomes. The USPSTF concludes with moderate certainty that screening for COPD in asymptomatic persons has no net benefit. CONCLUSIONS AND RECOMMENDATION The USPSTF recommends against screening for COPD in asymptomatic adults. (D recommendation) C1 [Siu, Albert L.] Mt Sinai Sch Med, New York, NY USA. [Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Bibbins-Domingo, Kirsten] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Grossman, David C.] Grp Hlth Res Inst, Seattle, WA USA. [Davidson, Karina W.] Columbia Univ, New York, NY USA. [Epling, John W., Jr.] SUNY Upstate Med Univ, Syracuse, NY 13210 USA. [Garcia, Francisco A. R.] Pima Cty Dept Hlth, Tucson, AZ USA. [Gillman, Matthew] Harvard Univ, Sch Med, Boston, MA USA. [Gillman, Matthew] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Kemper, Alex R.] Duke Univ, Durham, NC USA. [Krist, Alex H.] Fairfax Family Practice, Fairfax, VA USA. [Krist, Alex H.] Virginia Commonwealth Univ, Richmond, VA 23284 USA. [Kurth, Ann E.] Yale Univ, Sch Nursing, West Haven, CT USA. [Landefeld, C. Seth] Univ Alabama Birmingham, Birmingham, AL USA. [Mangione, Carol M.] Univ Calif Los Angeles, Los Angeles, CA USA. [Harper, Diane M.] Univ Louisville, Louisville, KY 40292 USA. [Phillips, William R.] Univ Washington, Seattle, WA 98195 USA. [Phipps, Maureen G.] Brown Univ, Providence, RI 02912 USA. [Pignone, Michael P.] Univ N Carolina, Chapel Hill, NC USA. RP Siu, AL (reprint author), Mt Sinai Sch Med, New York, NY USA. OI Epling, John W/0000-0001-9445-8669; Phillips, William/0000-0003-2802-4349 NR 18 TC 11 Z9 11 U1 1 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 5 PY 2016 VL 315 IS 13 BP 1372 EP 1377 DI 10.1001/jama.2016.2638 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DI3EP UT WOS:000373381500021 ER PT J AU Huber, BR Meabon, JS Hoffer, ZS Zhang, J Hoekstra, JG Pagulayan, KF McMillan, PJ Mayer, CL Banks, WA Kraemer, BC Raskind, MA McGavern, DB Peskind, ER Cook, DG AF Huber, B. R. Meabon, J. S. Hoffer, Z. S. Zhang, J. Hoekstra, J. G. Pagulayan, K. F. McMillan, P. J. Mayer, C. L. Banks, W. A. Kraemer, B. C. Raskind, M. A. McGavern, D. B. Peskind, E. R. Cook, D. G. TI BLAST EXPOSURE CAUSES DYNAMIC MICROGLIAL/MACROPHAGE RESPONSES AND MICRODOMAINS OF BRAIN MICROVESSEL DYSFUNCTION SO NEUROSCIENCE LA English DT Article DE blood-brain barrier; two-photon microscopy; neuropathology; microglia; macrophages ID CHRONIC TRAUMATIC ENCEPHALOPATHY; IN-VIVO; MICROGLIAL ACTIVATION; WHITE-MATTER; MOUSE MODEL; INJURY; BLOOD; BARRIER; CORTEX; IMPACT AB Exposure to blast overpressure (BOP) is associated with behavioral, cognitive, and neuroimaging abnormalities. We investigated the dynamic responses of cortical vasculature and its relation to microglia/macrophage activation in mice using intravital two-photon microscopy following mild blast exposure. We found that blast caused vascular dysfunction evidenced by microdomains of aberrant vascular permeability. Microglial/macrophage activation was specifically associated with these restricted microdomains, as evidenced by rapid microglial process retraction, increased ameboid morphology, and escape of blood-borne Q-dot tracers that were internalized in microglial/macrophage cell bodies and phagosome-like compartments. Microdomains of cortical vascular disruption and microglial/macrophage activation were also associated with aberrant tight junction morphology that was more prominent after repetitive (3 x) blast exposure. Repetitive, but not single, BOPs also caused TNF alpha elevation two weeks post-blast. In addition, following a single BOP we found that aberrantly phosphorylated tau rapidly accumulated in perivascular domains, but cleared within four hours, suggesting it was removed from the perivascular area, degraded, and/or dephosphorylated. Taken together these findings argue that mild blast exposure causes an evolving CNS insult that is initiated by discrete disturbances of vascular function, thereby setting the stage for more protracted and more widespread neuro-inflammatory responses. Published by Elsevier Ltd. on behalf of IBRO. C1 [Huber, B. R.] Boston Univ, VA Jamaica Plain, Dept Neurol, Sch Med, Jamaica Plain, MA USA. [Meabon, J. S.; Pagulayan, K. F.; McMillan, P. J.; Mayer, C. L.; Raskind, M. A.; Peskind, E. R.] VA Puget Sound Healthcare Syst, Northwest Network Mental Illness Res Educ & Clin, Seattle, WA USA. [Meabon, J. S.; Pagulayan, K. F.; McMillan, P. J.; Mayer, C. L.; Raskind, M. A.; Peskind, E. R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98108 USA. [Hoffer, Z. S.] US Army, Madigan Army Med Ctr, Joint Base Lewis Mcchord, WA USA. [Zhang, J.; Hoekstra, J. G.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98108 USA. [Banks, W. A.; Kraemer, B. C.; Cook, D. G.] Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. [Banks, W. A.; Kraemer, B. C.; Cook, D. G.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98108 USA. [McGavern, D. B.] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA. [Cook, D. G.] Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98108 USA. RP Cook, DG (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med, 1660 South Columbian Way, Seattle, WA 98108 USA. EM dgcook@u.washington.edu OI Hoekstra, Jake/0000-0001-6597-5878 FU Department of Veterans Affairs Office of Research and Development Medical Research Service; VA Rehabilitation Research and Development Service; University of Washington Royalty Research Fund [R01AG046619]; Northwest Network Mental Illness Research, Education and Clinical Center; Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs; NIH [T32 AG000258]; VA CSR&D Career Development Award [IK2 CX00516] FX This work was supported by the Department of Veterans Affairs Office of Research and Development Medical Research Service (D.G.C., B.C.K.), VA Rehabilitation Research and Development Service (E.R.P.), University of Washington Royalty Research Fund (D.G.C.); R01AG046619 (W.A.B.); Northwest Network Mental Illness Research, Education and Clinical Center (E.R.P., B.R.H., J.S.M., K.F.P., P.J.M., C.L.M.), Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs (B.R.H.); NIH T32 AG000258 (J.S.M.), VA CSR&D Career Development Award Program #IK2 CX00516 (K.F.P.). We thank Dr. Gerard Schellenberg (Univ. Pennsylvania) for providing Tau knock-out samples. NR 41 TC 3 Z9 3 U1 2 U2 15 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 EI 1873-7544 J9 NEUROSCIENCE JI Neuroscience PD APR 5 PY 2016 VL 319 BP 206 EP 220 DI 10.1016/j.neuroscience.2016.01.022 PG 15 WC Neurosciences SC Neurosciences & Neurology GA DD9RD UT WOS:000370262400019 PM 26777891 ER PT J AU Yetish, G Kaplan, H Gurven, M Wood, B Pontzer, H Manger, PR Wilson, C McGregor, R Siegel, JM AF Yetish, Gandhi Kaplan, Hillard Gurven, Michael Wood, Brian Pontzer, Herman Manger, Paul R. Wilson, Charles McGregor, Ronald Siegel, Jerome M. TI Ancestral sleep Response SO CURRENT BIOLOGY LA English DT Letter C1 [Yetish, Gandhi; Kaplan, Hillard] Univ New Mexico, Dept Anthropol, MSC01-1040, Albuquerque, NM 87131 USA. [Gurven, Michael] Univ Calif Santa Barbara, Dept Anthropol, 1210 Cheadle Hall, Santa Barbara, CA 93106 USA. [Wood, Brian] Yale Univ, Dept Anthropol, 10 Sachem St, New Haven, CT 06511 USA. [Pontzer, Herman] CUNY Hunter Coll, Dept Anthropol, 695 Pk Ave, New York, NY 10065 USA. [Manger, Paul R.] Univ Witwatersrand, Sch Anat Sci, 7 York Rd, ZA-2193 Johannesburg, South Africa. [Wilson, Charles] Univ Calif Los Angeles, Dept Neurol, 10833 Conte Ave, Los Angeles, CA 90095 USA. [Wilson, Charles; Siegel, Jerome M.] Univ Calif Los Angeles, Brain Res Inst, 10833 Conte Ave, Los Angeles, CA 90095 USA. [McGregor, Ronald; Siegel, Jerome M.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Siegel, Jerome M.] VA Greater Angeles Healthcare Syst, 16111 Plummer St, Los Angeles, CA 91343 USA. RP Siegel, JM (reprint author), Univ Calif Los Angeles, Brain Res Inst, 10833 Conte Ave, Los Angeles, CA 90095 USA.; Siegel, JM (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.; Siegel, JM (reprint author), VA Greater Angeles Healthcare Syst, 16111 Plummer St, Los Angeles, CA 91343 USA. EM jsiegel@ucla.edu NR 10 TC 0 Z9 0 U1 4 U2 10 PU CELL PRESS PI CAMBRIDGE PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA SN 0960-9822 EI 1879-0445 J9 CURR BIOL JI Curr. Biol. PD APR 4 PY 2016 VL 26 IS 7 BP R273 EP R274 PG 2 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA DI1RP UT WOS:000373273600008 PM 27046810 ER PT J AU Braquehais, MD Eiroa-Orosa, FJ Holmes, KM Lusilla, P Bravo, M Mozo, X Mezzatesta, M Casanovas, M Pujol, T Sher, L AF Dolores Braquehais, Maria Eiroa-Orosa, Francisco Jose Holmes, Kristin M. Lusilla, Pilar Bravo, Maria Mozo, Xulian Mezzatesta, Marcela Casanovas, Marta Pujol, Tania Sher, Leo TI Differences in Physicians' and Nurses' Recent Suicide Attempts: An Exploratory Study SO ARCHIVES OF SUICIDE RESEARCH LA English DT Article DE suicide attempts; nurses; physicians ID DOCTORS; RISK; DEPRESSION; IDEATION; GENDER; RATES AB The aim of this study was to examine the characteristics of physicians' and nurses' suicide attempts (SA). A retrospective review of 493 medical records of physicians and nurses admitted to an inpatient unit for health professionals; 36 patients had a recent SA. Depression, cluster B and C personality disorders, and a history of previous SA were more prevalent in patients with a recent SA compared to those without it. Both professional groups preferred drug overdose as a suicide method. Physicians made more lethal attempts and had a history of more previous stressors than nurses. Depression, cluster B and C personality disorders, and previous SA should be appropriately screened and treated in order to prevent SA amongst physicians and nurses. C1 [Dolores Braquehais, Maria; Bravo, Maria; Mozo, Xulian; Pujol, Tania] Generalitat Catalonia, Dept Hlth, Galatea Clin, Integral Care Program Sick Hlth Care Profess, Barcelona, Spain. [Dolores Braquehais, Maria; Bravo, Maria; Mozo, Xulian; Pujol, Tania] Coll Metges Barcelona, Galatea Fdn, Barcelona, Spain. [Dolores Braquehais, Maria; Lusilla, Pilar] Univ Autonoma Barcelona, CIBERSAM, Vall dHebron Univ Hosp, Dept Psychiat & Legal Med, E-08193 Barcelona, Spain. [Eiroa-Orosa, Francisco Jose] Univ E London, Sch Psychol, Water Lane, Stratford, England. [Holmes, Kristin M.; Sher, Leo] James J Peters Vet Adm Med Ctr, Dept Psychiat, New York, NY USA. [Holmes, Kristin M.; Sher, Leo] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Mezzatesta, Marcela] Fundacio Salut & Comunitat, Fundacio Orienta, Child & Adolescent Mental Hlth Unit, Barcelona, Spain. [Casanovas, Marta] Univ London Imperial Coll Sci Technol & Med, Ctr Mental Hlth, Hammersmith Hosp Campus, London, England. RP Braquehais, MD (reprint author), Galatea Fdn, Integral Care Program Sick Hlth Care Profess, Inpatient Psychiat Unit Hlth Profess, Galatea Clin, Passeig Bonanova 47, Barcelona 08017, Spain. EM mdbraquehais.paimm@comb.cat RI Eiroa Orosa, Francisco Jose/D-2510-2012 OI Eiroa Orosa, Francisco Jose/0000-0002-4163-6545 NR 17 TC 0 Z9 0 U1 0 U2 4 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1381-1118 EI 1543-6136 J9 ARCH SUICIDE RES JI Arch. Suicide Res. PD APR 2 PY 2016 VL 20 IS 2 BP 273 EP 279 DI 10.1080/13811118.2014.996693 PG 7 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA DJ0PG UT WOS:000373905800013 PM 25517040 ER PT J AU Gunnery, SD Ruben, MA AF Gunnery, Sarah D. Ruben, Mollie A. TI Perceptions of Duchenne and non-Duchenne smiles: A meta-analysis SO COGNITION & EMOTION LA English DT Article DE Duchenne smile; Non-Duchenne smile; Smile perceptions ID NON-ENJOYMENT SMILES; DETECTING HAPPINESS; NONENJOYMENT SMILES; FAKE SMILES; AUTHENTICITY; SENSITIVITY; EXPRESSIONS; CHILDRENS; GENUINE; MARKER AB A meta-analysis was conducted to compare perceptions of Duchenne smiles, smiles that include activation of the cheek raiser muscle that creates crow's feet around the eyes, with perceptions of non-Duchenne smiles, smiles without cheek raiser activation. In addition to testing the overall effect, moderator analyses were conducted to test how methodological, stimulus-specific and perceiver-specific differences between studies predicted the overall effect size. The meta-analysis found that, overall, Duchenne smiles and people producing Duchenne smiles are rated more positively (i.e., authentic, genuine, real, attractive, trustworthy) than non-Duchenne smiles and people producing non-Duchenne smiles. The difference between Duchenne and non-Duchenne smiles was greater when the stimuli were videos rather than photographs, when smiles were elicited naturally rather than through posing paradigms and when Duchenne and non-Duchenne smiles were not matched for intensity of the lip corner puller in addition to other perceiver and methodological moderators. C1 [Gunnery, Sarah D.] Tufts Univ, Dept Occupat Therapy, 26 Winthrop St, Medford, MA 02155 USA. [Ruben, Mollie A.] US Dept Vet Affairs, Ctr Healthcare Org & Implementat Res, Boston, MA USA. RP Gunnery, SD (reprint author), Tufts Univ, Dept Occupat Therapy, 26 Winthrop St, Medford, MA 02155 USA. EM sarah.gunnery@tufts.edu NR 36 TC 1 Z9 1 U1 6 U2 22 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0269-9931 EI 1464-0600 J9 COGNITION EMOTION JI Cogn. Emot. PD APR 2 PY 2016 VL 30 IS 3 BP 501 EP 515 DI 10.1080/02699931.2015.1018817 PG 15 WC Psychology, Experimental SC Psychology GA DB7VA UT WOS:000368723500008 PM 25787714 ER PT J AU Walker, RH AF Walker, Ruth H. TI The non-Huntington disease choreas Five new things SO NEUROLOGY-CLINICAL PRACTICE LA English DT Review ID FAMILIAL DYSKINESIA; FACIAL MYOKYMIA; NEUROFERRITINOPATHY; MOVEMENT; SLEEP; ANTIBODIES; DISORDER; MUTATION AB Purpose of review: Chorea can be due to a wide variety of causes. In this review, I provide updates on several recently identified genetic and autoimmune causes of chorea, and review evidence supporting the use of deep brain stimulation in chorea. Recent findings: New genes that may cause chorea include ADCY5 (encoding for adenylate cyclase 5) C9ORF72 (in addition to amyotrophic lateral sclerosis and frontotemporal dementia), and those responsible for the neurodegeneration with brain iron accumulation disorders. Novel autoantibodies are increasingly being identified as associated with a variety of neurologic syndromes, including chorea, in both paraneoplastic and non-paraneoplastic settings. Deep brain stimulation can be a useful intervention in patients with chorea who do not respond to oral medications, whether due to neurodegenerative or nondegenerative causes. Summary: New causes of chorea continue to be identified. Correct diagnosis is essential for prognostication and treatment. C1 [Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY 10468 USA. [Walker, Ruth H.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. EM ruth.walker@mssm.edu NR 20 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2163-0402 EI 2163-0933 J9 NEUROL-CLIN PRACT JI Neurol.-Clin. Pract. PD APR PY 2016 VL 6 IS 2 BP 150 EP 156 DI 10.1212/CPJ.0000000000000236 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA EI6JT UT WOS:000392602400014 ER PT J AU Koval, RD Mcdonagh, J Grubaugh, A Young, W Corcoran, B Lee, A Dumas, B Edlund, B AF Koval, Renee D. Mcdonagh, James Grubaugh, Anouk Young, Wendy Corcoran, Beth Lee, Angela Dumas, Bonnie Edlund, Barbara TI Implementation of Recovery Programming on an Inpatient Acute Psychiatric Unit and Its Impact on Readmission SO JOURNAL OF ADDICTIONS NURSING LA English DT Article DE mental health; readmissions; recovery; veterans ID ILLNESS MANAGEMENT AB Background: Recovery-oriented models of care are evidence based and have been shown to improve patient satisfaction and outcomes as well as decrease the percentage of readmissions to inpatient psychiatric units. Methods: This quality improvement project was implemented on a 16-bed inpatient adult mental health unit in a Veterans Affairs Medical Center. Percentages of readmissions were compared throughout the course of implementation of the recovery model. Readmissions during the months of July-September were tabulated over 3 subsequent years and compared readmission percentages before recovery implementation, during the early stage of recovery implementation, and finally, during ongoing recovery implementation. Results: A decrease in readmission percentages was seen with implementation of recovery-oriented care when comparing the same 3-month period over 3 years. Conclusion: After implementation of recovery-oriented care measures, there was a decrease in percentage of readmissions to the unit. In addition, this decrease was sustained and was shown to improve over time as recovery-oriented programming was further developed on the unit. These data suggest that Veterans Affairs Medical Centers should consider adding tools and procedures to successfully implement recovery programming on inpatient units and efforts should include direct involvement of patients in their own recovery journey, revision of policies and procedures to reflect the importance of recovery, thorough training of frontline staff regarding recovery principles, and transfer of recovery information directly from inpatient units to outpatient providers. C1 [Koval, Renee D.] Med Univ South Carolina, Coll Nursing, Charleston, SC USA. [Mcdonagh, James; Grubaugh, Anouk; Young, Wendy] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Corcoran, Beth] Lehigh Valley Hlth Network, LVPG Consultat Liaison Psychiat, Allentown, PA USA. [Lee, Angela] Multnomah Cty Hlth Dept Correct Hlth, Portland, OR USA. [Dumas, Bonnie; Edlund, Barbara] Med Univ South Carolina, Coll Nursing, Charleston, SC USA. RP Koval, RD (reprint author), 650 Enterprise Blvd Apt 1304, Charleston, SC 29492 USA. EM rkdnp15@gmail.com FU (Office of Academic Affiliations), at a south eastern VAMC; American Psychiatric Nurses Association FX The authors acknowledge the assistance of Dr. Christopher Pelic, MD, in preparation of the manuscript. In addition, the authors would also like to acknowledge the Psychiatric Nurse Practitioner Residency Program Directed by Dr. Janet York, PhD, PMHCS-BC, FAAN (funded by the Office of Academic Affiliations), at a south eastern VAMC and the American Psychiatric Nurses Association's Recovery to Practice training without which this project would not have been possible. NR 15 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1088-4602 EI 1548-7148 J9 J ADDICT NURS JI J. Addict. Nurs. PD APR-JUN PY 2016 VL 27 IS 2 BP 101 EP 108 DI 10.1097/JAN.0000000000000121 PG 8 WC Substance Abuse; Nursing SC Substance Abuse; Nursing GA EF0TO UT WOS:000390039100007 PM 27272994 ER PT J AU Aliberti, S Lonni, S Dore, S McDonnell, MJ Goeminne, PC Dimakou, K Fardon, TC Rutherford, R Pesci, A Restrepo, MI Sotgiu, G Chalmers, JD AF Aliberti, Stefano Lonni, Sara Dore, Simone McDonnell, Melissa J. Goeminne, Pieter C. Dimakou, Katerina Fardon, Thomas C. Rutherford, Robert Pesci, Alberto Restrepo, Marcos I. Sotgiu, Giovanni Chalmers, James D. TI Clinical phenotypes in adult patients with bronchiectasis SO EUROPEAN RESPIRATORY JOURNAL LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; CYSTIC FIBROSIS BRONCHIECTASIS; CLUSTER-ANALYSIS; SYSTEMIC INFLAMMATION; COPD PHENOTYPES; VALIDATION; EMPHYSEMA; AIRWAY AB Bronchiectasis is a heterogeneous disease. This study aimed at identifying discrete groups of patients with different clinical and biological characteristics and long-term outcomes. This was a secondary analysis of five European databases of prospectively enrolled adult outpatients with bronchiectasis. Principal component and cluster analyses were performed using demographics, comorbidities, and clinical, radiological, functional and microbiological variables collected during the stable state. Exacerbations, hospitalisations and mortality during a 3-year follow-up were recorded. Clusters were externally validated in an independent cohort of patients with bronchiectasis, also investigating inflammatory markers in sputum. Among 1145 patients (median age 66 years; 40% male), four clusters were identified driven by the presence of chronic infection with Pseudomonas aeruginosa or other pathogens and daily sputum: "Pseudomonas" (16%), "Other chronic infection" (24%), "Daily sputum" (33%) and "Dry bronchiectasis" (27%). Patients in the four clusters showed significant differences in terms of quality of life, exacerbations, hospitalisations and mortality during follow-up. In the validation cohort, free neutrophil elastase activity, myeloperoxidase activity and interleukin-1 beta levels in sputum were significantly different among the clusters. Identification of four clinical phenotypes in bronchiectasis could favour focused treatments in future interventional studies designed to alter the natural history of the disease. C1 [Aliberti, Stefano; Lonni, Sara; Pesci, Alberto] Univ Milano Bicocca, Sch Med & Surg, AO San Gerardo, Via Pergolesi 33, I-20052 Monza, Italy. [Dore, Simone; Sotgiu, Giovanni] Univ Sassari Res, Dept Biomed Sci, Med Educ & Profess Dev Unit, Clin Epidemiol & Med Stat Unit,AOU Sassari, Sassari, Italy. [McDonnell, Melissa J.; Rutherford, Robert] Galway Univ Hosp, Dept Resp Med, Galway, Ireland. [Goeminne, Pieter C.] Univ Hosp Gasthuisberg, Dept Resp Med, Leuven, Belgium. [Goeminne, Pieter C.] UZ Leuven, Dept Resp Med, Leuven, Belgium. [Dimakou, Katerina] Sotiria Chest Hosp, Dept Pulm 5, Athens, Greece. [Fardon, Thomas C.; Chalmers, James D.] Univ Dundee, Tayside Resp Res Grp, Dundee, Scotland. [Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Div Pulm Dis & Crit Care, San Antonio, TX USA. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Aliberti, S (reprint author), Univ Milano Bicocca, Sch Med & Surg, AO San Gerardo, Via Pergolesi 33, I-20052 Monza, Italy. EM stefano.aliberti@unimib.it OI Aliberti, Stefano/0000-0002-0090-4531 FU European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC); European Respiratory Society; Bayer HealthCare; Aradigm Corporation; Medical Research Council; Wellcome Trust; European Respiratory Society/European Lung Foundation; Health Research Board, Ireland; National Heart, Lung and Blood Institute [K23HL096054] FX This study was supported by the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC; www.bronchiectasis.eu). EMBARC is a European Respiratory Society Clinical Research Collaboration and has received funding from the European Respiratory Society, Bayer HealthCare and Aradigm Corporation. J.D. Chalmers acknowledges fellowship support from the Medical Research Council and the Wellcome Trust. M.J. McDonnell acknowledges fellowship support from the European Respiratory Society/European Lung Foundation and Health Research Board, Ireland. M.I. Restrepo's time is partially protected by Award Number K23HL096054 from the National Heart, Lung and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung and Blood Institute or the National Institutes of Health. The funding agencies had no role in the preparation, review or approval of the manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 25 TC 26 Z9 25 U1 0 U2 1 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND SN 0903-1936 EI 1399-3003 J9 EUR RESPIR J JI Eur. Resp. J. PD APR PY 2016 VL 47 IS 4 BP 1113 EP 1122 DI 10.1183/13993003.01899-2015 PG 10 WC Respiratory System SC Respiratory System GA DZ6EW UT WOS:000385955400018 PM 26846833 ER PT J AU Jackevicius, CA Tu, JV Krumholz, HM Austin, PC Ross, JS Stukel, TA Koh, M Chong, A Ko, DT AF Jackevicius, Cynthia A. Tu, Jack V. Krumholz, Harlan M. Austin, Peter C. Ross, Joseph S. Stukel, Therese A. Koh, Maria Chong, Alice Ko, Dennis T. TI Comparative Effectiveness of Generic Atorvastatin and Lipitor (R) in Patients Hospitalized with an Acute Coronary Syndrome SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE acute coronary syndrome; comparative effectiveness; statin ID BRAND-NAME STATINS; CARDIOVASCULAR-DISEASE; PROPENSITY SCORE; KOREAN ADULTS; DRUGS; TOLERABILITY; PERCEPTIONS; MEDICATIONS; EQUIVALENCE; MULTICENTER AB Background-Although generic medications are approved based on bioequivalence with brand-name medications, there remains substantial concern regarding their clinical effectiveness and safety. Lipitor (R), available as generic atorvastatin, is one of the most commonly prescribed statins. Therefore, we compared the effectiveness of generic atorvastatin products and Lipitor (R). Methods and Results-We conducted a population-based cohort study, using propensity score matching to minimize potential confounding of patients >= 65 years, discharged alive after acute coronary syndrome (ACS) hospitalization between 2008 and 2012 in Ontario, Canada, who were prescribed Lipitor (R) or generic atorvastatin within 7 days of discharge. The primary outcome was 1-year death/recurrent ACS hospitalization. Secondary outcomes included hospitalization for heart failure, stroke, new-onset diabetes, rhabdomyolysis, and renal failure. In the 7863 propensity-matched pairs (15 726 patients), mean age was 76.9 years, 56.3% were male, 87.6% had myocardial infarction, and all patients had complete follow-up. At 1 year, 17.7% of those prescribed generic atorvastatin and 17.7% of those prescribed Lipitor (R) experienced death or recurrent ACS (hazard ratio, 1.00; 95% CI, 0.93-1.08; P= 0.94). No significant differences in rates of secondary outcomes between groups were observed. Prespecified subgroup analyses by age, sex, diabetes, atorvastatin dose, or admission diagnosis found no outcome difference between groups. Conclusions-Among older adults discharged alive after ACS hospitalization, we found no significant difference in cardiovascular outcomes or serious, infrequent side effects in patients prescribed generic atorvastatin compared with those prescribed Lipitor (R) at 1 year. Our findings support the use of generic atorvastatin in ACS, which could lead to substantial cost saving for patients and health care plans without diminishing population clinical effectiveness. C1 [Jackevicius, Cynthia A.] Western Univ Hlth Sci, Coll Pharm, Dept Pharm Practice & Adm, Pomona, CA USA. [Jackevicius, Cynthia A.; Tu, Jack V.; Austin, Peter C.; Stukel, Therese A.; Koh, Maria; Chong, Alice; Ko, Dennis T.] Inst Clin Evaluat Sci, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Jackevicius, Cynthia A.; Tu, Jack V.; Austin, Peter C.; Stukel, Therese A.; Ko, Dennis T.] Univ Toronto, Fac Med, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada. [Tu, Jack V.; Ko, Dennis T.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Schulich Heart Ctr, Div Cardiol, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Univ Hlth Network, Toronto, ON, Canada. [Krumholz, Harlan M.] Yale Univ, Dept Med, Sect Cardiovasc Med, New Haven, CT 06520 USA. [Krumholz, Harlan M.; Ross, Joseph S.] Yale Univ, Yale New Haven Hosp, Sch Med, Ctr Outcomes Res & Evaluat, New Haven, CT USA. [Krumholz, Harlan M.] Yale Univ, Dept Epidemiol & Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT 06520 USA. [Krumholz, Harlan M.] Robert Wood Johnson Clin Scholars Program, New Haven, CT USA. [Ross, Joseph S.] Yale Univ, Dept Med, Gen Internal Med Sect, New Haven, CT 06520 USA. RP Jackevicius, CA (reprint author), Western Univ Hlth Sci, Coll Pharm, 309 E Second St, Pomona, CA 91766 USA. EM cjackevicius@westernu.edu FU Heart and Stroke Foundation (HSF) [G-14-0005977]; Ontario Ministry of Health and Long-Term Care (MOHLTC) FX This study was funded by a grant (G-14-0005977) from the Heart and Stroke Foundation (HSF). The Institute for Clinical Evaluative Sciences (ICES) is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results, and conclusions reported in this article are those of the authors and are independent from the funding sources. Furthermore, design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication were also independent from the funding sources. No endorsement by ICES, the MOHLTC, or the HSF is intended or should be inferred. NR 39 TC 1 Z9 1 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD APR PY 2016 VL 5 IS 4 AR e003350 DI 10.1161/JAHA.116.003350 PG 18 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DZ1PI UT WOS:000385609900033 PM 27098970 ER PT J AU Nettiksimmons, J Tranah, G Evans, DS Yokoyama, JS Yaffe, K AF Nettiksimmons, Jasmine Tranah, Gregory Evans, Daniel S. Yokoyama, Jennifer S. Yaffe, Kristine TI Gene-based aggregate SNP associations between candidate AD genes and cognitive decline SO AGE LA English DT Article DE SNP associations; Candidate AD genes; Cognitive decline ID GENOME-WIDE ASSOCIATION; ALZHEIMERS-DISEASE; OSTEOPOROTIC FRACTURES; COMMON VARIANTS; CD33; SIGLECS; RISK; EXPRESSION; ROLES; BRAIN AB Single nucleotide polymorphisms (SNPs) in and near ABCA7, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, complement receptor 1 (CR1), EPHA1, EXOC3L2, FERMT2, HLA cluster (DRB5-DQA), INPP5D, MEF2C, MS4A cluster (MS4A3-MS4A6E), NME8, PICALM, PTK2B, SLC24A4, SORL1, and ZCWPW1 have been associated with Alzheimer's disease (AD) in large meta-analyses. We aimed to determine whether established AD-associated genes are associated with longitudinal cognitive decline by examining aggregate variation across these gene regions. In two single-sex cohorts of older, community-dwelling adults, we examined the association between SNPs in previously implicated gene regions and cognitive decline (age-adjusted person-specific cognitive slopes) using a Sequence Kernel Association Test (SKAT). In regions which showed aggregate significance, we examined the univariate association between individual SNPs in the region and cognitive decline. Only two of the original AD-associated SNPs were significantly associated with cognitive decline in our cohorts. We identified significant aggregate-level associations between cognitive decline and the gene regions BIN1, CD33, CELF1, CR1, HLA cluster, and MEF2C in the allfemale cohort and significant associations with ABCA7, HLA cluster, MS4A6E, PICALM, PTK2B, SLC24A4, and SORL1 in the all-male cohort. We also identified a block of eight correlated SNPs in CD33 and several blocks of correlated SNPs in CELF1 that were significantly associated with cognitive decline in univariate analysis in the all-female cohort. C1 [Nettiksimmons, Jasmine] Univ Calif San Francisco, Dept Psychiat, 4150 Clement St,Box VAMC-116H, San Francisco, CA 94121 USA. [Tranah, Gregory] Univ Calif San Francisco, Dept Epidemiol & Biostat, Calif Pacific Med Ctr, Res Inst, Mission Hall Global Hlth & Clin Sci Bldg, San Francisco, CA 94158 USA. [Evans, Daniel S.] Calif Pacific Med Ctr, Res Inst, Mission Hall Global Hlth & Clin Sci Bldg, San Francisco, CA 94158 USA. [Yokoyama, Jennifer S.] Univ Calif San Francisco, Memory & Aging Ctr, Sandler Neurosci Ctr, 675 Nelson Rising Lane,Suite 190, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco Vet Affairs Med Ctr, 4150 Clement St,Box 181, San Francisco, CA 94121 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco Vet Affairs Med Ctr, 4150 Clement St,Box 181, San Francisco, CA 94121 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco Vet Affairs Med Ctr, 4150 Clement St,Box 181, San Francisco, CA 94121 USA. RP Nettiksimmons, J (reprint author), Univ Calif San Francisco, Dept Psychiat, 4150 Clement St,Box VAMC-116H, San Francisco, CA 94121 USA. EM jasminen@gmail.com; GTranah@psg.ucsf.edu; DEvans@psg.ucsf.edu; jyokoyama@memory.ucsf.edu; kristine.yaffe@ucsf.edu FU National Institutes of Health; National Institute on Aging (NIA) [R01 AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01 AG027574, R01 AG027576]; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Center for Advancing Translational Sciences (NCATS); NIH Roadmap for Medical Research [U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, UL1 TR000128]; NIAMS [RC2 AR058973, R01 AR051124]; National Institute of Aging [K24AG031155]; Larry L. Hillblom Foundation [2012-A-015-FEL]; National Institute on Aging [K01 AG049152]; Diversity Supplement [P50 AG023501]; AFTD Susan Marcus Memorial Fund Clinical Research Grant FX The Study of Osteoporotic Fractures (SOF) is supported by the National Institutes of Health funding. The National Institute on Aging (NIA) provides support under the following grant numbers: R01 AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01 AG027574, and R01 AG027576. The Osteoporotic Fractures in Men (MrOS) Study is supported by the National Institutes of Health funding. The following institutes provide support: the National Institute on Aging (NIA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Center for Advancing Translational Sciences (NCATS), and NIH Roadmap for Medical Research under the following grant numbers: U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, and UL1 TR000128. The NIAMS provides funding for the MrOS ancillary study "GWAS in MrOS and SOF" under the grant number RC2 AR058973. TheNIAMS provides funding for the MrOS ancillary study "Replication of candidate gene associations and bone strength phenotype in MrOS" under the grant number R01 AR051124. Dr. Yaffe is supported in part by a National Institute of Aging Grant (K24AG031155). Dr. Yokoyama is supported in part by Larry L. Hillblom Foundation 2012-A-015-FEL, National Institute on Aging K01 AG049152 and Diversity Supplement to P50 AG023501, and AFTD Susan Marcus Memorial Fund Clinical Research Grant. NR 33 TC 4 Z9 4 U1 3 U2 4 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0161-9152 EI 1574-4647 J9 AGE JI Age PD APR PY 2016 VL 38 IS 2 AR 41 DI 10.1007/s11357-016-9885-2 PG 10 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA DX9SM UT WOS:000384735400001 PM 27005436 ER PT J AU Schlosser, D Campellone, T Kim, D Truong, B Vergani, S Ward, C Vinogradov, S AF Schlosser, Danielle Campellone, Timothy Kim, Daniel Truong, Brandy Vergani, Silvia Ward, Charlie Vinogradov, Sophia TI Feasibility of PRIME: A Cognitive Neuroscience-Informed Mobile App Intervention to Enhance Motivated Behavior and Improve Quality of Life in Recent Onset Schizophrenia SO JMIR RESEARCH PROTOCOLS LA English DT Article DE schizophrenia; mobile app; smartphone; motivation; technology-based intervention; social networking; coaching; negative symptoms; quality of life ID NEGATIVE SYMPTOMS; ENVIRONMENTAL SUPPORTS; PHYSICAL-ACTIVITY; RECOVERY; OUTCOMES; PEOPLE; METAANALYSIS; OUTPATIENTS; DISORDERS; DEFICITS AB Background: Despite improvements in treating psychosis, schizophrenia remains a chronic and debilitating disorder that affects approximately 1% of the US population and costs society more than depression, dementia, and other medical illnesses across most of the lifespan. Improving functioning early in the course of illness could have significant implications for long-term outcome of individuals with schizophrenia. Yet, current gold-standard treatments do not lead to clinically meaningful improvements in outcome, partly due to the inherent challenges of treating a population with significant cognitive and motivational impairments. The rise of technology presents an opportunity to develop novel treatments that may circumvent the motivational and cognitive challenges observed in schizophrenia. Objective: The purpose of this study was two-fold: (1) to evaluate the feasibility and acceptability of implementing a Personalized Real-Time Intervention for Motivation Enhancement (PRIME), a mobile app intervention designed to target reward-processing impairments, enhance motivation, and thereby improve quality of life in recent onset schizophrenia, and (2) evaluate the empirical benefits of using an iterative, user-centered design (UCD) process. Methods: We conducted two design workshops with 15 key stakeholders, followed by a series of in-depth interviews in collaboration with IDEO, a design and innovation firm. The UCD approach ultimately resulted in the first iteration of PRIME, which was evaluated by 10 RO participants. Results from the Stage 1 participants were then used to guide the next iteration that is currently being evaluated in an ongoing RCT. Participants in both phases were encouraged to use the app daily with a minimum frequency of 1/week over a 12-week period. Results: The UCD process resulted in the following feature set: (1) delivery of text message (short message service, SMS)-based motivational coaching from trained therapists, (2) individualized goal setting in prognostically important psychosocial domains, (3) social networking via direct peer-to-peer messaging, and (4) community "moments feed" to capture and reinforce rewarding experiences and goal achievements. Users preferred an experience that highlighted several of the principles of self-determination theory, including the desire for more control of their future (autonomy and competence) and an approach that helps them improve existing relationships (relatedness). IDEO, also recommended an approach that was casual, friendly, and nonstigmatizing, which is in line with the recovery model of psychosis. After 12-weeks of using PRIME, participants used the app, on average, every other day, were actively engaged with its various features each time they logged in and retention and satisfaction was high (20/20, 100% retention, high satisfaction ratings). The iterative design process lead to a 2- to 3-fold increase in engagement from Stage 1 to Stage 2 in almost each aspect of the platform. Conclusions: These results indicate that the neuroscience-informed mobile app, PRIME, is a feasible and acceptable intervention for young people with schizophrenia. C1 [Schlosser, Danielle; Kim, Daniel; Truong, Brandy; Ward, Charlie; Vinogradov, Sophia] Univ Calif San Francisco, Dept Psychiat, 401 Parnassus Ave, San Francisco, CA 94134 USA. [Campellone, Timothy] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Vergani, Silvia] IDEO, Palo Alto, CA USA. [Vinogradov, Sophia] San Francisco VA Med Ctr, San Francisco, CA USA. RP Schlosser, D (reprint author), Univ Calif San Francisco, Dept Psychiat, 401 Parnassus Ave, San Francisco, CA 94134 USA. EM danielle.schlosser@ucsf.edu RI Emchi, Karma/Q-1952-2016 OI Schlosser, Danielle/0000-0001-7652-0924 FU NCATS NIH HHS [UL1 TR000004]; NIMH NIH HHS [K23 MH097795, R34 MH100399] NR 41 TC 0 Z9 0 U1 12 U2 15 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 1929-0748 J9 JMIR RES PROTOC JI JMIR RES. Protoc. PD APR-JUN PY 2016 VL 5 IS 2 AR e77 DI 10.2196/resprot.5450 PG 13 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DT1AH UT WOS:000381213600043 PM 27125771 ER PT J AU Li, L Shelton, RC Chassan, RA Hammond, JC Gower, BA Garvey, TW AF Li, Li Shelton, Richard Charles Chassan, Rachel Ann Hammond, John Charles Gower, Barbara Ann Garvey, Timothy W. TI Impact of Major Depressive Disorder on Prediabetes by Impairing Insulin Sensitivity SO JOURNAL OF DIABETES & METABOLISM LA English DT Article DE Insulin sensitivity; Prediabetes; Atherosclerosis; Phosphorylation; Cardiovascular diseases; Glucose tolerance test ID TYPE-2 DIABETES-MELLITUS; ORAL GLUCOSE-TOLERANCE; RISK-FACTOR; PLASMA-GLUCOSE; DSM-IV; RESISTANCE; METABOLISM; ADIPOSITY; DISEASE; HEALTH AB Reports regarding the associations between major depressive disorder (MDD) and diabetes remain heterogeneous. Our aim was to investigate whether glucose homeostasis and insulin sensitivity were impaired in the MDD patients and its mechanisms. A total of 30 patients with MDD and 30 matched controls were recruited. The oral glucose tolerance test and dual-energy X-ray absorptiometry scan were performed in each participant. Insulin signaling in postmortem brain tissues from other depressive patients and controls (obtained from Alabama brain bank) was examined. Insulin sensitivity was reduced substantially in the MDD patients, however, the fasting and 2-h glucose concentrations remained within the normal range through compensatory insulin secretion. Despite increased insulin secretion, 1-h glucose concentrations in the MDD patients were significantly elevated compared with the controls. MDD patients had greater visceral fat mass but lower adiponectin levels compared with the controls. Furthermore, phosphorylated-AKT levels in insulin signaling were decreased in postmortem brain tissues in patients with MDD. These results suggest that MDD patients are at a greater risk for diabetes due to decreased insulin sensitivity, reduced disposition index, and impaired glucose tolerance as manifested by elevated 1-h glucose concentrations following an oral glucose challenge. Mechanistic studies reveal that decreased insulin sensitivity is associated with increased visceral fat mass, lower adiponectin levels and impaired insulin action in postmortem brain tissues in the MDD patients. Our findings emphasize the importance of screening depressive patients to identify susceptible individuals for developing future diabetes with the hope of improving their health outcomes. C1 [Li, Li; Shelton, Richard Charles; Chassan, Rachel Ann; Hammond, John Charles] Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, 1720 Univ Blvd, Birmingham, AL 35294 USA. [Gower, Barbara Ann; Garvey, Timothy W.] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, Timothy W.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Li, L (reprint author), Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, 1720 Univ Blvd, Birmingham, AL 35294 USA. EM lili978@uab.edu NR 30 TC 0 Z9 0 U1 3 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 2155-6156 J9 J DIABETES METAB JI J. Diabetes Metab. PD APR PY 2016 VL 7 IS 4 AR UNSP 664 DI 10.4172/2155-6156.1000664 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DX6BB UT WOS:000384466000003 ER PT J AU Hermayer, KL AF Hermayer, Kathie L. TI The Diabetes Initiative of South Carolina Celebrates Over 20 Years of Professional Diabetes Education SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE Diabetes mellitus; South Carolina; Symposium; Education; Program AB Background: Diabetes is a major public health problem in South Carolina; however, the Diabetes Initiative of South Carolina (DSC) provides a realistic mechanism to address issues on a statewide basis. Methods: The Diabetes Center of Excellence in the DSC provides oversight for developing and supervising professional education programs for health care workers of all types in South Carolina to increase their knowledge and ability to care for people with diabetes. The DSC has developed many programs for the education of a variety of health professionals about diabetes and its complications. Results: The DSC has sponsored 21 Annual Diabetes Fall Symposia for primary health care professionals featuring education regarding many aspects of diabetes mellitus. The intent of the program is to enhance the lifelong learning process of physicians, advanced practice providers, nurses, pharmacists, dietitians, laboratorians and other health care professionals, by providing educational opportunities and to advance the quality and safety of patient care. The symposium is an annual 2-day statewide program that supplies both a comprehensive diabetes management update to all primary care professionals and an opportunity for attendees to obtain continuing education credits at a low cost. Conclusion: The overarching goal of the DSC is that the programs it sponsors and the development of new targeted initiatives will lead to continuous improvements in the care of people at risk and with diabetes along with a decrease in morbidity, mortality and costs of diabetes and its complications in South Carolina and elsewhere. C1 [Hermayer, Kathie L.] Med Univ South Carolina, Qual Dept, Charleston, SC USA. [Hermayer, Kathie L.] Med Univ South Carolina, Dept Med, Div Endocrinol, Charleston, SC USA. [Hermayer, Kathie L.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Hermayer, KL (reprint author), Med Univ South Carolina, 96 Jonathan Lucas St,CSB 938,MSC 624, Charleston, SC 29425 USA. EM hermayer@musc.edu NR 1 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9629 EI 1538-2990 J9 AM J MED SCI JI Am. J. Med. Sci. PD APR PY 2016 VL 351 IS 4 BP 325 EP 326 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DV1FJ UT WOS:000382665400001 PM 27079336 ER PT J AU Walker, RJ Williams, JS Egede, LE AF Walker, Rebekah J. Williams, Joni Strom Egede, Leonard E. TI Influence of Race, Ethnicity and Social Determinants of Health on Diabetes Outcomes SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE Social determinants of health; Diabetes; Health disparities; Psychosocial factors; Neighborhood factors ID SELF-CARE BEHAVIORS; NUTRITION EXAMINATION SURVEY; IMPROVE GLYCEMIC CONTROL; HISPANIC WHITE ADULTS; NEIGHBORHOOD FACTORS; UNITED-STATES; CARDIOVASCULAR-DISEASE; SOCIOECONOMIC-STATUS; RACIAL DISPARITIES; AFRICAN-AMERICANS AB Background: There is strong evidence that race, ethnicity and social determinants of health significantly influence outcomes for patients with diabetes. A better understanding of the mechanisms of these relationships or associations would improve development of cost-effective, culturally tailored programs for patients with diabetes. Methods: This article reviews the current state of the literature on the influence of race and ethnicity and social determinants of health on process of care, quality of care and outcomes for diabetes, with particular emphasis on the rural South to give an overview of the state of the literature. Results: The literature review shows that racial or ethnic differences in the clinical outcomes for diabetes, including glycemic, blood pressure (BP) and lipid control, continue to persist. In addition, the literature review shows that the role of social determinants of health on outcomes, and the possible role these determinants play in disparities have largely been ignored. Psychosocial factors, such as self-efficacy, depression, social support and perceived stress, show consistent associations with self-care, quality of life and glycemic control. Neighborhood factors, such as food insecurity, social cohesion and neighborhood esthetics have been associated with glycemic control. Perceived discrimination has also been associated with self-care and the psychological component of quality of life. Conclusion: Healthcare professionals need to be skilled in assessing social determinants of health and taking them into consideration in clinical care. In addition, more research is needed to identify the separate and combined influence of race and ethnicity and social determinants of health on process of care, quality of care and outcomes in diabetes, especially in the South, where the burden of disease is particularly high. C1 [Walker, Rebekah J.; Williams, Joni Strom; Egede, Leonard E.] Med Univ South Carolina, Ctr Hlth Dispar Res, Dept Med, 135 Rutledge Ave,Room 280G, Charleston, SC 29425 USA. [Walker, Rebekah J.; Williams, Joni Strom; Egede, Leonard E.] Med Univ South Carolina, Div Gen Internal Med & Geriatr, Dept Med, Charleston, SC USA. [Walker, Rebekah J.; Williams, Joni Strom; Egede, Leonard E.] Ralph H Johnson Vet Affairs Med Ctr, HEROIC, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ South Carolina, Ctr Hlth Dispar Res, Dept Med, 135 Rutledge Ave,Room 280G, Charleston, SC 29425 USA. EM egedel@musc.edu FU HSRD VA [I50 HX001229]; NIDDK NIH HHS [K24 DK093699, R01 DK098529] NR 69 TC 4 Z9 4 U1 10 U2 18 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9629 EI 1538-2990 J9 AM J MED SCI JI Am. J. Med. Sci. PD APR PY 2016 VL 351 IS 4 BP 366 EP 373 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA DV1FJ UT WOS:000382665400007 PM 27079342 ER PT J AU Shearer, JE Jenkins, CH Magwood, GS Pope, CA AF Shearer, Jennifer E. Jenkins, Carolyn H. Magwood, Gayenell S. Pope, Charlene A. TI Contested Ownership of Disease and Ambulatory-Sensitive Emergency Department Visits for Type 2 Diabetes SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE Type 2 diabetes; Emergency departmentuse; Ambulatory-sensitive conditions; Qualitative research; Grounded theory with dimensional analysis ID ILLNESS SELF-MANAGEMENT; AFRICAN-AMERICANS; GROUNDED THEORY; CARE; MODEL; PATIENT; LIFE AB Background: Approximately 21 million persons have diabetes and account for 11.9% of all emergency department (ED) visits for a total cost of $14.1 billion. Nonemergent visits for ambulatory-sensitive conditions that could be managed by the primary care provider make up almost one-third of the ED visits. African Americans comprise approximately 30% of South Carolina's population but make up approximately 50% of the ED visits for diabetes. The purpose of the research was to explore the experiences of 20 African-American adults with diabetes with ambulatory-sensitive ED use. Research Design and Methods: The research design for this study is grounded theory with dimensional analysis methods. Following ethics approval and informed consent, interviews were conducted, recorded and transcribed verbatim, and themes were analyzed to form the explanatory framework or matrix for ED use. The framework of context, conditions, processes and consequences provides a key for understanding the themes of the story embedded in the descriptive narratives. Results: The contested ownership of diabetes was the overarching perspective--"doing what I got to do," "it's always on mind wishing not to be a diabetic" and "it's a constant burden." And handling diabetes involved taking decisions "into your hands." The context of perceived urgency of symptoms included all the reasons that precipitated ED visit--personal experience, primary care access and services and social network support for decisions--influenced ownership of these decisions. C1 [Shearer, Jennifer E.; Jenkins, Carolyn H.] Charleston Southern Univ, Coll Nursing, Charleston, SC USA. [Jenkins, Carolyn H.; Magwood, Gayenell S.; Pope, Charlene A.] Med Univ South Carolina, Coll Nursing, 99 Jonathan Lucas St,MSC 160, Charleston, SC 29425 USA. [Pope, Charlene A.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Jenkins, CH (reprint author), Med Univ South Carolina, Coll Nursing, 99 Jonathan Lucas St,MSC 160, Charleston, SC 29425 USA. EM Jenkins@musc.edu FU NINR NIH HHS [R15 NR009486] NR 35 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9629 EI 1538-2990 J9 AM J MED SCI JI Am. J. Med. Sci. PD APR PY 2016 VL 351 IS 4 BP 400 EP 406 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA DV1FJ UT WOS:000382665400011 PM 27079346 ER PT J AU Larsen, BA Wassel, CL Kritchevsky, SB Strotmeyer, ES Criqui, MH Kanaya, AM Fried, LF Schwartz, AV Harris, TB Ix, JH AF Larsen, Britta A. Wassel, Christina L. Kritchevsky, Stephen B. Strotmeyer, Elsa S. Criqui, Michael H. Kanaya, Alka M. Fried, Linda F. Schwartz, Ann V. Harris, Tamara B. Ix, Joachim H. CA Hlth ABC Study TI Association of Muscle Mass, Area, and Strength With Incident Diabetes in Older Adults: The Health ABC Study SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID SKELETAL-MUSCLE; INSULIN SENSITIVITY; GLUCOSE-TOLERANCE; BODY-COMPOSITION; ADIPOSE-TISSUE; WOMEN; RESISTANCE; MORTALITY; MEN; OVERWEIGHT AB Context: Skeletal muscle plays a key role in glucose regulation, yet the association between muscle quantity or quality and the risk of developing type 2 diabetes has not been explored. Objective: The objective of the study was to assess the association between muscle quantity and strength and incident diabetes and to explore whether this association differs by body mass index (BMI) category. Design and Setting: Participants were 2166 older adults in the Health, Aging, and Body Composition Study who were free of diabetes at baseline (1997-1998). Computed tomography and dual-energy x-ray absorptiometry were used to measure abdominal and thigh muscle area and total body lean mass, respectively. Strength was quantified by grip and knee extensions. Main Outcome Measure: Incident diabetes, defined as fasting glucose of 126 mg/dL or greater, a physician's diagnosis, and/or the use of hypoglycemic medication were measured. Results: After a median 11.3 years of follow-up, there were 265 incident diabetes cases (12.2%). In fully adjusted models, no association was found between muscle or strength measures and incident diabetes (for all, P > .05). For women, there was a significant interaction with BMI category for both abdominal and thigh muscle, such that greater muscle predicted lower risk of incident diabetes for normal-weight women(hazard ratio 0.37 [0.17-0.83] and 0.58 [0.27-1.27] per SD, respectively) and a greater risk for overweight and obese women(hazard ratio 1.23 [0.98-1.54] and 1.28 [1.00-1.64], respectively). No significant interactions by BMI category existed for strength measures or any measures for men (for all, P > .05). Conclusions: Greater muscle area is associated with a lower risk of incident diabetes for older normal-weight women but not for men or overweight women. C1 [Larsen, Britta A.; Criqui, Michael H.; Ix, Joachim H.] Univ Calif San Diego, Dept Family Med & Publ Hlth, 9500 Gilman Dr, San Diego, CA 92093 USA. [Ix, Joachim H.] Univ Calif San Diego, Dept Med, San Diego, CA 92093 USA. [Wassel, Christina L.] Univ Vermont, Coll Med, Dept Pathol & Lab Med, Burlington, VT 05446 USA. [Kritchevsky, Stephen B.] Wake Forest Univ, Winston Salem, NC 27157 USA. [Kritchevsky, Stephen B.] Sch Med, Winston Salem, NC 27157 USA. [Strotmeyer, Elsa S.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15219 USA. [Schwartz, Ann V.] Univ Calif San Francisco, Div Gen Internal Med, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Fried, Linda F.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15261 USA. [Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA. [Harris, Tamara B.] NIA, Bethesda, MD 20892 USA. RP Larsen, BA (reprint author), Univ Calif San Diego, Dept Family Med & Publ Hlth, 9500 Gilman Dr, San Diego, CA 92093 USA. EM blarsen@ucsd.edu FU National Institute on Aging [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01-AG028050]; National Institute of Nursing Research Grant [R01-NR012459]; Intramural Research Program of the National Institute on Aging; Career Development Grant from National Institute of Diabetes and Digestive and Kidney Diseases [K01 DK101650]; Established Investigator Award from American Heart Association [14EIA18560026] FX This work was supported Contracts N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106 from the National Institute on Aging, National Institute on Aging Grant R01-AG028050 and National Institute of Nursing Research Grant R01-NR012459. This research was also supported in part by the Intramural Research Program of the National Institute on Aging. B.L. was supported by Career Development Grant K01 DK101650 from the National Institute of Diabetes and Digestive and Kidney Diseases. J.I. was supported by an Established Investigator Award from the American Heart Association (14EIA18560026). NR 26 TC 1 Z9 1 U1 0 U2 0 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD APR PY 2016 VL 101 IS 4 BP 1847 EP 1855 DI 10.1210/jc.2015-3643 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DU0YP UT WOS:000381931400060 PM 26930180 ER PT J AU Hjelmeland, A Zhang, JH AF Hjelmeland, Anita Zhang, Jianhua TI Metabolic, autophagic, and mitophagic activities in cancer initiation and progression SO BIOMEDICAL JOURNAL LA English DT Review DE Autophagy; Cancer; Mitochondria; Mitophagy; Oxidative stress; Reactive species ID TUMOR-SUPPRESSOR GENE; POSITRON-EMISSION-TOMOGRAPHY; FACTOR-INDEPENDENT SURVIVAL; TRANSCRIPTION FACTOR NRF2; PYRUVATE-KINASE M2; NITRIC-OXIDE; REACTIVE OXYGEN; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; THERAPEUTIC TARGET AB Cancer is a complex disease marked by uncontrolled cell growth and invasion. These processes are driven by the accumulation of genetic and epigenetic alterations that promote cancer initiation and progression. Contributing to genome changes are the regulation of oxidative stress and reactive species-induced damage to molecules and organelles. Redox regulation, metabolic plasticity, autophagy, and mitophagy play important and interactive roles in cancer hallmarks including sustained proliferation, activated invasion, and replicative immortality. However, the impact of these processes can differ depending on the signaling pathways altered in cancer, tumor type, tumor stage, and/or the differentiation state. Here, we highlight some of the representative studies on the impact of oxidative and nitrosative activities, mitochondrial bioenergetics, metabolism, and autophagy and mitophagy in the context of tumorigenesis. We discuss the implications of these processes for cellular activities in cancer for anti-cancer-based therapeutics. C1 [Hjelmeland, Anita] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL USA. [Hjelmeland, Anita; Zhang, Jianhua] Univ Alabama Birmingham, Ctr Free Radical Biol, Birmingham, AL USA. [Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Biomed Res Bldg 2,901 19th St South, Birmingham, AL 35294 USA. [Zhang, Jianhua] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL USA. RP Zhang, JH (reprint author), Univ Alabama Birmingham, Dept Pathol, Biomed Res Bldg 2,901 19th St South, Birmingham, AL 35294 USA. EM zhanja@uab.edu NR 168 TC 7 Z9 7 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2319-4170 EI 2320-2890 J9 BIOMED J JI Biomed. J. PD APR PY 2016 VL 39 IS 2 BP 98 EP 106 DI 10.1016/j.bj.2015.10.002 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DS3VN UT WOS:000380710900003 PM 27372165 ER PT J AU Russell, DW Gaggar, A Solomon, GM AF Russell, Derek W. Gaggar, Amit Solomon, George M. TI Neutrophil Fates in Bronchiectasis and Alpha-1 Antitrypsin Deficiency SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB The neutrophil is a powerful cellular defender of the vulnerable interface between the environment and pulmonary tissues. This cell's potent weapons are carefully calibrated in the healthy state to maximize effectiveness in fighting pathogens while minimizing tissue damage and allowing for repair of what damage does occur. The three related chronic airway disorders of cystic fibrosis, non-cystic fibrosis bronchiectasis, and alpha-1 antitrypsin deficiency all demonstrate significant derangements of this homeostatic system that result in their respective pathologies. An important shared feature among them is the inefficient resolution of chronic inflammation that serves as a central means for neutrophil-driven lung damage resulting in disease progression. Examining the commonalities and divergences between these diseases in the light of their immunopathology is informative and may help guide us toward future therapeutics designed to modulate the neutrophil's interplay with the pulmonary environment. C1 [Russell, Derek W.; Gaggar, Amit; Solomon, George M.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Gaggar, Amit; Solomon, George M.] Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Res Ctr, Birmingham, AL USA. [Russell, Derek W.; Gaggar, Amit] Univ Alabama Birmingham, Program Protease & Matrix Biol, Birmingham, AL USA. [Gaggar, Amit] Birmingham Vet Affairs Med Ctr, Med Serv, Birmingham, AL USA. RP Solomon, GM (reprint author), 1900 Univ Blvd,THT 422, Birmingham, AL 35294 USA. EM msolomon@uab.edu FU NIH [HL102371, HL126596]; Veterans Administration [1 I01 BX001756]; Cystic Fibrosis Foundation [CLANCY09Y0, SORSCH15RO] FX Supported by the NIH (HL102371 and HL126596 to A.G.), the Veterans Administration (1 I01 BX001756 to A.G.), and the Cystic Fibrosis Foundation (CLANCY09Y0 and SORSCH15RO to G.M.S.). NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD APR PY 2016 VL 13 SU 2 BP S123 EP S129 DI 10.1513/AnnalsATS.201512-805KV PG 7 WC Respiratory System SC Respiratory System GA DR7QM UT WOS:000380094800005 PM 27115946 ER PT J AU Bunch, PM Sheehan, SE Dyer, GS Sodickson, A Khurana, B AF Bunch, Paul M. Sheehan, Scott E. Dyer, George S. Sodickson, Aaron Khurana, Bharti TI A biomechanical approach to distal radius fractures for the emergency radiologist SO EMERGENCY RADIOLOGY LA English DT Review DE Radius; Fracture; Trauma; Wrist; Biomechanical; Mechanism ID TRIANGULAR FIBROCARTILAGE COMPLEX; RADIOULNAR JOINT SUBLUXATION; COMPUTED-TOMOGRAPHY; RADIOGRAPHIC EVALUATION; INTRAOBSERVER REPRODUCIBILITY; INTEROBSERVER RELIABILITY; INTRAARTICULAR FRACTURES; INTERNAL-FIXATION; EXTERNAL FIXATION; COLLES FRACTURES AB Distal radius fractures are the most common upper extremity fracture and account for approximately one sixth of all fractures treated in US emergency departments. These fractures are associated with significant morbidity and have a major economic impact. Radiographic evaluation of distal radius fractures is frequently performed in the emergency department setting, has a profound impact on initial management, and is essential to assessing the quality and relative success of the initial reduction. While the most appropriate definitive management of distal radius fractures remains controversial, overarching treatment principles reflect distal radius injury mechanisms and biomechanics. An intuitive understanding of the biomechanics of the distal radius and of common mechanisms of injury informs and improves the emergency radiologist's ability to identify key imaging findings with important management implications and to communicate the critical information that emergency physicians and orthopedic surgeons need to best manage distal radius fractures. C1 [Bunch, Paul M.; Sodickson, Aaron; Khurana, Bharti] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA. [Sheehan, Scott E.] William S Middleton Mem Vet Adm Med Ctr, Dept Radiol, 2500 Overlook Terrace, Madison, WI 53705 USA. [Dyer, George S.] Harvard Med Sch, Brigham & Womens Hosp, Dept Orthoped Surg, 75 Francis St, Boston, MA 02115 USA. RP Bunch, PM (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA. EM paul.m.bunch@gmail.com NR 73 TC 2 Z9 2 U1 2 U2 4 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1070-3004 EI 1438-1435 J9 EMERG RADIOL JI Emerg. Radiol. PD APR PY 2016 VL 23 IS 2 BP 175 EP 185 DI 10.1007/s10140-015-1363-0 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DR1BI UT WOS:000379640600012 PM 26564022 ER PT J AU Gibson, C Thurston, R Matthews, K AF Gibson, Carolyn Thurston, Rebecca Matthews, Karen TI DAILY ASSOCIATIONS BETWEEN DIARY-REPORTED HOT FLASHES AND CORTISOL SO PSYCHOSOMATIC MEDICINE LA English DT Meeting Abstract CT 74th Annual Meeting of the American-Psychosomatic-Society CY MAR 09-12, 2015 CL Denver, CO SP Amer Psychosomat Soc C1 [Gibson, Carolyn] San Francisco VA Med Ctr, San Francisco, CA USA. [Thurston, Rebecca; Matthews, Karen] Univ Pittsburgh, Psychol, Psychiat, Epidemiol, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0033-3174 EI 1534-7796 J9 PSYCHOSOM MED JI Psychosom. Med. PD APR PY 2016 VL 78 IS 3 MA 1079 BP A47 EP A47 PG 1 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA DJ1FX UT WOS:000373949800149 ER PT J AU Harris, KM Anderson, DR Landers, JD Emery, CF AF Harris, Kristie M. Anderson, Derek R. Landers, Jacob D. Emery, Charles F. TI COPING STYLE AND DESIRE FOR TREATMENT AMONG PATIENTS IN OUTPATIENT CARDIAC REHABILITATION SO PSYCHOSOMATIC MEDICINE LA English DT Meeting Abstract CT 74th Annual Meeting of the American-Psychosomatic-Society CY MAR 09-12, 2015 CL Denver, CO SP Amer Psychosomat Soc C1 [Harris, Kristie M.; Landers, Jacob D.; Emery, Charles F.] Ohio State Univ, Psychol, Columbus, OH 43210 USA. [Anderson, Derek R.] Vet Affairs Puget Sound Healthcare Syst, Rehabil Care Serv, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0033-3174 EI 1534-7796 J9 PSYCHOSOM MED JI Psychosom. Med. PD APR PY 2016 VL 78 IS 3 MA 1292 BP A57 EP A57 PG 1 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA DJ1FX UT WOS:000373949800176 ER PT J AU Walsh, CM Patel, N Walker, K Ruoff, L Varbel, J Wynn, M Miller, BL Neylan, TC Kramer, JH AF Walsh, Christine M. Patel, Nihar Walker, Kathleen Ruoff, Leslie Varbel, Jonathan Wynn, Matthew Miller, Bruce L. Neylan, Thomas C. Kramer, Joel H. TI The cognitive effects of disrupted sleep in healthy older adults SO PSYCHOSOMATIC MEDICINE LA English DT Meeting Abstract CT 74th Annual Meeting of the American-Psychosomatic-Society CY MAR 09-12, 2015 CL Denver, CO SP Amer Psychosomat Soc C1 [Walsh, Christine M.; Patel, Nihar; Walker, Kathleen; Wynn, Matthew; Miller, Bruce L.; Kramer, Joel H.] Univ Calif San Francisco, Neurol, San Francisco, CA 94143 USA. [Ruoff, Leslie; Varbel, Jonathan; Neylan, Thomas C.] San Francisco VA Med Ctr, Stress & Hlth Res, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0033-3174 EI 1534-7796 J9 PSYCHOSOM MED JI Psychosom. Med. PD APR PY 2016 VL 78 IS 3 MA 1442 BP A18 EP A19 PG 2 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA DJ1FX UT WOS:000373949800064 ER PT J AU Redmann, M Darley-Usmar, V Zhang, JH AF Redmann, Matthew Darley-Usmar, Victor Zhang, Jianhua TI The Role of Autophagy, Mitophagy and Lysosomal Functions in Modulating Bioenergetics and Survival in the Context of Redox and Proteotoxic Damage: Implications for Neurodegenerative Diseases SO AGING AND DISEASE LA English DT Review DE oxidative stress; reductive stress; mitochondrial dysfunction; prions; alpha-synuclein; neurodegenerative diseases ID EXTENDS LIFE-SPAN; LIPOFUSCINOSES BATTEN-DISEASE; MITOCHONDRIAL QUALITY-CONTROL; CUZN-SUPEROXIDE-DISMUTASE; D-DEFICIENT MICE; OXIDATIVE STRESS; PARKINSONS-DISEASE; ALPHA-SYNUCLEIN; ALZHEIMERS-DISEASE; REACTIVE OXYGEN AB Redox and proteotoxic stress contributes to age-dependent accumulation of dysfunctional mitochondria and protein aggregates, and is associated with neurodegeneration. The free radical theory of aging inspired many studies using reactive species scavengers such as alpha-tocopherol, ascorbate and coenzyme Q to suppress the initiation of oxidative stress. However, clinical trials have had limited success in the treatment of neurodegenerative diseases. We ascribe this to the emerging literature which suggests that the oxidative stress hypothesis does not encompass the role of reactive species in cell signaling and therefore the interception with reactive species with antioxidant supplementation may result in disruption of redox signaling. In addition, the accumulation of redox modified proteins or organelles cannot be reversed by oxidant intercepting antioxidants and must then be removed by alternative mechanisms. We have proposed that autophagy serves this essential function in removing damaged or dysfunctional proteins and organelles thus preserving neuronal function and survival. In this review, we will highlight observations regarding the impact of autophagy regulation on cellular bioenergetics and survival in response to reactive species or reactive species generating compounds, and in response to proteotoxic stress. C1 [Redmann, Matthew; Darley-Usmar, Victor; Zhang, Jianhua] Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35294 USA. [Redmann, Matthew; Darley-Usmar, Victor; Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Zhang, Jianhua] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL 35294 USA. RP Zhang, JH (reprint author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. EM zhanja@uab.edu FU [NIHR01-NS064090] FX This work was supported by NIHR01-NS064090 (to JZ). NR 149 TC 8 Z9 8 U1 4 U2 12 PU INT SOC AGING & DISEASE PI FORT WORTH PA EDITORIAL OFF, 3400 CAMP BOWIE BLVD, FORT WORTH, TX 76106 USA SN 2152-5250 J9 AGING DIS JI Aging Dis. PD APR PY 2016 VL 7 IS 2 BP 150 EP 162 DI 10.14336/AD.2015.0820 PG 13 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA DO5BD UT WOS:000377797700006 PM 27114848 ER PT J AU Yamada, A Sato, KK Kinuhata, S Uehara, S Endo, G Hikita, Y Fujimoto, WY Boyko, EJ Hayashi, T AF Yamada, Akiko Sato, Kyoko K. Kinuhata, Shigeki Uehara, Shinichiro Endo, Ginji Hikita, Yonezo Fujimoto, Wilfred Y. Boyko, Edward J. Hayashi, Tomoshige TI Association of Visceral Fat and Liver Fat With Hyperuricemia SO ARTHRITIS CARE & RESEARCH LA English DT Article ID URIC-ACID LEVEL; X-RAY ABSORPTIOMETRY; HIGH BLOOD-PRESSURE; INSULIN-RESISTANCE; COMPUTED-TOMOGRAPHY; METABOLIC SYNDROME; HEART-DISEASE; METAANALYSIS; GOUT; MEN AB Objective. To examine cross-sectionally whether intraabdominal fat area (IAFA), i.e., visceral fat, and liver fat assessed by computed tomography (CT) are independently associated with hyperuricemia. Methods. Subjects were 801 Japanese men not taking antidiabetic, antihypertensive, or urate-lowering medications, without any history of renal disease, cardiovascular disease, or cancer, and with serum creatinine <1.5 mg/dl. Abdominal, thoracic, and thigh fat areas were measured by CT. Total fat area (TFA) was the sum of these fat areas. Total subcutaneous fat area (TSFA) was TFA minus IAFA. Liver fat was assessed by liver-to-spleen (L/S) ratio measured by CT. Hyperuricemia was defined as serum uric acid level >7.0 mg/dl. Its association with adiposity was tested using logistic regression. Results. The prevalence of hyperuricemia was 19.6% (157 men). Both greater IAFA and lower L/S ratio were independently associated with hyperuricemia in models that simultaneously included IAFA and L/S ratio: multiple-adjusted odds ratios of hyperuricemia for quintiles 3, 4, and 5 of IAFA were 2.16 (95% confidence interval [95% CI] 1.02-4.59), 2.41 (95% CI 1.13-5.16), and 4.00 (95% CI 1.81-8.85), respectively, compared to quintile 1, and the L/S ratios for quintiles 3, 2, and 1 were 2.34 (95% CI 1.16-4.75), 2.15 (95% CI 1.06-4.34), and 2.79 (95% CI 1.35-5.76), respectively, compared to quintile 5. Both IAFA and L/S ratio remained significant even after adjusting for abdominal subcutaneous fat area, TFA, TSFA, body mass index, or waist circumference. Of all fat measurements, IAFA had the strongest association with hyperuricemia by Akaike's information criteria. Conclusion. Greater amounts of both visceral fat and liver fat were independently associated with hyperuricemia. C1 [Yamada, Akiko; Sato, Kyoko K.; Kinuhata, Shigeki; Uehara, Shinichiro; Endo, Ginji; Hayashi, Tomoshige] Osaka City Univ, Grad Sch Med, Osaka 558, Japan. [Hikita, Yonezo] Ohtori Hlth Promot Ctr, Sakai, Osaka, Japan. [Fujimoto, Wilfred Y.; Boyko, Edward J.; Hayashi, Tomoshige] Univ Washington, Seattle, WA 98195 USA. [Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. RP Hayashi, T (reprint author), Osaka City Univ, Grad Sch Med, Dept Prevent Med & Environm Hlth, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan. EM thayashi@med.osaka-cu.ac.jp OI Boyko, Edward/0000-0002-3695-192X FU Ministry of Education, Culture, Sports, Science and Technology [17390177, 20390187, 23390177]; VA Puget Sound Health Care System FX Supported by Grants-in-Aid for Scientific Research (17390177, 20390187, 23390177) from the Ministry of Education, Culture, Sports, Science and Technology, and by the Ohtori Health Promotion Center, which provided facilities and services.; Dr. Boyko's work was supported by the VA Puget Sound Health Care System. NR 41 TC 1 Z9 2 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD APR PY 2016 VL 68 IS 4 BP 553 EP 561 DI 10.1002/acr.22729 PG 9 WC Rheumatology SC Rheumatology GA DO6OG UT WOS:000377902400017 PM 26414410 ER PT J AU Myers, EA Smith, DA Allen, SR Kaplan, LJ AF Myers, Elizabeth A. Smith, David A. Allen, Steven R. Kaplan, Lewis J. TI Post-ICU syndrome: Rescuing the undiagnosed SO JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS LA English DT Review DE ICU; critical illness; post-traumatic stress disorder; delirium; postintensive care syndrome; PICS ID INTENSIVE CARE SYNDROME; LONG-TERM-OUTCOMES; CRITICAL ILLNESS; SURVIVORSHIP AB Survivors of critical illness may develop postintensive care syndrome (PICS), a spectrum of conditions that include persistent cognitive dysfunction, acquired weakness, and intrusive memories akin to post-traumatic stress disorder. Relatively few ICU survivors are routinely followed in the outpatient setting by intensivists, but are regularly evaluated by primary care physicians and physician assistants in their practices. Specific and focused education about the key features of PICS, its effect on patients as well as family members, and potential therapeutic interventions may increase recognition of PICS and reduce its effect on survivors of critical illness. C1 [Myers, Elizabeth A.] Medstar Southern Maryland Hosp Ctr, Emergency Med, Clinton, MD USA. [Smith, David A.] Salus Univ, PA Program, Elkins Pk, PA USA. [Smith, David A.] VA Med Ctr, Crit Care Med Surg ICU, Philadelphia, PA USA. [Allen, Steven R.] Penn States Hershey Med Ctr, Hershey, PA USA. [Kaplan, Lewis J.] Philadelphia VA Med Ctr, Surg Crit Care, Philadelphia, PA USA. [Kaplan, Lewis J.] Philadelphia VA Med Ctr, Surg, Philadelphia, PA USA. [Kaplan, Lewis J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Myers, EA (reprint author), Medstar Southern Maryland Hosp Ctr, Emergency Med, Clinton, MD USA. NR 13 TC 0 Z9 0 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1547-1896 EI 0893-7400 J9 JAAPA-J AM ACAD PHYS JI JAAPA-J. Am. Acad. Physician Assist. PD APR PY 2016 VL 29 IS 4 BP 34 EP 37 DI 10.1097/01.JAA.0000481401.21841.32 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA DO6FZ UT WOS:000377880000014 PM 27023654 ER PT J AU Byers, AL Lai, AX Arean, P Nelson, JC Yaffe, K AF Byers, Amy L. Lai, Amy X. Arean, Patricia Nelson, J. Craig Yaffe, Kristine TI Mental Health Service Use Across the Life Course Among Adults With Psychiatric Disorders and Prior Suicidal Behavior SO PSYCHIATRIC SERVICES LA English DT Article ID PERCEIVED NEED; CARE AB Objective: Little is known about mental health service use by adults with prior suicidal behavior and current mood or anxiety disorders. This study determined nationally representative prevalence estimates of current mental health service use by these adults, examining racial-ethnic, age, and gender differences. Methods: Service use across the life course was examined with Collaborative Psychiatric Epidemiology Survey data from 1,139 adults with a history of suicidal behavior and current mood or anxiety disorders. Results: Overall service use was 47.3%. Across the life course, African Americans showed increasing service use that paralleled use by non-Hispanic whites, Hispanics, and others, whereas use by these three groups decreased in the latter half of the life course (p interaction = .01). Conclusions: Adults with prior suicidal behavior and current mood or anxiety disorders have low mental health service use. Findings of racial-ethnic disparities in use can help identify those in need of care. C1 [Byers, Amy L.; Nelson, J. Craig; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Byers, Amy L.; Lai, Amy X.; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Arean, Patricia] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Byers, AL (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.; Byers, AL (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA. EM amy.byers@ucsf.edu FU National Institute on Aging [AG031155]; Avid; [MD007019] FX Dr. Byers is supported by R01 award MD007019, administered by the Northern California Institute for Research and Education, and by resources from the San Francisco Veterans Affairs Medical Center and the National Institutes of Health, National Institute on Minority Health and Health Disparities. Dr. Yaffe is partially supported by K24 midcareer investigator award AG031155 from the National Institute on Aging.; Dr. Nelson reports receiving lecture honoraria from Bristol-Myers Squibb, Genentech, and Otsuka; consulting for Corcept, Lundbeck, and Otsuka; serving on the advisory board for Genentech and Otsuka; receiving research support from Avid; and owning stock in Atossa. Dr. Yaffe reports that she serves on data and safety monitoring boards for Takeda and DIAN. The other authors report no financial relationships with commercial interests. NR 15 TC 0 Z9 0 U1 0 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR PY 2016 VL 67 IS 4 BP 452 EP 455 DI 10.1176/appi.ps.201500019 PG 4 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DO4TY UT WOS:000377778300019 PM 26766753 ER PT J AU Timko, C Gupta, S Schultz, N Harris, AHS AF Timko, Christine Gupta, Shalini Schultz, Nicole Harris, Alex H. S. TI Veterans' Service Utilization Patterns After Alcohol and Opioid Detoxification in VHA Care SO PSYCHIATRIC SERVICES LA English DT Article ID SUBSTANCE-ABUSE TREATMENT; INPATIENT; OUTCOMES AB Objective: This study aimed to examine detoxification-related service utilization in the Veterans Health Administration (VHA). Methods: VHA data for 266,908 patients were used to examine rates and predictors of receiving detoxification, attending post-detoxification appointments, and entering specialty treatment. Multilevel, mixed-effects logistic regressions were used to examine associations between patient and facility characteristics and service utilization. Results: Nationally, 8.0% of VHA patients with alcohol or opiate dependence received detoxification in fiscal year 2013 (facility range=.1% 220.4%); 43.1% of detoxified patients received follow-up (11.1% 276.4%), and 49.9% entered specialty treatment (13.0%-77.2%). In adjusted analyses, detoxification was more likely among male, younger, white, and homeless patients with documented alcohol or opiate disorders and comorbid general medical conditions but without previous addiction treatment. Detoxification was also more likely in facilities with fewer vacant addiction therapist positions. Follow-up and specialty treatments were more likely among younger, healthier homeless patients with previous addiction treatment and a documented alcohol use disorder. Conclusions: Detoxification-related service utilization was highly variable across the VHA. Interventions are needed to optimize use. C1 [Timko, Christine; Gupta, Shalini; Schultz, Nicole; Harris, Alex H. S.] US Dept Vet Affairs, Hlth Serv Res & Dev, Menlo Pk, CA 94025 USA. RP Timko, C (reprint author), US Dept Vet Affairs, Hlth Serv Res & Dev, Menlo Pk, CA 94025 USA. EM christine.timko@va.gov FU HSR&D Quality Enhancement Research Initiative [RRP 12-525]; HSRD [RCS 00-001, RCS 14-232] FX This work was supported by grant RRP 12-525 from HSR&D Quality Enhancement Research Initiative. Dr. Timko was supported by grant RCS 00-001 and Dr. Harris was supported by grant RCS 14-232, both from HSR&D. NR 17 TC 1 Z9 1 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR PY 2016 VL 67 IS 4 BP 460 EP 464 DI 10.1176/appi.ps.201400579 PG 5 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DO4TY UT WOS:000377778300021 PM 26766752 ER PT J AU Brennan, L Siderowf, A Rubright, JD Rick, J Dahodwala, N Duda, JE Hurtig, H Stern, M Xie, SX Rennert, L Karlawish, J Shea, JA Trojanowski, JQ Weintraub, D AF Brennan, Laura Siderowf, Andrew Rubright, Jonathan D. Rick, Jacqueline Dahodwala, Nabila Duda, John E. Hurtig, Howard Stern, Matthew Xie, Sharon X. Rennert, Lior Karlawish, Jason Shea, Judy A. Trojanowski, John Q. Weintraub, Daniel TI The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease SO PARKINSONISM & RELATED DISORDERS LA English DT Article DE Parkinson's disease; Instrumental activities of daily living; Cognition ID SOCIETY TASK-FORCE; ALZHEIMERS-DISEASE; IMPAIRMENT; DEMENTIA; AGREEMENT; PATIENT AB Introduction: To describe the psychometric properties of the Penn Parkinson's Daily Activities Questionnaire-15 (PDAQ-15), a 15-item measure of cognitive instrumental activities of daily living for Parkinson's disease (PD) patients derived from the original 50-item PDAQ. Methods: PDAQ-15 items were chosen by expert consensus. Knowledgeable informants of PD participants (n-= 161) completed the PDAQ-15. Knowledgeable informants were defined as an individual having regular contact with the PD participant. PD participants were assigned a diagnosis of normal cognition, mild cognitive impairment, or dementia based on expert consensus. Results: PDAQ-15 scores correlated strongly with global cognition (Dementia Rating Scale-2, r = 0.71, p < 0.001) and a performance-based functional measure (Direct Assessment of Functional Status, r = 0.83; p < 0.001). PDAQ-15 scores accurately discriminated between non-demented PD participants (normal cognition/mild cognitive impairment) and PD with dementia (ROC curve area = 0.91), participants with and without any cognitive impairment (normal cognition versus mild cognitive impairment/dementia, ROC curve area = 0.85) and between participants with mild cognitive impairment and dementia (ROC curve area = 0.84). Conclusions: The PDAQ-15 shows good discriminant validity across cognitive stages, correlates highly with global cognitive performance, and appears suitable to assess daily cognitive functioning in PD. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Brennan, Laura] Drexel Univ, Coll Med, Drexel Neurosci Inst, 245 N 15th St,7102 NCB, Philadelphia, PA 19102 USA. [Brennan, Laura; Weintraub, Daniel] Univ Penn, Sch Med, Dept Psychiat, 3615 Chestnut St,330, Philadelphia, PA 19104 USA. [Siderowf, Andrew] Avid Radiopharmaceut, 3711 Market St 7, Philadelphia, PA 19104 USA. [Rubright, Jonathan D.] Natl Board Med Examiners, 3750 Market St, Philadelphia, PA 19104 USA. [Rick, Jacqueline; Dahodwala, Nabila; Duda, John E.; Hurtig, Howard; Stern, Matthew; Trojanowski, John Q.; Weintraub, Daniel] Univ Penn, Sch Med, Dept Neurol, 330 S 9th St, Philadelphia, PA 19107 USA. [Duda, John E.; Rennert, Lior; Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA. [Xie, Sharon X.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, 8th Floor Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Karlawish, Jason] PENN CMU Roybal Ctr Behav Econ & Hlth, LDI Ctr Hlth Incent, Dept Med Eth & Med, 3401 Market St,Suite 320, Philadelphia, PA 19104 USA. [Karlawish, Jason] Alzheimers Dis Ctr, 3401 Market St,Suite 320, Philadelphia, PA 19104 USA. [Shea, Judy A.] Univ Penn, Sch Med, Dept Med, 3400 Civ Ctr Blvd,Bldg 421, Philadelphia, PA 19104 USA. [Rubright, Jonathan D.] Amer Inst Certified Publ Accountants, Durham, NC USA. RP Weintraub, D (reprint author), 3615 Chestnut St,330, Philadelphia, PA 19104 USA. EM daniel.weintraub@uphs.upenn.edu FU Morris K. Udall Parkinson's Disease Research Center of Excellence grant from NINDS [NS-053488]; Department of Health of the Commonwealth of Pennsylvania from the Tobacco Master Settlement Agreement [SAP4100027296] FX This study was funded by a Morris K. Udall Parkinson's Disease Research Center of Excellence grant from NINDS (NS-053488) and by SAP4100027296, a health research grant awarded by the Department of Health of the Commonwealth of Pennsylvania from the Tobacco Master Settlement Agreement under Act 2001-77. NR 25 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 EI 1873-5126 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD APR PY 2016 VL 25 BP 21 EP 26 DI 10.1016/j.parkreldis.2016.02.020 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA DK0QD UT WOS:000374616400004 PM 26923524 ER PT J AU Trikamji, B Thomas, M Hathout, G Mishra, S AF Trikamji, Bhavesh Thomas, Mariam Hathout, Gasser Mishra, Shrikant TI An unusual case of cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy with occipital lobe involvement SO ANNALS OF INDIAN ACADEMY OF NEUROLOGY LA English DT Article DE Cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL); dementia; migraine; magnetic resonance imaging (MRI); occipital lobe; seizures ID CADASIL; PATTERNS AB Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an autosomal dominant angiopathy caused by a mutation in the notch 3 gene on chromosome 19. Clinically, patients may be asymptomatic or can present with recurrent ischemic episodes and strokes leading to dementia, depression, pseudobulbar palsy, and hemi-or quadraplegia. Additional manifestations that have been described include migraine (mostly with aura), psychiatric disturbances, and epileptic seizures. Neuroimaging is essential to the diagnosis of CADASIL. On imaging CADASIL is characterized by symmetric involvement by confluent lesions located subcortically in the frontal and temporal lobes as well as in the insula, periventricularly, in the centrum semiovale, in the internal and external capsule, basal ganglia, and brain stem; with relative sparing of the fronto-orbital and the occipital subcortical regions. We describe a 49 year old male with CADASIL with absence of temporal lobe findings on MRI but predominant lesions within the periventricular white matter, occipital lobes with extension into the subcortical frontal lobes, corpus callosum and cerebellar white matter. Although CADASIL characteristically presents with anterior temporal lobe involvement, these findings may be absent and our case addresses the atypical imaging findings in CADASIL. C1 [Trikamji, Bhavesh; Thomas, Mariam; Hathout, Gasser; Mishra, Shrikant] Olive View UCLA Med Ctr, Dept Neurol, 14445 Olive View Dr, Sylmar, CA 91342 USA. [Trikamji, Bhavesh; Hathout, Gasser; Mishra, Shrikant] VA Greater Los Angeles Healthcare Syst, Dept Radiol, Los Angeles, CA USA. [Hathout, Gasser; Mishra, Shrikant] Univ Calif Los Angeles, Los Angeles, CA USA. [Mishra, Shrikant] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. RP Mishra, S (reprint author), 16111 Plummer St, North Hills, CA 91343 USA. EM smishra@usc.edu NR 7 TC 0 Z9 0 U1 0 U2 0 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 0972-2327 EI 1998-3549 J9 ANN INDIAN ACAD NEUR JI Ann. Indian Acad. Neurol. PD APR-JUN PY 2016 VL 19 IS 2 BP 272 EP 274 DI 10.4103/0972-2327.173403 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA DN0BE UT WOS:000376728600023 PM 27293347 ER PT J AU Parajuli, S Lockridge, JB Langewisch, ED Norman, DJ Kujovich, JL AF Parajuli, Sandesh Lockridge, Joseph B. Langewisch, Eric D. Norman, Douglas J. Kujovich, Jody L. TI Hypercoagulability in Kidney Transplant Recipients SO TRANSPLANTATION LA English DT Review ID FACTOR-V-LEIDEN; RENAL GRAFT THROMBOSIS; ANTIPHOSPHOLIPID ANTIBODY SYNDROME; MOLECULAR-WEIGHT HEPARIN; PROTEIN-S DEFICIENCY; ALLOGRAFT THROMBOSIS; RISK-FACTORS; SINGLE-CENTER; VASCULAR COMPLICATIONS; SURGICAL COMPLICATIONS AB Thrombosis remains an important complication after kidney transplantation. Outcomes for graft and deep vein thrombosis are not favorable. The majority of early kidney transplant failure in adults is due to allograft thrombosis. Risk stratification, early diagnosis, and appropriate intervention are critical to the management of thrombotic complications of transplant. In patients with end-stage renal disease, the prevalence of acquired risk factors for thrombosis is significantly high. Because of hereditary and acquired risk factors, renal transplant recipients manifest features of a chronic prothrombotic state. Identification of hereditary thrombotic risk factors before transplantation may be a useful tool for selecting appropriate candidates for thrombosis prophylaxis immediately after transplantation. Short-term anticoagulation may be appropriate for all patients after kidney transplantation. C1 [Parajuli, Sandesh] Univ Wisconsin, Sch Med & Publ Hlth, Univ Wisconsin Hosp & Clin, Div Nephrol,Dept Med, Madison, WI USA. [Parajuli, Sandesh; Lockridge, Joseph B.; Langewisch, Eric D.; Norman, Douglas J.] Oregon Hlth & Sci Univ, Dept Med, Div Nephrol, 2611 SW 3rd Ave,Ste 360, Portland, OR 97201 USA. [Lockridge, Joseph B.; Langewisch, Eric D.; Norman, Douglas J.] Portland VA Med Ctr, Portland, OR USA. [Kujovich, Jody L.] Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97201 USA. RP Norman, DJ (reprint author), Oregon Hlth & Sci Univ, Dept Med, Div Nephrol, 2611 SW 3rd Ave,Ste 360, Portland, OR 97201 USA. EM normand@ohsu.edu NR 100 TC 2 Z9 2 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD APR PY 2016 VL 100 IS 4 BP 719 EP 726 DI 10.1097/TP.0000000000000887 PG 8 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA DN5QR UT WOS:000377125700015 PM 26413991 ER PT J AU Lockhart, SR Fothergill, AW Iqbal, N Bolden, CB Grossman, NT Garvey, EP Brand, SR Hoekstra, WJ Schotzinger, RJ Ottinger, E Patterson, TF Wiederhold, NP AF Lockhart, Shawn R. Fothergill, Annette W. Iqbal, Naureen Bolden, Carol B. Grossman, Nina T. Garvey, Edward P. Brand, Stephen R. Hoekstra, William J. Schotzinger, Robert J. Ottinger, Elizabeth Patterson, Thomas F. Wiederhold, Nathan P. TI The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID ANTIFUNGAL SUSCEPTIBILITIES AB The in vitro activities of the novel fungal Cyp51 inhibitor VT-1129 were evaluated against a large panel of Cryptococcus neoformans and Cryptococcus gattii isolates. VT-1129 demonstrated potent activities against both Cryptococcus species as demonstrated by low MIC50 and MIC90 values. For C. gattii, the in vitro potency was maintained against all genotypes. In addition, significantly lower geometric mean MICs were observed for VT-1129 than for fluconazole against C. neoformans, including isolates with reduced fluconazole susceptibility. C1 [Lockhart, Shawn R.; Iqbal, Naureen; Bolden, Carol B.; Grossman, Nina T.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. [Fothergill, Annette W.; Patterson, Thomas F.; Wiederhold, Nathan P.] Univ Texas San Antonio, Hlth Sci Ctr, San Antonio, TX USA. [Garvey, Edward P.; Brand, Stephen R.; Hoekstra, William J.; Schotzinger, Robert J.] Viamet Pharmaceut Inc, Durham, NC USA. [Ottinger, Elizabeth] NIH, Therapeut Rare & Neglected Dis Bethesda, Bldg 10, Bethesda, MD 20892 USA. [Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Wiederhold, NP (reprint author), Univ Texas San Antonio, Hlth Sci Ctr, San Antonio, TX USA. EM wiederholdn@uthscsa.edu FU National Institutes of Health National Institute of Allergy and Infectious Diseases [N01-AI-25475]; National Institutes of Health, National Center for Advancing Translational Sciences, Therapeutics for Rare and Neglected Diseases (TRND) Program; Viamet Pharmaceuticals, Inc. FX This project was funded by the National Institutes of Health National Institute of Allergy and Infectious Diseases under contract no. N01-AI-25475 (Thomas F. Patterson), the National Institutes of Health, National Center for Advancing Translational Sciences, Therapeutics for Rare and Neglected Diseases (TRND) Program (Shawn R. Lockhart), and Viamet Pharmaceuticals, Inc. (Nathan P. Wiederhold). VT-1129 powder was provided by Viamet Pharmaceuticals, Inc. NR 18 TC 3 Z9 3 U1 2 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD APR PY 2016 VL 60 IS 4 BP 2528 EP 2531 DI 10.1128/AAC.02770-15 PG 4 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA DM6XL UT WOS:000376496100072 PM 26787697 ER PT J AU Yung, M Iafe, N Sarraf, D AF Yung, Madeline Iafe, Nicholas Sarraf, David TI Optical coherence tomography angiography of a retinal astrocytic hamartoma SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE LA English DT Letter C1 [Yung, Madeline; Iafe, Nicholas; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Los Angeles, CA 90095 USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Sarraf, D (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Los Angeles, CA 90095 USA.; Sarraf, D (reprint author), Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. EM dsarraf@ucla.edu NR 6 TC 0 Z9 0 U1 1 U2 1 PU CANADIAN OPHTHAL SOC PI OTTAWA PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA SN 0008-4182 EI 1715-3360 J9 CAN J OPHTHALMOL JI Can. J. Opthalmol.-J. Can. Opthalmol. PD APR PY 2016 VL 51 IS 2 BP E62 EP E64 DI 10.1016/j.jcjo.2015.11.005 PG 4 WC Ophthalmology SC Ophthalmology GA DM7BR UT WOS:000376508400010 PM 27085280 ER PT J AU Ranard, BL Werner, RM Antanavicius, T Schwartz, HA Smith, RJ Meisel, ZF Asch, DA Ungar, LH Merchant, RM AF Ranard, Benjamin L. Werner, Rachel M. Antanavicius, Tadas Schwartz, H. Andrew Smith, Robert J. Meisel, Zachary F. Asch, David A. Ungar, Lyle H. Merchant, Raina M. TI Yelp Reviews Of Hospital Care Can Supplement And Inform Traditional Surveys Of The Patient Experience Of Care SO HEALTH AFFAIRS LA English DT Review ID SOCIAL MEDIA; PERFORMANCE; QUALITY; RATINGS AB Little is known about how real-time online rating platforms such as Yelp may complement the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey, which is the US standard for evaluating patients' experiences after hospitalization. We compared the content of Yelp narrative reviews of hospitals to the topics in the HCAHPS survey, called domains in HCAHPS terminology. While the domains included in Yelp reviews covered the majority of HCAHPS domains, Yelp reviews covered an additional twelve domains not found in HCAHPS. The majority of Yelp topics that most strongly correlate with positive or negative reviews are not measured or reported by HCAHPS. The large collection of patient- and caregiver-centered experiences found on Yelp can be analyzed with natural language processing methods, identifying for policy makers the measures of hospital quality that matter most to patients and caregivers. The Yelp measures and analysis can also provide actionable feedback for hospitals. C1 [Ranard, Benjamin L.] Univ Penn, Med, Philadelphia, PA 19104 USA. [Ranard, Benjamin L.; Smith, Robert J.; Asch, David A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Werner, Rachel M.] Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Werner, Rachel M.] Univ Penn, Perelman Sch Med, Med, Philadelphia, PA 19104 USA. [Antanavicius, Tadas] Univ Penn, Philadelphia, PA 19104 USA. [Schwartz, H. Andrew] SUNY Stony Brook, Dept Comp Sci, Stony Brook, NY 11794 USA. [Meisel, Zachary F.] Hosp Univ Penn, Emergency Med, Philadelphia, PA 19104 USA. [Asch, David A.] Univ Penn, Ctr Hlth Care Innovat, Philadelphia, PA 19104 USA. [Asch, David A.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Ungar, Lyle H.] Univ Penn, Dept Comp & Informat Sci, Philadelphia, PA 19104 USA. [Merchant, Raina M.] Univ Penn, Penn Social Media & Hlth Innovat Lab, Philadelphia, PA 19104 USA. [Merchant, Raina M.] Univ Penn, Emergency Med, Philadelphia, PA 19104 USA. RP Ranard, BL (reprint author), Univ Penn, Med, Philadelphia, PA 19104 USA. EM Raina.merchant@uphs.upenn.edu OI Smith, Robert James/0000-0001-9746-1230 FU National Institutes of Health [K23-10714038, K24-AG047908] FX Funding and support were provided by the National Institutes of Health, Grant No. K23-10714038 (for Raina M. Merchant) and Grant No. K24-AG047908 (for Rachel M. Werner). The study sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the article; or decision to submit the article for publication. The authors thank Judith A. Long (Perelman School of Medicine, University of Pennsylvania) for her review of the article and her insightful comments. She received no financial compensation. The opinions expressed are those of the authors and not the Department of Veterans Affairs. NR 36 TC 4 Z9 4 U1 4 U2 9 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD APR PY 2016 VL 35 IS 4 BP 697 EP 705 DI 10.1377/hlthaff.2015.1030 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DK2SG UT WOS:000374764100020 PM 27044971 ER PT J AU Maleki-Yazdi, M Singh, D Anzueto, A Tombs, L Naya, I Harris, S Iqbal, A Rolke, M AF Maleki-Yazdi, M. Singh, D. Anzueto, A. Tombs, L. Naya, I. Harris, S. Iqbal, A. Rolke, M. TI Clinically relevant Deterioration in COPD Patients under treatment with Umeclidinium/Vilanterol, Tiotropium or Placebo: Pooled Data SO INTERNIST LA German DT Meeting Abstract C1 [Maleki-Yazdi, M.] Univ Toronto, Womens Coll Hosp, Div Resp Med, Toronto, ON, Canada. [Singh, D.] Univ Manchester, Med Evaluat Unit, Manchester, Lancs, England. [Anzueto, A.] Audie L Murphy Hosp, San Antonio, TX USA. [Tombs, L.; Naya, I.] GlaxoSmithKline, Resp Med Dev Ctr, Stockley Pk, Uxbridge, Middx, England. [Harris, S.; Iqbal, A.] GlaxoSmithKline, Resp & Immunoinflammat Res, Res Triangle Pk, NC USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0020-9554 EI 1432-1289 J9 INTERNIST JI Internist PD APR PY 2016 VL 57 SU 1 MA P038 BP S25 EP S25 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA DL1UG UT WOS:000375417500045 ER PT J AU Woodell, A Jones, BW Williamson, T Schnabolk, G Tomlinson, S Atkinson, C Rohrer, B AF Woodell, Alex Jones, Bryan W. Williamson, Tucker Schnabolk, Gloriane Tomlinson, Stephen Atkinson, Carl Rohrer, Baerbel TI A Targeted Inhibitor of the Alternative Complement Pathway Accelerates Recovery From Smoke-Induced Ocular Injury SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE alternative complement pathway; CR2-fH; knockout mouse; smoke exposure; mitochondria; Bruch's membrane deposits; dry age-related macular degeneration ID RETINAL-PIGMENT EPITHELIUM; CAUSES OXIDATIVE DAMAGE; AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; CIGARETTE-SMOKE; CHOROIDAL NEOVASCULARIZATION; MEDIATED INJURY; RPE CELLS; STRESS; ACTIVATION AB PURPOSE. Morphologic and genetic evidence exists that an overactive complement system driven by the complement alternative pathway (AP) is involved in pathogenesis of age-related macular degeneration (AMD). Smoking is the only modifiable risk factor for AMD. As we have shown that smoke-related ocular pathology can be prevented in mice that lack an essential activator of AP, we ask here whether this pathology can be reversed by increasing inhibition in AP. METHODS. Mice were exposed to either cigarette smoke (CS) or filtered air (6 hours/day, 5 days/week, 6 months). Smoke-exposed animals were then treated with the AP inhibitor (CR2-fH) or vehicle control (PBS) for the following 3 months. Spatial frequency and contrast sensitivity were assessed by optokinetic response paradigms at 6 and 9 months; additional readouts included assessment of retinal morphology by electron microscopy (EM) and gene expression analysis by quantitative RT-PCR. RESULTS. The CS mice treated with CR2-fH showed significant improvement in contrast threshold compared to PBS-treated mice, whereas spatial frequency was unaffected by CS or pharmacologic intervention. Treatment with CR2-fH in CS animals reversed thinning of the retina observed in PBS-treated mice as analyzed by spectral-domain optical coherence tomography, and reversed most morphologic changes in RPE and Bruch's membrane seen in CS animals by EM. CONCLUSIONS. Taken together, these findings suggest that AP inhibitors not only prevent, but have the potential to accelerate the clearance of complement-mediated ocular injury. Improving our understanding of the regulation of the AP is paramount to developing novel treatment approaches for AMD. C1 [Woodell, Alex; Rohrer, Baerbel] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Jones, Bryan W.] Univ Utah, Moran Eye Ctr, Salt Lake City, UT USA. [Williamson, Tucker; Tomlinson, Stephen; Atkinson, Carl] Med Univ S Carolina, Dept Microbiol & Immunol, 173 Ashley Ave, Charleston, SC 29425 USA. [Schnabolk, Gloriane; Tomlinson, Stephen; Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC USA. [Atkinson, Carl] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA. [Rohrer, Baerbel] Med Univ S Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA. RP Atkinson, C (reprint author), Med Univ S Carolina, Dept Microbiol & Immunol, 173 Ashley Ave, Charleston, SC 29425 USA.; Rohrer, B (reprint author), Med Univ S Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA. EM atkinsoc@musc.edu; rohrer@musc.edu FU National Institutes of Health (NIH) [R01EY019320, R01 NHLBI 091944, NIH EY015128, NIH EY02576, EY014800]; Department of Veterans Affairs [I01 RX000444]; Research to Prevent Blindness (RPB), Inc., New York, New York, United States; Vision Core from Research to Prevent Blindness; Edward N. and Della L. Thome Memorial Foundation; NIH [C06 RR015455] FX Supported in part by National Institutes of Health (NIH) Grants R01EY019320, R01 NHLBI 091944, NIH EY015128, NIH EY02576, and EY014800; Department of Veterans Affairs I01 RX000444; an unrestricted grant to the Medical University of South Carolina from Research to Prevent Blindness (RPB), Inc., New York, New York, United States; Vision Core, an unrestricted grant from Research to Prevent Blindness to the Moran Eye Center; Edward N. and Della L. Thome Memorial Foundation grant for Age-Related Macular Degeneration Research. Animal studies were conducted in a facility constructed with support from the NIH (C06 RR015455). CA, ST, and BR are patent holders for the use of CR2-fH in complement-dependent diseases. This patent is licensed to Alexion Therapeutics. NR 46 TC 0 Z9 0 U1 0 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD APR PY 2016 VL 57 IS 4 BP 1728 EP 1737 DI 10.1167/iovs.15-18471 PG 10 WC Ophthalmology SC Ophthalmology GA DL8XY UT WOS:000375926700027 PM 27064393 ER PT J AU Bradshaw, AD AF Bradshaw, Amy D. TI The role of secreted protein acidic and rich in cysteine (SPARC) in cardiac repair and fibrosis: Does expression of SPARC by macrophages influence outcomes? SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY LA English DT Article DE Matricellular; Inflammation; Collagen; Extracellular matrix; Osteonectin; BM40 ID FIBRILLAR COLLAGEN CONTENT; DIASTOLIC FUNCTION ROLE; EXTRACELLULAR-MATRIX; MYOCARDIAL-INFARCTION; INFLAMMATION; DEPOSITION; CARCINOMA; LEUKOCYTE; MONOCYTE; DERMIS AB Secreted protein acidic and rich in cysteine (SPARC) is a matricellular, collagen-binding protein. Matricellular proteins are described as extracellular matrix-associated proteins that do not serve classical structural roles in the matrix such as those ascribed to laminins and collagens. The family of matricellular proteins modulates cell:extracellular matrix interactions and is actively expressed during tissue remodeling. Functional activities attributed to SPARC in cultured cells include regulation of cell adhesion, cytoskeletal rearrangement, proliferation, and matrix assembly. The primary phenotype characteristic of SPARC-null mice is a deficit in amounts of fibrillar collagen and fibril morphology. Strikingly, SPARC-null mice demonstrate a blunted fibrotic response in a number of different tissue settings. The role of monocyte/macrophages as an important component of tissue fibrosis is becoming increasingly appreciated. Expression of SPARC by bone marrow derived inflammatory cells raises the interesting proposition that SPARC produced by infiltrating leukocytes might contribute to the course of inflammation and tissue fibrosis in the heart. This review will summarize results from studies defining the function of SPARC in myocardial repair and fibrosis and results from other non-cardiac tissues that shed light onto possible consequences of SPARC expression by monocyte/macrophages in the setting of heart disease. (C) 2015 Published by Elsevier Ltd. C1 [Bradshaw, Amy D.] Med Univ S Carolina, Gazes Cardiac Res Inst, Div Cardiol, Dept Med, MSC 773, Charleston, SC 29425 USA. [Bradshaw, Amy D.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP Bradshaw, AD (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Div Cardiol, Dept Med, MSC 773, Charleston, SC 29425 USA.; Bradshaw, AD (reprint author), Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. EM bradshad@musc.edu OI Bradshaw, Amy/0000-0002-9202-3044 FU Veterans Affairs Merit Award [BX001385]; American Heart Association Award [12GRNT12060193] FX This work was supported by a Veterans Affairs Merit Award (BX001385) and an American Heart Association Award (12GRNT12060193). NR 32 TC 4 Z9 4 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0022-2828 EI 1095-8584 J9 J MOL CELL CARDIOL JI J. Mol. Cell. Cardiol. PD APR PY 2016 VL 93 BP 156 EP 161 DI 10.1016/j.yjmcc.2015.11.014 PG 6 WC Cardiac & Cardiovascular Systems; Cell Biology SC Cardiovascular System & Cardiology; Cell Biology GA DM1ZL UT WOS:000376145300020 PM 26582465 ER PT J AU Fidler, R Johnson, M AF Fidler, Richard Johnson, Meshell TI Human Factors Approach to Comparative Usability of Hospital Manual Defibrillators SO RESUSCITATION LA English DT Article DE Defibrillator; Resuscitation equipment; Simulation; AED; Transcutaneous pacing; Synchronized cardioversion ID CARDIAC-ARREST; UNITED-STATES; SURVIVAL AB Introduction: Equipment-related issues have recently been cited as a significant contributor to the suboptimal outcomes of resuscitation management. A systematic evaluation of the human-device interface was undertaken to evaluate the intuitive nature of three different defibrillators. Devices tested were the Physio-Control LifePak 15, the Zoll R Series Plus, and the Philips MRx. Methods: A convenience sample of 73 multidisciplinary health care providers from 5 different hospitals participated in this study. All subjects' performances were evaluated without any training on the devices being studied to assess the intuitiveness of the user interface to perform the functions of delivering an Automated External Defibrillator (AED) shock, a manual defibrillation, pacing to achieve 100% capture, and synchronized cardioversion on a rhythm simulator. Results: Times to deliver an AED shock were fastest with the Zoll, whereas the Philips had the fastest times to deliver a manual defibrillation. Subjects took the least time to attain 100% capture for pacing with the Physio-Control device. No differences in performance times were seen with synchronized cardioversion among the devices. Human factors issues uncovered during this study included a preference for knobs over soft keys and a desire for clarity in control panel design. This study demonstrated no clearly superior defibrillator, as each of the models exhibited strengths in different areas. When asked their defibrillator preference, 67% of subjects chose the Philips. Conclusions: This comparison of user interfaces of defibrillators in simulated situations allows the assessment of usability that can provide manufacturers and educators with feedback about defibrillator implementation for these critical care devices. Published by Elsevier Ireland Ltd C1 [Fidler, Richard; Johnson, Meshell] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Johnson, Meshell] Univ Calif San Francisco, Northern Calif Inst Res & Educ, San Francisco, CA 94121 USA. [Fidler, Richard] Univ Calif San Francisco, Sch Nursing, Dept Anesthesia, San Francisco, CA 94121 USA. [Fidler, Richard] Univ Calif San Francisco, Sch Nursing, Dept Perioperat Med, San Francisco, CA 94121 USA. [Johnson, Meshell] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA. RP Fidler, R (reprint author), San Francisco VA Med Ctr, Dept Anesthesia, 4150 Clement St, San Francisco, CA 94121 USA.; Fidler, R (reprint author), San Francisco VA Med Ctr, Dept Perioperat Med, 4150 Clement St, San Francisco, CA 94121 USA. EM richard.fidler@ucsf.edu FU San Francisco Department of Veterans Affairs Medical Center FX The San Francisco Department of Veterans Affairs Medical Center supported this work. Philips Healthcare, Physio-Control, and Zoll Medical provided equipment support. NR 10 TC 1 Z9 1 U1 1 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0300-9572 J9 RESUSCITATION JI Resuscitation PD APR PY 2016 VL 101 BP 71 EP 76 DI 10.1016/j.resuscitation.2016.01.029 PG 6 WC Critical Care Medicine; Emergency Medicine SC General & Internal Medicine; Emergency Medicine GA DL8HR UT WOS:000375882300025 PM 26868076 ER PT J AU Bourguignon, LYW AF Bourguignon, Lilly Y. W. TI Matrix Hyaluronan Promotes Specific MicroRNA Upregulation Leading to Drug Resistance and Tumor Progression SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES LA English DT Review DE hyaluronan (HA); CD44; microRNA (miRNA); cancer stem cells (CSCs); signaling; chemoresistance; tumor progression ID BREAST-CANCER CELLS; EMBRYONIC STEM-CELLS; CYTOSKELETON ACTIVATION; HOMING RECEPTOR; MARKER NANOG; ACID BINDING; EXPRESSION; CD44; INVASION; METASTASIS AB Solid tumor invasion, metastasis and therapeutic drug resistance are the common causes for serious morbidity and cancer recurrence in patients. A number of research studies have searched for malignancy-related biomarkers and drug targets that are closely linked to tumor cell properties. One of the candidates is matrix hyaluronan (HA), which is known as one of the major extracellular matrix (ECM) components. HA serves as a physiological ligand for surface CD44 molecule and also functions as a bio-regulator. The binding of HA to CD44 has been shown to stimulate concomitant activation of a number of oncogenic pathways and abnormal cellular processes in cancer cells and cancer stem cells (CSCs). MicroRNAs (miRNAs) belong to a class of small RNAs containing similar to 20-25 nucleotides and are known to promote aberrant cellular functions in cancer cells. In this article, I have focused on the role of HA interaction with CD44 and several important signaling molecules in the regulation of unique miRNAs (e. g., miR-21, miR-302 and miR-10b) and their downstream targets leading to multiple tumor cell-specific functions (e. g., tumor cell growth, drug resistance and metastasis) and cancer progression. This new knowledge could provide the groundwork necessary for establishing new tumor markers and developing important, novel drugs targeted against HA/CD44-associated tumor progression, which can be utilized in the therapeutic treatment of metastatic cancer patients. C1 [Bourguignon, Lilly Y. W.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med, 4150 Clement St, San Francisco, CA 94121 USA. [Bourguignon, Lilly Y. W.] Endocrine Unit 111N2, 4150 Clement St, San Francisco, CA 94121 USA. RP Bourguignon, LYW (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med, 4150 Clement St, San Francisco, CA 94121 USA.; Bourguignon, LYW (reprint author), Endocrine Unit 111N2, 4150 Clement St, San Francisco, CA 94121 USA. EM lilly.bourguignon@ucsf.edu OI Bourguignon, Lilly/0000-0003-3172-9251 FU Veterans Affairs (VA) Merit Review Awards [RR & D-1I01 RX000601, BLR & D-5I01 BX000628]; United States Public Health [R01 CA66163]; DOD (Department of Defense) FX This work was supported by Veterans Affairs (VA) Merit Review Awards (RR & D-1I01 RX000601 and BLR & D-5I01 BX000628), United States Public Health grants (R01 CA66163) and DOD (Department of Defense) grant Lilly Y.W. Bourguignon is a VA Senior Research Career Scientist. NR 65 TC 3 Z9 3 U1 2 U2 11 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1422-0067 J9 INT J MOL SCI JI Int. J. Mol. Sci. PD APR PY 2016 VL 17 IS 4 AR 517 DI 10.3390/ijms17040517 PG 12 WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary SC Biochemistry & Molecular Biology; Chemistry GA DK0EL UT WOS:000374585300096 PM 27070574 ER PT J AU Hoang, B Shi, YJ Frost, PJ Mysore, V Bardeleben, C Lichtenstein, A AF Hoang, Bao Shi, Yijiang Frost, Patrick J. Mysore, Veena Bardeleben, Carolyne Lichtenstein, Alan TI SGK Kinase Activity in Multiple Myeloma Cells Protects against ER Stress Apoptosis via a SEK-Dependent Mechanism SO MOLECULAR CANCER RESEARCH LA English DT Article ID PRECLINICAL MODELS; PATHWAY; GENE; INHIBITOR; SERUM; AKT; SURVIVAL; RECEPTOR; GROWTH; PHOSPHORYLATION AB To assess the role of the serum and glucocorticoid-regulated kinase (SGK) kinase in multiple myeloma, we ectopically expressed wild type or a phosphomimetic version of SGK into multiple myeloma cell lines. These cells were specifically resistant to the ER stress inducers tunicamycin, thapsigargin, and bortezomib. In contrast, there was no alteration of sensitivity to dexamethasone, serum starvation, or mTORC inhibitors. Mining of genomic data from a public database indicated that low baseline SGK expression in multiple myeloma patients correlated with enhanced ability to undergo a complete response to subsequent bortezomib treatment and a longer time to progression and overall survival following treatment. SGK overexpressing multiple myeloma cells were also relatively resistant to bortezomib in a murine xenograft model. Parental/control multiple myeloma cells demonstrated a rapid upregulation of SGK expression and activity (phosphorylation of NDRG-1) during exposure to bortezomib and an SGK inhibitor significantly enhanced bortezomib-induced apoptosis in cell lines and primary multiple myeloma cells. In addition, a multiple myeloma cell line selected for bortezomib resistance demonstrated enhanced SGK expression and SGK activity. Mechanistically, SGK overexpression constrained an ER stress-induced JNK proapoptotic pathway and experiments with a SEK mutant supported the notion that SGK's protection against bortezomib was mediated via its phosphorylation of SEK (MAP2K4) which abated SEK/JNK signaling. These data support a role for SGK inhibitors in the clinical setting for myeloma patients receiving treatment with ER stress inducers like bortezomib. Implications: Enhanced SGK expression and activity in multiple myeloma cells contributes to resistance to ER stress, including bortezomib challenge. Mol Cancer Res; 14(4); 397-407. (C) 2016 AACR. C1 [Hoang, Bao; Shi, Yijiang; Frost, Patrick J.; Mysore, Veena; Bardeleben, Carolyne; Lichtenstein, Alan] UCLA Med Ctr, Johnsson Comprehens Canc Ctr, Div Hematol Oncol, Greater Los Angeles VA Healthcare Ctr,Dept Med, Los Angeles, CA 90073 USA. RP Lichtenstein, A (reprint author), UCLA Med Ctr, West Los Angeles VA Med Center, 11301 Wilshire Blvd,Bldg 304,Room E1-115, Los Angeles, CA 90073 USA. EM alan.lichtenstein@med.va.gov FU NIH [RO1CA168700, 2RO1CA111448, R21CA168491]; Veteran's Administration; Multiple Myeloma Research Foundation; CURE grant [P30 DK041301] FX This work was supported by NIH grants RO1CA168700, 2RO1CA111448, and R21CA168491 as well as research funds of the Veteran's Administration and Multiple Myeloma Research Foundation. The UCLA Vector Core Lab was supported by CURE grant P30 DK041301. NR 29 TC 0 Z9 0 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1541-7786 EI 1557-3125 J9 MOL CANCER RES JI Mol. Cancer Res. PD APR PY 2016 VL 14 IS 4 BP 397 EP 407 DI 10.1158/1541-7786.MCR-15-0422 PG 11 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DL7WX UT WOS:000375852200009 PM 26869290 ER PT J AU Kopacz, MS Nieuwsma, JA Jackson, GL Rhodes, JE Cantrell, WC Bates, MJ Meador, KG AF Kopacz, Marek S. Nieuwsma, Jason A. Jackson, George L. Rhodes, Jeffrey E. Cantrell, William C. Bates, Mark J. Meador, Keith G. TI Chaplains' Engagement with Suicidality among Their Service Users: Findings from the VA/DoD Integrated Mental Health Strategy SO SUICIDE AND LIFE-THREATENING BEHAVIOR LA English DT Article ID UNITED-STATES; ACTIVE-DUTY; VETERANS; RISK; ATTENDANCE; PERSONNEL; CHURCH; CARE AB Chaplains play an important role in supporting the mental health of current and former military personnel; in this study, the engagement of Department of Veterans Affairs (VA), Army, Navy, and Air Force chaplains with suicidality among their service users were examined. An online survey was used to collect data from 440 VA and 1,723 Department of Defense (DoD) chaplains as part of the VA/DoD Integrated Mental Health Strategy. Differences were noted for demographics, work setting characteristics, encountering suicidality, and self-perceived preparation for dealing with suicidality. Compared to DoD chaplains, VA chaplains encounter more at-risk service users, yet feel less prepared for dealing with suicidality. C1 [Kopacz, Marek S.] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. [Nieuwsma, Jason A.; Cantrell, William C.; Meador, Keith G.] Mid Atlantic Mental Illness Res Educ & Clin Ctr, Dept Vet Affairs, Mental Hlth & Chaplaincy, Durham, NC USA. [Nieuwsma, Jason A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. [Jackson, George L.] Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA. [Jackson, George L.] Duke Univ, Med Ctr, Div Gen Internal Med, Durham, NC 27710 USA. [Rhodes, Jeffrey E.; Bates, Mark J.] Def Ctr Excellence Psychol Hlth & Traumat Brain I, Deployment Hlth Clin Ctr, Psychol Hlth Promot, Silver Spring, MD USA. [Meador, Keith G.] Vanderbilt Univ, Ctr Biomed Eth & Soc, Dept Psychiat, 221 Kirkland Hall, Nashville, TN 37235 USA. [Meador, Keith G.] Vanderbilt Univ, Ctr Biomed Eth & Soc, Dept Hlth Policy, 221 Kirkland Hall, Nashville, TN 37235 USA. [Meador, Keith G.] Vanderbilt Univ, Grad Dept Relig, 221 Kirkland Hall, Nashville, TN 37235 USA. RP Kopacz, MS (reprint author), US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. EM marek.kopacz@va.gov FU VISN 2 Center of Excellence for Suicide Prevention in Canandaigua, New York FX The views expressed are those of the authors and do not reflect the official policy or position of the US Department of Veterans Affairs, the US Department of Defense, or the US Government. This work was funded, in part, by the VISN 2 Center of Excellence for Suicide Prevention in Canandaigua, New York. NR 23 TC 3 Z9 3 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0363-0234 EI 1943-278X J9 SUICIDE LIFE-THREAT JI Suicide Life-Threat. Behav. PD APR PY 2016 VL 46 IS 2 BP 206 EP 212 DI 10.1111/sltb.12184 PG 7 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA DK1TC UT WOS:000374696200007 PM 26255592 ER PT J AU Greenwood, TA Light, GA Swerdlow, NR Calkins, ME Green, MF Gur, RE Gur, RC Lazzeroni, LC Nuechterlein, KH Olincy, A Radant, AD Seidman, LJ Siever, LJ Silverman, JM Stone, WS Sugar, CA Tsuang, DW Tsuang, MT Turetsky, BI Freedman, R Braff, DL AF Greenwood, Tiffany A. Light, Gregory A. Swerdlow, Neal R. Calkins, Monica E. Green, Michael F. Gur, Raquel E. Gur, Ruben C. Lazzeroni, Laura C. Nuechterlein, Keith H. Olincy, Ann Radant, Allen D. Seidman, Larry J. Siever, Larry J. Silverman, Jeremy M. Stone, William S. Sugar, Catherine A. Tsuang, Debby W. Tsuang, Ming T. Turetsky, Bruce I. Freedman, Robert Braff, David L. TI Gating Deficit Heritability and Correlation With Increased Clinical Severity in Schizophrenia Patients With Positive Family History SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID SCHIZOTYPAL PERSONALITY-DISORDER; EVOKED RESPONSE SUPPRESSION; PREPULSE INHIBITION; P50 SUPPRESSION; ACOUSTIC STARTLE; CONSORTIUM; RELATIVES; GENETICS; RISK; ENDOPHENOTYPES AB Objective: The Consortium on the Genetics of Schizophrenia Family Study evaluated 12 primary and other supplementary neurocognitive and neurophysiological endophenotypes in schizophrenia probands and their families. Previous analyses of prepulse inhibition (PPI) and P50 gating measures in this sample revealed heritability estimates that were lower than expected based on earlier family studies. Here the authors investigated whether gating measures were more heritable in multiply affected families with a positive family history compared with families with only a single affected proband (singleton). Method: A total of 296 nuclear families consisting of a schizophrenia proband, at least one unaffected sibling, and both parents underwent a comprehensive endophenotype andclinical characterization. The Family Interview for Genetic Studies was administered to all participants and used to obtain convergent psychiatric symptom information for additional first-degree relatives. Among the families, 97 were multiply affected, and 96 were singletons. Results: Both PPI and P50 gating displayed substantially increased heritability in the 97 multiply affected families (47% and 36%, respectively) compared with estimates derived from the entire sample of 296 families (29% and 20%, respectively). However, no evidence for heritability was observed for either measure in the 96 singleton families. Schizophrenia probands derived from the multiply affected families also displayed a significantly increased severity of clinical symptoms compared with those from singleton families. Conclusions: PPI and P50 gating measures demonstrate substantially increased heritability in schizophrenia families with a higher genetic vulnerability for illness, providing further support for the commonality of genes underlying both schizophrenia and gating measures. C1 [Greenwood, Tiffany A.] UCSanDiego, Ctr Behav Genom, Dept Psychiat, La Jolla, CA USA. [Greenwood, Tiffany A.] UCSanDiego, Inst Genom Med, La Jolla, CA USA. VA San Diego Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 22, San Diego, CA USA. Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. Harvard Inst Psychiat Epidemiol & Genet, Boston, MA USA. Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr, Div Publ Psychiat, Boston, MA 02215 USA. Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. James J Peters VA Med Ctr, New York, NY USA. RP Greenwood, TA (reprint author), UCSanDiego, Ctr Behav Genom, Dept Psychiat, La Jolla, CA USA.; Greenwood, TA (reprint author), UCSanDiego, Inst Genom Med, La Jolla, CA USA. EM tgreenwood@ucsd.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894; Greenwood, Tiffany/0000-0002-6080-6503 FU NIMH [R01-MH065571, R01-MH065588, R01-MH065562, R01-MH065707, R01-MH065554, R01-MH065578, R01-MH065558, R01 MH86135, K01-MH087889]; Amgen; Brain Plasticity; Genentech; Janssen Scientific Affairs FX Supported by NIMH grants R01-MH065571, R01-MH065588, R01-MH065562, R01-MH065707, R01-MH065554, R01-MH065578, R01-MH065558, R01 MH86135, and K01-MH087889.; Dr. Freedman has a patent through the VA on DNA sequences in CHRNA7. Dr. Green has been a consultant to AbbVie, Biogen, DSP, EnVivo/Forum, and Roche; he is on the scientific advisory board of Mnemosyne; and he has received research funds from Amgen. Dr. R.E. Gur has served as a consultant for Otsuka. Dr. Lazzeroni is an inventor on a patent application filed by Stanford University on genetic polymorphisms associated with depression. Dr. Light has served as a consultant for Astellas, Forum, and Neuroverse. Dr. Nuechterlein has received research support from Brain Plasticity, Genentech, and Janssen Scientific Affairs, and has served as a consultant for Brain Plasticity, Genentech, Janssen, and Otsuka. Dr. Swerdlow has served as a consultant for Genco Sciences. The other authors report no financial relationships with commercial interests. NR 60 TC 3 Z9 3 U1 3 U2 4 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X EI 1535-7228 J9 AM J PSYCHIAT JI Am. J. Psychiat. PD APR PY 2016 VL 173 IS 4 BP 385 EP 391 DI 10.1176/appi.ajp.2015.15050605 PG 7 WC Psychiatry SC Psychiatry GA DK9ZH UT WOS:000375290400013 PM 26441157 ER PT J AU Mandal, R Duvvuri, U Ferris, RL Kaffenberger, TM Choby, GW Kim, S AF Mandal, Rajarsi Duvvuri, Umamaheswar Ferris, Robert L. Kaffenberger, Thomas M. Choby, Garret W. Kim, Seungwon TI Analysis of post-transoral robotic-assisted surgery hemorrhage: Frequency, outcomes, and prevention SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK LA English DT Article DE transoral robotic-assisted surgery (TORS); TORS hemorrhage; TORS bleeding; TORS complications; prophylactic arterial ligation ID OBSTRUCTIVE SLEEP-APNEA; ASCENDING PHARYNGEAL ARTERY; SQUAMOUS-CELL CARCINOMA; FUNCTIONAL OUTCOMES; PARAPHARYNGEAL SPACE; CLINICAL-EXPERIENCE; HYPOPNEA SYNDROME; CAROTID-ARTERY; FEASIBILITY; OROPHARYNX AB Background. Transoral robotic-assisted surgery (TORS) carries a small, but not insignificant, risk of life-threatening postsurgical hemorrhage. The purpose of this study was to analyze all post-TORS hemorrhagic events at our institution to establish preventative recommendations. Methods. We conducted a retrospective review of 224 consecutive patients who underwent TORS for any indication at a single tertiary care institution. Results. Twenty-two patients (n = 22; 9.82%) had varying degrees of postoperative bleeding. An impaired ability to protect the airway at the time of hemorrhage increased the rate of severe complications. Prophylactic transcervical arterial ligation did not significantly decrease overall postoperative bleeding rates (9.1% vs 9.9%; p = 1.00); however, there was a trend toward decreased hemorrhage severity in prophylactically ligated patients (3.0% vs 7.3%; p = .7040). Conclusion. Prophylactic transcervical arterial ligation may reduce the incidence of severe bleeding following TORS. Post-TORS patients displaying an inability to protect the airway should be strongly considered for prophylactic tracheostomy to assist airway protection. (C) 2015 Wiley Periodicals, Inc. C1 [Mandal, Rajarsi; Duvvuri, Umamaheswar; Ferris, Robert L.; Choby, Garret W.; Kim, Seungwon] Univ Pittsburgh, Dept Otolaryngol, Med Ctr, Pittsburgh, PA 15260 USA. [Duvvuri, Umamaheswar] Vet Affairs Pittsburgh Hlth Syst, Pittsburgh, PA USA. [Kaffenberger, Thomas M.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. RP Kim, S (reprint author), Eye & Ear Inst Pittsburgh, Suite 500,203 Lothrop St, Pittsburgh, PA 15213 USA. EM kimsw2@upmc.edu NR 25 TC 6 Z9 6 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1043-3074 EI 1097-0347 J9 HEAD NECK-J SCI SPEC JI Head Neck-J. Sci. Spec. Head Neck PD APR PY 2016 VL 38 SU 1 BP E776 EP E782 DI 10.1002/hed.24101 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA DK7OU UT WOS:000375116400093 PM 25916790 ER PT J AU Scales, CD Moin, T Fink, A Berry, SH Afsar-Manesh, N Mangione, CM Kerfoot, BP AF Scales, Charles D., Jr. Moin, Tannaz Fink, Arlene Berry, Sandra H. Afsar-Manesh, Nasim Mangione, Carol M. Kerfoot, B. Price TI A randomized, controlled trial of team-based competition to increase learner participation in quality-improvement education SO INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE LA English DT Article DE graduate medical education; randomized controlled trial; quality improvement; spaced education ID INTERACTIVE SPACED-EDUCATION; WEIGHT-LOSS; MEMORY; ENVIRONMENT; INCENTIVES; RETENTION; RETRIEVAL; PROGRAM; IMPACT; SAFETY AB Several barriers challenge resident engagement in learning quality improvement (QI). We investigated whether the incorporation of team-based game mechanics into an evidence-based online learning platform could increase resident participation in a QI curriculum. Randomized, controlled trial. Tertiary-care medical center residency training programs. Resident physicians (n = 422) from nine training programs (anesthesia, emergency medicine, family medicine, internal medicine, ophthalmology, orthopedics, pediatrics, psychiatry and general surgery) randomly allocated to a team competition environment (n = 200) or the control group (n = 222). Specialty-based team assignment with leaderboards to foster competition, and alias assignment to de-identify individual participants. Participation in online learning, as measured by percentage of questions attempted (primary outcome) and additional secondary measures of engagement (i.e. response time). Changes in participation measures over time between groups were assessed with a repeated measures ANOVA framework. Residents in the intervention arm demonstrated greater participation than the control group. The percentage of questions attempted at least once was greater in the competition group (79% [SD +/- 32] versus control, 68% [SD +/- 37], P= 0.03). Median response time was faster in the competition group (P= 0.006). Differences in participation continued to increase over the duration of the intervention, as measured by average response time and cumulative percent of questions attempted (each P < 0.001). Team competition increases resident participation in an online course delivering QI content. Medical educators should consider game mechanics to optimize participation when designing learning experiences. C1 [Scales, Charles D., Jr.; Fink, Arlene; Mangione, Carol M.] Univ Calif Los Angeles, Robert Wood Johnson Fdn, US Dept Vet Affairs, Clin Scholars Program, Los Angeles, CA USA. [Scales, Charles D., Jr.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Scales, Charles D., Jr.; Moin, Tannaz; Fink, Arlene; Afsar-Manesh, Nasim; Mangione, Carol M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Scales, Charles D., Jr.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Moin, Tannaz] Vet Affairs Greater Los Angeles Healthcare Syst, HSR&D Ctr Excellence Study Healthcare Innovat Imp, Los Angeles, CA USA. [Fink, Arlene; Mangione, Carol M.] Univ Calif Los Angeles, Dept Hlth Policy & Management, Fielding Sch Publ Hlth, Los Angeles, CA USA. [Berry, Sandra H.] RAND Corp, Santa Monica, CA USA. [Afsar-Manesh, Nasim] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA. [Kerfoot, B. Price] Vet Affairs Boston Healthcare Syst, Boston, MA USA. [Kerfoot, B. Price] Harvard Univ, Sch Med, Boston, MA USA. [Scales, Charles D., Jr.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA. [Scales, Charles D., Jr.] Duke Univ, Sch Med, Div Urol Surg, Durham, NC USA. RP Scales, CD (reprint author), Duke Clin Res Inst, DUMC 3707, Durham, NC 27710 USA.; Scales, CD (reprint author), Div Urol Surg, DUMC 3707, Durham, NC 27710 USA. EM chuck.scales@duke.edu NR 30 TC 4 Z9 4 U1 2 U2 8 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1353-4505 EI 1464-3677 J9 INT J QUAL HEALTH C JI Int. J. Qual. Health Care PD APR 1 PY 2016 VL 28 IS 2 BP 227 EP 232 DI 10.1093/intqhc/mzw008 PG 6 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DK7GU UT WOS:000375094000011 PM 26857941 ER PT J AU Li, XL Wilson, M Nylander, W Smith, T Lynn, M Gunnar, W AF Li, Xinli Wilson, Mark Nylander, William Smith, Tracy Lynn, Marilyn Gunnar, William TI Analysis of Morbidity and Mortality Outcomes in Postoperative Clostridium difficile Infection in the Veterans Health Administration SO JAMA SURGERY LA English DT Article ID RISK-FACTORS; TRANSPLANT RECIPIENTS; SURGERY; PROPHYLAXIS; OUTBREAK; DIARRHEA; COLITIS; IMPACT AB IMPORTANCE This study analyzes and reports Clostridium difficile infection (CDI) rates, risk factors, and associations with postoperative outcomes in the Veterans Health Administration (VHA). OBJECTIVE To report 30-day postoperative CDI rates and outcomes and identify associated risks by surgical procedures and preoperative patient demographics in a large integrated health care system. DESIGN, SETTING, AND PARTICIPANTS In a retrospective observational study conducted from September 2014 to April 2015, the Veterans Affairs Surgical Quality Improvement Program database and the Decision Support System pharmacy database were linked to analyze the association of postoperative CDI with patients' demographics, preoperative comorbidities, operative characteristics, and preoperative medications. The Veterans Affairs Surgical Quality Improvement Program assessments from October 1, 2009, to September 30, 2013, were investigated. The study was conducted at 134 VHA surgery programs, and the study population represents 12 surgical specialties: general, gynecological, neurosurgical, oral, orthopedics, otolaryngologic, plastic, podiatric, thoracic, transplant, urologic, and peripheral vascular. MAIN OUTCOMES AND MEASURES Thirty-day postoperative CDI rates, risk factors of CDI, and association of CDI with postoperative morbidity and mortality. RESULTS Among 468 386 surgical procedures, the postoperative CDI rate was 0.4% per year and varied by the VHA Surgery Program (0.0% to 1.4%) and surgical specialty (0.0% to 2.4%). Thirty-day CDI rates were higher in emergency procedures, procedures with greater complexity and higher relative value units, and those with a contaminated/ infected wound classification. Patients with postoperative CDI were significantly older, more frequently hospitalized after surgery (59.9% vs 15.4%), had longer preoperative hospital stays (9.1 days vs 1.9 days), and had received 3 or more classes of antibiotics (1.5% vs 0.3% for a single antibiotic class) (all P < .001). Patients with CDI had higher rates of other postoperative morbidity (86.0% vs 7.1%), 30-day mortality (5.3% vs 1.0%), and longer postoperative hospital stays (17.9 days vs 3.6 days). Independent risk factors for CDI included commonly identified patient factors (albumin, functional class, and weight loss), procedural characteristics (complexity, relative value units, emergency, and wound classification), surgical program complexity, the number of preoperative antibiotic classes, and length of preoperative hospital stay. CONCLUSIONS AND RELEVANCE The number and class of antibiotics administered after surgery, preoperative length of stay, procedural characteristics, surgical program complexity, and patient comorbidities are associated with postoperative CDI in the VHA. C1 [Li, Xinli; Wilson, Mark; Nylander, William; Smith, Tracy; Lynn, Marilyn; Gunnar, William] Vet Hlth Adm, Natl Surg Off, Washington, DC USA. [Wilson, Mark] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Wilson, Mark] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. [Gunnar, William] George Washington Univ, Washington, DC USA. RP Li, XL (reprint author), Vet Hlth Adm, Natl Surg Off, 4100 E Mississippi Ave,Ste 310, Glendale, CO 80246 USA. EM xinli.li2@va.gov NR 24 TC 6 Z9 6 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD APR PY 2016 VL 151 IS 4 BP 314 EP 322 DI 10.1001/jamasurg.2015.4263 PG 9 WC Surgery SC Surgery GA DJ7SE UT WOS:000374411000004 PM 26606675 ER PT J AU Waltz, PK Zuckerbraun, BS AF Waltz, Paul K. Zuckerbraun, Brian S. TI The High Stakes of Postoperative Clostridium difficile Infection SO JAMA SURGERY LA English DT Editorial Material C1 [Waltz, Paul K.; Zuckerbraun, Brian S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Waltz, Paul K.; Zuckerbraun, Brian S.] Univ Pittsburgh, 200 Lothrop St,F1200 PUH, Pittsburgh, PA 15213 USA. RP Zuckerbraun, BS (reprint author), Univ Pittsburgh, 200 Lothrop St,F1200 PUH, Pittsburgh, PA 15213 USA. EM zuckerbraunbs@upmc.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD APR PY 2016 VL 151 IS 4 BP 322 EP 322 DI 10.1001/jamasurg.2015.4254 PG 1 WC Surgery SC Surgery GA DJ7SE UT WOS:000374411000005 PM 26606279 ER PT J AU Lamming, DW Cummings, NE Apelo, SA Neuman, JC Schmidt, B Merrins, M Kimple, M Fontana, L AF Lamming, D. W. Cummings, N. E. Apelo, S. Arriola Neuman, J. C. Schmidt, B. Merrins, M. Kimple, M. Fontana, L. TI IMPROVING GLYCEMIC CONTROL THROUGH REDUCTION OF SPECIFIC DIETARY AMINO ACIDS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Midwestern Regional Meeting of the American-Federation-for-Medical-Research (AFMR) CY APR 21, 2016 CL Chicago, IL SP Amer Federat Med Res C1 [Lamming, D. W.; Cummings, N. E.; Apelo, S. Arriola; Neuman, J. C.; Schmidt, B.; Merrins, M.; Kimple, M.] Univ Wisconsin, Med, Madison, WI USA. [Lamming, D. W.; Cummings, N. E.; Apelo, S. Arriola; Neuman, J. C.; Schmidt, B.; Merrins, M.; Kimple, M.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Fontana, L.] Washington Univ, Geriatr & Nutr Sci, St Louis, MO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD APR PY 2016 VL 64 IS 4 MA 78 BP 926 EP 926 DI 10.1136/jim-2016-000120.32 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA DK3CI UT WOS:000374792900047 ER PT J AU Apelo, SA Pumper, CP Baar, EL Cummings, NE Brar, HK Kimple, ME Lamming, DW Neuman, JC AF Apelo, S. Arriola Pumper, C. P. Baar, E. L. Cummings, N. E. Brar, H. K. Kimple, M. E. Lamming, D. W. Neuman, J. C. TI ALTERNATIVE RAPAMYCIN TREATMENT REGIMENS MITIGATE THE IMPACT OF RAPAMYCIN ON GLUCOSE HOMEOSTASIS AND THE IMMUNE SYSTEM, AND EXTENDS LIFESPAN SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Midwestern Regional Meeting of the American-Federation-for-Medical-Research (AFMR) CY APR 21, 2016 CL Chicago, IL SP Amer Federat Med Res C1 [Apelo, S. Arriola; Pumper, C. P.; Baar, E. L.; Cummings, N. E.; Brar, H. K.; Kimple, M. E.; Lamming, D. W.] Univ Wisconsin, Div Endocrinol Diabet & Metab, Med, Madison, WI USA. [Neuman, J. C.] Univ Wisconsin, Interdisciplinary Grad Program Nutr Sci, Madison, WI USA. [Apelo, S. Arriola; Pumper, C. P.; Baar, E. L.; Cummings, N. E.; Brar, H. K.; Kimple, M. E.; Lamming, D. W.; Neuman, J. C.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD APR PY 2016 VL 64 IS 4 MA 21 DI 10.1136/jim-2016-000120.45 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA DK3CI UT WOS:000374792900060 ER PT J AU Graves, MC Harris, JR Kohn, M Hannon, PA Lichiello, PA Martin, DP Ahmed, F AF Graves, Meredith C. Harris, Jeffrey R. Kohn, Marlana Hannon, Peggy A. Lichiello, Patricia A. Martin, Diane P. Ahmed, Faruque TI Employers' Views on Influenza and Tetanus-Diphtheria-Pertussis Vaccination in the Workplace SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Letter ID UNITED-STATES; ADULTS; COSTS C1 [Harris, Jeffrey R.; Kohn, Marlana; Hannon, Peggy A.; Lichiello, Patricia A.; Martin, Diane P.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Harris, Jeffrey R.; Kohn, Marlana; Hannon, Peggy A.] Univ Washington, Hlth Promot Res Ctr, Ctr Dis Control & Prevent, Res Ctr, Seattle, WA 98195 USA. [Graves, Meredith C.] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Ahmed, Faruque] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. RP Graves, MC (reprint author), VA Puget Sound Healthcare Syst, Seattle, WA USA. NR 11 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD APR PY 2016 VL 58 IS 4 BP E157 EP E158 DI 10.1097/JOM.0000000000000693 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DK4ME UT WOS:000374891600009 PM 27058495 ER PT J AU Lee, LY Foley, DP AF Lee, Lung-Yi Foley, David P. TI Technical Aspects of Orthotopic Liver Transplantation for Hepatocellular Carcinoma SO SURGICAL CLINICS OF NORTH AMERICA LA English DT Article DE Liver transplantation; Surgery; Hepatocellular carcinoma; Piggyback technique; Portal vein thrombosis ID TRANSARTERIAL CHEMOEMBOLIZATION; BILIARY COMPLICATIONS; CANCER STATISTICS; HEPATIC-ARTERY; SURVIVAL; EXPERIENCE; CIRRHOSIS AB Hepatocellular carcinoma (HCC) remains a significant malignancy and is the second leading cause of cancer death worldwide. Multiple therapeutic strategies exist for patients with HCC including locoregional therapy, liver resection, and liver transplantation. In many instances locoregional therapy is used to decrease tumor burden and "bridge" patients to liver transplant. Surgical technique during liver transplantation may need to be altered in light of these preoperative therapies used for treating HCC. In this review, we discuss the technical aspects of liver transplantation and how they are impacted in patients with HCC. C1 [Lee, Lung-Yi; Foley, David P.] Univ Wisconsin, Dept Surg, Ctr Clin Sci, Sch Med & Publ Hlth, H4-766,600 Highland Ave, Madison, WI 53792 USA. [Foley, David P.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, 2500 Overlook Terrace, Madison, WI 53705 USA. RP Foley, DP (reprint author), Univ Wisconsin, Ctr Clin Sci, H4-766,600 Highland Ave, Madison, WI 53792 USA. EM foley@surgery.wisc.edu NR 28 TC 0 Z9 0 U1 4 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0039-6109 EI 1558-3171 J9 SURG CLIN N AM JI Surg. Clin.-North Am. PD APR PY 2016 VL 96 IS 2 BP 269 EP + DI 10.1016/j.suc.2015.11.004 PG 15 WC Surgery SC Surgery GA DK6GR UT WOS:000375021200011 PM 27017864 ER PT J AU Musher, DM AF Musher, Daniel M. TI Quantitative Molecular Approach to Diagnosing Pneumonia SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material DE community-acquired pneumonia; etiology; sputum; Gram stain ID COMMUNITY-ACQUIRED PNEUMONIA; ADULTS C1 [Musher, Daniel M.] Baylor Coll Med, Houston, TX 77030 USA. [Musher, Daniel M.] Michael E DeBakey VA Med Ctr, Infect Dis Sect, Med Care Line, Houston, TX USA. RP Musher, DM (reprint author), VA Med Ctr, 2002 Holcombe, Houston, TX 77030 USA. EM daniel.musher@va.gov NR 11 TC 4 Z9 4 U1 2 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2016 VL 62 IS 7 BP 824 EP 825 DI 10.1093/cid/civ1216 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DJ5LD UT WOS:000374248700002 PM 26747824 ER PT J AU Fox, GJ Mitnick, CD Benedetti, A Chan, ED Becerra, M Chiang, CY Keshavjee, S Koh, WJ Shiraishi, Y Viiklepp, P Yim, JJ Pasvol, G Robert, J Shim, TS Shin, SS Menzies, D AF Fox, Gregory J. Mitnick, Carole D. Benedetti, Andrea Chan, Edward D. Becerra, Mercedes Chiang, Chen-Yuan Keshavjee, Salmaan Koh, Won-Jung Shiraishi, Yuji Viiklepp, Piret Yim, Jae-Joon Pasvol, Geoffrey Robert, Jerome Shim, Tae Sun Shin, Sonya S. Menzies, Dick CA Collaborative Grp Meta-Anal Indivi TI Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE multidrug resistant tuberculosis; thoracic surgery; pneumonectomy; metaanalysis; individual patient data ID TREATMENT OUTCOMES AB Background. Medical treatment for multidrug-resistant (MDR)-tuberculosis is complex, toxic, and associated with poor outcomes. Surgical lung resection may be used as an adjunct to medical therapy, with the intent of reducing bacterial burden and improving cure rates. We conducted an individual patient data metaanalysis to evaluate the effectiveness of surgery as adjunctive therapy for MDR-tuberculosis. Methods. Individual patient data, was obtained from the authors of 26 cohort studies, identified from 3 systematic reviews of MDR-tuberculosis treatment. Data included the clinical characteristics and medical and surgical therapy of each patient. Primary analyses compared treatment success (cure and completion) to a combined outcome of failure, relapse, or death. The effects of all forms of resection surgery, pneumonectomy, and partial lung resection were evaluated. Results. A total of 4238 patients from 18 surgical studies and 2193 patients from 8 nonsurgical studies were included. Pulmonary resection surgery was performed on 478 patients. Partial lung resection surgery was associated with improved treatment success (adjusted odds ratio [aOR], 3.0; 95% confidence interval [CI], 1.5-5.9; I-R(2), 11.8%), but pneumonectomy was not (aOR, 1.1; 95% CI,.6-2.3; I-R(2), 13.2%). Treatment success was more likely when surgery was performed after culture conversion than before conversion (aOR, 2.6; 95% CI, 0.9-7.1; I-R(2), 0.2%). Conclusions. Partial lung resection, but not pneumonectomy, was associated with improved treatment success among patients with MDR-tuberculosis. Although improved outcomes may reflect patient selection, partial lung resection surgery after culture conversion may improve treatment outcomes in patients who receive optimal medical therapy. C1 [Fox, Gregory J.; Benedetti, Andrea; Menzies, Dick] McGill Univ, Montreal Chest Inst, Montreal, PQ H3A 2T5, Canada. [Mitnick, Carole D.; Becerra, Mercedes; Keshavjee, Salmaan] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA 02115 USA. [Chan, Edward D.] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA. [Chan, Edward D.] Denver Vet Affairs Med Ctr, Dept Acad Affairs, Denver, CO USA. [Chiang, Chen-Yuan] Taipei Med Univ, Wan Fang Hosp, Taipei, Taiwan. [Koh, Won-Jung] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea. [Shiraishi, Yuji] Fukujuji Hosp, Sect Chest Surg, Tokyo, Japan. [Viiklepp, Piret] Natl Inst Hlth Dev, Estonian TB Registry, Tallinn, Estonia. [Yim, Jae-Joon] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea. [Pasvol, Geoffrey] Univ London Imperial Coll Sci Technol & Med, Dept Infect & Trop Med, London, England. [Robert, Jerome] Univ Paris 06, Lab Bacteriol Hyg, Paris, France. [Shim, Tae Sun] Univ Ulsan, Coll Med, Dept Pulm & Crit Care Med, Asan Med Ctr, Seoul, South Korea. [Shin, Sonya S.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. RP Menzies, D (reprint author), 2155 Guy St, Montreal, PQ H3H 2R9, Canada. EM dick.menzies@mcgill.ca RI Koh, Won Jung/C-9595-2011 OI Hollm-Delgado, Maria-Graciela/0000-0003-1067-8520; ROBERT, JEROME/0000-0002-9380-0570 FU CJ Martin post-doctoral fellowship [APP1054107]; Australian National Health and Medical Research Council FX This work was supported by a CJ Martin post-doctoral fellowship (APP1054107) to G. J. F. from the Australian National Health and Medical Research Council. NR 17 TC 7 Z9 7 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2016 VL 62 IS 7 BP 887 EP 895 DI 10.1093/cid/ciw002 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DJ5LD UT WOS:000374248700011 PM 26757804 ER PT J AU Ovchinnikova, ES Schmitter, D Vegter, EL ter Maaten, JM Valente, MAE Liu, LCY van der Harst, P Pinto, YM de Boer, RA Meyer, S Teerlink, JR O'Connor, CM Metra, M Davison, BA Bloomfield, DM Cotter, G Cleland, JG Mebazaa, A Laribi, S Givertz, MM Ponikowski, P van der Meer, P van Veldhuisen, DJ Voors, AA Berezikov, E AF Ovchinnikova, Ekaterina S. Schmitter, Daniela Vegter, Eline L. ter Maaten, Jozine M. Valente, Mattia A. E. Liu, Licette C. Y. van der Harst, Pim Pinto, Yigal M. de Boer, Rudolf A. Meyer, Sven Teerlink, John R. O'Connor, Christopher M. Metra, Marco Davison, Beth A. Bloomfield, Daniel M. Cotter, Gadi Cleland, John G. Mebazaa, Alexandre Laribi, Said Givertz, Michael M. Ponikowski, Piotr van der Meer, Peter van Veldhuisen, Dirk J. Voors, Adriaan A. Berezikov, Eugene TI Signature of circulating microRNAs in patients with acute heart failure SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE Heart failure; Circulating microRNAs; Biomarkers ID DILATED CARDIOMYOPATHY; EJECTION FRACTION; CANDIDATE MARKERS; HYPERTROPHY; EXPRESSION; MIRNAS; BIOMARKERS; CARDIOMYOCYTES; MECHANISM; DIAGNOSIS AB AimsOur aim was to identify circulating microRNAs (miRNAs) associated with acute heart failure (AHF). Methods and resultsPlasma miRNA profiling included 137 patients with AHF from 3 different cohorts, 20 with chronic heart failure (CHF), 8 with acute exacerbation of COPD, and 41 healthy controls. Levels of circulating miRNAs were measured using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Plasma levels of miRNAs in patients with AHF were decreased compared with CHF patients or healthy subjects, whereas no significant changes were observed between acute COPD patients and controls. Fifteen miRNAs found in the discovery phase to differ most significantly between healthy controls and patients with AHF were further investigated in an extended cohort of 100 AHF patients at admission and a separate cohort of 18 AHF patients at different time points. Out of these 15 miRNAs, 12 could be confirmed in an additional AHF validation cohort and 7 passed the Bonferroni correction threshold (miR-18a-5p, miR-26b-5p, miR-27a-3p, miR-30e-5p, miR-106a-5p, miR-199a-3p, and miR-652-3p, all P < 0.00005). A further drop in miRNA levels within 48 h after AHF admission was associated with an increased risk of 180-day mortality in a subset of the identified miRNAs. ConclusionsDeclining levels of circulating miRNAs were associated with increasing acuity of heart failure. Early in-hospital decreasing miRNA levels were predictive for mortality in a subset of miRNAs in patients with AHF. The discovered miRNA panel may serve as a launch-pad for molecular pathway studies to identify new pharmacological targets and miRNA-based therapies. C1 [Ovchinnikova, Ekaterina S.; Vegter, Eline L.; ter Maaten, Jozine M.; Valente, Mattia A. E.; Liu, Licette C. Y.; van der Harst, Pim; de Boer, Rudolf A.; Meyer, Sven; van der Meer, Peter; van Veldhuisen, Dirk J.; Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, AB31,Hanzepl 1, NL-9713 GZ Groningen, Netherlands. [Ovchinnikova, Ekaterina S.; Berezikov, Eugene] Univ Groningen, Univ Med Ctr Groningen, European Res Inst Biol Ageing, Groningen, Netherlands. [Schmitter, Daniela] Momentum Res Inc, Allschwil, Switzerland. [Pinto, Yigal M.] Univ Amsterdam, Amsterdam, Netherlands. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [O'Connor, Christopher M.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Metra, Marco] Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Cardiol, Brescia, Italy. [Davison, Beth A.; Cotter, Gadi] Momentum Res, Durham, NC USA. [Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA. [Cleland, John G.] Univ London Imperial Coll Sci Technol & Med, Royal Brompton & Harefield Hosp, Natl Heart & Lung Inst, London, England. [Mebazaa, Alexandre] Univ Paris Diderot, St Louis Lariboisiere Univ Hosp, AP HP,INSERM,U942, Dept Anesthesiol & Crit Care, Paris, France. [Mebazaa, Alexandre] Univ Paris Diderot, St Louis Lariboisiere Univ Hosp, AP HP,INSERM,U942, Burn Unit, Paris, France. [Laribi, Said] St Louis Lariboisiere Univ Hosp, AP HP, INSERM,U942, Dept Emergency Med, Paris, France. [Givertz, Michael M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. RP Voors, AA (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, AB31,Hanzepl 1, NL-9713 GZ Groningen, Netherlands. EM a.a.voors@umcg.nl RI Laribi, said/S-3693-2016; Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; Berezikov, Eugene/0000-0002-1145-2884; Cleland, John/0000-0002-1471-7016 FU Dutch Heart Foundation: Approaching Heart Failure By Translational Research of RNA Mechanisms (ARENA); NovaCardia, a subsidiary of Merck; Netherlands Heart Foundation [2000Z003]; Biosite France SAS; Jouy-en-Josas, France (BNP); Roche Diagnostics Nederland BV, Venlo, The Netherlands (NT-proBNP); Novartis Pharma BV, Arnhem, The Netherlands FX This study was supported by a Grant from the Dutch Heart Foundation: Approaching Heart Failure By Translational Research of RNA Mechanisms (ARENA). The PROTECT trial was supported by NovaCardia, a subsidiary of Merck. COACH was supported by grant 2000Z003 from the Netherlands Heart Foundation and by additional unrestricted grants from Biosite France SAS, Jouy-en-Josas, France (BNP), Roche Diagnostics Nederland BV, Venlo, The Netherlands (NT-proBNP), and Novartis Pharma BV, Arnhem, The Netherlands. NR 44 TC 13 Z9 13 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD APR PY 2016 VL 18 IS 4 BP 414 EP 423 DI 10.1002/ejhf.332 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DJ6GK UT WOS:000374308700012 PM 26345695 ER PT J AU Samsky, MD Dunning, A DeVore, AD Schulte, PJ Starling, RC Tang, WHW Armstrong, PW Ezekowitz, JA Butler, J McMurray, JJ Teerlink, JR Voors, AA Metra, M Mentz, RJ O'Connor, CM Patel, CB Hernandez, AF AF Samsky, Marc D. Dunning, Allison DeVore, Adam D. Schulte, Phillip J. Starling, Randall C. Tang, W. H. Wilson Armstrong, Paul W. Ezekowitz, Justin A. Butler, Javed McMurray, John J. Teerlink, John R. Voors, Adrian A. Metra, Marco Mentz, Robert J. O'Connor, Christopher M. Patel, Chetan B. Hernandez, Adrian F. TI Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE Heart failure; Liver function tests; Outcomes ID FUNCTION ABNORMALITIES; PROGNOSTIC-SIGNIFICANCE; HYPOXIC HEPATITIS; VENOUS-PRESSURE; RENAL-FUNCTION; TASK-FORCE; DYSFUNCTION; PREVALENCE; CONGESTION; GUIDELINES AB AimsWe aimed to characterize abnormal liver function tests in patients with heart failure (HF), as they are commonly encountered yet poorly defined. Methods and resultsWe used data from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) to characterize associations with baseline liver function tests (LFTs). Each LFT was analysed as both a continuous and dichotomous variable [normal vs. abnormal; bilirubin >1.0mg/dL; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >35mmol/L]. Logistic regression assessed the association of LFTs and 30-day all-cause mortality and HF rehospitalization, and Cox proportional hazards assessed the association with 180-day all-cause mortality among patients alive at a 30-day landmark. In ASCEND-HF, 4228 (59%) had complete admission LFT data. Of these, 42% had abnormal bilirubin, 22% had abnormal ALT, and 30% had abnormal AST. Patients with abnormal LFTs were younger, had lower body mass index, and lower left ventricular ejection fraction. In multivariable models, increased total bilirubin was associated with increased 30-day mortality or HF rehospitalization [hazard ratio (HR) 1.17 per 1mg/dL increase, 95% confidence interval (CI) 1.04, 1.32; P=0.012], but not with an increase in 180-day mortality (HR 1.10, 95% CI 0.97, 1.25; P=0.13) per 1mg/dl increase. Compared with normal bilirubin levels, abnormal bilirubin was associated with increased 30-day mortality or HF rehospitalization (HR 1.24, 95% CI 1.00, 1.54; P=0.048) and 180-day mortality (HR 1.32, 95% CI 1.08, 1.62; P=0.007). We found no association with AST or ALT and outcomes. ConclusionGreater than 40% of patients hospitalized with acute HF had abnormal LFTs. After multivariable adjustment, only elevated bilirubin was independently associated with worse clinical outcomes and may represent an important prognostic variable. C1 [Samsky, Marc D.; DeVore, Adam D.; Mentz, Robert J.; O'Connor, Christopher M.; Patel, Chetan B.; Hernandez, Adrian F.] Duke Univ, Durham, NC USA. [Dunning, Allison; DeVore, Adam D.; Schulte, Phillip J.; Mentz, Robert J.; O'Connor, Christopher M.; Patel, Chetan B.; Hernandez, Adrian F.] Duke Clin Res Inst, Durham, NC USA. [Starling, Randall C.; Tang, W. H. Wilson] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA. [Armstrong, Paul W.] Canadian VIGOUR Ctr, Edmonton, AB, Canada. [Armstrong, Paul W.; Ezekowitz, Justin A.] Univ Alberta, Edmonton, AB, Canada. [Butler, Javed] Stony Brook Univ Hosp, Stony Brook, NY USA. [McMurray, John J.] Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland. [McMurray, John J.] Univ Glasgow, Glasgow, Lanark, Scotland. [Teerlink, John R.] Univ Calif San Francisco, San Francisco VA Hosp, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Voors, Adrian A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. [Metra, Marco] Univ Brescia, Brescia, Italy. RP Samsky, MD (reprint author), Duke Univ, Med Ctr, Duke North Hosp, Room 8254,2301 Erwin Rd, Durham, NC 27710 USA. EM marc.samsky@dm.duke.edu OI DeVore, Adam/0000-0002-4679-2221; mcmurray, john/0000-0002-6317-3975 FU Johnson and Johnson FX The ASCEND-HF trial was supported by Johnson and Johnson. NR 36 TC 6 Z9 6 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD APR PY 2016 VL 18 IS 4 BP 424 EP 432 DI 10.1002/ejhf.440 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DJ6GK UT WOS:000374308700013 PM 26707029 ER PT J AU Linnemann, AK Davis, DB AF Linnemann, Amelia K. Davis, Dawn Belt TI Glucagon-like peptide-1 and cholecystokinin production and signaling in the pancreatic islet as an adaptive response to obesity SO JOURNAL OF DIABETES INVESTIGATION LA English DT Article DE Cholecystokinin; Glucagon-like peptide-1; Pancreatic islet ID BETA-CELL MASS; FAT-FED MICE; TRANSCRIPTION FACTORS; GENE-TRANSCRIPTION; INSULIN-SECRETION; GLP-1 RECEPTORS; MOUSE MODELS; DOUBLE-BLIND; ALPHA-CELLS; IN-VITRO AB Precise control of blood glucose is dependent on adequate -cell mass and function. Thus, reductions in -cell mass and function lead to insufficient insulin production to meet demand, and result in diabetes. Recent evidence suggests that paracrine signaling in the islet might be important in obesity, and disruption of this signaling could play a role in the pathogenesis of diabetes. For example, we recently discovered a novel islet incretin axis where glucagon-like peptide-1 regulates -cell production of another classic gut hormone, cholecystokinin. This axis is stimulated by obesity, and plays a role in enhancing -cell survival. In the present review, we place our observations in the wider context of the literature on incretin regulation in the islet, and discuss the potential for therapeutic targeting of these pathways. C1 [Linnemann, Amelia K.; Davis, Dawn Belt] Univ Wisconsin, Dept Med, Div Endocrinol, Madison, WI USA. [Davis, Dawn Belt] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Linnemann, AK (reprint author), Univ Wisconsin, Dept Med, Div Endocrinol, Madison, WI USA. EM alinnemann@medicine.wisc.edu FU BLRD VA [I01 BX001880]; NIDDK NIH HHS [K01 DK102492] NR 50 TC 1 Z9 1 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2040-1116 EI 2040-1124 J9 J DIABETES INVEST JI J. Diabetes Investig. PD APR PY 2016 VL 7 SU 1 SI SI BP 44 EP 49 DI 10.1111/jdi.12465 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DK1HN UT WOS:000374663200009 PM 27186355 ER PT J AU Watanabe, C Komoto, S Tomita, K Hokari, R Tanaka, M Hirata, I Hibi, T Kaunitz, JD Miura, S AF Watanabe, Chikako Komoto, Shunsuke Tomita, Kengo Hokari, Ryota Tanaka, Masanori Hirata, Ichiro Hibi, Toshifumi Kaunitz, Jonathan D. Miura, Soichiro TI Endoscopic and clinical evaluation of treatment and prognosis of Cronkhite-Canada syndrome: a Japanese nationwide survey SO JOURNAL OF GASTROENTEROLOGY LA English DT Article DE Acquired gastrointestinal polyposis syndrome; Malnutrition; Gastric cancer; Colon cancer ID INTRAMUCOSAL GASTRIC-CANCER; GASTROINTESTINAL POLYPOSIS; COLON-CANCER; REMISSION; MANAGEMENT; DIAGNOSIS; PATHOLOGY; ALOPECIA AB Background First reported in 1955, Cronkhite-Canada syndrome (CCS), a rare syndrome characterized by ectodermal abnormalities and inflammatory changes of the gastrointestinal tract mucosa, has been associated with a poor prognosis and life-threatening malignant complications. In a large population survey, we endeavored to characterize the course and treatment outcome of CCS through clinical and endoscopic assessment, and to explore its optimal treatment and surveillance strategy. Methods A retrospective analysis of 210 patients with CCS was conducted via a questionnaire-based nationwide survey of 983 teaching hospitals located throughout Japan. We assessed clinical features, endoscopic findings, treatments used, and short-and long-term outcomes. Results The average age at diagnosis was 63.5 years. In all cases, upper or lower gastrointestinal tract polyposis was confirmed, accompanied by characteristic ectodermal abnormalities. Of the treatments used, oral corticosteroids (30-49 mg/day) were the most effective treatment for active disease, with adjunctive nutritional support considered beneficial. With corticosteroid treatment, abdominal symptoms were relieved within a few months, whereas polyp regression often required more than 6 months. Maintenance of endoscopic remission with or without steroids for 3 years significantly lowered the development of CCS-related cancer, compared with relapsers or nonresponders, underscoring the importance of sustained endoscopic remission for cancer prevention. Conclusions The prognosis of CCS has greatly improved through the use of improved medical treatment. Although CCS continues to be relentlessly progressive, carrying a high cancer risk, a sufficient dose and duration of corticosteroid therapy accompanied by nutritional support and periodic endoscopic surveillance appears to improve its natural history. C1 [Watanabe, Chikako; Komoto, Shunsuke; Tomita, Kengo; Hokari, Ryota; Miura, Soichiro] Natl Def Med Coll, Dept Internal Med, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan. [Tanaka, Masanori] Hirosaki City Hosp, Dept Pathol & Lab Med, Aomori, Japan. [Hirata, Ichiro] Fujita Hlth Univ, Dept Gastroenterol, Toyoake, Aichi, Japan. [Hibi, Toshifumi] Kitasato Inst Hosp, Ctr Adv IBD Res & Treatment, Tokyo, Japan. [Kaunitz, Jonathan D.] Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles VA Med Ctr, Los Angeles, CA 90095 USA. [Kaunitz, Jonathan D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Kaunitz, Jonathan D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. RP Watanabe, C (reprint author), Natl Def Med Coll, Dept Internal Med, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan. EM chikakow@ndmc.ac.jp FU Ministry of Health, Labour and Welfare of Japan; Japanese Ministry of Education, Culture, Sports, Science and Technology FX This study was supported by a Grant-in-Aid for the Intractable Disease Project of the Ministry of Health, Labour and Welfare of Japan, and by Grants-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology. The authors thank the following institutions for replying to the questionnaires in the first and second surveys: Asahikawa Medical University, Sapporo Medical University Hospital, Hokkaido University Hospital, Kushiro Rosai Hospital, KKR Sapporo Medical Center, National Hospital Organization Hokkaido Medical Center, Sapporo Higashi Tokushukai Hospital, Sunagawa City Medical Center, Iwate Medical University, Tohoku University Hospital, Akita University Hospital, Nakadori General Hospital, Tokyo Medical University Ibaraki Medical Center, Jichi Medical University Hospital, Isesaki Municipal Hospital, Saitama Medical University Hospital, Dokkyo Medical University Koshigaya Hospital, Saiseikai Kawaguchi General Hospital, Saitama Medical Center Jichi Medical University, Sekishindo Hospital, Chiba University Hospital, Funabashi Municipal Medical Center, The University of Tokyo Hospital, Kyorin University Hospital, Keio University Hospital, Tokyo Medical University Hachioji Medical Center, Tokyo Women's Medical University Hospital, Nihon University Itabashi Hospital, NTT Medical Center Tokyo, The Cancer Institute Hospital of JFCR, Hiratsuka GI Hospital, Kitasato University Kitasato Institute Hospital, Sanno Hospital, Shiseikai Daini Hospital, Toho University Ohashi Medical Center, Mishuku Hospital, Kitasato University Hospital, Showa University Fujigaoka Hospital, St. Marianna University School of Medicine, Yokohama City Seibu Hospital, Yokosuka Kyosai Hospital, Saiseikai Yokohamashi Nanbu Hospital, Nihon Koukan Hospital, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, National Hospital Organization Shinshu Ueda Medical Center, Niigata City General Hospital, Kanazawa University Hospital, Public Central Hospital of Matto Ishikawa, Toyama Rosai Hospital, Gifu Municipal Hospital, Nagano Chuo Hospital, Toki General Hospital, Juntendo Hospital Shizuoka Hospital, Hamamatsu Medical Center, Hamamatsu South Hospital, Nagoya City University Hospital, Fujita Health University Hospital, Aichi Cancer Center Hospital, Japanese Red Cross Nagoya Daiichi Hospital, Kainan Hospital, Daiyukai General Hospital, Saiseikai Matsusaka General Hospital, Japanese Red Cross Society Nagahama Hospital, Mitsubishi Kyoto Hospital, Osaka City University Hospital, Osaka Medical College Hospital, Kinki University Hospital, Osaka General Medical Center, Osaka Red Cross Hospital, Kitano Hospital, Osaka Saiseikai Nakatsu Hospital, Ishikiriseikikai Hospital, Sakai City Hospital, Yodogawa Christian Hospital, Maki Hospital, Kobe University Hospital, Hyogo College of Medicine, Takarazuka City Hospital, St.; Mary's Hospital, Miki-Sanyo Hospital, Yamato Takada Municipal Hospital, Wakayama Medical University Hospital, Shimane University Hospital, Masuda Red Cross Hospital, Okayama University Hospital, Kawasaki Medical School Hospital, Hiroshima City Hiroshima Citizens Hospital, Hiroshima General Hospital of West Japan Railway Company, Hiroshima City Asa Hospital, Yamaguchi University Hospital, Tokuyama Central Hospital, Yamaguchi Red Cross Hospital, Tokushima Prefecture Naruto Hospital, Tokushima Red Cross Hospital, Uwajima City Hospital, Matsuyama Red Cross Hospital, National Hospital Organization Kochi National Hospital, Takamatsu Municipal Hospital, Kurume University Hospital, Kitakyushu Municipal Medical Center, Tagawa Hospital, Kyushu Central Hospital, Fukuoka Higashi Medical Center, Nagata Hospital, Wakamatsu Hospital, University of Occupational and Environmental Health, Japan, Saga University Hospital, Kumamoto University Hospital, Beppu Medical Center, Nakatsu Municipal Hospital, Nakagami Hospital, Kyushu University Graduate School of Medical Sciences, Yame General Hospital, Fukuoka Sanno Hospital, University of Miyazaki Hospital, Iizuka Hospital, Kyoto University, Sapporo-Kosei General Hospital, Sannno Hospital, Nanbu Medical Center/Nanbu Child Medical Center, Jikei University, Jikei University Kashiwa Hospital, Jikei University Katsushika Medical Center, Nagoya Handa City Hospital, Tsuchiura Kyodo General Hospital, Yokohama Municipal Citizen's Hospital, Sano General Hospital, and National Defense Medical College. NR 47 TC 4 Z9 5 U1 2 U2 4 PU SPRINGER JAPAN KK PI TOKYO PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN SN 0944-1174 EI 1435-5922 J9 J GASTROENTEROL JI J. Gastroenterol. PD APR PY 2016 VL 51 IS 4 BP 327 EP 336 DI 10.1007/s00535-015-1107-7 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DK1JT UT WOS:000374669000003 PM 26216651 ER PT J AU Salinsky, M Parko, K Rutecki, P Boudreau, E Storzbach, D AF Salinsky, Martin Parko, Karen Rutecki, Paul Boudreau, Eilis Storzbach, Daniel TI Attributing seizures to TBI: Validation of a brief patient questionnaire SO EPILEPSY & BEHAVIOR LA English DT Article DE Psychogenic seizures; Epilepsy; TBI; Veterans ID TRAUMATIC BRAIN-INJURY; PSYCHOGENIC NONEPILEPTIC SEIZURES; VETERANS AB Puipose: Traumatic brain injury (TBI) is an important cause of epilepsy and has also been associated with psychogenic nonepileptic seizures (PNES). We designed a brief questionnaire assessing patient beliefs regarding TBI as the cause of their seizures (Patient Seizure Etiology Questionnaire; PSEQ). This study reports content validity for the PSEQ Methods: Ninety Veterans undergoing comprehensive evaluation at 3 VA epilepsy centers completed the PSEQ a series of questions regarding possible causes for their seizures, including TB1. The PSEQ was scored as YES vs. NO for TBI as the proposed cause of seizures. For each patient, two expert reviewers independently completed a structured chart review to determine whether TBI was the proposed cause of seizures (n = 180 reviews). Kappa statistic was used to assess agreement between the PSEQ and each chart review and between the PSEQ and combined chart reviews where both reviewers agreed on a TBI seizure etiology. Results: The PSEQ scored higher overall rates for a TBI seizure etiology than did expert chart reviews (40% vs. 28%; p < 0.001). The PSEQ agreed with 82% of 180 independent chart reviews (sensitivity 88%; specificity 79%). Kappa statistic for agreement was 0.60. The two reviewers agreed on a probable TB1 seizure etiology for SR of chart reviews. The PSEQ sensitivity increased to 100% when both reviewers were in agreement. Conclusion: The PSEQ provides a direct, standardized measure of patient beliefs regarding TBlas the cause of their seizures and has moderate-substantial agreement with expert chart reviews. Published by Elsevier Inc. C1 [Salinsky, Martin; Boudreau, Eilis; Storzbach, Daniel] Portland VA Med Ctr, Portland, OR USA. [Salinsky, Martin; Boudreau, Eilis] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Parko, Karen] San Francisco VA Med Ctr, San Francisco, CA USA. [Rutecki, Paul] William S Middleton Vet Affairs Med Ctr, Madison, WI USA. RP Salinsky, M (reprint author), Portland VAMC Epilepsy Ctr Excellence, 3710 SW US Vet Hosp Rd P3ECOE, Portland, OR 97239 USA. EM Salinsky@ohsu.edu FU Department of Veterans Affairs [5101CX000721-04] FX The authors thank S. Chen FNP, R. Kotloski MD PhD, and C. Evrard FNP for their participation in this project. This work was supported by grant # 5101CX000721-04 from the Department of Veterans Affairs. NR 13 TC 0 Z9 0 U1 2 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 EI 1525-5069 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD APR PY 2016 VL 57 BP 141 EP 144 DI 10.1016/j.yebeh.2016.02.003 PN A PG 4 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA DJ5NW UT WOS:000374256700024 PM 26953843 ER PT J AU Pugh, MJ AF Pugh, Mary Jo TI Clinical decision rules for epilepsy care: The case for thinking big SO EPILEPSY & BEHAVIOR LA English DT Editorial Material ID PREDICTION; VALIDATION; GUIDELINES; MANAGEMENT; STANDARDS; MEDICINE; SEIZURE; ADULTS; RISK C1 [Pugh, Mary Jo] STVHCS, VA Epilepsy Ctr Excellence, San Antonio, TX USA. [Pugh, Mary Jo] UTHSCSA, Dept Epidemiol & Biostat, San Antonio, TX USA. [Pugh, Mary Jo] South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. RP Pugh, MJ (reprint author), STVHCS, VA Epilepsy Ctr Excellence, San Antonio, TX USA.; Pugh, MJ (reprint author), UTHSCSA, Dept Epidemiol & Biostat, San Antonio, TX USA.; Pugh, MJ (reprint author), South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM Pughm@uthscsa.edu OI Pugh, Mary Jo/0000-0003-4196-7763 FU NCCIH NIH HHS [1R01AT008422-01] NR 18 TC 0 Z9 0 U1 1 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 EI 1525-5069 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD APR PY 2016 VL 57 BP 220 EP 221 DI 10.1016/j.yebeh.2016.02.034 PN A PG 2 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA DJ5NW UT WOS:000374256700037 PM 26979764 ER PT J AU Dullard, B Saunders, GH AF Dullard, Brittney Saunders, Gabrielle H. TI Documentation of Dual Sensory Impairment in Electronic Medical Records SO GERONTOLOGIST LA English DT Article DE Hearing impairment; Vision impairment; Interdisciplinary communication; Electronic medical records; Sensory disorders ID CONCURRENT HEARING; VISUAL IMPAIRMENT; VISION IMPAIRMENT; HEALTH-CARE; EXPERIENCES; PREVALENCE; PHYSICIANS; NEEDS AB Purpose of the Study: To examine the documentation of sensory impairment in the electronic medical records (EMRs) of Veterans with both hearing and vision losses (dual sensory impairment [DSI]). Design and Methods: A retrospective chart review of the EMRs of 20 patients with DSI was conducted. Providers' documentation of the presence of sensory impairment, the use of assistive technology during clinical appointments, and the content of notes mentioning communication issues were extracted from each chart note in the EMR for the prior 6 years. Results: Primary care providers documented DSI in 50% of EMRs, vision loss alone in 40%, and hearing loss alone in 10% of EMRs. Audiologists documented vision loss in 50% of cases, whereas ophthalmologists/optometrists documented hearing loss in 15% of cases. Examination of two selected cases illustrates that care can be compromised when providers do not take note of sensory impairments during planning and provision of clinical care. Implications: Sensory impairment is poorly documented by most providers in EMRs. This is alarming because vision and hearing affect patient-physician communication and the use of medical interventions. The results of this study raise awareness about the need to document the presence of sensory impairments and use the information when planning treatment for individuals with DSI. C1 [Dullard, Brittney] Univ Connecticut, Speech Language & Hearing Sci, Mansfield, CT 06250 USA. [Saunders, Gabrielle H.] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR USA. RP Dullard, B (reprint author), Univ Connecticut, Speech Language & Hearing Sci, Mansfield, CT 06250 USA. EM Brittney.Dullard@uconn.edu FU Portland VA Research Foundation; Department of Veterans Affairs Rehabilitation Research and Development [C9230C] FX This work was supported by a Portland VA Research Foundation Summer Fellowship and by the Department of Veterans Affairs Rehabilitation Research and Development (C9230C). NR 19 TC 3 Z9 3 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD APR PY 2016 VL 56 IS 2 BP 313 EP 317 DI 10.1093/geront/gnu032 PG 5 WC Gerontology SC Geriatrics & Gerontology GA DJ5BA UT WOS:000374220600017 PM 24846883 ER PT J AU Felker, P Bunch, R Leung, AM AF Felker, Peter Bunch, Ronald Leung, Angela M. TI Concentrations of thiocyanate and goitrin in human plasma, their precursor concentrations in brassica vegetables, and associated potential risk for hypothyroidism SO NUTRITION REVIEWS LA English DT Review DE broccoli; Chinese cabbage; glucosinolate; glucoraphanin; indole; kale; phase II enzymes ID PHASE-II ENZYMES; BRUSSELS-SPROUTS; FROZEN BROCCOLI; THIOL OXIDATION; FRESH BROCCOLI; BREAST-CANCER; IN-VIVO; SULFORAPHANE; ISOTHIOCYANATES; EXPRESSION AB Brassica vegetables are common components of the diet and have beneficial as well as potentially adverse health effects. Following enzymatic breakdown, some glucosinolates in brassica vegetables produce sulforaphane, phenethyl, and indolylic isothiocyanates that possess anticarcinogenic activity. In contrast, progoitrin and indolylic glucosinolates degrade to goitrin and thiocyanate, respectively, and may decrease thyroid hormone production. Radioiodine uptake to the thyroid is inhibited by 194 mu mol of goitrin, but not by 77 mu mol of goitrin. Collards, Brussels sprouts, and some Russian kale (Brassica napus) contain sufficient goitrin to potentially decrease iodine uptake by the thyroid. However, turnip tops, commercial broccoli, broccoli rabe, and kale belonging to Brassica oleracae contain less than 10 mu mol of goitrin per 100-g serving and can be considered of minimal risk. Using sulforaphane plasma levels following glucoraphanin ingestion as a surrogate for thiocyanate plasma concentrations after indole glucosinolate ingestion, the maximum thiocyanate contribution from indole glucosinolate degradation is estimated to be 10 mu M, which is significantly lower than background plasma thiocyanate concentrations (40-69 mu M). Thiocyanate generated from consumption of indole glucosinolate can be assumed to have minimal adverse risks for thyroid health. C1 [Felker, Peter; Bunch, Ronald] DArrigo Bros Co Calif, 21777 Harris Rd, Salinas, CA 93908 USA. [Leung, Angela M.] VA Greater Angeles Healthcare Syst, Div Endocrinol, Los Angeles, CA USA. [Leung, Angela M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol, Los Angeles, CA 90095 USA. RP Felker, P (reprint author), DArrigo Bros Co Calif, 21777 Harris Rd, Salinas, CA 93908 USA. EM Peter.Felker@darrigo.com FU National Institutes of Health [K23HD068552] FX The study was supported in part by National Institutes of Health K23HD068552 (A.M.L.). NR 66 TC 1 Z9 1 U1 6 U2 21 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0029-6643 EI 1753-4887 J9 NUTR REV JI Nutr. Rev. PD APR PY 2016 VL 74 IS 4 BP 248 EP 258 DI 10.1093/nutrit/nuv110 PG 11 WC Nutrition & Dietetics SC Nutrition & Dietetics GA DJ4OD UT WOS:000374184800003 PM 26946249 ER PT J AU Hogaboom, NS Diehl, JA Oyster, ML Koontz, AM Boninger, ML AF Hogaboom, Nathan S. Diehl, Jessica A. Oyster, Michelle L. Koontz, Alicia M. Boninger, Michael L. TI Ultrasonographic Median Nerve Changes After Repeated Wheelchair Transfers in Persons With Paraplegia: Relationship With Subject Characteristics and Transfer Skills SO PM&R LA English DT Article ID CARPAL-TUNNEL-SYNDROME; SPINAL-CORD-INJURY; UPPER EXTREMITY PAIN; SHOULDER PAIN; USERS; PREVALENCE; SONOGRAPHY; DIAGNOSIS; INDIVIDUALS; POPULATION AB Background: Wheelchair users with spinal cord injuries are susceptible to peripheral neuropathies from overuse, yet no studies have established a relationship between median neuropathy and wheelchair transfers. A more thorough understanding of how transfers and technique contribute to pathologic conditions may guide interventions that curtail its development. Objective: To evaluate the effects of repeated transfers on ultrasound markers for carpal tunnel syndrome (CTS) in people with spinal cord injuries and to relate changes to subject characteristics and transfer skills. Design: Cross-sectional, repeated measures. Setting: Research laboratory and national wheelchair sporting events. Participants: A convenience sample of 30 wheelchair users with nonprogressive paraplegia were recruited via research registries and at the 2013 National Veterans Wheelchair Games and 2014 Paralyzed Veterans of America Buckeye Games. Participants were older than 18 years and could complete transfers independently within 30 seconds without use of their leg muscles. Methods: Demographic questionnaires and physical examinations for CTS were completed. Quantitative ultrasound techniques were used to measure changes in the median nerve after a repeated-transfers protocol. The Transfer Assessment Instrument (TAI) was completed to quantify transfer ability. Main Outcome Measurements: Median nerve cross-sectional area at the level of the pisiform (PCSA) and swelling ratio (SR), transfer quality, and skills via the TAI. Results: PCSA increased after repeated transfers (P < .025). Participants who used safe hand positions had a lower baseline SR (beta = -0.728; P < .01). Participants with a higher body weight had a lower baseline SR provided they performed higher quality transfers. Participants who scooted to the front of the seat prior to transferring (TAI item 7; beta = 0.144; P < .05) and who weighed more (beta = 0.142; P < .05) exhibited greater increases in PCSA in response to transfers. Conclusions: An acute increase was observed in median nerve CSA at the pisiform after repeated wheelchair transfers. Changes were greater in persons with higher body weight and in persons who did not perform certain transfer skills correctly (according to the TAI). It is possible that these factors contribute to chronic injury and possibly CTS. C1 [Hogaboom, Nathan S.; Oyster, Michelle L.; Koontz, Alicia M.; Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA. [Hogaboom, Nathan S.; Oyster, Michelle L.; Koontz, Alicia M.; Boninger, Michael L.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Diehl, Jessica A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. RP Boninger, ML (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA.; Boninger, ML (reprint author), Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. EM boninger@pitt.edu OI Hogaboom, Nathan/0000-0002-0601-5751; Boninger, Michael/0000-0001-6966-919X FU National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitation Services, U. S. Department of Education [H133N110011]; National Science Foundation Graduate Research Fellowship [1247842] FX This article is the result of work supported with resources and the use of facilities at the Human Engineering Research Laboratories, VA Pittsburgh Healthcare System. This project was supported by the National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitation Services, U. S. Department of Education (H133N110011). This article is based on work supported by the National Science Foundation Graduate Research Fellowship (grant #1247842). Any opinion, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the view of the National Science Foundation. The contents of this paper do not represent the views of the Department of Veterans Affairs or the United States Government. NR 40 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 EI 1934-1563 J9 PM&R JI PM&R PD APR PY 2016 VL 8 IS 4 BP 305 EP 313 DI 10.1016/j.pmrj.2015.08.001 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA DJ4LE UT WOS:000374176100002 PM 26265431 ER PT J AU Sebastian, A Jung, P Neuhoff, J Wibral, M Fox, PT Lieb, K Fries, P Eickhoff, SB Tuscher, O Mobascher, A AF Sebastian, Alexandra Jung, Patrick Neuhoff, Jonathan Wibral, Michael Fox, Peter T. Lieb, Klaus Fries, Pascal Eickhoff, Simon B. Tuescher, Oliver Mobascher, Arian TI Dissociable attentional and inhibitory networks of dorsal and ventral areas of the right inferior frontal cortex: a combined task-specific and coordinate-based meta-analytic fMRI study SO BRAIN STRUCTURE & FUNCTION LA English DT Article DE Attentional capture; Functional magnetic resonance imaging; Meta-analytic connectivity modeling; Right inferior frontal cortex; Right inferior frontal junction; Stop signal task ID TEMPORO-PARIETAL JUNCTION; RESPONSE-INHIBITION; FUNCTIONAL CONNECTIVITY; COGNITIVE CONTROL; HUMAN BRAIN; MODEL; ACTIVATIONS; RELEVANCE; CONTEXT; CHOICE AB The right inferior frontal cortex (rIFC) is frequently activated during executive control tasks. Whereas the function of the dorsal portion of rIFC, more precisely the inferior frontal junction (rIFJ), is convergingly assigned to the attention system, the functional key role of the ventral portion, i.e., the inferior frontal gyrus (rIFG), is hitherto controversially debated. Here, we used a two-step methodical approach to clarify the differential function of rIFJ and rIFG. First, we used event-related functional magnetic resonance imaging (fMRI) during a modified stop signal task with an attentional capture condition (acSST) to delineate attentional from inhibitory motor processes (step 1). Then, we applied coordinate-based meta-analytic connectivity modeling (MACM) to assess functional connectivity profiles of rIFJ and rIFG across various paradigm classes (step 2). As hypothesized, rIFJ activity was associated with the detection of salient stimuli, and was functionally connected to areas of the ventral and dorsal attention network. RIFG was activated during successful response inhibition even when controlling for attentional capture and revealed the highest functional connectivity with core motor areas. Thereby, rIFJ and rIFG delineated largely independent brain networks for attention and motor control. MACM results attributed a more specific attentional function to rIFJ, suggesting an integrative role between stimulus-driven ventral and goal-directed dorsal attention processes. In contrast, rIFG was disclosed as a region of the motor control but not attention system, being essential for response inhibition. The current study provides decisive evidence regarding a more precise functional characterization of rIFC subregions in attention and inhibition. C1 [Sebastian, Alexandra; Jung, Patrick; Neuhoff, Jonathan; Lieb, Klaus; Tuescher, Oliver; Mobascher, Arian] Johannes Gutenberg Univ Mainz, Med Ctr Mainz, Dept Psychiat & Psychotherapy, Focus Program Translat Neurosci FTN, Untere Zahlbacher Str 8, D-55131 Mainz, Germany. [Wibral, Michael] Goethe Univ Frankfurt, Brain Imaging Ctr, MEG Unit, D-60054 Frankfurt, Germany. [Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Fox, Peter T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Fries, Pascal] Max Planck Gesell, Ernst Strungmann Inst ESI Neurosci Cooperat, Frankfurt, Germany. [Eickhoff, Simon B.] Univ Dusseldorf, Inst Clin Neurosci & Med Psychol, Dusseldorf, Germany. [Eickhoff, Simon B.] Forschungszentrum Julich, Inst Neurosci & Med INM 1, D-52425 Julich, Germany. [Tuescher, Oliver] Univ Freiburg, Med Ctr Freiburg, Dept Neurol, Hugstetter Str 55, D-79106 Freiburg, Germany. [Tuescher, Oliver] Univ Freiburg, Med Ctr Freiburg, Dept Psychiat, Hugstetter Str 55, D-79106 Freiburg, Germany. RP Jung, P (reprint author), Johannes Gutenberg Univ Mainz, Med Ctr Mainz, Dept Psychiat & Psychotherapy, Focus Program Translat Neurosci FTN, Untere Zahlbacher Str 8, D-55131 Mainz, Germany. EM patrjung@uni-mainz.de RI Fries, Pascal/E-3196-2010 OI Fries, Pascal/0000-0002-4270-1468; Wibral, Michael/0000-0001-8010-5862 FU MAIFOR program; Johannes Gutenberg University Medical Center Mainz, Germany; NIH/NIMH [R01 MH074457] FX This work was supported by internal grants of the MAIFOR program and the research focus translational neurosciences (FTN) of the Johannes Gutenberg University Medical Center Mainz, Germany. Comprehensive access to the BrainMap database was authorized by a collaborative-use license agreement, provided to Simon Eickhoff by the University of Texas Health Science Center at San Antonio. BrainMap is supported by NIH/NIMH R01 MH074457. Findings presented in this study are part of the doctoral thesis of Jonathan Neuhoff. NR 51 TC 4 Z9 4 U1 4 U2 12 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1863-2653 EI 1863-2661 J9 BRAIN STRUCT FUNCT JI Brain Struct. Funct. PD APR PY 2016 VL 221 IS 3 BP 1635 EP 1651 DI 10.1007/s00429-015-0994-y PG 17 WC Anatomy & Morphology; Neurosciences SC Anatomy & Morphology; Neurosciences & Neurology GA DI9DK UT WOS:000373801400027 PM 25637472 ER PT J AU Wehner, MR Linos, E Boscardin, WJ Chren, MM AF Wehner, Mackenzie R. Linos, Eleni Boscardin, W. John Chren, Mary-Margaret TI Competing Risk of Death in Kaplan-Meier Curves When Analyzing Subsequent Keratinocyte Cancer Reply SO JAMA DERMATOLOGY LA English DT Letter C1 [Wehner, Mackenzie R.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Linos, Eleni; Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, 2340 Sutter St,Rm N412,POB 0808, San Francisco, CA 94143 USA. [Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Chren, Mary-Margaret] San Francisco VA Med Ctr, Dermatol Serv, San Francisco, CA USA. RP Chren, MM (reprint author), Univ Calif San Francisco, Dept Dermatol, 2340 Sutter St,Rm N412,POB 0808, San Francisco, CA 94143 USA. EM chrenm@derm.ucsf.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6068 EI 2168-6084 J9 JAMA DERMATOL JI JAMA Dermatol. PD APR PY 2016 VL 152 IS 4 BP 494 EP 495 DI 10.1001/jamadermatol.2015.5153 PG 2 WC Dermatology SC Dermatology GA DJ0TF UT WOS:000373916600039 PM 27074364 ER PT J AU Isakova, T Cai, X Lee, J Katz, R Cauley, JA Fried, LF Hoofnagle, AN Satterfield, S Harris, TB Shlipak, MG Sarnak, MJ Ix, JH AF Isakova, Tamara Cai, Xuan Lee, Jungwha Katz, Ronit Cauley, Jane A. Fried, Linda F. Hoofnagle, Andrew N. Satterfield, Suzanne Harris, Tamara B. Shlipak, Michael G. Sarnak, Mark J. Ix, Joachim H. CA Hlth ABC Study TI Associations of FGF23 With Change in Bone Mineral Density and Fracture Risk in Older Individuals SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE FIBROBLAST GROWTH FACTOR 23; BONE MINERAL DENSITY; FRACTURE; CHRONIC KIDNEY DISEASE ID FIBROBLAST GROWTH FACTOR-23; CHRONIC KIDNEY-DISEASE; VITAMIN-D METABOLISM; OSTEOPOROTIC FRACTURES; CARDIOVASCULAR HEALTH; DIETARY PHOSPHATE; HIP-FRACTURES; FGF-23; MEN; FIBROBLAST-GROWTH-FACTOR-23 AB Elevated levels of the phosphate-regulating hormone fibroblast growth factor 23 (FGF23) have been linked to greater risk of fractures in some studies, especially among individuals with chronic kidney disease (CKD). We evaluated FGF23 as a risk factor for bone loss and fractures in the Health, Aging, and Body Composition (Health ABC) study, which is a prospective biracial cohort of well-functioning adults aged 70 to 79 years recruited at two clinical centers in the United States. The sample for the bone mineral density (BMD) analyses consisted of 2234 participants who had at least two serial total hip areal BMD measures. The fracture analyses included 2786 participants, 567 of whom sustained a fracture during a median follow up of 4.95 years. Linear mixed-effects models were used for longitudinal measurements of total hip areal BMD and the proportional subdistribution hazard regression model subject to competing risks of death was used for risk of fracture. The median FGF23 was 46.7 (interquartile range [IQR] 36.7 to 60.2) pg/mL. The mean annualized percent change in total hip areal BMD did not vary significantly according to FGF23 quartile in all participants (p for trend=0.70), but the effect was modified by CKD status (adjusted p for interaction <0.001). Among participants with CKD, the unadjusted mean annualized percent change in total hip areal BMD was greater with higher levels of FGF23 (unadjusted p for trend=0.02), but the trend was attenuated with adjustment for estimated glomerular filtration rate and parathyroid hormone (adjusted p for trend=0.30). FGF23 was not significantly associated with fracture risk in crude (hazard ratio [HR] per doubling of FGF23, 0.97; 95% CI, 0.85 to 1.12) or adjusted models (HR per doubling of FGF23, 1.02; 95% CI, 0.86 to 1.22), and these findings were not modified by gender or CKD status. FGF23 levels are not associated with bone loss or fracture risk in older adults with low prevalence of CKD. (c) 2015 American Society for Bone and Mineral Research. C1 [Isakova, Tamara] Northwestern Univ Feinberg, Sch Med, Dept Med, Div Nephrol & Hypertens, Chicago, IL USA. [Isakova, Tamara; Cai, Xuan] Northwestern Univ Feinberg, Sch Med, Inst Publ Hlth & Med, Ctr Translat Metab & Hlth, Chicago, IL USA. [Lee, Jungwha] Northwestern Univ Feinberg, Sch Med, Dept Preventat Med, Div Biostat, Chicago, IL USA. [Katz, Ronit; Hoofnagle, Andrew N.] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA. [Cauley, Jane A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Fried, Linda F.] Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Hoofnagle, Andrew N.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. [Satterfield, Suzanne] Univ Tennessee, Dept Prevent Med, Memphis, TN USA. [Harris, Tamara B.] NIA, Lab Epidemiol & Populat Sci, NIH, Rockville, MD USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol Biostat & Med, San Francisco, CA 94143 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Gen Internal Med, San Francisco, CA USA. [Sarnak, Mark J.] Tufts Med Ctr, Dept Med, Div Nephrol, Boston, MA USA. [Ix, Joachim H.] Univ Calif San Diego, Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA 92103 USA. [Ix, Joachim H.] Univ Calif San Diego, Div Nephrol & Prevent Med, San Diego, CA 92103 USA. RP Isakova, T (reprint author), 633 N St Clair St, Chicago, IL 60611 USA. EM tamara.isakova@northwestern.edu RI Cauley, Jane/N-4836-2015 OI Cauley, Jane/0000-0003-0752-4408 FU Carl W. Gottschalk Research Scholar Grant from the American Society of Nephrology Foundation for Kidney Research; National Institutes on Aging [R01AG027002]; National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01-AG028050]; NINR [R01-NR012459]; NIH, National Institute on Aging; [K23DK087858] FX TI was supported by K23DK087858 and by the Carl W. Gottschalk Research Scholar Grant from the American Society of Nephrology Foundation for Kidney Research. MGS, MS, and JHI and the FGF23 measurements were supported by a grant from the National Institutes on Aging (R01AG027002). The Health ABC Study was supported by the National Institute on Aging (NIA) Contracts N01-AG-6-2101; N01-AG-6-2103; N01-AG-6-2106; NIA grant R01-AG028050, and NINR grant R01-NR012459. This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging. NR 45 TC 3 Z9 3 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD APR PY 2016 VL 31 IS 4 BP 742 EP 748 DI 10.1002/jbmr.2750 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DJ2BH UT WOS:000374008200006 PM 26590361 ER PT J AU Melzer, AC Feemster, LC Collins, MP Au, DH AF Melzer, Anne C. Feemster, Laura C. Collins, Margaret P. Au, David H. TI Utilization and effectiveness of pharmacotherapy for Tobacco use following admission for exacerbation of COPD SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article DE Tobacco; smoking; pulmonary disease; chronic obstructive; nicotine replacement therapy ID OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CLINICAL-TRIAL; SMOKING-CESSATION; MYOCARDIAL-INFARCTION; DOUBLE-BLIND; HOSPITALIZED-PATIENTS; NICOTINE REPLACEMENT; STOP SMOKING; INTERVENTION; VARENICLINE AB BACKGROUNDPatients admitted for chronic obstructive pulmonary disease (COPD) commonly continue to smoke. The utilization and effectiveness of tobacco cessation medications after discharge is largely unknown. We sought to examine whether pharmacologic treatment of tobacco use following admission for COPD was associated with smoking cessation at 6 to 12 months. METHODSMultivariable logistic regression analysis of a cohort of 1334 smokers, discharged from hospital with a COPD exacerbation between 2005 and 2012, identified administratively within the Veterans Affairs Veterans Integrated Service Network-20, adjusted for variables chosen a priori. Our primary exposure was treatment with any 1 or combination of smoking cessation medications within 90 days of discharge determined from pharmacy records, with the outcome of smoking cessation at 6 to 12 months after discharge. MEASUREMENTS AND MAIN RESULTSFour hundred fifty (33.7%) of the patients were dispensed a smoking cessation medication, with 53.4% receiving a nicotine patch alone. Overall, 19.8% of patients reported quitting smoking at 6 to 12 months. Compared to those not receiving medications, the odds of quitting were not greater among patients dispensed any single or combination of smoking cessation medications within 90 days of discharge (odds ratio [OR]: 0.88, 95% confidence interval [CI]: 0.74-1.04). Among patients treated with medications compared to nicotine patch alone, varenicline (OR: 2.44, 95% CI: 1.48-4.05) was associated with increased odds of cessation, and short-acting nicotine replacement therapy alone (OR: 0.66, 95% CI: 0.51-0.85) was associated with decreased odds of cessation. CONCLUSIONSTreatment was provided to a minority of subjects and was not associated with cessation, with potential differences observed in effectiveness between medications. Systems-based changes may improve delivery of this key intervention. Journal of Hospital Medicine 2016;11:257-263. (c) 2015 Society of Hospital Medicine C1 [Melzer, Anne C.; Feemster, Laura C.; Au, David H.] Univ Washington, Div Pulm & Crit Care, Seattle, WA 98195 USA. [Melzer, Anne C.; Feemster, Laura C.; Collins, Margaret P.; Au, David H.] VA Puget Sound, Ctr Innovat Veteran Centered & Value Driven Care, Seattle, WA USA. RP Melzer, AC (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM acmelzer@uw.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development; University of Washington Department of Pulmonary and Critical Care [HL007287-36]; National Institutes of Health, National Heart, Lung, and Blood Institute [HL111116]; Gilead Sciences; VA Health Services Research and Development FX Dr. Melzer conceived of the research question and performed background reading, analyses, primary drafting, and final revision of the manuscript. Drs. Collins and Feemster participated in finalizing the research question, developing the cohort, performing data collection, and revising the manuscript. Dr. Au provided the database for analysis, helped finalize the research question, and assisted in interpretation of the data and revision of the manuscript. Dr. Au has personally reviewed the data, understands the statistical methods employed, and confirms an understanding of this analysis, that the methods are clearly described, and that they are a fair way to report the results. This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, who provided access to data, office space, and programming and data management. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs, the United States government, or the National Institutes of Health. Dr. Au is an unpaid research consultant for Analysis Group. None of the other authors have any conflicts of interest to disclose. Dr. Melzer is supported by an institutional F-32 (HL007287-36) through the University of Washington Department of Pulmonary and Critical Care. Dr. Feemster is supported by an National Institutes of Health, National Heart, Lung, and Blood Institute, K23 Mentored Career Development Award (HL111116). Partial support of this project was provided by Gilead Sciences with research funding to the Seattle Institute for Biomedical and Clinical Research. Additional support was received through the VA Health Services Research and Development. A portion of this work was presented in abstract form at the American Thoracic Society International Meeting, May 2015, in Denver, Colorado. NR 47 TC 1 Z9 1 U1 3 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD APR PY 2016 VL 11 IS 4 BP 257 EP 263 DI 10.1002/jhm.2519 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA DJ0TE UT WOS:000373916500003 PM 26663891 ER PT J AU Rocque, GB Taylor, RA Acemgil, A Li, XL Pisu, M Kenzik, K Jackson, BE Halilova, KI Demark-Wahnefried, W Meneses, K Li, YF Martin, MY Chambless, C Lisovicz, N Fouad, M Partridge, EE Kvale, EA AF Rocque, Gabrielle B. Taylor, Richard A. Acemgil, Aras Li, Xuelin Pisu, Maria Kenzik, Kelly Jackson, Bradford E. Halilova, Karina I. Demark-Wahnefried, Wendy Meneses, Karen Li, Yufeng Martin, Michelle Y. Chambless, Carol Lisovicz, Nedra Fouad, Mona Partridge, Edward E. Kvale, Elizabeth A. CA Patient Care Connect Grp TI Guiding Lay Navigation in Geriatric Patients With Cancer Using a Distress Assessment Tool SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Article ID PSYCHOLOGIC DISTRESS; OLDER PATIENTS; BREAST-CANCER; THERMOMETER; VALIDATION; CARE; INTERVENTION; WOMEN AB Background: There is growing interest in psychosocial care and evaluating distress in patients with cancer. As of 2015, the Commission on Cancer requires cancer centers to screen patients for distress, but the optimal approach to implementation remains unclear. Methods: We assessed the feasibility and impact of using distress assessments to frame lay navigator interactions with geriatric patients with cancer who were enrolled in navigation between January 1, 2014, and December 31, 2014. Results: Of the 5,121 patients enrolled in our lay patient navigation program, 4,520 (88%) completed at least one assessment using a standardized distress tool (DT). Navigators used the tool to structure both formal and informal distress assessments. Of all patients, 24% reported distress scores of 4 or greater and 5.5% reported distress scores of 8 or greater. The most common sources of distress at initial assessment were pain, balance/mobility difficulties, and fatigue. Minority patients reported similar sources of distress as the overall program population, with increased relative distress related to logistical issues, such as transportation and financial/insurance questions. Patients were more likely to ask for help with questions about insurance/financial needs (79%), transportation (76%), and knowledge deficits about diet/nutrition (76%) and diagnosis (66%) when these items contributed to distress. Conclusions: Lay navigators were able to routinely screen for patient distress at a high degree of penetration using a structured distress assessment. C1 [Rocque, Gabrielle B.; Taylor, Richard A.; Acemgil, Aras; Pisu, Maria; Halilova, Karina I.; Demark-Wahnefried, Wendy; Meneses, Karen; Li, Yufeng; Chambless, Carol; Lisovicz, Nedra; Fouad, Mona; Partridge, Edward E.; Kvale, Elizabeth A.] Univ Alabama Birmingham, Birmingham Comprehens Canc Ctr, Birmingham, AL USA. [Rocque, Gabrielle B.] Univ Alabama Birmingham, Birmingham Sch Med, Div Hematol & Oncol, Birmingham, AL USA. [Acemgil, Aras; Li, Xuelin; Pisu, Maria; Kenzik, Kelly; Jackson, Bradford E.; Li, Yufeng; Martin, Michelle Y.; Lisovicz, Nedra; Fouad, Mona] Univ Alabama Birmingham, Birmingham Sch Med, Div Prevent Med, Birmingham, AL USA. [Taylor, Richard A.; Meneses, Karen] Univ Alabama Birmingham, Birmingham Sch Nursing, Birmingham, AL USA. [Kvale, Elizabeth A.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Rocque, GB (reprint author), Univ Alabama Birmingham, Sch Med, 1824 6th Ave South,WTI 240E, Birmingham, AL 35294 USA. EM grocque@uabmc.edu FU Walter B. Frommeyer, Jr., Fellowship in Investigative Medicine; Department of Health and Human Services, Centers for Medicare & Medicaid Services [1C1CMS331023] FX Dr. Rocque is supported by a Walter B. Frommeyer, Jr., Fellowship in Investigative Medicine. This funding source had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; and preparation, review, or approval of the manuscript for publication. Dr. Kvale has disclosed that she is the Palliative Care Medical Director for Aspire Healthcare. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.; This publication was made possible by grant no. 1C1CMS331023 from the Department of Health and Human Services, Centers for Medicare & Medicaid Services. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the US Department of Health and Human Services or any of its agencies. NR 37 TC 1 Z9 1 U1 0 U2 2 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 EI 1540-1413 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD APR PY 2016 VL 14 IS 4 BP 407 EP 414 PG 8 WC Oncology SC Oncology GA DJ3CL UT WOS:000374082300005 PM 27059189 ER PT J AU Byne, W AF Byne, William TI Regulations Restrict Practice of Conversion Therapy SO LGBT HEALTH LA English DT Editorial Material DE continuing medical education; gender identity; legislation; LGBT conversion therapy; reparative therapy; sexual orientation ID GENDER DYSPHORIA; DISORDERS; GAY C1 [Byne, William] James J Peters VA Med Ctr, Bronx, NY USA. [Byne, William] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. RP Byne, W (reprint author), James J Peters VA Med Ctr, Bronx, NY USA.; Byne, W (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. EM william.byne@mssm.edu NR 22 TC 0 Z9 0 U1 7 U2 10 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2325-8292 EI 2325-8306 J9 LGBT HEALTH JI LGBT Health PD APR PY 2016 VL 3 IS 2 BP 97 EP 99 DI 10.1089/lgbt.2016.0015 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DJ0ZE UT WOS:000373932100001 PM 26990275 ER PT J AU Mizukami, K Akatsu, H Abrahamson, EE Mi, ZP Ikonomovic, MD AF Mizukami, Katsuyoshi Akatsu, Hiroyasu Abrahamson, Eric E. Mi, Zhiping Ikonomovic, Milos D. TI Immunohistochemical analysis of hippocampal butyrylcholinesterase: Implications for regional vulnerability in Alzheimer's disease SO NEUROPATHOLOGY LA English DT Article DE alzheimer's disease; amyloid; butyrylcholinesterase; hippocampus; tau ID SENILE PLAQUES; HYDROLYZE ACETYLCHOLINE; DYSTROPHIC NEURITES; AMYLOID PLAQUES; CEREBRAL-CORTEX; CHOLINESTERASES; BRAIN; PATHOLOGY; PROTEIN; BETA AB Studies of acetylcholine degrading enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) in Alzheimer's disease (AD) have suggested their potential role in the development of fibrillar amyloid- (A) plaques (amyloid plaques). A recent genome-wide association study analysis identified a novel association between genetic variations in the BCHE locus and amyloid burden. We studied BChE immunoreactivity in hippocampal tissue sections from AD and control cases, and examined its relationship with amyloid plaques, neurofibrillary tangles (NFT), dystrophic neurites (DN) and neuropil threads (NT). Compared to controls, AD cases had greater BChE immunoreactivity in hippocampal neurons and neuropils in CA2/3, but not in the CA1, CA4 and dentate gyrus. The majority of amyloid plaques (>80%, using a pan-amyloid marker X-34) contained discrete neuritic clusters which were dual-labeled with antibodies against BChE and phosphorylated tau (clone AT8). There was no association between overall regional BChE immunoreaction intensity and amyloid plaque burden. In contrast to previous reports, BChE was localized in only a fraction (similar to 10%) of classic NFT (positive for X-34). A similar proportion of BChE-immunoreactive pyramidal cells were AT8 immunoreactive. Greater NFT and DN loads were associated with greater BChE immunoreaction intensity in CA2/3, but not in CA1, CA4 and dentate gyrus. Our results demonstrate that in AD hippocampus, BChE accumulates in neurons and plaque-associated neuritic clusters, but only in a small proportion of NFT. The association between greater neurofibrillary pathology burden and markedly increased BChE immunoreactivity, observed selectively in CA2/3 region, could reflect a novel compensatory mechanism. Since CA2/3 is generally considered more resistant to AD pathology, BChE upregulation could impact the cholinergic modulation of glutamate neurotransmission to prevent/reduce neuronal excitotoxicity in AD hippocampus. C1 [Mizukami, Katsuyoshi] Univ Tsukuba, Fac Hlth & Sport Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan. [Mizukami, Katsuyoshi] Univ Tsukuba, Grad Sch Comprehens Human Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan. [Akatsu, Hiroyasu] Nagoya City Univ, Grad Sch Med, Dept Community Based Med, Nagoya, Aichi, Japan. [Akatsu, Hiroyasu] Fukushimura Hosp, Choju Med Inst, Toyohashi, Aichi, Japan. [Abrahamson, Eric E.; Mi, Zhiping; Ikonomovic, Milos D.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Ikonomovic, Milos D.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Abrahamson, Eric E.; Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Mizukami, K (reprint author), Univ Tsukuba, Grad Sch Comprehens Human Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan. EM kmizukam@taiiku.tsukuba.ac.jp FU NIH [NIA AG014449, AG025204]; Japanese Ministry of Education, Culture, Sports, Science and Technology FX We are indebted to the subjects from Choju Medical Institute, Fukushimura Hospital and Ishizaki Hospital in this study. This work was supported by NIH grants NIA AG014449 and AG025204 (MDI), and by a Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (KM). Ms. Lan Shao, Ms. Natsuko Kato and Ms. Megumi Mitani provided expert technical assistance. NR 39 TC 1 Z9 1 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0919-6544 EI 1440-1789 J9 NEUROPATHOLOGY JI Neuropathology PD APR PY 2016 VL 36 IS 2 BP 135 EP 145 DI 10.1111/neup.12241 PG 11 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA DJ2AT UT WOS:000374006800003 PM 26293308 ER PT J AU Floyd, JS Blondon, M Moore, KP Boyko, EJ Smith, NL AF Floyd, James S. Blondon, Marc Moore, Kathryn P. Boyko, Edward J. Smith, Nicholas L. TI Validation of methods for assessing cardiovascular disease using electronic health data in a cohort of Veterans with diabetes SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Article DE validation; electronic health data; diabetes mellitus; myocardial infarction; smoking; pharmacoepidemiology ID ACUTE MYOCARDIAL-INFARCTION; ADMINISTRATIVE DATA; DATA ALGORITHMS; DATABASES; EVENTS; CODES; RISK AB BackgroundElectronic health data are routinely used to conduct studies of cardiovascular disease in the setting of the Veterans Health Administration (VA). Previous studies have estimated the positive predictive value (PPV) of International Classification of Disease, Ninth Revision (ICD-9) codes for acute myocardial infarction (MI), but the sensitivity of these codes for all true events and the accuracy of coding algorithms for prevalent disease status at baseline are largely unknown. MethodsWe randomly sampled 180 Veterans from the VA Puget Sound Health Care System who initiated diabetes treatment. The full electronic medical record was reviewed to identify prevalent conditions at baseline and acute MI events during follow-up. The accuracy of various coding algorithms was assessed. ResultsAlgorithms for previous acute events at baseline had high PPV (previous MI: 97%; previous stroke: 81%) but low sensitivity (previous MI: 38%; previous stroke: 52%). Algorithms for chronic conditions at baseline had high PPV (heart failure: 72%; coronary heart disease [CHD]: 85%) and high sensitivity (heart failure: 90%, CHD: 84%). For current smoking status at baseline, ICD-9 codes with pharmacy data had a PPV of 77% and sensitivity of 73%. The coding algorithm for acute MI events during follow-up had high PPV (80%) and sensitivity (89%) ConclusionsICD-9 codes for acute MI events during follow-up had high PPV and sensitivity. The sensitivity of ICD-9 codes for previous acute events at baseline was low, but a composite variable for baseline CHD had good accuracy. Copyright (c) 2015 John Wiley & Sons, Ltd. C1 [Floyd, James S.; Smith, Nicholas L.] Univ Washington, Cardiovasc Hlth Res Unit, 1730 Minor Ave,Suite 1360, Seattle, WA 98101 USA. [Smith, Nicholas L.] Univ Washington, Dept Epidemiol, Seattle, WA 98101 USA. [Floyd, James S.; Boyko, Edward J.] Univ Washington, Med, Seattle, WA 98101 USA. [Moore, Kathryn P.; Boyko, Edward J.; Smith, Nicholas L.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Gen Med Serv, Seattle, WA USA. [Smith, Nicholas L.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA. [Blondon, Marc] Univ Hosp Geneva, Div Angiol & Haemostasis, Geneva, Switzerland. [Blondon, Marc] Fac Med, Geneva, Switzerland. RP Floyd, JS (reprint author), Univ Washington, Cardiovasc Hlth Res Unit, 1730 Minor Ave,Suite 1360, Seattle, WA 98101 USA. EM jfloyd@uw.edu RI Floyd, James/G-7563-2015 OI Boyko, Edward/0000-0002-3695-192X FU NHLBI NIH HHS [K08 HL116640, K08HL116640]; NIDDK NIH HHS [P30 DK017047] NR 16 TC 4 Z9 4 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD APR PY 2016 VL 25 IS 4 BP 467 EP 471 DI 10.1002/pds.3921 PG 5 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA DJ1ZI UT WOS:000374003100016 PM 26555025 ER PT J AU Smits, JAJ Zvolensky, MJ Davis, ML Rosenfield, D Marcus, BH Church, TS Powers, MB Frierson, GM Otto, MW Hopkins, LB Brown, RA Baird, SO AF Smits, Jasper A. J. Zvolensky, Michael J. Davis, Michelle L. Rosenfield, David Marcus, Bess H. Church, Timothy S. Powers, Mark B. Frierson, Georita M. Otto, Michael W. Hopkins, Lindsey B. Brown, Richard A. Baird, Scarlett O. TI The Efficacy of Vigorous-Intensity Exercise as an Aid to Smoking Cessation in Adults With High Anxiety Sensitivity: A Randomized Controlled Trial SO PSYCHOSOMATIC MEDICINE LA English DT Article DE smoking; smoking cessation; intervention; randomized controlled trial; exercise; aerobic exercise; anxiety; anxiety sensitivity ID PHYSICAL-ACTIVITY; AEROBIC EXERCISE; DAILY SMOKERS; WITHDRAWAL SYMPTOMS; CIGARETTE CRAVINGS; DEPRESSION; METAANALYSIS; VALIDATION; DIMENSIONS; CHALLENGE AB Objectives: High anxiety sensitivity predicts poor smoking cessation outcomes. Aerobic exercise reduces anxiety sensitivity and aspects of the risk conferred by anxiety sensitivity. In the current study, we examined whether exercise can aid smoking cessation in adults with high anxiety sensitivity. Methods: Participants were sedentary and low-activity adult daily smokers (n = 136) with elevated prescreen anxiety sensitivity. Participants received 15 weeks of standard smoking cessation treatment (ST; cognitive behavioral therapy plus nicotine replacement therapy). In addition, participants were simultaneously randomized to 15 weeks of either an exercise intervention (ST + EX; n = 72) or a wellness education control condition (ST + CTRL; n = 64). Self-reported smoking abstinence was assessed weekly during the intervention, at the end of treatment (10 weeks after the target quit date), and at 4 and 6 months after the target quit date. Abstinence was verified by expired carbon monoxide readings and saliva cotinine. Results: Results indicated that point prevalence abstinence (PPA) and prolonged abstinence (PA) rates were significantly higher for ST + EX than for ST + CTRL at each of the major end points among persons with high anxiety sensitivity (PPA: b = -0.91, standard error [SE] = 0.393, t(1171) = -2.33, p = .020; PA: b = -0.98, SE = 0.346, t(132) = -2.84, p = .005), but not among those with low anxiety sensitivity (PPA: b = -0.23, SE = 0.218, t(1171) = -1.06, p = .29; PA: b = -0.31, SE = 0.306, t(132) = -1.01, p = .32). Conclusions: The present results suggest that exercise facilitates the odds of quit success for smokers with high levels of anxiety sensitivity and therefore may be a useful therapeutic tactic for this high-risk segment of the smoking population. C1 [Smits, Jasper A. J.; Davis, Michelle L.; Powers, Mark B.; Baird, Scarlett O.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA. [Smits, Jasper A. J.; Davis, Michelle L.; Powers, Mark B.; Baird, Scarlett O.] Univ Texas Austin, Mental Hlth Res Inst, Austin, TX 78712 USA. [Zvolensky, Michael J.] Univ Houston, Dept Psychol, Houston, TX USA. [Zvolensky, Michael J.] Univ Texas MD Anderson Canc Ctr, Dept Behav Sci, Houston, TX 77030 USA. [Rosenfield, David] So Methodist Univ, Dept Psychol, Dallas, TX 75275 USA. [Marcus, Bess H.] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA. [Church, Timothy S.] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA. [Frierson, Georita M.] Howard Univ, Dept Psychol, Washington, DC 20059 USA. [Otto, Michael W.] Boston Univ, Dept Psychol, 64 Cummington St, Boston, MA 02215 USA. [Otto, Michael W.] Boston Univ, Dept Psychol & Brain Sci, Boston, MA 02215 USA. [Hopkins, Lindsey B.] San Francisco VA Med Ctr, Stress & Hlth Res Program, San Francisco, CA USA. [Brown, Richard A.] Univ Texas Austin, Sch Nursing, Austin, TX 78712 USA. RP Smits, JAJ (reprint author), Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA.; Smits, JAJ (reprint author), Univ Texas Austin, Mental Hlth Res Inst, Austin, TX 78712 USA. EM smits@utexas.edu OI Hopkins, Lindsey/0000-0002-0577-2961; Powers, Mark/0000-0001-7898-073X FU National Institute on Drug Abuse [R01DA027533] FX The authors have declared that no competing interests exist. This study was funded by a grant from the National Institute on Drug Abuse (R01DA027533). The National Institute on Drug Abuse plays no role in approving the publications. NR 52 TC 4 Z9 4 U1 4 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0033-3174 EI 1534-7796 J9 PSYCHOSOM MED JI Psychosom. Med. PD APR PY 2016 VL 78 IS 3 BP 354 EP 364 DI 10.1097/PSY.0000000000000264 PG 11 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA DJ1FY UT WOS:000373949900012 PM 26513517 ER PT J AU Tipps, ME Raybuck, JD Kozell, LB Lattal, KM Buck, KJ AF Tipps, Megan E. Raybuck, Jonathan D. Kozell, Laura B. Lattal, K. Matthew Buck, Kari J. TI G Protein-Gated Inwardly Rectifying Potassium Channel Subunit 3 Knock-Out Mice Show Enhanced Ethanol Reward SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE GIRK Channels; Reward; Conditioned Place Preference; Fear Conditioning; Ethanol ID CONDITIONED PLACE PREFERENCE; VENTRAL TEGMENTAL AREA; NULL MUTANT MICE; GIRK CHANNELS; ALCOHOL ADDICTION; DOPAMINE SYSTEM; DRUG-ADDICTION; K+ CHANNELS; HYBRID MICE; NEURONS AB BackgroundG protein-gated inwardly rectifying potassium (GIRK) channels contribute to the effects of a number of drugs of abuse, including ethanol. However, the roles of individual subunits in the rewarding effects of ethanol are poorly understood. MethodsWe compare conditioned place preference (CPP) in GIRK3 subunit knock-out (GIRK3(-/-)), heterozygote (GIRK3(+/-)), and wild-type (WT) mice. In addition, the development of locomotor tolerance/sensitization and the effects of EtOH intoxication on associative learning (fear conditioning) are also assessed. ResultsOur data show significant EtOH CPP in GIRK3(-/-) and GIRK3(+/-) mice, but not in the WT littermates. In addition, we demonstrate that these effects are not due to differences in EtOH metabolism, the development of EtOH tolerance/sensitivity, or associative learning abilities. While there were no consistent genotype differences in the fear conditioning assay, our data do show a selective sensitization of the impairing effects of EtOH intoxication on contextual learning, but no effect on cued learning. ConclusionsThese findings suggest that GIRK3 plays a role in EtOH reward. Furthermore, the selectivity of this effect suggests that GIRK channels could be an effective therapeutic target for the prevention and/or treatment of alcoholism. C1 [Tipps, Megan E.; Kozell, Laura B.; Buck, Kari J.] Portland VA Med Ctr, Portland Alcohol Res Ctr, Portland, OR USA. [Tipps, Megan E.; Raybuck, Jonathan D.; Kozell, Laura B.; Lattal, K. Matthew; Buck, Kari J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, 3181 SW Sam Jackson Pk Rd,Mail Code L470, Portland, OR 97239 USA. RP Tipps, ME (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, 3181 SW Sam Jackson Pk Rd,Mail Code L470, Portland, OR 97239 USA. EM metipps@gmail.com OI Kozell, Laura/0000-0003-3059-2046 FU NIH [F32 AA022011, T32 AA07468, F32DA031537, T32 DA07262, R01 AA011114, P60 AA10760, R24 AA020245, R01 DA005228, R01 DA025922]; VA; U.S. Department of the Army/DOD-TATRC [W81XWH-12-2-0048] FX This work was supported by NIH F32 AA022011 and T32 AA07468 (MET); NIH F32DA031537 and T32 DA07262 (JDR); NIH R01 AA011114, P60 AA10760, R24 AA020245, R01 DA005228, and the VA (KJB); NIH R01 DA025922 and U.S. Department of the Army/DOD-TATRC: W81XWH-12-2-0048 (KML). NR 52 TC 3 Z9 3 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD APR PY 2016 VL 40 IS 4 BP 857 EP 864 DI 10.1111/acer.13012 PG 8 WC Substance Abuse SC Substance Abuse GA DI8GK UT WOS:000373739300023 PM 27012303 ER PT J AU Rosendorff, C AF Rosendorff, Clive CA Writing Comm TI Treatment of Hypertension in Patients with Coronary Artery Disease. A Case-Based Summary of the 2015 AHA/ACC/ASH Scientific Statement SO AMERICAN JOURNAL OF MEDICINE LA English DT Review DE Acute Coronary Syndrome; Coronary Artery Disease; Heart Failure; Hypertension; Myocardial Infarction; Stable Angina; Unstable Angina ID COLLEGE-OF-CARDIOLOGY; LEFT-VENTRICULAR DYSFUNCTION; CONVERTING-ENZYME-INHIBITOR; ACUTE MYOCARDIAL-INFARCTION; AMERICAN-HEART-ASSOCIATION; PREVENTIVE-CARDIOVASCULAR-NURSES; BLOOD-PRESSURE CONTROL; HIGH-RISK PATIENTS; RANDOMIZED-TRIAL; PRACTICE GUIDELINES AB The 2015 American Heart Association/American College of Cardiology/American Society of Hypertension Scientific Statement "Treatment of Hypertension in Patients with Coronary Artery Disease" is summarized in the context of a clinical case. The Statement deals with target blood pressures, and the optimal agents for the treatment of hypertension in patients with stable angina, in acute coronary syndromes, and in patients with ischemic heart failure. In all cases, the recommended blood pressure target is < 140/90 mm Hg, but < 130/80 mm Hg may be appropriate, especially in those with a history of a previous myocardial infarction or stroke, or at high risk for developing either. These numbers may need to be revised after the publication of the SPRINT data. Appropriate management should include beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and in the case of heart failure, aldosterone antagonists. Thiazide or thiazide-like (chlorthalidone) diuretics and calcium channel blockers can be used for the management of hypertension, but the evidence for improved outcomes compared with other agents in hypertension with coronary artery disease is meager. Loop diuretics should be reserved for patients with New York Heart Association Class III and IV heart failure or with a glomerular filtration rate of < 30 mL/min. Published by Elsevier Inc. C1 Mt Sinai Heart, New York, NY USA. Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. James J Peters VA Med Ctr, Bronx, NY 10468 USA. RP Rosendorff, C (reprint author), James J Peters VA Med Ctr, Med 111, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM clive.rosendorff@va.gov OI Allison, Matthew/0000-0003-0777-8272 NR 37 TC 2 Z9 2 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 EI 1555-7162 J9 AM J MED JI Am. J. Med. PD APR PY 2016 VL 129 IS 4 BP 372 EP 378 DI 10.1016/j.amjmed.2015.10.045 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA DI4RH UT WOS:000373486500021 PM 26655222 ER PT J AU Kempen, JH Gewaily, DY Newcomb, CW Liesegang, TL Kacmaz, RO Levy-Clarke, GA Nussenblatt, RB Rosenbaum, JT Sen, HN Suhler, EB Thorne, JE Foster, CS Jabs, DA Payal, A Fitzgerald, TD AF Kempen, John H. Gewaily, Dina Y. Newcomb, Craig W. Liesegang, Teresa L. Kacmaz, R. Oktay Levy-Clarke, Grace A. Nussenblatt, Robert B. Rosenbaum, James T. Sen, H. Nida Suhler, Eric B. Thorne, Jennifer E. Foster, C. Stephen Jabs, Douglas A. Payal, Abhishek Fitzgerald, Tonetta D. CA Systemic Immunosuppressive Therapy TI Remission of Intermediate Uveitis: Incidence and Predictive Factors SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Article ID PARS-PLANA VITRECTOMY; OCULAR INFLAMMATORY DISEASES; CLINICAL-FEATURES; PLANITIS; THERAPY; PANUVEITIS; POSTERIOR; OUTCOMES; RISK; EYE AB PURPOSE: To evaluate the incidence of remission among patients with intermediate uveitis; to identify factors potentially predictive of remission. DESIGN: Retrospective cohort study. METHODS: Involved eyes of patients with primary noninfectious intermediate uveitis at 4 academic ocular inflammation subspecialty practices, followed sufficiently long to meet the remission outcome definition, were studied retrospectively by standardized chart review data. Remission of intermediate uveitis was defined as a lack of inflammatory activity at >= 2 visits spanning >= 90 days in the absence of any corticosteroid or immunosuppressant medications. Factors potentially predictive of intermediate uveitis remission were evaluated using survival analysis. RESULTS: Among 849 eyes (of 510 patients) with intermediate uveitis followed over 1934 eye-years, the incidence of intermediate uveitis remission was 8.6/100 eye-years (95% confidence interval [CI], 7.4-10.1). Factors predictive of disease remission included prior pars plana vitrectomy (PPV) (hazard ratio [HR] [vs no PPV] = 2.39; 95% CI, 1.42-4.00), diagnosis of intermediate uveitis within the last year (HR [vs diagnosis >5 years ago] = 3.82; 95% CI, 1.91-7.63), age >= 45 years (HR [vs age <45 years] = 1.79; 95% CI, 1.03-3.11), female sex (HR = 1.61; 95% CI, 1.04-2.49), and Hispanic race/ethnicity (HR [vs white race] = 2.81; 95% CI, 1.23-6.41). Presence/absence of a systemic inflammatory disease, laterality of uveitis, and smoking status, were not associated with differential incidence. CONCLUSIONS: Our results suggest that intermediate uveitis is a chronic disease with an overall low rate of remission. Recently diagnosed patients and older, female, and Hispanic patients were more likely to remit. With regard to management, pars plana vitrectomy was associated with increased probability of remission. (C) 2016 by Elsevier Inc. All rights reserved. C1 [Kempen, John H.; Gewaily, Dina Y.; Payal, Abhishek; Fitzgerald, Tonetta D.] Univ Penn, Perelman Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA. [Kempen, John H.; Newcomb, Craig W.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Kempen, John H.; Newcomb, Craig W.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Gewaily, Dina Y.] Deglin & Greene Retinal Ctr, Wynnewood, PA USA. [Liesegang, Teresa L.; Rosenbaum, James T.; Suhler, Eric B.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA. [Rosenbaum, James T.; Payal, Abhishek] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Kacmaz, R. Oktay; Foster, C. Stephen] Massachusetts Eye Res & Surg Inst, Waltham, MA USA. [Kacmaz, R. Oktay] Allergan Pharmaceut Inc, Dublin, Ireland. [Levy-Clarke, Grace A.; Nussenblatt, Robert B.; Sen, H. Nida] NEI, Immunol Lab, Bldg 10, Bethesda, MD 20892 USA. [Levy-Clarke, Grace A.] Tampa Bay Uveitis Ctr, Tampa, FL USA. [Rosenbaum, James T.] Devers Eye Inst, Portland, OR USA. [Suhler, Eric B.; Payal, Abhishek] Portland VA Med Ctr, Portland, OR USA. [Thorne, Jennifer E.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA. [Thorne, Jennifer E.; Jabs, Douglas A.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Foster, C. Stephen] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. [Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Dept Ophthalmol, New York, NY USA. [Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. RP Kempen, JH (reprint author), Univ Penn, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA. EM john.kempen@uphs.upenn.edu OI Payal, Abhishek/0000-0002-4484-8279 FU NATIONAL EYE INSTITUTE (BETHESDA, MD, USA) [EY014943]; Research to Prevent Blindness (New York, NY, USA); Paul and Evanina Mackall Foundation (New York, NY, USA); Lois Pope Life Foundation (New York, NY, USA); Veteran's Affairs Administration (Washington, DC, USA); National Eye Institute; Research to Prevent Blindness FX SUPPORTED PRIMARILY BY NATIONAL EYE INSTITUTE (BETHESDA, MD, USA) GRANT EY014943 (JOHN H. Kempen). Additional support was provided by Research to Prevent Blindness (New York, NY, USA), the Paul and Evanina Mackall Foundation (New York, NY, USA), and the Lois Pope Life Foundation (New York, NY, USA). During the course of the study, John H. Kempen was a Research to Prevent Blindness James S. Adams Special Scholar Award recipient, Jennifer E. Thorne was a Research to Prevent Blindness Harrington Special Scholar Award recipient, and Douglas A. Jabs and James T. Rosenbaum were Research to Prevent Blindness Senior Scientific Investigator Award recipients. Eric B. Suhler receives support from the Veteran's Affairs Administration (Washington, DC, USA). Grace A. Levy-Clarke was previously supported by and Robert B. Nussenblatt and H. Nida Sen continue to be supported by intramural funds of the National Eye Institute. The funding organizations had no role in the design or conduct of this research. NR 34 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9394 EI 1879-1891 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD APR PY 2016 VL 164 BP 110 EP 117 DI 10.1016/j.ajo.2015.12.034 PG 8 WC Ophthalmology SC Ophthalmology GA DI7CS UT WOS:000373657300014 PM 26772874 ER PT J AU Capurso, NA Petrakis, I AF Capurso, Noah A. Petrakis, Ismene TI Dyslipidemia associated with heavy alcohol use SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID CORONARY-HEART-DISEASE; SEVERE HYPERTRIGLYCERIDEMIA; LIPOPROTEIN-LIPASE; RISK; CONSUMPTION; MEN; MORTALITY; DRINKING AB Background and ObjectivesAlcohol has many effects on lipid metabolism and has been associated with elevated triglycerides. The purpose of this paper is to report a case of globally dysregulated lipids secondary to alcohol use and to describe the natural history of this phenomenon after drinking cessation. MethodsWe present a case of an otherwise healthy patient (N=1) who was admitted to our facility for alcohol detoxification and found to have extreme lipid dysregulation. He was treated with benzodiazepines for alcohol withdrawal but no hypolipidemic agents were given. ResultsLipid indices self-corrected and were found to be normal following just several weeks of sobriety in the absence of treatment with any hypolipidemic agents. DiscussionThe literature regarding the effects of alcohol on lipid metabolism is briefly reviewed followed by a discussion of how these findings might apply to this patient in particular as well as implications for broader clinical practice. Conclusion and Scientific SignificanceAlcohol has the ability to dysregulate several lipid indices in addition to elevating triglycerides. The rapid resolution of dyslipidemia suggests that additional treatment may not be necessary for patients who are able to abstain from alcohol but that hypolipidemic agents may be indicated for those patients who continue to drink. Additionally, clinicians should consider checking lipid panels in patients who present with alcohol intoxication and are found to have other laboratory abnormalites or those who have risk factors for hyperlipidemia. (Am J Addict 2016;25:188-190) C1 [Capurso, Noah A.; Petrakis, Ismene] Yale Univ, Sch Med, Dept Psychiat, 300 George St,Suite 901, New Haven, CT 06511 USA. [Petrakis, Ismene] VA Connecticut Healthcare Syst, US Dept Vet Affairs, West Haven, CT USA. RP Capurso, NA (reprint author), Yale Univ, Sch Med, Dept Psychiat, 300 George St,Suite 901, New Haven, CT 06511 USA. EM noah.capurso@yale.edu NR 19 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD APR PY 2016 VL 25 IS 3 BP 188 EP 190 DI 10.1111/ajad.12347 PG 3 WC Substance Abuse SC Substance Abuse GA DI5UA UT WOS:000373564800002 PM 26991470 ER PT J AU Emery, MJ Groves, CC Kruse, TN Shi, C Terman, GW AF Emery, Michael J. Groves, Chase C. Kruse, Timothy N. Shi, Chen Terman, Gregory W. TI Ventilation and the Response to Hypercapnia after Morphine in Opioid-naive and Opioid-tolerant Rats SO ANESTHESIOLOGY LA English DT Article ID INDUCED RESPIRATORY DEPRESSION; ADMINISTERED MORPHINE; POSTNATAL-DEVELOPMENT; RECURRENT HYPOXIA; CHRONIC PAIN; RECEPTORS; SLEEP; OVERDOSE; MECHANISMS; ANALGESIA AB Background: Opioid-related deaths are a leading cause of accidental death, with most occurring in patients receiving chronic pain therapy. Respiratory arrest is the usual cause of death, but mechanisms increasing that risk with increased length of treatment remain unclear. Repeated administration produces tolerance to opioid analgesia, prompting increased dosing, but depression of ventilation may not gain tolerance to the same degree. This study addresses differences in the degree to which chronic morphine (1) produces tolerance to ventilatory depression versus analgesia and (2) alters the magnitude and time course of ventilatory depression. Methods: Juvenile rats received subcutaneous morphine for 3 days (n = 116) or vehicle control (n = 119) and were then tested on day 4 following one of a range of morphine doses for (a) analgesia by paw withdraw from heat or (b) respiratory parameters by plethysmography-respirometry. Results: Rats receiving chronic morphine showed significant tolerance to morphine sedation and analgesia (five times increased ED50). When sedation was achieved for all animals in a dose group (lowest effective doses: opioid-tolerant, 15 mg/kg; opioid-naive, 3 mg/kg), the opioid-tolerant showed similar magnitudes of depressed ventilation (-41.4 7.0%, mean +/- SD) and hypercapnic response (-80.9 +/- 15.7%) as found for morphine-naive (-35.5 +/- 16.9% and -67.7 +/- 15.1%, respectively). Ventilation recovered due to tidal volume without recovery of respiratory rate or hypercapnic sensitivity and more slowly in morphine-tolerant. Conclusions: In rats, gaining tolerance to morphine analgesia does not reduce ventilatory depression effects when sedated and may inhibit recovery of ventilation. C1 [Emery, Michael J.; Groves, Chase C.; Kruse, Timothy N.; Shi, Chen; Terman, Gregory W.] Univ Washington, Sch Med, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA. [Emery, Michael J.] Vet Affairs Puget Sound Hlth Care Syst, Pulm & Crit Care Med, Seattle, WA USA. RP Emery, MJ (reprint author), Univ Washington, Sch Med, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA. EM mjemery@u.washington.edu FU University of Washington Alcohol and Drug Abuse Institute (Seattle, Washington) FX This study was supported by the University of Washington Alcohol and Drug Abuse Institute (Seattle, Washington). NR 56 TC 2 Z9 2 U1 3 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-3022 EI 1528-1175 J9 ANESTHESIOLOGY JI Anesthesiology PD APR PY 2016 VL 124 IS 4 BP 945 EP 957 DI 10.1097/ALN.0000000000000997 PG 13 WC Anesthesiology SC Anesthesiology GA DI2TO UT WOS:000373352000027 PM 26734964 ER PT J AU Park, M Shlipak, MG Thiessen-Philbrook, H Garg, AX Koyner, JL Coca, SG Parikh, CR AF Park, Meyeon Shlipak, Michael G. Thiessen-Philbrook, Heather Garg, Amit X. Koyner, Jay L. Coca, Steven G. Parikh, Chirag R. CA TRIBE-AKI Consortium TI Association of Peak Changes in Plasma Cystatin C and Creatinine With Death After Cardiac Operations SO ANNALS OF THORACIC SURGERY LA English DT Article ID GLOMERULAR-FILTRATION-RATE; ACUTE KIDNEY INJURY; SERUM CREATININE; CARDIOTHORACIC SURGERY; RISK; BIOMARKERS; EQUATION; FAILURE; MARKER AB Background. Acute kidney injury is a risk factor for death in cardiac surgical patients. Plasma cystatin C and creatinine have different temporal profiles in the postoperative setting, but the associations of simultaneous changes in both filtration markers compared with change in only one marker with prognosis after hospital discharge are not well described. Methods. This is a longitudinal study of 1,199 high-risk adult cardiac surgical patients in the TRIBE-AM (Translational Research Investigating Biomarker Endpoints for Acute Kidney Injury) Consortium who survived hospitalization. We examined in-hospital peak changes of cystatin C and creatinine in the 3 days after cardiac operations. We evaluated associations of these filtration markers with death, adjusting for demographics, operative characteristics, medical comorbidities, preoperative estimated glomerular filtration rate, preoperative urinary albumin-to-creatinine ratio, and site. Results. During the first 3 days of hospitalization, nearly twice as many patients had a 25% or higher rise in creatinine (30%) compared with a 25% or higher peak rise in cystatin C (15%). The risk of death was higher in those with elevations in cystatin C (adjusted hazard ratio [HR], 1.83; 95% confidence interval [CI], 1.4 to 2.37) or creatinine (adjusted HR, 1.90; 95% CI, 1.32 to 2.72) compared with patients who experienced a postoperative decrease in either filtration marker. Patients who had simultaneous elevations of 25% or higher in cystatin C and creatinine were at similar adjusted risk for 3-year mortality (HR, 1.79; 95% CI, 1.03 to 3.1) as those with a 25% or higher increase in cystatin C alone (HR, 2.2; 95% CI, 1.09 to 4.47). Conclusions. Elevations in creatinine postoperatively are more common than elevations in cystatin C. However, elevations in cystatin C appeared to be associated with a higher risk of death after hospital discharge. (C) 2016 by The Society of Thoracic Surgeons C1 Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Div Gen Internal Med, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. Univ Western Ontario, Dept Med, Div Nephrol, London, ON, Canada. Inst Clin Evaluat Sci, Toronto, ON, Canada. Univ Chicago, Dept Med, Nephrol Sect, 5841 S Maryland Ave, Chicago, IL 60637 USA. Mt Sinai Sch Med, Div Nephrol, New York, NY USA. Yale Univ, Sch Med, Nephrol Sect, New Haven, CT USA. RP Park, M (reprint author), 521 Parnassus Ave,C443,Box 0532, San Francisco, CA 94143 USA. EM meyeon.park@ucsf.edu FU Institute for Clinical Evaluative Sciences; Ontario Ministry of Health and Long-Term Care; National Institutes of Health (NIH) [R01-HL085757]; NIH National Institute of Diabetes and Digestive and Kidney Diseases [K23-DK099238]; Adam Linton Chair in Kidney Health Analytics; NIH [K23-DK081616, K23-DK080132, K24-DK090203, U01-DK082185]; Abbott Diagnostics; Sekisui Diagnostics Inc FX This study was supported by the Institute for Clinical Evaluative Sciences, funded by an annual grant from the Ontario Ministry of Health and Long-Term Care. The opinions, results, and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by Institute for Clinical Evaluative Sciences or the Ontario Ministry of Health and Long-Term Care is intended or should be inferred. This study was supported by National Institutes of Health (NIH) (R01-HL085757 C.R.P.) to fund the TRIBE-AKI Consortium to study novel biomarkers of AKI in cardiac surgery. Other support: NIH National Institute of Diabetes and Digestive and Kidney Diseases grant K23-DK099238 (M.P.), Adam Linton Chair in Kidney Health Analytics (A.X.G.), and NIH K23-DK081616 (J.L.K.), K23-DK080132 (S.G.C.), and K24-DK090203 (C.R.P.). S.G.C., A.X.G., and C.R.P. are also members of the NIH-sponsored Assess, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury Consortium (U01-DK082185). The granting agencies, Abbott Diagnostics and Sekisui Diagnostics Inc, did not participate in the design or conduct of the study, collection, management, analysis, interpretation of data, or preparation, review, or approval of the manuscript. NR 21 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD APR PY 2016 VL 101 IS 4 BP 1395 EP 1401 DI 10.1016/j.athoracsur.2015.12.010 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA DH1CT UT WOS:000372522700034 PM 26921980 ER PT J AU Balasubramanian, CK Li, CY Bowden, MG Duncan, PW Kautz, SA Velozo, CA AF Balasubramanian, Chitralakshmi K. Li, Chih-Ying Bowden, Mark G. Duncan, Pamela W. Kautz, Steven A. Velozo, Craig A. TI Dimensionality and Item-Difficulty Hierarchy of the Lower Extremity Fugl-Meyer Assessment in Individuals With Subacute and Chronic Stroke SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Lower extremity; Rehabilitation; Stroke ID ASSESSMENT SCALE; HEMIPLEGIC PATIENT; OUTCOME MEASURES; MOTOR RECOVERY; PERFORMANCE; POSTSTROKE; WALKING; REHABILITATION; COORDINATION; RELIABILITY AB Objective: To investigate the dimensionality and item-difficulty hierarchy of the Fugl-Meyer Assessment of the lower extremity (FMA-LE). Design: Secondary analyses of data pooled from 4 existing datasets: a phase III randomized controlled trial investigating the effectiveness of body weight support and a treadmill for rehabilitation of walking poststroke, and 3 cross-sectional studies investigating the link between impaired motor performance poststroke and walking. Setting: University research centers and rehabilitation centers. Participants: A pooled sample of individuals with a stroke (N=535, men = 313; mean age +/- SD, 61.91 +/- 12.42y). Interventions: Not applicable. Main Outcome Measures: Confirmatory factor analyses (CFA) and Rasch residual principal component analysis (PCA) investigated the dimensionality of the FMA-LE. The Rasch analysis rating scale model investigated item-difficulty hierarchy of the FMA-LE. Results: The CFA showed adequate fit of a 3-factor model, with 2 out of 3 indices (CFA=.95; Tucker-Lewis Index=.94; root mean square error of approximation=.124) showing good model fit. Rasch PCA showed that removal of the reflex and coordination items explained 90.8% of variance in the data, suggesting that the abnormal synergy items contributed to the measurement of a unidimensional construct. However, rating scale model results revealed deviations in the item-difficulty hierarchy of the unidimensional abnormal synergy items from the originally proposed stepwise sequence of motor recovery. Conclusions: Our findings suggest that the FMA-LE might represent a multidimensional construct, challenging the use of a total score of the FMA-LE to predict lower extremity motor recovery. Removal of the misfit items resulted in creation of a unidimensional scale composed of the abnormal synergy items. However, this unidimensional scale deviates from the originally proposed hierarchical ordering. (C) 2016 by the American Congress of Rehabilitation Medicine C1 [Balasubramanian, Chitralakshmi K.] Univ N Florida, Dept Clin & Appl Movement Sci, 1 UNF Dr, Jacksonville, FL 32224 USA. [Li, Chih-Ying; Bowden, Mark G.; Kautz, Steven A.] Med Univ S Carolina, Coll Hlth Profess, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Li, Chih-Ying; Bowden, Mark G.; Kautz, Steven A.] Med Univ S Carolina, Coll Hlth Profess, Div Phys Therapy, Charleston, SC 29425 USA. [Bowden, Mark G.; Kautz, Steven A.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Duncan, Pamela W.] Wake Forest Univ, Dept Neurol, Winston Salem, NC 27109 USA. [Velozo, Craig A.] Med Univ S Carolina, Coll Hlth Profess, Div Occupat Therapy, Charleston, SC 29425 USA. RP Balasubramanian, CK (reprint author), Univ N Florida, Dept Clin & Appl Movement Sci, 1 UNF Dr, Jacksonville, FL 32224 USA. EM c.k-balasubramanian@unf.edu FU National Institute of Neurologic Diseases and Stroke; National Center for Medical Rehabilitation Research [RO1 NS050506]; National Institutes of Health [HD46820]; Rehabilitation Research and Development Service of the U.S. Department of Veterans Affairs [B2748R]; Institutional Development Award from the National Institute of General Medical Sciences of the National Institutes of Health [P20-GM109040] FX Support for study 1 by the National Institute of Neurologic Diseases and Stroke and the National Center for Medical Rehabilitation Research (grant no. RO1 NS050506); for study 2, by the National Institutes of Health (grant no. HD46820); for study 3, by the Rehabilitation Research and Development Service of the U.S. Department of Veterans Affairs (grant no. B2748R); and for study 4, by an Institutional Development Award from the National Institute of General Medical Sciences of the National Institutes of Health (grant no. P20-GM109040). NR 47 TC 1 Z9 1 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD APR PY 2016 VL 97 IS 4 BP 582 EP 589 DI 10.1016/j.apmr.2015.12.012 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA DI5EM UT WOS:000373521700012 PM 26740065 ER PT J AU Johansen, KL Dalrymple, LS Glidden, D Delgado, C Kaysen, GA Grimes, B Chertow, GM AF Johansen, Kirsten L. Dalrymple, Lorien S. Glidden, David Delgado, Cynthia Kaysen, George A. Grimes, Barbara Chertow, Glenn M. TI Association of Performance-Based and Self-Reported Function-Based Definitions of Frailty with Mortality among Patients Receiving Hemodialysis SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID MAINTENANCE HEMODIALYSIS; CONSENSUS; DIALYSIS; DISEASE; HEALTH; OLDER AB Background and objectives Frailty is common among patients on dialysis and increases vulnerability to dependency and death. Design, setting, participants, & measurements We examined the predictive ability of frailty on the basis of physical performance and self-reported function in participants of a US Renal Data System special study that enrolled a convenience sample of 771 prevalent patients on hemodialysis from 14 facilities in the Atlanta and northern California areas from 2009 to 2011. Performance-based frailty was assessed using direct measures of grip strength (weakness) and gait speed along with weight loss, exhaustion, and low physical activity; poor self reported function was substituted for weakness and slow gait speed in the self reported function based definition. For both definitions, patients meeting three or more criteria were considered frail. Results The mean age of 762 patients included in analyses was 57.1 +/- 14.2 years old; 240 patients (31%) met the physical performance-based definition of frailty, and 396 (52%) met the self reported function-based definition. There were 106 deaths during 1.7 (interquartile range, 1.4-2.4) years of follow-up. After adjusting for demographic and clinical characteristics, the hazard ratio (HR) for mortality for the performance-based definition (2.16; 95% confidence interval [95% CI], 1.41 to 3.29) was slightly higher than that of the self reported function based definition (HR, 1.93; 95% CI, 1.24 to 3.00). Patients who met the self-report based definition but not the physical performance definition of frailty (n=192) were not at statistically significantly higher risk of mortality than those who were not frail by either definition (n=330; HR, 1.41; 95% CI, 0.81 to 2.45), but those who met both definitions of frailty (n=204) were at significantly higher risk (HR, 2.46; 95% CI, 1.51 to 4.01). Conclusions Frailty, defined using either direct tests of physical performance or self reported physical function, was associated with higher mortality among patients receiving hemodialysis. Future studies are needed to determine the utility of assessing frailty in clinical practice. C1 [Johansen, Kirsten L.; Delgado, Cynthia] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Johansen, Kirsten L.; Glidden, David; Grimes, Barbara] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Johansen, Kirsten L.; Delgado, Cynthia] San Francisco VA Med Ctr, Nephrol Sect, 111J,4150 Clement St, San Francisco, CA 94121 USA. [Dalrymple, Lorien S.; Kaysen, George A.] Univ Calif Davis, Div Nephrol, Davis, CA 95616 USA. [Chertow, Glenn M.] Stanford Univ, Sch Med, Div Nephrol, Stanford, CA 94305 USA. RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Nephrol Sect, 111J,4150 Clement St, San Francisco, CA 94121 USA. EM Kirsten.johansen@ucsf.edu FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [N01-DK-7-005, K24DK085153, K23DK093584, K24DK085446]; Career Development Award from US Department of Veterans Affairs [1K2CX000527]; Clinical Research and Development Program; National Center for Advancing Translational Sciences, National Institutes of Health through University of California; San Francisco-Clinical & Translational Science Institute grant [UL1 TR000004] FX This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Contract N01-DK-7-005 and NIDDK Grants K24DK085153 (to K.L.J.), K23DK093584 (to L.S.D.), and K24DK085446 (to G.M.C.). In addition, C.D. was supported by Career Development Award 1K2CX000527 from the US Department of Veterans Affairs, Clinical Research and Development Program. This publication was supported by the National Center for Advancing Translational Sciences, National Institutes of Health through University of California, San Francisco-Clinical & Translational Science Institute grant UL1 TR000004. NR 20 TC 3 Z9 3 U1 1 U2 3 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD APR PY 2016 VL 11 IS 4 BP 626 EP 632 DI 10.2215/CJN.03710415 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA DI5EV UT WOS:000373522600013 PM 26792529 ER PT J AU Bitzer, C AF Bitzer, Carolynn TI Evidence-Based Practice Research on Pole- vs Patient-Mounted Transducer Placement SO CRITICAL CARE NURSE LA English DT Meeting Abstract C1 [Bitzer, Carolynn] Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CRITICAL CARE NURSES PI ALISO VIEJO PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA SN 0279-5442 EI 1940-8250 J9 CRIT CARE NURSE JI Crit. Care Nurse PD APR PY 2016 VL 36 IS 2 MA EB66 BP E27 EP E28 PG 2 WC Critical Care Medicine; Nursing SC General & Internal Medicine; Nursing GA DI4CQ UT WOS:000373448300030 ER PT J AU Justice, AC McGinnis, KA Tate, JP Braithwaite, RS Bryant, KJ Cook, RL Edelman, EJ Fiellin, LE Freiberg, MS Gordon, AJ Kraemer, KL Marshall, BDL Williams, EC Fiellin, DA AF Justice, Amy C. McGinnis, Kathleen A. Tate, Janet P. Braithwaite, R. Scott Bryant, Kendall J. Cook, Robert L. Edelman, E. Jennifer Fiellin, Lynn E. Freiberg, Matthew S. Gordon, Adam J. Kraemer, Kevin L. Marshall, Brandon D. L. Williams, Emily C. Fiellin, David A. TI Risk of mortality and physiologic injury evident with lower alcohol exposure among HIV infected compared with uninfected men SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Alcohol; Mortality; Morbidity; VACS Index; AUDIT-C; Veteran; HIV ID VETERANS AGING COHORT; ALL-CAUSE MORTALITY; J-SHAPED CURVE; ANTIRETROVIRAL THERAPY; PRIMARY-CARE; AUDIT-C; MEDICATION ADHERENCE; ADMINISTRATIVE DATA; SCREENING SCORES; PROBLEM DRINKING AB Background: HIV infected (HIV+) individuals may be more susceptible to alcohol-related harm than uninfected individuals. Methods: We analyzed data on HIV+ and uninfected individuals in the Veterans Aging Cohort Study (VACS) with an Alcohol Use Disorders Identification Test-Consumption AUDIT-C score from 2008 to 2012. We used Cox proportional hazards models to examine the association between alcohol exposure and mortality through July, 2014; and linear regression models to assess the association between alcohol exposure and physiologic injury based on VACS Index Scores. Models were adjusted for age, race/ethnicity, smoking, and hepatitis C infection. Results: The sample included 18,145 HIV+ and 42,228 uninfected individuals. Among HIV+ individuals, 76% had undetectable HIV-1 RNA (<500 copies/ml). The threshold for an association of alcohol use with mortality and physiologic injury differed by HIV status. Among HIV+ individuals, AUDIT-C score >= 4 (hazard ratio [HR] 1.25, 95% CI 1.09-1.44) and >= 30 drinks per month (HR, 1.30, 95% CI 1.14-1.50) were associated with increased risk of mortality. Among uninfected individuals, AUDIT-C score >= 5 (HR, 1.19, 95% CI 1.07-1.32) and >= 70 drinks per month (HR 1.13, 95% CI 1.00-1.28) were associated with increased risk. Similarly, AUDIT-C threshold scores of 5-7 were associated with physiologic injury among HIV+ individuals (beta 0.47, 95% CI 0.22, 0.73) and a score of 8 or more was associated with injury in uninfected (beta 0.29, 95% CI 0.16, 0.42) individuals. Conclusions: Despite antiretroviral therapy, HIV+ individuals experienced increased mortality and physiologic injury at lower levels of alcohol use compared with uninfected individuals. Alcohol consumption limits should be lower among HIV+ individuals. Published by Elsevier Ireland Ltd. C1 [Justice, Amy C.; Tate, Janet P.; Edelman, E. Jennifer; Fiellin, David A.] West Haven VA Healthcare Syst, Vet Aging Cohort Study Coordinating Ctr, 950 Campbell Ave, West Haven, CT 06516 USA. [Justice, Amy C.; Tate, Janet P.; Edelman, E. Jennifer; Fiellin, Lynn E.; Fiellin, David A.] Yale Univ, Yale Sch Med, Dept Internal Med, 367 Cedar St, New Haven, CT 06510 USA. [Justice, Amy C.; Tate, Janet P.; Edelman, E. Jennifer; Fiellin, Lynn E.; Fiellin, David A.] Yale Univ, Yale Sch Med, CIRA, 367 Cedar St, New Haven, CT 06510 USA. [McGinnis, Kathleen A.; Gordon, Adam J.; Kraemer, Kevin L.] VA Pittsburgh Healthcare Syst, Univ Dr C, Pittsburgh, PA 15240 USA. [Braithwaite, R. Scott] NYU, Sch Med, Dept Populat Hlth, 227 East 30th St, New York, NY 10016 USA. [Bryant, Kendall J.] NIAAA, 5635 Fishers Lane,MSC 9304, Bethesda, MD 20892 USA. [Cook, Robert L.] Univ Florida, Dept Epidemiol, POB 100231, Gainesville, FL USA. [Freiberg, Matthew S.] Vanderbilt Univ, Sch Med, Div Cardiovasc Med, Nashville, TN 37212 USA. [Freiberg, Matthew S.] Vet Affairs Tennessee Valley Healthcare Syst, Geriatr Res Educ & Clin Ctr, 2525 West End Ave, Nashville, TN USA. [Gordon, Adam J.; Kraemer, Kevin L.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Suite 600,230 McKee Pl, Pittsburgh, PA 15213 USA. [Marshall, Brandon D. L.] Brown Univ, Sch Publ Hlth, Dept Epidemiol, 121 South Main St, Providence, RI 02912 USA. [Williams, Emily C.] Univ Washington, Sch Publ Hlth, 325 Ninth Ave,Box 359762, Seattle, WA 98195 USA. RP Justice, AC (reprint author), Yale Univ, Sch Med, VA Connecticut Healthcare Syst, 950 Campbell Ave,Bldg 35a Room 2-212 11 ACSLG, West Haven, CT 06516 USA. EM amy.Justice2@va.gov OI Fiellin, David/0000-0002-4006-010X; Justice, Amy/0000-0003-0139-5502 FU NHLBI NIH HHS [R01 HL090342, R01 HL095136, R01-HL090342, R01-HL095136, RC1 HL100347, RCI-HL100347]; NIA NIH HHS [R01-AG029154, R01 AG029154]; NIAAA NIH HHS [U10 AA013566, U10-AA13566, U13 AA022864, U24 AA022000, U24 AA022002, U24AA02002]; PHS HHS [U01-A1069918] NR 60 TC 13 Z9 13 U1 3 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD APR 1 PY 2016 VL 161 BP 95 EP 103 DI 10.1016/j.drugalcdep.2016.01.017 PG 9 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DI3SP UT WOS:000373419100013 PM 26861883 ER PT J AU Okita, K Ghahremani, DG Payer, DE Robertson, CL Dean, AC Mandelkern, MA London, ED AF Okita, Kyoji Ghahremani, Dara G. Payer, Doris E. Robertson, Chelsea L. Dean, Andy C. Mandelkern, Mark A. London, Edythe D. TI Emotion dysregulation and amygdala dopamine D2-type receptor availability in methamphetamine users SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Methamphetamine; Amygdala; Emotion dysregulation; Dopamine; [F-18]Fallypride; PET ID BORDERLINE PERSONALITY-DISORDER; REFERENCE TISSUE MODEL; HUMAN BRAIN; NEURAL MECHANISMS; IMPULSE CONTROL; ABSTINENCE; DEPENDENCE; CORTEX; DIFFICULTIES; INHIBITION AB Background: Individuals who use methamphetamine chronically exhibit emotional and dopaminergic neurochemical deficits. Although the amygdala has an important role in emotion processing and receives dopaminergic innervation, little is known about how dopamine transmission in this region contributes to emotion regulation. This investigation aimed to evaluate emotion regulation in subjects who met DSM-IV criteria for methamphetamine dependence, and to test for a relationship between self-reports of difficulty in emotion regulation and D2-type dopamine receptor availability in the amygdala. Method: Ninety-four methamphetamine-using and 102 healthy-control subjects completed the Difficulties in Emotion Regulation Scale (DERS); 33 of those who used methamphetamine completed the Addiction Severity Index (ASI). A subset of 27 methamphetamine-group and 20 control-group subjects completed positron emission tomography with [F-18]fallypride to assay amygdala D2-type dopamine receptor availability, measured as binding potential (BPND). Results: The methamphetamine group scored higher than the control group on the DERS total score (p < 0.001), with DERS total score positively correlated with the Drug Composite Score on the ASI (p = 0.02) in the methamphetamine group. The DERS total score was positively correlated with amygdala BPND in both groups and the combined group of participants (combined: r= 0.331, p= 0.02), and the groups did not differ in this relationship. Conclusion: These findings highlight problems with emotion regulation linked to methamphetamine use, possibly contributing to personal and interpersonal behavioral problems. They also suggest that D2-type dopamine receptors in the amygdala contribute to emotion regulation in both healthy and methamphetamine-using subjects. (c) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Okita, Kyoji; Ghahremani, Dara G.; Dean, Andy C.; London, Edythe D.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Robertson, Chelsea L.; London, Edythe D.] Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA. [London, Edythe D.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. [Payer, Doris E.] Ctr Addict & Mental Hlth, Addict Imaging Res Grp, Toronto, ON M5T 1R8, Canada. [Payer, Doris E.] Univ Toronto, Dept Psychiat, Toronto, ON M5T 1R8, Canada. [Okita, Kyoji; Robertson, Chelsea L.; Mandelkern, Mark A.; London, Edythe D.] VA Greater Los Angeles Healthcare Syst, Dept Res, Los Angeles, CA 90073 USA. [Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92697 USA. RP London, ED (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 760 Westwood Plaza,POB 175919, Los Angeles, CA 90095 USA. EM elondon@mednet.ucla.edu OI Payer, Doris/0000-0001-9313-2587 FU National Institute on Drug Abuse [R01 DA015179, R01 DA020726, P20 DA022539, T32 DA024635, K23 DA027734, R21 DA034928]; National Center for Research Resources [M01 RR00865]; Thomas P and Katherine K Pike Chair in Addiction Studies; Marjorie M Greene Trust; Department of Psychiatry, Chiba University, DOMONKAI fund FX This research was supported, in part, by grants from the National Institute on Drug Abuse (R01 DA015179, R01 DA020726, P20 DA022539, T32 DA024635, EDL; K23 DA027734, R21 DA034928, ACD) and the National Center for Research Resources (M01 RR00865), and endowments from the Thomas P and Katherine K Pike Chair in Addiction Studies and the Marjorie M Greene Trust. KO was partly supported by Department of Psychiatry, Chiba University, DOMONKAI fund. NR 68 TC 1 Z9 1 U1 8 U2 14 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD APR 1 PY 2016 VL 161 BP 163 EP 170 DI 10.1016/j.drugalcdep.2016.01.029 PG 8 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DI3SP UT WOS:000373419100021 PM 26880595 ER PT J AU Chavez, LJ Bradley, K Tefft, N Liu, CF Hebert, P Devine, B AF Chavez, Laura J. Bradley, Katharine Tefft, Nathan Liu, Chuan-Fen Hebert, Paul Devine, Beth TI Preference weights for the spectrum of alcohol use in the US Population SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Alcohol consumption; Health-related quality of life; preference weights ID QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; REPORTED HEALTH-STATUS; USE DISORDER SEVERITY; UNITED-STATES; GENERAL-POPULATION; PRIMARY-CARE; SCREENING SCORES; RISK-FACTORS; AUDIT-C AB Background: Little is known about the cost-utility of population-based alcohol interventions. One barrier to research has been the lack of preference weights needed to calculate Quality Adjusted Life Years (QALYs). Preference weights can be estimated from measures of health-related quality of life (HRQOL). The objective of this study was to describe preference weights for the full spectrum of alcohol use. Methods: This cross-sectional study included participants in both the National Health Interview Survey (NHIS; 1999-2002) and the Medical Expenditure Panel Survey (MEPS; 2000-2003). The AUDIT-C alcohol screen was derived from NHIS with scores categorized into 6 groups (0,1-3, 4-5, 6-7, 8-9,10-12 points), ranging from nondrinking (0) to very severe unhealthy alcohol use (10-12). AUDIT-C scores were mapped to EQ-5D and SF-6D preference weights using the linked datasets and analyses adjusted for demographics. Results: Among 17,440 participants, mean EQ-5D and SF-6D preference weights were 0.82 (95% CI 0.82-0.83) and 0.79 (95% CI 0.79-0.80), respectively. Adjusted EQ-5D preference weights for nondrinking (0.80; 95% CI 0.79-0.81) and moderate unhealthy drinking (0.85; 95% CI 0.84-0.86) were significantly different from low-risk drinking (0.83; 95% CI 0.83-0.84), but no other differences were significant. Results for the SF-GD were similar. Conclusions: This study provides EQ-5D and SF-6D preference weights for various alcohol use categories in a representative U.S. adult sample. However, neither measure suggested meaningful differences in HRQOL based on AUDIT-C categories. Self-reported alcohol consumption may not be associated with preference weights or generic instruments may not capture alcohol-related differences in HRQOL. (c) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Chavez, Laura J.; Bradley, Katharine; Liu, Chuan-Fen; Hebert, Paul] Vet Affairs Puget Sound Hlth Care Syst, Seattle Ctr Innovat Vet Ctr & Value Driven Care, Hlth Serv Res & Dev, 1660 S Columbian Way, Seattle, WA 98108 USA. [Bradley, Katharine] Vet Affairs Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, 1660 S Columbian Way, Seattle, WA 98108 USA. [Chavez, Laura J.; Bradley, Katharine; Liu, Chuan-Fen; Hebert, Paul; Devine, Beth] Univ Washington, Dept Hlth Serv, 1959 NE Pacific St,Box 357660, Seattle, WA 98195 USA. [Bradley, Katharine] Univ Washington, Dept Med, 1959 NE Pacific St, Seattle, WA 98195 USA. [Devine, Beth] Univ Washington, Dept Pharm, 1959 NE Pacific St, Seattle, WA 98195 USA. [Tefft, Nathan] Bates Coll, 2 Andrews Rd, Lewiston, ME 04240 USA. [Bradley, Katharine] Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA. RP Chavez, LJ (reprint author), Univ Washington, Dept Hlth Serv, 1959 NE Pacific St,Box 357660, Seattle, WA 98195 USA. EM ljchavez@u.washington.edu OI Bradley, Katharine/0000-0003-1933-4425; Tefft, Nathan/0000-0002-2758-8700 FU Agency for Healthcare Research and Quality (AHRQ) [NIH 1R36HS022800-01]; University of Washington Center of Excellence in Comparative Effectiveness Research; Pharmaceutical Researcher and Manufacturer's Association (PhRMA) Foundation FX Ms. Chavez's work on this study was supported by an Agency for Healthcare Research and Quality (AHRQ) Dissertation Grant (NIH 1R36HS022800-01) and a predoctoral fellowship from the University of Washington Center of Excellence in Comparative Effectiveness Research, sponsored by the Pharmaceutical Researcher and Manufacturer's Association (PhRMA) Foundation. Dr. Bradley's time on this study was supported by the Center of Excellence for Substance Abuse Treatment and Education (CESATE) at VA Puget Sound. NR 50 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD APR 1 PY 2016 VL 161 BP 206 EP 213 DI 10.1016/j.drugalcdep.2016.02.004 PG 8 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DI3SP UT WOS:000373419100026 PM 26900145 ER PT J AU Adappa, ND Workman, AD Hadjiliadis, D Dorgan, DJ Frame, D Brooks, S Doghramji, L Palmer, JN Mansfield, C Reed, DR Cohen, NA AF Adappa, Nithin D. Workman, Alan D. Hadjiliadis, Denis Dorgan, Daniel J. Frame, Danielle Brooks, Steven Doghramji, Laurel Palmer, James N. Mansfield, Corrine Reed, Danielle R. Cohen, Noam A. TI T2R38 genotype is correlated with sinonasal quality of life in homozygous F508 cystic fibrosis patients SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE chronic rhinosinusitis; cystic fibrosis; T2R38; SNOT-22; bitter taste receptor; genetics ID TASTE RECEPTOR T2R38; SINUS SURGERY; CHRONIC RHINOSINUSITIS; PSEUDOMONAS-AERUGINOSA; PARANASAL SINUSES; INFECTION; DISEASE; NASAL; MECHANISMS; PHENOTYPE AB BackgroundChronic rhinosinusitis (CRS) is very prevalent in the cystic fibrosis (CF) patient population, and leads to high morbidity and markedly decreased quality of life (QOL). Identification of genetic markers that contribute to CRS symptoms in these patients can allow for risk stratification and tailoring of medical and surgical treatments. T2R38 is a bitter taste receptor expressed in the sinonasal tract, and nonfunctional alleles of this receptor have been implicated in treatment-refractory CRS in non-CF patients. The purpose of this study is to investigate the significance of T2R38 genotype in the variability of sinonasal QOL and CRS disease severity in a sample of CF patients. MethodsF508 homozygous CF patients were recruited from the University of Pennsylvania Cystic Fibrosis Center and were genotyped for the TAS2R38 locus. To assess sinonasal symptom severity, a 22-item Sino-Nasal Outcome Test (SNOT-22) was collected from each patient. Additional demographic and medical history data was obtained at the time of patient enrollment. ResultsA total of 49 F508 homozygous CF patients aged 18 to 32 years were included in the final SNOT-22 score analysis. Individuals with 2 functional T2R38 alleles (PAV/PAV) had significantly lower SNOT-22 scores (n = 49, p < 0.05). On further breakdown of SNOT-22 subcategories, rhinologic symptoms specifically were less severe in PAV/PAV patients than patients with other genotypes (n = 47, p < 0.05). ConclusionOur investigation indicates that T2R38 genotype correlates both with SNOT-22 scores and rhinologic-specific QOL in F508 homozygous CF patients. C1 [Adappa, Nithin D.; Workman, Alan D.; Brooks, Steven; Doghramji, Laurel; Palmer, James N.; Cohen, Noam A.] Univ Penn, Perelman Sch Med, Dept Otorhinolaryngol Head & Neck Surg, 5th Floor Ravdin Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. [Hadjiliadis, Denis; Dorgan, Daniel J.; Frame, Danielle] Univ Penn, Dept Med, Perelman Sch Med, Paul Harron Jr Lung Ctr, 5th Floor Ravdin Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. [Mansfield, Corrine; Reed, Danielle R.; Cohen, Noam A.] Monell Smell & Taste Ctr, Philadelphia, PA USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Adappa, ND (reprint author), Univ Penn, Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, 5th Floor Ravdin Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. EM Nithin.Adappa@uphs.upenn.edu FU American Rhinology Society; Cystic Fibrosis Foundation FX American Rhinology Society (to N.D.A.); Cystic Fibrosis Foundation (to N.D.A.). NR 31 TC 6 Z9 6 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD APR PY 2016 VL 6 IS 4 BP 356 EP 361 DI 10.1002/alr.21675 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA DI6OH UT WOS:000373618500003 PM 26678226 ER PT J AU Reeves, GR Forman, DE AF Reeves, Gordon R. Forman, Daniel E. TI Gait Speed: Stepping Towards Improved Assessment of Heart Failure Patients SO JACC-HEART FAILURE LA English DT Editorial Material DE frailty; gait speed; heart failure; hospitalization; prognosis ID PRESERVED EJECTION FRACTION; CARDIOVASCULAR HEALTH; ELDERLY-PATIENTS; OLDER PERSONS; RISK-FACTORS; ADULTS; OUTCOMES; IMPACT; CARE C1 [Reeves, Gordon R.] Thomas Jefferson Univ, Dept Med, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA. [Forman, Daniel E.] Univ Pittsburgh, Med Ctr, Geriatr Cardiol Sect, Div Cardiol, Pittsburgh, PA 15213 USA. [Forman, Daniel E.] Univ Pittsburgh, Med Ctr, Geriatr Cardiol Sect, Div Geriatr, Pittsburgh, PA 15213 USA. [Forman, Daniel E.] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. [Forman, Daniel E.] Univ Pittsburgh, Dept Med, 930 Scaife Hall, Pittsburgh, PA 15213 USA. RP Forman, DE (reprint author), Univ Pittsburgh, Geriatr Cardiol Sect, 3471 Fifth Ave,Suite 500, Pittsburgh, PA 15213 USA. EM formand@pitt.edu NR 16 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1779 EI 2213-1787 J9 JACC-HEART FAIL JI JACC-Heart Fail. PD APR PY 2016 VL 4 IS 4 BP 299 EP 300 DI 10.1016/j.jchf.2016.02.002 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DI8KT UT WOS:000373750600010 PM 27033017 ER PT J AU Atkins, D Kansagara, D AF Atkins, David Kansagara, Devan TI Reducing Readmissions-Destination or Journey? SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID CARE TRANSITIONS; RATES C1 [Atkins, David] US Dept Vet Affairs, Off Res & Dev, Hlth Serv Res & Dev, 10P9H,810 Vermont Ave NW, Washington, DC 20420 USA. [Kansagara, Devan] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Kansagara, Devan] Vet Affairs Portland Healthcare Syst, Portland, OR USA. RP Atkins, D (reprint author), US Dept Vet Affairs, Off Res & Dev, Hlth Serv Res & Dev, 10P9H,810 Vermont Ave NW, Washington, DC 20420 USA. EM David.atkins@va.gov NR 8 TC 1 Z9 1 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD APR PY 2016 VL 176 IS 4 BP 493 EP 495 DI 10.1001/jamainternmed.2015.8603 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA DI3EG UT WOS:000373380600018 PM 26954103 ER PT J AU McIlvennan, CK Jones, J Allen, LA Swetz, KM Nowels, C Matlock, DD AF McIlvennan, Colleen K. Jones, Jacqueline Allen, Larry A. Swetz, Keith M. Nowels, Carolyn Matlock, Daniel D. TI Bereaved Caregiver Perspectives on the End-of-Life Experience of Patients With a Left Ventricular Assist Device SO JAMA INTERNAL MEDICINE LA English DT Article ID DESTINATION THERAPY; SUPPORT AB IMPORTANCE For patients and their loved ones, decisions regarding the end of life in the setting of chronic progressive illness are among the most complex in health care. Complicating these decisions are increasingly available, invasive, and potentially life-prolonging technologies such as the left ventricular assist device (LVAD). OBJECTIVE To understand the experience of bereaved caregivers and patients at the end of life who have an LVAD. DESIGN, SETTING, AND PARTICIPANTS Semistructured, in-depth interviews were conducted between September 10 and November 21, 2014, with 8 bereaved caregivers of patients with an LVAD who were recruited from a single institution. Data were analyzed from December 13, 2014, to February 18, 2015, using a mixed inductive and deductive approach. MAIN OUTCOMES AND MEASURES Themes from semistructured interviews. RESULTS The 8 caregivers (6 females) described 3 main themes that coalesced around feelings of confusion in the final weeks with their loved ones: (1) the process of death with an LVAD, (2) the legal and ethically permissible care of patients with an LVAD approaching death, and (3) fragmented integration of palliative and hospice care. CONCLUSIONS AND RELEVANCE Despite increasing use of LVADs in patients with advanced heart failure, bereaved caregivers of patients with an LVAD describe a high level of confusion at the end of life. There remains a need for the health care community to develop clear guidance on the management of patients with an LVAD at the end of life. Future work will focus on the educational process and the ideal timing and reiteration of such information to patients and families. C1 [McIlvennan, Colleen K.; Allen, Larry A.] Univ Colorado, Sch Med, Div Cardiol, Sect Adv Heart Failure & Transplantat, 12631 E 17th Ave,Mail Code B130, Aurora, CO 80045 USA. [McIlvennan, Colleen K.; Allen, Larry A.; Matlock, Daniel D.] Univ Colorado, Sch Med, Colorado Cardiovasc Outcomes Res Consortium, 12631 E 17th Ave,Mail Code B130, Aurora, CO 80045 USA. [Jones, Jacqueline] Univ Colorado, Sch Nursing, 12631 E 17th Ave,Mail Code B130, Aurora, CO 80045 USA. [Nowels, Carolyn; Matlock, Daniel D.] Univ Colorado, Sch Med, Div Gen Internal Med, 12631 E 17th Ave,Mail Code B130, Aurora, CO 80045 USA. [Swetz, Keith M.] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. [Swetz, Keith M.] Univ Alabama Birmingham, Ctr Palliat & Support Care, Birmingham, AL USA. RP McIlvennan, CK (reprint author), Univ Colorado, Sch Med, Div Cardiol, Sect Adv Heart Failure & Transplantat, 12631 E 17th Ave,Mail Code B130, Aurora, CO 80045 USA. EM colleen.mcilvennan@ucdenver.edu NR 28 TC 5 Z9 5 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD APR PY 2016 VL 176 IS 4 BP 534 EP 539 DI 10.1001/jamainternmed.2015.8528 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DI3EG UT WOS:000373380600026 PM 26998594 ER PT J AU Kerlikowske, K AF Kerlikowske, Karla TI Progress Toward Consensus on Breast Cancer Screening Guidelines and Reducing Screening Harms Reply SO JAMA INTERNAL MEDICINE LA English DT Letter ID WOMEN C1 [Kerlikowske, Karla] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Kerlikowske, Karla] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Kerlikowske, Karla] Univ Calif San Francisco, Dept Vet Affairs, Gen Internal Med Sect, San Francisco, CA 94143 USA. RP Kerlikowske, K (reprint author), San Francisco VA Med Ctr, Gen Internal Med Sect, 4150 Clement St,111A1, San Francisco, CA 94121 USA. EM karla.kerlikowske@ucsf.edu FU NCI NIH HHS [P01 CA154292, P01CA154292] NR 6 TC 0 Z9 0 U1 2 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD APR PY 2016 VL 176 IS 4 BP 562 EP 563 DI 10.1001/jamainternmed.2016.0225 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DI3EG UT WOS:000373380600043 PM 27043108 ER PT J AU Hauberg, ME Roussos, P Grove, J Borglum, AD Mattheisen, M AF Hauberg, Mads Engel Roussos, Panos Grove, Jakob Borglum, Anders Dupont Mattheisen, Manuel CA Psychiat Genomics Consortium TI Analyzing the Role of MicroRNAs in Schizophrenia in the Context of Common Genetic Risk Variants SO JAMA PSYCHIATRY LA English DT Article ID GENOME-WIDE ASSOCIATION; SYNAPTIC PLASTICITY; TARGET GENES; BRAIN; LOCI; NEUROGENESIS; ARCHITECTURE; ENRICHMENT; DATABASE; DISEASE AB IMPORTANCE The recent implication of 108 genomic loci in schizophrenia marked a great advancement in our understanding of the disease. Against the background of its polygenic nature there is a necessity to identify how schizophrenia risk genes interplay. As regulators of gene expression, microRNAs (miRNAs) have repeatedly been implicated in schizophrenia etiology. It is therefore of interest to establish their role in the regulation of schizophrenia risk genes in disease-relevant biological processes. OBJECTIVE To examine the role of miRNAs in schizophrenia in the context of disease-associated genetic variation. DESIGN, SETTING, AND PARTICIPANTS The basis of this study was summary statistics from the largest schizophrenia genome-wide association study meta-analysis to date (83 550 individuals in a meta-analysis of 52 genome-wide association studies) completed in 2014 along with publicly available data for predicted miRNA targets. We examined whether schizophrenia risk genes were more likely to be regulated by miRNA. Further, we used gene set analyses to identify miRNAs that are regulators of schizophrenia risk genes. MAIN OUTCOMES AND MEASURES Results from association tests for miRNA targetomes and related analyses. RESULTS In line with previous studies, we found that similar to other complex traits, schizophrenia risk genes were more likely to be regulated by miRNAs (P < 2 x 10(-16)). Further, the gene set analyses revealed several miRNAs regulating schizophrenia risk genes, with the strongest enrichment for targets of miR-9-5p (P = .0056 for enrichment among the top 1% most-associated single-nucleotide polymorphisms, corrected for multiple testing). It is further of note that MIR9-2 is located in a genomic region showing strong evidence for association with schizophrenia (P = 7.1 x 10(-8)). The second and third strongest gene set signals were seen for the targets of miR-485-5p and miR-137, respectively. CONCLUSIONS AND RELEVANCE This study provides evidence for a role of miR-9-5p in the etiology of schizophrenia. Its implication is of particular interest as the functions of this neurodevelopmental miRNA tie in with established disease biology: it has a regulatory loop with the fragile X mental retardation homologue FXR1 and regulates dopamine D-2 receptor density. C1 [Hauberg, Mads Engel; Grove, Jakob; Borglum, Anders Dupont; Mattheisen, Manuel] Aarhus Univ, Dept Biomed, iPSYCH, Wilhelm Meyers Alle 1, DK-8000 Aarhus C, Denmark. [Hauberg, Mads Engel; Grove, Jakob; Borglum, Anders Dupont; Mattheisen, Manuel] Lundbeck Fdn Initiat Integrat Psychiat Res, iPSYCH, Lundbeck, Denmark. [Hauberg, Mads Engel; Grove, Jakob; Borglum, Anders Dupont; Mattheisen, Manuel] Aarhus Univ, Ctr Integrat Sequencing, iPSYCH, DK-8000 Aarhus C, Denmark. [Roussos, Panos] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Roussos, Panos] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. [Roussos, Panos] Icahn Sch Med Mt Sinai, Inst Genom & Multiscale Biol, New York, NY 10029 USA. [Roussos, Panos] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. [Roussos, Panos] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. [Grove, Jakob] Aarhus Univ, Bioinformat Res Ctr, DK-8000 Aarhus C, Denmark. [Borglum, Anders Dupont] Aarhus Univ Hosp, Res Dept P, iPSYCH, Risskov, Denmark. [Borglum, Anders Dupont] Aarhus Univ, Dept Clin Med, Translat Neuropsychiat Unit, iPSYCH, DK-8000 Aarhus C, Denmark. RP Mattheisen, M (reprint author), Aarhus Univ, Dept Biomed, iPSYCH, Wilhelm Meyers Alle 1, DK-8000 Aarhus C, Denmark. EM mm@biomed.au.dk RI Roussos, Panos/J-7090-2013 OI Roussos, Panos/0000-0002-4640-6239; Grove, Jakob/0000-0003-2284-5744 FU Lundbeck Foundation; Centre for Integrative Sequencing, Aarhus University; Faculty of Health, Aarhus University FX This work was supported by the Lundbeck Foundation; the Centre for Integrative Sequencing, Aarhus University; and the Faculty of Health, Aarhus University. NR 47 TC 5 Z9 5 U1 1 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD APR PY 2016 VL 73 IS 4 BP 369 EP 377 DI 10.1001/jamapsychiatry.2015.3018 PG 9 WC Psychiatry SC Psychiatry GA DI4BI UT WOS:000373444700012 PM 26963595 ER PT J AU Painter, JM Kring, AM AF Painter, Janelle M. Kring, Ann M. TI Toward an Understanding of Anticipatory Pleasure Deficits in Schizophrenia: Memory, Prospection, and Emotion Experience SO JOURNAL OF ABNORMAL PSYCHOLOGY LA English DT Article DE schizophrenia; memory; prospection; emotion; narratives ID MENTAL TIME-TRAVEL; AUTOBIOGRAPHICAL MEMORY; NEGATIVE SYMPTOMS; COGNITIVE NEUROSCIENCE; AFFECTIVE REACTIVITY; FUTURE; IMAGINE; THINKING; EVENTS; BRAIN AB Anticipatory pleasure deficits have been observed in people with schizophrenia. Less is known about the extent to which interrelated processes that comprise anticipatory pleasure, including memory, prospection, and emotion experience are disrupted. We asked people with (n = 32) and without (n = 29) schizophrenia or schizoaffective disorder to provide memory and prospection narratives in response to specific cues. Half of the prospections followed a memory task, and half followed a control task. People with schizophrenia generated memories similar in content and experience as controls even as they described them less clearly. However, people with schizophrenia were less likely to explicitly reference the past in their prospections, and their prospections were less detailed and richly experienced than controls, regardless of the task completed before prospection. People with schizophrenia reported similar levels of positive emotion (current and predicted) in positive prospections that followed the memory task, but less positive emotion than controls in positive prospections that followed the control task. Taken together, these results suggest that people with schizophrenia experience difficulties drawing from past experiences and generating detailed prospections. However, asking people with schizophrenia to recall and describe memories prior to prospection may increase the likelihood of drawing from the past in prospections, and may help boost current and predicted pleasure. C1 [Painter, Janelle M.; Kring, Ann M.] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Painter, Janelle M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Painter, JM (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 1660 South Columbian Way S-116, Seattle, WA 98108 USA. EM janelle.painter@va.gov FU National Institutes of Health Grant [1R01MH082890] FX This study was supported in part by National Institutes of Health Grant 1R01MH082890 to Ann M. Kring. NR 46 TC 0 Z9 0 U1 4 U2 5 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0021-843X EI 1939-1846 J9 J ABNORM PSYCHOL JI J. Abnorm. Psychol. PD APR PY 2016 VL 125 IS 3 BP 442 EP 452 DI 10.1037/abn0000151 PG 11 WC Psychology, Clinical; Psychology, Multidisciplinary SC Psychology GA DI7XE UT WOS:000373714500012 PM 26950753 ER PT J AU Rudd-Barnard, G Walbom, A Pangarkar, S Baria, A AF Rudd-Barnard, G. Walbom, A. Pangarkar, S. Baria, A. TI A case study investigating opioid medication utilization in patients with complex regional pain syndrome before and after ketamine infusion therapy SO JOURNAL OF PAIN LA English DT Meeting Abstract C1 [Rudd-Barnard, G.; Walbom, A.; Pangarkar, S.; Baria, A.] Univ Calif Los Angeles, Greater Los Angeles VA Hlth Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD APR PY 2016 VL 17 IS 4 SU 1 MA 406 BP S76 EP S76 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DI5EZ UT WOS:000373523000305 PM 28162651 ER PT J AU Rudd-Barnard, G Pangarkar, S Moaleji, N Glassman, P AF Rudd-Barnard, G. Pangarkar, S. Moaleji, N. Glassman, P. TI Epidemiology of naloxone use for opioid overdose in a tertiary care medical center SO JOURNAL OF PAIN LA English DT Meeting Abstract C1 [Rudd-Barnard, G.; Pangarkar, S.; Moaleji, N.; Glassman, P.] Greater Los Angeles VA Hlth Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD APR PY 2016 VL 17 IS 4 SU 1 MA 141 BP S11 EP S11 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DI5EZ UT WOS:000373523000043 PM 28162348 ER PT J AU Stegner, A Cook, D AF Stegner, A. Cook, D. TI Resistance exercise training in Gulf War Veterans with chronic unexplained muscle pain: impact on pain, fatigue, mood and global impression of change SO JOURNAL OF PAIN LA English DT Meeting Abstract C1 [Stegner, A.; Cook, D.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD APR PY 2016 VL 17 IS 4 SU 1 MA 484 BP S95 EP S96 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DI5EZ UT WOS:000373523000382 PM 28162735 ER PT J AU Katz, DA Stewart, K Paez, M Holman, J Adams, SL Vander Weg, MW Battaglia, CT Joseph, AM Titler, MG Ono, S AF Katz, David A. Stewart, Kenda Paez, Monica Holman, John Adams, Susan L. Vander Weg, Mark W. Battaglia, Catherine T. Joseph, Anne M. Titler, Marita G. Ono, Sarah TI "Let Me Get You a Nicotine Patch": Nurses' Perceptions of Implementing Smoking Cessation Guidelines for Hospitalized Veterans SO MILITARY MEDICINE LA English DT Article ID CONTROLLED-TRIAL; STANDARDIZED PATIENTS; CARE; SERVICE; INTERVENTIONS; PREVENTION; PROGRAM AB Many hospitalized smokers do not receive guideline-recommended tobacco treatment, but little is known about the perceptions of inpatient nurses with regard to tobacco treatment. We used a sequential explanatory mixed methods design to help explain the findings of an academic detailing intervention trial on the inpatient medicine units of four Veterans Affairs (VA) hospitals. We surveyed 164 nurses and conducted semistructured interviews in a purposeful sample of 33 nurses with different attitudes toward cessation counseling. Content analysis was used to inductively characterize the issues raised by participants. Emerging themes were categorized using the knowledge-attitudes-behavior framework of guideline adherence. Knowledge-related and attitudinal barriers included perceived lack of skills in cessation counseling and skepticism about the effectiveness of cessation guidelines in hospitalized veterans. Nurses also reported multiple behavioral and organizational barriers to guideline adherence: resistance from patients, insufficient time and resources, the presence of smoking areas on VA premises, and lack of coordination with primary care. VA hospitals should train inpatient staff how to negotiate behavior change, integrate cessation counseling into nurses' workflow, develop alternative referral mechanisms for post-discharge cessation counseling, and adopt hospital policies to promote inpatient abstinence. C1 [Katz, David A.; Stewart, Kenda; Paez, Monica; Holman, John; Adams, Susan L.; Vander Weg, Mark W.; Ono, Sarah] Iowa City VA Hlth Care Syst, Comprehens Access & Delivery Res & Evaluat CADRE, Iowa City, IA USA. [Katz, David A.; Vander Weg, Mark W.] Univ Iowa, Dept Med, Iowa City, IA 52242 USA. [Katz, David A.] Univ Iowa, Dept Epidemiol, Iowa City, IA USA. [Vander Weg, Mark W.] Univ Iowa, Dept Psychol, Iowa City, IA 52242 USA. [Battaglia, Catherine T.] VA Eastern Colorado Hlth Care Syst, Dept Med, Denver, CO USA. [Battaglia, Catherine T.] Denver Seattle Ctr Vet Centr Value Based Res DiSC, Denver, CO USA. Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA. [Titler, Marita G.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA. [Ono, Sarah] Portland VA Med Ctr, Ctr Improve Vet Involvement Care, Portland, OR USA. RP Katz, DA (reprint author), Iowa City VA Hlth Care Syst, Comprehens Access & Delivery Res & Evaluat CADRE, Iowa City, IA USA. FU Veterans Affairs Health Services Research and Development [IIR 07-113] FX The authors acknowledge Jonathan Thomas for assistance with transcription of in-depth interviews, George Bailey, MS and Ray Opiola for assisting with database design and data management, Bonnie Bootsmiller, PhD and Sue Kieffer for administrative support, and Jennifer Reed for assistance with manuscript preparation. This work was funded by the Veterans Affairs Health Services Research and Development (IIR 07-113). NR 41 TC 2 Z9 2 U1 4 U2 6 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD APR PY 2016 VL 181 IS 4 BP 373 EP 382 DI 10.7205/MILMED-D-15-00101 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA DI3NO UT WOS:000373405600015 PM 27046185 ER PT J AU Mayer, VL McDonough, K Seligman, H Mitra, N Long, JA AF Mayer, Victoria L. McDonough, Kevin Seligman, Hilary Mitra, Nandita Long, Judith A. TI Food insecurity, coping strategies and glucose control in low-income patients with diabetes SO PUBLIC HEALTH NUTRITION LA English DT Article DE Diabetes; Nutrition; Vulnerable populations; Socio-economic factors; Disease management ID NUTRITION ASSISTANCE PROGRAM; OF-THE-LITERATURE; GLYCEMIC CONTROL; DIETARY QUALITY; ADULTS; HEALTH; MANAGEMENT; OBESITY; PARTICIPANTS; SUFFICIENCY AB Objective: To examine the relationship between food insecurity and coping strategies (actions taken to manage economic stress) hypothesized to worsen glucose control in patients with diabetes. Design: Using a cross-sectional telephone survey and clinical data, we compared food-insecure and food-secure individuals in their use of coping strategies. Using logistic regression models, we then examined the association between poor glucose control (glycated Hb, HbA1c >= 8.0 %), food insecurity and coping strategies. Setting: An urban medical centre, between June and December 2013. Subjects: Four hundred and seven adults likely to be low income (receiving Medicaid or uninsured and/or residing in a zip code with >30 % of the population below the federal poverty level) with type 2 diabetes. Results: Of respondents, 40.5 % were food insecure. A significantly higher percentage of the food-insecure group reported use of most examined coping strategies, including foregone medical care, participation in the Supplemental Nutrition Assistance Program (SNAP)) and use of emergency food programmes. Food insecurity was associated with poor glucose control (OR=2.23; 95 % CI 1.22, 4.10); coping strategies that were more common among the food insecure were not associated with poor glucose control. Among the food insecure, receipt of SNAP was associated with lower risk of poor glucose control (OR=0.27; 95 % CI 0.09, 0.80). Conclusions: While food insecurity was associated with poor glucose control, most examined coping strategies did not explain this relationship. However, receipt of SNAP among food-insecure individuals was associated with better diabetes control, suggesting that such programmes may play a role in improving health. C1 [Mayer, Victoria L.] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, 1 Gustave L Levy Pl,Box 1077, New York, NY 10029 USA. [Mayer, Victoria L.] Icahn Sch Med Mt Sinai, Dept Med, Div Gen Internal Med, New York, NY 10029 USA. [McDonough, Kevin] Univ Penn, Sch Arts & Sci, Philadelphia, PA 19104 USA. [Seligman, Hilary] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. [Mitra, Nandita] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Mitra, Nandita; Long, Judith A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Long, Judith A.] Univ Penn, Dept Med, Perelman Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Long, Judith A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Mayer, VL (reprint author), Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, 1 Gustave L Levy Pl,Box 1077, New York, NY 10029 USA.; Mayer, VL (reprint author), Icahn Sch Med Mt Sinai, Dept Med, Div Gen Internal Med, New York, NY 10029 USA. EM victoria.mayer@mountsinai.org FU Division of General Internal Medicine Matt Slap Award from the Perelman School of Medicine at the University of Pennsylvania; National Institutes of Health Institutional Training Grant [5-T32-HP-100296-20-00]; Empire Clinical Research Investigator Program FX V.L.M. was supported with funding from the Division of General Internal Medicine Matt Slap Award from the Perelman School of Medicine at the University of Pennsylvania and the National Institutes of Health Institutional Training Grant 5-T32-HP-100296-20-00. She is currently supported by the Empire Clinical Research Investigator Program (Investigator Dr Carol Horowitz). The funders had no role in the design, analysis, or writing of this article.Principal NR 52 TC 0 Z9 0 U1 3 U2 11 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 1368-9800 EI 1475-2727 J9 PUBLIC HEALTH NUTR JI Public Health Nutr. PD APR PY 2016 VL 19 IS 6 BP 1103 EP 1111 DI 10.1017/S1368980015002323 PG 9 WC Public, Environmental & Occupational Health; Nutrition & Dietetics SC Public, Environmental & Occupational Health; Nutrition & Dietetics GA DI7US UT WOS:000373708100019 PM 26328922 ER PT J AU Pierre, JM Gandal, M Son, M AF Pierre, Joseph M. Gandal, Michael Son, Maya TI Cannabis-induced psychosis associated with high potency "wax dabs" SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Marijuana; Tetrahydrocannabinol; Cannabis; Cannabis oil; Cannabis wax; Cannabis-induced psychosis, catatonia ID MARIJUANA; DANGERS; RISK AB With mounting evidence that the risk of cannabis-induced psychosis may be related to both dose and potency of tetrahydrocannbinol (THC), increasing reports of psychosis associated with cannabinoids containing greater amounts of THC are anticipated. We report two cases of emergent psychosis after using a concentrated THC extract known as cannabis "wax," "oil," or "dabs" raising serious concerns about its psychotic liability. Although "dabbing" with cannabis wax is becoming increasingly popular in the US for both recreational and "medicinal" intentions, our cases raise serious concerns about its psychotic liability and highlight the importance of understanding this risk by physicians recommending cannabinoids for purported medicinal purposes. Published by Elsevier B.V. C1 [Pierre, Joseph M.; Gandal, Michael] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Pierre, Joseph M.] VA Greater Los Angeles Healthcare Syst, Dept Vet Affairs, Los Angeles, CA USA. [Son, Maya] Univ Vermont, Coll Med, Burlington, VT USA. RP Pierre, JM (reprint author), 11301 Wilshire Blvd,Bldg 210 Room15, Los Angeles, CA 90073 USA. EM joseph.pierre2@va.gov NR 10 TC 2 Z9 2 U1 4 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD APR PY 2016 VL 172 IS 1-3 BP 211 EP 212 DI 10.1016/j.schres.2016.01.056 PG 2 WC Psychiatry SC Psychiatry GA DI5GY UT WOS:000373528100034 PM 26876313 ER PT J AU Leung, AM Korevaar, TIM Peeters, RP Zoeller, RT Kohrle, J Duntas, LH Brent, GA Demeneix, BA AF Leung, Angela M. Korevaar, Tim I. M. Peeters, Robin P. Zoeller, R. Thomas Koehrle, Josef Duntas, Leonidas H. Brent, Gregory A. Demeneix, Barbara A. TI Exposure to Thyroid-Disrupting Chemicals: A Transatlantic Call for Action SO THYROID LA English DT Editorial Material C1 [Leung, Angela M.; Brent, Gregory A.] Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol, Los Angeles, CA 90095 USA. [Leung, Angela M.; Brent, Gregory A.] VA Greater Los Angeles Healthcare Syst, Div Endocrinol, Los Angeles, CA USA. [Korevaar, Tim I. M.; Peeters, Robin P.] Erasmus MC, Generat R Study Grp, Rotterdam, Netherlands. [Korevaar, Tim I. M.; Peeters, Robin P.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands. [Korevaar, Tim I. M.; Peeters, Robin P.] Erasmus MC, Rotterdam Thyroid Ctr, Rotterdam, Netherlands. [Zoeller, R. Thomas] Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA. [Zoeller, R. Thomas] Univ Massachusetts, Program Mol & Cellular Biol, Amherst, MA 01003 USA. [Koehrle, Josef] Charite, Inst Expt Endokrinol, D-13353 Berlin, Germany. [Duntas, Leonidas H.] Univ Athens, Thyroid Unit, Evgenid Hosp, Athens, Greece. [Demeneix, Barbara A.] Museum Natl Hist Nat, Dept Regulat Dev & Diversite Mol, Evolut Regulat Endocriniennes, F-75231 Paris, France. RP Leung, AM (reprint author), VA Greater Angeles Healthcare Syst, Div Endocrinol 111D, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM amleung@mednet.ucla.edu OI Kohrle, Josef/0000-0002-9187-9078 FU NICHD NIH HHS [K23HD068552, K23 HD068552] NR 4 TC 3 Z9 3 U1 1 U2 4 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1050-7256 EI 1557-9077 J9 THYROID JI Thyroid PD APR 1 PY 2016 VL 26 IS 4 BP 479 EP 480 DI 10.1089/thy.2016.0077 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DI1DY UT WOS:000373237400001 PM 26906244 ER PT J AU Greiman, A Shah, J Bhavsar, R Armeson, K Caulder, S Jones, R Keane, TE Clarke, HS Savage, SJ AF Greiman, Alyssa Shah, Jaimin Bhavsar, Robin Armeson, Kent Caulder, Susan Jones, Rabun Keane, Thomas E. Clarke, Harry S. Savage, Stephen J. TI Six Weeks of Fluoroquinolone Antibiotic Therapy for Patients With Elevated Serum Prostate-specific Antigen Is Not Clinically Beneficial: A Randomized Controlled Clinical Trial SO UROLOGY LA English DT Article ID PSA LEVELS; CANCER; BIOPSY; BENIGN; MARKER AB OBJECTIVE To evaluate asymptomatic men with elevated serum prostate-specific antigen (PSA) to determine whether a 6-week course of fluoroquinolone antibiotics lowers serum PSA and affects recommendations for prostate biopsy. MATERIALS AND METHODS A randomized, single-center prospective trial of 150 men with an initial elevated PSA was conducted. Patients were randomized to 6 weeks of ciprofloxacin or observation. Those patients with persistently elevated PSA were recommended to proceed with transrectal ultrasound-guided 12-core biopsy. Those with reduced PSA were offered transrectal ultrasound-guided biopsy but could opt to continue serial digital rectal examination/PSA. Patients were followed an average of 4.6 years to assess trends in PSA and biopsy results. RESULTS Of 136 men who completed the trial, 63 were in the treatment and 73 were in the observation group. The average PSA change from baseline was borderline statistically significant with a change of -0.68 ng/mL in the treatment arm and 0.01 ng/mL in the observation arm (P = .052). Of those who underwent biopsy, prostate cancer was diagnosed in the first biopsy in 24 (63%) of the treatment vs 27 (52%) of the observation group (P = .60) over follow-up. CONCLUSION In a cohort of asymptomatic men with elevated PSA, there was only a borderline statistically significant change in serum PSA between patients randomized to a 6-week course of fluoroquinolones vs observation, and there was no difference in positive prostate biopsy results. Our clinical recommendation is one should not treat patients with elevated serum PSA with antibiotics in the absence of clinical symptoms of prostatitis. Published by Elsevier Inc. C1 [Greiman, Alyssa; Shah, Jaimin; Bhavsar, Robin; Armeson, Kent; Caulder, Susan; Jones, Rabun; Keane, Thomas E.; Clarke, Harry S.; Savage, Stephen J.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Dept Urol, Urol Sect, 96 Jonathan Lucas St,CSB 644, Charleston, SC 29425 USA. RP Greiman, A (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Dept Urol, Urol Sect, 96 Jonathan Lucas St,CSB 644, Charleston, SC 29425 USA. EM greiman@musc.edu NR 30 TC 1 Z9 1 U1 2 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD APR PY 2016 VL 90 BP 32 EP 37 DI 10.1016/j.urology.2015.11.046 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA DI4JT UT WOS:000373466900017 PM 26802800 ER PT J AU Vasilevskis, EE Kripalani, S Ong, MK Rosenthal, JT Longnecker, DE Harmon, B Hohmann, SF Wright, K Black, JT AF Vasilevskis, Eduard E. Kripalani, Sunil Ong, Michael K. Rosenthal, J. Thomas Longnecker, David E. Harmon, Brian Hohmann, Samuel F. Wright, Kelly Black, Jeanne T. TI Variability in Implementation of Interventions Aimed at Reducing Readmissions Among Patients With Heart SO ACADEMIC MEDICINE LA English DT Article ID HOSPITAL READMISSIONS; 30-DAY READMISSIONS; RANDOMIZED-TRIALS; TRANSITIONAL CARE; FAILURE PATIENTS; PALLIATIVE CARE; HEALTH-CARE; FOLLOW-UP; STRATEGIES; RATES AB Purpose To highlight teaching hospitals' efforts to reduce readmissions by describing interventions implemented to improve care transitions for heart failure (HF) patients and the variability in implemented HF-specific and care transition interventions. Method In 2012, the authors surveyed a network of 17 teaching hospitals to capture information about the number, type, stage of implementation, and structure of 4 HF-specific and 21 care transition (predischarge, bridging, and postdischarge) interventions implemented to reduce readmissions among patients with HF. The authors summarized data using descriptive statistics, including the mean number of interventions implemented and the frequency and stage of specific interventions, and descriptive plots of the structure of two common interventions (multidisciplinary rounds and follow-up telephone calls). Results Sixteen hospitals (94%) responded. The number and stage of implementation of the HF-specific and care transition interventions implemented varied across institutions. The mean number of interventions at an advanced stage of implementation (i.e., implemented for 75% of HF patients on the cardiology service or on all services) was 10.9 (standard deviation = 4.3). Overall, predischarge interventions were more common than bridging or postdischarge interventions. There was variability in the personnel involved in multidisciplinary rounds and in the processes/content of follow-up telephone calls. Conclusions Teaching hospitals have implemented a wide range of interventions aimed at reducing hospital readmissions, but there is substantial variability in the types, stages, and structure of their interventions. This heterogeneity highlights the need for collaborative efforts to improve understanding of intervention effectiveness. C1 [Vasilevskis, Eduard E.] Vanderbilt Univ, Dept Med, Div Gen Internal Med & Publ Hlth, Med,Sect Hosp Med, Nashville, TN 37232 USA. [Vasilevskis, Eduard E.] VA Tennessee Valley Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Nashville, TN USA. [Kripalani, Sunil] Vanderbilt Univ, Dept Med, Div Gen Internal Med & Publ Hlth, Ctr Clin Qual & Implementat Res,Sect Hosp Med, Nashville, TN 37232 USA. [Ong, Michael K.] Univ Calif Los Angeles, Dept Med, Med, Los Angeles, CA 90024 USA. [Ong, Michael K.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Rosenthal, J. Thomas] Univ Calif Los Angeles Hlth Syst, Los Angeles, CA USA. [Longnecker, David E.] Univ Penn, Anesthesiol, Philadelphia, PA 19104 USA. [Longnecker, David E.] Coalit Transform Adv Care, Washington, DC USA. [Harmon, Brian] Childrens Hosp & Clin Minnesota, Minneapolis, MN USA. [Hohmann, Samuel F.] Univ HealthSyst Consortium, Comparat Data & Informat Res, Chicago, IL USA. [Hohmann, Samuel F.] Rush Univ, Dept Hlth Syst Management, Chicago, IL 60612 USA. [Wright, Kelly] Vanderbilt Univ, Div Gen Internal Med & Publ Hlth, Sect Hosp Med, Dept Med, Nashville, TN 37232 USA. [Black, Jeanne T.] Cedars Sinai Hlth Syst, Hlth Policy & Program Evaluat, Los Angeles, CA USA. RP Vasilevskis, EE (reprint author), Vanderbilt Univ, Med Ctr, 1215 21st Ave S,6006 Med Ctr East NT, Nashville, TN 37232 USA. EM eduard.vasilevskis@vanderbilt.edu FU National Institutes of Health [K23 AG040157]; Tennessee Valley Geriatric Research, Education and Clinical Center (GRECC); Robert Wood Johnson Foundation [RWJF 67627] FX Funding for E.E. Vasilevskis was provided by the National Institutes of Health (K23 AG040157) and the Tennessee Valley Geriatric Research, Education and Clinical Center (GRECC). The Variations Collaborative Study Group additionally received support from the Robert Wood Johnson Foundation (RWJF 67627). NR 40 TC 2 Z9 2 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD APR PY 2016 VL 91 IS 4 BP 522 EP 529 PG 8 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA DH6XW UT WOS:000372936400027 PM 26579793 ER PT J AU Hser, YI Evans, E Huang, D Weiss, R Saxon, A Carroll, KM Woody, G Liu, D Wakim, P Matthews, AG Hatch-Maillette, M Jelstrom, E Wiest, K McLaughlin, P Ling, W AF Hser, Yih-Ing Evans, Elizabeth Huang, David Weiss, Robert Saxon, Andrew Carroll, Kathleen M. Woody, George Liu, David Wakim, Paul Matthews, Abigail G. Hatch-Maillette, Mary Jelstrom, Eve Wiest, Katharina McLaughlin, Paul Ling, Walter TI Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial SO ADDICTION LA English DT Article DE Buprenorphine; methadone; opioid dependence; longitudinal; outcomes; opioid use; mortality ID MAINTENANCE THERAPY; OPIOID DEPENDENCE; RETENTION; ADDICTION; METHAMPHETAMINE; PERSPECTIVES; MEDICATION; HEALTH; ENTRY; USERS AB AimsTo compare long-term outcomes among participants randomized to buprenorphine or methadone. Design, Setting and ParticipantsFollow-up was conducted in 2011-14 of 1080 opioid-dependent participants entering seven opioid treatment programs in the United States between 2006 and 2009 and randomized (within each program) to receive open-label buprenorphine/naloxone or methadone for up to 24weeks; 795 participants completed in-person interviews (similar to 74% follow-up interview rate) covering on average 4.5years. MeasurementsOutcomes were indicated by mortality and opioid use. Covariates included demographics, site, cocaine use and treatment experiences. FindingsMortality was not different between the two randomized conditions, with 23 (3.6%) of 630 participants randomized to buprenorphine having died versus 26 (5.8%) of 450 participants randomized to methadone. Opioid use at follow-up was higher among participants randomized to buprenorphine relative to methadone [42.8 versus 31.7% positive opioid urine specimens, P<0.01, effect size (h)=0.23 (0.09, 0.38); 5.8days versus 4.4days of past 30-day heroin use, P<0.05, effect size (d)=0.14 (0.00, 0.28)]. Opioid use during the follow-up period by randomization condition was also significant (F-(7,F-39600)=3.16; P<0.001) due mainly to less treatment participation among participants randomized to buprenorphine than methadone. Less opioid use was associated with both buprenorphine and methadone treatment (relative to no treatment); no difference was found between the two treatments. Individuals who are white or used cocaine at baseline responded better to methadone than to buprenorphine. ConclusionsThere are few differences in long-term outcomes between buprenorphine and methadone treatment for opioid dependence, and treatment with each medication is associated with a strong reduction in opioid use. C1 [Hser, Yih-Ing; Evans, Elizabeth; Huang, David; Weiss, Robert; Ling, Walter] Univ Calif Los Angeles, Los Angeles, CA USA. [Saxon, Andrew] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Carroll, Kathleen M.] Yale Univ, Sch Med, New Haven, CT USA. [Woody, George] Univ Penn, Philadelphia, PA 19104 USA. [Liu, David; Wakim, Paul] NIDA, Bethesda, MD 20892 USA. [Matthews, Abigail G.; Jelstrom, Eve] Emmes Corp, Rockville, MD USA. [Hatch-Maillette, Mary] Univ Washington, Seattle, WA 98195 USA. [Wiest, Katharina] CODA Inc, Portland, OR USA. [McLaughlin, Paul] Hartford Dispensary, Hartford, CT USA. RP Hser, YI (reprint author), Univ Calif Los Angeles, Integrated Subst Abuse Programs, 11075 Santa Monica Blvd,Suite 200, Los Angeles, CA USA. EM yhser@ucla.edu FU National Institute on Drug Abuse (NIDA) through the Clinical Trials Network (CTN) [U10 DA01714, U10 DA 015815, U10 DA13038, U10 DA13043, U10 DA13045]; NIDA [P30DA016383] FX The corresponding author, Yih-Ing Hser, has full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Sincere appreciation to our participating networks: the Pacific Northwest Node and Evergreen Treatment Services; the Western States Node and CODA Inc. and Bi-Valley Medical Clinic; the New England Node and Connecticut Counseling Centers and Yale and Hartford Dispensary; the Delaware Valley Node and NET Steps; the Pacific Region Node and Matrix Institute; and the EMMES Corporation (CCC); the CCTN and NIDA. The main study funding was provided by the National Institute on Drug Abuse (NIDA) through the Clinical Trials Network (CTN) through a series of grants provided to each participating node: the Pacific Northwest Node (U10 DA01714); the Western States Node (U10 DA 015815); the New England Node (U10 DA13038); the Delaware Valley Node (U10 DA13043); and he Pacific Region Node (U10 DA13045). Funding was also provided by NIDA through grant number P30DA016383. NR 29 TC 2 Z9 2 U1 5 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD APR PY 2016 VL 111 IS 4 BP 695 EP 705 DI 10.1111/add.13238 PG 11 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DH6NM UT WOS:000372907400022 PM 26599131 ER PT J AU Axon, RN Gebregziabher, M Everett, CJ Heidenreich, P Hunt, KJ AF Axon, R. Neal Gebregziabher, Mulugeta Everett, Charles J. Heidenreich, Paul Hunt, Kelly J. TI Dual health care system use is associated with higher rates of hospitalization and hospital readmission among veterans with heart failure SO AMERICAN HEART JOURNAL LA English DT Article ID GUIDELINES PROGRAM; AMBULATORY-CARE; MEDICARE; OUTCOMES; INPATIENT; MORTALITY; ADMISSION; SERVICES; REGRESSION; PATIENT AB Background Heart failure (HF) frequently causes hospital admission and readmission. Patients receiving care from multiple providers and facilities (dual users) may risk higher health care utilization and worse health outcomes. Methods To determine rates of emergency department (ED) visits, hospitalizations, and hospital readmissions relative to dual use among HF patients, we analyzed a retrospective cohort of 13,977 veterans with HF hospitalized at the Veterans Affairs (VA) or non-VA facilities from 2007 to 2011; we analyzed rates of acute health care utilization using zero-inflated negative binomial regression. Results Compared to VA-only users and dual users, individuals receiving all of their ED and hospital care outside the VA tended to be older, more likely to be non-Hispanic white and married, and less likely to have high levels of service connected disability. Compared to VA-only users, dual users had significantly higher rates of ED visits for HF as a primary diagnosis (adjusted rate ratio 1.15, 95% CI 1.04-1.27), hospitalization for HF (adjusted rate ratio 1.4, 95% CI 1.26-1.56), hospital readmission after HF hospitalization (all cause) (1.46, 95% CI 1.30-1.65), and HF-specific hospital readmission after HF hospitalization (1.46, 95% CI 1.31-1.63). With the exception of hospitalization for any primary diagnosis, non-VA-only users had significantly lower rates of ED visits, hospitalization, and readmission compared to VA-only users. Conclusions Dual use is associated with higher rates of health care utilization among patients with HF. Interventions should be devised to encourage continuity of care where possible and to improve the effectiveness and safety of dual use in instances where it is necessary or desired. C1 [Axon, R. Neal; Gebregziabher, Mulugeta; Everett, Charles J.; Hunt, Kelly J.] Ralph H Johnson VA Med Ctr, Charleston Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA. [Axon, R. Neal] Med Univ S Carolina, Dept Med, Div Gen Internal Med, Charleston, SC 29425 USA. [Gebregziabher, Mulugeta; Hunt, Kelly J.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Heidenreich, Paul] Stanford Univ, Med Ctr, Div Cardiol, VA Palo Alto Healthcare Syst, Palo Alto, CA 94304 USA. RP Axon, RN (reprint author), 109 Bee St,Mail Code 111, Charleston, SC 29401 USA. EM axon@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU VA Health Services Research and Development [IIR 12-331] FX VA Health Services Research and Development (IIR 12-331, Axon-PI). NR 40 TC 0 Z9 0 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD APR PY 2016 VL 174 BP 157 EP 163 DI 10.1016/j.ahj.2015.09.023 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DH1IV UT WOS:000372538500023 PM 26995383 ER PT J AU Hill, SY Jones, BL Steinhauer, SR Zezza, N Stiffler, S AF Hill, Shirley Y. Jones, Bobby L. Steinhauer, Stuart R. Zezza, Nicholas Stiffler, Scott TI Longitudinal predictors of cannabis use and dependence in offspring from families at ultra high risk for alcohol dependence and in control families SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE CNR1; D2; cannabis use; cannabis abuse; cannabis dependence ID RECEPTOR GENE CNR1; EVENT-RELATED POTENTIALS; LINKAGE-PHYSICAL MAP; SUBSTANCE USE; P300 AMPLITUDE; MARIJUANA USE; DEVELOPMENTAL TRAJECTORIES; HAPLOTYPE RECONSTRUCTION; GENOTYPE DATA; HUMAN GENOME AB Cannabis use is common among adolescents. Identification of the factors associated with continued heavy use into young adulthood and development of cannabis abuse and dependence is of considerable importance. The role of familial risk for addiction and an associated endophenotype, P300 amplitude, has not previously been related to cannabis use and dependence. A prospective longitudinal study spanning childhood and young adulthood provided the opportunity for exploring these factors, along with genetic variation, in the cannabis use behaviors of 338 young adult offspring from high and low familial risk for alcohol dependence families (ages 19-30). P300 data were collected multiple times in childhood. The association between young adult patterns of cannabis use or cannabis abuse/dependence was tested with genetic variation in the cannabinoid gene, CNR1, the ANKK1-DRD2 gene, and childhood developmental trajectories of P300. Young adult patterns of cannabis use was characterized by three patterns: (i) no use throughout; (ii) declining use from adolescence through young adulthood; and (iii) frequent use throughout. Following the low P300 trajectory in childhood predicted cannabis abuse and dependence by young adulthood. A four SNP ANKK1-DRD2 haplotype (G-G-G-C) was found to be significantly associated with the frequency of use patterns (P=0.0008). Although CNR1 variation overall was not significantly associated with these patterns, among individuals with cannabis abuse/dependence the presence of one or both copies of the rs806368 A>G minor allele conferred a 5.4-fold increase (P=0.003) in the likelihood that they would be in the frequent and persistent use group rather than the declining use group. (c) 2016 Wiley Periodicals, Inc. C1 [Hill, Shirley Y.; Jones, Bobby L.; Zezza, Nicholas; Stiffler, Scott] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Steinhauer, Stuart R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Hill, SY (reprint author), Univ Pittsburgh, Dept Psychiat, Med Ctr, 3811 O Hara St, Pittsburgh, PA 15213 USA. EM syh50@imap.pitt.edu FU NIAAA [AA018289, AA05909, AA08082, AA015168] FX Grant sponsor: NIAAA; Grant numbers: AA018289, AA05909, AA08082, AA015168. NR 76 TC 0 Z9 0 U1 5 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4841 EI 1552-485X J9 AM J MED GENET B JI Am. J. Med. Genet. B PD APR PY 2016 VL 171 IS 3 BP 383 EP 395 DI 10.1002/ajmg.b.32417 PG 13 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA DH8FO UT WOS:000373029100009 PM 26756393 ER PT J AU Das, F Ghosh-Choudhury, N Mariappan, MM Kasinath, BS Choudhury, GG AF Das, Falguni Ghosh-Choudhury, Nandini Mariappan, Meenalakshmi M. Kasinath, Balakuntalam S. Choudhury, Goutam Ghosh TI Hydrophobic motif site-phosphorylated protein kinase C beta II between mTORC2 and Akt regulates high glucose-induced mesangial cell hypertrophy SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Article DE diabetic nephropathy; signal transduction; mTOR complex; protein kinase C ID GROWTH-FACTOR-BETA; DIABETIC-NEPHROPATHY; RENAL HYPERTROPHY; IN-VIVO; PHOSPHOINOSITIDE 3-KINASE; TRANSPLANT RECIPIENTS; RAPAMYCIN COMPLEXES; DIACYLGLYCEROL MASS; ENDOTHELIAL-CELLS; BINDING PARTNER AB PKC beta II controls the pathologic features of diabetic nephropathy, including glomerular mesangial cell hypertrophy. PKC beta II contains the COOH-terminal hydrophobic motif site Ser-660. Whether this hydrophobic motif phosphorylation contributes to high glucose-induced mesangial cell hypertrophy has not been determined. Here we show that, in mesangial cells, high glucose increased phosphorylation of PKC beta II at Ser-660 in a phosphatidylinositol 3-kinase (PI3-kinase)-dependent manner. Using siRNAs to downregulate PKC beta II, dominant negative PKC beta II, and PKC beta II hydrophobic motif phosphorylation-deficient mutant, we found that PKCbII regulates activation of mechanistic target of rapamycin complex 1 (mTORC1) and mesangial cell hypertrophy by high glucose. PKCbII via its phosphorylation at Ser-660 regulated phosphorylation of Akt at both catalytic loop and hydrophobic motif sites, resulting in phosphorylation and inactivation of its substrate PRAS40. Specific inhibition of mTORC2 increased mTORC1 activity and induced mesangial cell hypertrophy. In contrast, inhibition of mTORC2 decreased the phosphorylation of PKC beta II and Akt, leading to inhibition of PRAS40 phosphorylation and mTORC1 activity and prevented mesangial cell hypertrophy in response to high glucose; expression of constitutively active Akt or mTORC1 restored mesangial cell hypertrophy. Moreover, constitutively active PKC beta II reversed the inhibition of high glucose-stimulated Akt phosphorylation and mesangial cell hypertrophy induced by suppression of mTORC2. Finally, using renal cortexes from type 1 diabetic mice, we found that increased phosphorylation of PKC beta II at Ser-660 was associated with enhanced Akt phosphorylation and mTORC1 activation. Collectively, our findings identify a signaling route connecting PI3-kinase to mTORC2 to phosphorylate PKC beta II at the hydrophobic motif site necessary for Akt phosphorylation and mTORC1 activation, leading to mesangial cell hypertrophy. C1 [Das, Falguni; Mariappan, Meenalakshmi M.; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Nandini; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Vet Affairs Res, San Antonio, TX USA. [Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Res, San Antonio, TX USA. [Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. RP Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM choudhuryg@uthscsa.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [R01-DK-50190]; Veterans Affairs (VA) Research Service Merit Review Grant [5I01BX000926]; VA Senior Research Career Scientist Award; VA Merit Review Grants [5I01BX000150, 5I01BX001340] FX This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grant R01-DK-50190 and Veterans Affairs (VA) Research Service Merit Review Grant 5I01BX000926 (to G. G. Choudhury). G. G. Choudhury is a recipient of VA Senior Research Career Scientist Award. N. Ghosh-Choudhury and B. S. Kasinath are supported by VA Merit Review Grants 5I01BX000150 and 5I01BX001340, respectively. NR 87 TC 1 Z9 1 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 EI 1522-1563 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD APR 1 PY 2016 VL 310 IS 7 BP C583 EP C596 DI 10.1152/ajpcell.00266.2015 PG 14 WC Cell Biology; Physiology SC Cell Biology; Physiology GA DI1RR UT WOS:000373273900009 PM 26739493 ER PT J AU Wang, J Han, L Sinnett-Smith, J Han, LL Stevens, JV Rozengurt, N Young, SH Rozengurt, E AF Wang, Jia Han, Liang Sinnett-Smith, James Han, Li-Li Stevens, Jan V. Rozengurt, Nora Young, Steven H. Rozengurt, Enrique TI Positive cross talk between protein kinase D and beta-catenin in intestinal epithelial cells: impact on beta-catenin nuclear localization and phosphorylation at Ser552 SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Article DE G protein-coupled receptors; angiotensin II; IEC-18 cells; PKA; PKD family inhibitors; CRT006610; kb NB 142-70; PKD1 transgenic mice ID ACTIVATION LOOP SER(744); STEM-CELLS; IN-VIVO; ANG-II; G(Q)-COUPLED RECEPTORS; SIGNALING PATHWAYS; COUPLED RECEPTOR; ANGIOTENSIN-II; DNA-SYNTHESIS; LYSOPHOSPHATIDIC ACID AB Given the fundamental role of beta-catenin signaling in intestinal epithelial cell proliferation and the growth-promoting function of protein kinase D1 (PKD1) in these cells, we hypothesized that PKDs mediate cross talk with beta-catenin signaling. The results presented here provide several lines of evidence supporting this hypothesis. We found that stimulation of intestinal epithelial IEC-18 cells with the G protein-coupled receptor (GPCR) agonist angiotensin II (ANG II), a potent inducer of PKD activation, promoted endogenous beta-catenin nuclear localization in a time-dependent manner. A significant increase was evident within 1 h of ANG II stimulation (P < 0.01), peaked at 4 h (P < 0.001), and declined afterwards. GPCR stimulation also induced a marked increase in beta-catenin-regulated genes and phosphorylation at Ser(552) in intestinal epithelial cells. Exposure to preferential inhibitors of the PKD family (CRT006610 or kb NB 142-70) or knockdown of the isoforms of the PKD family prevented the increase in beta-catenin nuclear localization and phosphorylation at Ser(552) in response to ANG II. GPCR stimulation also induced the formation of a complex between PKD1 and beta-catenin, as shown by coimmuno-precipitation that depended on PKD1 catalytic activation, as it was abrogated by cell treatment with PKD family inhibitors. Using transgenic mice that express elevated PKD1 protein in the intestinal epithelium, we detected a marked increase in the localization of beta-catenin in the nucleus of crypt epithelial cells in the ileum of PKD1 transgenic mice, compared with nontransgenic littermates. Collectively, our results identify a novel cross talk between PKD and beta-catenin in intestinal epithelial cells, both in vitro and in vivo. C1 [Wang, Jia; Han, Liang; Sinnett-Smith, James; Han, Li-Li; Stevens, Jan V.; Young, Steven H.; Rozengurt, Enrique] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Sinnett-Smith, James; Rozengurt, Nora; Rozengurt, Enrique] Digest Dis Res Ctr, CURE, Los Angeles, CA USA. [Rozengurt, Enrique] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA. [Sinnett-Smith, James; Young, Steven H.; Rozengurt, Enrique] Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RP Rozengurt, E (reprint author), Univ Calif Los Angeles, Sch Med, Dept Med, Warren Hall Rm 11-124,900 Vet Ave, Los Angeles, CA 90095 USA. EM erozengurt@mednet.ucla.edu FU National Institutes of Health [R01-DK-100405, P30-DK-41301, P01-CA-163200]; Department of Veterans Affair Grant [1I01BX001473]; Chinese Scholarship Council FX This work was supported by National Institutes of Health Grants R01-DK-100405, P30-DK-41301, and P01-CA-163200 and by Department of Veterans Affair Grant 1I01BX001473 (to E. Rozengurt). L. Han and L.-L. Han were both supported by a scholarship from the Chinese Scholarship Council. NR 85 TC 0 Z9 0 U1 1 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 EI 1522-1563 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD APR 1 PY 2016 VL 310 IS 7 BP C542 EP C557 DI 10.1152/ajpcell.00302.2015 PG 16 WC Cell Biology; Physiology SC Cell Biology; Physiology GA DI1RR UT WOS:000373273900005 PM 26739494 ER PT J AU Patterson, RE Kalavalapalli, S Williams, CM Nautiyal, M Mathew, JT Martinez, J Reinhard, MK McDougall, DJ Rocca, JR Yost, RA Cusi, K Garrett, TJ Sunny, NE AF Patterson, Rainey E. Kalavalapalli, Srilaxmi Williams, Caroline M. Nautiyal, Manisha Mathew, Justin T. Martinez, Janie Reinhard, Mary K. McDougall, Danielle J. Rocca, James R. Yost, Richard A. Cusi, Kenneth Garrett, Timothy J. Sunny, Nishanth E. TI Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE steatosis; hepatic insulin resistance; mitochondria; nonalcoholic steatohepatitis ID NONALCOHOLIC FATTY LIVER; HEPATIC INSULIN-RESISTANCE; TCA CYCLE; MITOCHONDRIAL DYSFUNCTION; GLUCOSE-PRODUCTION; AMINO-ACIDS; DISEASE; METABOLISM; MODEL; GLUCONEOGENESIS AB The hepatic tricarboxylic acid (TCA) cycle is central to integrating macro-nutrient metabolism and is closely coupled to cellular respiration, free radical generation, and inflammation. Oxidative flux through the TCA cycle is induced during hepatic insulin resistance, in mice and humans with simple steatosis, reflecting early compensatory remodeling of mitochondrial energetics. We hypothesized that progressive severity of hepatic insulin resistance and the onset of nonalcoholic steatohepatitis (NASH) would impair oxidative flux through the hepatic TCA cycle. Mice (C57/BL6) were fed a high-trans-fat high-fructose diet (TFD) for 8 wk to induce simple steatosis and NASH by 24 wk. In vivo fasting hepatic mitochondrial fluxes were determined by C-13-nuclear magnetic resonance (NMR)-based isotopomer analysis. Hepatic metabolic intermediates were quantified using mass spectrometry- based targeted metabolomics. Hepatic triglyceride accumulation and insulin resistance preceded alterations in mitochondrial metabolism, since TCA cycle fluxes remained normal during simple steatosis. However, mice with NASH had a twofold induction (P < 0.05) of mitochondrial fluxes (mu mol/min) through the TCA cycle (2.6 +/- 0.5 vs. 5.4 +/- 0.6), anaplerosis (9.1 +/- 1.2 vs. 16.9 +/- 2.2), and pyruvate cycling (4.9 +/- 1.0 vs. 11.1 +/- 1.9) compared with their age-matched controls. Induction of the TCA cycle activity during NASH was concurrent with blunted ketogenesis and accumulation of hepatic diacylglycerols (DAGs), ceramides (Cer), and long-chain acylcar-nitines, suggesting inefficient oxidation and disposal of excess free fatty acids (FFA). Sustained induction of mitochondrial TCA cycle failed to prevent accretion of "lipotoxic" metabolites in the liver and could hasten inflammation and the metabolic transition to NASH. C1 [Patterson, Rainey E.; McDougall, Danielle J.; Yost, Richard A.] Univ Florida, Dept Chem, Gainesville, FL 32610 USA. [Kalavalapalli, Srilaxmi; Nautiyal, Manisha; Mathew, Justin T.; Martinez, Janie; Cusi, Kenneth; Sunny, Nishanth E.] Univ Florida, Dept Med, Div Endocrinol Diabet & Metab, 1600 SW Archer Rd, Gainesville, FL 32610 USA. [Williams, Caroline M.] Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA. [Reinhard, Mary K.] Univ Florida, Anim Care Serv, Gainesville, FL 32610 USA. [Rocca, James R.] Univ Florida, McKnight Brain Inst, Adv Magnet Resonance Imaging & Spect Facil, Gainesville, FL 32610 USA. [Cusi, Kenneth] Malcom Randall Vet Adm Med Ctr, Div Endocrinol Diabet & Metab, Gainesville, FL USA. [Cusi, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, Div Diabet, San Antonio, TX 78229 USA. [Cusi, Kenneth] Audie L Murphy Vet Adm Med Ctr, Div Diabet, San Antonio, TX USA. [Yost, Richard A.; Garrett, Timothy J.] Univ Florida, Dept Pathol, Gainesville, FL 32610 USA. RP Sunny, NE (reprint author), Univ Florida, Dept Med, Div Endocrinol Diabet & Metab, 1600 SW Archer Rd, Gainesville, FL 32610 USA. EM nishanth.sunny@medicine.ufl.edu FU University of Florida [00089467]; Southeast Center for Integrated Metabolomics National Institute of Diabetes and Digestive and Kidney Diseases Grant [U24-DK-097209]; National Center for Research Resources Clinical and Translational Science Award [UL1-TR-00064]; National Institutes of Health FX This work was supported by a University of Florida Research Opportunity Seed Fund Award (00089467; to N. E. Sunny), a Southeast Center for Integrated Metabolomics National Institute of Diabetes and Digestive and Kidney Diseases Grant (U24-DK-097209), and a National Institutes of Health and National Center for Research Resources Clinical and Translational Science Award to the University of Florida (UL1-TR-00064). NR 45 TC 4 Z9 4 U1 2 U2 8 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 EI 1522-1555 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD APR 1 PY 2016 VL 310 IS 7 BP E484 EP E494 DI 10.1152/ajpendo.00492.2015 PG 11 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA DI1RJ UT WOS:000373272900002 PM 26814015 ER PT J AU Blevins, JE Thompson, BW Anekonda, VT Ho, JM Graham, JL Roberts, ZS Hwang, BH Ogimoto, K Wolden-Hanson, T Nelson, J Kaiyala, KJ Havel, PJ Bales, KL Morton, GJ Schwartz, MW Baskin, DG AF Blevins, James E. Thompson, Benjamin W. Anekonda, Vishwanath T. Ho, Jacqueline M. Graham, James L. Roberts, Zachary S. Hwang, Bang H. Ogimoto, Kayoko Wolden-Hanson, Tami Nelson, Jarrell Kaiyala, Karl J. Havel, Peter J. Bales, Karen L. Morton, Gregory J. Schwartz, Michael W. Baskin, Denis G. TI Chronic CNS oxytocin signaling preferentially induces fat loss in high-fat diet-fed rats by enhancing satiety responses and increasing lipid utilization SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE obesity; food intake; energy expenditure; oxytocin ID BROWN ADIPOSE-TISSUE; TYPE-2 DIABETIC-PATIENTS; CAUSES WEIGHT-LOSS; NERVOUS-SYSTEM OUTFLOW; INDUCED OBESE RATS; FOOD-INTAKE; ENERGY-EXPENDITURE; PARAVENTRICULAR NUCLEUS; METABOLIC SYNDROME; BODY-WEIGHT AB Based largely on a number of short-term administration studies, growing evidence suggests that central oxytocin is important in the regulation of energy balance. The goal of the current work is to determine whether long-term third ventricular (3V) infusion of oxytocin into the central nervous system (CNS) is effective for obesity prevention and/or treatment in rat models. We found that chronic 3V oxytocin infusion between 21 and 26 days by osmotic minipumps both reduced weight gain associated with the progression of high-fat diet (HFD)-induced obesity and elicited a sustained reduction of fat mass with no decrease of lean mass in rats with established diet-induced obesity. We further demonstrated that these chronic oxytocin effects result from 1) maintenance of energy expenditure at preintervention levels despite ongoing weight loss, 2) a reduction in respiratory quotient, consistent with increased fat oxidation, and 3) an enhanced satiety response to cholecystokinin-8 and associated decrease of meal size. These weight-reducing effects persisted for approximately 10 days after termination of 3V oxytocin administration and occurred independently of whether sucrose was added to the HFD. We conclude that long-term 3V administration C1 [Blevins, James E.; Thompson, Benjamin W.; Anekonda, Vishwanath T.; Ho, Jacqueline M.; Roberts, Zachary S.; Hwang, Bang H.; Wolden-Hanson, Tami; Baskin, Denis G.] Vet Affairs Puget Sound Hlth Care Syst, Off Res & Dev Med Res Serv, Dept Vet Affairs Med Ctr, Seattle, WA 98108 USA. [Blevins, James E.; Ho, Jacqueline M.; Morton, Gregory J.; Schwartz, Michael W.; Baskin, Denis G.] Univ Washington, Sch Med, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Ogimoto, Kayoko; Nelson, Jarrell; Morton, Gregory J.; Schwartz, Michael W.] Univ Washington, Sch Med, Diabet & Obes Ctr Excellence, Seattle, WA USA. [Kaiyala, Karl J.] Univ Washington, Sch Dent, Dept Oral Hlth Sci, Seattle, WA 98195 USA. [Graham, James L.; Havel, Peter J.] Univ Calif Davis, Sch Vet Med, Dept Nutr, Davis, CA 95616 USA. [Graham, James L.; Havel, Peter J.] Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA. [Bales, Karen L.] Univ Calif Davis, Dept Psychol, Davis, CA 95616 USA. RP Blevins, JE (reprint author), VA Puget Sound Hlth Care Syst, Res 151, 1660 South Columbian Way, Seattle, WA 98108 USA. EM jeblevin@u.washington.edu FU Office of Research and Development, Medical Research Service, Department of Veterans Affairs (VA); VA Puget Sound Health Care System Rodent Metabolic and Behavioral Phenotyping Core; Cellular and Molecular Imaging Core of the Diabetes Research Center at the University of Washington; National Institutes of Health (NIH) [P30DK017047, P30 DK035816, P30DK017047-31689, 2T32DK007247]; Energy Balance and Glucose Metabolism Core of the Nutrition Obesity Research Center at the University of Washington; Department of Veterans Affairs Biomedical Laboratory R&D Merit Review Program; NIH [DK-095980, HL-091333, HL-107256]; University of California Office of the President; VA Senior Research Career Scientist award FX This material is based upon work supported by the Office of Research and Development, Medical Research Service, Department of Veterans Affairs (VA), the VA Puget Sound Health Care System Rodent Metabolic and Behavioral Phenotyping Core, and the Cellular and Molecular Imaging Core of the Diabetes Research Center at the University of Washington. This study was supported by National Institutes of Health (NIH) Grant P30DK017047. This work is also supported by the Energy Balance and Glucose Metabolism Core of the Nutrition Obesity Research Center at the University of Washington and supported by National Institutes of Health (NIH) Grant P30 DK035816. The research in our laboratory has been supported by the Department of Veterans Affairs Biomedical Laboratory R&D Merit Review Program as well as National Institutes of Health Grants P30DK017047-31689 and the Diabetes, Obesity, and Metabolism Training Grant 2T32DK007247. P. J. Havel's research program also receives research support from NIH Grants DK-095980, HL-091333, HL-107256, HL-107256 and a Multi-campus grant from the University of California Office of the President. D. G. Baskin is the recipient of a VA Senior Research Career Scientist award. NR 105 TC 8 Z9 8 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 EI 1522-1490 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD APR 1 PY 2016 VL 310 IS 7 BP R640 EP R658 DI 10.1152/ajpregu.00220.2015 PG 19 WC Physiology SC Physiology GA DI1PU UT WOS:000373268800012 PM 26791828 ER PT J AU Morgan, TA Chandran, S Burger, IM Zhang, CA Goldstein, RB AF Morgan, T. A. Chandran, S. Burger, I. M. Zhang, C. A. Goldstein, R. B. TI Complications of Ultrasound-Guided Renal Transplant Biopsies SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article ID KIDNEY BIOPSY; CORE BIOPSY; SAFETY; NEEDLE; GUN; ALLOGRAFTS; ADEQUACY; EFFICACY; YIELD; TRIAL AB Renal transplant biopsies to diagnose transplant pathology are routinely performed using ultrasound guidance. Few large studies have assessed the rate and risk factors of major biopsy complications. This study is a single-center 5-year retrospective cohort analysis of 2514 biopsies. Major complications occurred in 47 of 2514 patients (1.9%) and included hospitalization, transfusion of blood products, operative exploration and interventional radiology procedures. The complication rate among cause biopsies was significantly higher than in protocol biopsies (2.7% vs. 0.33%, p < 0.001). Complications presented on postbiopsy days 0-14, with the majority diagnosed on the same day as the biopsy and manifested by hematocrit drop, although the presence of such delayed presentation of complications occurring >24 h after the biopsy on days 2-14 is previously unreported. Specific patient characteristics associated with increased risk of a complication were increased age and blood urea nitrogen, decreased platelet count, history of prior renal transplant, deceased donor transplant type and use of anticoagulant medications but not aspirin. The authors review the incidence of major complications associated with ultrasound-guided renal transplant biopsies, including timing, presentation, and association with clinical factors, including patient demographics and prebiopsy laboratory values. C1 [Morgan, T. A.; Zhang, C. A.; Goldstein, R. B.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Chandran, S.] Univ Calif San Francisco, Dept Med, Kidney Transplant Serv, Div Nephrol, San Francisco, CA USA. [Burger, I. M.] Kaiser Permanente Los Angeles, VA Greater Angeles Healthcare Syst, Dept Radiol, Los Angeles, CA USA. RP Morgan, TA (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. EM tara.morgan@ucsf.edu NR 25 TC 2 Z9 2 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2016 VL 16 IS 4 BP 1298 EP 1305 DI 10.1111/ajt.13622 PG 8 WC Surgery; Transplantation SC Surgery; Transplantation GA DH8VQ UT WOS:000373075400031 PM 26601796 ER PT J AU Aplin, AC Nicosia, RF AF Aplin, Alfred C. Nicosia, Roberto F. TI Hypoxia paradoxically inhibits the angiogenic response of isolated vessel explants while inducing overexpression of vascular endothelial growth factor SO ANGIOGENESIS LA English DT Article DE Endothelial cells; Pericytes; Neovessels; Vascular endothelial growth factor; Aorta; Vein; Collagen; Neovascularization ID AORTIC RING MODEL; SOLUBLE VEGF RECEPTOR-1; RAT AORTA; IN-VITRO; OXYGEN; CELLS; PERMEABILITY; EXPRESSION; SYSTEM; PHOSPHORYLATION AB This study was designed to investigate how changes in O-2 levels affected angiogenesis in vascular organ culture. Although hypoxia is a potent inducer of angiogenesis, aortic rings cultured in collagen paradoxically failed to produce an angiogenic response in 1-4 % O-2. Additionally, aortic neovessels preformed in atmospheric O-2 lost pericytes and regressed at a faster rate than control when exposed to hypoxia. Aortic explants remained viable in hypoxia and produced an angiogenic response when returned to atmospheric O-2. Hypoxic aortic rings were unresponsive to VEGF, while increased oxygenation of the system dose-dependently enhanced VEGF-induced angiogenesis. Hypoxia-induced refractoriness to angiogenic stimulation was not restricted to the aorta because similar results were obtained with vena cava explants or isolated endothelial cells. Unlike endothelial cells, aorta-derived mural cells were unaffected by hypoxia. Hypoxia downregulated expression in aortic explants of key signaling molecules including VEGFR2, NRP1 and Prkc-beta while upregulating expression of VEGFR1. Medium conditioned by hypoxic cultures exhibited angiostatic and anti-VEGF activities likely mediated by sVEGFr1. Hypoxia reduced expression of VEGFR1 and VEGFR2 in endothelial cells while upregulating VEGFR1 in macrophages and VEGF in both macrophages and mural cells. Thus, changes in O-2 levels profoundly affect the endothelial response to angiogenic stimuli. These results suggest that hypoxia-induced angiogenesis is fine-tuned by complex regulatory mechanisms involving not only production of angiogenic factors including VEGF but also differential regulation of VEGFR expression in different cell types and production of inhibitors of VEGF function such as sVEGFR1. C1 [Aplin, Alfred C.; Nicosia, Roberto F.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Nicosia, Roberto F.] VA Puget Sound Hlth Care Syst, Pathol & Lab Med Serv S Lab 113, Seattle, WA USA. RP Nicosia, RF (reprint author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.; Nicosia, RF (reprint author), VA Puget Sound Hlth Care Syst, Pathol & Lab Med Serv S Lab 113, Seattle, WA USA. EM Roberto.Nicosia@va.gov FU United States (U.S.) Department of Veterans Affairs Biomedical Laboratory Research and Development Service; American Heart Association FX This work was supported in part by a Merit Review Award from the United States (U.S.) Department of Veterans Affairs Biomedical Laboratory Research and Development Service. The contents do not represent the views of the U.S. Department of Veteran Affairs or the United States Government. In addition, we gratefully acknowledge the support of a grant-in-aid from the American Heart Association. NR 55 TC 2 Z9 2 U1 2 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0969-6970 EI 1573-7209 J9 ANGIOGENESIS JI Angiogenesis PD APR PY 2016 VL 19 IS 2 BP 133 EP 146 DI 10.1007/s10456-015-9493-2 PG 14 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DI0IK UT WOS:000373178900003 PM 26748649 ER PT J AU Domsic, RT Nihtyanova, SI Wisniewski, SR Fine, MJ Lucas, M Kwoh, CK Denton, CP Medsger, TA AF Domsic, Robyn T. Nihtyanova, Svetlana I. Wisniewski, Stephen R. Fine, Michael J. Lucas, Mary Kwoh, C. Kent Denton, Christopher P. Medsger, Thomas A., Jr. TI Derivation and External Validation of a Prediction Rule for Five-Year Mortality in Patients With Early Diffuse Cutaneous Systemic Sclerosis SO ARTHRITIS & RHEUMATOLOGY LA English DT Article ID CLINICAL-PREDICTION; EUSTAR DATABASE; SCLERODERMA; SURVIVAL; FEATURES; DEATH; EMPHASIS; DISEASE; COHORT; MODEL AB ObjectiveAlthough diffuse cutaneous systemic sclerosis (dcSSc) is associated with a reduction in life expectancy, there are no validated prognostic models for determining 5-year mortality in patients with dcSSc. The objective of this study was to derive and validate a rule for predicting 5-year mortality in patients with early dcSSc. MethodsWe studied an inception cohort of 388 US Caucasian patients with early dcSSc (<2 years from the appearance of the first symptom). Predefined baseline variables were analyzed in a stepwise logistic regression model in order to identify factors independently associated with 5-year all-cause mortality. We rounded the beta weights to the nearest integer and summed the points assigned to each variable in order to stratify patients into low-risk (<0 points), moderate-risk (1-2 points), and high-risk (3 points) groups. We then applied this rule to an external validation cohort of 144 Caucasian patients with early dcSSc from the Royal Free Hospital cohort and compared stratum-specific 5-year mortality. ResultsSix independent predictors (rounded beta weight) comprised the model: age at first visit (points allotted: -1, 0, or 1), male sex (points allotted: 0 or 1), tendon friction rubs (points allotted: 0 or 1), gastrointestinal involvement (points allotted: 0 or 1), RNA polymerase III antibodies (points allotted: 0 or 1), and anemia (points allotted: 0 or 1). The 3-level risk stratification model performed well, with no significant differences between the US derivation cohort and the UK validation cohort. ConclusionWe derived and externally validated, in US and UK cohorts, an easy-to-use 6-variable prediction rule that assigns low-risk, moderate-risk, and high-risk categories for 5-year mortality in patients with early dcSSc. Only history, physical examination, and basic laboratory assessments are required. C1 [Domsic, Robyn T.; Wisniewski, Stephen R.; Lucas, Mary; Medsger, Thomas A., Jr.] Univ Pittsburgh, Pittsburgh, PA USA. [Nihtyanova, Svetlana I.; Denton, Christopher P.] UCL, Sch Med, Royal Free Hosp, Mortimer St, London W1N 8AA, England. [Fine, Michael J.] Univ Pittsburgh, Pittsburgh, PA USA. [Fine, Michael J.] Vet Affairs Pittsburgh Healthcare, Vet Affairs Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Kwoh, C. Kent] Univ Arizona, Arthrit Ctr, Tucson, AZ USA. RP Domsic, RT (reprint author), Univ Pittsburgh, S724 Biomed Sci Tower,3500 Terrace St, Pittsburgh, PA 15261 USA. EM rtd4@pitt.edu OI Wisniewski, Stephen/0000-0002-3877-9860 FU NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases) [K23-AR-057845] FX Dr. Domsic's work was supported by the NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases grant K23-AR-057845). NR 40 TC 2 Z9 2 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD APR PY 2016 VL 68 IS 4 BP 993 EP 1003 DI 10.1002/art.39490 PG 11 WC Rheumatology SC Rheumatology GA DH9QH UT WOS:000373130300026 PM 26554637 ER PT J AU Fisher, MB Belkin, NS Milby, AH Henning, EA Soegaard, N Kim, M Pfeifer, C Saxena, V Dodge, GR Burdick, JA Schaer, TP Steinberg, DR Mauck, RL AF Fisher, Matthew B. Belkin, Nicole S. Milby, Andrew H. Henning, Elizabeth A. Soeegaard, Nicole Kim, Minwook Pfeifer, Christian Saxena, Vishal Dodge, George R. Burdick, Jason A. Schaer, Thomas P. Steinberg, David R. Mauck, Robert L. TI Effects of Mesenchymal Stem Cell and Growth Factor Delivery on Cartilage Repair in a Mini-Pig Model SO CARTILAGE LA English DT Article DE cartilage; repair; mesenchymal stem cells; TGF-3; animal models ID HYALURONIC-ACID HYDROGELS; AUTOLOGOUS CHONDROCYTE IMPLANTATION; ENGINEERED CARTILAGE; IN-VIVO; OSTEOCHONDRAL DEFECTS; ARTICULAR-CARTILAGE; CHONDROGENIC DIFFERENTIATION; ALGINATE MICROSPHERES; STROMAL CELLS; MATRIX AB Objective We have recently shown that mesenchymal stem cells (MSCs) embedded in a hyaluronic acid (HA) hydrogel and exposed to chondrogenic factors (transforming growth factor-3 [TGF-3]) produce a cartilage-like tissue in vitro. The current objective was to determine if these same factors could be combined immediately prior to implantation to induce a superior healing response in vivo relative to the hydrogel alone. Design Trochlear chondral defects were created in Yucatan mini-pigs (6 months old). Treatment groups included an HA hydrogel alone and hydrogels containing allogeneic MSCs, TGF-3, or both. Six weeks after surgery, micro-computed tomography was used to quantitatively assess defect fill and subchondral bone remodeling. The quality of cartilage repair was assessed using the ICRS-II histological scoring system and immunohistochemistry for type II collagen. Results Treatment with TGF-3 led to a marked increase in positive staining for collagen type II within defects (P < 0.05), while delivery of MSCs did not (P > 0.05). Neither condition had an impact on other histological semiquantitative scores (P > 0.05), and inclusion of MSCs led to significantly less defect fill (P < 0.05). For all measurements, no synergistic interaction was found between TGF-3 and MSC treatment when they were delivered together (P > 0.05). Conclusions At this early healing time point, treatment with TGF-3 promoted the formation of collagen type II within the defect, while allogeneic MSCs had little benefit. Combination of TGF-3 and MSCs at the time of surgery did not produce a synergistic effect. An in vitro precultured construct made of these components may be required to enhance in vivo repair in this model system. C1 [Fisher, Matthew B.; Belkin, Nicole S.; Milby, Andrew H.; Henning, Elizabeth A.; Soeegaard, Nicole; Kim, Minwook; Pfeifer, Christian; Saxena, Vishal; Dodge, George R.; Steinberg, David R.; Mauck, Robert L.] Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA. [Fisher, Matthew B.; Belkin, Nicole S.; Milby, Andrew H.; Henning, Elizabeth A.; Soeegaard, Nicole; Kim, Minwook; Pfeifer, Christian; Saxena, Vishal; Dodge, George R.; Burdick, Jason A.; Steinberg, David R.; Mauck, Robert L.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA USA. [Fisher, Matthew B.] Univ N Carolina, Dept Biomed Engn, Chapel Hill, NC USA. [Fisher, Matthew B.] N Carolina State Univ, Raleigh, NC 27695 USA. [Pfeifer, Christian] Univ Regensburg, Med Ctr, Dept Trauma Surg, D-93053 Regensburg, Germany. [Burdick, Jason A.; Mauck, Robert L.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA. [Schaer, Thomas P.] Univ Penn, Sch Vet Med, Comparat Orthopaed Res Lab, Philadelphia, PA 19104 USA. RP Mauck, RL (reprint author), Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, 424 Stemmler Hall,36th St & Hamilton Walk, Philadelphia, PA 19104 USA.; Mauck, RL (reprint author), Univ Penn, Perelman Sch Med, Dept Bioengn, 424 Stemmler Hall,36th St & Hamilton Walk, Philadelphia, PA 19104 USA. EM lemauck@mail.med.upenn.edu FU National Institutes of Health [R01 EB008722, F32 AR062971]; Department of Veterans Affairs [I01 RX000700]; AO Foundation; Orthopaedic Research and Education Foundation FX The authors thank Liming Bian, Megan Farrell, Tristan Driscoll, Sylvia Qu, and Marc Bostrom for their technical assistance. This work was supported by the National Institutes of Health (R01 EB008722 and F32 AR062971), the Department of Veterans Affairs (I01 RX000700), the AO Foundation, and the Orthopaedic Research and Education Foundation (Resident Clinician Scientist Training Grant). NR 52 TC 1 Z9 1 U1 7 U2 19 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1947-6035 EI 1947-6043 J9 CARTILAGE JI Cartilage PD APR PY 2016 VL 7 IS 2 BP 174 EP 184 DI 10.1177/1947603515623030 PG 11 WC Orthopedics SC Orthopedics GA DH6LG UT WOS:000372901500006 PM 27047640 ER PT J AU Post, RM Leverich, GS Kupka, R Keck, PE McElroy, SL Altshuler, LL Frye, MA Rowe, M Grunze, H Suppes, T Nolen, WA AF Post, Robert M. Leverich, Gabriele S. Kupka, Ralph Keck, Paul E., Jr. McElroy, Susan L. Altshuler, Lori L. Frye, Mark A. Rowe, Michael Grunze, Heinz Suppes, Trisha Nolen, Willem A. TI Clinical correlates of sustained response to individual drugs used in naturalistic treatment of patients with bipolar disorder SO COMPREHENSIVE PSYCHIATRY LA English DT Article ID LIFE-CHART METHOD; I DISORDER; ANTIDEPRESSANT TREATMENT; CONTROLLED-TRIAL; DOUBLE-BLIND; EARLY-ONSET; STEP-BD; LITHIUM; OUTPATIENTS; DEPRESSION AB Objective: To report use and treatment success rates of medications for bipolar disorder as a function of patients' clinical characteristics. Method: Outpatients with bipolar illness diagnosed by SCID were rated by research assistants on the NIMH-LCM and those who had an good response for at least 6 months (much or very much improved on the CGI-BP) were considered responders (treatment "success"). Clinical characteristics associated with treatment response in the literature were examined for how often a drug was in a successful regimen when a given characteristic was either present or absent. Results: Lithium was less successful in those with histories of rapid cycling, substance abuse, or (surprisingly) a positive parental history of mood disorders. Valproate was less successful in those with >= 20 prior episodes. Lamotrigine (LTG) was less successful in those with a parental history of mood disorders or in BP-I compared to BP-II disorder. Antidepressants (ADs) had low success rates, especially in those with a history of anxiety disorders. Benzodiazepines had low success rates in those with child abuse, substance use, or >= 20 episodes. Atypical antipsychotics were less successful in the presence of rapid cycling, >= 20 prior episodes, or a greater number of poor prognosis factors. Conclusion: Success rates reflect medications used in combination with an average of two other drugs during naturalistic treatment and thus should be considered exploratory. However, the low long-term success rates of drugs (even when used in combination with others) that occurred in the presence of many very common clinical characteristics of bipolar illness speak to the need for the development of alternative treatment strategies. (C) 2016 Elsevier Inc. All rights reserved. C1 [Post, Robert M.; Leverich, Gabriele S.; Rowe, Michael] Bipolar Collaborat Network, Bethesda, MD USA. [Post, Robert M.] George Washington Univ, Dept Psychiat & Behav Sci, Washington, DC USA. [Kupka, Ralph] Vrije Univ Amsterdam, Med Ctr, Dept Psychiat, Amsterdam, Netherlands. [Keck, Paul E., Jr.] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA. [Keck, Paul E., Jr.; McElroy, Susan L.] Lindner Ctr HOPE, Mason, OH USA. [McElroy, Susan L.] Univ Cincinnati, Coll Med, Biol Psychiat Program, Cincinnati, OH USA. [Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Altshuler, Lori L.] West Los Angeles Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Frye, Mark A.] Mayo Clin, Dept Psychiat, Rochester, MI USA. [Grunze, Heinz] Newcastle Univ, Acad Psychiat, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Suppes, Trisha] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Suppes, Trisha] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Nolen, Willem A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. RP Post, RM (reprint author), Bipolar Collaborat Network, 5415 West Cedar Lane,Suite 201-B, Bethesda, MD 20814 USA. EM robert.post@speakeasy.net OI Grunze, Heinz/0000-0003-4712-8979 NR 43 TC 2 Z9 2 U1 2 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0010-440X EI 1532-8384 J9 COMPR PSYCHIAT JI Compr. Psychiat. PD APR PY 2016 VL 66 BP 146 EP 156 DI 10.1016/j.comppsych.2016.01.009 PG 11 WC Psychiatry SC Psychiatry GA DH4ML UT WOS:000372760000020 PM 26995248 ER PT J AU Lynch, CP Williams, JS Voronca, D Walker, RJ Egede, LE AF Lynch, Cheryl P. Williams, Joni Strom Voronca, Delia Walker, Rebekah J. Egede, Leonard E. TI Meaning of Illness and Cardiovascular Risk Factors in Patients With Type 2 Diabetes SO DIABETES EDUCATOR LA English DT Article ID SELF-MANAGEMENT; DEPRESSION; MELLITUS; ADULTS; HEALTH; QUESTIONNAIRE; RELIABILITY; ASSOCIATION; DISTRESS; VALIDITY AB Purpose The purpose of this study was to examine the relationship between meaning of illness and cardiovascular disease risk factors in patients with type 2 diabetes. Methods The sample population was recruited from primary care clinics in the southeastern United States. The meaning of illness was assessed by a validated questionnaire with 5 subscales. The primary outcomes were cardiovascular disease (CVD) risk factors, assessed by A1C, systolic and diastolic blood pressure (SBP and DBP, respectively), and low-density lipoprotein cholesterol (LDL-C). Multivariate linear regression models investigated associations between the clinical outcomes and the 5 MIQ factors, controlling for possible confounders. Results The sample comprised 302 black and white participants of whom more than half were elderly (65+ years) and the vast majority were male (98%). Systolic blood pressure was positively associated with non-anticipated vulnerability. Diastolic blood pressure was negatively associated with degree of stress/change in commitments and positively associated with challenge/motivation/hope and non-anticipated vulnerability. Low-density lipoprotein cholesterol was significantly and negatively associated with degree of stress/change in commitments. Conclusions Meaning of illness had a significant effect on measured outcomes of CVD risk. The specific factor included in the overarching concept of meaning of illness differed in its influence, with more positive views of stress/commitments associated with lower blood pressure and LDL but more positive views of the challenge/hope/motivation and negative views of non-anticipated vulnerability associated with diabetes associated with higher systolic and diastolic blood pressure. C1 [Lynch, Cheryl P.; Walker, Rebekah J.; Egede, Leonard E.] Ralph H Johnson Vet Affairs Med Ctr, HEROIC, Charleston, SC USA. [Lynch, Cheryl P.; Williams, Joni Strom; Voronca, Delia; Walker, Rebekah J.; Egede, Leonard E.] Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Lynch, Cheryl P.; Williams, Joni Strom; Voronca, Delia; Egede, Leonard E.] Med Univ S Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, Hlth Equ & Rural Outreach Innovat Ctr, 135 Rutledge Ave,Room 280G,POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu FU VHA Health Services Research and Development (HSRD) program [TRP 04-038] FX This study was supported by grant No. TRP 04-038 funded by the VHA Health Services Research and Development (HSR&D) program. The funding agency did not participate in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. The manuscript represents the views of the authors and not those of the VA or HSR&D. NR 29 TC 0 Z9 0 U1 1 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0145-7217 EI 1554-6063 J9 DIABETES EDUCATOR JI Diabetes Educ. PD APR PY 2016 VL 42 IS 2 BP 220 EP 227 DI 10.1177/0145721716631430 PG 8 WC Endocrinology & Metabolism; Public, Environmental & Occupational Health SC Endocrinology & Metabolism; Public, Environmental & Occupational Health GA DH6DV UT WOS:000372882100007 PM 26879460 ER PT J AU Francis, FF Kulich, SM Hashash, JG AF Francis, Fadi F. Kulich, Scott M. Hashash, Jana G. TI Diarrhea, Ascites, and Eosinophilia Image 3: Hypereosinophilic Syndrome SO GASTROENTEROLOGY LA English DT Editorial Material C1 [Francis, Fadi F.] VA Pittsburgh Hlth Care Syst, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA. [Francis, Fadi F.; Hashash, Jana G.] Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA. [Kulich, Scott M.] VA Pittsburgh Hlth Care Syst, Dept Pathol, Pittsburgh, PA USA. [Kulich, Scott M.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA. RP Francis, FF (reprint author), VA Pittsburgh Hlth Care Syst, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA.; Francis, FF (reprint author), Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA. NR 3 TC 0 Z9 0 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2016 VL 150 IS 4 BP E6 EP E8 DI 10.1053/j.gastro.2015.10.019 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DH4BH UT WOS:000372730000003 PM 26930018 ER PT J AU White, PL Wiederhold, NP Loeffler, J Najvar, LK Melchers, W Herrera, M Bretagne, S Wickes, B Kirkpatrick, WR Barnes, RA Donnelly, JP Patterson, TF AF White, P. Lewis Wiederhold, Nathan P. Loeffler, Juergen Najvar, Laura K. Melchers, Willem Herrera, Monica Bretagne, Stephane Wickes, Brian Kirkpatrick, William R. Barnes, Rosemary A. Donnelly, J. Peter Patterson, Thomas F. TI Comparison of Nonculture Blood-Based Tests for Diagnosing Invasive Aspergillosis in an Animal Model SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID HIGH-RISK HEMATOLOGY; RANDOMIZED CONTROLLED-TRIAL; GUINEA-PIG MODEL; REAL-TIME PCR; FUNGAL DISEASE; PULMONARY ASPERGILLOSIS; AMPHOTERICIN-B; FUMIGATUS DNA; GALACTOMANNAN; SERUM AB The European Aspergillus PCR Initiative (EAPCRI) has provided recommendations for the PCR testing of whole blood (WB) and serum/plasma. It is important to test these recommended protocols on nonsimulated "in vivo" specimens before full clinical evaluation. The testing of an animal model of invasive aspergillosis (IA) overcomes the low incidence of disease and provides experimental design and control that is not possible in the clinical setting. Inadequate performance of the recommended protocols at this stage would require reassessment of methods before clinical trials are performed and utility assessed. The manuscript describes the performance of EAPCRI protocols in an animal model of invasive aspergillosis. Blood samples taken from a guinea pig model of IA were used for WB and serum PCR. Galactomannan and beta-D-glucan detection were evaluated, with particular focus on the timing of positivity and on the interpretation of combination testing. The overall sensitivities for WB PCR, serum PCR, galactomannan, and beta-D-glucan were 73%, 65%, 68%, and 46%, respectively. The corresponding specificities were 92%, 79%, 80%, and 100%, respectively. PCR provided the earliest indicator of IA, and increasing galactomannan and beta-D-glucan values were indicators of disease progression. The combination of WB PCR with galactomannan and beta-D-glucan proved optimal (area under the curve [AUC], 0.95), and IA was confidently diagnosed or excluded. The EAPRCI-recommended PCR protocols provide performance comparable to commercial antigen tests, and clinical trials are warranted. By combining multiple tests, IA can be excluded or confirmed, highlighting the need for a combined diagnostic strategy. However, this approach must be balanced against the practicality and cost of using multiple tests. C1 [White, P. Lewis] PHW Microbiol, Cardiff, S Glam, Wales. [Wiederhold, Nathan P.; Najvar, Laura K.; Herrera, Monica; Wickes, Brian; Kirkpatrick, William R.; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio Ctr Med Mycol, San Antonio, TX 78229 USA. [Loeffler, Juergen] Univ Wurzburg, D-97070 Wurzburg, Germany. [Melchers, Willem; Donnelly, J. Peter] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands. [Bretagne, Stephane] Hop St Louis, Paris, France. [Barnes, Rosemary A.] Cardiff Univ, UHW, Cardiff CF10 3AX, S Glam, Wales. [Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP White, PL (reprint author), PHW Microbiol, Cardiff, S Glam, Wales. EM lewis.white@wales.nhs.uk OI Bretagne, Stephane/0000-0001-6870-3800; Wiederhold, Nathan/0000-0002-2225-5122; Donnelly, J Peter/0000-0002-8521-335X FU HHS\ NIH\ National Institute of Allergy and Infectious Diseases (NIAID) [N01-AI-30041] FX HHS vertical bar NIH vertical bar National Institute of Allergy and Infectious Diseases (NIAID) provided funding to Nathan P. Wiederhold, Laura K. Najvar, Monica L. Herrera, Brian L. Wickes, William R. Kirkpatrick, and Thomas F. Patterson under grant number N01-AI-30041. NR 30 TC 2 Z9 2 U1 1 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD APR PY 2016 VL 54 IS 4 BP 960 EP 966 DI 10.1128/JCM.03233-15 PG 7 WC Microbiology SC Microbiology GA DI2OX UT WOS:000373337100015 PM 26791366 ER PT J AU Wahbeh, H Goodrich, E Goy, E Oken, BS AF Wahbeh, Helane Goodrich, Elena Goy, Elizabeth Oken, Barry S. TI Mechanistic Pathways of Mindfulness Meditation in Combat Veterans With Posttraumatic Stress Disorder SO JOURNAL OF CLINICAL PSYCHOLOGY LA English DT Article DE meditation; mindfulness; veteran; combat; posttraumatic stress disorder ID AUTONOMIC NERVOUS-SYSTEM; HEART-RATE-VARIABILITY; PSYCHOMETRIC PROPERTIES; CLINICAL-TRIAL; WAR VETERANS; METAANALYSIS; PTSD; SYMPTOMS; EEG; QUESTIONNAIRE AB ObjectiveThis study's objective was to evaluate the effect of two common components of meditation (mindfulness and slow breathing) on potential mechanistic pathways. MethodsA total of 102 combat veterans with posttraumatic stress disorder (PTSD) were randomized to (a) the body scan mindfulness meditation (MM), (b) slow breathing (SB) with a biofeedback device, (c) mindful awareness of the breath with an intention to slow the breath (MM+SB), or (d) sitting quietly (SQ). Participants had 6 weekly one-on-one sessions with 20 minutes of daily home practice. The mechanistic pathways and measures were as follows: (a) autonomic nervous system (hyperarousal symptoms, heart rate [HR], and heart rate variability [HRV]); (b) frontal cortex activity (attentional network task [ANT] conflict effect and event-related negativity and intrusive thoughts); and (c) hypothalamic-pituitary-adrenal axis (awakening cortisol). PTSD measures were also evaluated. ResultsMeditation participants had significant but modest within-group improvement in PTSD and related symptoms, although there were no effects between groups. Perceived impression of PTSD symptom improvement was greater in the meditation arms compared with controls. Resting respiration decreased in the meditation arms compared with SQ. For the mechanistic pathways, (a) subjective hyperarousal symptoms improved within-group (but not between groups) for MM, MM+SB, and SQ, while HR and HRV did not; (b) intrusive thoughts decreased in MM compared with MM+SB and SB, while the ANT measures did not change; and (c) MM had lower awakening cortisol within-group (but not between groups). ConclusionTreatment effects were mostly specific to self-report rather than physiological measures. Continued research is needed to further evaluate mindfulness meditation's mechanism in people with PTSD. C1 [Wahbeh, Helane; Goodrich, Elena; Oken, Barry S.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Wahbeh, Helane] Natl Coll Nat Med, Portland, OR USA. [Goy, Elizabeth] Portland VA Med Ctr, Portland, OR USA. RP Wahbeh, H (reprint author), 3181 SW Sam Jackson Pk Rd CR120, Portland, OR 97239 USA. EM wahbehh@ohsu.edu FU National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR000128]; National Center for Complementary and Alternative Medicine of the National Institutes of Health [T32AT002688, K01AT004951, K24AT005121] FX Research reported in this publication was supported by National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR000128 and the National Center for Complementary and Alternative Medicine of the National Institutes of Health [grant numbers T32AT002688, K01AT004951, K24AT005121]. NR 81 TC 0 Z9 0 U1 9 U2 22 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0021-9762 EI 1097-4679 J9 J CLIN PSYCHOL JI J. Clin. Psychol. PD APR PY 2016 VL 72 IS 4 BP 365 EP 383 DI 10.1002/jclp.22255 PG 19 WC Psychology, Clinical SC Psychology GA DH7KX UT WOS:000372973800005 PM 26797725 ER PT J AU Turner, AP Hartoonian, N Sloan, AP Benich, M Kivlahan, DR Hughes, C Hughes, AJ Haselkorn, JK AF Turner, Aaron P. Hartoonian, Narineh Sloan, Alicia P. Benich, Marisa Kivlahan, Daniel R. Hughes, Christina Hughes, Abbey J. Haselkorn, Jodie K. TI Improving Fatigue and Depression in Individuals With Multiple Sclerosis Using Telephone-Administered Physical Activity Counseling SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE fatigue; depression; physical activity; motivational interviewing; self-management ID QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; DISABILITY STATUS SCALE; SELF-REPORT; MAJOR DEPRESSION; CLINICAL-TRIALS; MENTAL-HEALTH; PRIMARY-CARE; MS PATIENTS; EXERCISE AB Objective: To evaluate the impact of a physical activity intervention consisting of telephone counseling with home-based monitoring to improve fatigue and depression in individuals with multiple sclerosis (MS). Method: Single-blind randomized controlled trial. Sixty-four individuals with MS received either telephone counseling (N = 31), or self-directed physical activity education (N = 33). The education condition (EC) consisted of advice to increase physical activity and a DVD with examples of in-home exercises for multiple physical ability levels. The telephone counseling condition (TC) included EC as well as mailed graphic feedback, 6 telephone counseling sessions using principles of motivational interviewing, and telehealth home monitoring to track progress on physical activity goals. Booster sessions were provided when participants indicated they did not meet their goals. Assessment was conducted at baseline, 3-month, and 6-month follow-up. Results: TC participants reported significantly reduced fatigue (d = -.70), reduced depression (d = -.72) and increased physical activity (d =.92) relative to EC participants. Of individuals receiving TC, 33.3% experienced clinically significant improvement in fatigue (vs. 18.2% in EC) and 53.3% experienced clinically significant improvement in depression (vs. 9.1% in EC). Improvements in physical activity mediated improvements in fatigue with a similar trend for depression. TC was highly feasible (participants completed 99.5% of schedule telephone sessions) and well tolerated (100% rated it highly successful). Conclusion: Telephone-based counseling with home monitoring is a promising modality to improve physical activity and treat fatigue and depression. C1 [Turner, Aaron P.; Benich, Marisa; Hughes, Abbey J.] VA Puget Sound Hlth Care Syst, VA Multiple Sclerosis Ctr Excellence, Seattle, WA USA. [Turner, Aaron P.; Hughes, Abbey J.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Hartoonian, Narineh; Sloan, Alicia P.; Haselkorn, Jodie K.] VA Multiple Sclerosis Ctr Excellence West, Seattle, WA USA. [Kivlahan, Daniel R.] Vet Hlth Adm, Mental Hlth Serv, Washington, DC USA. [Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Haselkorn, Jodie K.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Turner, AP (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv, S-117 RCS,1660 South Columbian Way, Seattle, WA 98108 USA. EM Aaron.Turner@med.va.gov OI Turner, Aaron/0000-0001-6897-8003 FU Department of Veterans Affairs Rehabilitation Research and Development Service Career Development Award [B4927W]; VA Multiple Sclerosis Center of Excellence West; VA Center of Excellence for Limb Loss Prevention and Prosthetic Engineering; VA Center of Excellence in Substance Abuse Treatment and Education FX This research was supported by Department of Veterans Affairs Rehabilitation Research and Development Service Career Development Award B4927W to Aaron P. Turner. Additional support was provided by the VA Multiple Sclerosis Center of Excellence West, the VA Center of Excellence for Limb Loss Prevention and Prosthetic Engineering, and the VA Center of Excellence in Substance Abuse Treatment and Education. Trial Registration clinicaltrials.gov Identifier: NCT01198977. Special thanks to Charles Bombardier who provided mentorship and consultation on this project. NR 75 TC 1 Z9 1 U1 12 U2 20 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X EI 1939-2117 J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD APR PY 2016 VL 84 IS 4 BP 297 EP 309 DI 10.1037/ccp0000086 PG 13 WC Psychology, Clinical SC Psychology GA DH8PP UT WOS:000373057100002 PM 26913621 ER PT J AU Jarrett, RB Minhajuddin, A Vittengl, JR Clark, LA Thase, ME AF Jarrett, Robin B. Minhajuddin, Abu Vittengl, Jeffrey R. Clark, Lee Anna Thase, Michael E. TI Quantifying and Qualifying the Preventive Effects of Acute-Phase Cognitive Therapy: Pathways to Personalizing Care SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE depression; cognitive therapy; relapse; recurrence; predictors of outcomes ID MAJOR DEPRESSIVE DISORDER; ATTRIBUTIONAL STYLE QUESTIONNAIRE; RECURRENT DEPRESSION; CONTINUATION PHASE; FOLLOW-UP; SOCIAL-ADJUSTMENT; RANDOMIZED-TRIAL; PILL PLACEBO; SELF-CONTROL; RELAPSE AB Objective: To determine the extent to which prospectively identified responders to cognitive therapy (CT) for recurrent major depressive disorder (MDD) hypothesized to be lower risk show significantly less relapse or recurrence than treated higher risk counterparts across 32 months. Method: Outpatients (N = 523), aged 18-70, with recurrent MDD received 12-14 weeks of CT. The last 7 consecutive scores from the Hamilton Rating Scale for Depression (HRSD-17) were used to stratify or define responders (n = 290) into lower (7 HRSD-17 scores of less than or equal to 6; n = 49; 17%) and higher risk (n = 241; 83%). The lower risk patients entered the 32-month follow-up. Higher risk patients were randomized to 8 months of continuation-phase CT or clinical management plus double-blind fluoxetine or pill placebo, with a 24-month follow-up. Results: Lower risk patients were significantly less likely to relapse over the first 8 months compared to higher risk patients (Kaplan-Meier [KM] estimates; i.e., 4.9% = lower risk; 22.1% = higher risk; log-rank chi(2) = 6.83, p = .009). This increased risk was attenuated, but not completely neutralized, by active continuation-phase therapy. Over the subsequent 24 months, the lower and higher risk groups did not differ in relapse or recurrence risk. Conclusions: Rapid and sustained acute-phase CT remission identifies responders who do not require continuation-phase treatment to prevent relapse (i.e., return of an index episode). To prevent recurrence (i.e., new episodes), however, strategic allocation and more frequent "dosing" of CT and/or targeted maintenance-phase treatments may be required. Longitudinal follow-up is recommended. C1 [Jarrett, Robin B.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. [Minhajuddin, Abu] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. [Vittengl, Jeffrey R.] Truman State Univ, Dept Psychol, Kirksville, MO USA. [Clark, Lee Anna] Univ Notre Dame, Dept Psychol, Notre Dame, IN 46556 USA. [Thase, Michael E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Jarrett, RB (reprint author), Univ Texas SW Med Ctr Dallas, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. EM robin.jarrett@utsouthwestern.edu FU Alkermes; Assurerx; AstraZeneca; Avenir; Eli Lilly and Company; Forest Laboratories; Janssen/Johnson Johnson; Otsuka; Roche; Agency for Healthcare Research and Quality; National Institute of Mental Health (NIMH); NIMH [K24 MH001571, R01 MH058397, R01 MH069619, R01 MH058356, R01 MH069618] FX During the past 3 years, Michael E. Thase has consulted with and/or served on advisory boards for Advir, Alkermes, Allergan, AstraZeneca, Avenir, Bristol-Myers Squibb Company, Cerecor, Cerenex, Eli Lilly and Company, Forest Laboratories, Janssen Pharmaceutica, Johnson & Johnson, Lundbeck, MedAvante, Merck, Moksha8, Naurex, Neuronetics, Novartis, Otsuka, Nestle (formerly Pamlab), Pfizer Pharmaceuticals, Roche, Shire, Sunovion, Takeda, and Teva. During this time, he has received grant support from Alkermes, Assurerx, AstraZeneca, Avenir, Eli Lilly and Company, Forest Laboratories, Janssen/Johnson & Johnson, Otsuka, and Roche, as well as funding from the Agency for Healthcare Research and Quality and the National Institute of Mental Health (NIMH). He has equity holdings for MedAvante, Inc., and has received royalties from American Psychiatric Publishing, Inc. (APPI), Guilford Publications, Herald House, and W. W. Norton & Company, Inc. Two books currently promoted by the APPI specifically pertain to cognitive therapy. Michael E. Thase also discloses that his spouse is an employee of Peloton Advantage, which does business with several pharmaceutical companies that market medications used to treat depression. Robin B. Jarrett's medical center collects the payments from the cognitive therapy she provides to patients. Jarrett is a paid consultant to the NIMH and the National Institutes of Health (NIH). Robin B. Jarrett and Jeffrey R. Vittengl are paid reviewers for UpToDate.; This report was supported by Grants K24 MH001571, R01 MH058397, and R01 MH069619 (to Robin B. Jarrett) and R01 MH058356 and R01 MH069618 (to Michael E. Thase) from the NIMH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIMH or the NIH. We also wish to acknowledge the unrestricted support of Eli Lilly and Company, which provided fluoxetine and matched pill placebo for the first 6 years of the study. Thereafter, study materials were purchased and prepared to appear identical for both sites by the pharmacy at The University of Texas Southwestern Medical Center. We are grateful to our patients, research teams, and colleagues at The University of Texas Southwestern Medical Center, the University of Pittsburgh, and the University of Pennsylvania who made this trial possible. We appreciate the assistance of Lauren Singer, M. S. and Joanne Sanders, M. S. for their research support. NR 47 TC 1 Z9 1 U1 8 U2 11 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X EI 1939-2117 J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD APR PY 2016 VL 84 IS 4 BP 365 EP 376 DI 10.1037/ccp0000069 PG 12 WC Psychology, Clinical SC Psychology GA DH8PP UT WOS:000373057100008 PM 26654211 ER PT J AU Lightner, AL Shannon, E Gibbons, MM Russell, MM AF Lightner, Amy L. Shannon, Evan Gibbons, Melinda Maggard Russell, Marcia M. TI Primary Gastrointestinal Non-Hodgkin's Lymphoma of the Small and Large Intestines: a Systematic Review SO JOURNAL OF GASTROINTESTINAL SURGERY LA English DT Review DE Lymphoma; Small intestine; Large intestine; Surgery; Outcomes ID B-CELL LYMPHOMA; PRIMARY COLONIC LYMPHOMA; FOLLICULAR LYMPHOMA; CLINICAL-FEATURES; CLINICOPATHOLOGICAL ANALYSIS; MALT LYMPHOMA; POPULATION; MANAGEMENT; RITUXIMAB; TRACT AB Primary gastrointestinal non-Hodgkin's lymphoma (PGINHL) of small and large intestines is a group of heterogeneous, rare malignancies. Optimal treatment practices remain undefined. A systematic review (2003-2015) was performed to assess tumor characteristics, treatment practices, and treatment outcomes of PGINHL of small and large intestines. Twenty-eight studies (1658 patients) were included; five focused on follicular lymphoma subtype. Of the non-follicular patients, 59.3 % presented with abdominal pain, 37.2 % were located in ileocecum, and 53.6 % were diffuse large B cell lymphoma subtype. The majority of patients (60.7 %) were treated with a combination of surgery and chemotherapy. Forty-three percent of studies concluded an overall survival benefit with surgery; none reported increased postoperative morbidity or mortality. Survival outcomes were not typically stratified by emergent versus elective surgery. Multivariate analysis within individual studies associated B cell lymphoma and ileocecum location with higher survival, while advanced stage and B symptoms were associated with poorer survival. Patients with asymptomatic follicular lymphoma had no progression with a watchful waiting approach. The majority of patients with non-follicular small and large intestinal PGINHLs are treated with both chemotherapy and surgery. Although surgery appears to be an important part of the treatment algorithm, definitive statements regarding its survival benefit remain limited due to lack of patient stratification based on timing and indication for surgery. C1 [Lightner, Amy L.; Gibbons, Melinda Maggard; Russell, Marcia M.] Univ Calif Los Angeles, Dept Surg, David Geffen Sch Med, 200 1st St SW Rochester, Los Angeles, MN 55905 USA. [Shannon, Evan] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. [Russell, Marcia M.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. RP Lightner, AL (reprint author), Univ Calif Los Angeles, Dept Surg, David Geffen Sch Med, 200 1st St SW Rochester, Los Angeles, MN 55905 USA. EM Lightner.amy@mayo.edu NR 57 TC 2 Z9 2 U1 2 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1091-255X EI 1873-4626 J9 J GASTROINTEST SURG JI J. Gastrointest. Surg. PD APR PY 2016 VL 20 IS 4 BP 827 EP 839 DI 10.1007/s11605-015-3052-4 PG 13 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA DI0BB UT WOS:000373158700021 PM 26676930 ER PT J AU Harris, AHS Chen, C Rubinsky, AD Hoggatt, KJ Neuman, M Vanneman, ME AF Harris, Alex H. S. Chen, Cheng Rubinsky, Anna D. Hoggatt, Katherine J. Neuman, Matthew Vanneman, Megan E. TI Are Improvements in Measured Performance Driven by Better Treatment or "Denominator Management"? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE quality measurement; measurement reactivity; performance contracts ID PREVENTING UNINTENDED CONSEQUENCES; QUALITY MEASUREMENT; REPORT CARDS; INFORMATION AB Process measures of healthcare quality are usually formulated as the number of patients who receive evidence-based treatment (numerator) divided by the number of patients in the target population (denominator). When the systems being evaluated can influence which patients are included in the denominator, it is reasonable to wonder if improvements in measured quality are driven by expanding numerators or contracting denominators. In 2003, the US Department of Veteran Affairs (VA) based executive compensation in part on performance on a substance use disorder (SUD) continuity-of-care quality measure. The first goal of this study was to evaluate if implementing the measure in this way resulted in expected improvements in measured performance. The second goal was to examine if the proportion of patients with SUD who qualified for the denominator contracted after the quality measure was implemented, and to describe the facility-level variation in and correlates of denominator contraction or expansion. Using 40 quarters of data straddling the implementation of the performance measure, an interrupted time series design was used to evaluate changes in two outcomes. All veterans with an SUD diagnosis in all VA facilities from fiscal year 2000 to 2009. The two outcomes were 1) measured performance-patients retained/patients qualified and 2) denominator prevalence-patients qualified/patients with SUD program contact. Measured performance improved over time (P < 0.001). Notably, the proportion of patients with SUD program contact who qualified for the denominator decreased more rapidly after the measure was implemented (p = 0.02). Facilities with higher pre-implementation denominator prevalence had steeper declines in denominator prevalence after implementation (p < 0.001). These results should motivate the development of measures that are less vulnerable to denominator management, and also the exploration of "shadow measures" to monitor and reduce undesirable denominator management. C1 [Harris, Alex H. S.; Chen, Cheng; Rubinsky, Anna D.; Neuman, Matthew; Vanneman, Megan E.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd, Menlo Pk, CA 94025 USA. [Hoggatt, Katherine J.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Hoggatt, Katherine J.] Univ Calif Los Angeles, Los Angeles, CA USA. [Vanneman, Megan E.] Stanford Univ, Ctr Hlth Policy Primary Care & Outcomes Res, Sch Med, Stanford, CA 94305 USA. RP Harris, AHS (reprint author), VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd, Menlo Pk, CA 94025 USA. EM Alexander.Harris2@va.gov FU VA Health Services Research and Development (HSRD) Service [IIR 10-370-2]; VA Substance Use Disorder Quality Enhancement Research Initiative (SUD QUERI) [SUDQ-LIP-1208, SUDQ-LIP-1314]; VA HSR&D/QUERI Career Development Award; VA HSR&D Postdoctoral Fellowship; VA HSR&D Research Career Scientist Award [RCS-14-232] FX This study was funded by the VA Health Services Research and Development (HSR&D) Service (IIR 10-370-2), VA Substance Use Disorder Quality Enhancement Research Initiative (SUD QUERI; SUDQ-LIP-1208; SUDQ-LIP-1314), a VA HSR&D/QUERI Career Development Award to Dr. Hoggatt, a VA HSR&D Postdoctoral Fellowship to Dr. Vanneman, and a VA HSR&D Research Career Scientist Award (RCS-14-232) to Dr. Harris. The views expressed herein are not necessarily those of the Department of Veterans Affairs. NR 21 TC 2 Z9 2 U1 3 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2016 VL 31 SU 1 BP 21 EP 27 DI 10.1007/s11606-015-3558-1 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DI0BN UT WOS:000373159900006 PM 26951270 ER PT J AU Farmer, MM Rubenstein, LV Sherbourne, CD Huynh, A Chu, K Lam, CA Fickel, JJ Lee, ML Metzger, ME Verchinina, L Post, EP Chaney, EF AF Farmer, Melissa M. Rubenstein, Lisa V. Sherbourne, Cathy D. Huynh, Alexis Chu, Karen Lam, Christine A. Fickel, Jacqueline J. Lee, Martin L. Metzger, Maureen E. Verchinina, Lilia Post, Edward P. Chaney, Edmund F. TI Depression Quality of Care: Measuring Quality over Time Using VA Electronic Medical Record Data SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE performance measurement; depression; Veterans; measurement; quality assessment ID RANDOMIZED CONTROLLED-TRIAL; COLLABORATIVE CARE; PERFORMANCE-MEASURES; CHRONIC DISEASE; MENTAL-HEALTH; IMPROVEMENT; OUTCOMES; IMPACT AB The Veterans Health Administration (VA) has invested substantially in evidence-based mental health care. Yet no electronic performance measures for assessing the level at which the population of Veterans with depression receive appropriate care have proven robust enough to support rigorous evaluation of the VA's depression initiatives. Our objectives were to develop prototype longitudinal electronic population-based measures of depression care quality, validate the measures using expert panel judgment by VA and non-VA experts, and examine detection, follow-up and treatment rates over a decade (2000-2010). We describe our development methodology and the challenges to creating measures that capture the longitudinal course of clinical care from detection to treatment. Data come from the National Patient Care Database and Pharmacy Benefits Management Database for primary care patients from 1999 to 2011, from nine Veteran Integrated Service Networks. We developed four population-based quality metrics for depression care that incorporate a 6-month look back and 1-year follow-up: detection of a new episode of depression, 84 and 180 day follow-up, and minimum appropriate treatment 1-year post detection. Expert panel techniques were used to evaluate the measure development methodology and results. Key challenges to creating valid longitudinal measures are discussed. Over the decade, the rates for detection of new episodes of depression remained stable at 7-8 %. Follow-up at 84 and 180 days were 37 % and 45 % in 2000 and increased to 56 % and 63 % by 2010. Minimum appropriate treatment remained relatively stable over the decade (82-84 %). The development of valid longitudinal, population-based quality measures for depression care is a complex process with numerous challenges. If the full spectrum of care from detection to follow-up and treatment is not captured, performance measures could actually mask the clinical areas in need of quality improvement efforts. C1 [Farmer, Melissa M.; Rubenstein, Lisa V.; Huynh, Alexis; Chu, Karen; Lam, Christine A.; Fickel, Jacqueline J.; Lee, Martin L.] VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implementat, 16111 Plummer St 152, Sepulveda, CA 91343 USA. [Rubenstein, Lisa V.; Sherbourne, Cathy D.] RAND Corp, Santa Monica, CA USA. [Rubenstein, Lisa V.; Lee, Martin L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Rubenstein, Lisa V.; Lee, Martin L.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA. [Metzger, Maureen E.; Verchinina, Lilia; Post, Edward P.] HSR&D Ctr Clin Management Res, VA Ann Arbor, Ann Arbor, MI USA. [Post, Edward P.] Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA. [Chaney, Edmund F.] Univ Washington, Sch Med, Seattle, WA 98195 USA. RP Farmer, MM (reprint author), VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implementat, 16111 Plummer St 152, Sepulveda, CA 91343 USA. EM Melissa.Farmer@va.gov FU VA Health Services Research Development [IIR 11-326] FX Funding for this research was supported by a grant from VA Health Services Research & Development (Project #IIR 11-326; PI: Farmer). We would like to acknowledge the expert panelists for their contribution as well as Britney Chow, MPH and Ismelda Canelo, MPA for administrative support. NR 33 TC 3 Z9 3 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2016 VL 31 SU 1 BP 36 EP 45 DI 10.1007/s11606-015-3563-4 PG 10 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DI0BN UT WOS:000373159900008 PM 26951274 ER PT J AU Saini, SD Powell, AA Dominitz, JA Fisher, DA Francis, J Kinsinger, L Pittman, KS Schoenfeld, P Moser, SE Vijan, S Kerr, EA AF Saini, Sameer D. Powell, Adam A. Dominitz, Jason A. Fisher, Deborah A. Francis, Joseph Kinsinger, Linda Pittman, Kathleen S. Schoenfeld, Philip Moser, Stephanie E. Vijan, Sandeep Kerr, Eve A. TI Developing and Testing an Electronic Measure of Screening Colonoscopy Overuse in a Large Integrated Healthcare System SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE performance measurement; colorectal cancer; screening; health services research ID SOCIETY TASK-FORCE; COLORECTAL-CANCER; MEDICARE POPULATION; QUALITY MEASURES; GUIDELINES AB Most existing performance measures focus on underuse of care, but there is growing interest in identifying and reducing overuse. We aimed to develop a valid and reliable electronic performance measure of overuse of screening colonoscopy in the Veterans Affairs Health Care System (VA), and to quantify overuse in VA. This was a cross-sectional study with multiple cross-sections. U.S. Veterans who underwent screening colonoscopy between 2011 and 2013. Overuse of screening colonoscopy, using a validated electronic measure developed by an expert workgroup. Compared to results obtained from manual record review, the electronic measure was highly specific (97 %) for overuse, but not sensitive (20 %). After exclusion of diagnostic and high-risk screening or surveillance procedures, the validated electronic measure identified 88,754 average-risk screening colonoscopies performed in VA during 2013. Of these, 20,530 (23 %) met the definition for probable (17 %) or possible (6 %) overuse. Substantial variation in colonoscopy overuse was noted between Veterans Integrated Care Networks (VISNs) and between facilities, with a nearly twofold difference between the maximum and minimum rates of overuse at the VISN level and a nearly eightfold difference at the facility level. Overuse at the VISN and facility level was relatively stable over time. Overuse of screening colonoscopy can be measured reliably and with high specificity using electronic data, and is common in a large integrated healthcare system. Overuse measures, such as those we have specified through a consensus workgroup process, could be combined with underuse measures to improve the appropriateness of colorectal cancer screening. C1 [Saini, Sameer D.; Schoenfeld, Philip; Moser, Stephanie E.; Vijan, Sandeep; Kerr, Eve A.] Vet Affairs Ctr Clin Management Res CCMR, 2215 Fuller Rd,111D, Ann Arbor, MI 48105 USA. [Saini, Sameer D.; Schoenfeld, Philip; Vijan, Sandeep; Kerr, Eve A.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Saini, Sameer D.; Schoenfeld, Philip; Vijan, Sandeep; Kerr, Eve A.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA. [Powell, Adam A.] Minneapolis VA HealthCare Syst, CCDOR, Minneapolis, MN USA. [Powell, Adam A.] Anthem Inc, Minneapolis, MN USA. [Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Fisher, Deborah A.] Durham Vet Affairs Med Ctr, Durham, NC USA. [Fisher, Deborah A.] Duke Univ, Dept Med, Durham, NC USA. [Francis, Joseph] VHA Off Analyt & Business Intelligence, Washington, DC USA. [Kinsinger, Linda; Pittman, Kathleen S.] VHA Natl Ctr Hlth Promot & Dis Prevent, Durham, NC USA. [Vijan, Sandeep] Univ Michigan, Dept Anesthesiol, Ann Arbor, MI 48109 USA. RP Saini, SD (reprint author), Vet Affairs Ctr Clin Management Res CCMR, 2215 Fuller Rd,111D, Ann Arbor, MI 48105 USA. EM sdsaini@umich.edu FU VA Health Services Research and Development [CDA 09-213-2, RRP 12-184]; Veterans Health Administration (VHA) Office of Informatics and Analytics (OIA) FX This work was funded by VA Health Services Research and Development (CDA 09-213-2 and RRP 12-184). Partial funding for this work was provided by the Veterans Health Administration (VHA) Office of Informatics and Analytics (OIA). These funding agencies had no role in the design and conduct of the study. VHA OIA reviewed the manuscript prior to submission. The opinions expressed in this paper are of the authors and do not necessarily reflect those of the Department of Veterans Affairs. NR 22 TC 2 Z9 2 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2016 VL 31 SU 1 BP 53 EP 60 DI 10.1007/s11606-015-3569-y PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DI0BN UT WOS:000373159900010 PM 26951277 ER PT J AU Kondo, KK Damberg, CL Mendelson, A Motu'apuaka, M Freeman, M O'Neil, M Relevo, R Low, A Kansagara, D AF Kondo, Karli K. Damberg, Cheryl L. Mendelson, Aaron Motu'apuaka, Makalapua Freeman, Michele O'Neil, Maya Relevo, Rose Low, Allison Kansagara, Devan TI Implementation Processes and Pay for Performance in Healthcare: A Systematic Review SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Review DE pay for performance; financial incentives; implementation; performance metrics; systematic review ID FOR-PERFORMANCE; OUTCOMES-FRAMEWORK; GENERAL PRACTICES; DIABETES CARE; PRACTICE SIZE; QUALITY; PROGRAM; INCENTIVES; IMPACT; CONTRACT AB Over the last decade, various pay-for-performance (P4P) programs have been implemented to improve quality in health systems, including the VHA. P4P programs are complex, and their effects may vary by design, context, and other implementation processes. We conducted a systematic review and key informant (KI) interviews to better understand the implementation factors that modify the effectiveness of P4P. We searched PubMed, PsycINFO, and CINAHL through April 2014, and reviewed reference lists. We included trials and observational studies of P4P implementation. Two investigators abstracted data and assessed study quality. We interviewed P4P researchers to gain further insight. Among 1363 titles and abstracts, we selected 509 for full-text review, and included 41 primary studies. Of these 41 studies, 33 examined P4P programs in ambulatory settings, 7 targeted hospitals, and 1 study applied to nursing homes. Related to implementation, 13 studies examined program design, 8 examined implementation processes, 6 the outer setting, 18 the inner setting, and 5 provider characteristics. Results suggest the importance of considering underlying payment models and using statistically stringent methods of composite measure development, and ensuring that high-quality care will be maintained after incentive removal. We found no conclusive evidence that provider or practice characteristics relate to P4P effectiveness. Interviews with 14 KIs supported limited evidence that effective P4P program measures should be aligned with organizational goals, that incentive structures should be carefully considered, and that factors such as a strong infrastructure and public reporting may have a large influence. There is limited evidence from which to draw firm conclusions related to P4P implementation. Findings from studies and KI interviews suggest that P4P programs should undergo regular evaluation and should target areas of poor performance. Additionally, measures and incentives should align with organizational priorities, and programs should allow for changes over time in response to data and provider input. C1 [Kondo, Karli K.; Motu'apuaka, Makalapua; Freeman, Michele; O'Neil, Maya; Relevo, Rose; Low, Allison; Kansagara, Devan] Evidence Based Synth Program, Portland Vet Affairs Med Ctr, Mailcode RD71,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. [Damberg, Cheryl L.] RAND Corp, Santa Monica, CA USA. [Kondo, Karli K.; Mendelson, Aaron; O'Neil, Maya; Kansagara, Devan] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Kondo, KK (reprint author), Evidence Based Synth Program, Portland Vet Affairs Med Ctr, Mailcode RD71,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM karli.kondo@va.gov RI haron, suhaila/E-9360-2017 OI Low, Allison/0000-0003-2088-2429 FU U.S. Department of Veterans Affairs, Veterans Health Administration (VHA) ESP [05-225] FX This project was funded by the U.S. Department of Veterans Affairs, Veterans Health Administration (VHA) ESP Project #05-225. NR 49 TC 4 Z9 4 U1 11 U2 22 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2016 VL 31 SU 1 BP 61 EP 69 DI 10.1007/s11606-015-3567-0 PG 9 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DI0BN UT WOS:000373159900011 PM 26951276 ER PT J AU Oslin, DW Lynch, KG Maisto, SA Lantinga, LJ Mckay, JR Possemato, K Ingram, E Wierzbicki, M AF Oslin, David W. Lynch, Kevin G. Maisto, Stephen A. Lantinga, Larry J. McKay, James R. Possemato, Kyle Ingram, Erin Wierzbicki, Michael TI A Randomized Clinical Trial of Alcohol Care Management Delivered in Department of Veterans Affairs Primary Care Clinics Versus Specialty Addiction Treatment (vol 29, pg 162, 2014) SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Correction C1 [Oslin, David W.; McKay, James R.; Ingram, Erin] Univ Penn, Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. [Oslin, David W.; Lynch, Kevin G.; McKay, James R.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Maisto, Stephen A.; Lantinga, Larry J.; Possemato, Kyle] Syracuse Univ, Dept Psychol, Syracuse, NY USA. [Maisto, Stephen A.; Lantinga, Larry J.; Possemato, Kyle] VISN2, Dept Vet Affairs, Ctr Integrated Healthcare, Syracuse, NY USA. [Wierzbicki, Michael] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. RP Oslin, DW (reprint author), Univ Penn, Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA 19104 USA.; Oslin, DW (reprint author), Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2016 VL 31 IS 4 BP 449 EP 449 DI 10.1007/s11606-015-3419-y PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DI0BR UT WOS:000373160300023 PM 26055225 ER PT J AU Ghosh, A Leahy, KP Singhal, S Einhorn, E Howlett, P Cohen, NA Mirza, N AF Ghosh, A. Leahy, K. P. Singhal, S. Einhorn, E. Howlett, P. Cohen, N. A. Mirza, N. TI A murine model of subglottic granulation SO JOURNAL OF LARYNGOLOGY AND OTOLOGY LA English DT Article DE Subglottic Stenosis, Acquired; Airway Obstruction; Granulation Tissue; Animal Model ID RABBIT MODEL; STENOSIS; INJURY AB Objective: This study aimed to develop a functional model of subglottic stenosis by inducing direct airway irritation in transplanted mouse laryngotracheal complexes. Methods: Laryngotracheal complexes from C57BL/6 mice were harvested and divided into three groups: uninjured, mechanically injured and chemically injured. Donor laryngotracheal complexes from each group were placed in dorsal subcutaneous pockets of recipient mice. Each week, the transplanted laryngotracheal complexes were harvested, and tissues were fixed, sectioned, and stained with haematoxylin and eosin. Representative slides were reviewed by a blinded pathologist, to determine the formation of granulation tissue, and graded as to the degree of granulation formation. Results: Direct airway irritation induced granulation tissue formation under the disrupted epithelium of airway mucosa; this was seen as early as two weeks after chemical injury. Conclusion: Results indicate that granulation tissue formation in a murine model may be an efficient tool for investigating the development and treatment of subglottic stenosis. C1 [Ghosh, A.; Leahy, K. P.; Cohen, N. A.; Mirza, N.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, 3400 Spruce St,5 Ravdin, Philadelphia, PA 19104 USA. [Singhal, S.] Univ Penn, Dept Thorac Surg, 3400 Spruce St,5 Ravdin, Philadelphia, PA 19104 USA. [Einhorn, E.; Howlett, P.] Philadelphia Vet Affairs Med Ctr, Dept Pathol, Philadelphia, PA USA. RP Ghosh, A (reprint author), Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, 3400 Spruce St,5 Ravdin, Philadelphia, PA 19104 USA. EM ankona.ghosh@uphs.upenn.edu OI Cohen, Noam/0000-0002-9462-3932 NR 9 TC 0 Z9 0 U1 0 U2 1 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 0022-2151 EI 1748-5460 J9 J LARYNGOL OTOL JI J. Laryngol. Otol. PD APR PY 2016 VL 130 IS 4 BP 380 EP 387 DI 10.1017/S0022215116000049 PG 8 WC Otorhinolaryngology SC Otorhinolaryngology GA DH9PJ UT WOS:000373127800013 PM 26991876 ER PT J AU Schreibeis-Baum, HC Xenakis, LE Chen, EK Hanson, M Ahluwalia, S Ryan, G Lorenz, KA AF Schreibeis-Baum, Hannah C. Xenakis, Lea E. Chen, Emily K. Hanson, Mark Ahluwalia, Sangeeta Ryan, Gery Lorenz, Karl A. TI A Qualitative Inquiry on Palliative and End-of-Life Care Policy Reform SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID TOBACCO CONTROL; HEALTH; OPPORTUNITIES; SMOKING AB Background: There is increasing recognition of the role of palliative care (PC) in health care delivery, but priorities for state and federal policy to support PC are unclear and have sometimes engendered controversy. We canvassed experts to shed light on general recommendations for improving PC. Objective: The study objective was to identify challenges to and potential solutions for promoting, adopting, and implementing policies that would support or expand high-quality PC. Methods: Semistructured telephone interviews were used to solicit challenges to and potential solutions for promoting, adopting, and implementing policies that would support or expand high-quality PC. Interviews were analyzed using qualitative methods. The subjects were a purposive sample of 22 professional state and federal-level advocates who work in the field of aging and/or PC. Results: Respondents identified four central challenges to advancing PC policies: (1) knowledge about PC in the health care setting, (2) cultural beliefs about PC, (3) payment/reimbursement for PC services, and (4) public understanding of PC. Of the wide range of solutions proposed by respondents, we present the eight most frequently discussed solutions to these challenges targeted towards policymakers, health care professionals, research, and the general public. Respondents' understanding of the relationships between problems and solutions revealed many dependencies and interconnectedness. Conclusions: A qualitative approach of querying experts identified multiple significant challenges to improving and expanding PC, most of which are acknowledged in existing consensus statements. Proposed solutions were more numerous and diffuse than descriptions of the problems, signaling the need for further consensus building around actionable policy, and better understanding of how to advance a PC policy agenda. C1 [Schreibeis-Baum, Hannah C.] VA Greater Angeles, Ctr Healthcare Innovat Implementat & Policy, Hlth Serv Res & Dev, Los Angeles, CA USA. [Xenakis, Lea E.; Chen, Emily K.; Hanson, Mark; Ahluwalia, Sangeeta; Ryan, Gery; Lorenz, Karl A.] RAND Corp, RAND Hlth, Santa Monica, CA USA. [Lorenz, Karl A.] VA Palo Alto, Ctr Innovat Implementat Ci2i, Palo Alto, CA USA. [Lorenz, Karl A.] Stanford Univ, Sch Med, Sect Palliat Med, Stanford, CA 94305 USA. RP Lorenz, KA (reprint author), Stanford Univ, Sch Med, Div Gen Med Disciplines, Sch Med, Off Bldg,1265 Welch Rd,Room X3c46,MC 5411, Stanford, CA 94305 USA. EM kalorenz@stanford.edu FU National Institute of Nursing Research [NINR R01NR013372]; California Healthcare Foundation [CHCF 17173] FX The Trajectories and Palliation Study (TAPS) was funded by a grant from the National Institute of Nursing Research (NINR R01NR013372), and the TAPS Policy Project was funded by the California Healthcare Foundation (CHCF 17173). NR 22 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD APR 1 PY 2016 VL 19 IS 4 BP 400 EP 407 DI 10.1089/jpm.2015.0296 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DI1DZ UT WOS:000373237500013 PM 27035522 ER PT J AU Sadeghi, B Walling, AM Romano, PS Ahluwalia, SC Ong, MK AF Sadeghi, Bahman Walling, Anne M. Romano, Patrick S. Ahluwalia, Sangeeta C. Ong, Michael K. TI A Hospital-Based Advance Care Planning Intervention for Patients with Heart Failure: A Feasibility Study SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; LIFE-SUSTAINING TREATMENT; DECISION-MAKING; PREFERENCES; ADULTS AB Background: Early discussions about advance care planning (ACP) have been associated with improved patient and caregiver outcomes for patients with serious illness. Many patients with heart failure (HF) may benefit from more timely ACP, in part due to the unpredictable trajectory of the disease. Objectives: The purpose of this study was to evaluate the feasibility of implementing a multiple-component hospital-based intervention on completion of ACP forms among HF patients. Methods: A brief hospital-based ACP intervention was led by a nonclinician health educator that included (1) an educational video about shared decision making and (2) a protocol to engage HF providers in patients' ACP decision making after the hospitalization. We surveyed patients regarding attitudes toward the ACP intervention and studied completion rates of advance directives (ADs) or physician orders for life sustaining treatment (POLST) forms six months following discharge. Results: The educational video component of this intervention was considered helpful by 92% of participants, and 70% said they were more likely to talk with their physician about their end-of-life preferences after watching the video and interacting with the health educator. Of 37 participants, 49% had evidence of completion of an AD or POLST in their medical records six months after the index hospitalization compared to 32% before the intervention. The number of patients having a signed scanned POLST form increased from 10 (27%) before the intervention to 16 (43%) six months after the intervention (p = 0.03). Conclusions: A hospital-based ACP intervention using nonclinician health educators is feasible to implement and has the potential to facilitate the ACP process. C1 [Sadeghi, Bahman; Walling, Anne M.; Ong, Michael K.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, 10940 Wilshire Blvd, Los Angeles, CA 90024 USA. [Walling, Anne M.; Ong, Michael K.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Romano, Patrick S.] Univ Calif Davis, Dept Internal Med, Davis, CA 95616 USA. [Romano, Patrick S.] Univ Calif Davis, Dept Pediat, Davis, CA 95616 USA. [Ahluwalia, Sangeeta C.] RAND Corp, Santa Monica, CA USA. [Ahluwalia, Sangeeta C.] Univ Calif Los Angeles, UCLA Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90024 USA. RP Ong, MK (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, 10940 Wilshire Blvd, Los Angeles, CA 90024 USA. EM mong@mednet.ucla.edu FU California Healthcare Foundation [15666]; Agency for Healthcare Research and Quality [R01 HS019311]; NIH National Center for Advancing Translational Science UCLA Clinical and Translational Science Institute (CTSI) [UL1TR000124]; NIH Loan Repayment Program; Foundation for Informed Medical Decision Making FX This study was supported by a grant from the California Healthcare Foundation (#15666). The authors would like to acknowledge the work of Kymberly Aoki, Jennifer Matsui, Wern Ong, and Matt Tiacharoen at the UCLA Medical Center and Mauricio Rodriguez and Meghan Soulsby at the UCD Medical Center. We acknowledge the support we received for the patient screening process from the BEAT-HF study funded by a grant from the Agency for Healthcare Research and Quality (#R01 HS019311). Dr. Walling was also supported by the NIH National Center for Advancing Translational Science UCLA Clinical and Translational Science Institute (CTSI) (#UL1TR000124) and the NIH Loan Repayment Program. We appreciate the support from the Foundation for Informed Medical Decision Making with regards to the videos used in this study. NR 15 TC 1 Z9 1 U1 3 U2 7 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD APR 1 PY 2016 VL 19 IS 4 BP 451 EP 455 DI 10.1089/jpm.2015.0269 PG 5 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DI1DZ UT WOS:000373237500019 PM 26862682 ER PT J AU Bekelman, DB Rabin, BA Nowels, CT Sahay, A Heidenreich, PA Fischer, SM Main, DS AF Bekelman, David B. Rabin, Borsika A. Nowels, Carolyn T. Sahay, Anju Heidenreich, Paul A. Fischer, Stacy M. Main, Deborah S. TI Barriers and Facilitators to Scaling Up Outpatient Palliative Care SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID CHRONIC HEART-FAILURE; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; IMPLEMENTATION SCIENCE; INTERVENTION; CONSULTATION; PROGRAMS; OUTCOMES; FRAMEWORK; ADOPTION AB Background: The Institute of Medicine recommends people with serious advanced illness have access to skilled palliative care. However, the predominant delivery model of nonhospice palliative care is inpatient, consultative care focused on the end of life, with a small specialist palliative care workforce. Objective: The study objective was to understand organizational factors that could influence the adoption and scale-up of outpatient palliative care in chronic advanced illness, using the example of heart failure. Methods: This was a cross-sectional qualitative study. Participants were 17 health care providers and local, regional, and national health system leaders from the Veterans Health Administration (VHA) who were considering whether and how to adopt and sustain outpatient palliative care. Individual interviews using semistructured questions assessed domains of the Consolidated Framework for Implementation Science. Results: Most providers and leaders perceived outpatient palliative care as high priority in the VHA given its patient-centeredness and potential to decrease health care use and costs associated with conditions like heart failure. They also supported a collaborative care team model of outpatient palliative care delivery where a palliative care specialist collaborates with medical nurses and social workers. They reported lack of performance measures/incentives for patient-centered care processes and outcomes as a potential barrier to implementation. Features of outpatient palliative care viewed as important for successful adoption and scale-up included coordination and communication with other providers, ease of integration into existing programs, and evidence of improving quality of care while not substantially increasing overall health care costs. Conclusion: Incentives such as performance measures and collaboration with local VHA providers and leaders could improve adoption and scale-up of outpatient palliative care. C1 [Bekelman, David B.] Eastern Colorado Hlth Care Syst, Dept Vet Affairs, Denver, CO USA. [Bekelman, David B.; Nowels, Carolyn T.; Fischer, Stacy M.] Univ Colorado, Sch Med, Dept Med, Anschutz Med Campus, Aurora, CO USA. [Rabin, Borsika A.] Univ Colorado, Sch Med, Dept Family Med, Anschutz Med Campus, Aurora, CO USA. [Rabin, Borsika A.] Univ Colorado, Sch Med, Colorado Hlth Outcomes Program, Anschutz Med Campus, Aurora, CO USA. [Sahay, Anju; Heidenreich, Paul A.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Main, Deborah S.] Univ Colorado, Dept Hlth & Behav Sci, Denver, CO 80202 USA. RP Bekelman, DB (reprint author), Denver VA Med Ctr, 1055 Clermont St,Res 151, Denver, CO 80220 USA. EM david.bekelman@va.gov FU VA HSR&D Quality Enhancement Research Initiative (QUERI) Rapid Response Project [11-239] FX This study was funded by VA HSR&D Quality Enhancement Research Initiative (QUERI) Rapid Response Project #11-239. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 28 TC 2 Z9 2 U1 5 U2 10 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD APR 1 PY 2016 VL 19 IS 4 BP 456 EP 459 DI 10.1089/jpm.2015.0280 PG 4 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DI1DZ UT WOS:000373237500020 PM 26974489 ER PT J AU Kougias, P Tiwari, V Berger, DH AF Kougias, Panos Tiwari, Vikram Berger, David H. TI Use of simulation to assess a statistically driven surgical scheduling system SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE Simulation; Statistical modeling; Effectiveness ID OPERATING-ROOM EFFICIENCY; TIMES; EXPENDITURES; VARIABILITY; PREDICTION; SURGERY; THEATER; LENGTH; MODEL AB Background: To maximize operating room (OR) utilization, better estimates of case duration lengths are needed. We used computerized simulation to determine whether scheduling OR cases using a statistically driven system that incorporates patient and surgery-specific factors in the process of case duration prediction improves OR throughput and utilization. Methods: We modeled surgical and anesthetic length of vascular surgical procedures as a function of patient and operative characteristics using a multivariate linear regression approach (Predictive Modeling System [PMS]). Mean historical operative time per surgeon (HMS) and mean anesthetic time were also calculated for each procedure type. A computerized simulation of scheduling in a single OR performing vascular operations was then created using either the PMS or the HMS. Results: Compared to HMS, scheduling the operating room using the PMS increased throughput by a minimum of 15% (99.8% cumulative probability, P < 0.001). The PMS was slightly more likely to lead to overtime (mean 13% versus 11% of operative days during a calendar year, P < 0.001). However, the overtime lasted longer in the HMS group (mean 140 versus 95 min per day of overtime, P < 0.001). PMS was associated with lower OR underutilization rate (mean 23% versus 34% of operative days, P < 0.001) and less lengthy OR underutilization (mean 120 versus 193 min per day of underutilization, P < 0.001). Conclusions: This computerized simulation demonstrates that using the PMS for scheduling in a single operating room increases throughput and other measures of surgical efficiency. Published by Elsevier Inc. C1 [Kougias, Panos; Berger, David H.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Kougias, Panos] Baylor Coll Med, Div Vasc Surg, Houston, TX 77030 USA. [Kougias, Panos; Berger, David H.] Ctr Innovat Qual Effectiveness & Safety, Houston, TX USA. [Tiwari, Vikram] Vanderbilt Univ, Dept Anesthesiol, 221 Kirkland Hall, Nashville, TN 37235 USA. [Berger, David H.] Baylor Coll Med, Dept Surg, Houston, TX 77030 USA. RP Kougias, P (reprint author), Houston VAMC, Michael E DeBakey Dept Surg, 2002 Holcombe Blvd OCL 112, Houston, TX 77030 USA. EM pkougias@bcm.edu NR 17 TC 2 Z9 2 U1 4 U2 8 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 EI 1095-8673 J9 J SURG RES JI J. Surg. Res. PD APR PY 2016 VL 201 IS 2 BP 306 EP 312 DI 10.1016/j.jss.2015.10.043 PG 7 WC Surgery SC Surgery GA DH8VS UT WOS:000373075600010 PM 27020812 ER PT J AU Friedlander, AH Chang, TI Aghazadehsanai, N Graves, LL AF Friedlander, Arthur H. Chang, Tina I. Aghazadehsanai, Nona Graves, Lindsay L. TI COST-EFFECTIVENESS OF ANTIBIOTIC PROPHYLAXIS SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Letter C1 [Friedlander, Arthur H.] Vet Affairs Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA USA. [Friedlander, Arthur H.] Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, Qual Assurance, Los Angeles, CA USA. [Friedlander, Arthur H.; Chang, Tina I.] Univ Calif Los Angeles, Sch Dent, Dept Oral & Maxillofacial Surg, Los Angeles, CA 90024 USA. [Chang, Tina I.] Vet Affairs Greater Los Angeles Healthcare Syst, Inpatient Oral & Maxillofacial Surg, Los Angeles, CA USA. [Aghazadehsanai, Nona; Graves, Lindsay L.] Vet Affairs Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Surg Sect, Dent Serv, Los Angeles, CA USA. RP Friedlander, AH (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA USA.; Friedlander, AH (reprint author), Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, Qual Assurance, Los Angeles, CA USA.; Friedlander, AH (reprint author), Univ Calif Los Angeles, Sch Dent, Dept Oral & Maxillofacial Surg, Los Angeles, CA 90024 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 EI 1943-4723 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD APR PY 2016 VL 147 IS 4 BP 229 EP 230 DI 10.1016/j.adaj.2016.02.004 PG 3 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA DH9LD UT WOS:000373116700003 PM 27017589 ER PT J AU Wrocklage, KM Schweinsburg, BC Krystal, JH Trejo, M Roy, A Weisser, V Moore, TM Southwick, SM Scott, JC AF Wrocklage, Kristen M. Schweinsburg, Brian C. Krystal, John H. Trejo, Marcia Roy, Alicia Weisser, Valerie Moore, Tyler M. Southwick, Steven M. Scott, J. Cobb TI Neuropsychological Functioning in Veterans with Posttraumatic Stress Disorder: Associations with Performance Validity, Comorbidities, and Functional Outcomes SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article DE Posttraumatic stress disorder; Neuropsychology; Cognitive abilities; Memory; Executive functions; Quality of life; Occupational functioning ID TRAUMATIC BRAIN-INJURY; TERM BENZODIAZEPINE USE; MEMORY PERFORMANCE; COMBAT EXPOSURE; VERBAL MEMORY; ARMY SOLDIERS; WAR VETERANS; FOLLOW-UP; PTSD; HEALTH AB Objectives: Numerous studies have shown that individuals with posttraumatic stress disorder (PTSD) display reduced performances on neuropsychological tests, although most prior research has not adequately accounted for comorbidities or performance validity concerns that are common in this population and could partially account for the observed neurocognitive findings. Moreover, few studies have examined the functional implications of neuropsychological results in PTSD. Methods: We examined neuropsychological functioning in 44 veterans with PTSD and 40 veteran trauma comparison (TC) participants with combat exposure and no PTSD. Results: After excluding four veterans with PTSD for performance validity concerns, multivariate analyses of variance by neurocognitive domain revealed significantly worse performance by the PTSD group in the domains of speed of information processing (p = .035) and executive functions (p = .017), but no group differences in attention/working memory, verbal/language functioning, visuoconstruction, or episodic memory. Group differences by PTSD status were still present after covarying for depression, a history of head injuries, and substance use disorders. Executive functioning performance was associated with poorer self-reported occupational functioning and physical health-related quality of life, while speed of information processing performance was associated with poorer physical health-related quality of life. Discussion: These results are generally consistent with a fronto-limbic conceptualization of PTSD-associated neuropsychological dysfunction and show that cognitive functioning may be associated with critical functional outcomes. Taken together, results suggest that consideration of neurocognitive functioning may enhance the clinical management of individuals with PTSD. C1 [Wrocklage, Kristen M.; Schweinsburg, Brian C.; Krystal, John H.; Trejo, Marcia; Roy, Alicia; Weisser, Valerie; Southwick, Steven M.] Natl Ctr PTSD, Clin Neurosci Div, West Haven, CT USA. [Wrocklage, Kristen M.; Schweinsburg, Brian C.; Krystal, John H.; Trejo, Marcia; Roy, Alicia; Weisser, Valerie; Southwick, Steven M.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Schweinsburg, Brian C.; Krystal, John H.; Roy, Alicia; Southwick, Steven M.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Krystal, John H.] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA. [Krystal, John H.] Yale New Haven Med Ctr, Psychiat Serv, 20 York St, New Haven, CT 06504 USA. [Moore, Tyler M.; Scott, J. Cobb] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Scott, J. Cobb] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN4, Philadelphia, PA 19104 USA. RP Scott, JC (reprint author), Philadelphia VA Med Ctr, MIRECC 116, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM scott1@upenn.edu FU Department of Veterans Affairs Career Development Award [IK2CX000772]; National Center for PTSD (NCPTSD); National Center for Advancing Translational Science [1UH2TR000960-01]; Department of Veterans Affairs (NCPTSD); National Institute on Alcohol Abuse and Alcoholism [P50AA12870, M01RR00125]; Yale Center for Clinical Investigation [UL1 RR024139] FX This work was supported by a Department of Veterans Affairs Career Development Award (IK2CX000772) to Dr. Scott, as well as the National Center for PTSD (NCPTSD). Dr. Krystal's participation was supported by the National Center for Advancing Translational Science (1UH2TR000960-01), the Department of Veterans Affairs (NCPTSD), the National Institute on Alcohol Abuse and Alcoholism (P50AA12870, M01RR00125), and the Yale Center for Clinical Investigation (UL1 RR024139). Portions of this research were presented at the 2014 Annual Meeting of the American Psychological Association (APA). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. The authors declare no conflicts of interest. NR 92 TC 5 Z9 5 U1 6 U2 12 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1355-6177 EI 1469-7661 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD APR PY 2016 VL 22 IS 4 BP 399 EP 411 DI 10.1017/S1355617716000059 PG 13 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA DI1ZK UT WOS:000373295300003 PM 26892753 ER PT J AU Sorensen, MD AF Sorensen, Mathew D. TI A Prospective Randomized Controlled Trial of the Efficacy of External Physical Vibration Lithecbole after Extracorporeal Shock Wave Lithotripsy for a Lower Pole Renal Stone Less Than 2 cm EDITORIAL COMMENT SO JOURNAL OF UROLOGY LA English DT Editorial Material C1 [Sorensen, Mathew D.] Univ Washington, Dept Urol, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Sorensen, MD (reprint author), Univ Washington, Dept Urol, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 EI 1527-3792 J9 J UROLOGY JI J. Urol. PD APR PY 2016 VL 195 IS 4 BP 970 EP 970 PN 1 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA DI3LW UT WOS:000373401200048 PM 26812396 ER PT J AU Kikuchi, S Kenagy, RD Gao, L Wight, TN Azuma, N Sobel, M Clowes, AW AF Kikuchi, Shinsuke Kenagy, Richard D. Gao, Lu Wight, Thomas N. Azuma, Nobuyoshi Sobel, Michael Clowes, Alexander W. TI Surgical marking pen dye inhibits saphenous vein cell proliferation and migration in saphenous vein graft tissue SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID LOWER-EXTREMITY BYPASS; SMOOTH-MUSCLE; INTIMAL HYPERPLASIA; RANDOMIZED-TRIAL; PROGENITOR CELLS; METHYLENE-BLUE; NEOINTIMA; INSITU; MYOFIBROBLASTS; APOPTOSIS AB Objective: Markers containing dyes such as crystal violet (CAS 548-62-9) are routinely used on the adventitia of vein bypass grafts to avoid twisting during placement. Because little is known about how these dyes affect vein graft healing and function, we determined the effect of crystal violet on cell migration and proliferation, which are responses to injury after grafting. Methods: Fresh human saphenous veins were obtained as residual specimens from leg bypass surgeries. Portions of the vein that had been surgically marked with crystal violet were analyzed separately from those that had no dye marking. In the laboratory, they were split into easily dissected inner and outer layers after removal of endothelium. This cleavage plane was within the circular muscle layer of the media. Cell migration from explants was measured daily as either (1) percentage of migration-positive explants, which exclusively measures migration, or (2) number of cells on the plastic surrounding each explant, which measures migration plus proliferation. Cell proliferation and apoptosis (Ki67 and TUNEL staining, respectively) were determined in dye-marked and unmarked areas of cultured vein rings. The dose-dependent effects of crystal violet were measured for cell migration from explants as well as for proliferation, migration, and death of cultured outer layer cells. Dye was extracted from explants with ethanol and quantified by spectrophotometry. Results: There was significantly less cell migration from visibly blue compared with unstained outer layer explants by both methods. There was no significant difference in migration from inner layer explants adjacent to blue-stained or unstained sections of vein because dye did not penetrate to the inner layer. Ki67 staining of vein in organ culture, which is a measure of proliferation, progressively increased up to 6 days in nonblue outer layer and was abolished in the blue outer layer. Evidence of apoptosis (TUNEL staining) was present throughout the wall and not different in blue-stained and unstained vein wall segments. Blue outer layer explants had 65.9 +/- 8.0 ng dye/explant compared with 2.1 +/- 1.3 for nonblue outer layer explants. Dye applied in vitro to either outer or inner layer explants dose dependently inhibited migration (IC50 similar to 10 ng/explant). The IC(50)s of crystal violet for outer layer cell proliferation and migration were 0.1 and 1.2 mg/mL, whereas the EC50 for death was between 1 and 10 mg/mL. Conclusions: Crystal violet inhibits venous cell migration and proliferation, indicating that alternative methods should be considered for marking vein grafts. C1 [Kikuchi, Shinsuke; Kenagy, Richard D.; Gao, Lu; Sobel, Michael; Clowes, Alexander W.] Univ Washington, Dept Surg, Seattle, WA 98195 USA. [Kikuchi, Shinsuke; Azuma, Nobuyoshi] Asahikawa Med Univ, Dept Vasc Surg, Asahikawa, Hokkaido, Japan. [Wight, Thomas N.] Virginia Mason, Benaroya Res Inst, Matrix Biol Program, Seattle, WA USA. [Sobel, Michael] VA Puget Sound Hlth Care Syst, Div Vasc Surg, Seattle, WA USA. [Sobel, Michael] Univ Washington, Seattle, WA 98195 USA. RP Kenagy, RD (reprint author), Univ Washington, Ctr Cardiovasc Biol, POB 358050,850 Republican St, Seattle, WA 98109 USA. EM rkenagy@u.washington.edu FU CSRD VA [I01 CX000712]; NHLBI NIH HHS [R41 HL106967, R01 HL030946, R01 HL30946] NR 34 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD APR PY 2016 VL 63 IS 4 BP 1044 EP 1050 DI 10.1016/j.jvs.2014.10.017 PG 7 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA DH7FR UT WOS:000372958200031 PM 25935273 ER PT J AU Bates, SE Fojo, T AF Bates, Susan E. Fojo, Tito TI New drug for pancreatic cancer highlights the dual effect of regulatory approvals SO NATURE REVIEWS CLINICAL ONCOLOGY LA English DT Editorial Material ID PACLITAXEL PLUS GEMCITABINE; FOLFIRINOX; TRIALS AB The recent FDA approval of MM-398 as a second-line treatment of metastatic pancreatic cancer, based on a 1.9-month overall survival benefit observed in the NAPOLI-1 trial, adds a new therapeutic option for this notoriously difficult-to-treat disease; however, by discouraging clinical trial enrolment, this approval might have negative consequences for the development of novel agents, which remain an essential unmet need. C1 [Bates, Susan E.; Fojo, Tito] Columbia Univ, Med Ctr, Dept Med, Div Hematol Oncol, Herbert Irving Pavil,9th Floor, New York, NY 10032 USA. [Bates, Susan E.; Fojo, Tito] James J Peters VA Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. RP Bates, SE (reprint author), Columbia Univ, Med Ctr, Dept Med, Div Hematol Oncol, Herbert Irving Pavil,9th Floor, New York, NY 10032 USA.; Bates, SE (reprint author), James J Peters VA Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM seb2227@cumc.columbia.edu NR 9 TC 0 Z9 0 U1 1 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-4774 EI 1759-4782 J9 NAT REV CLIN ONCOL JI Nat. Rev. Clin. Oncol. PD APR PY 2016 VL 13 IS 4 BP 205 EP 206 DI 10.1038/nrclinonc.2016.22 PG 2 WC Oncology SC Oncology GA DH4DF UT WOS:000372735000002 PM 26902963 ER PT J AU Banks, WA AF Banks, William A. TI From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery SO NATURE REVIEWS DRUG DISCOVERY LA English DT Review ID AMYLOID-BETA-PROTEIN; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MICROVASCULAR ENDOTHELIAL-CELLS; RECEPTOR-RELATED PROTEIN-1; CEREBRAL-ARTERY OCCLUSION; NECROSIS-FACTOR-ALPHA; SPINAL-CORD BARRIER; ALZHEIMERS-DISEASE AB One of the biggest challenges in the development of therapeutics for central nervous system (CNS) disorders is achieving sufficient blood-brain barrier (BBB) penetration. Research in the past few decades has revealed that the BBB is not only a substantial barrier for drug delivery to the CNS but also a complex, dynamic interface that adapts to the needs of the CNS, responds to physiological changes, and is affected by and can even promote disease. This complexity confounds simple strategies for drug delivery to the CNS, but provides a wealth of opportunities and approaches for drug development. Here, I review some of the most important areas that have recently redefined the BBB and discuss how they can be applied to the development of CNS therapeutics. C1 [Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA. [Banks, William A.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, 1660 S Columbian Way, Seattle, WA 98108 USA. RP Banks, WA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA.; Banks, WA (reprint author), Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, 1660 S Columbian Way, Seattle, WA 98108 USA. EM wabanks1@uw.edu FU US Department of Veterans Affairs; US National Institute on Aging [R01 AG046619] FX The author is supported by the US Department of Veterans Affairs and a grant from the US National Institute on Aging (grant R01 AG046619). NR 174 TC 20 Z9 20 U1 22 U2 54 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1474-1776 EI 1474-1784 J9 NAT REV DRUG DISCOV JI Nat. Rev. Drug Discov. PD APR PY 2016 VL 15 IS 4 BP 275 EP + DI 10.1038/nrd.2015.21 PG 18 WC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy SC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy GA DI0ZM UT WOS:000373225800017 PM 26794270 ER PT J AU McCarthy, MS Warren, M Roberts, PR AF McCarthy, Mary S. Warren, Malissa Roberts, Pamela R. TI Recent Critical Care Nutrition Trials and the Revised Guidelines: Do They Reconcile? SO NUTRITION IN CLINICAL PRACTICE LA English DT Editorial Material ID SUPPLEMENTAL PARENTERAL-NUTRITION; IMMUNE-MODULATING NUTRIENTS; OIL LIPID EMULSIONS; ILL PATIENT SOCIETY; ACUTE LUNG INJURY; CLINICAL-TRIAL; GASTROINTESTINAL SURGERY; ENTERAL NUTRITION; RANDOMIZED-TRIAL; NOSOCOMIAL INFECTIONS C1 [McCarthy, Mary S.] Madigan Army Med Ctr, Ctr Nursing Sci & Clin Inquiry, 9040 Jackson Ave, Tacoma, WA 98431 USA. [Warren, Malissa] Portland VA Med Ctr, Portland, OR USA. [Roberts, Pamela R.] Univ Oklahoma, Coll Med, Dept Anesthesiol, Oklahoma City, OK 73190 USA. RP McCarthy, MS (reprint author), Madigan Army Med Ctr, Ctr Nursing Sci & Clin Inquiry, 9040 Jackson Ave, Tacoma, WA 98431 USA. EM Mary.s.mccarthy1.civ@mail.mil NR 34 TC 1 Z9 1 U1 1 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0884-5336 EI 1941-2452 J9 NUTR CLIN PRACT JI Nutr. Clin. Pract. PD APR PY 2016 VL 31 IS 2 BP 150 EP 154 DI 10.1177/0884533616630301 PG 5 WC Nutrition & Dietetics SC Nutrition & Dietetics GA DH6LS UT WOS:000372902700002 PM 26915509 ER PT J AU Curtis, CS Busch, RA Crass, RL Webb, AP Kudsk, KA AF Curtis, Caitlin S. Busch, Rebecca A. Crass, Ryan L. Webb, Aaron P. Kudsk, Kenneth A. TI Use of Premixed Parenteral Nutrition During a Phosphate Shortage in a Non-Critically Ill Population SO NUTRITION IN CLINICAL PRACTICE LA English DT Article DE parenteral nutrition; nutritional support; dietary phosphorus; phosphates ID DRUG SHORTAGES; IMPACT AB Background: Drug shortages pose prescribing problems to clinicians. During fiscal year (FY) 2014, an acute shortage of intravenous potassium phosphate (K-Phos IV), a common supplement in parenteral nutrition (PN), prompted the use of premixed instead of individualized PN to conserve K-Phos IV. Here we quantify the K-Phos IV conserved by using premixed PN and the associated cost differences. Materials and Methods: Costs of preparing premixed PN vs individualized PN of equivalent composition were calculated for FY 2014 at a single-center tertiary care facility. Quantity and cost of K-Phos IV saved were calculated based on the number of premixed PN prescriptions. Costs for FY 2015 were projected based on drug costs from July 2014. Results: During FY 2014, prescribing premixed in lieu of individualized PN conserved 16,440 mmol K-Phos IV but increased the cost of PN by $4080.45. However, increases in K-Phos IV cost at the end of FY 2014 resulted in premixed PN as a relatively less expensive therapy than individualized PN for our institution. Cost savings of $7092.20 due to use of premixed PN is projected for FY 2015. Conclusions: Prescribing premixed PN conserves K-Phos IV during shortages, but it increased direct drug spending in non-critically ill patients at our institution during FY 2014. Persistent shortages can drive market costs of K-Phos IV, however, necessitating frequent reconsideration of resource utilization. C1 [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Veteran Adm Surg Serv, Madison, WI USA. [Curtis, Caitlin S.; Webb, Aaron P.] Univ Wisconsin Hosp & Clin, Dept Pharm, Madison, WI 53792 USA. [Busch, Rebecca A.; Kudsk, Kenneth A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI USA. [Crass, Ryan L.] Univ Wisconsin, Sch Pharm, 425 N Charter St, Madison, WI 53706 USA. RP Kudsk, KA (reprint author), G5 341 Clin Sci Ctr, 600 Highland Ave, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu FU Surgical Oncology Research Training Program [T32 CA090217]; William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin FX This material is the result of work supported with the resources and use of facilities at the William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States government. The project described was supported in part by the Surgical Oncology Research Training Program T32 CA090217. NR 9 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0884-5336 EI 1941-2452 J9 NUTR CLIN PRACT JI Nutr. Clin. Pract. PD APR PY 2016 VL 31 IS 2 BP 218 EP 222 DI 10.1177/0884533615583093 PG 5 WC Nutrition & Dietetics SC Nutrition & Dietetics GA DH6LS UT WOS:000372902700012 PM 25896971 ER PT J AU Holland, CL Rubio, D Rodriguez, KL Kraemer, KL Day, N Arnold, RM Tarr, JA Chang, JC AF Holland, Cynthia L. Rubio, Doris Rodriguez, Keri L. Kraemer, Kevin L. Day, Nancy Arnold, Robert M. Tarr, Jill A. Chang, Judy C. TI Obstetric Health Care Providers' Counseling Responses to Pregnant Patient Disclosures of Marijuana Use SO OBSTETRICS AND GYNECOLOGY LA English DT Article; Proceedings Paper CT International Conference on Communication in Healthcare CY OCT 25-28, 2015 CL New Orleans, LA ID EXPOSURE; ATTENTION; BEHAVIOR; ALCOHOL; ABUSE; DRUG; AGE AB OBJECTIVE: To describe obstetric health care providers' responses and counseling approaches to patients' disclosures of marijuana use during first prenatal visits. METHODS: We performed a content analysis of audio-recorded patient-health care provider first prenatal visits for obstetrics health care providers' responses to patients' disclosure of marijuana use. The study was conducted at five urban outpatient clinics located in Pittsburgh, Pennsylvania. RESULTS: Among 468 audio-recorded first obstetric encounters, 90 patients (19%) disclosed marijuana use to 47 health care providers; mean number of recoded encounters containing marijuana disclosures for participating health providers was 1.8 +/- 1.4. In 48% of these 90 visits, obstetric health care providers did not respond to marijuana use disclosures or offer counseling. When counseling was offered, it consisted of general statements without specific information on the risks or outcomes related to marijuana use in pregnancy, discussions regarding the need for urine toxicology testing, and warnings that use detected at the time of delivery would initiate child protective services involvement. CONCLUSION: Obstetric health care provider responses to disclosure of marijuana use occurred in approximately half of patient encounters when marijuana use was disclosed and focused on legal and procedural consequences with less focus on health or medical implications. Our results suggest a need for health care provider training on potential consequences of perinatal marijuana use and communication skills for counseling patients about perinatal marijuana. C1 Magee Womens Res Inst, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA. Univ Pittsburgh, Dept Internal Med, Ctr Res Hlth Care, Div Gen Internal Med,Clin & Translat Sci Inst, Pittsburgh, PA USA. Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. Ctr Res Hlth Care, Inst Enhance Palliat Care, Sect Palliat Care & Med Eth, Inst Doctor Patient Commun, Pittsburgh, PA USA. RP Chang, JC (reprint author), 300 Halket St, Pittsburgh, PA 15213 USA. EM jchang@mail.magee.edu RI Day, Nancy/H-3171-2016 FU NCATS NIH HHS [UL1 TR000005, UL1TR000005]; NIDA NIH HHS [1R01DA026410-01A1, R01 DA026410] NR 24 TC 2 Z9 2 U1 2 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD APR PY 2016 VL 127 IS 4 BP 681 EP 687 DI 10.1097/AOG.0000000000001343 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DH4YF UT WOS:000372791000009 PM 26959210 ER PT J AU McCarrier, KP Deal, LS Abraham, L Blum, SI Bush, EN Martin, ML Thase, ME Coons, SJ AF McCarrier, Kelly P. Deal, Linda S. Abraham, Lucy Blum, Steven I. Bush, Elizabeth Nicole Martin, Mona L. Thase, Michael E. Coons, Stephen Joel CA PRO Consortium's Depression Workin TI Patient-Centered Research to Support the Development of the Symptoms of Major Depressive Disorder Scale (SMDDS): Initial Qualitative Research SO PATIENT-PATIENT CENTERED OUTCOMES RESEARCH LA English DT Article ID OUTCOMES PRO INSTRUMENTS; RATING-SCALE; INTERRATER RELIABILITY; SELF-REPORT; MELANCHOLIA; VALIDATION; SEVERITY AB Content valid, patient-reported outcome (PRO) measures of major depressive disorder (MDD) symptoms are needed to assess MDD treatment benefit. While a range of questionnaires are currently available to evaluate aspects of depression from the patient's perspective, their comprehensiveness and qualitative development histories are unclear. The objective of this study was to describe the process and results of the preliminary qualitative development of a new symptom-based PRO measure intended to assess treatment benefit in MDD clinical trials. Qualitative interviews were conducted with adult MDD patients in the USA who recently experienced a major depressive episode. Experienced interviewers conducted concept elicitation (CE) and cognitive interviews using semi-structured interview guides. The CE interview guide was used to elicit spontaneous reports of symptom experiences along with probing to further explore and confirm concepts. The cognitive interview guide was developed to evaluate concept relevance, understandability, and structure of the draft items, and to facilitate further instrument refinement. Forty patients participated in the CE interviews. A total of 3022 symptom codes, representing 84 different concepts were derived from the transcripts. Data from the CE interviews were considered alongside existing literature and clinical expert opinion during an item-generation process, leading to development of a preliminary version of the Symptoms of Major Depressive Disorder Scale (SMDDS). Fifteen patients participated in three waves of cognitive interviews, during which the SMDDS was further refined. The SMDDS is a 35-item PRO measure intended for use as an endpoint in MDD clinical trials to support medical product labeling. The SMDDS uses a 7-day recall period and verbal rating scales. It was developed in accordance with the US Food and Drug Administration (FDA)'s PRO Guidance and best practices. Qualitative interviews have provided evidence for content validity. Future quantitative studies will confirm the SMDDS's measurement properties and support FDA qualification. C1 [McCarrier, Kelly P.; Martin, Mona L.] Hlth Res Associates Inc, 6505 216th St SW Suite 105, Mountlake Terrace, WA 98043 USA. [Deal, Linda S.] Shire, Clin Outcomes Assessment, Wayne, PA USA. [Abraham, Lucy] Pfizer Ltd, Outcomes & Evidence, Tadworth, Surrey, England. [Blum, Steven I.] GlaxoSmithKline, Patient Reported Outcomes, King Of Prussia, PA USA. [Bush, Elizabeth Nicole] Eli Lilly & Co, PRO Ctr Expertise, Indianapolis, IN 46285 USA. [Thase, Michael E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Coons, Stephen Joel] Crit Path Inst, Patient Reported Outcome Consortium, Tucson, AZ USA. RP McCarrier, KP (reprint author), Hlth Res Associates Inc, 6505 216th St SW Suite 105, Mountlake Terrace, WA 98043 USA. EM mccarrier@hrainc.net FU AbbVie; Bristol-Myers Squibb; Eli Lilly and Company; Forest Research Institute; Janssen; Pfizer; Roche Products Limited; Shire; Sunovion; Takeda; United States Food and Drug Administration [U01FD003865] FX This research was funded by the following members of the PRO Consortium: AbbVie, Bristol-Myers Squibb, Eli Lilly and Company, Forest Research Institute, Janssen, Pfizer, Roche Products Limited, Shire, Sunovion, and Takeda. The PRO Consortium receives support through Grant U01FD003865 from the United States Food and Drug Administration to the Critical Path Institute. NR 28 TC 1 Z9 1 U1 0 U2 1 PU ADIS INT LTD PI NORTHCOTE PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND SN 1178-1653 EI 1178-1661 J9 PATIENT JI Patient PD APR PY 2016 VL 9 IS 2 BP 117 EP 134 DI 10.1007/s40271-015-0132-1 PG 18 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DH6EL UT WOS:000372883700003 PM 26113249 ER PT J AU Berg, AT Baca, CB Rychlik, K Vickrey, BG Caplan, R Testa, FM Levy, SR AF Berg, Anne T. Baca, Christine B. Rychlik, Karen Vickrey, Barbara G. Caplan, Rochelle Testa, Francine M. Levy, Susan R. TI Determinants of Social Outcomes in Adults With Childhood-onset Epilepsy SO PEDIATRICS LA English DT Article ID LONG-TERM PROGNOSIS; ABSENCE EPILEPSY; 2 DECADES; CHILDREN; SEIZURES; DIAGNOSIS; BEHAVIOR; DUTCH AB BACKGROUND: Adults with childhood-onset epilepsy experience poorer adult social outcomes than their peers. The relative roles of seizures over time versus learning and psychiatric problems are unclear. METHODS: We examined independent influences of psychiatric and learning disorders and of seizure course in 241 young adults (22-35 years old) with uncomplicated epilepsy in a longitudinal community-based cohort study. Social outcomes were ascertained throughout the study. A history of psychiatric and learning problems was ascertained similar to 9 years after study entry. Seizure course was: "Excellent," no seizures after the first year, in complete remission at last contact (N = 95, 39%); " Good, " seizures occurred 1 to 5 years after diagnosis, in complete remission at last contact (N = 56, 23%); " Fluctuating, " more complicated trajectories, but never pharmacoresistant (N = 70, 29%); " Pharmacoresistant, " long-term pharmacoresistant (N = 20, 8%). Multiple logistic regression was used to identify contributors to each social outcome. RESULTS: Better seizure course predicted college completion, being either employed or pursuing a degree, and driving, but was not substantially associated with other social outcomes. Poorer seizure course was associated with a greater likelihood of having offspring, particularly in women without partners. Learning problems, psychiatric disorders, or both negatively influenced all but 2 of the social outcomes. CONCLUSIONS: In young adults with uncomplicated epilepsy, the course of seizures contributed primarily to education, employment, and driving. A history of learning problems and psychiatric disorders adversely influenced most adult outcomes. These findings identify potential reasons for vocational and social difficulties encountered by young adults with childhood epilepsy and areas to target for counseling and transition planning. C1 [Berg, Anne T.] Ann & Robert H Lurie Childrens Hosp Chicago, Epilepsy Ctr, Box 29,225 East Chicago Ave, Chicago, IL 60611 USA. [Rychlik, Karen] Ann & Robert H Lurie Childrens Hosp Chicago, Stanley Manne Childrens Res Inst, Biostat Res Core, Chicago, IL 60611 USA. [Berg, Anne T.] Northwestern Feinberg Sch Med, Dept Pediat, Chicago, IL USA. [Baca, Christine B.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Neurol, Los Angeles, CA 90024 USA. [Caplan, Rochelle] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Baca, Christine B.] VA Greater Los Angeles Hlth Care Syst, Dept Neurol, Los Angeles, CA USA. [Vickrey, Barbara G.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Testa, Francine M.; Levy, Susan R.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA. [Testa, Francine M.; Levy, Susan R.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA. RP Berg, AT (reprint author), Ann & Robert H Lurie Childrens Hosp Chicago, Epilepsy Ctr, Box 29,225 East Chicago Ave, Chicago, IL 60611 USA. EM atberg@luriechildrens.org FU National Institute of Neurologic Disorders and Stroke [R37-NS31146]; National Institutes of Health (NIH) FX This study was funded by grant R37-NS31146 from the National Institute of Neurologic Disorders and Stroke. Funded by the National Institutes of Health (NIH). NR 37 TC 2 Z9 2 U1 1 U2 4 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD APR PY 2016 VL 137 IS 4 AR e20153944 DI 10.1542/peds.2015-3944 PG 10 WC Pediatrics SC Pediatrics GA DI0OU UT WOS:000373197500049 ER PT J AU Kittiskulnam, P Chertow, GM Kaysen, GA Delgado, C Dalrymple, LS Johansen, KL AF Kittiskulnam, Piyawan Chertow, Glenn M. Kaysen, George A. Delgado, Cynthia Dalrymple, Lorien S. Johansen, Kirsten L. TI Misclassification of Obesity by Body Mass Index Among Patients Receiving Hemodialysis SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Letter ID WAIST CIRCUMFERENCE; DIAGNOSING OBESITY; POPULATION; MORTALITY; DISEASE C1 [Kittiskulnam, Piyawan; Delgado, Cynthia; Johansen, Kirsten L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Kittiskulnam, Piyawan; Delgado, Cynthia; Johansen, Kirsten L.] San Francisco VA Med Ctr, San Francisco, CA USA. [Kittiskulnam, Piyawan] Chulalongkorn Univ, Bangkok, Thailand. [Kittiskulnam, Piyawan] King Chulalongkorn Mem Hosp, Thai Red Cross Soc, Bangkok, Thailand. [Chertow, Glenn M.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Kaysen, George A.; Dalrymple, Lorien S.] Univ Calif Davis, Sacramento, CA 95817 USA. [Johansen, Kirsten L.] Univ Calif San Francisco, US Renal Data Syst Nutr Special Studies Ctr, San Francisco, CA 94143 USA. RP Johansen, KL (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA.; Johansen, KL (reprint author), San Francisco VA Med Ctr, San Francisco, CA USA.; Johansen, KL (reprint author), Univ Calif San Francisco, US Renal Data Syst Nutr Special Studies Ctr, San Francisco, CA 94143 USA. EM kirsten.johansen@ucsf.edu FU CSRD VA [IK2 CX000527]; NIDDK NIH HHS [K24DK085153, N01-DK-7-0005, K23DK093584]; PHS HHS [KD-7-5004] NR 10 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2016 VL 67 IS 4 BP 709 EP 711 DI 10.1053/j.ajkd.2015.09.028 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA DH3XO UT WOS:000372720300027 PM 26612278 ER PT J AU Thomas, KM Wright, AGC Lukowitsky, MR Donnellan, MB Hopwood, CJ AF Thomas, Katherine M. Wright, Aidan G. C. Lukowitsky, Mark R. Donnellan, M. Brent Hopwood, Christopher J. TI Correction to "Evidence for the Criterion Validity and Clinical Utility of the Pathological Narcissism Inventory" SO ASSESSMENT LA English DT Article DE correction; narcissism; validity; clinical utility AB In our article Evidence for the Criterion Validity and Clinical Utility of the Pathological Narcissism Inventory (2012), we provided incorrect values for the r(contrast-cv) coefficients we presented in Table 1. In the current report, we provide correct r(contrast-cv) values in Table 1 and discuss the implications of our updated results, particularly with respect to how these results differ from our initial report. C1 [Thomas, Katherine M.; Hopwood, Christopher J.] Michigan State Univ, E Lansing, MI 48824 USA. [Thomas, Katherine M.] San Francisco VA Med Ctr, Bldg 8 Behav Hlth, San Francisco, CA 94118 USA. [Wright, Aidan G. C.] Univ Pittsburgh, Pittsburgh, PA USA. [Lukowitsky, Mark R.] Albany Med Ctr, Albany, NY USA. [Donnellan, M. Brent] Texas A&M Univ, College Stn, TX USA. RP Thomas, KM (reprint author), San Francisco VA Med Ctr, Bldg 8 Behav Hlth, San Francisco, CA 94118 USA. EM thomas.kate.m@gmail.com NR 5 TC 1 Z9 1 U1 0 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1073-1911 EI 1552-3489 J9 ASSESSMENT JI Assessment PD APR PY 2016 VL 23 IS 2 BP 262 EP 263 DI 10.1177/1073191115584971 PG 2 WC Psychology, Clinical SC Psychology GA DG8CO UT WOS:000372310200011 PM 26019298 ER PT J AU Shahid, H Singh, JA AF Shahid, Hania Singh, Jasvinder A. TI Racial/Ethnic Disparity in Rates and Outcomes of Total Joint Arthroplasty SO CURRENT RHEUMATOLOGY REPORTS LA English DT Article DE Total joint arthroplasty (TJA); Race; Ethnicity; Disparity; Total joint replacement (TJR); Total knee arthroplasty (TKA); Total hip arthroplasty (THA); Total ankle arthroplasty (TAA); Total elbow arthroplasty (TEA); Total shoulder arthroplasty (TSA); Osteoarthritis (OA); Rheumatoid arthritis (RA); White; Caucasian; African American (AA); Black; Hispanic ID TOTAL KNEE REPLACEMENT; TOTAL HIP-REPLACEMENT; STATES MEDICARE POPULATION; CLINICAL DECISION-MAKING; QUALITY-OF-LIFE; RACIAL DISPARITIES; UNITED-STATES; AFRICAN-AMERICANS; SHOULDER ARTHROPLASTY; PATIENT EXPECTATIONS AB Racial/ethnic disparity in total joint arthroplasty (TJA) has grown over the last two decades as studies have documented the widening gap between Blacks and Whites in TJA utilization rates despite the known benefits of TJA. Factors contributing to this disparity have been explored and include demographics, socioeconomic status, patient knowledge, patient preference, willingness to undergo TJA, patient expectation of post-arthroplasty outcome, religion/spirituality, and physician-patient interaction. Improvement in patient knowledge by effective physician-patient communication and other methods can possibly influence patient's perception of the procedure. Such interventions can provide patient-relevant data on benefits/risks and dispel myths related to benefits/risks of arthroplasty and possibly reduce this disparity. This review will summarize the literature on racial/ethnic disparity on TJA utilization and outcomes and the factors underlying this disparity. C1 [Shahid, Hania] Rawalpindi Med Coll, Dept Med, Rawalpindi, Pakistan. [Shahid, Hania; Singh, Jasvinder A.] UAB, Sch Med, Dept Med, Birmingham, AL USA. [Singh, Jasvinder A.] UAB, Sch Publ Hlth, Div Epidemiol, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), UAB, Sch Med, Dept Med, Birmingham, AL USA.; Singh, JA (reprint author), UAB, Sch Publ Hlth, Div Epidemiol, Birmingham, AL USA.; Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.; Singh, JA (reprint author), Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. EM Jasvinder.md@gmail.com FU UAB Division of Rheumatology FX This material is the result of work supported by research funds from UAB Division of Rheumatology and the resources and use of facilities at the Birmingham VA Medical Center. NR 90 TC 0 Z9 0 U1 5 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3774 EI 1534-6307 J9 CURR RHEUMATOL REP JI Curr. Rheumatol. Rep. PD APR PY 2016 VL 18 IS 4 AR 20 DI 10.1007/s11926-016-0570-3 PG 13 WC Rheumatology SC Rheumatology GA DH2DO UT WOS:000372594600003 PM 26984804 ER PT J AU Pugliese, A Boulware, D Yu, LP Babu, S Steck, AK Becker, D Rodriguez, H DiMeglio, L Evans-Molina, C Harrison, LC Schatz, D Palmer, JP Greenbaum, C Eisenbarth, GS Sosenko, JM AF Pugliese, Alberto Boulware, David Yu, Liping Babu, Sunanda Steck, Andrea K. Becker, Dorothy Rodriguez, Henry DiMeglio, Linda Evans-Molina, Carmella Harrison, Leonard C. Schatz, Desmond Palmer, Jerry P. Greenbaum, Carla Eisenbarth, George S. Sosenko, Jay M. CA Type 1 Diabet TrialNet Study Grp TI HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression SO DIABETES LA English DT Article ID CLASS-II MOLECULES; GLUTAMIC-ACID DECARBOXYLASE; TRIALNET NATURAL-HISTORY; 1ST DEGREE RELATIVES; DOMINANT PROTECTION; IMPROVE PREDICTION; ISLET AUTOIMMUNITY; HLA; MELLITUS; INSULIN AB The HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 haplotype is linked to protection from the development of type 1 diabetes (T1D). However, it is not known at which stages in the natural history of T1D development this haplotype affords protection. We examined a cohort of 3,358 auto antibody -positive relatives of T1D patients in the Pathway to Prevention (PTP) Study of the Type 1 Diabetes Trial Net. The PTP study examines risk factors for T1D and disease progression in relatives. HLA typing revealed that 155 relatives carried this protective haplotype. A comparison with 60 autoantibody-negative relatives suggested protection from autoantibody development. Moreover, the relatives with DRB1*15:01-D0A1*01:02-DQB1*06:02 less frequently expressed autoantibodies associated with higher T1D risk, were less likely to have multiple autoantibodies at baseline, and rarely converted from single to multiple autoantibody positivity on follow-up. These relatives also had lower frequencies of metabolic abnormalities at baseline and exhibited no overall metabolic worsening on follow-up. Ultimately, they had a very low 5-year cumulative incidence of T1D. In conclusion, the protective influence of DRB1*15:01-DQA1*01:02-DQB1*06:02 spans from autoantibody development through all stages of progression, and relatives with this allele only rarely develop T1D. C1 [Pugliese, Alberto; Sosenko, Jay M.] Univ Miami, Diabet Res Inst, Miller Sch Med, Miami, FL USA. [Pugliese, Alberto] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL USA. [Boulware, David] Univ Miami, Div Endocrinol Metab & Diabet, Dept Med, Miller Sch Med, Miami, FL USA. [Yu, Liping; Babu, Sunanda; Steck, Andrea K.; Eisenbarth, George S.] Univ S Florida, Div Bioinformat & Biostat, Tampa, FL USA. [Becker, Dorothy] Univ Colorado, Barbara Davis Ctr Childhood Diabet, Anschutz Med Campus, Aurora, CO USA. [Rodriguez, Henry] Univ Pittsburgh, Med Ctr, Dept Pediat, Childrens Hosp Pittsburgh, Pittsburgh, PA USA. [DiMeglio, Linda] Univ S Florida, Dept Pediat, Morsani Coll Med, Tampa, FL USA. [Evans-Molina, Carmella] Indiana Univ Hlth, Riley Hosp Children, Dept Pediat Endocrinol, Indianapolis, IN USA. [Harrison, Leonard C.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA. [Harrison, Leonard C.] Richard L Roudebush VA Med Ctr, Indianapolis, IN USA. [Schatz, Desmond] Univ Melbourne, Dept Med Biol, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia. [Palmer, Jerry P.] Univ Florida, Dept Pediat, Gainesville, FL USA. [Greenbaum, Carla] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Greenbaum, Carla] Univ Washington, Seattle, WA 98195 USA. [Sosenko, Jay M.] Benaroya Res Inst, Seattle, WA USA. RP Pugliese, A (reprint author), Univ Miami, Diabet Res Inst, Miller Sch Med, Miami, FL USA.; Pugliese, A (reprint author), Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL USA. EM apuglies@med.miami.edu FU National Institutes of Health_(NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development [U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085465, U01 DK085453, U01 DK085461, U01 DK085463, U01 DK085466, U01 DK085499, U01 DK085504, U01 DK085505, U01 DK085509, U01 DK103180, U01 DK103153, U01 DK085476, U01 DK103266]; JDRF FX The sponsor of the trial was the Type 1 Diabetes TrialNet Pathway to Prevention Study Group. Type 1 Diabetes TrialNet Pathway to Prevention Study Group is a clinical trials network funded by the National Institutes of Health_(NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development through the cooperative agreements U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085465, U01 DK085453, U01 DK085461, U01 DK085463, U01 DK085466, U01 DK085499, U01 DK085504, U01 DK085505, U01 DK085509, U01 DK103180, U01 DK103153, U01 DK085476, and U01 DK103266. The study group is also funded by JDRF. NR 48 TC 0 Z9 0 U1 1 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD APR PY 2016 VL 65 IS 4 BP 1109 EP 1119 DI 10.2337/db15-1105 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DH5VC UT WOS:000372859200028 PM 26822082 ER PT J AU Vindigni, SM Kaz, AM AF Vindigni, Stephen M. Kaz, Andrew M. TI Universal Screening of Colorectal Cancers for Lynch Syndrome: Challenges and Opportunities SO DIGESTIVE DISEASES AND SCIENCES LA English DT Review DE Lynch syndrome; Hereditary non-polyposis colorectal cancer; HNPCC; Universal screening; Universal testing; Colorectal cancer screening; Genetic testing ID REVISED BETHESDA GUIDELINES; COST-EFFECTIVENESS ANALYSIS; GENETIC TESTING STRATEGIES; MSH6 GERMLINE MUTATIONS; MICROSATELLITE-INSTABILITY; COLON-CANCER; FOLLOW-UP; IDENTIFICATION; IMMUNOHISTOCHEMISTRY; INDIVIDUALS AB Lynch syndrome (LS) is the most common heritable colorectal cancer (CRC) syndrome, accounting for approximately 3 % of CRC cases in the USA each year. LS results from a genetic mutation in one of the four mismatch repair genes, and clinically LS is associated with CRC and other gastrointestinal and extra-gastrointestinal malignancies. In this review, we describe the various clinical criteria utilized for the identification of LS patients and the inherent flaws with these criteria. We discuss the concept of universal testing for LS in all cases of newly diagnosed CRC, along with the potential benefits and challenges of universal testing. Several studies have shown that universal tumor testing is cost-effective and identifies cases of LS that are missed using traditional clinical criteria, which may result in reduced cancer mortality for probands and their families. Yet the full benefits of universal tumor testing may be limited by the availability and patient acceptance of genetic testing, and by logistical obstacles affecting the implementation of universal testing programs. Lastly, we comment on developing technologies such as massively parallel next-generation sequencing, which permits simultaneous sequencing of multiple genes involved in LS and other inherited colon cancer syndromes. C1 [Vindigni, Stephen M.; Kaz, Andrew M.] Univ Washington, Div Gastroenterol, Sch Med, 1959 NE Pacific St,Box 356424, Seattle, WA 98105 USA. [Kaz, Andrew M.] VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S 111 Gastro, Seattle, WA 98108 USA. RP Kaz, AM (reprint author), Univ Washington, Div Gastroenterol, Sch Med, 1959 NE Pacific St,Box 356424, Seattle, WA 98105 USA.; Kaz, AM (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S 111 Gastro, Seattle, WA 98108 USA. EM vindigni@uw.edu; Andrew.kaz@va.gov NR 52 TC 1 Z9 1 U1 0 U2 4 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD APR PY 2016 VL 61 IS 4 BP 969 EP 976 DI 10.1007/s10620-015-3964-6 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DG7ZJ UT WOS:000372301900008 PM 26602911 ER PT J AU Muehe, AM Feng, D Eyben, R Luna-Fineman, S Link, MP Muthig, T Huddleston, AE Neuwelt, EA Daldrup-Link, HE AF Muehe, Anne M. Feng, Dan von Eyben, Rie Luna-Fineman, Sandra Link, Michael P. Muthig, Travis Huddleston, Amy E. Neuwelt, Edward A. Daldrup-Link, Heike E. TI Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults SO INVESTIGATIVE RADIOLOGY LA English DT Article DE pediatric; ferric compounds; ferumoxytol; adverse events/adverse effects; safety; toxicity; contrast media ID IRON-OXIDE NANOPARTICLES; HEMODIALYSIS-PATIENTS; DEFICIENCY ANEMIA; ADVERSE-REACTIONS; KIDNEY-DISEASE; CONTRAST AGENT; LIFE-SUPPORT; MRI; THERAPY; MANAGEMENT AB Objective The aim of this study was to assess the safety profile of ferumoxytol as an intravenous magnetic resonance imaging contrast agent in children. Materials and Methods We prospectively evaluated the safety of ferumoxytol administrations as an "off-label" contrast agent for magnetic resonance imaging in nonrandomized phase 4 clinical trials at 2 centers. From September 2009 to February 2015, 49 pediatric patients (21 female and 28 male, 5-18 years) and 19 young adults (8 female and 11 male, 18-25 years) were reported under an investigator-initiated investigational new drug investigation with institutional review board approval, in health insurance portability and accountability act compliance, and after written informed consent of the child's legal representative or the competent adult patient was obtained. Patients received either a single dose (5 mg Fe/kg) or up to 4 doses of ferumoxytol (0.7-4 mg Fe/kg) intravenously, which were approximately equivalent to one third of the dose for anemia treatment. We monitored vital signs and adverse events directly for up to 1 hour after injection. In addition, we examined weekly vitals, hematologic, renal, and liver serum panels for 1 month after injection in over 20 pediatric patients. At fixed time points before and after ferumoxytol injection, data were evaluated for significant differences by a repeated measures linear mixed model. Results Four mild adverse events, thought to be related to ferumoxytol, were observed within 1 hour of 85 ferumoxytol injections: 2 episodes of mild hypotension and 1 case of nausea in 65 injections in pediatric patients without related clinical symptoms. One young adult patient developed warmness and erythema at the injection site. All adverse events were self-resolving. No spontaneous serious adverse events were reported. At a dose of 5 mg Fe/kg or lower, intravenous ferumoxytol injection had no clinical relevance or statistically significant effect (P > 0.05) on vital signs, hematological parameters, kidney function, or liver enzymes within 1 month of the injection. Conclusions Ferumoxytol was overall well tolerated among 49 pediatric and 19 young adult patients experiencing various tumors or kidney transplants without major adverse events or signs of hematologic and kidney impairment or liver toxicity. Larger studies are needed to determine the incidence of anaphylactic reactions. C1 [Muehe, Anne M.; Feng, Dan; Daldrup-Link, Heike E.] Stanford Univ, Mol Imaging Program Stanford, Dept Radiol, Stanford, CA 94305 USA. [Muehe, Anne M.; Feng, Dan; Daldrup-Link, Heike E.] Stanford Univ, Lucile Packard Childrens Hosp, Stanford, CA 94305 USA. [von Eyben, Rie] Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA. [Luna-Fineman, Sandra; Link, Michael P.] Stanford Univ, Sect Pediat Hematol & Oncol, Dept Pediat, Stanford, CA 94305 USA. [Muthig, Travis] Univ S Carolina, Sch Med, Columbia, SC USA. [Huddleston, Amy E.; Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97201 USA. [Neuwelt, Edward A.] Portland VA Med Ctr, Portland, OR USA. RP Daldrup-Link, HE (reprint author), Stanford Sch Med, Dept Radiol, 725 Welch Rd, Stanford, CA 94305 USA. EM H.E.Daldrup-Link@stanford.edu RI Daldrup-Link, Heike/D-9829-2012 OI Daldrup-Link, Heike/0000-0002-4929-819X FU National Institute of Child Health and Human Development [R01 HD081123A]; Translational Research and Applied Medicine Program at Stanford University; National Institute of Health [CA137488]; Walter S. and Lucienne Driskill Foundation; Stanford Medical Scholars Fellowship Program FX Supported by R01 HD081123A from the National Institute of Child Health and Human Development, a grant from the Translational Research and Applied Medicine Program at Stanford University (H.E.D.L. and D.F.), by National Institute of Health grant CA137488, and by the Walter S. and Lucienne Driskill Foundation to Oregon Health & Science University (E.A.N.). D.F. was supported by a stipend from the Stanford Medical Scholars Fellowship Program. NR 41 TC 10 Z9 10 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0020-9996 EI 1536-0210 J9 INVEST RADIOL JI Invest. Radiol. PD APR PY 2016 VL 51 IS 4 BP 221 EP 227 DI 10.1097/RLI.0000000000000230 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DH0CX UT WOS:000372451200002 PM 26656202 ER PT J AU Einstein, AJ Lloyd, SG Chaudhry, FA AlJaroudi, WA Hage, FG AF Einstein, Andrew J. Lloyd, Steven G. Chaudhry, Farooq A. AlJaroudi, Wael A. Hage, Fadi G. TI Multi-modality Imaging: Bird's eye view from the 2015 American Heart Association Scientific Sessions SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Article DE AHA; cardiac computed tomography; CMRI ID CORONARY FLOW RESERVE AB Multiple novel studies were presented at the 2015 American Heart Association Scientific Sessions which was considered a successful conference at many levels. In this review, we will summarize key studies in nuclear cardiology, cardiac magnetic resonance, echocardiography, and cardiac computed tomography that were presented at the Sessions. We hope that this bird's eye view will keep readers updated on the newest imaging studies presented at the meeting whether or not they were able to attend the meeting. C1 [Einstein, Andrew J.] Columbia Univ, New York Presbyterian Hosp, Med Ctr, New York, NY USA. [Lloyd, Steven G.; Hage, Fadi G.] Univ Alabama Birmingham, Lyons Harrison Res Bldg 314,1900 Univ BLVD, Birmingham, AL 35294 USA. [Lloyd, Steven G.; Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Chaudhry, Farooq A.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [AlJaroudi, Wael A.] Clemenceau Med Ctr, Beirut, Lebanon. RP Hage, FG (reprint author), Univ Alabama Birmingham, Lyons Harrison Res Bldg 314,1900 Univ BLVD, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 FU Astellas Pharma FX Dr Hage reports grant support from Astellas Pharma. NR 35 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD APR PY 2016 VL 23 IS 2 BP 235 EP 243 DI 10.1007/s12350-016-0404-8 PG 9 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA DG7UR UT WOS:000372289700008 PM 26818142 ER PT J AU Harmon, JL Wills, LP McOmish, CE Demireva, EY Gingrich, JA Beeson, CC Schnellmann, RG AF Harmon, Jennifer L. Wills, Lauren P. McOmish, Caitlin E. Demireva, Elena Y. Gingrich, Jay A. Beeson, Craig C. Schnellmann, Rick G. TI 5-HT2 Receptor Regulation of Mitochondrial Genes: Unexpected Pharmacological Effects of Agonists and Antagonists SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID ACUTE KIDNEY INJURY; PROXIMAL TUBULES; OXIDATIVE STRESS; CHOROID-PLEXUS; ANIMAL-MODELS; SB 242084; BIOGENESIS; DYSFUNCTION; PGC-1-ALPHA; CELLS AB In acute organ injuries, mitochondria are often dysfunctional, and recent research has revealed that recovery of mitochondrial and renal functions is accelerated by induction of mitochondrial biogenesis (MB). We previously reported that the nonselective 5-HT2 receptor agonist DOI [1-(4-iodo-2,5-dimethoxyphenyl) propan-2-amine] induced MB in renal proximal tubular cells (RPTCs). The goal of this study was to determine the role of 5-HT2 receptors in the regulation of mitochondrial genes and oxidative metabolism in the kidney. The 5-HT2C receptor agonist CP-809,101 [2-[(3-chlorophenyl)methoxy]-6-(1-piperazinyl)pyrazine] and antagonist SB-242,084 [6-chloro-2,3-dihydro-5-methyl-N-[6-[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl]-1H-indole-1-carboxyamide dihydrochloride] were used to examine the induction of renal mitochondrial genes and oxidative metabolism in RPTCs and in mouse kidneys in the presence and absence of the 5-HT2C receptor. Unexpectedly, both CP-809,101 and SB-242,084 increased RPTC respiration and peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha) mRNA expression in RPTCs at 1-10 nM. In addition, CP-809,101 and SB-242,084 increased mRNA expression of PGC-1 alpha and the mitochondrial proteins NADH dehydrogenase subunit 1 and NADH dehydrogenase (ubiquinone) beta subcomplex 8 in mice. These compounds increased mitochondrial genes in RPTCs in which the 5-HT2C receptor was downregulated with small interfering RNA and in the renal cortex of mice lacking the 5-HT2C receptor. By contrast, the ability of these compounds to increase PGC-1 alpha mRNA and respiration was blocked in RPTCs treated with 5-HT2A receptor small interfering RNA or the 5-HT2A receptor antagonist eplivanserin. In addition, the 5-HT2A receptor agonist NBOH-2C-CN [4-[2-[[(2-hydroxyphenyl)methyl]amino]ethyl]-2,5-dimethoxybenzonitrile] increased RPTC respiration at 1-100 nM. These results suggest that agonism of the 5-HT2A receptor induces MB and that the classic 5-HT2C receptor agonist CP-809,101 and antagonist SB-242,084 increase mitochondrial genes and oxidative metabolism through the 5-HT2A receptor. To our knowledge, this is the first report that links 5-HT2A receptor agonism to mitochondrial function. C1 [Harmon, Jennifer L.; Wills, Lauren P.; Beeson, Craig C.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, 280 Calhoun St,MSC140, Charleston, SC 29425 USA. [McOmish, Caitlin E.; Demireva, Elena Y.; Gingrich, Jay A.] Columbia Univ, Dept Psychiat, Sackler Inst Dev Psychobiol, New York, NY USA. [McOmish, Caitlin E.] Univ Melbourne, Div Mol Psychiat, Florey Inst Neurosci & Mental Hlth, Melbourne Brain Ctr, Parkville, Vic 3052, Australia. [Demireva, Elena Y.; Gingrich, Jay A.] New York State Psychiat Inst & Hosp, Div Dev Neurosci, New York, NY 10032 USA. [Schnellmann, Rick G.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Schnellmann, RG (reprint author), Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, 280 Calhoun St,MSC140, Charleston, SC 29425 USA. EM schnell@musc.edu FU National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [F30DK091107, T32DK083262]; National Health and Medical Research Council; Brain and Behavior Research Foundation; National Institutes of Health National Institute of Mental Health [R21MH099458, R01MH080116]; National Institutes of Health National Institute of General Medical Sciences [R01GM084147, P20GM103542-02]; National Institutes of Health National Center for Research Resources [UL1RR029882, C06RR015455]; Biomedical Laboratory Research and Development Program of the U.S. Department of Veterans Affairs [5I01 BX-000851]; South Carolina Clinical and Translational Research Institute at the Medical University of South Carolina FX This research was supported in part by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [Grants F30DK091107 and T32DK083262 (to J.L.H.)]; the National Health and Medical Research Council [C.J. Martin Overseas Biomedical Fellowship (to C.E.M.)]; the Brain and Behavior Research Foundation [Young Investigator Award (to C.E.M.)]; the National Institutes of Health National Institute of Mental Health [Grants R21MH099458 and R01MH080116 (to J.A.G.)]; the National Institutes of Health National Institute of General Medical Sciences [Grants R01GM084147 (to R.G.S) and P20GM103542-02 (to South Carolina COBRE in Oxidants, Redox Balance, and Stress Signaling)]; the National Institutes of Health National Center for Research Resources [Grant UL1RR029882]; the Biomedical Laboratory Research and Development Program of the U.S. Department of Veterans Affairs [Grant 5I01 BX-000851 (to R.G.S.)]; and the South Carolina Clinical and Translational Research Institute at the Medical University of South Carolina. Animal facilities were funded by the National Institutes of Health National Center for Research Resources [Grant C06RR015455]. NR 44 TC 1 Z9 1 U1 1 U2 3 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 EI 1521-0103 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD APR PY 2016 VL 357 IS 1 BP 1 EP 9 DI 10.1124/jpet.115.228395 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DG5TX UT WOS:000372142800001 PM 26787771 ER PT J AU Keating, JJ Okusanya, OT De Jesus, E Judy, R Jiang, J Deshpande, C Nie, S Low, P Singhal, S AF Keating, Jane J. Okusanya, Olugbenga T. De Jesus, Elizabeth Judy, Ryan Jiang, Jack Deshpande, Charuhas Nie, Shuming Low, Philip Singhal, Sunil TI Intraoperative Molecular Imaging of Lung Adenocarcinoma Can Identify Residual Tumor Cells at the Surgical Margins SO MOLECULAR IMAGING AND BIOLOGY LA English DT Article DE Surgical oncology; Molecular imaging; Lung cancer; Thoracic surgery; Folate receptor alpha ID FOLATE RECEPTOR-ALPHA; FLUORESCENCE-GUIDED SURGERY; TARGETED IMMUNOTHERAPY; INFLAMMATORY DISEASES; PANCREATIC-CANCER; MOUSE MODELS; RESECTION; THERAPY; CHEMOTHERAPY; ANTIBODY AB Purpose: During lung surgery, identification of surgical margins is challenging. We hypothesized that molecular imaging with a fluorescent probe to pulmonary adenocarcinomas could enhance residual tumor during resection. Procedures: Mice with flank tumors received a contrast agent targeting folate receptor alpha. Optimal dose and time of injection was established. Margin detection was compared using traditional methods versus molecular imaging. A pilot study was then performed in three humans with lung adenocarcinoma. Results: The peak tumor-to-background ratio (TBR) of murine tumors was 3.9. Fluorescence peaked at 2 h and was not improved beyond 0.1 mg/kg. Traditional inspection identified 30 % of mice with positive margins. Molecular imaging identified an additional 50 % of residual tumor deposits (p < 0.05). The fluorescent probe visually enhanced all human tumors with a mean TBR of 3.5. Conclusions: Molecular imaging is an important adjunct to traditional inspection to identify surgical margins after tumor resection. C1 [Keating, Jane J.; Okusanya, Olugbenga T.; De Jesus, Elizabeth; Judy, Ryan; Jiang, Jack; Singhal, Sunil] Univ Penn, Dept Surg, Div Thorac Surg, Philadelphia, PA 19104 USA. [Keating, Jane J.; Okusanya, Olugbenga T.; De Jesus, Elizabeth; Judy, Ryan; Jiang, Jack; Singhal, Sunil] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Deshpande, Charuhas] Univ Penn, Perelman Sch Med, Dept Pathol, Philadelphia, PA 19104 USA. [Nie, Shuming] Emory Univ, Dept Biomed Engn, Atlanta, GA 30322 USA. [Nie, Shuming] Emory Univ, Dept Chem, Atlanta, GA 30322 USA. [Low, Philip] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA. [Singhal, Sunil] Univ Penn, Sch Med, Div Thorac Surg, 6 White Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. RP Singhal, S (reprint author), Univ Penn, Dept Surg, Div Thorac Surg, Philadelphia, PA 19104 USA.; Singhal, S (reprint author), Philadelphia VA Med Ctr, Philadelphia, PA USA.; Singhal, S (reprint author), Univ Penn, Sch Med, Div Thorac Surg, 6 White Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. EM sunil.singhal@uphs.upenn.edu OI Low, Philip/0000-0001-9042-5528 FU National Institutes of Health [RO1CA163256] FX This work was supported by the National Institutes of Health RO1CA163256. NR 30 TC 6 Z9 6 U1 2 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1536-1632 EI 1860-2002 J9 MOL IMAGING BIOL JI Mol. Imaging. Biol. PD APR PY 2016 VL 18 IS 2 BP 209 EP 218 DI 10.1007/s11307-015-0878-9 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DG7JP UT WOS:000372260900007 PM 26228697 ER PT J AU Friedlander, AH Giaconi, JA Tsui, I Aghazadehsanai, N Chang, TI Garrett, NR AF Friedlander, Arthur H. Giaconi, JoAnn A. Tsui, Irena Aghazadehsanai, Nona Chang, Tina I. Garrett, Neal R. TI Meaningful correlation between asymptomatic retinal arteriole emboli and calcified carotid plaque found on panoramic dental imaging of males with diabetes SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY LA English DT Article ID BEAVER DAM EYE; CHOLESTEROL EMBOLI; RADIOGRAPHY; DISEASE; ATHEROMA; STROKE; RISK; CALCIFICATIONS; DUPLEX; AID AB Objective. There is ongoing controversy with regard to the stability of calcified carotid artery plaques (CCAPs) seen in the bifurcation area on panoramic images (PIs). Therefore, we sought to evaluate the possibility of these plaques shedding emboli by observing their relationship with ipsilateral retinal emboli. Study Design. The study group included 50 neurologically and visually asymptomatic males with diabetes, with PIs that incidentally demonstrated CCAPs (CCAP+) and contemporaneous digital retinal images that had been obtained for evaluation of diabetic retinopathy. The control group consisted of 50 males with diabetes who were matched for age and body mass index and had undergone both imaging studies and whose PIs were devoid of carotid plaques (CCAP-). The presence of retinal emboli was determined by two ophthalmologists blinded to the patients' medical histories, and the prevalence rates for the two groups were calculated. Results. The presence of asymptomatic retinal arteriolar emboli was found in the eye ipsilateral to the radiographically observed carotid atheroma in 10 of 50 (20%) of the patients in the CCAP+ group, compared with 2 of 50 (4%) in the CCAP- group, and this difference was statistically significant (Fisher's exact P <.03). Conclusions. Some male patients with diabetes mellitus type II having calcified carotid artery atheromas in the bifurcation area, as visualized on PIs, may have significant sequelae as evidenced by retinal artery emboli. C1 [Friedlander, Arthur H.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, Qual Assurance, Los Angeles, CA USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Oral & Maxillofacial Surg, Los Angeles, CA 90024 USA. [Giaconi, JoAnn A.] Vet Affairs Greater Los Angeles Healthcare Syst, Ophthalmol, Los Angeles, CA USA. [Giaconi, JoAnn A.; Tsui, Irena] Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA USA. [Tsui, Irena] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Aghazadehsanai, Nona] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Chang, Tina I.] Univ Calif Los Angeles, Sch Dent, Vet Affairs Greater Los Angeles Healthcare Syst, Res Fellowship & Inpatient Oral & Maxillofacial S, Los Angeles, CA 90024 USA. [Chang, Tina I.] Univ Calif Los Angeles, Sch Dent, Oral & Maxillofacial Surg, Los Angeles, CA 90024 USA. [Garrett, Neal R.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, Grad Med Educ, 11301 Wilshire Blvd 14, Los Angeles, CA 90073 USA. EM Arthur.friedlander@va.gov NR 29 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2212-4403 EI 1528-395X J9 OR SURG OR MED OR PA JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. PD APR PY 2016 VL 121 IS 4 BP 434 EP 440 DI 10.1016/j.oooo.2015.12.005 PG 7 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA DG3UU UT WOS:000371996800018 PM 26972542 ER PT J AU Wen, JC Jiang, FG Yeh, CK Sun, YY AF Wen, Jianchuan Jiang, Fuguang Yeh, Chih-Ko Sun, Yuyu TI Controlling fungal biofilms with functional drug delivery denture biomaterials SO COLLOIDS AND SURFACES B-BIOINTERFACES LA English DT Article DE Denture; Grafting; Drug delivery; Fungal; Biofilm-controlling ID IN-VITRO; BIOMEDICAL APPLICATIONS; SILVER NANOPARTICLES; SURFACE MODIFICATION; ANTIFUNGAL ACTIVITY; MICONAZOLE-NITRATE; CANDIDA-ALBICANS; STOMATITIS; PLASMA; ETIOLOGY AB Candida-associated denture stomatitis (CADS), caused by colonization and biofilm-formation of Candida species on denture surfaces, is a significant clinical concern. We show here that modification of conventional denture materials with functional groups can significantly increase drug binding capacity and control drug release rate of the resulting denture materials for potentially managing CADS. In our approach, poly(methyl methacrylate) (PMMA)-based denture resins were surface grafted with three kinds of polymers, poly(1-vinyl-2-pyrrolidinone) (PNVP), poly(methacrylic acid) (PMAA), and poly(2-hydroxyethyl methacrylate) (PHEMA), through plasma-initiated grafting polymerization. With a grafting yield as low as 2 wt%, the three classes of new functionalized denture materials showed significantly higher drug binding capacities toward miconazole, a widely used antifungal drug, than the original PMMA denture resin control, leading to sustained drug release and potent biofilm-controlling effects against Candida. Among the three classes of functionalized denture materials, PNVP-grafted resin provided the highest miconazole binding capability and the most powerful antifungal and biofilm-controlling activities. Drug binding mechanisms were studied. These results demonstrated the importance of specific interactions between drug molecules and functional groups on biomaterials, shedding lights on future design of CADS-managing denture materials and other related devices for controlled drug delivery. (C) 2015 Elsevier B.V. All rights reserved. C1 [Wen, Jianchuan; Jiang, Fuguang; Sun, Yuyu] Univ Massachusetts, Dept Chem, Lowell, MA 01854 USA. [Yeh, Chih-Ko] South Texas Vet Hlth Care Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Yeh, Chih-Ko] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA. RP Sun, YY (reprint author), Univ Massachusetts, Dept Chem, Lowell, MA 01854 USA. EM yuyu_sun@uml.edu FU NIDCR, NIH [R01 DE021084]; VA Merit Review [1I01BX001103] FX This study was supported by NIDCR, NIH (R01 DE021084) and VA Merit Review (1I01BX001103). NR 51 TC 3 Z9 3 U1 8 U2 26 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0927-7765 EI 1873-4367 J9 COLLOID SURFACE B JI Colloid Surf. B-Biointerfaces PD APR 1 PY 2016 VL 140 BP 19 EP 27 DI 10.1016/j.colsurfb.2015.12.028 PG 9 WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials SC Biophysics; Chemistry; Materials Science GA DF6DG UT WOS:000371445500003 PM 26731194 ER PT J AU Kaz, AM Anwar, A O'Neill, DR Dominitz, JA AF Kaz, Andrew M. Anwar, Asma O'Neill, Darby Robinson Dominitz, Jason A. TI Use of a novel polyp "ruler snare" improves estimation of colon polyp size SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID SOCIETY-TASK-FORCE; COLORECTAL-CANCER; COLONOSCOPY SURVEILLANCE; POLYPECTOMY; ACCURATE; GUIDELINE AB Background and Aims: Prior studies have demonstrated that endoscopists' estimates of polyp size are imprecise. The aim of this study was to determine whether a modified polypectomy "ruler snare" improves the accuracy of assessment of polyp size in real time without the use of additional devices. Methods: Ten artificial polyps of predetermined sizes (4 to 25 mm) were affixed to the inside of a colon model. A standard polypectomy snare was modified by adding 5-mm graduated markings to the distal end of the plastic sheath. Study participants estimated the sizes of the artificial polyps during simulated colonoscopies, first using a standard snare and then with the modified ruler snare. Results: Thirty-four private practice and academic gastroenterologists participated in the study. Endoscopists' ability to accurately classify polyps by size (diminutive, small, or large) improved from 48.5% to 60.3% with the ruler snare (P = .002). The greatest improvement in precision was seen among the large polyps, where accuracy increased from 35.9% to 58.2% with use of the ruler snare (P < .0001). Participants underestimated polyp size by a mean of 3.6 mm (interquartile range, -5 to -2 mm) with the standard snare and 1.8 mm (interquartile range, -3 to 0 mm) with the ruler snare, which corresponded to a 44.2% improvement in accuracy with the ruler snare (P < .05). Conclusions: The modified ruler snare improved polyp size assessment compared with a standard snare, particularly with large polyps. Overall, although size estimation continues to be imprecise, the addition of calibrated markings to a polypectomy snare is a simple and likely low-cost means to improve neoplasia surveillance recommendations. C1 [Kaz, Andrew M.; Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Gastroenterol Sect, Seattle, WA USA. [Kaz, Andrew M.; Anwar, Asma; Dominitz, Jason A.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [O'Neill, Darby Robinson] Everett Clin, Gastroenterol & Liver Dis, Everett, WA USA. RP Dominitz, JA (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-111 Gastro, Seattle, WA 98108 USA. OI Dominitz, Jason/0000-0002-8070-7086 NR 16 TC 1 Z9 1 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD APR PY 2016 VL 83 IS 4 BP 812 EP 816 DI 10.1016/j.gie.2015.08.082 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DG2JX UT WOS:000371894300023 PM 26382052 ER PT J AU Ashack, KA Burton, KA Johnson, TR Currie, DW Comstock, RD Dellavalle, RP AF Ashack, Kurt A. Burton, Kyle A. Johnson, Teresa R. Currie, Dustin W. Comstock, R. Dawn Dellavalle, Robert P. TI Skin infections among US high school athletes: A national survey SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article DE athletes; competition; high school; injury; prevention; skin infections; sports ID HERPES GLADIATORUM; COMPETITIVE SPORTS; DISEASE OUTBREAKS; INJURIES AB Background: Skin infections have long been a reported problem among high school athletes, particularly wrestlers. There has yet to be a national study describing the epidemiology of skin infections across multiple high school sports. Objective: We sought to report the epidemiology of skin infections among US high school athletes. Methods: High school sports-related skin infections resulting in time loss were reported by a convenience sample of US high schools from 2009/2010 through 2013/2014 via High School Reporting Information Online. Results: During the study, 474 skin infections were reported among 20,858,781 athlete exposures, a rate of 2.27 per 100,000 athlete exposures. The largest number of skin infections occurred in wrestling (73.6%) followed by football (17.9%). The most common infections were bacterial (60.6%) and tinea (28.4%) infections. Body parts most often affected were the head/face (25.3%) followed by the forearm (12.7%). Limitations: The study included only high schools with National Athletic Trainers' Associationeaffiliated athletic trainers, which may limit generalizability. However, using athletic trainers as data reporters improved data quality. Conclusions: Skin infections are an important subset of high school sports-related adverse events. An understanding of the epidemiology of sports-related skin infections should promote awareness and drive evidence-based prevention efforts. C1 [Ashack, Kurt A.] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA. [Johnson, Teresa R.] Univ Cent Florida, Coll Med, Dept Med Educ, Orlando, FL 32816 USA. [Burton, Kyle A.] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA. [Currie, Dustin W.; Comstock, R. Dawn; Dellavalle, Robert P.] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Anschutz Med Campus, Aurora, CO USA. [Comstock, R. Dawn] Univ Colorado, Dept Pediat Emergency Med, Anschutz Med Campus, Aurora, CO USA. [Dellavalle, Robert P.] Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO USA. [Dellavalle, Robert P.] US Dept Vet Affairs, Dermatol Serv, Eastern Colorado Hlth Care Syst, Denver, CO USA. RP Dellavalle, RP (reprint author), US Dept Vet Affairs, Dermatol Serv, 1055 Clermont St,Box 165, Denver, CO 80220 USA. EM robert.dellavalle@ucdenver.edu FU Centers for Disease Control and Prevention [R49/CE000674-01, R49/CE001172-01]; National Federation of State High School Associations; National Operating Committee on Standards for Athletic Equipment; DonJoy Orthotics; EyeBlack FX The content of this report representing data collection by the National High School Sports-Related Injury Surveillance Study (High School Reporting Information Online) was funded in part by the Centers for Disease Control and Prevention grants R49/CE000674-01 and R49/CE001172-01. We also acknowledge the generous research funding contributions of the National Federation of State High School Associations, the National Operating Committee on Standards for Athletic Equipment, DonJoy Orthotics, and EyeBlack. The content of this report is solely the responsibility of the authors and does not necessarily represent the official views of the Centers for Disease Control and Prevention or any of the other institutions that provided financial support for this research. NR 21 TC 0 Z9 0 U1 3 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD APR PY 2016 VL 74 IS 4 BP 679 EP U156 DI 10.1016/j.jaad.2015.10.042 PG 7 WC Dermatology SC Dermatology GA DG0ZM UT WOS:000371794800021 PM 26850656 ER PT J AU Minzenberg, MJ Yoon, JH Cheng, YA Carter, CS AF Minzenberg, Michael J. Yoon, Jong H. Cheng, Yaoan Carter, Cameron S. TI Sustained Modafinil Treatment Effects on Control-Related Gamma Oscillatory Power in Schizophrenia SO NEUROPSYCHOPHARMACOLOGY LA English DT Article ID INDEPENDENT COMPONENT ANALYSIS; COGNITIVE CONTROL; PREFRONTAL CORTEX; LOCUS-COERULEUS; RULE SELECTION; WORKING-MEMORY; IN-VITRO; MODULATION; DOPAMINE; NOREPINEPHRINE AB Control-related cognitive processes such as rule selection and maintenance are associated with cortical oscillations in the gamma range, and modulated by catecholamine neurotransmission. Control-related gamma power is impaired in schizophrenia, and an understudied treatment target. It remains unknown whether pro-catecholamine pharmacological agents augment control-related gamma oscillations in schizophrenia. We tested the effects of 4-week fixed-dose daily adjunctive modafinil (MOD) 200 mg, in a randomized double-blind, placebo-controlled, parallel-groups design. Twenty-seven stable schizophrenia patients performed a cognitive control task during EEG, at baseline and after 4 weeks of treatment. EEG data underwent time-frequency decomposition with Morlet wavelets to determine power of 4-80 Hz oscillations. The modafinil group (n = 14), relative to placebo group (n = 13), exhibited enhanced oscillatory power associated with high-control rule selection in the gamma range after treatment, with additional effects during rule maintenance in gamma and sub-gamma ranges. MOD-treated patients who exhibited improved task performance with treatment also showed greater treatment-related delay period gamma compared with MOD-treated patients without improved performance. This is the first evidence in schizophrenia of augmentation of cognition-related gamma oscillations by an FDA-approved agent with therapeutic potential. Gamma oscillations represent a novel treatment target in this disorder, and modulation of catecholamine signaling may represent a viable strategy at this target. C1 [Minzenberg, Michael J.; Cheng, Yaoan] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA 94143 USA. [Minzenberg, Michael J.; Cheng, Yaoan] San Francisco VA Med Ctr, San Francisco, CA USA. [Yoon, Jong H.] Stanford Univ, Sch Med, Dept Psychiat, Palo Alto, CA 94304 USA. [Yoon, Jong H.] Palo Alto Vet Affairs Med Ctr, Palo Alto, CA USA. [Carter, Cameron S.] Univ Calif Davis, Sch Med, Dept Psychiat, Sacramento, CA 95817 USA. [Carter, Cameron S.] Univ Calif Davis, Ctr Neurosci, Program Neurosci, Davis, CA 95616 USA. RP Minzenberg, MJ (reprint author), UCSF, Psychiat, Outpatient Mental Hlth Serv, San Francisco Vet Affairs Ctr, 116C,4150 Clement St, San Francisco, CA 94121 USA. EM Michael.minzenberg@ucsf.edu OI Cheng, Yaoan/0000-0001-5858-6161 FU Clinical Scientist Development Award from the Doris Duke Charitable Foundation; Young Investigator award from NARSAD (Brain and Behavior Foundation) FX This work was supported by Clinical Scientist Development Award from the Doris Duke Charitable Foundation, and a Young Investigator award from NARSAD (Brain and Behavior Foundation), to MJM. The authors declare no conflict of interest. NR 60 TC 1 Z9 1 U1 1 U2 12 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD APR PY 2016 VL 41 IS 5 BP 1231 EP 1240 DI 10.1038/npp.2015.271 PG 10 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA DG1BW UT WOS:000371801200006 PM 26329382 ER PT J AU Crossley, NA Fox, PT Bullmore, ET AF Crossley, N. A. Fox, P. T. Bullmore, E. T. TI Meta-connectomics: human brain network and connectivity meta-analyses SO PSYCHOLOGICAL MEDICINE LA English DT Review DE Connectome; cytoarchitectonics; gene expression; graph theory; neuroimaging ID RICH-CLUB ORGANIZATION; FUNCTIONAL CONNECTIVITY; CEREBRAL-CORTEX; COACTIVATION PATTERNS; PREFRONTAL CORTEX; SCHIZOPHRENIA; FMRI; DISORDERS; MODEL; HETEROGENEITY AB Abnormal brain connectivity or network dysfunction has been suggested as a paradigm to understand several psychiatric disorders. We here review the use of novel meta-analytic approaches in neuroscience that go beyond a summary description of existing results by applying network analysis methods to previously published studies and/or publicly accessible databases. We define this strategy of combining connectivity with other brain characteristics as meta-connectomics'. For example, we show how network analysis of task-based neuroimaging studies has been used to infer functional co-activation from primary data on regional activations. This approach has been able to relate cognition to functional network topology, demonstrating that the brain is composed of cognitively specialized functional subnetworks or modules, linked by a rich club of cognitively generalized regions that mediate many inter-modular connections. Another major application of meta-connectomics has been efforts to link meta-analytic maps of disorder-related abnormalities or MRI lesions' to the complex topology of the normative connectome. This work has highlighted the general importance of network hubs as hotspots for concentration of cortical grey-matter deficits in schizophrenia, Alzheimer's disease and other disorders. Finally, we show how by incorporating cellular and transcriptional data on individual nodes with network models of the connectome, studies have begun to elucidate the microscopic mechanisms underpinning the macroscopic organization of whole-brain networks. We argue that meta-connectomics is an exciting field, providing robust and integrative insights into brain organization that will likely play an important future role in consolidating network models of psychiatric disorders. C1 [Crossley, N. A.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychosis Studies, London WC2R 2LS, England. [Crossley, N. A.] P Catholic Univ Chile, Inst Biol & Med Engn, Sch Med, Santiago, Chile. [Crossley, N. A.] P Catholic Univ Chile, Sch Biol Sci & Engn, Santiago, Chile. [Crossley, N. A.] P Catholic Univ Chile, Sch Med, Dept Psychiat, Santiago, Chile. [Fox, P. T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Fox, P. T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Fox, P. T.] South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA. [Bullmore, E. T.] Univ Cambridge, Dept Psychiat, Behav & Clin Neurosci Inst, Cambridge, England. [Bullmore, E. T.] Cambridgeshire & Peterborough NHS Fdn Trust, Cambridge, England. [Bullmore, E. T.] GlaxoSmithKline, ImmunoPsychiat Alternat Discovery & Dev, Cambridge, England. RP Crossley, NA (reprint author), Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychosis Studies, London WC2R 2LS, England. EM nicolas.crossley@kcl.ac.uk OI Bullmore, Edward/0000-0002-8955-8283; Crossley, Nicolas/0000-0002-3060-656X FU National Institute of Health (NIH) [R01MH074457] FX PTF is supported by a National Institute of Health (NIH) award (R01MH074457). NR 70 TC 4 Z9 5 U1 3 U2 24 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 EI 1469-8978 J9 PSYCHOL MED JI Psychol. Med. PD APR PY 2016 VL 46 IS 5 BP 897 EP 907 DI 10.1017/S0033291715002895 PG 11 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA DF8PQ UT WOS:000371620700001 PM 26809184 ER PT J AU Dasari, M Borrero, S Akers, AY Sucato, GS Dick, R Hicks, A Miller, E AF Dasari, Mohini Borrero, Sonya Akers, Aletha Y. Sucato, Gina S. Dick, Rebecca Hicks, Angela Miller, Elizabeth TI Barriers to Long-Acting Reversible Contraceptive Uptake Among Homeless Young Women SO JOURNAL OF PEDIATRIC AND ADOLESCENT GYNECOLOGY LA English DT Article DE Contraception; LARC; IUD; Implant; Homelessness; Mixed-methods ID ADOLESCENT; ATTITUDES; PERSPECTIVES; YOUTH; LARC AB Study Objective: To identify barriers to long-acting reversible contraception (LARC) uptake among homeless young women. Design: In this mixed methods study surveys and guided interviews were used to explore women's contraceptive and reproductive experiences, interactions with the health care system, and their histories of homelessness. Setting: All surveys and interviews were conducted at a homeless drop-in center or shelter. Participants: Fifteen women between 18 and 24 years of age with a past year history of homelessness. Interventions: None. Main Outcome Measures: Perceived barriers to contraceptive use, including knowledge and access barriers and interactions with the health care system around reproductive health. Results: Confusion about the possibility of early termination of LARC, and the perception that providers deliberately withhold selective information about contraceptive options to bias contraceptive decision-making, were 2 key new findings. Women also reported interest in visual aids accompanying verbal contraceptive counseling. Pregnancy attitudes and history of reproductive and sexual coercion also influenced contraceptive decision-making and reported interest in LARC methods. Conclusion: Comprehensive counseling about all contraceptive options, including LARC, are important for targeting the perceived gaps in contraceptive education and care among homeless young women. C1 [Dasari, Mohini] Univ Pittsburgh, Sch Med, M240 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. [Borrero, Sonya] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA 15261 USA. [Borrero, Sonya] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA USA. [Akers, Aletha Y.] Childrens Hosp Philadelphia, Craig Dalsimer Div Adolescent Med, Philadelphia, PA 19104 USA. [Sucato, Gina S.] Seattle Childrens Hosp, Adolescent Hlth, Grp Hlth Cooperat, Seattle, WA USA. [Dick, Rebecca; Hicks, Angela; Miller, Elizabeth] Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, Div Adolescent & Young Adult Med, Pittsburgh, PA 15261 USA. [Miller, Elizabeth] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA. RP Dasari, M (reprint author), Univ Pittsburgh, Sch Med, M240 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM mod13@pitt.edu NR 26 TC 0 Z9 0 U1 5 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-3188 EI 1873-4332 J9 J PEDIATR ADOL GYNEC JI J. Pediatr Adolesc. Gynecol. PD APR PY 2016 VL 29 IS 2 BP 104 EP 110 DI 10.1016/j.jpag.2015.07.003 PG 7 WC Obstetrics & Gynecology; Pediatrics SC Obstetrics & Gynecology; Pediatrics GA DF2SA UT WOS:000371192900006 PM 26210293 ER PT J AU Pope, CA Escobar-Gomez, M Davis, BH Roberts, JR O'Brien, ES Hinton, E Darden, PM AF Pope, C. A. Escobar-Gomez, M. Davis, B. H. Roberts, J. R. O'Brien, E. S. Hinton, E. Darden, P. M. TI The challenge of tetradic relationships in medically interpreted pediatric primary care visits: A descriptive study of communication practices SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Adolescent; Primary care; Healthcare disparities; Communication barriers; Linguistics; Hispanic Americans ID LIMITED ENGLISH PROFICIENCY; OF-THE-LITERATURE; LANGUAGE SERVICES; HEALTH-CARE; CONSULTATIONS; FAMILIES AB Objective: To examine spoken interactions between pediatricians and community-based interpreters speaking with adolescents and parents with Limited English proficiency (LEP) in primary care to identify the challenges of interpreting in a four-person or tetradic visit, its sources of co-constructed errors, and specific practices for educational intervention. Methods: As part of a larger study of vaccine decision-making at six clinical sites in two states, this descriptive study used discourse analysis to examine 20 routine primary care visits in a Latino Clinic in interactions between adolescents, parents, community-based interpreters, and pediatricians. Specific patterns of communication practices were identified that contributed to inaccuracies in medical interpretation Results: Practices needing improvement were tallied for simple frequencies and included: omissions; false fluency; substitutions; editorializing; added clarification, information, or questions; medical terminology; extra explanation to mother; and, cultural additions. Of these speaking practices, omissions were the most common (123 out of 292 total) and the most affected by pediatricians. Conclusion: The dynamics of both pediatricians and interpreters contributed to identification of areas for improvement, with more adolescent participation in bilingual than monolingual visits. Practice implications: These observations provide opportunities for mapping a communication skills training intervention based on observations for future testing of an evidence-based curriculum. Published by Elsevier Ireland Ltd. C1 [Pope, C. A.] Med Univ S Carolina, Coll Nursing, 99 Jonathan Lucas St SN511,MSC 160, Charleston, SC 29425 USA. [Pope, C. A.] Ralph H Johnson Vet Affairs VA Med Ctr, Charleston, SC 29401 USA. [Davis, B. H.] Univ N Carolina, Dept English, Charlotte, NC 28223 USA. [Roberts, J. R.; O'Brien, E. S.; Hinton, E.] Med Univ S Carolina, Coll Med, Dept Pediat, Charleston, SC 29425 USA. [Darden, P. M.] Univ Oklahoma, Hlth Sci Ctr, Gen & Community Pediat, Oklahoma City, OK 73104 USA. [Escobar-Gomez, M.] Bilingo LLC, Goose Creek, SC USA. RP Pope, CA (reprint author), Med Univ S Carolina, Coll Nursing, 99 Jonathan Lucas St SN511,MSC 160, Charleston, SC 29425 USA. EM popec@musc.edu; eskobarm@gmail.com; bdavis@uncc.edu; robertsj@musc.edu; obriene@musc.edu; HintonE@musc.edu; paul-darden@ouhsc.edu FU South Carolina Pediatric Practice Research Network; Oklahoma Child Health Research Network; Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Research Program [R40 MC 21522] FX This research was supported by funding from the R40 MC 21522 through the Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Research Program, Principal Investigator, Dr. Paul Darden. We are grateful to the adolescents, parents, and pediatric practices that allowed us to record and learn from their encounters and the support of the South Carolina Pediatric Practice Research Network and the Oklahoma Child Health Research Network. NR 31 TC 0 Z9 0 U1 6 U2 10 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD APR PY 2016 VL 99 IS 4 BP 542 EP 548 DI 10.1016/j.pec.2015.10.032 PG 7 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA DH7IE UT WOS:000372965900008 PM 26796067 ER PT J AU Lee, JD Friedmann, PD Kinlock, TW Nunes, EV Boney, TY Hoskinson, RA Wilson, D McDonald, R Rotrosen, J Gourevitch, MN Gordon, M Fishman, M Chen, DT Bonnie, RJ Cornish, JW Murphy, SM O'Brien, CP AF Lee, Joshua D. Friedmann, Peter D. Kinlock, Timothy W. Nunes, Edward V. Boney, Tamara Y. Hoskinson, Randall A., Jr. Wilson, Donna McDonald, Ryan Rotrosen, John Gourevitch, Marc N. Gordon, Michael Fishman, Marc Chen, Donna T. Bonnie, Richard J. Cornish, James W. Murphy, Sean M. O'Brien, Charles P. TI Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID RANDOMIZED CLINICAL-TRIAL; METHADONE-MAINTENANCE; BUPRENORPHINE; DEPENDENCE; TIME; PROBATIONERS; POSTRELEASE; ADDICTION; SEVERITY; PAROLEES AB BACKGROUND Extended-release naltrexone, a sustained-release monthly injectable formulation of the full mu-opioid receptor antagonist, is effective for the prevention of relapse to opioid dependence. Data supporting its effectiveness in U.S. criminal justice populations are limited. METHODS In this five-site, open-label, randomized trial, we compared a 24-week course of extended-release naltrexone (Vivitrol) with usual treatment, consisting of brief counseling and referrals for community treatment programs, for the prevention of opioid relapse among adult criminal justice offenders (i.e., persons involved in the U.S. criminal justice system) who had a history of opioid dependence and a preference for opioid-free rather than opioid maintenance treatments and who were abstinent from opioids at the time of randomization. The primary outcome was the time to an opioid-relapse event, which was defined as 10 or more days of opioid use in a 28-day period as assessed by self-report or by testing of urine samples obtained every 2 weeks; a positive or missing sample was computed as 5 days of opioid use. Post-treatment follow-up occurred at weeks 27, 52, and 78. RESULTS A total of 153 participants were assigned to extended-release naltrexone and 155 to usual treatment. During the 24-week treatment phase, participants assigned to extended-release naltrexone had a longer median time to relapse than did those assigned to usual treatment (10.5 vs. 5.0 weeks, P<0.001; hazard ratio, 0.49; 95% confidence interval [CI], 0.36 to 0.68), a lower rate of relapse (43% vs. 64% of participants, P<0.001; odds ratio, 0.43; 95% CI, 0.28 to 0.65), and a higher rate of opioid-negative urine samples (74% vs. 56%, P<0.001; odds ratio, 2.30; 95% CI, 1.48 to 3.54). At week 78 (approximately 1 year after the end of the treatment phase), rates of opioid-negative urine samples were equal (46% in each group, P = 0.91). The rates of other prespecified secondary outcome measures - self-reported cocaine, alcohol, and intravenous drug use, unsafe sex, and reincarceration - were not significantly lower with extended-release naltrexone than with usual treatment. Over the total 78 weeks observed, there were no overdose events in the extended-release naltrexone group and seven in the usual-treatment group (P = 0.02). CONCLUSIONS In this trial involving criminal justice offenders, extended-release naltrexone was associated with a rate of opioid relapse that was lower than that with usual treatment. Opioid-use prevention effects waned after treatment discontinuation. C1 [Lee, Joshua D.; McDonald, Ryan; Gourevitch, Marc N.] NYU, Dept Populat Hlth, 227 E 30th St, New York, NY 10016 USA. [Lee, Joshua D.] NYU, Dept Med, Div Gen Internal Med & Clin Innovat, New York, NY USA. [Rotrosen, John] NYU, Dept Psychiat, New York, NY USA. [Nunes, Edward V.] Columbia Univ, Coll Phys & Surg, New York State Psychiat Inst, New York, NY USA. [Friedmann, Peter D.; Hoskinson, Randall A., Jr.; Wilson, Donna] Rhode Isl Hosp, Div Gen Internal Med, Dept Med, Providence, RI USA. [Friedmann, Peter D.; Hoskinson, Randall A., Jr.; Wilson, Donna] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA. [Kinlock, Timothy W.; Gordon, Michael; Fishman, Marc] Univ Baltimore, Sch Criminal Justice, Friends Res Inst, Baltimore, MD 21201 USA. [Fishman, Marc] Maryland Treatment Ctr, Baltimore, MD USA. [Boney, Tamara Y.; Cornish, James W.; O'Brien, Charles P.] Univ Penn, Philadelphia, PA 19104 USA. [Cornish, James W.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Chen, Donna T.] Univ Virginia, Ctr Biomed Eth & Humanities, Sch Med, Charlottesville, VA USA. [Bonnie, Richard J.] Univ Virginia, Sch Law, Charlottesville, VA USA. [Murphy, Sean M.] Washington State Univ, Spokane, WA USA. RP Lee, JD (reprint author), NYU, Dept Populat Hlth, 227 E 30th St, New York, NY 10016 USA. EM joshua.lee@nyumc.org OI Gourevitch, Marc/0000-0001-6865-2126 FU National Institute on Drug Abuse FX Funded by the National Institute on Drug Abuse NR 24 TC 14 Z9 14 U1 4 U2 10 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 31 PY 2016 VL 374 IS 13 BP 1232 EP 1242 DI 10.1056/NEJMoa1505409 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA DH8ZM UT WOS:000373085500006 PM 27028913 ER PT J AU Coughlin, B Schnabolk, G Joseph, K Raikwar, H Kunchithapautham, K Johnson, K Moore, K Wang, Y Rohrer, B AF Coughlin, Beth Schnabolk, Gloriane Joseph, Kusumam Raikwar, Himanshu Kunchithapautham, Kannan Johnson, Krista Moore, Kristi Wang, Yi Rohrer, Baerbel TI Connecting the innate and adaptive immune responses in mouse choroidal neovascularization via the anaphylatoxin C5a and gamma delta T-cells SO SCIENTIFIC REPORTS LA English DT Article ID RETINAL-PIGMENT EPITHELIUM; COMPLEMENT-MEDIATED INJURY; FACTOR-H POLYMORPHISM; MACULAR DEGENERATION; OXIDATIVE STRESS; RISK-FACTORS; MONOCLONAL-ANTIBODY; FACTOR-B; ACTIVATION; DRUSEN AB Neovascular age-related macular degeneration (AMD) is characterized by choroidal neovascularization (CNV). An overactive complement system is associated with AMD pathogenesis, and serum proinflammatory cytokines, including IL-17, are elevated in AMD patients. IL-17 is produced by complement C5a-receptor-expressing T-cells. In murine CNV, infiltrating gamma delta T-rather than Th17-cells produce the IL-17 measurable in lesioned eyes. Here we asked whether C5a generated locally in response to CNV recruits IL-17-producing T-cells to the eye. CNV lesions were generated using laser photocoagulation and quantified by imaging; T-lymphocytes were characterized by QRT-PCR. CNV resulted in an increase in splenic IL-17-producing gamma delta T- and Th17-cells; yet in the CNV eye, only elevated levels of gamma delta T-cells were observed. Systemic administration of anti-C5- or anti-C5a-blocking antibodies blunted the CNV-induced production of splenic Th17- and gamma delta T-cells, reduced CNV size and eliminated ocular gamma delta T-cell infiltration. In ARPE-19 cell monolayers, IL-17 triggered a pro-inflammatory state; and splenocyte proliferation was elevated in response to ocular proteins. Thus, we demonstrated that CNV lesions trigger a systemic immune response, augmenting local ocular inflammation via the infiltration of IL-17-producing gamma delta T-cells, which are presumably recruited to the eye in a C5a-dependent manner. Understanding the complexity of complement-mediated pathological mechanisms will aid in the development of an AMD treatment. C1 [Coughlin, Beth; Joseph, Kusumam; Raikwar, Himanshu; Kunchithapautham, Kannan; Rohrer, Baerbel] Med Univ S Carolina, Dept Ophthalmol, 171 Ashley Ave, Charleston, SC 29425 USA. [Schnabolk, Gloriane; Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA. [Johnson, Krista; Moore, Kristi; Wang, Yi] Alex Pharmaceut, 352 Knotter Dr, Cheshire, CT 06410 USA. [Raikwar, Himanshu] Pandit Bhagwat Dayal Sharma Post Grad Inst Med Sc, Rohtak, Haryana, India. RP Rohrer, B (reprint author), Med Univ S Carolina, Dept Ophthalmol, 171 Ashley Ave, Charleston, SC 29425 USA.; Rohrer, B (reprint author), Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA. EM rohrer@musc.edu FU National Institutes of Health (NIH) [R01EY019320, C06 RR015455]; Department of Veterans Affairs [I01 RX000444]; Foundation Fighting Blindness; Alexion Therapeutics; Research to Prevent Blindness (RPB), Inc., New York, NY FX Supported in part by the National Institutes of Health (NIH) (R01EY019320), Department of Veterans Affairs (I01 RX000444), Foundation Fighting Blindness, an unrestricted grant to MUSC from Research to Prevent Blindness (RPB), Inc., New York, NY and a sponsored research agreement by Alexion Therapeutics to BR. Animal studies were conducted in a facility constructed with support from the NIH (C06 RR015455). NR 84 TC 2 Z9 2 U1 2 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD MAR 31 PY 2016 VL 6 AR 23794 DI 10.1038/srep23794 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DI0ET UT WOS:000373168600001 PM 27029558 ER PT J AU Lee, MH Appleton, KM Strungs, EG Kwon, JY Morinelli, TA Peterson, YK Laporte, SA Luttrell, LM AF Lee, Mi-Hye Appleton, Kathryn M. Strungs, Erik G. Kwon, Joshua Y. Morinelli, Thomas A. Peterson, Yuri K. Laporte, Stephane A. Luttrell, Louis M. TI The conformational signature of beta-arrestin2 predicts its trafficking and signalling functions SO NATURE LA English DT Article ID COUPLED RECEPTOR ACTIVATION; BETA-ARRESTIN; G-PROTEIN; CRYSTAL-STRUCTURE; CLATHRIN ADAPTER; BIASED AGONISM; LIVING CELLS; ENDOCYTOSIS; MECHANISM; PHOSPHORYLATION AB Arrestins are cytosolic proteins that regulate G-protein-coupled receptor (GPCR) desensitization, internalization, trafficking and signalling(1,2). Arrestin recruitment uncouples GPCRs from heterotrimeric G proteins, and targets the proteins for internalization via clathrin-coated pits(3,4). Arrestins also function as ligand-regulated scaffolds that recruit multiple non-G-protein effectors into GPCR-based 'signalsomes'(5,6). Although the dominant function(s) of arrestins vary between receptors, the mechanism whereby different GPCRs specify these divergent functions is unclear. Using a panel of intramolecular fluorescein arsenical hairpin (FlAsH) bioluminescence resonance energy transfer (BRET) reporters(7) to monitor conformational changes in beta-arrestin2, here we show that GPCRs impose distinctive arrestin 'conformational signatures' that reflect the stability of the receptor-arrestin complex and role of a-arrestin2 in activating or dampening downstream signalling events. The predictive value of these signatures extends to structurally distinct ligands activating the same GPCR, such that the innate properties of the ligand are reflected as changes in beta-arrestin2 conformation. Our findings demonstrate that information about ligand-receptor conformation is encoded within the population average a-arrestin2 conformation, and provide insight into how different GPCRs can use a common effector for different purposes. This approach may have application in the characterization and development of functionally selective GPCR ligands(8,9) and in identifying factors that dictate arrestin conformation and function. C1 [Lee, Mi-Hye; Appleton, Kathryn M.; Strungs, Erik G.; Kwon, Joshua Y.; Morinelli, Thomas A.; Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Peterson, Yuri K.] Med Univ S Carolina, Coll Pharm, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA. [Laporte, Stephane A.] McGill Univ, Res Inst, Ctr Hlth, Dept Med, Quebec City, PQ H4A 3J1, Canada. [Laporte, Stephane A.] McGill Univ, Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada. [Laporte, Stephane A.] McGill Univ, Anat & Cell Biol, Quebec City, PQ H3A 0C7, Canada. [Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA. RP Luttrell, LM (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.; Luttrell, LM (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA. EM luttrell@musc.edu FU National Institutes of Health [DK055524, GM095497, RR027777]; Dialysis Clinics, Inc.; Research Service of the Charleston, SC Veterans Affairs Medical Center; Canadian Institutes of Health [MOP-74603] FX This work was supported by National Institutes of Health grants DK055524 (L.M.L.) and GM095497 (L.M.L.), funds provided by Dialysis Clinics, Inc. (T.A.M), and the Research Service of the Charleston, SC Veterans Affairs Medical Center (L.M.L.). Supported by Canadian Institutes of Health Research operating grant MOP-74603 (S.A.L.). National Institutes of Health grant RR027777 (L.M.L.) supported the FLIPRTETRA facility. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government. NR 33 TC 21 Z9 21 U1 8 U2 23 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 EI 1476-4687 J9 NATURE JI Nature PD MAR 31 PY 2016 VL 531 IS 7596 BP 665 EP + DI 10.1038/nature17154 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DH8EX UT WOS:000373027400044 PM 27007854 ER PT J AU Yuan, GD Zhang, BX Yang, SZ Jin, L Datta, A Bae, S Chen, XP Datta, PK AF Yuan, Guandou Zhang, Bixiang Yang, Shanzhong Jin, Lin Datta, Arunima Bae, Sejong Chen, Xiaoping Datta, Pran K. TI Novel role of STRAP in progression and metastasis of colorectal cancer through Wnt/beta-catenin signaling SO ONCOTARGET LA English DT Article DE STRAP; beta-catenin; CRC; metastasis; tissue microarray ID RECEPTOR-ASSOCIATED PROTEIN; BETA-CATENIN; DESTRUCTION COMPLEX; KINASE; EXPRESSION; INHIBITION; APC; IDENTIFICATION; ACTIVATION; GSK3-BETA AB Serine-Threonine Kinase Receptor-Associated Protein (STRAP) interacts with a variety of proteins and influences a wide range of cellular processes. Aberrant activation of Wnt/beta-catenin signaling has been implicated in the development of colorectal cancer (CRC). Here, we show the molecular mechanism by which STRAP induces CRC metastasis by promoting beta-catenin signaling through its stabilization. We have genetically engineered a series of murine and human CRC and lung cancer cell lines to investigate the effects of STRAP on cell migration and invasion in vitro, and on tumorigenicity and metastasis in vivo. Downregulation of STRAP inhibits invasion, tumorigenicity, and metastasis of CRC cells. Mechanistically, STRAP binds with GSK-3 beta and reduces the phosphorylation, ubiquitylation, and degradation of beta-catenin through preventing its binding to the destruction complex. This leads to an inhibition of Wnt/beta-catenin signaling and reduction in the expression of downstream targets, such as Cyclin D1, matrix metalloproteinases 2 and 9, and beta-TrCP. In human CRC specimens, higher STRAP expression correlates significantly with beta-catenin expression with increased nuclear levels (R = 0.696, p < .0001, n = 128). Together, these results suggest that STRAP increases invasion and metastasis of CRC partly through inhibiting ubiquitin-dependent degradation of beta-catenin and promoting Wnt/beta-catenin signaling. C1 [Yuan, Guandou; Yang, Shanzhong; Jin, Lin; Datta, Arunima; Datta, Pran K.] Univ Alabama Birmingham, Dept Med, UAB Comprehens Canc Ctr, Div Hematol & Oncol, Birmingham, AL 35294 USA. [Datta, Pran K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Yuan, Guandou; Zhang, Bixiang; Chen, Xiaoping] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan 430074, Peoples R China. [Bae, Sejong] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL USA. RP Datta, PK (reprint author), Univ Alabama Birmingham, Dept Med, UAB Comprehens Canc Ctr, Div Hematol & Oncol, Birmingham, AL 35294 USA.; Datta, PK (reprint author), Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.; Chen, XP (reprint author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan 430074, Peoples R China. EM chenxpchenxp@163.com; prandatta@uabmc.edu FU National Cancer Institute [R01 CA95195]; Veterans Affairs Merit Review Award; UAB Comprehensive Cancer Center [P30 CA013148] FX This study was supported by National Cancer Institute R01 CA95195, Veterans Affairs Merit Review Award, and a Faculty Development Award from UAB Comprehensive Cancer Center, P30 CA013148 (to PK Datta). NR 46 TC 3 Z9 3 U1 1 U2 1 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD MAR 29 PY 2016 VL 7 IS 13 BP 16023 EP 16037 PG 15 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DL5QW UT WOS:000375692900057 PM 26910283 ER PT J AU Maron, BA Hess, E Maddox, TM Opotowsky, AR Tedford, RJ Lahm, T Joynt, KE Kass, DJ Stephens, T Stanislawski, MA Swenson, ER Goldstein, RH Leopold, JA Zamanian, RT Elwing, JM Plomondon, ME Grunwald, GK Baron, AE Rumsfeld, JS Choudhary, G AF Maron, Bradley A. Hess, Edward Maddox, Thomas M. Opotowsky, Alexander R. Tedford, Ryan J. Lahm, Tim Joynt, Karen E. Kass, Daniel J. Stephens, Thomas Stanislawski, Maggie A. Swenson, Erik R. Goldstein, Ronald H. Leopold, Jane A. Zamanian, Roham T. Elwing, Jean M. Plomondon, Mary E. Grunwald, Gary K. Baron, Anna E. Rumsfeld, John S. Choudhary, Gaurav TI Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program SO CIRCULATION LA English DT Article DE pulmonary hypertension; pulmonary heart disease; outcome assessment ID REDUCED EJECTION FRACTION; ARTERY SYSTOLIC PRESSURE; HEART-FAILURE; AFRICAN-AMERICANS; DIAGNOSIS; CLASSIFICATION AB Background- Pulmonary hypertension (PH) is associated with increased morbidity across the cardiopulmonary disease spectrum. Based primarily on expert consensus opinion, PH is defined by a mean pulmonary artery pressure (mPAP) >= 25 mm Hg. Although mPAP levels below this threshold are common among populations at risk for PH, the relevance of mPAP < 25 mm Hg to clinical outcome is unknown. Methods and Results- We analyzed retrospectively all US veterans undergoing right heart catheterization (2007-2012) in the Veterans Affairs healthcare system (n=21 727; 908-day median follow-up). Cox proportional hazards models were used to evaluate the association between mPAP and outcomes of all-cause mortality and hospitalization, adjusted for clinical covariates. When treating mPAP as a continuous variable, the mortality hazard increased beginning at 19 mm Hg (hazard ratio [HR]=1.183; 95% confidence interval [CI], 1.004-1.393) relative to 10 mm Hg. Therefore, patients were stratified into 3 groups: (1) referent (<= 18 mm Hg; n=4 207); (2) borderline PH (19-24 mm Hg; n=5 030); and (3) PH (>= 25 mm Hg; n=12 490). The adjusted mortality hazard was increased for borderline PH (HR=1.23; 95% CI, 1.12-1.36; P < 0.0001) and PH (HR=2.16; 95% CI, 1.96-2.38; P < 0.0001) compared with the referent group. The adjusted hazard for hospitalization was also increased in borderline PH (HR=1.07; 95% CI, 1.01-1.12; P=0.0149) and PH (HR=1.15; 95% CI, 1.09-1.22; P < 0.0001). The borderline PH cohort remained at increased risk for mortality after excluding the following high-risk subgroups: (1) patients with pulmonary artery wedge pressure > 15 mm Hg; (2) pulmonary vascular resistance >= 3.0 Wood units; or (3) inpatient status at the time of right heart catheterization. Conclusions- These data illustrate a continuum of risk according to mPAP level and that borderline PH is associated with increased mortality and hospitalization. Future investigations are needed to test the generalizability of our findings to other populations and study the effect of treatment on outcome in borderline PH. C1 [Maron, Bradley A.; Goldstein, Ronald H.] Vet Affairs Boston Healthcare Syst, West Roxbury, MA 02132 USA. [Maron, Bradley A.; Opotowsky, Alexander R.; Stephens, Thomas; Leopold, Jane A.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Maron, Bradley A.; Opotowsky, Alexander R.; Stephens, Thomas; Leopold, Jane A.] Harvard Univ, Sch Med, Boston, MA USA. [Hess, Edward; Maddox, Thomas M.; Stanislawski, Maggie A.; Plomondon, Mary E.; Grunwald, Gary K.; Baron, Anna E.; Rumsfeld, John S.] Vet Affairs Eastern Colorado Hlth Care Syst, Denver, CO USA. [Maddox, Thomas M.] Univ Colorado, Sch Med, Boulder, CO 80309 USA. [Opotowsky, Alexander R.] Boston Childrens Hosp, Boston, MA USA. [Tedford, Ryan J.] Johns Hopkins Sch Med, Div Cardiol, Dept Med, Baltimore, MD USA. [Lahm, Tim] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Lahm, Tim] Richard L Roudebush Vet Affairs Med Ctr, 1481 W 10th St, Indianapolis, IN 46202 USA. [Joynt, Karen E.] US Dept HHS, Off Assistant Secretary Planning & Evaluat, Washington, DC 20201 USA. [Kass, Daniel J.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Swenson, Erik R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Swenson, Erik R.] Univ Washington, Seattle, WA 98195 USA. [Zamanian, Roham T.] Stanford Univ, Sch Med, Vera Moulton Wall Ctr Pulm Vasc Dis, Stanford, CA 94305 USA. [Elwing, Jean M.] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA. [Elwing, Jean M.] Univ Cincinnati, Cincinnati, OH 45221 USA. [Choudhary, Gaurav] Brown Univ, Providence Vet Affairs Med Ctr, Providence, RI 02912 USA. [Choudhary, Gaurav] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA. RP Maron, BA (reprint author), Vet Affairs Boston Healthcare Syst, Div Cardiol, Dept Med, 1400 VFW Pkwy, West Roxbury, MA 02132 USA. EM Bradley.Maron@va.gov FU National Institutes of Health (NIH) [1K08HL11207-01A1]; American Heart Association [15GRNT25080016]; Pulmonary Hypertension Association; Cardiovascular Medical Research and Education Fund; Klarman Foundation at Brigham and Women's Hospital; Gilead Young Scholars Foundation (Gilead Sciences); Veterans Affairs Health Services Research and Development Career Development Award [CDA 08-021]; Dunlevie Family Fund; Office of Research and Development: Biomedical Laboratory Research and Development Service (MERIT Review Award) [1I01BX002042-01A2, IBX000711A]; Department of Veterans Affairs, Veterans Health Administration; Catherine and Lowe Berger and Pauline L. Ford Scholarship in Pulmonary Medicine; Department of Medicine, Indiana University; VA Merit Award from the Department of Veterans Affairs, Veterans Health Administration; Office of Research and Development: Clinical Science Research and Development Service; NIH/National Heart, Lung, and Blood Institute (NHLBI) [1U01HL125215-01]; Junior Faculty Endowment by Vera Moulton Wall Center for Pulmonary Vascular Disease; NIH/NHLBI/National Institute of Allergy and Infectious Diseases [PO1 HL108797, UO1 HL107393, R24 HL123767, N01 HV00242, ASCO1]; Department of Medicine, Alpert Medical School FX Dr Maron was supported by National Institutes of Health (NIH) Grant 1K08HL11207-01A1, American Heart Association Grant 15GRNT25080016, the Pulmonary Hypertension Association, the Cardiovascular Medical Research and Education Fund, the Klarman Foundation at Brigham and Women's Hospital, and Gilead Young Scholars Foundation (Gilead Sciences). Dr Maddox was supported by Veterans Affairs Health Services Research and Development Career Development Award CDA 08-021. Dr Opotowsky was supported by the Dunlevie Family Fund. Dr Lahm was supported by Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development: Biomedical Laboratory Research and Development Service (MERIT Review Award 1I01BX002042-01A2), and Catherine and Lowe Berger and Pauline L. Ford Scholarship in Pulmonary Medicine, Department of Medicine, Indiana University. Dr Goldstein was supported by VA Merit Award from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development: Clinical Science Research and Development Service. Dr Leopold was supported by NIH/National Heart, Lung, and Blood Institute (NHLBI) Grant 1U01HL125215-01. Dr Zamanian was supported by Junior Faculty Endowment by Vera Moulton Wall Center for Pulmonary Vascular Disease and NIH/NHLBI/National Institute of Allergy and Infectious Diseases Grants PO1 HL108797, UO1 HL107393, R24 HL123767, N01 HV00242, and ASCO1. Dr Choudhary was supported by Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development: Biomedical Laboratory Research and Development Service (MERIT Review Award IBX000711A) and the Department of Medicine, Alpert Medical School. NR 30 TC 11 Z9 11 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD MAR 29 PY 2016 VL 133 IS 13 BP 1240 EP 1248 DI 10.1161/CIRCULATIONAHA.115.020207 PG 9 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DH5ST UT WOS:000372852800004 PM 26873944 ER PT J AU Arsalan, M Szerlip, M Vemulapalli, S Holper, EM Arnold, SV Li, ZK DiMaio, MJ Rumsfeld, JS Brown, DL Mack, MJ AF Arsalan, Mani Szerlip, Molly Vemulapalli, Sreekanth Holper, Elizabeth M. Arnold, Suzanne V. Li, Zhuokai DiMaio, Michael J. Rumsfeld, John S. Brown, David L. Mack, Michael J. TI Should Transcatheter Aortic Valve Replacement Be Performed in Nonagenarians? Insights From the STS/ACC TVT Registry SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE centenarians; elderly; quality of life; TAVI; TAVR; transcatheter aortic valve implantation ID CITY CARDIOMYOPATHY QUESTIONNAIRE; END-POINT DEFINITIONS; CARDIAC-SURGERY; IMPLANTATION; STENOSIS; OUTCOMES; MANAGEMENT; VERSION; RISK; SAFE AB BACKGROUND Data demonstrating the outcome of transcatheter aortic valve replacement (TAVR) in the very elderly patients are limited, as they often represent only a small proportion of the trial populations. OBJECTIVES The purpose of this study was to compare the outcomes of nonagenarians to younger patients undergoing TAVR in current practice. METHODS We analyzed data from the Society of Thoracic Surgeons/American College of Cardiology TVT (Transcatheter Valve Therapy) Registry. Outcomes at 30 days and 1 year were compared between patients >= 90 years versus <90 years of age using cumulative incidence curves. Quality of life was assessed with the 12-item Kansas City Cardiomyopathy Questionnaire. RESULTS Between November 2011 and September 2014, 24,025 patients underwent TAVR in 329 participating hospitals, of which 3,773 (15.7%) were age >= 90 years. The 30-day and 1-year mortality rates were significantly higher among nonagenarians (age >= 90 years vs. <90 years: 30-day: 8.8% vs. 5.9%; p < 0.001; 1 year: 24.8% vs. 22.0%; p < 0.001, absolute risk: 2.8%, relative risk: 12.7%). However, nonagenarians had a higher mean Society of Thoracic Surgeons Predicted Risk of Operative Mortality score (10.9% vs. 8.1%; p < 0.001) and, therefore, had similar ratios of observed to expected rates of 30-day death (age >= 90 years vs. <90 years: 0.81, 95% confidence interval: 0.70 to 0.92 vs. 0.72, 95% confidence interval: 0.67 to 0.78). There were no differences in the rates of stroke, aortic valve reintervention, or myocardial infarction at 30 days or 1 year. Nonagenarians had lower (worse) median Kansas City Cardiomyopathy Questionnaire scores at 30 days; however, there was no significant difference at 1 year. CONCLUSIONS In current U.S. clinical practice, approximately 16% of patients undergoing TAVR are >= 90 years of age. Although 30-day and 1-year mortality rates were statistically higher compared with younger patients undergoing TAVR, the absolute and relative differences were clinically modest. TAVR also improves quality of life to the same degree in nonagenarians as in younger patients. These data support safety and efficacy of TAVR in select very elderly patients. (C) 2016 by the American College of Cardiology Foundation. C1 [Arsalan, Mani; Szerlip, Molly; Holper, Elizabeth M.; DiMaio, Michael J.; Brown, David L.; Mack, Michael J.] Heart Hosp Baylor Plano, 1100 Allied Dr, Plano, TX 75093 USA. [Arsalan, Mani] Kerckhoff Heart Ctr, Bad Nauheim, Germany. [Vemulapalli, Sreekanth; Li, Zhuokai] Duke Clin Res Inst, Durham, NC USA. [Arnold, Suzanne V.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA. [Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA. RP Mack, MJ (reprint author), Heart Hosp Baylor Plano, 1100 Allied Dr, Plano, TX 75093 USA. EM MichaeMa@baylorhealth.edu RI Li, Zhuokai/F-4681-2017 FU American College of Cardiology's National Cardiovascular Data Registry (NCDR); Abbott Vascular; Boston Scientific; American College of Cardiology FX The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (STS/ACC TVT) Registry is an initiative of the Society of Thoracic Surgeons and the American College of Cardiology. This research was supported by the American College of Cardiology's National Cardiovascular Data Registry (NCDR). The views expressed in this paper represent those of the author(s) and do not necessarily represent the official views of the NCDR or its associated professional societies identified at CVQuality.ACC.org/NCDR. Dr. Szerlip has served as a speaker for Edwards Lifesciences. Dr. Vemulapalli has received research grants from Abbott Vascular, Boston Scientific, and the American College of Cardiology. Dr. Holper has been a consultant to Boston Scientific and Asahi Intecc. Dr. Rumsfeld is Chief Science Officer of the NCDR. Dr. Mack is an uncompensated member of the executive committee of the PARTNER (Placement of Aortic Transcatheter Valve) trial of Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. NR 25 TC 4 Z9 4 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 29 PY 2016 VL 67 IS 12 BP 1387 EP 1395 DI 10.1016/j.jacc.2016.01.055 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DG9NA UT WOS:000372408500001 PM 27012397 ER PT J AU Teerlink, JR Felker, GM McMurray, JJV Ponikowski, P Metra, M Filippatos, GS Ezekowitz, JA Dickstein, K Cleland, JGF Kim, JB Lei, L Knusel, B Wolff, AA Malik, FI Wasserman, SM AF Teerlink, John R. Felker, G. Michael McMurray, John J. V. Ponikowski, Piotr Metra, Marco Filippatos, Gerasimos S. Ezekowitz, Justin A. Dickstein, Kenneth Cleland, John G. F. Kim, Jae B. Lei, Lei Knusel, Beat Wolff, Andrew A. Malik, Fady I. Wasserman, Scott M. CA ATOMIC-AHF Investigators TI Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure The ATOMIC-AHF Study SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE arrhythmia; cardiac myosin activator; dyspnea; inotrope ID CARDIAC MYOSIN ACTIVATOR; MYOCARDIAL OXYGEN-CONSUMPTION; TASK-FORCE; CONTROLLED TRIAL; ATPASE ACTIVITY; RELAX-AHF; ASCEND-HF; ASSOCIATION; OUTCOMES; HOSPITALIZATION AB BACKGROUND Omecamtiv mecarbil (OM) is a selective cardiac myosin activator that increases myocardial function in healthy volunteers and in patients with chronic heart failure. OBJECTIVES This study evaluated the pharmacokinetics, pharmacodynamics, tolerability, safety, and efficacy of OM in patients with acute heart failure (AHF). METHODS Patients admitted for AHF with left ventricular ejection fraction <= 40%, dyspnea, and elevated plasma concentrations of natriuretic peptides were randomized to receive a double-blind, 48-h intravenous infusion of placebo or OM in 3 sequential, escalating-dose cohorts. RESULTS In 606 patients, OM did not improve the primary endpoint of dyspnea relief (3 OM dose groups and pooled placebo: placebo, 41%; OM cohort 1, 42%; cohort 2, 47%; cohort 3, 51%; p = 0.33) or any of the secondary outcomes studied. In supplemental, pre-specified analyses, OM resulted in greater dyspnea relief at 48 h (placebo, 37% vs. OM, 51%; p = 0.034) and through 5 days (p = 0.038) in the high-dose cohort. OM exerted plasma concentration-related increases in left ventricular systolic ejection time (p < 0.0001) and decreases in end-systolic dimension (p < 0.05). The adverse event profile and tolerability of OM were similar to those of placebo, without increases in ventricular or supraventricular tachyarrhythmias. Plasma troponin concentrations were higher in OM-treated patients compared with placebo (median difference at 48 h, 0.004 ng/ml), but with no obvious relationship with OM concentration (p = 0.95). CONCLUSIONS In patients with AHF, intravenous OM did not meet the primary endpoint of dyspnea improvement, but it was generally well tolerated, it increased systolic ejection time, and it may have improved dyspnea in the high-dose group. (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure [ATOMIC-AHF]; NCT01300013) (C) 2016 by the American College of Cardiology Foundation. C1 [Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Teerlink, John R.] San Francisco VA Med Ctr, Sect Cardiol, San Francisco, CA 94121 USA. [Felker, G. Michael] Duke Univ, Sch Med, Div Cardiol, Durham, NC USA. [McMurray, John J. V.] Univ Glasgow, British Heart Fdn Cardiovasc Res Ctr, Glasgow, Lanark, Scotland. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Dept Heart Dis, Wroclaw, Poland. [Metra, Marco] Univ Brescia, Div Cardiol, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Brescia, Italy. [Filippatos, Gerasimos S.] Univ Athens, Hosp Attikon, Dept Cardiol, Athens, Greece. [Ezekowitz, Justin A.] Univ Alberta, Canadian VIGOUR Ctr, Edmonton, AB, Canada. [Dickstein, Kenneth] Univ Bergen, Cardiol Div, Bergen, Norway. [Dickstein, Kenneth] Stavanger Univ Hosp, Cardiol Div, Stavanger, Norway. [Cleland, John G. F.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Royal Brompton Hosp, London, England. [Cleland, John G. F.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Harefield Hosp, London, England. [Kim, Jae B.; Lei, Lei; Knusel, Beat; Wasserman, Scott M.] Amgen Inc, Thousand Oaks, CA 91320 USA. [Wolff, Andrew A.; Malik, Fady I.] Cytokinetics Inc, San Francisco, CA USA. RP Teerlink, JR (reprint author), San Francisco VA Med Ctr, Cardiol, 111C,4150 Clement St, San Francisco, CA 94121 USA. EM john.teerlink@ucsf.edu RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; mcmurray, john/0000-0002-6317-3975 FU Amgen, Inc.; Cytokinetics, Inc.; Amgen; Cytokinetics; Mast Therapeutics; Novartis; Sorbent; Trevena; Roche Diagnostics; Otsuka; National Heart, Lung, and Blood Institute; Singulex; Bayer; Servier; Cardiorentis; Vifor; European Union; Abbott; AstraZeneca; Biotronik; Boston Scientific; Johnson Johnson; Medtronic; Merck; Pfizer; Sanofi; Sorin; St. Jude Medical; University of Bergen; Alere; Philips; StealthPeptides FX The ATOMIC-AHF study was funded by Amgen, Inc. in collaboration with Cytokinetics, Inc. The design of the study protocols was the responsibility of the authors, Amgen, Inc., and Cytokinetics, Inc. All statistical analyses were performed by Amgen, Inc. Dr. Teerlink received research grants from Amgen, Cytokinetics, Mast Therapeutics, Novartis, Sorbent, and Trevena; and has served as a consultant to Amgen, Cytokinetics, Mast Therapeutics, Novartis, and Trevena. Dr. Felker has received research grants from Amgen, Roche Diagnostics, Novartis, Otsuka, and the National Heart, Lung, and Blood Institute; and has served as a consultant for Amgen, Novartis, Roche Diagnostics, Singulex, Trevena, Celladon, Bristol-Myers Squibb, Merck, and Medtronic. Dr. McMurray's employer, Glasgow University, has been paid by Cytokinetics and Amgen for his time spent working on the clinical trial program with omecamtiv mecarbil. Dr. McMurray has had travel and accommodation costs paid by Cytokinetics and Amgen in relation to advisory board and clinical trial meetings about omecamtiv mecarbil. Dr. Ponikowski has received consultancy and speaker honoraria from Amgen, Bayer, Cardiorentis, Johnson & Johnson, Novartis, and Servier; and has received an institutional research grant from Singulex. Dr. Metra has received consulting fees from Amgen, Bayer, Mast Therapeutics, Novartis, Servier, and Trevena. Dr. Filippatos has received research grants or consulting fees, or both, from Bayer, Novartis, Cardiorentis, Vifor, and the European Union. Dr. Ezekowitz has received research grants or honoraria from Amgen, Novartis, Trevena, and Cardiorentis. Dr. Dickstein has received honoraria and research support from Abbott, Amgen, AstraZeneca, Bayer, Biotronik, Boston Scientific, Johnson & Johnson, Medtronic, Merck, Novartis, Pfizer, Sanofi, Servier, Sorin, and St. Jude Medical; and has received a research grant from the University of Bergen. Dr. Cleland has received research grants from Alere, Amgen, Roche Diagnostics, Novartis, Philips, Servier, and StealthPeptides; has served as a consultant for Amgen, Novartis, Philips, Roche Diagnostics, Merck, Medtronic, Servier, and Zoll; and has received speaker honoraria from Bayer and Novartis. Dr. Kim is a former employee of and shareholder in Amgen; and is current employee of and shareholder in MyoKardia. Drs. Wolff and Malik are employees of and shareholders in Cytokinetics. Drs. Lei, Knusel, and Wasserman are employees of and shareholders in Amgen. NR 29 TC 17 Z9 17 U1 3 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 29 PY 2016 VL 67 IS 12 BP 1444 EP 1455 DI 10.1016/j.jacc.2016.01.031 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DG9NA UT WOS:000372408500009 PM 27012405 ER PT J AU Bilen, O Kamal, A Virani, SS AF Bilen, Ozlem Kamal, Ayeesha Virani, Salim S. TI Lipoprotein abnormalities in South Asians and its association with cardiovascular disease: Current state and future directions SO WORLD JOURNAL OF CARDIOLOGY LA English DT Review DE Dyslipidemia; South Asians; Asian Indians; Cardiovascular disease ID CORONARY-HEART-DISEASE; LOW-DENSITY-LIPOPROTEIN; INTIMA-MEDIA THICKNESS; APOLIPOPROTEIN-A-I; RISK-FACTORS; ARTERY-DISEASE; MYOCARDIAL-INFARCTION; ELEVATED LIPOPROTEIN(A); INDIAN SUBCONTINENT; CHOLESTEROL EFFLUX AB South Asians have a high prevalence of coronary heart disease (CHD) and suffer from early-onset CHD compared to other ethnic groups. Conventional risk factors may not fully explain this increased CHD risk in this population. Indeed, South Asians have a unique lipid profile which may predispose them to premature CHD. Dyslipidemia in this patient population seems to be an important contributor to the high incidence of coronary atherosclerosis. The dyslipidemia in South Asians is characterized by elevated levels of triglycerides, low levels of high-density lipoprotein (HDL) cholesterol, elevated lipoprotein(a) levels, and a higher atherogenic particle burden despite comparable low-density lipoprotein cholesterol levels compared with other ethnic subgroups. HDL particles also appear to be smaller, dysfunctional, and proatherogenic in South Asians. Despite the rapid expansion of the current literature with better understanding of the specific lipid abnormalities in this patient population, studies with adequate sample sizes are needed to assess the significance and contribution of a given lipid parameter on overall cardiovascular risk in this population. Specific management goals and treatment thresholds do not exist for South Asians because of paucity of data. Current treatment recommendations are mostly extrapolated from Western guidelines. Lastly, large, prospective studies with outcomes data are needed to assess cardiovascular benefit associated with various lipid-lowering therapies (including combination therapy) in this patient population. C1 [Bilen, Ozlem; Virani, Salim S.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Kamal, Ayeesha] Aga Khan Univ Hosp, Dept Med, Neurol Sect, Karachi 3500, Pakistan. RP Virani, SS (reprint author), Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Hlth Serv Res & Dev 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM virani@bcm.edu OI Virani, Salim/0000-0001-9541-6954 NR 92 TC 2 Z9 2 U1 1 U2 2 PU BAISHIDENG PUBLISHING GROUP INC PI PLEASANTON PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA SN 1949-8462 J9 WORLD J CARDIOL JI World J. Cardiol. PD MAR 26 PY 2016 VL 8 IS 3 BP 247 EP 257 DI 10.4330/wjc.v8.i3.247 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA DH4LF UT WOS:000372756800001 PM 27022456 ER PT J AU Batth, I Yun, HY Hussain, S Meng, P Osumulski, P Huang, THM Bedolla, R Profit, A Reddick, R Kumar, A AF Batth, Izhar Yun, Huiyoung Hussain, Suleman Meng, Peng Osumulski, Powel Huang, Tim Hui-Ming Bedolla, Roble Profit, Amanda Reddick, Robert Kumar, Addanki TI Crosstalk between RON and androgen receptor signaling in the development of castration resistant prostate cancer SO ONCOTARGET LA English DT Article DE castrate resistant prostate cancer; apoptosis; FLIP; RON; MSTIR ID EPITHELIAL-MESENCHYMAL TRANSITION; TYROSINE KINASE; PANCREATIC-CANCER; DEPRIVATION THERAPY; ALTERED EXPRESSION; TUMOR PROGRESSION; BREAST-CANCER; C-MET; CELLS; GROWTH AB Castrate-resistant prostate cancer (CRPC) is the fatal form of prostate cancer. Although reactivation of androgen receptor (AR) occurs following androgen deprivation, the precise mechanism involved is unclear. Here we show that the receptor tyrosine kinase, RON alters mechanical properties of cells to influence epithelial to mesenchymal transition and functions as a transcription factor to differentially regulate AR signaling. RON inhibits AR activation and subset of AR-regulated transcripts in androgen responsive LNCaP cells. However in C4-2B, a castrate-resistant sub-line of LNCaP and AR-negative androgen independent DU145 cells, RON activates subset of AR-regulated transcripts. Expression of AR in PC-3 cells leads to activation of RON under androgen deprivation but not under androgen proficient conditions implicating a role for RON in androgen independence. Consistently, RON expression is significantly elevated in castrate resistant prostate tumors. Taken together our results suggest that RON activation could aid in promoting androgen independence and that inhibition of RON in combination with AR antagonist(s) merits serious consideration as a therapeutic option during hormone deprivation therapy. C1 [Batth, Izhar; Meng, Peng; Bedolla, Roble; Kumar, Addanki] Dept Urol, San Antonio, TX USA. [Yun, Huiyoung; Hussain, Suleman; Kumar, Addanki] Univ Texas San Antonio, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. [Osumulski, Powel; Huang, Tim Hui-Ming; Kumar, Addanki] Dept Mol Med, San Antonio, TX USA. [Profit, Amanda; Reddick, Robert] Univ Texas San Antonio, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA. [Huang, Tim Hui-Ming; Kumar, Addanki] Dept Canc Therapy & Res Ctr, San Antonio, TX USA. [Kumar, Addanki] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Kumar, Addanki] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Meng, Peng] Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA USA. [Batth, Izhar] Univ Texas MD Anderson Canc Ctr, Dept Pediat, Houston, TX 77030 USA. RP Kumar, A (reprint author), Dept Urol, San Antonio, TX USA.; Kumar, A (reprint author), Univ Texas San Antonio, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.; Kumar, A (reprint author), Dept Mol Med, San Antonio, TX USA.; Kumar, A (reprint author), Dept Canc Therapy & Res Ctr, San Antonio, TX USA.; Kumar, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.; Kumar, A (reprint author), South Texas Vet Hlth Care Syst, San Antonio, TX USA. EM kumara3@uthscsa.edu FU Veterans Affairs-Merit Award [I01 BX 000766-01, 1R01CA135451, 1R01AT007448]; CTRC at UT Health Science Center San Antonio (UTHSCSA) through the National Cancer Institute [2P30 CA 054174-17]; CTRC 40th Anniversary Distinguished Professor of Oncology Endowment FX This work was supported in part by funds from Veterans Affairs-Merit Award I01 BX 000766-01, 1R01CA135451 and 1R01AT007448 (APK). We acknowledge support provided by CTRC at UT Health Science Center San Antonio (UTHSCSA) through the National Cancer Institute support grant #2P30 CA 054174-17. We acknowledge support provided by the CTRC 40th Anniversary Distinguished Professor of Oncology Endowment to APK. We thank Dr. JW Freeman, (UTHSCSA) for the RON-reporter; Dr. A. Lowey, (UC-San Diego) for the RON expression plasmid; Dr. D. Tindall, (Mayo Clinic Rochester) for pGL3-PSAARE constructs; and Dr. R. Vadlamudi (UTHSCSA) for providing PC-3AR cells. We sincerely thank Dr. R. Ghosh, (UTHSCSA) for critically reading the manuscript. NR 56 TC 1 Z9 1 U1 0 U2 0 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD MAR 22 PY 2016 VL 7 IS 12 BP 14048 EP 14063 PG 16 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DL5OT UT WOS:000375687200058 PM 26872377 ER PT J AU Cong, LL Muir, ER Chen, C Qian, YS Liu, JW Biju, KC Clark, RA Li, SL Duong, TQ AF Cong, Linlin Muir, Eric R. Chen, Cang Qian, Yusheng Liu, Jingwei Biju, K. C. Clark, Robert A. Li, Senlin Duong, Timothy Q. TI Multimodal MRI Evaluation of the MitoPark Mouse Model of Parkinson's Disease SO PLOS ONE LA English DT Article ID CEREBRAL-BLOOD-FLOW; DEFICIENT DOPAMINE NEURONS; IRON-DEPOSITION; COGNITIVE IMPAIRMENT; SUBSTANTIA-NIGRA; ANIMAL-MODELS; BRAIN-TISSUE; IN-VIVO; DIFFUSION; MICE AB The MitoPark mouse, a relatively new genetic model of Parkinson's disease (PD), has a dopaminergic neuron-specific knock-out that inactivates the mitochondrial transcription factor A (Tfam), a protein essential for mitochondrial DNA expression and maintenance. This study used multimodal MRI to characterize the neuroanatomical correlates of PD-related deficits in MitoPark mice, along with functional behavioral tests. Compared with age-matched wild-type animals, MitoPark mice at 30 weeks showed: i) reduced whole-brain volume and increased ventricular volume, indicative of brain atrophy, ii) reduced transverse relaxation time (T-2*) of the substantia nigra and striatum, suggestive of abnormal iron accumulation, iii) reduced apparent diffusion coefficient in the substantia nigra, suggestive of neuronal loss, iv) reduced fractional anisotropy in the corpus callosum and substantia nigra, indicative of white-matter damages, v) cerebral blood flow was not significantly affected, and vi) reduced motor activity in open-field tests, reduced memory in novel object recognition tests, as well as decreased mobility in tail suspension tests, an indication of depression. In sum, MitoPark mice recapitulate changes in many MRI parameters reported in PD patients. Multimodal MRI may prove useful for evaluating neuroanatomical correlates of PD pathophysiology in MitoPark mice, and for longitudinally monitoring disease progression and therapeutic interventions for PD. C1 [Cong, Linlin; Muir, Eric R.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Cong, Linlin] Univ Texas San Antonio, Grad Sch Biomed Sci, San Antonio, TX USA. [Muir, Eric R.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. [Chen, Cang; Qian, Yusheng; Liu, Jingwei; Biju, K. C.; Clark, Robert A.; Li, Senlin] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Clark, Robert A.; Li, Senlin; Duong, Timothy Q.] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. RP Muir, ER; Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.; Muir, ER; Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.; Duong, TQ (reprint author), South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. EM muire@uthscsa.edu; duongt@uthscsa.edu FU United States (U.S.) Department of Veterans Biomedical Laboratory Research and Development Service [I01BX000737]; William and Ella Owens Medical Research Foundation FX work was supported by Merit Review Award #I01BX000737 from the United States (U.S.) Department of Veterans Biomedical Laboratory Research and Development Service and by a grant from the William and Ella Owens Medical Research Foundation awarded to S.L. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 56 TC 0 Z9 0 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 22 PY 2016 VL 11 IS 3 AR e0151884 DI 10.1371/journal.pone.0151884 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DH3OX UT WOS:000372697400053 PM 27003179 ER PT J AU Lynch, CP Williams, JS Ruggiero, KJ Knapp, RG Egede, LE AF Lynch, Cheryl P. Williams, Joni S. Ruggiero, Kenneth J. Knapp, Rebecca G. Egede, Leonard E. TI Tablet-Aided BehavioraL intervention EffecT on Self-management skills (TABLETS) for Diabetes SO TRIALS LA English DT Article ID AMERICAN-HEART-ASSOCIATION; DISEASE RISK-FACTORS; CARDIOVASCULAR-DISEASE; PHYSICAL-ACTIVITY; RANDOMIZED-TRIAL; ETHNIC-DIFFERENCES; EMPOWERMENT SCALE; GLYCEMIC CONTROL; HEALTH LITERACY; PEER SUPPORT AB Background: Multiple randomized controlled trials (RCTs) show that behavioral lifestyle interventions are effective in improving diabetes management and that comprehensive risk factor management improves cardiovascular disease (CVD) outcomes. The role of technology has been gaining strong support as evidence builds of its potential to improve diabetes management; however, evaluation of its impact in minority populations is limited. This study intends to provide early evidence of a theory-driven intervention, Tablet-Aided BehavioraL intervention EffecT on Self-management skills (TABLETS), using real-time videoconferencing for education and skills training. We examine the potential for TABLETS to improve health risk behaviors and reduce CVD risk outcomes among a low-income African American (AA) population with poorly controlled type 2 diabetes. Methods: The study is a two-arm, pilot controlled trial that randomizes 30 participants to the TABLETS intervention and 30 participants to a usual care group. Blinded outcome assessments will be completed at baseline, 2.5 months (immediate post-intervention), and 6.5 months (follow-up). The TABLETS intervention consists of culturally tailored telephone-delivered diabetes education and skills training delivered via videoconferencing on tablet devices, with two booster sessions delivered via tablet-based videoconferencing at 3 months and 5 months to stimulate ongoing use of the tablet device with access to intervention materials via videoconferencing slides and a manual of supplementary materials. The primary outcomes are physical activity, diet, medication adherence, and self-monitoring behavior, whereas the secondary outcomes are HbA1c, low-density lipoprotein cholesterol (LDL-C), BP, CVD risk, and quality of life. Discussion: This study provides a unique opportunity to assess the feasibility and efficacy of a theory-driven, tablet-aided behavioral intervention that utilizes real-time videoconferencing technology for education and skills training on self-management behaviors and quality of life among a high-risk, low-income AA population with an uncontrolled dyad or triad of CVD risk factors (diabetes with or without hypertension or hyperlipidemia). The intervention leverages the use of novel technology for education and skill-building to foster improved diabetes self-management. The findings of this study will inform the process of disseminating the intervention to a broader and larger sample of people and can potentially be refined to align with clinical workflows that target a subsample of patients with poor diabetes self-management. C1 [Lynch, Cheryl P.; Williams, Joni S.; Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Ctr Hlth Dispar Res, 135 Rutledge Ave,MSC 593, Charleston, SC 29425 USA. [Lynch, Cheryl P.; Ruggiero, Kenneth J.; Knapp, Rebecca G.; Egede, Leonard E.] Ralph H Johnson VAMC, Hlth Equity & Rural Outreach Innovat Ctr, 109 Bee St, Charleston, SC 29401 USA. [Ruggiero, Kenneth J.] Med Univ S Carolina, Coll Nursing, 19 Hagood Ave,Suite 1002,MSC 160, Charleston, SC 29425 USA. [Ruggiero, Kenneth J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 19 Hagood Ave,Suite 1002,MSC 160, Charleston, SC 29425 USA. [Knapp, Rebecca G.] Med Univ S Carolina, Dept Publ Hlth Sci, 135 Cannon St,MSC 835, Charleston, SC 29425 USA. RP Lynch, CP (reprint author), Med Univ S Carolina, Div Gen Internal Med & Geriatr, Ctr Hlth Dispar Res, 135 Rutledge Ave,MSC 593, Charleston, SC 29425 USA.; Lynch, CP (reprint author), Ralph H Johnson VAMC, Hlth Equity & Rural Outreach Innovat Ctr, 109 Bee St, Charleston, SC 29401 USA. EM lynchcp@musc.edu FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH) [R03DK098489] FX The study is funded by grant number R03DK098489 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH). NR 72 TC 1 Z9 1 U1 3 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1745-6215 J9 TRIALS JI Trials PD MAR 22 PY 2016 VL 17 AR 157 DI 10.1186/s13063-016-1243-2 PG 12 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DH2HC UT WOS:000372604300006 PM 27005766 ER PT J AU Leventhal, JS Ni, J Osmond, M Lee, K Gusella, GL Salem, F Ross, MJ AF Leventhal, Jeremy S. Ni, Jie Osmond, Morgan Lee, Kyung Gusella, G. Luca Salem, Fadi Ross, Michael J. TI Autophagy Limits Endotoxemic Acute Kidney Injury and Alters Renal Tubular Epithelial Cell Cytokine Expression SO PLOS ONE LA English DT Article ID SEPSIS; MICE; PROTECTS; DISEASE; INACTIVATION; APOPTOSIS; PREVENTS; FAILURE; PLAYS; GENE AB Sepsis related acute kidney injury (AKI) is a common in-hospital complication with a dismal prognosis. Our incomplete understanding of disease pathogenesis has prevented the identification of hypothesis-driven preventive or therapeutic interventions. Increasing evidence in ischemia-reperfusion and nephrotoxic mouse models of AKI support the theory that autophagy protects renal tubular epithelial cells (RTEC) from injury. However, the role of RTEC autophagy in septic AKI remains unclear. We observed that lipopolysaccharide (LPS), a mediator of gram-negative bacterial sepsis, induces RTEC autophagy in vivo and in vitro through TLR4-initiated signaling. We modeled septic AKI through intraperitoneal LPS injection in mice in which autophagy-related protein 7 was specifically knocked out in the renal proximal tubules (ATG7KO). Compared to control littermates, ATG7KO mice developed more severe renal dysfunction (24hr BUN 100.1mg/dl +/- 14.8 vs 54.6mg/dl +/- 11.3) and parenchymal injury. After injection with LPS, analysis of kidney lysates identified higher IL-6 expression and increased STAT3 activation in kidney lysates from ATG7KO mice compared to controls. In vitro experiments confirmed an altered response to LPS in RTEC with genetic or pharmacological impairment of autophagy. In conclusion, RTEC autophagy protects against endotoxin induced injury and regulates downstream effects of RTEC TLR4 signaling. C1 [Leventhal, Jeremy S.; Ni, Jie; Osmond, Morgan; Lee, Kyung; Gusella, G. Luca; Ross, Michael J.] Icahn Sch Med Mt Sinai, Dept Med, Div Nephrol, New York, NY 10029 USA. [Leventhal, Jeremy S.; Ross, Michael J.] James J Peters Bronx VA Med Ctr, Div Renal, Bronx, NY USA. [Salem, Fadi] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA. RP Leventhal, JS (reprint author), Icahn Sch Med Mt Sinai, Dept Med, Div Nephrol, New York, NY 10029 USA.; Leventhal, JS (reprint author), James J Peters Bronx VA Med Ctr, Div Renal, Bronx, NY USA. EM jeremy.leventhal@mssm.edu FU NIH/NIDDK grant [R01 DK101338, DK108346, K08 DK090217] FX This research was supported by the NIH/NIDDK grant R01 DK101338 and DK108346 (MR) and an NIH/NIDDK K08 DK090217 grant (JSL).; This research was supported by the NIH/NIDDK grant R01 DK101338 and DK108346 (M.R.) and an NIH/NIDDK K08 DK090217 (J.S.L). Microscopy was performed at the Microscopy CORE at the Icahn School of Medicine at Mount Sinai. NR 32 TC 1 Z9 3 U1 1 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 18 PY 2016 VL 11 IS 3 AR e0150001 DI 10.1371/journal.pone.0150001 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DH1ZE UT WOS:000372582800023 PM 26990086 ER PT J AU Baenninger, A Hernandez, LD Rieger, K Ford, JM Kottlow, M Koenig, T AF Baenninger, Anja Hernandez, Laura Diaz Rieger, Kathryn Ford, Judith M. Kottlow, Mara Koenig, Thomas TI Inefficient Preparatory fMRI-BOLD Network Activations Predict Working Memory Dysfunctions in Patients with Schizophrenia SO FRONTIERS IN PSYCHIATRY LA English DT Article DE schizophrenia; working memory; temporally coherent networks; state-dependent information processing; simultaneous EEG-fMRI; covariance mapping ID DEFAULT MODE NETWORK; DORSOLATERAL PREFRONTAL CORTEX; CORTICAL OSCILLATORY ACTIVITY; RESTING-STATE; FUNCTIONAL CONNECTIVITY; BRAIN NETWORKS; EXECUTIVE NETWORKS; SUBSEQUENT-MEMORY; EEG ABNORMALITIES; HEALTHY CONTROLS AB Patients with schizophrenia show abnormal dynamics and structure of temporally coherent networks (TCNs) assessed using fMRI, which undergo adaptive shifts in preparation for a cognitively demanding task. During working memory (WM) tasks, patients with schizophrenia show persistent deficits in TCNs as well as EEG indices of WM. Studying their temporal relationship during WM tasks might provide novel insights into WM performance deficits seen in schizophrenia. Simultaneous EEG-fMRI data were acquired during the performance of a verbal Sternberg WM task with two load levels (load 2 and load 5) in 17 patients with schizophrenia and 17 matched healthy controls. Using covariance mapping, we investigated the relationship of the activity in the TCNs before the memoranda were encoded and EEG spectral power during the retention interval. We assessed four TCNs- default mode network (DMN), dorsal attention network (dAN), left and right working memory networks (WMNs)- and three EEG bands- theta, alpha, and beta. In healthy controls, there was a load-dependent inverse relation between DMN and frontal midline theta power and an anti-correlation between DMN and dAN. Both effects were not significantly detectable in patients. In addition, healthy controls showed a left-lateralized load dependent recruitment of the WMNs. Activation of the WMNs was bilateral in patients, suggesting more resources were recruited for successful performance on the WM task. Our findings support the notion of schizophrenia patients showing deviations in their neurophysiological responses before the retention of relevant information in a verbal WM task. Thus, treatment strategies as neurofeedback targeting prestates could be beneficial as task performance relies on the preparatory state of the brain. C1 [Baenninger, Anja; Hernandez, Laura Diaz; Kottlow, Mara; Koenig, Thomas] Univ Bern, Univ Hosp Psychiat & Psychotherapy, Translat Res Ctr, Bern, Switzerland. [Baenninger, Anja; Ford, Judith M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Hernandez, Laura Diaz; Rieger, Kathryn; Kottlow, Mara; Koenig, Thomas] Univ Bern, Ctr Cognit Learning & Memory, Bern, Switzerland. [Ford, Judith M.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Baenninger, A (reprint author), Univ Bern, Univ Hosp Psychiat & Psychotherapy, Translat Res Ctr, Bern, Switzerland.; Baenninger, A (reprint author), San Francisco VA Med Ctr, San Francisco, CA USA. EM anja.baenninger@puk.unibe.ch RI Koenig, Thomas/F-6454-2010 OI Koenig, Thomas/0000-0002-1472-4638; Baenninger, Anja/0000-0001-8921-5216; Diaz Hernandez, Laura/0000-0003-3452-8797 NR 87 TC 1 Z9 1 U1 2 U2 10 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-0640 J9 FRONT PSYCHIATRY JI Front. Psychiatry PD MAR 18 PY 2016 VL 7 AR 29 DI 10.3389/fpsyt.2016.00029 PG 15 WC Psychiatry SC Psychiatry GA DG8XY UT WOS:000372368100002 PM 27047395 ER PT J AU Downey, JE Weiss, JM Muelling, K Venkatraman, A Valois, JS Hebert, M Bagnell, JA Schwartz, AB Collinger, JL AF Downey, John E. Weiss, Jeffrey M. Muelling, Katharina Venkatraman, Arun Valois, Jean-Sebastien Hebert, Martial Bagnell, J. Andrew Schwartz, Andrew B. Collinger, Jennifer L. TI Blending of brain-machine interface and vision-guided autonomous robotics improves neuroprosthetic arm performance during grasping SO JOURNAL OF NEUROENGINEERING AND REHABILITATION LA English DT Article DE Brain-machine interface; Brain-computer interface; Neuroprosthetic; Shared mode control; Assistive technology ID SPINAL-CORD-INJURY; COMPUTER INTERFACE; PRIORITIES; USERS AB Background: Recent studies have shown that brain-machine interfaces (BMIs) offer great potential for restoring upper limb function. However, grasping objects is a complicated task and the signals extracted from the brain may not always be capable of driving these movements reliably. Vision-guided robotic assistance is one possible way to improve BMI performance. We describe a method of shared control where the user controls a prosthetic arm using a BMI and receives assistance with positioning the hand when it approaches an object. Methods: Two human subjects with tetraplegia used a robotic arm to complete object transport tasks with and without shared control. The shared control system was designed to provide a balance between BMI-derived intention and computer assistance. An autonomous robotic grasping system identified and tracked objects and defined stable grasp positions for these objects. The system identified when the user intended to interact with an object based on the BMI-controlled movements of the robotic arm. Using shared control, BMI controlled movements and autonomous grasping commands were blended to ensure secure grasps. Results: Both subjects were more successful on object transfer tasks when using shared control compared to BMI control alone. Movements made using shared control were more accurate, more efficient, and less difficult. One participant attempted a task with multiple objects and successfully lifted one of two closely spaced objects in 92 % of trials, demonstrating the potential for users to accurately execute their intention while using shared control. Conclusions: Integration of BMI control with vision-guided robotic assistance led to improved performance on object transfer tasks. Providing assistance while maintaining generalizability will make BMI systems more attractive to potential users. C1 [Downey, John E.; Weiss, Jeffrey M.; Schwartz, Andrew B.; Collinger, Jennifer L.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15213 USA. [Downey, John E.; Schwartz, Andrew B.; Collinger, Jennifer L.] Ctr Neural Basis Cognit, Pittsburgh, PA USA. [Weiss, Jeffrey M.; Collinger, Jennifer L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA. [Muelling, Katharina; Venkatraman, Arun; Valois, Jean-Sebastien; Hebert, Martial; Bagnell, J. Andrew] Carnegie Mellon Univ, Inst Robot, Pittsburgh, PA 15213 USA. [Schwartz, Andrew B.] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA 15213 USA. [Collinger, Jennifer L.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Collinger, Jennifer L.] Univ Pittsburgh, 3520 5th Ave,Suite 300, Pittsburgh, PA 15213 USA. RP Collinger, JL (reprint author), Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15213 USA.; Collinger, JL (reprint author), Ctr Neural Basis Cognit, Pittsburgh, PA USA. EM collinger@pitt.edu OI Downey, John/0000-0002-2992-2848 FU US Food and Drug Administration [NCT01364480, NCT01894802]; Defense Advanced Research Projects Agency's (DARPA, Arlington, VA, USA) Revolutionizing Prosthetics program [N66001-10-C-4056]; Autonomous Robotic Manipulation Software Track (ARM-S) program; National Science Foundation's NRI Purposeful Prediction program [1227495]; GRF program [DGE-1252522] FX This study was done under investigational device exemptions granted by the US Food and Drug Administration (NCT01364480 and NCT01894802). We thank Jan Scheuermann and Nathan Copeland for their extraordinary commitment and effort in relation to this study and insightful discussions with the study team; Karina Palko for her participation as an honorary research team member and support of the study; Debbie Harrington (Physical Medicine and Rehabilitation) for regulatory management of the study; the University of Pittsburgh Clinical and Translational Science Institute and the Office of Investigator-Sponsored Investigational New Drugs and Investigational Device Exemption support for assistance with protocol development and regulatory reporting and compliance; the volunteer members of the DSMB for their continued monitoring of this study; and Blackrock Microsystems (Salt Lake City, UT, USA) for technical support in relation to this project. This research was developed with funding from the Defense Advanced Research Projects Agency's (DARPA, Arlington, VA, USA) Revolutionizing Prosthetics program (contract number N66001-10-C-4056), and the Autonomous Robotic Manipulation Software Track (ARM-S) program. National Science Foundation's NRI Purposeful Prediction program (award no. 1227495) and GRF program (award no. DGE-1252522). The views, opinions, and/or findings contained in this article are those of the authors and should not be interpreted as representing the official views or policies of the Department of Veterans Affairs, Department of Defense, or US Government. NR 23 TC 0 Z9 0 U1 4 U2 21 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1743-0003 J9 J NEUROENG REHABIL JI J. NeuroEng. Rehabil. PD MAR 18 PY 2016 VL 13 AR 28 DI 10.1186/s12984-016-0134-9 PG 12 WC Engineering, Biomedical; Neurosciences; Rehabilitation SC Engineering; Neurosciences & Neurology; Rehabilitation GA DH2DW UT WOS:000372595400001 PM 26987662 ER PT J AU Nicholl, MB Chen, XH Qin, CL Bai, Q Zhu, ZW Davis, MR Fang, YJ AF Nicholl, Michael B. Chen, Xuhui Qin, Chenglu Bai, Qian Zhu, Ziwen Davis, Matthew R. Fang, Yujiang TI IL-32 has differential effects on proliferation and apoptosis of human melanoma cell lines SO JOURNAL OF SURGICAL ONCOLOGY LA English DT Article DE IL-32; apoptosis; proliferation ID NATURAL-KILLER-CELLS; NF-KAPPA-B; RHEUMATOID-ARTHRITIS; GASTRIC-CANCER; T-CELLS; INTERLEUKIN-32; DEATH; EXPRESSION; GROWTH; METASTASIS AB BackgroundInterleukin-32 (IL-32) is a recently recognized intracellular, proinflammatory cytokine which may play a role in cancer metastasis and patient survival. The role of IL-32 in cancer, especially its direct effect on cancer cells, is not well understood. Material and MethodsClonogenic assay, PCNA staining, Quick Cell Proliferation assay, TUNEL staining, and caspase-3 activity assay were used to investigate the in vitro role for IL-32 in human melanoma growth. We further investigated the possible molecular mechanisms using RT-PCR and immunohistochemical staining. ResultsExogenous administration of IL-32 inhibited proliferation of the HTB-72 human melanoma cell line, but had little effect on other melanoma cell lines. Inhibition of proliferation in HTB-72 correlated with increased expression of p21 and p53. IL-32 administration also increased apoptosis in HTB-72. This finding correlated with increased expression of TRAILR1. ConclusionsThe data presented suggest a direct effect of IL-32 on the growth of human melanoma and give some insight into the mechanisms which may in part govern this effect. J. Surg. Oncol. 2016;113:364-369. (c) 2016 Wiley Periodicals, Inc. C1 [Nicholl, Michael B.; Chen, Xuhui; Qin, Chenglu; Bai, Qian; Zhu, Ziwen; Davis, Matthew R.; Fang, Yujiang] Univ Missouri, Sch Med, Ellis Fischel Canc Ctr, Columbia, MO USA. [Nicholl, Michael B.] South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. [Chen, Xuhui; Qin, Chenglu] Luohu Hosp, Shenzhen, Peoples R China. [Fang, Yujiang] Des Moines Univ, Des Moines, IA 50312 USA. RP Nicholl, MB (reprint author), South Texas Vet Hlth Care Syst, Dept Surg, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.; Fang, YJ (reprint author), Des Moines Univ, Coll Osteopath Med, Dept Microbiol Immunol & Pathol, Des Moines, IA 50312 USA. EM michaelnicholl@gmail.com; yujiang.fang@dmu.edu RI Zhu, Ziwen/I-1895-2014 OI Zhu, Ziwen/0000-0002-6681-9153 FU University of Missouri; Des Moines University FX Grant sponsor: University of Missouri; Grant sponsor: Des Moines University NR 39 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4790 EI 1096-9098 J9 J SURG ONCOL JI J. Surg. Oncol. PD MAR 15 PY 2016 VL 113 IS 4 BP 364 EP 369 DI 10.1002/jso.24142 PG 6 WC Oncology; Surgery SC Oncology; Surgery GA DK1YK UT WOS:000374711400004 PM 27100023 ER PT J AU Cavusoglu, E Marmur, JD Kassotis, JT Yanamadala, S Chopra, V Eng, C AF Cavusoglu, Erdal Marmur, Jonathan D. Kassotis, John T. Yanamadala, Sunitha Chopra, Vineet Eng, Calvin TI Usefulness of Plasma Matrix Metalloproteinase-3 Levels to Predict Myocardial Infarction in Men With and Without Acute Coronary Syndrome SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID ALL-CAUSE MORTALITY; ATHEROSCLEROTIC PLAQUES; STROMELYSIN-1 MMP-3; INDEPENDENT PREDICTOR; GENE-EXPRESSION; PROMOTER; MACROPHAGES; INSTABILITY; PROGRESSION; ACTIVATION AB Matrix metalloproteinase-3 (MMP-3), or stromelysin-1, is a matrix metalloproteinase which is expressed in atherosclerotic plaques and which has been implicated in the pathogenesis of acute coronary syndrome (ACS). Functional polymorphisms in the promoter region of the human MMP-3 gene resulting in an increased expression of MMP-3 have been shown to predict the risk of incident myocardial infarction (MI). However, there have been no studies that have specifically examined the utility of baseline plasma MMP-3 levels for the prediction of long-term MI. In this study, baseline plasma MMP-3 levels were measured in 355 male patients who were referred for coronary angiography and followed prospectively for the development of enzymatically confirmed MI out to 5 years. After adjustment for a variety of baseline clinical, angiographic, and laboratory parameters, plasma MMP-3 levels were an independent predictor of MI at 5 years (hazards ratio 1.42, 95% CI 1.13 to 1.79; p = 0.0023). Furthermore, in 5 additional multivariate models that included a variety of contemporary biomarkers associated with adverse outcomes and MI, MMP-3 remained an independent predictor of MI at 5 years. Similar results were obtained when the analyses were restricted to the subpopulation of patients presenting with ACS. In conclusion, elevated levels of MMP-3 are associated with an increased risk of long-term MI in patients with and without ACS referred for coronary angiography. Furthermore, this association is independent of a variety of clinical, angiographic, laboratory variables, including biomarkers with established prognostic efficacy for the prediction of MI. (c) 2016 Elsevier Inc. All rights reserved. C1 [Cavusoglu, Erdal; Chopra, Vineet; Eng, Calvin] Bronx Vet Affairs Med Ctr, Dept Med, Div Cardiol, Bronx, NY USA. [Cavusoglu, Erdal; Marmur, Jonathan D.; Kassotis, John T.; Yanamadala, Sunitha] Suny Downstate Med Ctr, Dept Med, Div Cardiol, Brooklyn, NY 11203 USA. RP Cavusoglu, E (reprint author), Bronx Vet Affairs Med Ctr, Dept Med, Div Cardiol, Bronx, NY USA.; Cavusoglu, E (reprint author), Suny Downstate Med Ctr, Dept Med, Div Cardiol, Brooklyn, NY 11203 USA. EM ECavusoglu@aol.com NR 30 TC 0 Z9 0 U1 1 U2 1 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 EI 1879-1913 J9 AM J CARDIOL JI Am. J. Cardiol. PD MAR 15 PY 2016 VL 117 IS 6 BP 881 EP 886 DI 10.1016/j.amjcard.2015.12.022 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DG5RH UT WOS:000372135800001 PM 26805660 ER PT J AU Giordano, S Zhao, XM Xing, D Hage, F Oparil, S Cooke, JP Lee, J Nakayama, KH Huang, NF Chen, YF AF Giordano, Samantha Zhao, Xiangmin Xing, Daisy Hage, Fadi Oparil, Suzanne Cooke, John P. Lee, Jieun Nakayama, Karina H. Huang, Ngan F. Chen, Yiu-Fai TI Targeted delivery of human iPS-ECs overexpressing IL-8 receptors inhibits neointimal and inflammatory responses to vascular injury in the rat SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE targeted cell therapy; human induced pluripotent stem cells; endothelial cells; vascular injury; inflammation vascular injury; restenosis ID PLURIPOTENT STEM-CELLS; PERIPHERAL ARTERIAL-DISEASE; ENDOTHELIAL GROWTH-FACTOR; MYOCARDIAL-INFARCTION; CAROTID ARTERIES; BALLOON INJURY; INTERLEUKIN-8; ESTROGEN; PROLIFERATION; HYPERTENSION AB Interleukin-8 (IL8) is highly expressed by injured arteries in a variety of diseases and is a chemoattractant for neutrophils which express IL8 receptors IL8RA and RB (IL8RA/B) on their membranes. Neutrophils interact with the damaged endothelium and initiate an inflammatory cascade at the site of injury. We have generated a novel translational targeted cell therapy for acute vascular injury using adenoviral vectors to overexpress IL8RA/B and green fluorescent protein (GFP) on the surface of endothelial cells (ECs) derived from human induced pluripotent stem cells (HiPS-IL8RA/B-ECs). We hypothesize that HiPS-IL8RA/B-ECs transfused intravenously into rats with balloon injury of the carotid artery will target to the injured site and compete with neutrophils, thus inhibiting inflammation and neointima formation. Young adult male Sprague-Dawley rats underwent balloon injury of the right carotid artery and received intravenous transfusion of saline vehicle, 1.5 x 10(6) HiPS-ECs, 1.5 x 10(6) HiPS-Null-ECs, or 1.5 x 10(6) HiPS-IL8RA/B-ECs immediately after endoluminal injury. Tissue distribution of HiPS-IL8RA/B-ECs was analyzed by a novel GFP DNA qPCR method. Cytokine and chemokine expression and leukocyte infiltration were measured in injured and uninjured arteries at 24 h postinjury by ELISA and immunohistochemistry, respectively. Neointimal, medial areas, and reendothelialization were measured 14 days postinjury. HiPS-IL8RA/B-ECs homed to injured arteries, inhibited inflammatory mediator expression and inflammatory cell infiltration, accelerated reendothelialization, and attenuated neointima formation after endoluminal injury while control HiPS-ECs and HiPS-Null-ECs did not. HiPS-IL8RA/B-ECs transfused into rats with endoluminal carotid artery injury target to the injured artery and provide a novel strategy to treat vascular injury. C1 [Giordano, Samantha; Xing, Daisy; Hage, Fadi; Oparil, Suzanne; Chen, Yiu-Fai] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Vasc Biol & Hypertens Program, Birmingham, AL 35294 USA. [Zhao, Xiangmin] Univ Illinois, Coll Med, Dept Pulm Crit Care Sleep & Allergy, Chicago, IL USA. [Hage, Fadi] Birmingham Vet Affairs Med Ctr, Div Cardiol, Birmingham, AL USA. [Cooke, John P.] Houston Methodist Res Inst, Houston, TX USA. [Lee, Jieun] Stanford Univ, Div Cardiovasc Med, Stanford, CA 94305 USA. [Nakayama, Karina H.; Huang, Ngan F.] Stanford Univ, Cardiovasc Inst, Stanford, CA 94305 USA. [Nakayama, Karina H.; Huang, Ngan F.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Huang, Ngan F.] Stanford Univ, Dept Cardiothorac Surg, Stanford, CA 94305 USA. RP Chen, YF (reprint author), Univ Alabama Birmingham, Dept Med, 1008 Zeigler Res Bldg,703 19th St South, Birmingham, AL 35294 USA. EM yfchen@uab.edu OI Cooke, John/0000-0003-0033-9138; Hage, Fadi/0000-0002-1397-4942 FU UAB CCVC William W. Featheringill Innovative Award; National Institutes of Health [RO1-HL-116727, RO1-HL-087980, T32-HL-07457, U01-HL-100397, RC2-HL-103400, R00-HL-098688]; American Heart Association [AHA-SDG-0930098N]; Veterans Affairs Biomedical Laboratory Research & Development Service Merit Award [OMB 4040-0001] FX This work was supported, in part, by UAB CCVC William W. Featheringill Innovative Award (Y. F. Chen); by National Institutes of Health Grants RO1-HL-116727 (Y. F. Chen), RO1-HL-087980 (S. Oparil), T32-HL-07457 (S. Oparil, S. Giordano); U01-HL-100397 and RC2-HL-103400 (J. P. Cooke), and R00-HL-098688 (N. F. Huang); by American Heart Association Grant AHA-SDG-0930098N (F. G. Hage); and by Veterans Affairs Biomedical Laboratory Research & Development Service Merit Award OMB 4040-0001 (F. G. Hage). NR 24 TC 2 Z9 2 U1 0 U2 6 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 EI 1522-1539 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD MAR 15 PY 2016 VL 310 IS 6 BP H705 EP H715 DI 10.1152/ajpheart.00587.2015 PG 11 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA DG4ZX UT WOS:000372082900005 PM 26801304 ER PT J AU Finegersh, A Kulich, S Duvvuri, U AF Finegersh, A. Kulich, S. Duvvuri, U. TI DNA Methylation Regulates ANO1 Expression Through Alternate Mechanisms at 3 Distinct CpG Islands in Head and Neck Squamous Cell Carcinoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT Multidisciplinary Head and Neck Cancer Symposium CY FEB 18-20, 2016 CL Scottsdale, AZ SP Amer Head & Neck Soc, Amer Soc Clin Oncol, ASTRO C1 [Finegersh, A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Kulich, S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Duvvuri, U.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD MAR 15 PY 2016 VL 94 IS 4 MA 283 BP 942 EP 942 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA DF8BM UT WOS:000371581900220 ER PT J AU Durazzo, TC Meyerhoff, DJ Mon, A Abe, C Gazdzinski, S Murray, DE AF Durazzo, Timothy C. Meyerhoff, Dieter J. Mon, Anderson Abe, Christoph Gazdzinski, Stefan Murray, Donna E. TI Chronic Cigarette Smoking in Healthy Middle-Aged Individuals Is Associated With Decreased Regional Brain N-acetylaspartate and Glutamate Levels SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Brain metabolites; Cigarette smoking; Decision making and impulsivity; Magnetic resonance; Neurocognition; Spectroscopy ID MAGNETIC-RESONANCE-SPECTROSCOPY; ALCOHOL-DEPENDENT INDIVIDUALS; RISK TASK BART; EARLY ABSTINENCE; SMOKERS; NEUROCOGNITION; VOLUMES; IMPULSIVENESS; NEUROBIOLOGY; METABOLITES AB BACKGROUND: Cigarette smoking is associated with metabolite abnormalities in anterior brain regions, but it is unclear if these abnormalities are apparent in other regions. Additionally, relationships between regional brain metabolite levels and measures of decision making, risk taking, and impulsivity in smokers and nonsmokers have not been investigated. METHODS: In young to middle-aged (predominately male) nonsmokers (n = 30) and smokers (n = 35), N-acetylaspartate (NAA), choline-containing compounds, creatine-containing compounds (Cr), myo-inositol (mI), and glutamate (Glu) levels in the anterior cingulate cortex and right dorsolateral prefrontal cortex (DLPFC) were compared via 4-tesla proton single volume magnetic resonance spectroscopy. Groups also were compared on NAA, choline-containing compounds, Cr, and mI concentrations in the gray matter and white matter of the four cerebral lobes and subcortical nuclei/regions with 1.5-tesla proton magnetic resonance spectroscopy. Associations of regional metabolite levels with neurocognitive, decision-making, risk-taking, and self-reported impulsivity measures were examined. RESULTS: Smokers showed lower DLPFC NAA, Cr, mI and Glu concentrations and lower lenticular nuclei NAA level; smokers also demonstrated greater age-related decreases of DLPFC NAA and anterior cingulate cortex and DLPFC Glu levels. Smokers exhibited poorer decision making and greater impulsivity. Across the sample, higher NAA and Glu in the DLPFC and NAA concentrations in multiple lobar gray matter and white matter regions and subcortical nuclei were associated with better neurocognition and lower impulsivity. CONCLUSIONS: This study provides additional novel evidence that chronic smoking in young and middle-aged individuals is associated with significant age-related neurobiological abnormalities in anterior frontal regions implicated in the development and maintenance of addictive disorders. C1 San Francisco Vet Adm Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. RP Durazzo, TC (reprint author), San Francisco Vet Adm Med Ctr, Ctr Imaging Neurodegenerat Dis 114M, 4150 Clement St 114M, San Francisco, CA 94121 USA. EM timothy.durazzo@ucsf.edu OI Abe, Christoph/0000-0002-1680-8480 FU National Institutes of Health/National Institute on Drug Abuse Grant [DA24136]; National Institutes of Health/National Institute on Alcohol Abuse and Alcoholism Grant [AA10788] FX This work was supported by National Institutes of Health/National Institute on Drug Abuse Grant No. DA24136 (to TCD) and National Institutes of Health/National Institute on Alcohol Abuse and Alcoholism Grant No. AA10788 (to DJM), with resources and the use of facilities at the San Francisco Veterans Administration Medical Center, San Francisco CA. NR 58 TC 7 Z9 8 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 15 PY 2016 VL 79 IS 6 BP 481 EP 488 DI 10.1016/j.biopsych.2015.03.029 PG 8 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DD6GY UT WOS:000370023900010 PM 25979621 ER PT J AU Maguen, S Hoerster, KD Littman, AJ Klingaman, EA Evans-Hudnall, G Holleman, R Kim, HM Goodrich, DE AF Maguen, Shira Hoerster, Katherine D. Littman, Alyson J. Klingaman, Elizabeth A. Evans-Hudnall, Gina Holleman, Rob Kim, H. Myra Goodrich, David E. TI Iraq and Afghanistan veterans with PTSD participate less in VA's weight loss program than those without PTSD SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Weight loss; Care engagement; Veterans; Mental health; Comorbidity; Sex; Obesity ID MENTAL-HEALTH DISORDERS; SERVICES TASK-FORCE; POSTTRAUMATIC-STRESS; MILITARY PERSONNEL; OBESITY; CARE; ADULTS; MANAGEMENT; HOME AB Background: Three-quarters of Iraq and Afghanistan veterans enrolled in Veterans Health Administration (VHA) care are overweight or obese. The VHA MOVE! weight management program can mitigate the risks of obesity-related morbidity. However, many Iraq and Afghanistan veterans experience barriers to VHA services, which may affect participation, especially among those with posttraumatic stress disorder (PTSD) and/or depression. Little is known about MOVE! engagement among recent veterans. We describe a retrospective evaluation of MOVE! participation among Iraq and Afghanistan veterans with and without mental health problems. Methods: As part of a national VHA mental health evaluation study, we accessed VHA patient care databases to identify Iraq and Afghanistan veterans receiving care from 2008-2013 who had >= 1 MOVE! visit(s) and >= 1 weight measurements (N=24,899). We used logistic regression to determine whether mental health conditions were associated with having 12 visits/year (desirable dose of care), adjusting for demographic, health, and utilization factors. Results: Among Iraq and Afghanistan veterans enrolled in MOVE!, 4% had a desirable dose of participation. In adjusted models, desirable MOVE! participation was more likely among those without PTSD; those who were older, female, and unmarried; and those who had higher baseline weight, more medical comorbidities, no pain, psychotropic medication use, higher disability ratings, and more mental health visits. Limitations: We used administrative ICD-9 codes. Sample only included veterans in VHA care. Conclusions: Iraq and Afghanistan veterans, particularly those with PTSD, had low participation in VHA weight management programming. Correlates of MOVE! participation were identified, highlighting opportunities to tailor MOVE! to improve participation for these veterans. Published by Elsevier B.V. C1 [Maguen, Shira] San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. [Maguen, Shira] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hoerster, Katherine D.; Littman, Alyson J.] VA Puget Sound Healthcare Syst, Seattle Div, Seattle, WA USA. [Hoerster, Katherine D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Littman, Alyson J.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Klingaman, Elizabeth A.] VA Maryland Healthcare Syst, Baltimore, MD USA. [Klingaman, Elizabeth A.] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD USA. [Evans-Hudnall, Gina] Houston VA Med Ctr, Houston, TX USA. [Holleman, Rob; Kim, H. Myra; Goodrich, David E.] VA Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI USA. RP Maguen, S (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM Shira.Maguen@va.gov FU VA Health Services Research and Development Quality Enhancement Research Initiative (QUERI) [QLP 55-017]; VA Rehabilitation Research & Development Career Development Award [6982]; VA Health Services Research & Development Career Development Award [12-263]; Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment FX This analysis is part of a larger quality improvement evaluation of MOVE! requested by the VHA Center for Health Promotion & Disease Prevention (NCP) and conducted by VA National Serious Mental Illness Treatment and Evaluation Center (SMITREC). Funding for this study was provided by VA Health Services Research and Development Quality Enhancement Research Initiative (QUERI) programs for Diabetes and Mental Health research as a locally initiated project (QLP 55-017). Dr. Littman's time was supported in part through a VA Rehabilitation Research & Development Career Development Award (#6982). Dr. Hoerster's time was supported in part through a VA Health Services Research & Development Career Development Award (#12-263). Dr. Klingaman's time was supported by the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment. NR 24 TC 0 Z9 0 U1 1 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD MAR 15 PY 2016 VL 193 BP 289 EP 294 DI 10.1016/j.jad.2015.12.078 PG 6 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DD0BT UT WOS:000369586000041 PM 26774516 ER PT J AU Weinrich, S Hardin, S Glaser, D Barger, M Bormann, J Lizarraga, C Terry, M Criscenzo, J Allard, CB AF Weinrich, Sally Hardin, Sally Glaser, Dale Barger, Mary Bormann, Jill Lizarraga, Cabiria Terry, Micheal Criscenzo, Jeeni Allard, Carolyn B. TI Assessing sexual trauma histories in homeless women SO JOURNAL OF TRAUMA & DISSOCIATION LA English DT Article DE Homeless women; sexual trauma; military sexual trauma ID VETERANS; MILITARY; PREVALENCE; ASSAULT AB Almost 1 out of every 3 homeless women (32%) in the United States, United Kingdom, and Australia has experienced childhood sexual trauma. We assessed lifetime sexual trauma histories among 29 homeless women from three Southern California community sites: one residential safe house and two safe parking areas. More than half of the women (54%) reported a history of sexual trauma. That rate was higher (86%) among women living at the safe home than among women staying at the safe parking sites (only 42%). All four of the women who had served in the military reported having experienced military sexual trauma. The high percentages of sexual trauma found in homeless women highlight the need for effective interventions for sexual trauma. C1 [Weinrich, Sally; Hardin, Sally; Glaser, Dale; Barger, Mary; Bormann, Jill; Terry, Micheal] Univ San Diego, Hahn Sch Nursing & Hlth Sci, 5998 Alcala Pk, San Diego, CA 92110 USA. [Weinrich, Sally; Hardin, Sally; Glaser, Dale; Barger, Mary; Bormann, Jill; Terry, Micheal] Univ San Diego, Betty & Bob Beyster Inst Nursing Res Adv Practice, 5998 Alcala Pk, San Diego, CA 92110 USA. [Bormann, Jill] US Dept Vet Affairs, Ctr Excellence Stress & Mental Hlth, San Diego, CA USA. [Lizarraga, Cabiria] Sharp Grossmont Hosp, La Mesa, CA USA. [Criscenzo, Jeeni] Amikas, San Diego, CA USA. [Allard, Carolyn B.] Univ Calif San Diego, Vet Affairs San Diego Healthcare Syst, Mil Sexual Trauma & Interpersonal Trauma Clin, San Diego, CA 92110 USA. RP Weinrich, S (reprint author), Univ San Diego, Hahn Sch Nursing & Hlth Sci, 5998 Alcala Pk, San Diego, CA 92110 USA.; Weinrich, S (reprint author), Univ San Diego, Betty & Bob Beyster Inst Nursing Res Adv Practice, 5998 Alcala Pk, San Diego, CA 92110 USA. EM sallyweinrich@sandiego.edu FU Jonas Center for Nursing and Veterans Healthcare; University of San Diego Hahn School of Nursing and Health Science Faculty Research Fund FX Funding was received from the Jonas Center for Nursing and Veterans Healthcare and the University of San Diego Hahn School of Nursing and Health Science Faculty Research Fund. NR 22 TC 1 Z9 1 U1 1 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1529-9732 EI 1529-9740 J9 J TRAUMA DISSOCIATIO JI J. Trauma Dissociation PD MAR 14 PY 2016 VL 17 IS 2 BP 237 EP 243 DI 10.1080/15299732.2015.1089968 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DG6MA UT WOS:000372197700009 PM 26583457 ER PT J AU Jimenez, AM Lee, J Wynn, JK Cohen, MS Engel, SA Glahn, DC Nuechterlein, KH Reavis, EA Green, MF AF Jimenez, Amy M. Lee, Junghee Wynn, Jonathan K. Cohen, Mark S. Engel, Stephen A. Glahn, David C. Nuechterlein, Keith H. Reavis, Eric A. Green, Michael F. TI Abnormal Ventral and Dorsal Attention Network Activity during Single and Dual Target Detection in Schizophrenia SO FRONTIERS IN PSYCHOLOGY LA English DT Article DE schizophrenia; fMRI; visual attention; RSVP; attentional blink ID SERIAL VISUAL PRESENTATION; NEGATIVE SYMPTOMS; HUMAN BRAIN; BLINK; SALIENCE; MEMORY; TASK; FMRI; DEACTIVATION; ENVIRONMENT AB Early visual perception and attention are impaired in schizophrenia, and these deficits can be observed on target detection tasks. These tasks activate distinct ventral and dorsal brain networks which support stimulus-driven and goal-directed attention, respectively. We used single and dual target rapid serial visual presentation (RSVP) tasks during fMRI with an ROI approach to examine regions within these networks associated with target detection and the attentional blink (AB) in 21 schizophrenia outpatients and 25 healthy controls. In both tasks, letters were targets and numbers were distractors. For the dual target task, the second target (T2) was presented at three different lags after the first target (T1) (lag1 = 100 ms, lag3 = 300 ms, lag7 = 700ms). For both single and dual target tasks, patients identified fewer targets than controls. For the dual target task, both groups showed the expected AB effect with poorer performance at lag 3 than at lags 1 or 7, and there was no group by lag interaction. During the single target task, patients showed abnormally increased deactivation of the temporo-parietal junction (TPJ), a key region of the ventral network. When attention demands were increased during the dual target task, patients showed overactivation of the posterior intraparietal cortex, a key dorsal network region, along with failure to deactivate TPJ. Results suggest inefficient and faulty suppression of salience-oriented processing regions, resulting in increased sensitivity to stimuli in general, and difficulty distinguishing targets from non-targets. C1 [Jimenez, Amy M.; Lee, Junghee; Wynn, Jonathan K.; Reavis, Eric A.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Desert Pacific MIRECC, Los Angeles, CA USA. [Jimenez, Amy M.; Lee, Junghee; Wynn, Jonathan K.; Cohen, Mark S.; Nuechterlein, Keith H.; Reavis, Eric A.; Green, Michael F.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Engel, Stephen A.] Univ Minnesota, Dept Psychol, Minneapolis, MN USA. [Glahn, David C.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. RP Jimenez, AM (reprint author), VA Greater Los Angeles Healthcare Syst, Desert Pacific MIRECC, Los Angeles, CA USA.; Jimenez, AM (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. EM amjimenez@ucla.edu RI Wynn, Jonathan/H-3749-2014; Lee, Junghee/C-5226-2014 OI Wynn, Jonathan/0000-0002-1763-8540; Lee, Junghee/0000-0001-9567-8700 FU NIMH [MH043292]; Brain Mapping Medical Research Organization; Brain Mapping Support Foundation; Pierson-Lovelace Foundation; Ahmanson Foundation; William M. and Linda R. Dietel Philanthropic Fund at the Northern Piedmont Community Foundation; Tamkin Foundation; Jennifer Jones-Simon Foundation; Capital Group Companies Charitable Foundation; Robson Family; Northstar Fund FX This research was supported by NIMH Grant MH043292 (PI: MG). Writing of this manuscript was supported by the Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs. For generous support, we also thank the Brain Mapping Medical Research Organization, Brain Mapping Support Foundation, Pierson-Lovelace Foundation, The Ahmanson Foundation, William M. and Linda R. Dietel Philanthropic Fund at the Northern Piedmont Community Foundation, Tamkin Foundation, Jennifer Jones-Simon Foundation, Capital Group Companies Charitable Foundation, Robson Family, and Northstar Fund. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 53 TC 0 Z9 0 U1 4 U2 8 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-1078 J9 FRONT PSYCHOL JI Front. Psychol. PD MAR 8 PY 2016 VL 7 AR 323 DI 10.3389/fpsyg.7015.00323 PG 11 WC Psychology, Multidisciplinary SC Psychology GA DF5NF UT WOS:000371398100001 PM 27014135 ER PT J AU Lipska, KJ Krumholz, H Soones, T Lee, SJ AF Lipska, Kasia J. Krumholz, Harlan Soones, Tacara Lee, Sei J. TI Polypharmacy in the Aging Patient A Review of Glycemic Control in Older Adults With Type 2 Diabetes SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Review ID INTENSIVE GLUCOSE CONTROL; CLINICAL-PRACTICE GUIDELINES; DRUG-DRUG INTERACTIONS; CARDIOVASCULAR OUTCOMES; RISK-FACTORS; SEVERE HYPOGLYCEMIA; INSULIN-RESISTANCE; ACCORD TRIAL; FOLLOW-UP; HEMOGLOBIN A(1C) AB IMPORTANCE There is substantial uncertainty about optimal glycemic control in older adults with type 2 diabetes mellitus. OBSERVATIONS Four large randomized clinical trials (RCTs), ranging in size from 1791 to 11 440 patients, provide the majority of the evidence used to guide diabetes therapy. Most RCTs of intensive vs standard glycemic control excluded adults older than 80 years, used surrogate end points to evaluate microvascular outcomes and provided limited data on which subgroups are most likely to benefit or be harmed by specific therapies. Available data from randomized clinical trials suggest that intensive glycemic control does not reduce major macrovascular events in older adults for at least 10 years. Furthermore, intensive glycemic control does not lead to improved patient-centered microvascular outcomes for at least 8 years. Data from randomized clinical trials consistently suggest that intensive glycemic control immediately increases the risk of severe hypoglycemia 1.5-to 3-fold. Based on these data and observational studies, for the majority of adults older than 65 years, the harms associated with a hemoglobin A1c (HbA1c) target lower than 7.5% or higher than 9% are likely to outweigh the benefits. However, the optimal target depends on patient factors, medications used to reach the target, life expectancy, and patient preferences about treatment. If only medications with low treatment burden and hypoglycemia risk (such as metformin) are required, a lower HbA1c targetmay be appropriate. If patients strongly prefer to avoid injections or frequent fingerstick monitoring, a higher HbA1c target that obviates the need for insulin may be appropriate. CONCLUSIONS AND RELEVANCE High-quality evidence about glycemic treatment in older adults is lacking. Optimal decisions need to be made collaboratively with patients, incorporating the likelihood of benefits and harms and patient preferences about treatment and treatment burden. For the majority of older adults, an HbA1c target between 7.5% and 9% will maximize benefits and minimize harms. C1 [Lipska, Kasia J.] Yale Univ, Sch Med, Dept Internal Med, Endocrinol Sect, 333 Cedar St,POB 208020, New Haven, CT 06520 USA. [Krumholz, Harlan] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA. [Krumholz, Harlan] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT 06520 USA. [Krumholz, Harlan] Yale Univ, Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, New Haven, CT 06520 USA. [Krumholz, Harlan] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT 06520 USA. [Soones, Tacara] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Lee, Sei J.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Lee, Sei J.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Lipska, KJ (reprint author), Yale Univ, Sch Med, Dept Internal Med, Endocrinol Sect, 333 Cedar St,POB 208020, New Haven, CT 06520 USA. EM kasia.lipska@yale.edu FU Beeson Career Development Award from the National Institute on Aging; American Federation of Aging Research [K23AG048359, K23AG040779]; Early Career Award from the S. D. Bechtel Jr Foundation FX Dr Lipska's effort on this project was supported through the Beeson Career Development Award from the National Institute on Aging and the American Federation of Aging Research (K23AG048359). Dr Lee's effort on this project was supported through the Beeson Career Development Award from the National Institute on Aging and the American Federation of Aging Research (K23AG040779) and an Early Career Award from the S. D. Bechtel Jr Foundation. NR 84 TC 16 Z9 16 U1 10 U2 15 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 8 PY 2016 VL 315 IS 10 BP 1034 EP 1045 DI 10.1001/jama.2016.0299 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA DF7LW UT WOS:000371540200016 PM 26954412 ER PT J AU Zhang, W Hartmann, R Tun, HM Elson, CO Khafipour, E Garvey, WT AF Zhang, Wei Hartmann, Riley Tun, Hein Min Elson, Charles O. Khafipour, Ehsan Garvey, W. Timothy TI Deletion of the Toll-Like Receptor 5 Gene Per Se Does Not Determine the Gut Microbiome Profile That Induces Metabolic Syndrome: Environment Trumps Genotype SO PLOS ONE LA English DT Article ID INTESTINAL MICROBIOTA; INNATE IMMUNITY; OBESITY; MICE; COMMUNITIES; DIET; SEQUENCE; SHAPES AB Over the past decade, emerging evidence has linked alterations in the gut microbial composition to a wide range of diseases including obesity, type 2 diabetes, and cardiovascular disease. Toll-like receptors (TLRs) are the major mediators for the interactions between gut microbiota and host innate immune system, which is involved in the localization and structuring of host gut microbiota. A previous study found that TLR5 deficient mice (TLR5KO1) had altered gut microbial composition which led to the development of metabolic syndrome including hyperlipidemia, hypertension, insulin resistance and increased adiposity. In the current study, a second TLR5-deficient mouse model was studied (TLR5KO2). TLR5 deficient mice did not manifest metabolic abnormalities related to the metabolic syndrome compared with littermate controls maintained on normal chow or after feeding a high fat diet. Analysis of the gut microbial composition of littermate TLR5KO2 and wild type mice revealed no significant difference in the overall microbiota structure between genotypes. However, the TLR5KO2 microbiota was distinctly different from that previously reported for TLR5KO1 mice with metabolic syndrome. We conclude that an altered composition of the microbiota in a given environment can result in metabolic syndrome, but it is not a consequence of TLR5 deficiency per se. C1 [Zhang, Wei; Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Sch Hlth Profess, Birmingham, AL 35294 USA. [Hartmann, Riley; Khafipour, Ehsan] Univ Manitoba, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada. [Tun, Hein Min; Khafipour, Ehsan] Univ Manitoba, Dept Anim Sci, Winnipeg, MB R3T 2N2, Canada. [Elson, Charles O.] Univ Alabama Birmingham, Sch Med, Div Gastroenterol & Hepatol, Birmingham, AL USA. [Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA. RP Garvey, WT (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Sch Hlth Profess, Birmingham, AL 35294 USA.; Khafipour, E (reprint author), Univ Manitoba, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada.; Khafipour, E (reprint author), Univ Manitoba, Dept Anim Sci, Winnipeg, MB R3T 2N2, Canada.; Garvey, WT (reprint author), Birmingham VA Med Ctr, Birmingham, AL USA. EM Ehsan.Khafipour@umanitoba.ca; garveyt@uab.edu OI Khafipour, Ehsan/0000-0003-4673-7633 FU UAB Diabetes Research Center (NIDDK) [P60 DK-079626]; National Institutes of Health [RO1 DK083562, R01 DK-38765]; Merit Review Research Grant from the Department of Veterans Affairs FX The authors acknowledge support from UAB Diabetes Research Center (NIDDK, P60 DK-079626), individual research grants from the National Institutes of Health (RO1 DK083562; R01 DK-38765), and a Merit Review Research Grant from the Department of Veterans Affairs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 47 TC 2 Z9 2 U1 2 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 7 PY 2016 VL 11 IS 3 AR e0150943 DI 10.1371/journal.pone.0150943 PG 21 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DG3SL UT WOS:000371990100072 PM 26950299 ER PT J AU Beste, LA Moseley, RH Saint, S Cornia, PB AF Beste, Lauren A. Moseley, Richard H. Saint, Sanjay Cornia, Paul B. TI Too Much of a Good Thing SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID PORTAL-HYPERTENSION; HISTORY C1 [Beste, Lauren A.] Vet Affairs VA Puget Sound Hlth Care Syst, Gen Med Serv, Seattle, WA USA. [Beste, Lauren A.] Vet Affairs VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Beste, Lauren A.; Cornia, Paul B.] Vet Affairs VA Puget Sound Hlth Care Syst, Hosp & Specialty Med Serv, Seattle, WA USA. [Beste, Lauren A.; Cornia, Paul B.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Moseley, Richard H.; Saint, Sanjay] VA Ann Arbor Healthcare Syst, Med Serv, Ann Arbor, MI USA. [Moseley, Richard H.; Saint, Sanjay] Univ Michigan Hlth Syst, Dept Internal Med, Ann Arbor, MI USA. RP Beste, LA (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way S-111-GI, Seattle, WA 98108 USA. EM lab25@uw.edu FU Doximity; Jvion FX Dr. Saint reports receiving fees for serving on advisory boards from Doximity and Jvion. No other potential conflict of interest relevant to this article was reported. NR 9 TC 0 Z9 0 U1 1 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 3 PY 2016 VL 374 IS 9 BP 873 EP 878 DI 10.1056/NEJMcps1405984 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DF2FT UT WOS:000371158400013 PM 26962907 ER PT J AU Sandford, E Bird, TD Li, JZ Burmeister, M AF Sandford, Erin Bird, Thomas D. Li, Jun Z. Burmeister, Margit TI PRICKLE2 Mutations Might Not Be Involved in Epilepsy SO AMERICAN JOURNAL OF HUMAN GENETICS LA English DT Letter ID PROGRESSIVE MYOCLONUS; ATAXIA; A467T; POLG C1 [Sandford, Erin; Burmeister, Margit] Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA. [Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Bird, Thomas D.] Univ Washington, Dept Med Med Genet, Seattle, WA 98195 USA. [Bird, Thomas D.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98101 USA. [Li, Jun Z.; Burmeister, Margit] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA. [Li, Jun Z.; Burmeister, Margit] Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA. [Burmeister, Margit] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. RP Burmeister, M (reprint author), Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA.; Burmeister, M (reprint author), Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA.; Burmeister, M (reprint author), Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA.; Burmeister, M (reprint author), Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. EM margit@umich.edu FU NINDS NIH HHS [R01 NS078560, R01-NS078560] NR 10 TC 1 Z9 3 U1 0 U2 0 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0002-9297 EI 1537-6605 J9 AM J HUM GENET JI Am. J. Hum. Genet. PD MAR 3 PY 2016 VL 98 IS 3 BP 588 EP 589 DI 10.1016/j.ajhg.2016.01.009 PG 2 WC Genetics & Heredity SC Genetics & Heredity GA DG9DN UT WOS:000372383100021 PM 26942291 ER PT J AU McGowan, SK Espejo, EP Balliett, N Werdowatz, EA AF McGowan, Sarah Kate Espejo, Emmanuel P. Balliett, Noelle Werdowatz, Emily A. TI The Effects of Transdiagnostic Group CBT for Anxiety on Insomnia Symptoms SO COGNITIVE BEHAVIOUR THERAPY LA English DT Article DE Anxiety; insomnia; anxious arousal; cognitive behavior therapy ID COGNITIVE-BEHAVIOR THERAPY; SLEEP DISTURBANCES; PANIC DISORDER; METAANALYSIS; DEPRESSION; PSYCHOTHERAPY; EPIDEMIOLOGY; EXPOSURE; IMPACT; MODEL AB Insomnia is a common feature among individuals with anxiety disorders. Studies of cognitive behavioral therapy (CBT) for anxiety report moderate effects on concomitant insomnia symptoms, but further research is still needed especially toward understanding how CBT for anxiety renders beneficial effects on insomnia. The current study examined changes in insomnia symptoms reported by 51 Veterans who participated in a group-based transdiagnostic CBT for anxiety intervention. In addition, insomnia symptoms were examined in relation to symptoms of general distress (GD), anhedonic depression (AD), and anxious arousal (AA) pre- to post-treatment. Results revealed a small, though statistically significant (p<.05) beneficial effect on insomnia symptoms. When changes in GD, AD, and AA were simultaneously examined in relation to changes in insomnia, change in AA was the only significant predictor of insomnia symptoms. The current study highlights the role of AA in the relationship between anxiety disorders and insomnia and demonstrates that reductions in insomnia during transdiagnostic CBT for anxiety can be largely attributed to changes in AA. C1 [McGowan, Sarah Kate; Espejo, Emmanuel P.] VA San Diego Healthcare Syst, Psychol Serv, San Diego, CA USA. [Balliett, Noelle] VA Puget Sound Hlth Care Syst, Psychol, Tacoma, WA USA. [Werdowatz, Emily A.] VA San Diego Healthcare Syst, Res Serv, San Diego, CA USA. RP Espejo, EP (reprint author), VA San Diego Healthcare Syst, Psychol Serv, San Diego, CA USA. EM eespejo@ucsd.edu FU Clinical Scientist Training Initiative Award FX Training in transdiagnostic group cognitive-behavioral therapy of anxiety by Dr. Peter Norton was supported by a Clinical Scientist Training Initiative Award issued to the VA San Diego Psychology Service by the Society for a Science of Clinical Psychology. The contents do not reflect the views of the Department of Veterans Affairs or the United States Government. There are no conflicts to report. We would like to thank Dr. Peter Norton for providing training in his transdiagnostic group cognitive-behavioral therapy of anxiety protocol and for providing materials to assist in the delivery of the group treatment and the conduct of this research study. We would also like to thank Natalie Castriotta, Ph.D., Kim Roser-Kedward, LCSW, Lesley Boutah, LCSW, Kathryn Seay, M.A., and Alexandrea Harmell, M.A. who assisted with co-leading the anxiety groups included in this study. NR 48 TC 0 Z9 0 U1 3 U2 8 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1650-6073 EI 1651-2316 J9 COGN BEHAV THERAPY JI Cogn. Behav. Ther. PD MAR 3 PY 2016 VL 45 IS 2 BP 163 EP 175 DI 10.1080/16506073.2015.1134639 PG 13 WC Behavioral Sciences; Psychology, Clinical SC Behavioral Sciences; Psychology GA DG4JE UT WOS:000372037700006 PM 26838091 ER PT J AU Pearlman, RA Foglia, MB Fox, E Cohen, JH Chanko, BL Berkowitz, KA AF Pearlman, Robert A. Foglia, Mary Beth Fox, Ellen Cohen, Jennifer H. Chanko, Barbara L. Berkowitz, Kenneth A. TI Ethics Consultation Quality Assessment Tool: A Novel Method for Assessing the Quality of Ethics Case Consultations Based on Written Records SO AMERICAN JOURNAL OF BIOETHICS LA English DT Article DE professional ethics; organizational ethics; clinical ethics; ethics consultation ID CLINICAL-ETHICS; SERVICE AB Although ethics consultation is offered as a clinical service in most hospitals in the United States, few valid and practical tools are available to evaluate, ensure, and improve ethics consultation quality. The quality of ethics consultation is important because poor quality ethics consultation can result in ethically inappropriate outcomes for patients, other stakeholders, or the health care system. To promote accountability for the quality of ethics consultation, we developed the Ethics Consultation Quality Assessment Tool (ECQAT). ECQAT enables raters to assess the quality of ethics consultations based on the written record. Through rigorous development and preliminary testing, we identified key elements of a quality ethics consultation (ethics question, consultation-specific information, ethical analysis, and conclusions and/or recommendations), established scoring criteria, developed training guidelines, and designed a holistic assessment process. This article describes the development of the ECQAT, the resulting product, and recommended future testing and potential uses for the tool. C1 [Pearlman, Robert A.; Foglia, Mary Beth; Cohen, Jennifer H.; Chanko, Barbara L.; Berkowitz, Kenneth A.] Natl Ctr Eth Hlth Care, Dept Vet Affairs, Zurich, Switzerland. [Fox, Ellen] Fox Eth Consulting, Zurich, Switzerland. RP Pearlman, RA (reprint author), VA Puget Sound Hlth Care Syst, Natl Ctr Eth Hlth Care, S-182 GEC,1660 South Columbian Way, Seattle, WA 98108 USA. EM Robert.Pearlman@va.gov NR 34 TC 12 Z9 12 U1 5 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1526-5161 EI 1536-0075 J9 AM J BIOETHICS JI Am. J. Bioeth. PD MAR 3 PY 2016 VL 16 IS 3 BP 3 EP 14 DI 10.1080/15265161.2015.1134704 PG 12 WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical SC Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences GA DF7NJ UT WOS:000371544100002 PM 26913651 ER PT J AU Pearlman, RA Foglia, MB Cohen, JH Chanko, BL Berkowitz, KA AF Pearlman, Robert A. Foglia, Mary Beth Cohen, Jennifer H. Chanko, Barbara L. Berkowitz, Kenneth A. TI Response to Open Peer Commentaries on "Ethics Consultation Quality Assessment Tool: A Novel Method for Assessing the Quality of Ethics Case Consultations Based on Written Records" SO AMERICAN JOURNAL OF BIOETHICS LA English DT Letter C1 [Pearlman, Robert A.; Foglia, Mary Beth; Cohen, Jennifer H.; Chanko, Barbara L.; Berkowitz, Kenneth A.] Natl Ctr Eth Hlth Care, Dept Vet Affairs, Seattle, WA 98108 USA. RP Pearlman, RA (reprint author), Natl Ctr Eth Hlth Care, VA Puget Sound Hlth Care Syst, S 182-GEC,1660 South Columbian Way, Seattle, WA 98108 USA. EM Robert.Pearlman@va.gov NR 2 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1526-5161 EI 1536-0075 J9 AM J BIOETHICS JI Am. J. Bioeth. PD MAR 3 PY 2016 VL 16 IS 3 BP W1 EP W2 DI 10.1080/15265161.2016.1150532 PG 2 WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical SC Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences GA DF7NO UT WOS:000371544600001 PM 26913669 ER PT J AU Shura, RD Miskey, HM Rowland, JA Yoash-Gantz, RE Denning, JH AF Shura, Robert D. Miskey, Holly M. Rowland, Jared A. Yoash-Gantz, Ruth E. Denning, John H. TI Embedded Performance Validity Measures with Postdeployment Veterans: Cross-Validation and Efficiency with Multiple Measures SO APPLIED NEUROPSYCHOLOGY-ADULT LA English DT Article DE multiple measures; veteran; neuropsychological assessment; Word Memory Test; performance validity ID TRAUMATIC BRAIN-INJURY; WORD MEMORY TEST; COMPLEX FIGURE TEST; TEST FAILURE; MALINGERING DETECTION; EVALUATION CONTEXT; LIKELIHOOD RATIOS; INADEQUATE EFFORT; SUSPECT EFFORT; RESPONSE BIAS AB Embedded validity measures support comprehensive assessment of performance validity. The purpose of this study was to evaluate the accuracy of individual embedded measures and to reduce them to the most efficient combination. The sample included 212 postdeployment veterans (average age=35 years, average education=14 years). Thirty embedded measures were initially identified as predictors of Green's Word Memory Test (WMT) and were derived from the California Verbal Learning Test-Second Edition (CVLT-II), Conners' Continuous Performance Test-Second Edition (CPT-II), Trail Making Test, Stroop, Wisconsin Card Sorting Test-64, the Wechsler Adult Intelligence Scale-Third Edition Letter-Number Sequencing, Rey Complex Figure Test (RCFT), Brief Visuospatial Memory Test-Revised, and the Finger Tapping Test. Eight nonoverlapping measures with the highest area-under-the-curve (AUC) values were retained for entry into a logistic regression analysis. Embedded measure accuracy was also compared to cutoffs found in the existing literature. Twenty-one percent of the sample failed the WMT. Previously developed cutoffs for individual measures showed poor sensitivity (SN) in the current sample except for the CPT-II (Total Errors, SN=.41). The CVLT-II (Trials 1-5 Total) showed the best overall accuracy (AUC=.80). After redundant measures were statistically eliminated, the model included the RCFT (Recognition True Positives), CPT-II (Total Errors), and CVLT-II (Trials 1-5 Total) and increased overall accuracy compared with the CVLT-II alone (AUC=.87). The combination of just 3 measures from the CPT-II, CVLT-II, and RCFT was the most accurate/efficient in predicting WMT performance. C1 [Shura, Robert D.; Miskey, Holly M.; Rowland, Jared A.; Yoash-Gantz, Ruth E.] WG Bill Hefner Vet Affairs Med Ctr, Mid Atlantic Mental Illness Res Educ & Clin Ctr, Salisbury, Wilts, England. [Shura, Robert D.; Miskey, Holly M.; Rowland, Jared A.; Yoash-Gantz, Ruth E.] WG Bill Hefner Vet Affairs Med Ctr, Mental Hlth & Behav Sci Serv Line, Salisbury, Wilts, England. [Shura, Robert D.; Miskey, Holly M.; Yoash-Gantz, Ruth E.] Wake Forest Sch Med, Dept Psychiat & Behav Sci, Winston Salem, NC USA. [Rowland, Jared A.] Wake Forest Sch Med, Dept Psychiat & Behav Sci, Dept Anat & Neurobiol, Winston Salem, NC USA. [Denning, John H.] Alvin C York Vet Affairs Med Ctr, Tennessee Valley Healthcare Syst, Murfreesboro, TN USA. [Denning, John H.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Shura, RD (reprint author), Hefner VAMC, 11M-2 MH BS,1601 Brenner Ave, Salisbury, NC 28144 USA. EM robert.shura2@va.gov OI Miskey, Holly/0000-0002-5139-4586 FU W. G. "Bill" Hefner Veterans Affairs Medical Center; Mid-Atlantic Mental Illness Research Education and Clinical Center; Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment FX This work was supported by the This research was supported by resources of the W. G. "Bill" Hefner Veterans Affairs Medical Center, the Mid-Atlantic Mental Illness Research Education and Clinical Center, and the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment.. NR 57 TC 1 Z9 1 U1 2 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 2327-9095 EI 2327-9109 J9 APPL NEUROPSYCH-ADUL JI Appl. Neuropsychol.-Adult PD MAR 3 PY 2016 VL 23 IS 2 BP 94 EP 104 DI 10.1080/23279095.2015.1014556 PG 11 WC Clinical Neurology; Psychology SC Neurosciences & Neurology; Psychology GA DE4TK UT WOS:000370623000003 PM 26375185 ER PT J AU Gaines, KD Soper, HV Berenji, GR AF Gaines, Katy D. Soper, Henry V. Berenji, Gholam R. TI Executive Functioning of Combat Mild Traumatic Brain Injury SO APPLIED NEUROPSYCHOLOGY-ADULT LA English DT Article DE traumatic brain injury; mild TBI; military; psychology; neuropsychology; executive ID HEAD-INJURY; SELF-AWARENESS; DYSFUNCTION; METAANALYSIS; CONCUSSION; NEUROSCIENCE; COGNITION; SYMPTOMS; RECOVERY; SEQUELAE AB This study investigates neuropsychological deficits in recently deployed veterans with mild traumatic brain injury (mTBI). Veterans discharged from 2007 to 2012 were recruited from Veterans Affairs clinics. Independent groups of participants with mTBI (n=57) and those without TBI (n=57) were administered the Beck Depression Inventory-II, Combat Exposure Scale, Word Memory Test, and the Self-Awareness of Deficits Interview. Neuropsychological instruments included the Rey-Osterrieth Complex Figure Test, Letter and Category Fluency, Trail-Making Test-Parts A and B, Christiansen H-abbreviated, Soper Neuropsychology Screen, Wechsler Memory Scale subtests Logical Memory I and II, and the Street Completion Test. The mTBI group performed significantly worse on all of the executive and nonexecutive measurements with the exception of Category Fluency, after controlling for age, depression effort, and combat exposure. Depression and combat exposure were greater for the mTBI group. The mTBI group scored poorer on effort, but only the Multiple Choice subtest was significant. The mTBI group had good awareness of their deficits. C1 [Gaines, Katy D.; Berenji, Gholam R.] Vet Affairs Greater Los Angeles Healthcare Syst, Nucl Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. [Soper, Henry V.] Fielding Grad Univ, Sch Psychol, Santa Barbara, CA USA. RP Gaines, KD (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Nucl Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM drdgaines@gmail.com FU Veterans Affairs of Greater Los Angeles Health Care System [PCC2011-070727] FX This work was supported by the This work was supported by the Veterans Affairs of Greater Los Angeles Health Care System [PCC2011-070727].. NR 79 TC 0 Z9 1 U1 1 U2 16 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 2327-9095 EI 2327-9109 J9 APPL NEUROPSYCH-ADUL JI Appl. Neuropsychol.-Adult PD MAR 3 PY 2016 VL 23 IS 2 BP 115 EP 124 DI 10.1080/23279095.2015.1012762 PG 10 WC Clinical Neurology; Psychology SC Neurosciences & Neurology; Psychology GA DE4TK UT WOS:000370623000005 PM 26496530 ER PT J AU Fei, P Lee, J Packard, RRS Sereti, KI Xu, H Ma, JG Ding, YC Kang, H Chen, H Sung, K Kulkarni, R Ardehali, R Kuo, CCJ Xu, XL Ho, CM Hsiai, TK AF Fei, Peng Lee, Juhyun Packard, Rene R. Sevag Sereti, Konstantina-Ioanna Xu, Hao Ma, Jianguo Ding, Yichen Kang, Hanul Chen, Harrison Sung, Kevin Kulkarni, Rajan Ardehali, Reza Kuo, C. -C. Jay Xu, Xiaolei Ho, Chih-Ming Hsiai, Tzung K. TI Cardiac Light-Sheet Fluorescent Microscopy for Multi-Scale and Rapid Imaging of Architecture and Function SO SCIENTIFIC REPORTS LA English DT Article ID PLANE ILLUMINATION MICROSCOPY; RESOLUTION; ZEBRAFISH; HEART; TOMOGRAPHY; EMBRYOS; FETAL; RECONSTRUCTION; MYOCARDIUM; DIFFUSION AB Light Sheet Fluorescence Microscopy (LSFM) enables multi-dimensional and multi-scale imaging via illuminating specimens with a separate thin sheet of laser. It allows rapid plane illumination for reduced photo-damage and superior axial resolution and contrast. We hereby demonstrate cardiac LSFM (c-LSFM) imaging to assess the functional architecture of zebrafish embryos with a retrospective cardiac synchronization algorithm for four-dimensional reconstruction (3-D space + time). By combining our approach with tissue clearing techniques, we reveal the entire cardiac structures and hypertrabeculation of adult zebrafish hearts in response to doxorubicin treatment. By integrating the resolution enhancement technique with c-LSFM to increase the resolving power under a large field-of-view, we demonstrate the use of low power objective to resolve the entire architecture of large-scale neonatal mouse hearts, revealing the helical orientation of individual myocardial fibers. Therefore, our c-LSFM imaging approach provides multi-scale visualization of architecture and function to drive cardiovascular research with translational implication in congenital heart diseases. C1 [Fei, Peng] Huazhong Univ Sci & Technol, Sch Opt & Elect Informat, Wuhan 430074, Peoples R China. [Fei, Peng; Ho, Chih-Ming] Univ Calif Los Angeles, Dept Mech & Aerosp Engn, Los Angeles, CA USA. [Lee, Juhyun; Packard, Rene R. Sevag; Chen, Harrison; Sung, Kevin; Hsiai, Tzung K.] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA USA. [Packard, Rene R. Sevag; Hsiai, Tzung K.] Univ Calif Los Angeles, Dept Mol Cellular & Integrat Physiol, Los Angeles, CA USA. [Packard, Rene R. Sevag; Sereti, Konstantina-Ioanna; Ma, Jianguo; Ding, Yichen; Kang, Hanul; Kulkarni, Rajan; Ardehali, Reza; Hsiai, Tzung K.] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA. [Xu, Hao; Kuo, C. -C. Jay] Univ So Calif, Dept Elect Engn, Los Angeles, CA 90089 USA. [Kang, Hanul; Hsiai, Tzung K.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Cardiol, Los Angeles, CA USA. [Xu, Xiaolei] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN USA. RP Hsiai, TK (reprint author), Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA USA.; Hsiai, TK (reprint author), Univ Calif Los Angeles, Dept Mol Cellular & Integrat Physiol, Los Angeles, CA USA.; Hsiai, TK (reprint author), Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA.; Hsiai, TK (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Div Cardiol, Los Angeles, CA USA. EM THsiai@mednet.ucla.edu OI Packard, Rene/0000-0002-8520-5843 FU National Institutes of Health [HL083015, HL111437, HL129727, HL81753, HL127728, T32HL007895]; UCLA STAR Program; AHA Pre-Doctoral Fellowship [15PRE21400019] FX This study was supported by National Institutes of Health HL083015 (T.K.H.), HL111437 (T.K.H.), HL129727 (T.K.H.), HL81753 (X.X.), HL127728 (R.A.), T32HL007895 (R.R.S.P.), UCLA STAR Program (R.R.S.P.) and AHA Pre-Doctoral Fellowship 15PRE21400019 (J.L.). NR 36 TC 3 Z9 3 U1 2 U2 19 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD MAR 3 PY 2016 VL 6 AR 22489 DI 10.1038/srep22489 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DF3FS UT WOS:000371230000001 PM 26935567 ER PT J AU Pursley, AJ Saunders, GH AF Pursley, Alyssa J. Saunders, Gabrielle H. TI Knowledge, attitudes, behaviors, and noise exposure of baristas SO INTERNATIONAL JOURNAL OF AUDIOLOGY LA English DT Article DE questionnaires; cafes; Hearing conservation; health belief model; noise-induced hearing loss ID HEARING-LOSS PREVENTION; HEALTH PROMOTION MODEL; PROTECTION AB Objective: To examine the daily noise exposure of baristas working in cafes, and to measure their knowledge, attitudes, and behaviors regarding hearing conservation and perceptions of noise in their work environment. Design: Fifteen baristas from six cafes in Portland completed the Knowledge, Attitudes and Behaviors questionnaire, a sound disturbance survey, and a structured interview to document perceptions of noise in the work environment. To measure daily noise exposure, a subset of eight participants wore a personal dosimeter for three different work shifts. Study sample: A total of 11 females and four males, aged between 19 and 36 years old (mean: 26.3, SD: 4.6) recruited from independently owned cafes in the Portland metro area. Results: Dosimetry measurements revealed Leq measurements between 71 and 83 dBA, with noise doses ranging from 4% to 74%, indicating that baristas are not exposed to sound levels above the regulatory criterion. Questionnaire results indicated that baristas have low awareness about the hazards of noise, are not opposed to hearing conservation, and rarely use hearing protection when engaged in noisy activities. Conclusions: Baristas here lacked the pertinent education and motivation to commit to invaluable hearing conservation practices. C1 [Pursley, Alyssa J.] Washington Univ, Sch Med, Program Audiol & Commun Sci, 660 S Euclid Ave,Campus Box 8042, St Louis, MO 63110 USA. [Saunders, Gabrielle H.] Portland VA Med Ctr, NCRAR, Portland, OR USA. RP Pursley, AJ (reprint author), Washington Univ, Sch Med, Program Audiol & Commun Sci, 660 S Euclid Ave,Campus Box 8042, St Louis, MO 63110 USA. EM alyssa.pursley@wustl.edu FU NIH National Institute on Deafness and other Communicative Disorders Predoctoral Short-term Training Grant [DC008764, T-35] FX This study was supported by a NIH National Institute on Deafness and other Communicative Disorders T-35 Predoctoral Short-term Training Grant (Grant number DC008764). Portions of this work were presented at the American Auditory Society Annual Conference, Phoenix, USA (March 6, 2015), the Missouri Academy of Audiology Annual Conference, Saint Louis, USA (September 12, 2014), and the International Hearing Aid Research Conference, Lake Tahoe, USA (August 14, 2014). NR 16 TC 0 Z9 0 U1 3 U2 5 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1499-2027 EI 1708-8186 J9 INT J AUDIOL JI Int. J. Audiol. PD MAR 3 PY 2016 VL 55 IS 3 BP 184 EP 188 DI 10.3109/14992027.2015.1124295 PG 5 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA DE5BO UT WOS:000370646000007 PM 26795371 ER PT J AU Williams, NR Hopkins, TR Short, EB Sahlem, GL Snipes, J Revuelta, GJ George, MS Takacs, I AF Williams, Nolan R. Hopkins, Thomas R. Short, E. Baron Sahlem, Gregory L. Snipes, Jonathan Revuelta, Gonzalo J. George, Mark S. Takacs, Istvan TI Reward circuit DBS improves Parkinson's gait along with severe depression and OCD SO NEUROCASE LA English DT Article DE Deep brain stimulation; Parkinson's disease; depression; apathy; obsessive-compulsive disorder ID OBSESSIVE-COMPULSIVE DISORDER; DEEP BRAIN-STIMULATION; SUBTHALAMIC NUCLEUS STIMULATION; DISEASE; STRIATUM AB A 59-year-old Caucasian man with a past history of Parkinson's disease (PD) status post-bilateral subthalamic nucleus (STN) deep brain stimulation (DBS), who also had treatment-resistant (TR) obsessive-compulsive disorder (OCD), and treatment-resistant depression (TRD), presented for further evaluation and management of his TR OCD. After an unsuccessful attempt to treat his OCD by reprogramming his existing STN DBS, he was offered bilateral ventral capsule/ventral striatum (VC/VS) DBS surgery. In addition to the expected improvement in OCD symptoms, he experienced significant improvement in both PD-related apathy and depression along with resolution of suicidal ideation. Furthermore, the patient's festinating gait dramatically improved. This case demonstrates that DBS of both the STN and VC/VS appears to have an initial signal of safety and tolerability. This is the first instance where both the STN and the VC/VS DBS targets have been implanted in an individual and the first case where a patient with PD has received additional DBS in mood-regulatory circuitry. C1 [Williams, Nolan R.] Stanford Univ, Dept Psychiat, Stanford, CA 94305 USA. [Hopkins, Thomas R.; Short, E. Baron; Sahlem, Gregory L.; Snipes, Jonathan; George, Mark S.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA. [Revuelta, Gonzalo J.; George, Mark S.; Takacs, Istvan] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Williams, NR (reprint author), Stanford Univ, Dept Psychiat, Stanford, CA 94305 USA. EM nolrywillia@gmail.com OI Williams, Nolan/0000-0003-4368-3203 FU National Institute of Drug Abuse [R25 DA020537] FX NRW and TRH are both funded through National Institute of Drug Abuse [grant number R25 DA020537]. NR 18 TC 3 Z9 3 U1 3 U2 18 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1355-4794 EI 1465-3656 J9 NEUROCASE JI Neurocase PD MAR 3 PY 2016 VL 22 IS 2 BP 201 EP 204 DI 10.1080/13554794.2015.1112019 PG 4 WC Clinical Neurology; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA DD2RR UT WOS:000369770400011 PM 26644268 ER PT J AU Singh, JA Yu, SH AF Singh, Jasvinder A. Yu, Shaohua TI Gout-related inpatient utilization: a study of predictors of outcomes and time trends SO ARTHRITIS RESEARCH & THERAPY LA English DT Article DE Gout; Inpatient utilization; Hospitalization; Comorbidity; Predictors; Length of stay; Hospital discharge; Resource utilization; Charges ID HEALTH-CARE UTILIZATION; HEART-FAILURE; MANAGEMENT; COMORBIDITIES; PREVALENCE; HOSPITALIZATION; HYPERURICEMIA; POPULATION; COSTS AB Background: To assess inpatient healthcare burden of gout n the USA after an Emergency Department (ED) visit and the predictors of gout-related hospitalizations. Method: We used the 2009, 2010 and 2012 US National ED Sample (NEDS) data to examine the time trends in inpatient visits with gout as the primary diagnosis. We used the 2012 NEDS data to assess multivariable-adjusted predictors of length of hospital stay, discharge to home (versus other) and total charges for gout-related inpatient visits. Results: Of the 205,152 ED visits for gout as the primary diagnosis in 2012, 77 % resulted in hospitalization. In 2009, 2010 and 2012, 63 36, 63 % and 64.5 36 of hospitalized patients were discharged home; respective durations of hospital stay were 4.15, 4.00 and 3.86 days. Older age 50 to <65 years (ref <50), renal failure, heart failure, osteoarthritis and diabetes were associated with a longer hospital stay and self-pay/uninsured status, hospital location in the Midwest or Western USA with a shorter hospital stay for gout. Similar factors were associated with total charges for gout-related admissions. Older age (65 to <80 and >= 80, relative to <50 years), diabetes, self-pay/no charge insurance status, metropolitan area residence, and a longer length of hospital stay were associated with lower odds of discharge to home; and self-pay/no charge (uninsured) status was associated with higher odds of discharge to borne, compared to Medicare coverage. Conclusions: Using a national sample, we noted declining duration of hospital stay and identified factors associated with the length of hospital stay, discharge to borne and charges for gout hospitalization following an ED visit. Future studies should examine whether better management of comorbidities in patients with gout can further reduce utilization and cost of gout-related hospitalizations. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, 700 South 19th St, Birmingham, AL 35233 USA. [Singh, Jasvinder A.; Yu, Shaohua] Univ Alabama Birmingham, Sch Med, Dept Med, 1705 Univ Blvd, Birmingham, AL 35233 USA. [Singh, Jasvinder A.; Yu, Shaohua] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, 1705 Univ Blvd, Birmingham, AL 35233 USA. [Singh, Jasvinder A.] Mayo Clin, Dept Orthoped Surg, Coll Med, 200 1st St SW, Rochester, MN 55905 USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, 700 South 19th St, Birmingham, AL 35233 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Sch Med, Dept Med, 1705 Univ Blvd, Birmingham, AL 35233 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, 1705 Univ Blvd, Birmingham, AL 35233 USA.; Singh, JA (reprint author), Mayo Clin, Dept Orthoped Surg, Coll Med, 200 1st St SW, Rochester, MN 55905 USA. EM jassingh@uab.edu FU Univetsity of Alabama at Birmingham (JAB) Division of Rheumatology; National Institute of Arthritis, Musculoskeletal and skin Diseases (NIAMS) [P50 AR060772] FX This material is the resuIt of work supported by research funds from the Univetsity of Alabama at Birmingham (JAB) Division of Rheumatology and the resources and use of facilities at the Birmingham VA Medical Center. JAS is also suppoqed it grant from the National Institute of Arthritis, Musculoskeletal and skin Diseases (NIAMS) P50 AR060772. NR 32 TC 0 Z9 0 U1 1 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 EI 1478-6362 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PD MAR 2 PY 2016 VL 18 DI 10.1186/s13075-016-0936-y PG 10 WC Rheumatology SC Rheumatology GA DF3YU UT WOS:000371285300001 PM 26935737 ER PT J AU Gray, NE Harris, CJ Quinn, JF Soumyanath, A AF Gray, Nora E. Harris, Christopher J. Quinn, Joseph F. Soumyanath, Amala TI Centella asiatica modulates antioxidant and mitochondrial pathways and improves cognitive function in mice SO JOURNAL OF ETHNOPHARMACOLOGY LA English DT Article DE Aging; Cognition; Centella asiatica; Mitochondrial dysfunction; Reactive oxygen species ID AMYLOID-BETA TOXICITY; OXIDATIVE STRESS; ALZHEIMERS-DISEASE; NEURODEGENERATIVE DISEASES; SYNAPTIC PLASTICITY; BRAIN-REGIONS; RATS; MEMORY; MOUSE; DYSFUNCTION AB Ethnopharmacological relevance: This study investigates the cognitive enhancing effects of the plant Centella asiatica which is widely used Ayurvedic and traditional Chinese medicine. Aim of the study: The goal of this study was to determine the effects of a water extract of the medicinal plant Centella asiatica (CAW) on cognitive ability as well as mitochondrial and antioxidant response pathways in vivo. Materials and methods: Old and young C57BL/6 mice were treated with CAW (2 mg/mL) in their drinking water. Learning and memory was assessed using Morris Water Maze (MWM) and then tissue was collected and gene expression analyzed. Results: CAW improved performance in the MWM in aged animals and had a modest effect on the performance of young animals. CAW also increased the expression of mitochondria] and antioxidant response genes in the brain and liver of both young and old animals. Expression of synaptic markers was also increased in the hippocampus and frontal cortex, but not in the cerebellum of CAW-treated animals. Conclusions: These data indicate a cognitive enhancing effect of CAW in healthy mice. The gene expression changes caused by CAW suggest a possible effect on mitochondrial biogenesis, which in conjunction with activation of antioxidant response genes could contribute to cognitive improvement. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Gray, Nora E.; Harris, Christopher J.; Quinn, Joseph F.; Soumyanath, Amala] Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. [Quinn, Joseph F.] Portland VA Med Ctr, Dept Neurol, Portland, OR 97239 USA. [Quinn, Joseph F.] Portland VA Med Ctr, Parkinsons Dis Res Educ & Clin Care Ctr PADRECC, Portland, OR 97239 USA. RP Gray, NE (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM grayn@ohsu.edu FU NIH-NCCAM Grant [R01AT008099]; Oregon Alzheimer's Disease Center (OADC) [3P30-AG008017 24 S1]; NIH-NCCAM [AT002688]; Department of Veterans Affairs FX This work was funded by NIH-NCCAM Grant R01AT008099 (Soumyanath), an Oregon Alzheimer's Disease Center (OADC) Grant 3P30-AG008017 24 S1 (Soumyanath), a T32 grant on which N. Gray was a trainee from NIH-NCCAM AT002688, and by a Department of Veterans Affairs Merit Review grant (Quinn). NR 40 TC 1 Z9 1 U1 1 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0378-8741 J9 J ETHNOPHARMACOL JI J. Ethnopharmacol. PD MAR 2 PY 2016 VL 180 BP 78 EP 86 DI 10.1016/j.jep.2016.01.013 PG 9 WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine GA DF7TN UT WOS:000371560600010 PM 26785167 ER PT J AU Hirano, AA Liu, X Boulter, J Grove, J Muller, LPD Barnes, S Brecha, NC AF Hirano, Arlene A. Liu, Xue Boulter, Jim Grove, James Mueller, Luis Perez de Sevilla Barnes, Steven Brecha, Nicholas C. TI Targeted Deletion of Vesicular GABA Transporter from Retinal Horizontal Cells Eliminates Feedback Modulation of Photoreceptor Calcium Channels SO ENEURO LA English DT Article DE Ca channels; Cx57-iCre; GABA receptors; inhibitory feedback; retinal horizontal cells; synaptic vesicles ID GAMMA-AMINOBUTYRIC-ACID; MOUSE RETINA; MAMMALIAN RETINA; GUINEA-PIG; INTRACELLULAR CALCIUM; CONE PHOTORECEPTORS; TRANSMITTER RELEASE; ROD PHOTORECEPTORS; VERTEBRATE RETINA; RABBIT RETINA AB The cellular mechanisms underlying feedback signaling from horizontal cells to photoreceptors, which are important for the formation of receptive field surrounds of early visual neurons, remain unsettled. Mammalian horizontal cells express a complement of synaptic proteins that are necessary and sufficient for calcium-dependent exocytosis of inhibitory neurotransmitters at their contacts with photoreceptor terminals, suggesting that they are capable of releasing GABA via vesicular release. To test whether horizontal cell vesicular release is involved in feedback signaling, we perturbed inhibitory neurotransmission in these cells by targeted deletion of the vesicular GABA transporter (VGAT), the protein responsible for the uptake of inhibitory transmitter by synaptic vesicles. To manipulate horizontal cells selectively, an iCre mouse line with Cre recombinase expression controlled by connexin57 (Cx57) regulatory elements was generated. In Cx57-iCre mouse retina, only horizontal cells expressed Cre protein, and its expression occurred in all retinal regions. After crossing with a VGAT(flox/flox) mouse line, VGAT was selectively eliminated from horizontal cells, which was confirmed immunohistochemically. Voltage-gated ion channel currents in horizontal cells of Cx57-VGAT(-/-) mice were the same as Cx57-VGAT(+/+) controls, as were the cell responses to the ionotropic glutamate receptor agonist kainate, but the response to the GABA(A) receptor agonist muscimol in Cx57-VGAT(-/-) mice was larger. In contrast, the feedback inhibition of photoreceptor calcium channels, which in control animals is induced by horizontal cell depolarization, was completely absent in Cx57-VGAT(-/-) mice. The results suggest that vesicular release of GABA from horizontal cells is required for feedback inhibition of photoreceptors. C1 [Hirano, Arlene A.; Liu, Xue; Grove, James; Mueller, Luis Perez de Sevilla; Barnes, Steven; Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. [Hirano, Arlene A.; Barnes, Steven; Brecha, Nicholas C.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Boulter, Jim] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Hatos Res Ctr Neuropharmacol,David Geffen Sch Med, Los Angeles, CA 90095 USA. [Barnes, Steven] Dalhousie Univ, Dept Physiol & Biophys, Halifax, NS B3H 4R2, Canada. [Barnes, Steven] Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS B3H 4R2, Canada. [Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA. [Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Liu, Xue] Chongqing Univ Sci & Technol, Biomat & Live Cell Imaging Inst, Chongqing 400044, Peoples R China. RP Hirano, AA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. EM ahirano@mednet.ucla.edu OI Hirano, Arlene/0000-0001-8842-3582 FU National Institutes of Health [EY-15573]; UCLA Oppenheimer Seed Grant; Plum Foundation; Veterans Administration Career Scientist Award; Canadian Institutes of Health Research-Nova Scotia Health Research Foundation Regional Partnership Program Grant [MOP10968]; Natural Sciences and Engineering Research Council of Canada Discovery Award [194640] FX This research was supported by National Institutes of Health Grant EY-15573 (N.C.B.), UCLA Oppenheimer Seed Grant (A.A.H., J.B., N.C.B.), the Plum Foundation (S.B., N.C.B.), a Veterans Administration Career Scientist Award (N.C.B.), Canadian Institutes of Health Research-Nova Scotia Health Research Foundation Regional Partnership Program Grant MOP10968 (S.B.), and Natural Sciences and Engineering Research Council of Canada Discovery Award 194640 (S.B.). NR 61 TC 2 Z9 2 U1 0 U2 0 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 2373-2822 J9 ENEURO JI eNeuro PD MAR-APR PY 2016 VL 3 IS 2 AR UNSP e0148-15.2016 DI 10.1523/ENEURO.0148-15.2016 PG 13 WC Neurosciences SC Neurosciences & Neurology GA EH7AY UT WOS:000391926400031 ER PT J AU Schwartz, MD Nguyen, AT Warrier, DR Palmerston, JB Thomas, AM Morairty, SR Neylan, TC Kilduff, TS AF Schwartz, Michael D. Nguyen, Alexander T. Warrier, Deepti R. Palmerston, Jeremiah B. Thomas, Alexia M. Morairty, Stephen R. Neylan, Thomas C. Kilduff, Thomas S. TI Locus Coeruleus and Tuberomammillary Nuclei Ablations Attenuate Hypocretin/Orexin Antagonist-Mediated REM Sleep SO ENEURO LA English DT Article DE arousal; hypnotics; insomnia; monoamine; orexin; paradoxical sleep ID EYE-MOVEMENT SLEEP; ALMOREXANT PROMOTES SLEEP; WAKING CYCLE; HISTAMINERGIC NEURONS; LATERAL HYPOTHALAMUS; RECEPTOR ANTAGONISTS; PONTINE CARBACHOL; OREXIN RECEPTOR-1; PARADOXICAL SLEEP; FOS EXPRESSION AB Hypocretin 1 and 2 (Hcrts; also known as orexin A and B), excitatory neuropeptides synthesized in cells located in the tuberal hypothalamus, play a central role in the control of arousal. Hcrt inputs to the locus coeruleus norepinephrine (LC NE) system and the posterior hypothalamic histaminergic tuberomammillary nuclei (TMN HA) are important efferent pathways for Hcrt-induced wakefulness. The LC expresses Hcrt receptor 1 (HcrtR1), whereas HcrtR2 is found in the TMN. Although the dual Hcrt/orexin receptor antagonist almorexant (ALM) decreases wakefulness and increases NREM and REM sleep time, the neural circuitry that mediates these effects is currently unknown. To test the hypothesis that ALM induces sleep by selectively disfacilitating subcortical wake-promoting populations, we ablated LC NE neurons (LCx) or TMN HA neurons (TMNx) in rats using cell-type-specific saporin conjugates and evaluated sleep/wake following treatment with ALM and the GABAA receptor modulator zolpidem (ZOL). Both LCx and TMNx attenuated the promotion of REM sleep by ALM without affecting ALM-mediated increases in NREM sleep. Thus, eliminating either HcrtR1 signaling in the LC or HcrtR2 signaling in the TMN yields similar effects on ALM-induced REM sleep without affecting NREM sleep time. In contrast, neither lesion altered ZOL efficacy on any measure of sleep-wake regulation. These results contrast with those of a previous study in which ablation of basal forebrain cholinergic neurons attenuated ALM-induced increases in NREM sleep time without affecting REM sleep, indicating that Hcrt neurotransmission influences distinct aspects of NREM and REM sleep at different locations in the sleep-wake regulatory network. C1 [Schwartz, Michael D.; Nguyen, Alexander T.; Warrier, Deepti R.; Palmerston, Jeremiah B.; Thomas, Alexia M.; Morairty, Stephen R.; Kilduff, Thomas S.] SRI Int, Biosci Div, Ctr Neurosci, 333 Ravenswood Ave, Menlo Pk, CA 94025 USA. [Neylan, Thomas C.] Univ Calif San Francisco, San Francisco VA Med Ctr, NCIRE, San Francisco, CA 94121 USA. RP Kilduff, TS (reprint author), SRI Int, 333 Ravenswood Ave, Menlo Pk, CA 94025 USA. EM thomas.kilduff@sri.com OI Kilduff, Thomas/0000-0002-6823-0094 FU U.S. Army Medical Research Acquisition Activity [W81XWH-09-2-0081]; NIH [R01 NS077408] FX This work was supported by the U.S. Army Medical Research Acquisition Activity award number W81XWH-09-2-0081 and NIH R01 NS077408 to T.S.K. We thank Drs Priyattam J. Shiromani and Carlos Blanco-Centurion for providing Hcrt2-SAP; Tsui-Ming Chen, Alan Wilk, and Dr Simon Fisher for technical assistance; Dr Ling Jong for synthesis of almorexant; and Drs Sarah Black and Gregory Parks for helpful comments on data analysis and the paper. NR 77 TC 0 Z9 0 U1 0 U2 0 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 2373-2822 J9 ENEURO JI eNeuro PD MAR-APR PY 2016 VL 3 IS 2 AR UNSP e0018-16.2016 DI 10.1523/ENEURO.0018-16.2016 PG 16 WC Neurosciences SC Neurosciences & Neurology GA EH7AY UT WOS:000391926400007 ER PT J AU Ellis, C Hoffman, W Jaehnert, S Plagge, J Loftis, JM Schwartz, D Huckans, M AF Ellis, Carilyn Hoffman, William Jaehnert, Sarah Plagge, Jane Loftis, Jennifer M. Schwartz, Daniel Huckans, Marilyn TI Everyday Problems With Executive Dysfunction and Impulsivity in Adults Recovering From Methamphetamine Addiction SO ADDICTIVE DISORDERS & THEIR TREATMENT LA English DT Article DE methamphetamine; impulsivity; executive function ID DEPENDENT INDIVIDUALS; ABUSE; USERS; SYMPTOMS; THERAPY AB Objectives: Compared with nonaddicted controls (CTLs), adults in remission from methamphetamine addiction (MAREM) evidence impairments on objective measures of executive functioning and impulsivity. Methods: To evaluate the impact of these impairments in MA-REM adults, demographically matched groups (MA-REM, n=30; CTLs, n=24) completed objective and self-report measures of executive functioning and impulsivity. Results: MA-REMadults demonstrated significantly (P < 0.050) greater objective and subjective problems with executive functioning and impulsivity. Conclusions: These results suggest that adults in MA-REM are aware of their deficits and that these deficits have significant impact in everyday life. C1 [Ellis, Carilyn; Hoffman, William; Jaehnert, Sarah; Loftis, Jennifer M.; Schwartz, Daniel; Huckans, Marilyn] Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA. [Ellis, Carilyn; Hoffman, William; Jaehnert, Sarah; Plagge, Jane; Huckans, Marilyn] Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97239 USA. [Ellis, Carilyn; Hoffman, William; Jaehnert, Sarah; Loftis, Jennifer M.; Schwartz, Daniel; Huckans, Marilyn] Oregon Hlth & Sci Univ, Sch Med, Methamphetamine Abuse Res Ctr, Portland, OR 97201 USA. [Hoffman, William; Loftis, Jennifer M.; Schwartz, Daniel; Huckans, Marilyn] Oregon Hlth & Sci Univ, Sch Med, Dept Psychiat, Portland, OR 97201 USA. [Hoffman, William; Huckans, Marilyn] Oregon Hlth & Sci Univ, Sch Med, Dept Behav Neurosci, Portland, OR 97201 USA. [Ellis, Carilyn] George Fox Univ, Grad Dept Clin Psychol, Newberg, OR USA. [Jaehnert, Sarah] Univ Pacific, Sch Profess Psychol, Hillsboro, OR USA. RP Huckans, M (reprint author), Portland VA Med Ctr, P3MHN,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM marilyn.huckans@va.gov FU BLRD VA [I01 BX002061]; NIDA NIH HHS [P50 DA018165] NR 28 TC 1 Z9 1 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1531-5754 EI 1535-1122 J9 ADDICT DISORD TREAT JI Addict. Disord. Treat. PD MAR PY 2016 VL 15 IS 1 BP 1 EP 5 DI 10.1097/ADT.0000000000000059 PG 5 WC Substance Abuse SC Substance Abuse GA EE5QZ UT WOS:000389664100001 PM 27034621 ER PT J AU VanEpps, EM Roberto, CA Park, S Economos, CD Bleich, SN AF VanEpps, Eric M. Roberto, Christina A. Park, Sara Economos, Christina D. Bleich, Sara N. TI Restaurant Menu Labeling Policy: Review of Evidence and Controversies SO CURRENT OBESITY REPORTS LA English DT Review DE Menu labeling; Calorie labeling; Obesity prevention; Food policy ID FAST-FOOD RESTAURANTS; OF-THE-LITERATURE; AMERICAN-HEART-ASSOCIATION; FULL-SERVICE RESTAURANTS; CHAIN RESTAURANTS; SCIENTIFIC STATEMENT; PHYSICAL-ACTIVITY; CALORIE LABELS; ENERGY-INTAKE; PORTION SIZE AB In response to high rates of obesity in the USA, several American cities, counties, and states have passed laws requiring restaurant chains to post labels identifying the energy content of items on menus, and nationwide implementation of menu labeling is expected in late 2016. In this review, we identify and summarize the results of 16 studies that have assessed the impact of real-world numeric calorie posting. We also discuss several controversies surrounding the US Food and Drug Administration's implementation of federally mandated menu labeling. Overall, the evidence regarding menu labeling is mixed, showing that labels may reduce the energy content of food purchased in some contexts, but have little effect in other contexts. However, more data on a range of ong-term consumption habits and restaurant responses is needed to fully understand the impact menu labeling laws will have on the US population's diet. C1 [VanEpps, Eric M.] VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Roberto, Christina A.; Park, Sara] Perelman Sch Med, Dept Med Eth & Hlth Policy, 423 Guardian Dr,1105b Blockley Hall, Philadelphia, PA 19104 USA. [Economos, Christina D.] Tufts Univ, Friedman Sch Nutr Sci & Policy, ChildObesity180, Boston, MA 02111 USA. [Economos, Christina D.] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Bleich, Sara N.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA. RP Roberto, CA (reprint author), Perelman Sch Med, Dept Med Eth & Hlth Policy, 423 Guardian Dr,1105b Blockley Hall, Philadelphia, PA 19104 USA. EM croberto@mail.med.upenn.edu FU NIA NIH HHS [P30 AG034546] NR 47 TC 1 Z9 1 U1 1 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 2162-4968 J9 CURR OBES REP JI Curr. Obes. Rep. PD MAR PY 2016 VL 5 IS 1 BP 72 EP 80 DI 10.1007/s13679-016-0193-z PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EB0SH UT WOS:000387055300009 PM 26877095 ER PT J AU Dehlendorf, C Fox, E Sobel, L Borrero, S AF Dehlendorf, Christine Fox, Edith Sobel, Lauren Borrero, Sonya TI Patient-Centered Contraceptive Counseling: Evidence to Inform Practice SO CURRENT OBSTETRICS AND GYNECOLOGY REPORTS LA English DT Article DE Contraception; Contraceptive counseling; Patient-centered; Decision making ID RANDOMIZED CONTROLLED-TRIAL; DECISION-MAKING; UNINTENDED PREGNANCY; QUALITATIVE-ANALYSIS; WOMENS PERSPECTIVES; REPRODUCTIVE AGE; HEALTH-CARE; SERVICES; KNOWLEDGE; ATTITUDES AB Patient centeredness is an increasingly recognized aspect of quality health care. The application of this framework to contraceptive counseling and care has not been well described. We propose a definition of patient-centered contraceptive counseling that focuses on and prioritizes each patient's individual needs and preferences regarding contraceptive methods and the counseling experience. Guided by this definition, we review recent research that has advanced our understanding of how patient-centered contraceptive counseling can be delivered in practice, focusing on how women decide on a contraceptive method, their preferences for counseling, and their experiences with counseling. This research provides evidence that women have diverse preferences around attributes of their contraceptive methods and value personal, supportive relationships with their family planning providers that focus on their individual preferences. We discuss the implications of this research for practice and review recent interventions that incorporate patient centeredness to varying degrees. C1 [Dehlendorf, Christine; Fox, Edith] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA. [Dehlendorf, Christine] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA. [Dehlendorf, Christine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Sobel, Lauren] Touro Univ Calif Vallejo, Coll Osteopath Med, Vallejo, CA USA. [Borrero, Sonya] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Borrero, Sonya] VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Fox, E (reprint author), Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA. EM christine.dehlendorf@ucsf.edu; edith.fox@ucsf.edu; lauren.sobel@tu.edu; borrsp@upmc.edu NR 62 TC 3 Z9 3 U1 7 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 2161-3303 J9 CURR OBSTET GYNECOL JI CURR. OBSTET. GYNECOL. REP. PD MAR PY 2016 VL 5 IS 1 BP 55 EP 63 DI 10.1007/s13669-016-0139-1 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA EA0DA UT WOS:000386254400007 ER PT J AU Obedin-Maliver, J Makadon, HJ AF Obedin-Maliver, Juno Makadon, Harvey J. TI Transgender men and pregnancy SO OBSTETRIC MEDICINE LA English DT Review DE Transgender pregnancy; gender identity; counseling; sexual orientation; primary care transgender people; obstetrical care of transgender people; behavioral aspects of transgender pregnancy; testosterone in pregnancy ID TESTOSTERONE LEVELS; BIRTH AB Transgender people have experienced significant advances in societal acceptance despite experiencing continued stigma and discrimination. While it can still be difficult to access quality health care, and there is a great deal to be done to create affirming health care organizations, there is growing interest around the United States in advancing transgender health. The focus of this commentary is to provide guidance to clinicians caring for transgender men or other gender nonconforming people who are contemplating, carrying, or have completed a pregnancy. Terms transgender and gender nonconforming specifically refer to those whose gender identity (e.g., being a man) differs from their female sex assigned at birth. Many, if not most transgender men retain their female reproductive organs and retain the capacity to have children. Review of their experience demonstrates the need for preconception counseling that includes discussion of stopping testosterone while trying to conceive and during pregnancy, and anticipating increasing experiences of gender dysphoria during and after pregnancy. The clinical aspects of delivery itself fall within the realm of routine obstetrical care, although further research is needed into how mode and environment of delivery may affect gender dysphoria. Postpartum considerations include discussion of options for chest (breast) feeding, and how and when to reinitiate testosterone. A positive perinatal experience begins from the moment transgender men first present for care and depends on comprehensive affirmation of gender diversity. C1 [Obedin-Maliver, Juno] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Obedin-Maliver, Juno] San Francisco VA Med Ctr, Dept Gynecol, San Francisco, CA USA. [Makadon, Harvey J.] Fenway Inst, Natl LGBT Hlth Educ Ctr, 1340 Boylston St, Boston, MA 02215 USA. [Makadon, Harvey J.] Harvard Med Sch, Boston, MA USA. RP Makadon, HJ (reprint author), Fenway Inst, Natl LGBT Hlth Educ Ctr, 1340 Boylston St, Boston, MA 02215 USA. EM hmakadon@fenwayhealth.org NR 41 TC 1 Z9 1 U1 4 U2 4 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1753-495X EI 1753-4968 J9 OBSTET MED JI Obstet. Med. PD MAR PY 2016 VL 9 IS 1 BP 4 EP 8 DI 10.1177/1753495X15612658 PG 5 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DV7LR UT WOS:000383118000002 ER PT J AU Wong, CA Ostapovich, G Kramer-Golinkoff, E Griffis, H Asch, DA Merchant, RM AF Wong, Charlene A. Ostapovich, Gabrielle Kramer-Golinkoff, Emily Griffis, Heather Asch, David A. Merchant, Raina M. TI How U.S. children's hospitals use social media: A mixed methods study SO HEALTHCARE-THE JOURNAL OF DELIVERY SCIENCE AND INNOVATION LA English DT Article ID HEALTH RESEARCH; CARE; INFORMATION; FACEBOOK; TWITTER; YOUTUBE; SITES AB Background: Social media provide new channels for hospitals to engage with communities, a goal of increasing importance as non-profit hospitals face stricter definitions of community benefit under the Affordable Care Act. We describe the variability in social media presence among US children's hospitals and the distribution of their Facebook content curation. Methods: Social media data from freestanding children's hospitals were extracted from September November 2013. Social media adoption was reviewed for each hospital-generated Facebook, Twitter, YouTube, Google + and Pinterest platform. Facebook page (number of Likes) and Twitter account (number of followers) engagement were examined by hospital characteristics. Facebook posts from each hospital over a 6-week period were thematically characterized. Results: We reviewed 5 social media platforms attributed to 45 children's hospitals and 2004 associated Facebook posts. All hospitals maintained Facebook and Twitter accounts and most used YouTube (82%), Google+ (53%) and Pinterest (69%). Larger hospitals were more often high performers for Facebook (67% versus 10%, p < 0.01) and Twitter (75% versus 17%, p < 0.05) engagement than small hospitals. The most common Facebook post-themes were hospital promotion 35% (706), education and information 35% (694), community partnership or benefit 24% (474), fundraising 21% (426), and narratives 12% (241). Of health education posts, 73% (509) provided pediatric health supervision and anticipatory guidance. Conclusions: Social media adoption by US children's hospitals was widespread. Implications: Beyond its traditional marketing role, social media can serve as a conduit for health education, engagement with communities, including community benefit. (C) 2015 Elsevier Inc. All rights reserved. C1 [Wong, Charlene A.; Asch, David A.; Merchant, Raina M.] Univ Penn, Robert Wood Johnson Fdn, Clin Scholars Program, 1303 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Wong, Charlene A.; Ostapovich, Gabrielle; Kramer-Golinkoff, Emily; Griffis, Heather; Asch, David A.; Merchant, Raina M.] Univ Penn, Penn Med Social Media & Hlth Innovat Lab, Penn Med Ctr Hlth Care Innovat, Philadelphia, PA 19104 USA. [Asch, David A.; Merchant, Raina M.] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Wong, CA (reprint author), Univ Penn, Robert Wood Johnson Fdn, Clin Scholars Program, 1303 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM charwong@upenn.edu NR 30 TC 0 Z9 0 U1 5 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2213-0764 EI 2213-0772 J9 HEALTHCARE JI HealthCare PD MAR PY 2016 VL 4 IS 1 BP 15 EP 21 DI 10.1016/j.hjdsi.2015.12.004 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DQ5LK UT WOS:000379246500006 PM 27001094 ER PT J AU Mota, N Tsai, J Kirwin, PD Harpaz-Rotem, I Krystal, JH Southwick, SM Pietrzak, RH AF Mota, Natalie Tsai, Jack Kirwin, Paul D. Harpaz-Rotem, Ilan Krystal, John H. Southwick, Steven M. Pietrzak, Robert H. TI Late-Life Exacerbation of PTSD Symptoms in US Veterans: Results From the National Health and Resilience in Veterans Study SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; OLDER-ADULTS; CASE SERIES; DSM-IV; TRAUMA; EXPOSURE; ONSET; INTERVENTIONS; TRAJECTORIES AB Objective: More than 60% of US military veterans are 55 years or older. Although several case studies have suggested that older age is associated with a higher likelihood of reactivated or delayed-onset posttraumatic stress disorder (PTSD) symptoms in veterans, population-based data on the prevalence and determinants of this phenomenon are lacking. Method: Using data from the National Health and Resilience in Veterans Study (NHRVS: Wave 1 = October 2011-December 2011; Wave 2 = September 2013), a nationally representative, cohort study of US veterans, we evaluated the prevalence and determinants of exacerbated PTSD symptoms in 1,441 veterans 55 years or older using a DSM-IV-based measure in 2011 and a DSM-5-based measure in 2013. Veterans whose worst trauma occurred at least 5 years prior to Wave 2 of the NHRVS (mean = 28.6 years) and who reported a clinically significant increase (ie, >= 0.5 standard deviation [SD]; mean = 1.27, SD = 0.78) in PTSD symptoms from Wave 1 (lifetime) to Wave 2 (past-month) were identified as having exacerbated PTSD symptoms. Results: Results revealed that 9.9% of older US veterans experienced exacerbated PTSD symptoms an average of nearly 3 decades after their worst trauma. A multivariable logistic regression model indicated that greater self-reported cognitive difficulties at Wave 1 independently predicted exacerbated PTSD symptoms at Wave 2. Post hoc analysis revealed that this association was driven by greater severity of executive dysfunction (adjusted odds ratio range, 1.27-3.22). Conclusions: Approximately 1 in 10 older US veterans experiences a clinically significant exacerbation of PTSD symptoms in late life. Executive dysfunction may contribute to risk for exacerbated PTSD symptoms. These results suggest that exacerbated PTSD symptoms are prevalent in US veterans and highlight potential targets for identifying veterans at risk for this phenomenon. (C) Copyright 2016 Physicians Postgraduate Press, Inc. C1 [Mota, Natalie; Tsai, Jack; Kirwin, Paul D.; Harpaz-Rotem, Ilan; Krystal, John H.; Southwick, Steven M.; Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Mota, Natalie; Kirwin, Paul D.; Harpaz-Rotem, Ilan; Krystal, John H.; Southwick, Steven M.; Pietrzak, Robert H.] US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Clin Neurosci Div, West Haven, CT USA. [Tsai, Jack] US Dept Vet Affairs, New England Mental Illness Res Educ & Clin Ctr, West Haven, CT USA. [Mota, Natalie] Univ Manitoba, Dept Clin Hlth Psychol, Winnipeg, MB, Canada. [Mota, Natalie] Yale Univ, Natl Ctr Posttraumat Stress Disorder, New Haven, CT 06520 USA. RP Mota, N (reprint author), 817 Bannatyne Ave, Winnipeg, MB R3E 0W2, Canada. EM natalie.mota@umanitoba.ca FU US Department of Veterans Affairs National Center for Posttraumatic Stress Disorder FX The National Health and Resilience in Veterans Study (NHRVS) was funded by the US Department of Veterans Affairs National Center for Posttraumatic Stress Disorder. NR 40 TC 0 Z9 0 U1 2 U2 4 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD MAR PY 2016 VL 77 IS 3 BP 348 EP 354 DI 10.4088/JCP.15m10101 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DQ5LC UT WOS:000379245700015 PM 27046308 ER PT J AU George, B Denney, T Gupta, H Dell'Italia, L Aban, I AF George, Brandon Denney, Thomas, Jr. Gupta, Himanshu Dell'Italia, Louis Aban, Inmaculada TI APPLYING A SPATIOTEMPORAL MODEL FOR LONGITUDINAL CARDIAC IMAGING DATA SO ANNALS OF APPLIED STATISTICS LA English DT Article DE Spatiotemporal; imaging; correlation; separable; summary measures ID ISOLATED MITRAL REGURGITATION; CARDIOCYTE; BLOCKADE AB Longitudinal imaging studies have both spatial and temporal correlation among the multiple outcome measurements from a subject. Statistical methods of analysis must properly account for this autocorrelation. In this work we discuss how a linear model with a separable parametric correlation structure could be used to analyze data from such a study. The goal of this paper is to provide an easily understood description of how such a model works and discuss how it can be applied to real data. Model assumptions are discussed and the process of selecting a working correlation structure is thoroughly discussed. The steps necessitating collaboration between statistical and scientific investigators have been highlighted, as have considerations for missing data or uneven follow-up. The results from a completed longitudinal cardiac imaging study were considered for illustration purposes. The data comes from a clinical trial for medical therapy for patients with mitral regurgitation, with repeated measurements taken at sixteen locations from the left ventricle to measure disease progression. The spatiotemporal correlation model was compared to previously used summary measures to demonstrate improved power as well as increased flexibility in the use of time- and space- varying predictors. C1 [George, Brandon; Aban, Inmaculada] Univ Alabama Birmingham, Dept Biostat, 1720 2nd Ave S, Birmingham, AL 35233 USA. [Denney, Thomas, Jr.] Auburn Univ, Dept Elect & Comp Engn, Broun Hall,341 War Eagle Way, Auburn, AL 36849 USA. [Gupta, Himanshu; Dell'Italia, Louis] Univ Alabama Birmingham, Dept Med, 1808 7th Ave S, Birmingham, AL 35294 USA. [Gupta, Himanshu; Dell'Italia, Louis] Birmingham Vet Affairs Med Ctr, 700 South 19th St, Birmingham, AL 35233 USA. RP George, B (reprint author), Univ Alabama Birmingham, Dept Biostat, 1720 2nd Ave S, Birmingham, AL 35233 USA. EM brgeorge@uab.edu; caban@uab.edu FU NHLBI [T32HL079888]; National Institutes of Health Specialized Center of Clinically Oriented Research in Cardiac Dysfunction [P50-HL077100] FX Predoctoral funding was provided by NHLBI T32HL079888. The UAB SCCOR study was supported by National Institutes of Health Specialized Center of Clinically Oriented Research in Cardiac Dysfunction P50-HL077100. NR 31 TC 0 Z9 0 U1 0 U2 0 PU INST MATHEMATICAL STATISTICS PI CLEVELAND PA 3163 SOMERSET DR, CLEVELAND, OH 44122 USA SN 1932-6157 J9 ANN APPL STAT JI Ann. Appl. Stat. PD MAR PY 2016 VL 10 IS 1 BP 527 EP 548 DI 10.1214/16-AOAS911 PG 22 WC Statistics & Probability SC Mathematics GA DO9OU UT WOS:000378116900022 PM 27087884 ER PT J AU Novais, EA Baumal, CR Sarraf, D Freund, KB Duker, JS AF Novais, Eduardo A. Baumal, Caroline R. Sarraf, David Freund, K. Bailey Duker, Jay S. TI Multimodal Imaging in Retinal Disease: A Consensus Definition SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA LA English DT Editorial Material ID OPTICAL COHERENCE TOMOGRAPHY; OCCULT MACULAR DYSTROPHY; CHOROIDAL NEOVASCULARIZATION; ANGIOGRAPHY; DEGENERATION; FUTURE C1 [Novais, Eduardo A.; Baumal, Caroline R.; Duker, Jay S.] Tufts Med Ctr, New England Eye Ctr, 260 Tremont St,Biewend Bldg,9-11th Floor, Boston, MA 02116 USA. [Novais, Eduardo A.] Univ Fed Sao Paulo, Sch Med, Sao Paulo, Brazil. [Sarraf, David] Univ Calif Los Angeles, Stein Eye Inst, Los Angeles, CA USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA. [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA. RP Duker, JS (reprint author), Tufts Med Ctr, New England Eye Ctr, 260 Tremont St,Biewend Bldg,9-11th Floor, Boston, MA 02116 USA. EM jduker@tuftsmedicalcenter.org OI Freund, K. Bailey/0000-0002-7888-9773 NR 34 TC 1 Z9 1 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 2325-8160 EI 2325-8179 J9 OSLI RETINA JI Ophthalmic Surg. Lasers Imag. Retin. PD MAR PY 2016 VL 47 IS 3 BP 201 EP + DI 10.3928/23258160-20160229-01 PG 6 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA DP9VF UT WOS:000378844900001 PM 26985792 ER PT J AU Harriff, MJ Karamooz, E Burr, A Grant, WF Canfield, ET Sorensen, ML Moita, LF Lewinsohn, DM AF Harriff, Melanie J. Karamooz, Elham Burr, Ansen Grant, Wilmon F. Canfield, Elizabeth T. Sorensen, Michelle L. Moita, Luis F. Lewinsohn, David M. TI Endosomal MR1 Trafficking Plays a Key Role in Presentation of Mycobacterium tuberculosis Ligands to MAIT Cells SO PLOS PATHOGENS LA English DT Article ID INVARIANT T-CELLS; MHC CLASS-I; CD1 ANTIGEN PRESENTATION; ENDOPLASMIC-RETICULUM; BACTERIAL-INFECTION; SYNTAXIN 18; Q-SNARE; RECEPTOR; PATHWAY; INVOLVEMENT AB Mucosal-Associated Invariant T (MAIT) cells, present in high frequency in airway and other mucosal tissues, have Th1 effector capacity positioning them to play a critical role in the early immune response to intracellular pathogens, including Mycobacterium tuberculosis (Mtb). MR1 is a highly conserved Class I-like molecule that presents vitamin B metabolites to MAIT cells. The mechanisms for loading these ubiquitous small molecules are likely to be tightly regulated to prevent inappropriate MAIT cell activation. To define the intracellular localization of MR1, we analyzed the distribution of an MR1-GFP fusion protein in antigen presenting cells. We found that MR1 localized to endosomes and was translocated to the cell surface upon addition of 6-formyl pterin (6-FP). To understand the mechanisms by which MR1 antigens are presented, we used a lentiviral shRNA screen to identify trafficking molecules that are required for the presentation of Mtb antigen to HLA-diverse T cells. We identified Stx18, VAMP4, and Rab6 as trafficking molecules regulating MR1-dependent MAIT cell recognition of Mtb-infected cells. Stx18 but not VAMP4 or Rab6 knockdown also resulted in decreased 6-FP-dependent surface translocation of MR1 suggesting distinct pathways for loading of exogenous ligands and intracellular mycobacterially-derived ligands. We postulate that endosome-mediated trafficking of MR1 allows for selective sampling of the intracellular environment. C1 [Harriff, Melanie J.; Karamooz, Elham; Burr, Ansen; Sorensen, Michelle L.; Lewinsohn, David M.] Portland VA Med Ctr, Portland, OR 97239 USA. [Harriff, Melanie J.; Karamooz, Elham; Grant, Wilmon F.; Canfield, Elizabeth T.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Pulm & Crit Care Med, Portland, OR 97201 USA. [Moita, Luis F.] Inst Gulbenkian Ciencias, Oeiras, Portugal. [Lewinsohn, David M.] Oregon Hlth & Sci Univ, Mol Microbiol & Immunol, Portland, OR 97201 USA. RP Harriff, MJ (reprint author), Portland VA Med Ctr, Portland, OR 97239 USA.; Harriff, MJ (reprint author), Oregon Hlth & Sci Univ, Pulm & Crit Care Med, Portland, OR 97201 USA. EM harriffm@ohsu.edu; lewinsod@ohsu.edu OI Moita, Luis/0000-0003-0707-315X FU Career Development Award from the U.S. Department of Veterans Affairs Clinical Sciences Research and Development Program [IK2 CX000538]; U.S. Department of Veterans Affairs Biomedical Laboratory Research and Development Program [I01 BX000533]; American Lung Association [RT-350058] FX This work was supported in part by Career Development Award #IK2 CX000538 from the U.S. Department of Veterans Affairs Clinical Sciences Research and Development Program (MJH) and in part by Merit Award #I01 BX000533 from the U.S. Department of Veterans Affairs Biomedical Laboratory Research and Development Program (DML). EK also received support from the American Lung Association (RT-350058). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 34 TC 2 Z9 2 U1 4 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7366 EI 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD MAR PY 2016 VL 12 IS 3 AR e1005524 DI 10.1371/journal.ppat.1005524 PG 19 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA DP0CH UT WOS:000378154800039 PM 27031111 ER PT J AU Bowhay-Carnes, EA Lee, S Datta, P AF Bowhay-Carnes, Elizabeth Ann Lee, Shuko Datta, Paromita TI Evaluation of leukocytosis: Benign or malignant. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO Quality Care Symposium CY FEB 26-27, 2016 CL Phoenix, AZ SP Amer Soc Clin Oncol C1 Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAR 1 PY 2016 VL 34 IS 7 SU S MA 245 PG 1 WC Oncology SC Oncology GA DO9ME UT WOS:000378109900236 ER PT J AU Clarke, CA Baker, LC Malin, J Parker, J Holliday-Hanson, M Fong, N Teleki, S Lang, L O'Sullivan, M AF Clarke, Christina A. Baker, Laurence C. Malin, Jennifer Parker, Joseph Holliday-Hanson, Merry Fong, Niya Teleki, Stephanie Lang, Lance O'Sullivan, Maryann TI Creating an online resource providing hospital cancer surgery volumes in California. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO Quality Care Symposium CY FEB 26-27, 2016 CL Phoenix, AZ SP Amer Soc Clin Oncol C1 Canc Prevent Inst Calif, Fremont, CA USA. Stanford Univ, Palo Alto, CA 94304 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Calif Off Statewide Hlth Planning & Dev, Sacramento, CA USA. Calif HealthCare Fndtn, Oakland, CA USA. Calif Qual Collaborat, Berkeley, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAR 1 PY 2016 VL 34 IS 7 SU S MA 172 PG 1 WC Oncology SC Oncology GA DO9ME UT WOS:000378109900168 ER PT J AU Kaplan, MS Huguet, N McFarland, BH Caetano, R Conner, KR Nolte, KB Giesbrecht, N AF Kaplan, Mark S. Huguet, Nathalie McFarland, Bentson H. Caetano, Raul Conner, Kenneth R. Nolte, Kurt B. Giesbrecht, Norman TI Heavy Alcohol Use Among Suicide Decedents: Differences in Risk Across Racial-Ethnic Groups SO PSYCHIATRIC SERVICES LA English DT Editorial Material ID UNITED-STATES C1 [Kaplan, Mark S.] Univ Calif Los Angeles, Luskin Sch Publ Affairs, Los Angeles, CA 90095 USA. [Huguet, Nathalie; McFarland, Bentson H.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Caetano, Raul] Pacific Inst Res & Evaluat, Oakland, CA USA. [Conner, Kenneth R.] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY USA. [Conner, Kenneth R.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Nolte, Kurt B.] Univ New Mexico, Albuquerque, NM 87131 USA. [Giesbrecht, Norman] Ctr Addict & Mental Hlth, Toronto, ON, Canada. RP Kaplan, MS (reprint author), Univ Calif Los Angeles, Luskin Sch Publ Affairs, Los Angeles, CA 90095 USA. EM kaplanm@luskin.ucla.edu FU National Institute on Alcohol Abuse and Alcoholism [R01-AA020063] FX This research was supported by the National Institute on Alcohol Abuse and Alcoholism (grant R01-AA020063). NR 2 TC 2 Z9 2 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD MAR PY 2016 VL 67 IS 3 BP 258 EP 258 DI 10.1176/appi.ps.201500494 PG 1 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DO4TI UT WOS:000377776600002 PM 26725300 ER PT J AU Harrington, AT Black, JA Clarridge, JE AF Harrington, Amanda T. Black, Jennifer A. Clarridge, Jill E., III TI In Vitro Activity of Retapamulin and Antimicrobial Susceptibility Patterns in a Longitudinal Collection of Methicillin-Resistant Staphylococcus aureus Isolates from a Veterans Affairs Medical Center SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID MUPIROCIN RESISTANCE; COLONIZATION; DECOLONIZATION; PLEUROMUTILIN; EPIDEMIOLOGY; INHIBITION; INFECTION; OINTMENT AB Mupirocin is a topical antimicrobial used to decolonize patients who carry methicillin-resistant Staphylococcus aureus (MRSA), and the topical agent retapamulin may be a potential alternative therapy. The goal of this study was to determine the in vitro activity of retapamulin as well as a panel of 15 antimicrobial agents, including mupirocin, for 403 MRSA isolates collected longitudinally from a naive population at the Veterans Affairs Puget Sound Health Care System. The MICs for retapamulin had a unimodal distribution, ranging from 0.008 to 0.5 mu g/ml. One isolate had an MIC of > 16 mu g/ml, was also resistant to clindamycin and erythromycin, and was recovered from the nares of a patient undergoing hemodialysis. Twenty-four isolates (6%) and 11 isolates (3%) demonstrated low-level resistance (MICs of 8 to 64 mu g/ml) and high-level resistance (MICs of> 512 mu g/ml), respectively, to mupirocin. Isolates were recovered from 10 patients both before and after mupirocin therapy. Of those, isolates from 2 patients demonstrated MIC changes postmupirocin therapy; in both cases, however, strain typing demonstrated that the pre and postmupirocin strains were different. A total of 386 isolates (96%) had vancomycin MICs of <= 1.0 mu g/ml; 340 isolates (84%) were resistant to levofloxacin, 18 isolates (4.5%) were resistant to trimethoprim-sulfamethoxazole, and 135 isolates (33%) had elevated MICs of 4 mu g/ml for linezolid. The baseline levels of resistance were low for mupirocin (9%) and even lower for retapamulin (0.25%) Although the use of mupirocin is currently the standard therapy for decolonization practices, the activity of retapamulin warrants its consideration as an alternative therapy in MRSA decolonization regimens. C1 [Harrington, Amanda T.; Clarridge, Jill E., III] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Harrington, Amanda T.; Black, Jennifer A.; Clarridge, Jill E., III] Univ Washington, Seattle, WA 98195 USA. [Harrington, Amanda T.] Univ Illinois, Chicago, IL USA. RP Harrington, AT (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA USA.; Harrington, AT (reprint author), Univ Illinois, Chicago, IL USA. EM harria@uic.edu FU North Carolina GlaxoSmithKline Foundation FX North Carolina GlaxoSmithKline Foundation provided funding to Amanda T. Harrington. NR 24 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD MAR PY 2016 VL 60 IS 3 BP 1298 EP 1303 DI 10.1128/AAC.01568-15 PG 6 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA DM6VM UT WOS:000376490800016 ER PT J AU Shields, RK Nguyen, MH Press, EG Cumbie, R Driscoll, E Pasculle, AW Clancy, CJ AF Shields, Ryan K. Nguyen, M. Hong Press, Ellen G. Cumbie, Richard Driscoll, Eileen Pasculle, A. William Clancy, Cornelius J. TI Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection (vol 59, pg 7465, 2015) SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Correction C1 [Shields, Ryan K.; Nguyen, M. Hong; Press, Ellen G.; Clancy, Cornelius J.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Shields, Ryan K.; Nguyen, M. Hong; Clancy, Cornelius J.] Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA USA. [Cumbie, Richard; Driscoll, Eileen; Pasculle, A. William] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Shields, RK (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.; Shields, RK (reprint author), Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD MAR PY 2016 VL 60 IS 3 BP 1954 EP 1954 DI 10.1128/AAC.00183-16 PG 1 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA DM6VM UT WOS:000376490800110 PM 26921416 ER PT J AU Yao, JK Dougherty, GG Gautier, CH Haas, GL Condray, R Kasckow, JW Kisslinger, BL Gurklis, JA Messamore, E AF Yao, Jeffrey K. Dougherty, George G., Jr. Gautier, Clara H. Haas, Gretchen L. Condray, Ruth Kasckow, John W. Kisslinger, Benjamin L. Gurklis, John A. Messamore, Erik TI Prevalence and Specificity of the Abnormal Niacin Response: A Potential Endophenotype Marker in Schizophrenia SO SCHIZOPHRENIA BULLETIN LA English DT Article DE niacin-induced flush response; laser Doppler flowmeter; EC50; maximal blood flow; bipolar disorder; phospholipid-arachidonate-eicosanoid signaling ID SKIN FLUSH RESPONSE; NICOTINIC-ACID; ARACHIDONIC-ACID; FATTY-ACIDS; PHOSPHOLIPASE-A2 ACTIVITY; LANGERHANS CELLS; ABSENT RESPONSE; TOPICAL NIACIN; CHALLENGE TEST; PATHWAY AB The skin flush response to niacin is abnormally blunted among a subset of patients with schizophrenia (SZ), preferentially associates with SZ compared to other mental illnesses, occurs frequently in nonpsychotic members of SZ-affected families, appears heritable, and shows evidence of genetic association. The niacin response abnormality (NRA) may prove to be a useful SZ endophenotype. Using a laser Doppler flowmeter, we undertook this study to estimate the prevalence of NRA in SZ (n = 70), bipolar disorder (BP, n = 59), and healthy control (HC, n = 87) groups, and to estimate its specificity for the illness. From the dose-response curves, we calculated the concentration of methylnicotinate required to elicit a half-maximal blood flow (MBF) response (EC50 value) and MBF value for each subject. The median log(10) EC50 of the SZ was above the third quartile of log(10)EC(50) of either the HC or BP groups, whereas the MBF was significantly lower in the SZ than in the HC or BP groups. With a definition of NRA of having both EC50 above the ninetieth percentile of the control samples and MBF response below the sixtieth percentile for the control range, the NRA predicted SZ with 31% sensitivity and 97% specificity. Moreover, the NRA was not influenced by age, gender, race, and cigarette smoking. In summary, the NRA may define a SZ subtype with a clinically significant phospholipid signaling defect. Understanding its molecular origins may shed light on the pathophysiology of SZ and suggest new tools for its early diagnosis and treatment. C1 [Yao, Jeffrey K.; Dougherty, George G., Jr.; Gautier, Clara H.; Haas, Gretchen L.; Condray, Ruth; Kasckow, John W.; Kisslinger, Benjamin L.; Gurklis, John A.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA 15240 USA. [Yao, Jeffrey K.; Dougherty, George G., Jr.; Haas, Gretchen L.; Kasckow, John W.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Yao, Jeffrey K.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. [Messamore, Erik] Univ Cincinnati, Dept Psychiat, Cincinnati, OH USA. [Messamore, Erik] Lindner Ctr Hope, Cincinnati, OH USA. RP Yao, JK (reprint author), VA Pittsburgh Healthcare Syst, B1-2E-140,Univ Dr C, Pittsburgh, PA 15240 USA. EM jkyao@pitt.edu FU Department of Veterans Affairs [1I01CX000110]; Senior Research Career Scientist Award; VA VISN4 Mental Illness Research, Education and Clinical Center (MIRECC); VA Pittsburgh Healthcare System FX This work was supported in part by Department of Veterans Affairs (Merit Reviews 1I01CX000110 and Senior Research Career Scientist Award to J K Y); VA VISN4 Mental Illness Research, Education and Clinical Center (MIRECC Director: D. Oslin; Associate Director: G. Haas); and the VA Pittsburgh Healthcare System. NR 36 TC 1 Z9 1 U1 3 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2016 VL 42 IS 2 BP 369 EP 376 DI 10.1093/schbul/sbv130 PG 8 WC Psychiatry SC Psychiatry GA DM5PG UT WOS:000376401500014 PM 26371338 ER PT J AU Li, QW Zhan, M Chen, W Zhao, BP Yang, K Yang, J Yi, J Huang, QH Mohan, M Hou, ZY Wang, J AF Li, Qiwei Zhan, Ming Chen, Wei Zhao, Benpeng Yang, Kai Yang, Jie Yi, Jing Huang, Qihong Mohan, Man Hou, Zhaoyuan Wang, Jian TI Phenylethyl isothiocyanate reverses cisplatin resistance in biliary tract cancer cells via glutathionylation-dependent degradation of Mcl-1 SO ONCOTARGET LA English DT Article DE biliary tract cancer; PEITC; cisplatin; Mcl-1; glutathionylation ID SIDE POPULATION CELLS; MILD OXIDATIVE STRESS; MRP1 DOWN-REGULATION; GALLBLADDER CANCER; MEDIATED MECHANISM; DRUG-RESISTANCE; PLATINUM DRUGS; LUNG-CANCER; STEM-CELLS; EMODIN AB Biliary tract cancer (BTC) is a highly malignant cancer. BTC exhibits a low response rate to cisplatin (CDDP) treatment, and therefore, an understanding of the mechanism of CDDP resistance is urgently needed. Here, we show that BTC cells develop CDDP resistance due, in part, to upregulation of myeloid cell leukemia 1 (Mcl-1). Phenylethyl isothiocyanate (PEITC), a natural compound found in watercress, could enhance the efficacy of CDDP by degrading Mcl-1. PEITC-CDDP co-treatment also increased the rate of apoptosis of cancer stem-like side population (SP) cells and inhibited xenograft tumor growth without obvious toxic effects. In vitro, PEITC decreased reduced glutathione (GSH), which resulted in decreased GSH/oxidized glutathione (GSSG) ratio and increased glutathionylation of Mcl-1, leading to rapid proteasomal degradation of Mcl-1. Furthermore, we identified Cys16 and Cys286 as Mcl-1 glutathionylation sites, and mutating them resulted in PEITC-mediated degradation resistant Mcl-1 protein. In conclusion, we demonstrate for the first time that CDDP resistance is partially associated with Mcl-1 in BTC cells and we identify a novel mechanism that PEITC can enhance CDDP-induced apoptosis via glutathionylation-dependent degradation of Mcl-1. Hence, our results provide support that dietary intake of watercress may help reverse CDDP resistance in BTC patients. C1 [Li, Qiwei; Zhan, Ming; Chen, Wei; Wang, Jian] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Biliary Pancreat Surg, Shanghai 200030, Peoples R China. [Zhao, Benpeng; Yang, Kai; Yang, Jie; Yi, Jing; Mohan, Man; Hou, Zhaoyuan] Shanghai Jiao Tong Univ, Shanghai Key Lab Tumor Microenvironment & Inflamm, Dept Biochem & Mol Cell Biol, Inst Med Sci,Sch Med, Shanghai 200030, Peoples R China. [Huang, Qihong] Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA. [Huang, Qihong] Vet Affairs Med Ctr, Philadelphia, PA USA. RP Wang, J (reprint author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Biliary Pancreat Surg, Shanghai 200030, Peoples R China. EM dr_wangjian@126.com FU National Natural Science Foundation of China [81072011]; National Key Technology R D Program [2012BAI06B01]; Shanghai Science and Technology Fund [12XD1403400]; Shanghai Municipal Public Health Bureau, China [XBR2011035] FX This work was supported by grants from National Natural Science Foundation of China (81072011, J. Wang), National Key Technology R & D Program (2012BAI06B01, J. Wang), Shanghai Science and Technology Fund (12XD1403400, J. Wang) and Shanghai Municipal Public Health Bureau, China (XBR2011035, J. Wang). NR 45 TC 1 Z9 1 U1 0 U2 1 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD MAR 1 PY 2016 VL 7 IS 9 BP 10271 EP 10282 PG 12 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DL5JI UT WOS:000375672900050 PM 26848531 ER PT J AU Blosnich, JR Marsiglio, MC Gao, SS Gordon, AJ Shipherd, JC Kauth, M Brown, GR Fine, MJ AF Blosnich, John R. Marsiglio, Mary C. Gao, Shasha Gordon, Adam J. Shipherd, Jillian C. Kauth, Michael Brown, George R. Fine, Michael J. TI Mental Health of Transgender Veterans in US States With and Without Discrimination and Hate Crime Legal Protection SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID SEXUAL MINORITY VETERANS; STRUCTURAL STIGMA; BISEXUAL POPULATIONS; CARE UTILIZATION; UNITED-STATES; GAY; SUICIDE; PEOPLE; VIOLENCE; RISK AB Objectives. To examine whether indicators of community-and state-level lesbian, gay, bisexual, and transgender equality are associated with transgender veterans' mental health. Methods. We extracted Veterans Administration data for patients who were diagnosed with gender identity disorder, had at least 1 visit in 2013, and lived in a zip code with a Municipality Equality Index score (n = 1640). We examined the associations of whether a state included transgender status in employment nondiscrimination laws and in hate crimes laws with mood disorders; alcohol, illicit drug, and tobacco use disorders; posttraumatic stress disorder; and suicidal ideation or attempt. Results. Nearly half (47.3%) of the sample lived in states with employment discrimination protection, and 44.8% lived in states with hate crimes protection. Employment nondiscrimination protection was associated with 26% decreased odds of mood disorders (adjusted odds ratio [AOR] = 0.74; 95% confidence interval [CI] = 0.59, 0.93) and 43% decreased odds of self-directed violence (AOR = 0.57; 95% CI = 0.34, 0.95). Conclusions. Understanding lesbian, gay, bisexual, and transgender social stressors can inform treatment and care coordination for transgender populations. C1 [Blosnich, John R.; Gao, Shasha; Gordon, Adam J.; Kauth, Michael] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Univ Dr C 151C U,Bldg 30, Pittsburgh, PA 15240 USA. [Marsiglio, Mary C.] Portland VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Portland, OR USA. [Shipherd, Jillian C.; Kauth, Michael] VA Off Patient Care Serv, Dept Vet Affairs, Washington, DC USA. [Brown, George R.] Mt Home VA Med Ctr, Mountain Home, TN USA. RP Blosnich, JR (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Univ Dr C 151C U,Bldg 30, Pittsburgh, PA 15240 USA. EM John.blosnich@va.gov FU Department of Veterans Affairs (VA) Office of Academic Affiliations; Center for Health Equity Research and Promotion at the VA Pittsburgh Healthcare System; VA Health Service Research and Development [LIP 72-077, LIP 72-080] FX This work was supported by a postdoctoral fellowship through the Department of Veterans Affairs (VA) Office of Academic Affiliations and the Center for Health Equity Research and Promotion at the VA Pittsburgh Healthcare System (to J. R. B) and by the VA Health Service Research and Development (awards LIP 72-077 and LIP 72-080). NR 46 TC 0 Z9 0 U1 7 U2 15 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAR PY 2016 VL 106 IS 3 BP 534 EP 540 DI 10.2105/AJPH.2015.302981 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DL2EA UT WOS:000375444800031 PM 26794162 ER PT J AU Hedayati, SS Daniel, DM Cohen, S Comstock, B Cukor, D Diaz-Linhart, Y Dember, LM Dubovsky, A Greene, T Grote, N Heagerty, P Katon, W Kimmel, PL Kutner, N Linke, L Quinn, D Rue, T Trivedi, MH Unruh, M Weisbord, S Young, BA Mehrotra, R AF Hedayati, S. Susan Daniel, Divya M. Cohen, Scott Comstock, Bryan Cukor, Daniel Diaz-Linhart, Yaminette Dember, Laura M. Dubovsky, Amelia Greene, Tom Grote, Nancy Heagerty, Patrick Katon, Wayne Kimmel, Paul L. Kutner, Nancy Linke, Lori Quinn, Davin Rue, Tessa Trivedi, Madhukar H. Unruh, Mark Weisbord, Steven Young, Bessie A. Mehrotra, Rajnish TI Rationale and design of A Trial of Sertraline vs. Cognitive Behavioral Therapy for End-stage Renal Disease Patients with Depression (ASCEND) SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE End Stage Renal Disease (ESRD); Hemodialysis; Depression; Engagement interview; Cognitive behavioral therapy (CBT); Sertraline ID QUALITY-OF-LIFE; CHRONIC KIDNEY-DISEASE; CHRONIC-HEMODIALYSIS PATIENTS; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; PERITONEAL-DIALYSIS PATIENTS; MAJOR DEPRESSION; PRACTICE PATTERNS; ANTIDEPRESSANT TREATMENT; PSYCHOSOCIAL FACTORS; NUTRITIONAL-STATUS AB Major Depressive Disorder (MDD) is highly prevalent in patients with End Stage Renal Disease (ESRD) treated with maintenance hemodialysis (HD). Despite the high prevalence and robust data demonstrating an independent association between depression and poor clinical and patient-reported outcomes, MDD is under-treated when identified in such patients. This may in part be due to the paucity of evidence confirming the safety and efficacy of treatments for depression in this population. It is also unclear whether HD patients are interested in receiving treatment for depression. ASCEND (Clinical Trials Identifier Number NCT02358343),A Trial of Sertraline vs. Cognitive Behavioral Therapy (CBT) for End-stage Renal Disease Patients with Depression, was designed as a multi-center, 12-week, open-label, randomized, controlled trial of prevalent HD patients with comorbid MDD or dysthymia. It will compare (1) a single Engagement Interview vs. a control visit for the probability of initiating treatment for comorbid depression in up to 400 patients; and (2) individual chair-side CBT vs. flexible-dose treatment with a selective serotonin reuptake inhibitor, sertraline, for improvement of depressive symptoms in 180 of the up to 400 patients. The evolution of depressive symptoms will also be examined in a prospective longitudinal cohort of 90 HD patients who choose not to be treated for depression. We discuss the rationale and design of ASCEND, the first large-scale randomized controlled trial evaluating efficacy of non-pharmacologic vs. pharmacologic treatment of depression in HD patients for patient-centered outcomes. Published by Elsevier Inc. C1 [Hedayati, S. Susan] VA North Texas Hlth Care Syst, Renal Sect, Dallas, TX 75216 USA. [Hedayati, S. Susan] Univ Texas Southwestern Med Ctr, Div Nephrol, Dallas, TX 75390 USA. [Daniel, Divya M.; Linke, Lori; Young, Bessie A.; Mehrotra, Rajnish] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA. [Cohen, Scott] George Washington Univ, Div Nephrol, Washington, DC 20052 USA. [Comstock, Bryan; Heagerty, Patrick; Rue, Tessa] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. [Cukor, Daniel] Suny Downstate Med Ctr, Dept Psychiat, Brooklyn, NY 11203 USA. [Diaz-Linhart, Yaminette] Boston Univ, Sch Med, Boston Med Ctr, Boston, MA 02215 USA. [Dember, Laura M.] Univ Penn, Div Nephrol, Philadelphia, PA 19104 USA. [Dubovsky, Amelia; Katon, Wayne] Univ Washington, Dept Psychiat, Seattle, WA 98195 USA. [Greene, Tom] Univ Utah, Salt Lake City, UT 84112 USA. [Grote, Nancy] Univ Washington, Sch Social Work, Seattle, WA 98195 USA. [Kutner, Nancy] Emory Univ, Atlanta, GA 30322 USA. [Quinn, Davin] Univ New Mexico, Dept Psychiat, Albuquerque, NM 87131 USA. [Trivedi, Madhukar H.] Univ Texas Southwestern Med Ctr, Dept Psychiat, Dallas, TX 75390 USA. [Unruh, Mark] Univ New Mexico, Div Nephrol, Albuquerque, NM 87131 USA. [Weisbord, Steven] VA Pittsburgh Healthcare Syst, Div Nephrol, Pittsburgh, PA USA. [Weisbord, Steven] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. RP Hedayati, SS (reprint author), VA North Texas Hlth Care Syst, Nephrol Sect, MC 111G1,4500 South Lancaster Rd, Dallas, TX 75216 USA. EM susan.hedayati@va.gov FU Dialysis Clinic, Inc. FX There are no financial disclosures other than listed: Mark Unruh receives research support from Dialysis Clinic, Inc. NR 84 TC 4 Z9 4 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD MAR PY 2016 VL 47 BP 1 EP 11 DI 10.1016/j.cct.2015.11.020 PG 11 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA DK0MM UT WOS:000374606900001 PM 26621218 ER PT J AU Marriott, BP Hibbeln, JR Killeen, TK Magruder, KM Holes-Lewis, K Tolliver, BK Turner, TH AF Marriott, Bernadette P. Hibbeln, Joseph R. Killeen, Therese K. Magruder, Kathryn M. Holes-Lewis, Kelly Tolliver, Bryan K. Turner, Travis H. CA BRAVO Grp TI Design and methods for the Better Resiliency Among Veterans and non-Veterans with Omega-3's (BRAVO) study: A double blind, placebo-controlled trial of omega-3 fatty acid supplementation among adult individuals at risk of suicide SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Suicide; Omega-3 fatty acids; Adults ID FATTY-ACIDS; DIETARY SUPPLEMENTATION; MAJOR DEPRESSION; BEHAVIOR; SCALE; VALIDATION; MILITARY; DISORDER; IDEATION; ALCOHOL AB Suicide remains the 10th leading cause of death among adults in the United States (U.S.). Annually, approximately 30 per 100,000 U.S. military Veterans commit suicide, compared to 14 per 100,000 U.S. civilians. Symptoms associated with suicidality can be treatment resistant and proven-effective pharmaceuticals may have adverse side-effects. Thus, a critical need remains to identify effective approaches for building psychological resiliency in at-risk individuals. Omega-3 highly unsaturated fatty acids (n-3 HUFAs) are essential nutrients, which must be consumed in the diet. N-3 HUFAs have been demonstrated to reduce symptoms of depression, anxiety, and impulsivity which are associated with suicide risk. Here we present the design and methods for the Better Resiliency Among Veterans and non-Veterans with Omega-3's (BRAVO) study, which is a double blind, randomized, controlled trial among individuals at risk of suicide of an n-3 HUFA versus placebo supplementation in the form of all natural fruit juice beverages. The BRAVO study seeks to determine if dietary supplementation with n-3 HUFAs reduces the risk for serious suicidal behaviors, suicidal thinking, negative emotions, and symptoms associated with suicide risk. Sub-analyses will evaluate efficacy in reducing depressive symptoms, alcohol, and nicotine use. A sub-study utilizes functional magnetic resonance imaging (JMRI) to evaluate the neuropsychological and neurophysiological effects of n-3 HUFAs. We also outline selection of appropriate proxy outcome measures for detecting response to treatment and collection of ancillary data, such as diet and substance use, that are critical for interpretation of results. (C) 2016 Elsevier Inc. All rights reserved. C1 [Marriott, Bernadette P.] Med Univ S Carolina, Div Gastroenterol & Hepatol, Dept Med, Nutr Sect,Coll Med, 114 Doughty St,Ste 630D,MSC774, Charleston, SC 29425 USA. [Marriott, Bernadette P.] Med Univ S Carolina, Mil Div, Dept Psychiat, Coll Med, 114 Doughty St,Ste 630D,MSC774, Charleston, SC 29425 USA. [Hibbeln, Joseph R.] NIAAA, Sect Nutr Neurosci, LMBB, NIH, 5625 Fishers Lane,Rm 3N-07,MSC 9410, Bethesda, MD 20892 USA. [Killeen, Therese K.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Addict Sci Div, 67 President St,POB 25086, Charleston, SC 29425 USA. [Magruder, Kathryn M.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Dept Publ Hlth Sci, Mil Sci Div,Div Epidemiol,Off Res Integr, 109 Bee St, Charleston, SC 29401 USA. [Holes-Lewis, Kelly] Med Univ S Carolina, Dept Psychiat & Behav Sci, Div Brain Res & Integrat Neuropsychopharmacol, 67 President St, Charleston, SC 29425 USA. [Tolliver, Bryan K.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Div Addict Sci, 67 President St, Charleston, SC 29425 USA. [Turner, Travis H.] Ralph H Johnson VAMC, 109 Bee St, Charleston, SC 29410 USA. [Turner, Travis H.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Dept Neurosci Neurol, 67 President St, Charleston, SC 29425 USA. RP Marriott, BP (reprint author), Med Univ S Carolina, Div Gastroenterol & Hepatol, Dept Med, 114 Doughty St,Suite 629,MSC 774, Charleston, SC 29425 USA. EM marriobp@musc.edu FU Department of Defense (DoD), U.S. Army Medical Research and Materiel Command (USAMRMC), Congressionally Directed Medical Research Programs (CDMRP) through the U.S. Army Medical Research Acquisition Authority (USAMRAA) [W81XWH-13-2-0015]; National Institute on Alcohol Abuse and Alcoholism FX The BRAVO study is sponsored by award # W81XWH-13-2-0015 from the Department of Defense (DoD), U.S. Army Medical Research and Materiel Command (USAMRMC), Congressionally Directed Medical Research Programs (CDMRP) through the U.S. Army Medical Research Acquisition Authority (USAMRAA). The intramural program of the National Institute on Alcohol Abuse and Alcoholism also provides support for this study. The BRAVO study team wishes to acknowledge the excellent-support of Samantha Wise in all aspects of the study. The DoD or its representatives had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. All views and opinions expressed herein are those of the authors and do not necessarily reflect the funding agency. NR 49 TC 1 Z9 1 U1 2 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD MAR PY 2016 VL 47 BP 325 EP 333 DI 10.1016/j.cct.2016.02.002 PG 9 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA DK0MM UT WOS:000374606900042 PM 26855120 ER PT J AU VanEpps, EM Downs, JS Loewenstein, G AF VanEpps, Eric M. Downs, Julie S. Loewenstein, George TI Calorie Label Formats: Using Numeric and Traffic Light Calorie Labels to Reduce Lunch Calories SO JOURNAL OF PUBLIC POLICY & MARKETING LA English DT Article DE calorie labeling; traffic light labeling; nutrition; online decision making; field experiment ID FRONT-OF-PACKAGE; BODY-MASS INDEX; FOOD CHOICE; NUTRITION; INFORMATION; OBESITY; CONSUMPTION; CONVENIENCE; INTENTIONS; CONSUMERS AB In a field experiment involving online workplace lunch orders, this study examines the impact of numeric and traffic light calorie labels on calorie intake. Employees of a large corporation ordered lunches through a website of the authors' design, on which they were presented menus with numeric calorie labels, traffic light labels, or both together, and the authors compared the calorie content of the ordered lunches with that of diners randomized to receive no calorie information. Each label type reduced lunch calories by approximately 10%. Nutrition knowledge was not improved by any menu format. Traffic light labels achieved meaningful reductions in calories ordered even in the absence of numeric information, and the authors found no apparent benefit or detriment of combining label types. These findings suggest that consumers may benefit most from help in identifying relatively healthier choices but rely little on information about the exact caloric content of items. C1 [VanEpps, Eric M.] Univ Penn, VA Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Downs, Julie S.] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. [Loewenstein, George] Carnegie Mellon Univ, Econ & Psychol, Pittsburgh, PA 15213 USA. RP VanEpps, EM (reprint author), Univ Penn, VA Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA.; Downs, JS (reprint author), Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.; Loewenstein, G (reprint author), Carnegie Mellon Univ, Econ & Psychol, Pittsburgh, PA 15213 USA. EM vanepps@mail.med.upenn.edu; downs@cmu.edu; gl20@andrew.cmu.edu NR 52 TC 2 Z9 2 U1 11 U2 18 PU AMER MARKETING ASSOC PI CHICAGO PA 311S WACKER DR, STE 5800, CHICAGO, IL 60606-6629 USA SN 0743-9156 EI 1547-7207 J9 J PUBLIC POLICY MARK JI J. Public Policy Mark. PD SPR PY 2016 VL 35 IS 1 BP 26 EP 36 DI 10.1509/jppm.14.112 PG 11 WC Business SC Business & Economics GA DL8EY UT WOS:000375874600003 ER PT J AU Kahi, CJ Boland, CR Dominitz, JA Giardiello, FM Johnson, DA Kaltenbach, T Lieberman, D Levin, TR Robertson, DJ Rex, DK AF Kahi, Charles J. Boland, C. Richard Dominitz, Jason A. Giardiello, Francis M. Johnson, David A. Kaltenbach, Tonya Lieberman, David Levin, Theodore R. Robertson, Douglas J. Rex, Douglas K. TI Colonoscopy Surveillance after Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID EARLY RECTAL-CANCER; TRANSANAL ENDOSCOPIC MICROSURGERY; COMPUTED TOMOGRAPHIC COLONOGRAPHY; CONTRAST BARIUM ENEMA; FOLLOW-UP STRATEGIES; COLLEGE-OF-RADIOLOGY; CURATIVE RESECTION; CT COLONOGRAPHY; LOCAL EXCISION; RADICAL SURGERY AB The US Multi-Society Task Force has developed updated recommendations to guide health care providers with the surveillance of patients after colorectal cancer (CRC) resection with curative intent. This document is based on a critical review of the literature regarding the role of colonoscopy, flexible sigmoidoscopy, endoscopic ultrasound, fecal testing and CT colonography in this setting. The document addresses the effect of surveillance, with focus on colonoscopy, on patient survival after CRC resection, the appropriate use and timing of colonoscopy for perioperative clearing and for postoperative prevention of metachronous CRC, specific considerations for the detection of local recurrence in the case of rectal cancer, as well as the place of CT colonography and fecal tests in post-CRC surveillance. C1 [Kahi, Charles J.] Richard L Roudebush VA Med Ctr, Indianapolis, IN USA. [Kahi, Charles J.; Rex, Douglas K.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Boland, C. Richard] Baylor Univ, Med Ctr Dallas, Dallas, TX USA. [Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Dominitz, Jason A.] Univ Washington, Sch Med, Seattle, WA USA. [Giardiello, Francis M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Johnson, David A.] Eastern VA Med Sch, Norfolk, VA USA. [Kaltenbach, Tonya] Vet Affairs Palo Alto, Palo Alto, CA USA. [Kaltenbach, Tonya] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. [Lieberman, David] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Levin, Theodore R.] Kaiser Permanente Med Ctr, Walnut Creek, CA USA. [Robertson, Douglas J.] VA Med Ctr, White River Jct, VT USA. [Robertson, Douglas J.] Geisel Sch Med Dartmouth, Hanover, NH USA. RP Kahi, CJ (reprint author), Indiana Univ Sch Med, Richard L Roudebush VA Med Ctr, 1481 W 10th St,111G, Indianapolis, IN 46202 USA. EM ckahi2@iu.edu NR 122 TC 1 Z9 1 U1 3 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD MAR PY 2016 VL 111 IS 3 BP 337 EP 346 DI 10.1038/ajg.2016.22 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DL1OB UT WOS:000375400500014 PM 26871541 ER PT J AU Lowry, EA Greninger, DA Porco, TC Naseri, A Stamper, RL Han, Y AF Lowry, Eugene A. Greninger, Daniel A. Porco, Travis C. Naseri, Ayman Stamper, Robert L. Han, Ying TI A Comparison of Resident-performed Argon and Selective Laser Trabeculoplasty in Patients With Open-angle Glaucoma SO JOURNAL OF GLAUCOMA LA English DT Article DE laser trabeculoplasty; resident education; glaucoma; ALT; SLT ID TRIAL AB Purpose: To compare intraocular pressure (IOP) reduction and complications of resident-performed argon laser trabeculoplasty (ALT) and selective laser trabeculoplasty (SLT). Patients and Methods: This was a retrospective, interventional, comparative case series performed at the San Francisco Veterans Affairs Hospital. The study included 77 patients each undergoing 1 resident-performed ALT procedure from April 2006 through November 2009, and 81 patients each undergoing 1 resident-performed SLT procedure from November 2009 through December 2011. Reduction in IOP at 12 months and a longitudinal analysis across 24 months was determined. Secondary outcomes investigated included additional interventions of either repeat trabeculoplasty or trabeculectomy as well as change in eye drop medications. Results: There was no evidence of a difference between IOP reductions in patients undergoing ALT compared with SLT at 12 months (P=0.41, linear modeling) or across all follow-up appointments (P=0.62, linear-mixed effects regression). Patients undergoing ALT had a significantly increased number of eye drops (+ 0.6 vs. -0.1 drops, P<0.001, Wilcoxon rank-sum test) and trend toward increased rates of additional interventions (P=0.06, Weibull regression). There was no difference in immediate post-procedure IOP rise between the 2 groups (P=0.75, Wilcoxon rank-sum test) or any evidence of change in visual acuity. Conclusions: We found no difference in IOP reduction between patients undergoing resident-performed ALT compared with SLT. However, patients undergoing ALT had a significant increase in eye drop medications and trend toward additional interventions compared with patients undergoing SLT. C1 [Lowry, Eugene A.; Greninger, Daniel A.; Porco, Travis C.; Naseri, Ayman; Stamper, Robert L.; Han, Ying] Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way, San Francisco, CA 94143 USA. [Porco, Travis C.; Naseri, Ayman; Han, Ying] Univ Calif San Francisco, Francis I Proctor Fdn, 10 Koret Way, San Francisco, CA 94143 USA. [Porco, Travis C.] Univ Calif San Francisco, Dept Epidemiol & Biostat, Div Prevent Med & Publ Hlth, 10 Koret Way, San Francisco, CA 94143 USA. [Naseri, Ayman; Stamper, Robert L.; Han, Ying] San Francisco VA Med Ctr, Dept Ophthalmol, San Francisco, CA USA. [Greninger, Daniel A.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA. RP Han, Y (reprint author), Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way, San Francisco, CA 94143 USA. EM ying.han@ucsf.edu NR 23 TC 1 Z9 1 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1057-0829 EI 1536-481X J9 J GLAUCOMA JI J. Glaucoma PD MAR PY 2016 VL 25 IS 3 BP E157 EP E161 DI 10.1097/IJG.0000000000000207 PG 5 WC Ophthalmology SC Ophthalmology GA DK3MO UT WOS:000374821000007 PM 25651207 ER PT J AU Mitchell, NS Prochazka, AV Glasgow, RE AF Mitchell, Nia S. Prochazka, Allan V. Glasgow, Russell E. TI Time to RE-AIM: Why Community Weight Loss Programs Should Be Included in Academic Obesity Research SO PREVENTING CHRONIC DISEASE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; DIABETES PREVENTION PROGRAM; UNITED-STATES; INTERVENTION; PREVALENCE; REDUCTION; CHILDHOOD; HEALTH; CARE AB Despite decades of efficacy-based research on weight loss interventions, the obesity epidemic in the United States persists, especially in underserved populations. We used the RE-AIM (Reach, Efficacy/Effectiveness, Adoption, Implementation, and Maintenance) framework to describe the limitations of the current paradigm of efficacy-based research for weight loss interventions. We also used RE-AIM to propose that existing weight loss interventions (community-based programs) such as Jenny Craig, Take Off Pounds Sensibly (TOPS), and Weight Watchers be studied to supplement the efficacy-based research approaches to achieve population-level impact on obesity. C1 [Mitchell, Nia S.] Univ Colorado, Div Gen Internal Med, Anschutz Hlth & Wellness Ctr, Adult & Child Consortium Hlth Outcomes Res & Deli, Anschutz Med Campus,Mail Stop C263, Aurora, CO 80045 USA. [Prochazka, Allan V.] Denver VA Med Ctr, Denver, CO USA. [Prochazka, Allan V.] Univ Colorado, Anschutz Med Coll, Aurora, CO USA. [Glasgow, Russell E.] Univ Colorado, Anschutz Med Campus, Aurora, CO USA. RP Mitchell, NS (reprint author), Univ Colorado, Div Gen Internal Med, Anschutz Hlth & Wellness Ctr, Adult & Child Consortium Hlth Outcomes Res & Deli, Anschutz Med Campus,Mail Stop C263, Aurora, CO 80045 USA. EM Nia.Mitchell@ucdenver.edu NR 23 TC 1 Z9 1 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD MAR PY 2016 VL 13 AR 150436 DI 10.5888/pcd13.150436 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DK8UG UT WOS:000375203200008 ER PT J AU O'Toole, TP Johnson, EE Aiello, R Kane, V Pape, L AF O'Toole, Thomas P. Johnson, Erin E. Aiello, Riccardo Kane, Vincent Pape, Lisa TI Tailoring Care to Vulnerable Populations by Incorporating Social Determinants of Health: the Veterans Health Administration's "Homeless Patient Aligned Care Team" Program SO PREVENTING CHRONIC DISEASE LA English DT Article ID EMERGENCY-DEPARTMENT VISITS; MEDICAL-CARE; ADULTS; SERVICES; MODEL; MORTALITY; ACCESS; BOSTON; COSTS; NEEDS AB Introduction Although the clinical consequences of homelessness are well described, less is known about the role for health care systems in improving clinical and social outcomes for the homeless. We described the national implementation of a "homeless medical home" initiative in the Veterans Health Administration (VHA) and correlated patient health outcomes with characteristics of high-performing sites. Methods We conducted an observational study of 33 VHA facilities with homeless medical homes and patient-aligned care teams that served more than 14,000 patients. We correlated site-specific health care performance data for the 3,543 homeless veterans enrolled in the program from October 2013 through March 2014, including those receiving ambulatory or acute health care services during the 6 months prior to enrollment in our study and 6 months post-enrollment with corresponding survey data on the Homeless Patient Aligned Care Team (H-PACT) program implementation. We defined high performance as high rates of ambulatory care and reduced use of acute care services. Results More than 96% of VHA patients enrolled in these programs were concurrently receiving VHA homeless services. Of the 33 sites studied, 82% provided hygiene care (on-site showers, hygiene kits, and laundry), 76% provided transportation, and 55% had an onsite clothes pantry; 42% had a food pantry and provided on-site meals or other food assistance. Six-month patterns of acute-care use pre-enrollment and post-enrollment for 3,543 consecutively enrolled patients showed a 19.0% reduction in emergency department use and a 34.7% reduction in hospitalizations. Three features were significantly associated with high performance: 1) higher staffing ratios than other sites, 1) integration of social supports and social services into clinical care, and 3) outreach to and integration with community agencies. Conclusion Integrating social determinants of health into clinical care can be effective for high-risk homeless veterans. C1 [O'Toole, Thomas P.] Providence VA Med Ctr, Natl Ctr Homelessness Vet, 830 Chalkstone Ave, Providence, RI 02909 USA. [Johnson, Erin E.; Aiello, Riccardo; Kane, Vincent; Pape, Lisa] US Dept Vet Affairs, Natl Ctr Homelessness Vet, Off Homeless Programs, Providence, RI USA. [Kane, Vincent] Lebanon VA Med Ctr, Lebanon, NH USA. RP O'Toole, TP (reprint author), Providence VA Med Ctr, Natl Ctr Homelessness Vet, 830 Chalkstone Ave, Providence, RI 02909 USA. EM Thomas.OToole@va.gov FU VHA National Center on Homelessness Among Veterans FX The authors report no conflicts of interest. This project was internally supported by VHA National Center on Homelessness Among Veterans as part of its ongoing program evaluation efforts. Dr O'Toole is also affiliated with Warren Alpert Medical School at Brown University and with the Providence VA Medical Center. NR 29 TC 2 Z9 2 U1 3 U2 13 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD MAR PY 2016 VL 13 AR 150567 DI 10.5888/pcd13.150567 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DK8UG UT WOS:000375203200015 ER PT J AU Zhao, HS Carney, KE Falgoust, L Pan, JW Sun, DD Zhang, ZL AF Zhao, Hanshu Carney, Karen E. Falgoust, Lindsay Pan, Jullie W. Sun, Dandan Zhang, Zhongling TI Emerging roles of Na+/H+ exchangers in epilepsy and developmental brain disorders SO PROGRESS IN NEUROBIOLOGY LA English DT Review DE ADHD; Autism; Excitability; NHE1; NHE6; NHE9 ID CARBONIC-ANHYDRASE-II; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; GAMMA-AMINOBUTYRIC-ACID; CENTRAL-NERVOUS-SYSTEM; COUPLED BICARBONATE TRANSPORTERS; CATION-CHLORIDE COTRANSPORTERS; CULTURED HIPPOCAMPAL-NEURONS; LINKED MENTAL-RETARDATION; ANGELMAN-LIKE SYNDROME AB Epilepsy is a common central nervous system (CNS) disease characterized by recurrent transient neurological events occurring due to abnormally excessive or synchronous neuronal activity in the brain. The CNS is affected by systemic acid-base disorders, and epileptic seizures are sensitive indicators of underlying imbalances in cellular pH regulation. Na+/H+ exchangers (NHEs) are a family of membrane transporter proteins actively involved in regulating intracellular and organellar pH by extruding H+ in exchange for Na+ influx. Altering NHE function significantly influences neuronal excitability and plays a role in epilepsy. This review gives an overview of pH regulatory mechanisms in the brain with a special focus on the NHE family and the relationship between epilepsy and dysfunction of NHE isoforms. We first discuss how cells translocate acids and bases across the membrane and establish pH homeostasis as a result of the concerted effort of enzymes and ion transporters. We focus on the specific roles of the NHE family by detailing how the loss of NHE1 in two NHE mutant mice results in enhanced neuronal excitability in these animals. Furthermore, we highlight new findings on the link between mutations of NHE6 and NHE9 and developmental brain disorders including epilepsy, autism, and attention deficit hyperactivity disorder (ADHD). These studies demonstrate the importance of NHE proteins in maintaining H+ homeostasis and their intricate roles in the regulation of neuronal function. A better understanding of the mechanisms underlying NHE1, 6, and 9 dysfunctions in epilepsy formation may advance the development of new epilepsy treatment strategies. Published by Elsevier Ltd. C1 [Zhao, Hanshu; Zhang, Zhongling] Harbin Med Univ, Dept Neurol, Affiliated Hosp 1, 23 You Zheng St, Harbin 150001, Heilongjiang Pr, Peoples R China. [Zhao, Hanshu; Carney, Karen E.; Falgoust, Lindsay; Pan, Jullie W.; Sun, Dandan] Univ Pittsburgh, Dept Neurol, S-598 South Biomed Sci Tower BST,3500 Terrance St, Pittsburgh, PA 15213 USA. [Sun, Dandan] Ctr Geriatr Res Educ & Clin, Vet Affairs Pittsburgh Hlth Care Syst, Pittsburgh, PA 15213 USA. RP Zhang, ZL (reprint author), Harbin Med Univ, Dept Neurol, Affiliated Hosp 1, 23 You Zheng St, Harbin 150001, Heilongjiang Pr, Peoples R China.; Sun, DD (reprint author), Univ Pittsburgh, Dept Neurol, S-598 South Biomed Sci Tower BST,3500 Terrance St, Pittsburgh, PA 15213 USA. EM sund@upmc.edu; zhangzhongling@outlook.com FU NIH [R01NS048216] FX The research was supported by NIH R01NS048216 (DS). NR 227 TC 6 Z9 6 U1 1 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0301-0082 EI 1873-5118 J9 PROG NEUROBIOL JI Prog. Neurobiol. PD MAR-MAY PY 2016 VL 138 BP 19 EP 35 DI 10.1016/j.pneurobio.2016.02.002 PG 17 WC Neurosciences SC Neurosciences & Neurology GA DK4VZ UT WOS:000374919700002 PM 26965387 ER PT J AU Gibson, CJ Gray, KE Katon, JG Simpson, TL Lehavot, K AF Gibson, Carolyn J. Gray, Kristen E. Katon, Jodie G. Simpson, Tracy L. Lehavot, Keren TI Sexual Assault, Sexual Harassment, and Physical Victimization during Military Service across Age Cohorts of Women Veterans SO WOMENS HEALTH ISSUES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH; ADMINISTRATION OUTPATIENTS; FEMALE VETERANS; TRAUMA; PREVALENCE; RISK; SYMPTOMATOLOGY; ASSOCIATION; SOLDIERS AB Objectives: Exposure to sexual and physical trauma during military service is associated with adverse mental and physical health outcomes. Little is known about their prevalence and impact in women veterans across age cohorts. Methods: Data from a 2013 national online survey of women veterans was used to examine associations between age and trauma during military service, including sexual assault, sexual harassment, and physical victimization. Analyses were conducted using logistic regression, adjusting for service duration and demographic factors. In secondary analyses, the moderating role of age in the relationship between trauma and self-reported health was examined. Results: The sample included 781 women veterans. Compared with the oldest age group (>= 65), all except the youngest age group had consistently higher odds of reporting trauma during military service. These differences were most pronounced in women aged 45 to 54 years (sexual assault odds ratio [OR], 3.81 [95% CI, 2.77-6.71]; sexual harassment, OR, 3.99 [95% CI, 2.25-7.08]; and physical victimization, OR, 5.72 [95% CI, 3.32-9.85]). The association between trauma during military service and self-reported health status also varied by age group, with the strongest negative impact observed among women aged 45 to 54 and 55 to 64. Conclusions: Compared with other age groups, women in midlife were the most likely to report trauma during military service, and these experiences were associated with greater negative impact on their self-reported health. Providers should be aware that trauma during military service may be particularly problematic for the cohort of women currently in midlife, who represent the largest proportion of women who use Department of Veterans Affairs health care. Published by Elsevier Inc. on behalf of the Jacobs Institute of Women's Health. C1 [Gibson, Carolyn J.] San Francisco VA Med Ctr, Med Serv Line, San Francisco, CA USA. [Gray, Kristen E.; Katon, Jodie G.; Lehavot, Keren] Dept Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Gray, Kristen E.; Katon, Jodie G.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Katon, Jodie G.] Dept Vet Affairs, Vet Hlth Adm, Off Patient Care Serv, Womens Hlth Serv, Washington, DC USA. [Simpson, Tracy L.; Lehavot, Keren] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Simpson, Tracy L.; Lehavot, Keren] VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA USA. [Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, CESATE, Seattle, WA USA. RP Gibson, CJ (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM Carolyn.Gibson2@va.gov FU VSN-20 Mental Illness, Research, Education, and Clinical Center (MIRECC); VA Career Development Award from CSRD [1K2 CX000867] FX This research was supported by funding from the VSN-20 Mental Illness, Research, Education, and Clinical Center (MIRECC) to Drs. Lehavot and Simpson. Dr. Lehavot was supported by a VA Career Development Award from CSR&D (1K2 CX000867). NR 36 TC 1 Z9 1 U1 4 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD MAR-APR PY 2016 VL 26 IS 2 BP 225 EP 231 DI 10.1016/j.whi.2015.09.013 PG 7 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA DK6TJ UT WOS:000375058000014 PM 26632005 ER PT J AU Cucciare, MA Lewis, ET Hoggatt, KJ Bean-Mayberry, B Timko, C Durazo, EM Jamison, AL Frayne, SM AF Cucciare, Michael A. Lewis, Eleanor T. Hoggatt, Katherine J. Bean-Mayberry, Bevanne Timko, Christine Durazo, Eva M. Jamison, Andrea L. Frayne, Susan M. TI Factors Affecting Women's Disclosure of Alcohol Misuse in Primary Care: A Qualitative Study with US Military Veterans SO WOMENS HEALTH ISSUES LA English DT Article ID SUBSTANCE-ABUSE; PATIENT-RELATIONSHIP; USE DISORDERS; HEALTH; IMPLEMENTATION; INTERVENTIONS; AFGHANISTAN; DRINKING; THERAPY; AUDIT AB Background: One in five women veterans screens positive for alcohol misuse. Women may be less likely than men to disclose alcohol use to a primary care provider (PCP), resulting in women being less likely to receive effective interventions. We sought to qualitatively examine factors that may affect women veterans' willingness to disclose alcohol use to a PCP. Methods: Between October 2012 and May 2013, in-depth interviews were conducted with 30 women veterans at two Department of Veterans Affairs (VA) medical facilities. Qualitative data analyses identified common themes representing factors that influence women's decision to disclose alcohol use to a PCP. Findings: Nine themes were endorsed by women veterans as influencing their willingness to disclose alcohol use to their PCP. Themes included provider behaviors perceived as encouraging or discouraging disclosure of alcohol misuse, perceived positive relationship with provider, negative emotions such as concerns about being judged or labeled an "alcoholic," health concerns about drinking, non-health-related concerns about drinking, self-appraisal of drinking behavior, social support, and clinic factors. Conclusions: Our findings demonstrate the importance of social relationships, comfort with one's provider, and education on the potential harms (especially health related) associated with alcohol in encouraging disclosure of alcohol use in women veterans. Our results also support VA national health care efforts, including the provision of brief alcohol counseling and the use of primary care clinics specializing in the care of women veterans. Published by Elsevier Inc. on behalf of the Jacobs Institute of Women's Health. C1 [Cucciare, Michael A.] Cent Arkansas Vet Affairs Healthcare Syst, Ctr Mental Healthcare & Outcomes Res, Little Rock, AR USA. [Cucciare, Michael A.] Cent Arkansas Vet Healthcare Syst, VA South Cent VISN Mental Illness Res Educ & Clin, 2200 Ft Roots Dr, Little Rock, AR 72205 USA. [Cucciare, Michael A.] Univ Arkansas Med Sci, Dept Psychiat, Little Rock, AR 72205 USA. [Lewis, Eleanor T.; Timko, Christine; Durazo, Eva M.; Jamison, Andrea L.; Frayne, Susan M.] VA Palo Alto Healthcare Syst, Ctr Innovat Implementat, Menlo Pk, CA USA. [Hoggatt, Katherine J.; Bean-Mayberry, Bevanne] VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Innovat Implementat & Policy, Sepulveda, CA USA. [Hoggatt, Katherine J.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA USA. [Bean-Mayberry, Bevanne] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Timko, Christine] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Frayne, Susan M.] VA Palo Alto Hlth Care Syst, Womens Hlth Serv, Palo Alto, CA USA. [Frayne, Susan M.] Stanford Univ, Sch Med, Div Gen Med Disciplines, Stanford, CA 94305 USA. RP Cucciare, MA (reprint author), Cent Arkansas Vet Healthcare Syst, Ctr Mental Healthcare & Outcomes Res, 2200 Ft Roots Dr, North Little Rock, AR 72205 USA. EM macucciare@uams.edu FU Rapid Response Project by the VA Substance Use Disorder Quality Enhancement Research Initiative [RRP 11-436]; Department of Veterans Affairs (VA) Health Services Research and Development (HSRD) Service [CDA 08-004, RCS 00-001]; VA HSR&D QUERI Career Development Award at the VA Greater Los Angeles [CDA 11-261] FX This research was supported by a Rapid Response Project (RRP 11-436) to Dr. Cucciare by the VA Substance Use Disorder Quality Enhancement Research Initiative. This research was also supported by a Career Development Award-2 (CDA 08-004) to Dr. Cucciare, and by a Senior Research Career Scientist Award (RCS 00-001) to Dr. Timko, by the Department of Veterans Affairs (VA) Health Services Research and Development (HSR&D) Service. Dr. Hoggatt is funded through a VA HSR&D QUERI Career Development Award (CDA 11-261) at the VA Greater Los Angeles. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. There are no financial conflicts to disclose. NR 34 TC 2 Z9 2 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD MAR-APR PY 2016 VL 26 IS 2 BP 232 EP 239 DI 10.1016/j.whi.2015.07.010 PG 8 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA DK6TJ UT WOS:000375058000015 PM 26341569 ER PT J AU Ellingson, LD Stegner, AJ Schwabacher, IJ Koltyn, KF Cook, DB AF Ellingson, Laura D. Stegner, Aaron J. Schwabacher, Isaac J. Koltyn, Kelli F. Cook, Dane B. TI Exercise Strengthens Central Nervous System Modulation of Pain in Fibromyalgia SO BRAIN SCIENCES LA English DT Article DE modulation; exercise; chronic pain; imaging; fibromyalgia ID SMOKING-RELATED IMAGES; PHYSICAL-ACTIVITY; HEALTHY-INDIVIDUALS; CIGARETTE CRAVINGS; ISOMETRIC-EXERCISE; RESPONSE FUNCTION; BRAIN ACTIVATION; FUNCTIONAL MRI; HEART-RATE; WOMEN AB To begin to elucidate the mechanisms underlying the benefits of exercise for chronic pain, we assessed the influence of exercise on brain responses to pain in fibromyalgia (FM). Complete data were collected for nine female FM patients and nine pain-free controls (CO) who underwent two functional neuroimaging scans, following exercise (EX) and following quiet rest (QR). Brain responses and pain ratings to noxious heat stimuli were compared within and between groups. For pain ratings, there was a significant (p < 0.05) Condition by Run interaction characterized by moderately lower pain ratings post EX compared to QR (d = 0.39-0.41) for FM but similar to ratings in CO (d = 0.10-0.26), thereby demonstrating that exercise decreased pain sensitivity in FM patients to a level that was analogous to pain-free controls. Brain responses demonstrated a significant within-group difference in FM patients, characterized by less brain activity bilaterally in the anterior insula following QR as compared to EX. There was also a significant Group by Condition interaction with FM patients showing less activity in the left dorsolateral prefrontal cortex following QR as compared to post-EX and CO following both conditions. These results suggest that exercise appeared to stimulate brain regions involved in descending pain inhibition in FM patients, decreasing their sensitivity to pain. Thus, exercise may benefit patients with FM via improving the functional capacity of the pain modulatory system. C1 [Ellingson, Laura D.] Iowa State Univ, Dept Kinesiol, Ames, IA 50011 USA. [Stegner, Aaron J.; Schwabacher, Isaac J.; Cook, Dane B.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53706 USA. [Stegner, Aaron J.; Schwabacher, Isaac J.; Koltyn, Kelli F.; Cook, Dane B.] Univ Wisconsin, Dept Kinesiol, Madison, WI 53706 USA. RP Ellingson, LD (reprint author), Iowa State Univ, Dept Kinesiol, Ames, IA 50011 USA. EM ellingl@iastate.edu; astegner@wisc.edu; ischwabacher@wisc.edu; kelli.koltyn@wisc.edu; dane.cook@wisc.edu OI Cook, Dane/0000-0002-3992-4820 NR 43 TC 3 Z9 3 U1 2 U2 3 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 2076-3425 EI 2976-3425 J9 BRAIN SCI JI Brain Sci. PD MAR PY 2016 VL 6 IS 1 AR 8 DI 10.3390/brainsci6010008 PG 13 WC Neurosciences SC Neurosciences & Neurology GA DJ2QC UT WOS:000374048900007 ER PT J AU Giardina, TD Sarkar, U Gourley, G Modi, V Meyer, AND Singh, H AF Giardina, Traber Davis Sarkar, Urmimala Gourley, Gato Modi, Varsha Meyer, Ashley N. D. Singh, Hardeep TI Online public reactions to frequency of diagnostic errors in US outpatient care SO DIAGNOSIS LA English DT Article DE diagnostic error burden; public perceptions ID PATIENT SAFETY; INTERVENTIONS AB Background: Diagnostic errors pose a significant threat to patient safety but little is known about public perceptions of diagnostic errors. A study published in BMJ Quality & Safety in 2014 estimated that diagnostic errors affect at least 5% of US adults (or 12 million) per year. We sought to explore online public reactions to media reports on the reported frequency of diagnostic errors in the US adult population. Methods: We searched the World Wide Web for any news article reporting findings from the study. We then gathered all the online comments made in response to the news articles to evaluate public reaction to the newly reported diagnostic error frequency (n = 241). Two coders conducted content analyses of the comments and an experienced qualitative researcher resolved differences. Results: Overall, there were few comments made regarding the frequency of diagnostic errors. However, in response to the media coverage, 44 commenters shared personal experiences of diagnostic errors. Additionally, commentary centered on diagnosis-related quality of care as affected by two emergent categories: (1) US health care providers (n = 79; 63 commenters) and (2) US health care reform-related policies, most commonly the Affordable Care Act (ACA) and insurance/reimbursement issues (n = 62; 47 commenters). Conclusion: The public appears to have substantial concerns about the impact of the ACA and other reform initiatives on the diagnosis-related quality of care. However, policy discussions on diagnostic errors are largely absent from the current national conversation on improving quality and safety. Because outpatient diagnostic errors have emerged as a major safety concern, researchers and policymakers should consider evaluating the effects of policy and practice changes on diagnostic accuracy. C1 [Giardina, Traber Davis] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr 152, Houston VA HSR&D Ctr Innovat, 2002 Holcombe Blvd, Houston, TX 77030 USA. [Giardina, Traber Davis; Modi, Varsha; Meyer, Ashley N. D.; Singh, Hardeep] Baylor Coll Med, Sect Hlth Serv Res, Dept Med, 2002 Holcombe Blvd, Houston, TX 77030 USA. [Sarkar, Urmimala; Gourley, Gato] San Francisco Gen Hosp, UCSF Ctr Vulnerable Populat, San Francisco, CA 94110 USA. [Sarkar, Urmimala; Gourley, Gato] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div Gen Internal Med, San Francisco, CA USA. [Modi, Varsha; Meyer, Ashley N. D.; Singh, Hardeep] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston VA HSR&D Ctr Innovat, Houston, TX 77030 USA. RP Giardina, TD (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr 152, Houston VA HSR&D Ctr Innovat, 2002 Holcombe Blvd, Houston, TX 77030 USA.; Giardina, TD (reprint author), Baylor Coll Med, Sect Hlth Serv Res, Dept Med, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM Traberd@bcm.edu FU AHRQ HHS [P30 HS023558, R01 HS022087, R21 HS023602]; NCI NIH HHS [K23 CA125585] NR 34 TC 0 Z9 0 U1 2 U2 4 PU WALTER DE GRUYTER GMBH PI BERLIN PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY SN 2194-8011 EI 2194-802X J9 DIAGNOSIS JI Diagnosis PD MAR PY 2016 VL 3 IS 1 BP 17 EP 22 DI 10.1515/dx-2015-0022 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DJ3LI UT WOS:000374106300004 PM 27347474 ER PT J AU Fritz, JM Rundell, SD Dougherty, P Gentili, A Kochersberger, G Morone, NE Raja, SN Rodriguez, E Rossi, MI Shega, J Sowa, G Weiner, DK AF Fritz, Julie M. Rundell, Sean D. Dougherty, Paul Gentili, Angela Kochersberger, Gary Morone, Natalia E. Raja, Srinivasa Naga Rodriguez, Eric Rossi, Michelle I. Shega, Joseph Sowa, Gwendolyn Weiner, Debra K. TI Deconstructing Chronic Low Back Pain in the Older Adult-Step by Step Evidence and Expert-Based Recommendations for Evaluation and Treatment. Part VI: Lumbar Spinal Stenosis SO PAIN MEDICINE LA English DT Article DE Aged; Assessment; Lumbar Spinal Stenosis; Spinal Stenosis; Chronic Pain; Elderly; Low Back Pain; Primary Care; Chronic Low Back Pain ID UNITED-STATES TRENDS; PHYSICAL-THERAPY; NATURAL-HISTORY; SURGERY; DIAGNOSIS; OSTEOARTHRITIS; COMPLICATIONS; METAANALYSIS; MANAGEMENT; INJECTIONS AB Methods. The evaluation and treatment algorithm, a table articulating the rationale for the individual algorithm components, and stepped-care drug recommendations were developed using a modified Delphi approach. The Principal Investigator, a five-member content expert panel and a nine-member primary care panel were involved in the iterative development of these materials. The illustrative clinical case was taken from the clinical practice of a contributor's colleague (SR). Results. We present an algorithm and supportive materials to help guide the care of older adults with LSS, a condition that occurs not uncommonly in those with CLBP. The case illustrates the importance of function-focused management and a rational approach to conservative care. Conclusions. Lumbar spinal stenosis exists not uncommonly in older adults with CLBP and management often can be accomplished without surgery. Treatment should address all conditions in addition to LSS contributing to pain and disability. C1 [Fritz, Julie M.] Univ Utah, Dept Phys Therapy, Salt Lake City, UT USA. [Fritz, Julie M.] Univ Utah, Coll Hlth, Salt Lake City, UT USA. [Rundell, Sean D.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Dougherty, Paul; Kochersberger, Gary] Canandaigua VA Med Ctr, Canandaigua, NY USA. [Dougherty, Paul] New York Chiropract Coll, Dept Res, Seneca Falls, NY USA. [Dougherty, Paul; Kochersberger, Gary] Univ Rochester, Sch Med & Dent, Div Geriatr, Rochester, NY USA. [Gentili, Angela] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA. [Gentili, Angela] Virginia Commonwealth Univ Hlth Syst, Richmond, VA USA. [Morone, Natalia E.; Rossi, Michelle I.; Weiner, Debra K.] Vet Affairs Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA USA. [Morone, Natalia E.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Ctr Res Hlth Care, Pittsburgh, PA USA. [Morone, Natalia E.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Rodriguez, Eric; Rossi, Michelle I.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA 15213 USA. [Raja, Srinivasa Naga] Johns Hopkins Univ, Sch Med, Dept Anesthesiol, Baltimore, MD USA. [Raja, Srinivasa Naga] Johns Hopkins Univ, Sch Med, Crit Care Med, Baltimore, MD USA. [Raja, Srinivasa Naga] Johns Hopkins Univ, Sch Med, Div Pain Med, Baltimore, MD USA. [Shega, Joseph] VITAS Healthcare, Miami, FL USA. [Sowa, Gwendolyn] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Sowa, Gwendolyn] Univ Pittsburgh, Dept Orthoped Surg, Pittsburgh, PA USA. [Sowa, Gwendolyn] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiolgoy, Pittsburgh, PA USA. RP Weiner, DK (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr C,1A-118,Res Off Bldg, Pittsburgh, PA 15240 USA. EM Debra.Weiner@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service FX This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service. NR 46 TC 1 Z9 1 U1 2 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD MAR PY 2016 VL 17 IS 3 BP 501 EP 510 DI 10.1093/pm/pnw011 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA DI8DL UT WOS:000373731300009 PM 26962233 ER PT J AU Billings, CJ Penman, TM Ellis, EM Baltzell, LS McMillan, GP AF Billings, Curtis J. Penman, Tina M. Ellis, Emily M. Baltzell, Lucas S. McMillan, Garnett P. TI Phoneme and Word Scoring in Speech-in-Noise Audiometry SO AMERICAN JOURNAL OF AUDIOLOGY LA English DT Article ID MINI-MENTAL-STATE; HEARING-LOSS; ELDERLY LISTENERS; RECOGNITION; AGE; DIFFICULTIES; PERCEPTION; DEFICITS; MASKING; LEVEL AB Purpose: Understanding speech in background noise is difficult for many individuals; however, time constraints have limited its inclusion in the clinical audiology assessment battery. Phoneme scoring of words has been suggested as a method of reducing test time and variability. The purposes of this study were to establish a phoneme scoring rubric and use it in testing phoneme and word perception in noise in older individuals and individuals with hearing impairment. Method: Words were presented to 3 participant groups at 80 dB in speech-shaped noise at 7 signal-to-noise ratios (-10 to 35 dB). Responses were scored for words and phonemes correct. Results: It was not surprising to find that phoneme scores were up to about 30% better than word scores. Word scoring resulted in larger hearing loss effect sizes than phoneme scoring, whereas scoring method did not significantly modify age effect sizes. There were significant effects of hearing loss and some limited effects of age; age effect sizes of about 3 dB and hearing loss effect sizes of more than 10 dB were found. Conclusion: Hearing loss is the major factor affecting word and phoneme recognition with a subtle contribution of age. Phoneme scoring may provide several advantages over word scoring. A set of recommended phoneme scoring guidelines is provided. C1 [Billings, Curtis J.; Penman, Tina M.; Ellis, Emily M.; Baltzell, Lucas S.; McMillan, Garnett P.] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR 97239 USA. [Billings, Curtis J.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Billings, CJ (reprint author), Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR 97239 USA.; Billings, CJ (reprint author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA. EM billings2@va.gov FU NIH/NIDCD [R03DC10914]; VA/RRD [C4844C, C8006W] FX This work was supported by grants to the first author (NIH/NIDCD R03DC10914; VA/RR&D C4844C and C8006W). The contents do not represent the views of the U.S. Department of Veterans Affairs or the U.S. Government. Participants provided informed consent, and research was completed with the approval from the pertinent Institutional Review Boards. Authors' contributions to this study include study design and data collection (EE, LB, TP, and CB), analysis and interpretation of data (GM, CB, and TP), and manuscript preparation (CB, TP, EE, LB, and GM). The authors thank Melissa Papesh, Angela Eilbes, and Paul Pendergraft for their contributions. Portions of these data were presented in 2013 at the AudiologyNow! and the Joint Defense Veterans Audiology Conference. NR 32 TC 0 Z9 0 U1 0 U2 4 PU AMER SPEECH-LANGUAGE-HEARING ASSOC PI ROCKVILLE PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA SN 1059-0889 EI 1558-9137 J9 AM J AUDIOL JI Am. J. Audiol. PD MAR PY 2016 VL 25 IS 1 BP 75 EP 83 DI 10.1044/2016_AJA-15-0068 PG 9 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA DI3VC UT WOS:000373425600008 PM 26989823 ER PT J AU Rinne, ST Liu, CF Wong, ES Hebert, PL Heidenreich, P Bastian, LA Au, DH AF Rinne, Seppo T. Liu, Chuan-Fen Wong, Edwin S. Hebert, Paul L. Heidenreich, Paul Bastian, Lori A. Au, David H. TI Organizational Structure for Chronic Heart Failure and Chronic Obstructive Pulmonary Disease SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID QUALITY-OF-CARE; ACUTE EXACERBATIONS; MATCHING-MICHIGAN; ADHERENCE; HEALTH; PROGRAM; READMISSIONS; IMPROVEMENT; GUIDELINES; MANAGEMENT AB Objectives: In contrast to chronic heart failure (CHF), measures of quality of care for chronic obstructive pulmonary disease (COPD) are poor. Our objective was to examine differences in organizational structure available to support quality of care for patients with CHF and COPD. Study Design: We performed 2 nationwide surveys exploring organizational structure for the management of CHF and COPD. We surveyed the chief of medicine and the chief of cardiology and pulmonary medicine at 120 Veterans Affairs facilities in the United States. Methods: Analogous questions about organizational structure that enhanced adherence to guideline-based care were compared between CHF and COPD surveys. Results: We found large and notable differences in the organizational structure for disease management, with systematically less attention given to COPD than CHF. These differences were evident in multiple processes of care. Key differences included fewer facilities: having COPD clinics than CHF clinics (12.7% vs 50.8%; P <. 01), relating performance measures with COPD providers than CHF providers (17.1% vs 70%; P <. 01), and having home monitoring programs for COPD than for CHF (50.5% vs 87.4%; P <. 01). Conclusions: Despite the growing burden of COPD, less organizational structure existed for COPD than CHF. Lack of organizational structure for COPD likely impedes an organization's abilities to encourage high-quality care and avoid recently implemented hospital readmission penalties. Our results suggest the need to develop a systematic approach for healthcare systems to provide essential organizational structure based on the burden of disease in the population. C1 [Rinne, Seppo T.; Bastian, Lori A.] VA Connecticut Hlth Care Syst, Dept Vet Affairs, West Haven, CT USA. [Rinne, Seppo T.] Yale Univ, Sect Pulm & Crit Care, Dept Internal Med, New Haven, CT USA. [Liu, Chuan-Fen; Wong, Edwin S.; Hebert, Paul L.; Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Dept Vet Affairs, Seattle, WA USA. [Liu, Chuan-Fen; Wong, Edwin S.; Hebert, Paul L.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Au, David H.] Univ Washington, Dept Med, Div Pulm, Seattle, WA USA. [Au, David H.] Univ Washington, Dept Med, Div Crit Care, Seattle, WA USA. [Heidenreich, Paul] VA Palo Alto Hlth Care Syst, Hlth Res & Policy, Dept Vet Affairs, Palo Alto, CA USA. [Bastian, Lori A.] Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT USA. RP Au, DH (reprint author), 1100 Olive Way,Ste 1400, Seattle, WA 98104 USA. EM David.Au@va.gov FU Veterans Affairs clinical research grant [IIR-09-354] FX Funding for this research was provided by a Veterans Affairs clinical research grant IIR-09-354. The views expressed here are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 33 TC 1 Z9 1 U1 1 U2 2 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD MAR PY 2016 VL 22 IS 3 BP E82 EP + PG 8 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DI5XL UT WOS:000373573700001 PM 26978239 ER PT J AU Szul, T Bratcher, PE Fraser, KB Kong, M Tirouvanziam, R Ingersoll, S Sztul, E Rangarajan, S Blalock, JE Xu, X Gaggar, A AF Szul, Tomasz Bratcher, Preston E. Fraser, Kyle B. Kong, Michele Tirouvanziam, Rabindra Ingersoll, Sarah Sztul, Elizabeth Rangarajan, Sunil Blalock, J. Edwin Xu, Xin Gaggar, Amit TI Toll-Like Receptor 4 Engagement Mediates Prolyl Endopeptidase Release from Airway Epithelia via Exosomes SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY LA English DT Article DE protease; Toll-like receptor 4; exosome; cystic fibrosis; pulmonary ID EXTRACELLULAR-MATRIX DEGRADATION; CELL-DERIVED EXOSOMES; CYSTIC-FIBROSIS; NEUTROPHILIC INFLAMMATION; PROTEIN SECRETION; VESICLES; LUNG; MICROVESICLES; TRAFFICKING; BIOGENESIS AB Proteases are important regulators of pulmonary remodeling and airway inflammation. Recently, we have characterized the enzyme prolyl endopeptidase (PE), a serine peptidase, as a critical protease in the generation of the neutrophil chemoattractant tripeptide Pro-Gly-Pro (PGP) from collagen. However, PE has been characterized as a cytosolic enzyme, and the mechanism mediating PE release extracellularly remains unknown. We examined the role of exosomes derived from airway epithelia as a mechanism for PE release and the potential extracellular signals that regulate the release of these exosomes. We demonstrate a specific regulatory pathway of exosome release from airway epithelia and identify PE as novel exosome cargo. LPS stimulation of airway epithelial cells induces release of PE-containing exosomes, which is significantly attenuated by small interfering RNA depletion of Toll-like receptor 4 (TLR4). These differences were recapitulated upon intratracheal LPS administration in mice competent versus deficient for TLR4 signaling. Finally, sputum samples from subjects with cystic fibrosis colonized with Pseudomonas aeruginosa demonstrate elevated exosome content and increased PE levels. This TLR4-based mechanism highlights the first report of nonstochastic release of exosomes in the lung and couples TLR4 activation with matrikine generation. The increased quantity of these proteolytic exosomes in the airways of subjects with chronic lung disease highlights a new mechanism of injury and inflammation in the pathogenesis of pulmonary disorders. C1 [Szul, Tomasz; Bratcher, Preston E.; Rangarajan, Sunil; Blalock, J. Edwin; Xu, Xin; Gaggar, Amit] Univ Alabama Birmingham, Dept Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA. [Szul, Tomasz; Bratcher, Preston E.; Tirouvanziam, Rabindra; Blalock, J. Edwin; Xu, Xin; Gaggar, Amit] Univ Alabama Birmingham, Program Protease & Matrix Biol, Birmingham, AL 35294 USA. [Fraser, Kyle B.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA. [Kong, Michele] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35294 USA. [Kong, Michele; Xu, Xin; Gaggar, Amit] Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Res Ctr, Birmingham, AL 35294 USA. [Sztul, Elizabeth; Gaggar, Amit] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294 USA. [Blalock, J. Edwin; Gaggar, Amit] Univ Alabama Birmingham, Lung Hlth Ctr, Birmingham, AL 35294 USA. [Tirouvanziam, Rabindra; Ingersoll, Sarah] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA. [Tirouvanziam, Rabindra; Ingersoll, Sarah] Emory Univ, Emory Childrens Ctr Cyst Fibrosis & Airways Dis R, Atlanta, GA 30322 USA. [Gaggar, Amit] Birmingham Vet Affairs Med Ctr, Med Serv, Birmingham, AL USA. RP Gaggar, A (reprint author), Univ Alabama Birmingham, Dept Med, Div Pulm Allergy & Crit Care, Birmingham, AL 35294 USA. EM agaggar1@uab.edu FU American Heart Association postdoctoral fellowship; National Institutes of Health training grant [5T32HL007457]; National Heart, Lung, and Blood Institute [HL07783, HL090999, HL087824, HL102371]; Veterans Administration grant [1 I01BX001756]; Ismail Moustapha Scholar Fund; National Institutes of Health; Family Smoking Prevention and Tobacco Control Act FX This work was supported by an American Heart Association postdoctoral fellowship (T.S.); by National Institutes of Health training grant 5T32HL007457; by National Heart, Lung, and Blood Institute grants HL07783, HL090999, and HL087824 (J.E.B.) and HL102371 (A.G.); by Veterans Administration grant 1 I01BX001756 (A.G.); and by the Ismail Moustapha Scholar Fund (A.G.). Research reported in this publication was supported by the National Institutes of Health and the Family Smoking Prevention and Tobacco Control Act. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Food and Drug Administration. NR 44 TC 3 Z9 3 U1 2 U2 5 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1044-1549 EI 1535-4989 J9 AM J RESP CELL MOL JI Am. J. Respir. Cell Mol. Biol. PD MAR PY 2016 VL 54 IS 3 BP 359 EP 369 DI 10.1165/rcmb.2015-0108OC PG 11 WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System GA DI7UB UT WOS:000373706400008 PM 26222144 ER PT J AU Herzig, MCS Zavadil, JA Street, K Hildreth, K Drinkwater, NR Reddick, T Herbert, DC Hanes, MA McMahan, CA Reddick, RL Walter, CA AF Herzig, Maryanne C. S. Zavadil, Jessica A. Street, Karah Hildreth, Kim Drinkwater, Norman R. Reddick, Traci Herbert, Damon C. Hanes, Martha A. McMahan, C. Alex Reddick, Robert L. Walter, Christi A. TI DNA Alkylating Agent Protects Against Spontaneous Hepatocellular Carcinoma Regardless of O-6-Methylguanine-DNA Methyltransferase Status SO CANCER PREVENTION RESEARCH LA English DT Article ID LIVER-CANCER; TRANSGENIC MICE; UNITED-STATES; REPAIR; HEPATOCARCINOGENESIS; RISK; CARCINOGENESIS; MUTAGENESIS; CULTURE; LINES AB Hepatocellular carcinoma is increasingly important in the United States as the incidence rate rose over the last 30 years. C3HeB/FeJ mice serve as a unique model to study hepatocellular carcinoma tumorigenesis because they mimic human hepatocellular carcinoma with delayed onset, male gender bias, approximately 50% incidence, and susceptibility to tumorigenesis is mediated through multiple genetic loci. Because a human O-6-methylguanine-DNA methyltransferase (hMGMT) transgene reduces spontaneous tumorigenesis in this model, we hypothesized that hMGMT would also protect from methylation-induced hepatocarcinogenesis. To test this hypothesis, wild-type and hMGMT transgenic C3HeB/FeJ male mice were treated with two monofunctional alkylating agents: diethylnitrosamine (DEN; 0.025 mu mol/g body weight) on day 12 of life with evaluation for glucose-6-phosphatase-deficient (G6PD) foci at 16, 24, and 32 weeks or N-methyl-N-nitrosurea (MNU; 25 mg MNU/kg body weight) once monthly for 7 months starting at 3 months of age with evaluation for liver tumors at 12 to 15 months of age. No difference in abundance or size of G6PD foci was measured with DEN treatment. In contrast, it was unexpectedly found that MNU reduces liver tumor prevalence in wildtype and hMGMT transgenic mice despite increased tumor prevalence in other tissues. hMGMT and MNU protections were additive, suggesting that MNU protects through a different mechanism, perhaps through the cytotoxic N7-alkylguanine and N3-alkyladenine lesions which have low mutagenic potential compared with O-6-alkylguanine lesions. Together, these results suggest that targeting the repair of cytotoxic lesions may be a good preventative for patients at high risk of developing hepatocellular carcinoma. (C) 2015 AACR. C1 [Herzig, Maryanne C. S.; Zavadil, Jessica A.; Hildreth, Kim; Herbert, Damon C.; Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, Mail Code 7762,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Street, Karah] Saddleback Coll, Mission Viejo, CA USA. [Drinkwater, Norman R.] Univ Wisconsin Madison, McArdle Lab Canc Res, Madison, WI USA. [Reddick, Traci] Duke Univ, Med Ctr, Transgen Mouse Facil, Durham, NC USA. [Hanes, Martha A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Lab Anim Resources, San Antonio, TX 78229 USA. [McMahan, C. Alex; Reddick, Robert L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Ctr Longev & Aging Studies, San Antonio, TX 78229 USA. [Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio Canc Inst, San Antonio, TX 78229 USA. [Walter, Christi A.] Audie Murphy Hosp, South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Walter, CA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, Mail Code 7762,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM walter@uthscsa.edu FU VA Merit grant; CPRIT Research Training Award [RP140105]; [P30 CA014520] FX These studies were supported by a VA Merit grant to C.A. Walter and CPRIT Research Training Award (RP140105) to J.A. Zavadil. The histochemical staining for the G6PD studies was done by the Experimental Pathology Core of the University of Wisconsin Carbone Cancer Center Cancer Center supported by Grant P30 CA014520. The Ki67-staining conducted by the Histology and Immunohistochemistry Laboratory of the Department of Pathology at University of Texas Health Science Center San Antonio. NR 34 TC 0 Z9 0 U1 2 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1940-6207 EI 1940-6215 J9 CANCER PREV RES JI Cancer Prev. Res. PD MAR PY 2016 VL 9 IS 3 BP 245 EP 252 DI 10.1158/1940-6207.CAPR-15-0251 PG 8 WC Oncology SC Oncology GA DI4BS UT WOS:000373445800005 PM 26667451 ER PT J AU Inagami, S Gao, SS Karimi, H Shendge, MM Probst, JC Stone, RA AF Inagami, Sanae Gao, Shasha Karimi, Hassan Shendge, Martine M. Probst, Janice C. Stone, Roslyn A. TI Adapting the Index of Relative Rurality (IRR) to Estimate Rurality at the ZIP Code Level: A Rural Classification System in Health Services Research SO JOURNAL OF RURAL HEALTH LA English DT Article DE geography; health services research; index of relative rurality; observational data; rural classification ID URBAN; ACCESS; POLICY; AREAS; CARE AB BackgroundAccurate analysis of health problems facing rural residents depends on how rurality is defined. Health services research relies frequently on the rural urban commuting area (RUCA) codes to estimate rurality at the small area level. We modified the county-level Index of Relative Rurality (IRR) to the ZIP code level (IRRZIP) to create an alternative small-area-level rural classification system. We then compared how the 2 rural classification systems differ in how rural areas and populations are defined and in methodological analysis. MethodsWe linked data for veterans (n = 37,466) who attended the VA Pittsburgh Healthcare System to 2000 United States Census and the US Department of Agriculture's Economic Research Service data. ResultsThe RUCA and the IRRZIP do not consistently classify the same ZIP code areas and populations as rural. Using the IRRZIP, each 10th increment in increased rurality was associated with a 2.6 increased odds of receiving primary care at a satellite clinic. ConclusionsThe IRRZIP is a straightforward measure that is easy to use and interpret and may be a relevant alternative rural classification system that can be used in health services research. C1 [Inagami, Sanae] VA Pittsburgh Hlth Care Syst, Primary Care Serv Line, Pittsburgh, PA USA. [Inagami, Sanae] Univ Penn, Dept Gen Internal Med, Pittsburgh, PA USA. [Gao, Shasha; Stone, Roslyn A.] VA Pittsburgh Hlth Care Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Karimi, Hassan] Univ Pittsburgh, Sch Informat Sci, Pittsburgh, PA USA. [Probst, Janice C.] Univ S Carolina, Arnold Sch Publ Hlth, Hlth Serv Policy & Management, Columbia, SC 29208 USA. [Probst, Janice C.] South Carolina Rural Hlth Res Ctr, Columbia, SC USA. RP Inagami, S (reprint author), VA Pittsburgh Hlth Care Syst, Primary Care Serv Line, Pittsburgh, PA USA. EM sanae.inagami@va.gov FU Department of Veterans Affairs [72-047] FX Support for this paper was provided by Locally Initiated Project 72-047 from the Department of Veterans Affairs. NR 14 TC 0 Z9 0 U1 3 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0890-765X EI 1748-0361 J9 J RURAL HEALTH JI J. Rural Health PD SPR PY 2016 VL 32 IS 2 BP 219 EP 227 DI 10.1111/jrh.12148 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DI6MD UT WOS:000373612100011 PM 26397170 ER PT J AU Chao, LL Reeb, R Esparza, IL Abadjian, LR AF Chao, Linda L. Reeb, Rosemary Esparza, Iva L. Abadjian, Linda R. TI Associations between the self-reported frequency of hearing chemical alarms in theater and regional brain volume in Gulf War Veterans SO NEUROTOXICOLOGY LA English DT Article DE Brain imaging; Cerebral volume; Chemical warfare agents; Gulf War veterans ID LOW-LEVEL SARIN; GENOME-WIDE ASSOCIATION; SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; US ARMY VETERANS; CYCLOSARIN EXPOSURE; ALZHEIMERS-DISEASE; TOKYO SUBWAY; ORGANOPHOSPHATE PESTICIDES; IDENTIFIES VARIANTS AB Background: We previously reported evidence of reduced cortical gray matter (GM), white matter (WM), and hippocampal volume in Gulf War (GW) veterans with predicted exposure to low-levels of nerve agent according to the 2000 Khamisiyah plume model analysis. Because there is suggestive evidence that other nerve agent exposures may have occurred during the Gulf War, we examined the association between the self-reported frequency of hearing chemical alarms sound during deployment in the Gulf War and regional brain volume in GW veterans. Methods: Ninety consecutive GW veterans (15 female, mean age: 52 +/- 8 years) participating in a VA funded study underwent structural magnetic resonance imaging (MRI) on a 3T scanner. Freesurfer (version 5.1) was used to obtain regional measures of cortical GM, WM, hippocampal, and insula volume. Multiple linear regression was used to determine the association between the self-reported frequencies of hearing chemical alarms during the Gulf War and regional brain volume. Results: There was an inverse association between the self-reported frequency of hearing chemical alarms sound and total cortical GM (adjusted p= 0.007), even after accounting for potentially confounding demographic and clinical variables, the veterans' current health status, and other concurrent deployment-related exposures that were correlated with hearing chemical alarms. Post-hoc analyses extended the inverse relationship between the frequency of hearing chemical alarms to GM volume in the frontal (adjusted p= 0.02), parietal (adjusted p= 0.01), and occipital (adjusted p = 0.001) lobes. In contrast, regional brain volumes were not significantly associated with predicted exposure to the Khamisiyah plume or with Gulf War Illness status defined by the Kansas or Centers for Disease Control and Prevention criteria. Conclusions: Many veterans reported hearing chemical alarms sound during the Gulf War. The current findings suggest that exposure to substances that triggered those chemical alarms during the Gulf War likely had adverse neuroanatomical effects. Published by Elsevier Inc. C1 [Chao, Linda L.; Reeb, Rosemary; Esparza, Iva L.; Abadjian, Linda R.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, 4150 Clement St,114 M, San Francisco, CA 94121 USA. [Chao, Linda L.; Reeb, Rosemary] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Chao, Linda L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Chao, LL (reprint author), 4150 Clement St,114M, San Francisco, CA 94121 USA. EM linda.chao@ucsf.edu FU VA grant entitled 'Longitudinal Assessment of Gulf War Veterans with Suspected Sarin Exposure' [CX000798] FX The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the Army, Department of Defense, or Department of Veterans Affairs. This study supported by VA grant No. CX000798 entitled 'Longitudinal Assessment of Gulf War Veterans with Suspected Sarin Exposure'. This material is the result of work supported with resources and the use of facilities at the San Francisco Veterans Affairs Medical Center. The authors would like to thank the Gulf War veterans who participated in these studies. NR 67 TC 1 Z9 1 U1 3 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0161-813X EI 1872-9711 J9 NEUROTOXICOLOGY JI Neurotoxicology PD MAR PY 2016 VL 53 BP 246 EP 256 DI 10.1016/j.neuro.2016.02.009 PG 11 WC Neurosciences; Pharmacology & Pharmacy; Toxicology SC Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology GA DI3UK UT WOS:000373423800028 PM 26920621 ER PT J AU Johnson, TJ Hickey, RW Switzer, GE Miller, E Winger, DG Nguyen, M Saladino, RA Hausmann, LRM AF Johnson, Tiffani J. Hickey, Robert W. Switzer, Galen E. Miller, Elizabeth Winger, Daniel G. Margaret Nguyen Saladino, Richard A. Hausmann, Leslie R. M. TI The Impact of Cognitive Stressors in the Emergency Department on Physician Implicit Racial Bias SO ACADEMIC EMERGENCY MEDICINE LA English DT Article ID CLINICAL DECISION-MAKING; ASSOCIATION TEST; ACHIEVEMENT GAP; EXPLICIT ATTITUDES; AFRICAN-AMERICANS; MEDICAL-STUDENTS; UNCONSCIOUS RACE; TIME PRESSURE; HEALTH-CARE; STEREOTYPES AB ObjectivesThe emergency department (ED) is characterized by stressors (e.g., fatigue, stress, time pressure, and complex decision-making) that can pose challenges to delivering high-quality, equitable care. Although it has been suggested that characteristics of the ED may exacerbate reliance on cognitive heuristics, no research has directly investigated whether stressors in the ED impact physician racial bias, a common heuristic. We seek to determine if physicians have different levels of implicit racial bias post-ED shift versus preshift and to examine associations between demographics and cognitive stressors with bias. MethodsThis repeated-measures study of resident physicians in a pediatric ED used electronic pre- and postshift assessments of implicit racial bias, demographics, and cognitive stressors. Implicit bias was measured using the Race Implicit Association Test (IAT). Linear regression models compared differences in IAT scores pre- to postshift and determined associations between participant demographics and cognitive stressors with postshift IAT and pre- to postshift difference scores. ResultsParticipants (n = 91) displayed moderate prowhite/antiblack bias on preshift (mean SD = 0.50 +/- 0.34, d = 1.48) and postshift (mean +/- SD = 0.55 +/- 0.39, d = 1.40) IAT scores. Overall, IAT scores did not differ preshift to postshift (mean increase = 0.05, 95% CI = -0.02 to 0.14, d = 0.13). Subanalyses revealed increased pre- to postshift bias among participants working when the ED was more overcrowded (mean increase = 0.09, 95% CI = 0.01 to 0.17, d = 0.24) and among those caring for >10 patients (mean increase = 0.17, 95% CI = 0.05 to 0.27, d = 0.47). Residents' demographics (including specialty), fatigue, busyness, stressfulness, and number of shifts were not associated with postshift IAT or difference scores. In multivariable models, ED overcrowding was associated with greater postshift bias (coefficient = 0.11 per 1 unit of NEDOCS score, SE = 0.05, 95% CI = 0.00 to 0.21). ConclusionsWhile resident implicit bias remained stable overall preshift to postshift, cognitive stressors (overcrowding and patient load) were associated with increased implicit bias. Physicians in the ED should be aware of how cognitive stressors may exacerbate implicit racial bias. C1 [Johnson, Tiffani J.] Univ Penn, Sch Med, PolicyLab, Div Pediat Emergency Med, Philadelphia, PA 19104 USA. [Johnson, Tiffani J.] Univ Penn, Sch Med, Childrens Hosp Philadelphia, Ctr Perinatal & Pediat Hlth Dispar Res, Philadelphia, PA 19104 USA. [Johnson, Tiffani J.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. [Hickey, Robert W.; Saladino, Richard A.] Univ Pittsburgh, Dept Pediat, Div Pediat Emergency Med, Pittsburgh, PA 15260 USA. [Switzer, Galen E.; Hausmann, Leslie R. M.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Miller, Elizabeth] Univ Pittsburgh, Dept Pediat, Div Adolescent & Young Adult Med, Pittsburgh, PA 15260 USA. [Winger, Daniel G.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA 15260 USA. [Margaret Nguyen] Rady Childrens Hosp San Diego, Dept Emergency Med, San Diego, CA USA. [Switzer, Galen E.; Hausmann, Leslie R. M.] Ctr Hlth Equ Res & Promot, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Johnson, TJ (reprint author), Univ Penn, Sch Med, PolicyLab, Div Pediat Emergency Med, Philadelphia, PA 19104 USA.; Johnson, TJ (reprint author), Univ Penn, Sch Med, Childrens Hosp Philadelphia, Ctr Perinatal & Pediat Hlth Dispar Res, Philadelphia, PA 19104 USA.; Johnson, TJ (reprint author), Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. EM johnsont6@email.chop.edu FU Agency for Healthcare Research and Quality [T32 HS 017587]; National Heart, Lung, and Blood Institute [K12 HL109009]; University of Pittsburgh Clinical and Translational Science Institute (CTSI) through the National Institutes of Health [UL1-TR-000005] FX This research was conducted while Dr. Johnson was a fellow at the Children's Hospital of Pittsburgh and supported by a grant from the Agency for Healthcare Research and Quality (T32 HS 017587). Data analysis and manuscript preparation was completed while Dr. Johnson was funded by the National Heart, Lung, and Blood Institute (K12 HL109009). The project was also supported by the University of Pittsburgh Clinical and Translational Science Institute (CTSI) through the National Institutes of Health through grant UL1-TR-000005. The sponsoring agencies had no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the sponsoring agencies. There are no financial disclosures or conflicts of interest to report. NR 69 TC 5 Z9 5 U1 7 U2 10 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1069-6563 EI 1553-2712 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD MAR PY 2016 VL 23 IS 3 BP 297 EP 305 DI 10.1111/acem.12901 PG 9 WC Emergency Medicine SC Emergency Medicine GA DH9HF UT WOS:000373106300008 PM 26763939 ER PT J AU Ruggiero, NA Kish, TD Lee, ML AF Ruggiero, Nicole A. Kish, Troy D. Lee, Mikyung L. TI Metformin-Induced Hemolytic Anemia in a Patient With Glucose-6-Phosphate Dehydrogenase Deficiency SO AMERICAN JOURNAL OF THERAPEUTICS LA English DT Article DE glucose-6-phosphate dehydrogenase deficiency; hemolytic anemia; metformin AB Metformin, an oral antidiabetic agent, is considered the preferred first-line therapy for patients with type II diabetes. Between 2010 and 2012, it has been estimated that 14 million Americans were administered an oral antidiabetic agent, suggesting the extensive use of metformin among the diabetic population. There have been few case reports implicating metformin in causing hemolytic anemia. We present a case of a 53-year-old white male who developed hemolytic anemia after the initiation of treatment with metformin 500 mg twice daily. The patient experienced a 1.5 g/dL decrease in hemoglobin from baseline and a 2.8 mg/dL increase in total bilirubin within 1 day of treatment. Laboratory results confirmed that the patient was also glucose-6-phosphate dehydrogenase deficient. The hemolytic anemia resolved on discontinuation of metformin. Although this adverse effect seems to be rare, it is important to consider its seriousness. Clinicians should be advised to closely monitor patients newly started on metformin. C1 [Ruggiero, Nicole A.; Lee, Mikyung L.] James J Peters VA Med Ctr, Dept Pharm, 130 West Kingsbridge Rd,119, Bronx, NY 10468 USA. [Kish, Troy D.] Long Isl Univ, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY USA. RP Ruggiero, NA (reprint author), James J Peters VA Med Ctr, Dept Pharm, 130 West Kingsbridge Rd,119, Bronx, NY 10468 USA. EM nicole.ruggiero@va.gov NR 13 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1075-2765 EI 1536-3686 J9 AM J THER JI Am. J. Ther. PD MAR-APR PY 2016 VL 23 IS 2 BP E575 EP E578 DI 10.1097/MJT.0000000000000194 PG 4 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DG6EX UT WOS:000372176400032 PM 25756470 ER PT J AU Snyder, M Kish, T AF Snyder, Mitchell Kish, Troy TI Sertraline-Induced Rhabdomyolysis: A Case Report and Literature Review SO AMERICAN JOURNAL OF THERAPEUTICS LA English DT Review DE depression; psychiatry; SSRIs; sertraline; adverse event report ID SEROTONIN; DEPRESSION; INHIBITORS; EFFICACY; OVERDOSE AB The objective of this study is to report a case of sertraline-induced rhabdomyolysis in a female patient with a history of depression. A 25-year-old Hispanic woman with a history of depression reported to the emergency department (ED) with a chief complaint of muscle swelling and soreness and dark urine. The patient's creatine phosphokinase was 15,103 U/L. Despite treatment with IV normal saline, the patient's symptoms persisted and the creatine phosphokinase continued to rise to a peak of 16,778 U/L on day 2. The patient reported completing a strenuous, although routine, exercise the day before arriving at the ED, and her medication history was only significant for sertraline. Of note, 6 weeks before her visit to the ED, sertraline was increased from 100 mg daily to 150 mg daily. The patient's rhabdomyolysis was attributed to sertraline in conjunction with recent exercise. Selective serotonin reuptake inhibitor (SSRI)-induced rhabdomyolysis has been documented in 5 case reports. Similar to most reports, our patient presented with rhabdomyolysis in the presence of both SSRI use and exercise. Unlike the majority of previous reports, our patient was not taking other medications with documented association to rhabdomyolysis and had performed routine exercise before presenting with rhabdomyolysis. Although the mechanism of SSRI-induced rhabdomyolysis is not known, a theory posits that sertraline may have a role in muscle contraction and relaxation, leading to shorter time to contracture and longer time of contraction. The use of sertraline and other SSRIs may be associated with development of rhabdomyolysis, especially in the presence of strenuous exercise. C1 [Snyder, Mitchell] James J Peters VA Med Ctr, 130 West Kingsbridge Rd 119, Bronx, NY 10468 USA. [Kish, Troy] Long Isl Univ, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY USA. RP Snyder, M (reprint author), James J Peters VA Med Ctr, 130 West Kingsbridge Rd 119, Bronx, NY 10468 USA. EM mitchell.snyder@va.gov NR 22 TC 0 Z9 0 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1075-2765 EI 1536-3686 J9 AM J THER JI Am. J. Ther. PD MAR-APR PY 2016 VL 23 IS 2 BP E561 EP E565 DI 10.1097/MJT.0000000000000196 PG 5 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DG6EX UT WOS:000372176400028 PM 25581857 ER PT J AU Perlick, DA Berk, L Kaczynski, R Gonzalez, J Link, B Dixon, L Grier, S Miklowitz, DJ AF Perlick, Deborah A. Berk, Lesley Kaczynski, Richard Gonzalez, Jodi Link, Bruce Dixon, Lisa Grier, Savannah Miklowitz, David J. TI Caregiver burden as a predictor of depression among family and friends who provide care for persons with bipolar disorder SO BIPOLAR DISORDERS LA English DT Article DE bipolar disorder; burden; depression; family ID SERIOUS MENTAL-ILLNESS; TREATMENT ENHANCEMENT PROGRAM; RANDOMIZED CONTROLLED-TRIAL; EXPRESSED EMOTION; DISEASE CAREGIVERS; SCHIZOPHRENIA; PEOPLE; IMPACT; SYMPTOMS; INTERVENTION AB ObjectivesOver one-third of caregivers of people with bipolar disorder report clinically significant levels of depressive symptoms. This study examined the causal relationship between depression and caregiver burden in a large sample of caregivers of adult patients with bipolar disorder. MethodsParticipants were 500 primary caregivers of persons with bipolar disorder enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).This study evaluates the strength and direction of the associations between caregiver burden and depressive symptoms at baseline and at six- and 12-month follow-up using cross-lagged panel analyses, controlling for the clinical status of patients and sociodemographic variables. ResultsHigher levels of overall caregiver burden at baseline were associated with increased levels of depressive symptoms among caregivers at follow-up (F = 8.70, df = 1,290, p < 0.001), after controlling for baseline caregiver depression, gender, race, age, social support, and patients' clinical status. By contrast, caregiver depression at baseline was not significantly associated with caregiver burden at follow-up (F = 1.65, p = 0.20). ConclusionsCaregiver burden is a stronger predictor of caregiver depressive symptoms over time than the reverse. Interventions that help alleviate caregiver burden may decrease depressive symptoms. C1 [Perlick, Deborah A.; Grier, Savannah] Vet Affairs Med Ctr, James J Peters Dept, Bronx, NY USA. [Perlick, Deborah A.; Grier, Savannah] VISN 3 Mental Illness Res Educ & Clin Ctr MIRECC, Bronx, NY USA. [Perlick, Deborah A.; Grier, Savannah] Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave L Levy Pl, New York, NY 10029 USA. [Berk, Lesley] Deakin Univ, Fac Hlth, Mental Hlth & Wellbeing Res Ctr, Geelong, Vic 3217, Australia. [Berk, Lesley] Univ Melbourne, Dept Psychiat, Parkville, Vic 3052, Australia. [Kaczynski, Richard] Vet Affairs New England Mental Illness Res Educ &, West Haven, CT USA. [Kaczynski, Richard] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Gonzalez, Jodi] Univ Texas San Antonio, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. [Link, Bruce] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. [Dixon, Lisa] Columbia Univ, Dept Psychiat, New York, NY USA. [Dixon, Lisa] New York State Psychiat Inst & Hosp, Ctr Practice Innovat, New York, NY 10032 USA. [Miklowitz, David J.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Semel Inst, Div Child & Adolescent Psychiat, Los Angeles, CA 90095 USA. RP Perlick, DA (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave L Levy Pl, New York, NY 10029 USA. EM deborah.perlick@mssm.edu FU National Institute of Mental Health [MH-65015, NIMH-8001] FX This study was supported by grants MH-65015 and NIMH-8001 from the National Institute of Mental Health. NR 59 TC 0 Z9 0 U1 5 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-5647 EI 1399-5618 J9 BIPOLAR DISORD JI Bipolar Disord. PD MAR PY 2016 VL 18 IS 2 BP 183 EP 191 DI 10.1111/bdi.12379 PG 9 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DH9OB UT WOS:000373124400010 PM 27004622 ER PT J AU Umezaki, Y Badran, BW DeVries, WH Moss, J Gonzales, T George, MS AF Umezaki, Yojiro Badran, Bashar W. DeVries, William H. Moss, Jkeonye Gonzales, Theresa George, Mark S. TI The Efficacy of Daily Prefrontal Repetitive Transcranial Magnetic Stimulation (rTMS) for Burning Mouth Syndrome (BMS): A Randomized Controlled Single-blind Study SO BRAIN STIMULATION LA English DT Article DE Burning mouth syndrome; Repetitive transcranial magnetic stimulation; Left dorsolateral prefrontal cortex; Chronic pain ID ALPHA-LIPOIC ACID; TREATMENT-RESISTANT DEPRESSION; CEREBRAL-BLOOD-FLOW; CHRONIC PAIN; OROFACIAL PAIN; OPEN-LABEL; CORTEX; TMS; TRIAL; FMRI AB Background: Burning mouth syndrome (BMS) is a burning oral sensation without any corresponding abnormal findings. In some cases, BMS is refractory to pharmacologic treatments. Repetitive transcranial magnetic stimulation (rTMS) over left prefrontal cortex induces analgesic effect in both acute and chronic pain. However, its effect for BMS has not been evaluated. Objective: The aim of this randomized, controlled, single-blind study was to assess the efficacy of prefrontal rTMS for BMS. Method: Twenty patients with BMS were recruited and randomized to receive 30,000 pulses in total at 10 Hz TMS (n = 12) or sham TMS (n = 8). We assessed the change of BMS pain condition, functional status and mood until 2 months after the beginning of treatment. Results: In the real group, the BMS pain intensity decreased 67%, and 75% of the patients reported >50% pain decrease on final assessment compared to baseline, without heavy side effects. There was significant pain reduction in subjects in the real group immediately after 1 week of treatment, whereas there was none in those in the sham group. Similar tendency was confirmed in change of functional status. Mood and the affective aspect of pain were not changed in this study. Conclusion: BMS pain was significantly improved with 2 weeks of treatment of high frequency rTMS over left DLPFC compared to sham stimulation. Further study is needed to refine and improve TMS as a potential treatment of BMS. (C) 2016 Elsevier Inc. All rights reserved. C1 [Umezaki, Yojiro; Badran, Bashar W.; DeVries, William H.; Moss, Jkeonye; George, Mark S.] Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, 67 President St, Charleston, SC 29425 USA. [Gonzales, Theresa] Med Univ S Carolina, Coll Dent Med, Div Oral Pathol, 173 Ashley Ave, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA. RP Umezaki, Y (reprint author), Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, 67 President St, Charleston, SC 29425 USA. EM umezaki@yahoo.com NR 55 TC 3 Z9 3 U1 5 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD MAR-APR PY 2016 VL 9 IS 2 BP 234 EP 242 DI 10.1016/j.brs.2015.10.005 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DH5UC UT WOS:000372856500010 PM 26597930 ER PT J AU Philip, NS Dunner, DL Dowd, SM Aaronson, ST Brock, DG Carpenter, LL Demitrack, MA Hovav, S Janicak, PG George, MS AF Philip, Noah S. Dunner, David L. Dowd, Sheila M. Aaronson, Scott T. Brock, David G. Carpenter, Linda L. Demitrack, Mark A. Hovav, Sarit Janicak, Philip G. George, Mark S. TI Can Medication Free, Treatment-Resistant, Depressed Patients Who Initially Respond to TMS Be Maintained Off Medications? A Prospective, 12-Month Multisite Randomized Pilot Study SO BRAIN STIMULATION LA English DT Article DE Transcranial magnetic stimulation; Maintenance of effect; Long term outcome; Pilot clinical trial ID TRANSCRANIAL MAGNETIC STIMULATION; OPEN-LABEL; MAJOR DEPRESSION; REFRACTORY DEPRESSION; CONTROLLED-TRIAL; DISORDER; THERAPY; SCALE; RTMS; EFFICACY AB Background: Repetitive transcranial magnetic stimulation (TMS) is efficacious for acute treatment of resistant major depressive disorder (MDD), but there is little information on maintenance TMS after acute response. Objective/hypothesis: This pilot feasibility study investigated 12-month outcomes comparing two maintenance TMS approaches - a scheduled, single TMS session delivered monthly (SCH) vs. observation only (OBS). Methods: Antidepressant-free patients with unipolar, non-psychotic, treatment-resistant MDD participated in a randomized, open-label, multisite trial. Patients meeting protocol-defined criteria for improvement after six weeks of acute TMS were randomized to SCH or OBS regimens. TMS reintroduction was available for symptomatic worsening; all patients remained antidepressant-free during the trial. Results: Sixty-seven patients enrolled in the acute phase, and 49 (73%) met randomization criteria. Groups were matched, although more patients in the SCH group had failed >= 2 antidepressants (p = .035). There were no significant group differences on any outcome measure. SCH patients had nonsignificantly longer time to first TMS reintroduction, 91 +/- 66 days, vs. OBS, 77 52 days; OBS patients were nonsignificantly more likely to need reintroduction (odds ratio = 1.21; 95% Cl.38-3.89). Reintroduction lasted 14.3 +/- 17.8 days (SCH) and 16.9 +/- 18.9 days (OBS); 14/18 (78%) SCH and 17/27 (63%) OBS responded to reintroduction. Sixteen patients (32.7%) completed all 53 weeks of the study. Conclusions: Maintaining treatment-resistant depressed patients off medications with periodic TMS appears feasible in some cases. There was no statistical advantage of SCH vs. OBS, although SCH was associated with a nonsignificantly longer time to relapse. Those who initially respond to TMS have a strong chance of re-responding if relapse occurs. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). C1 [Philip, Noah S.] Prov VA Med Ctr, Ctr Neurorestorat & Neurotechnol, Providence, RI USA. [Philip, Noah S.; Carpenter, Linda L.] Butler Hosp, Providence, RI 02906 USA. [Dunner, David L.] Ctr Anxiety & Depress, Mercer Isl, WA USA. [Dowd, Sheila M.; Janicak, Philip G.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Aaronson, Scott T.] Sheppard Pratt Hlth Syst, Baltimore, MD USA. [Brock, David G.; Demitrack, Mark A.] Neuronetics Inc, Malvern, PA USA. [Hovav, Sarit] Creighton Univ, Univ Nebraska Med Ctr, Omaha, NE 68178 USA. [George, Mark S.] Med Univ S Carolina, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Philip, NS (reprint author), Prov VA Med Ctr, Ctr Neurorestorat & Neurotechnol, Providence, RI USA.; Philip, NS (reprint author), Butler Hosp, Providence, RI 02906 USA. EM Noah_Philip@Brown.edu OI Philip, Noah/0000-0002-4889-8775 FU Neuronetics, Inc. FX Supported by Neuronetics, Inc. NR 26 TC 3 Z9 3 U1 2 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD MAR-APR PY 2016 VL 9 IS 2 BP 251 EP 257 DI 10.1016/j.brs.2015.11.007 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DH5UC UT WOS:000372856500012 PM 26708778 ER PT J AU Demissei, BG Valente, MAE Cleland, JG O'Connor, CM Metra, M Ponikowski, P Teerlink, JR Cotter, G Davison, B Givertz, MM Bloomfield, DM Dittrich, H van der Meer, P van Veldhuisen, DJ Hillege, HL Voors, AA AF Demissei, Biniyam G. Valente, Mattia A. E. Cleland, John G. O'Connor, Christopher M. Metra, Marco Ponikowski, Piotr Teerlink, John R. Cotter, Gad Davison, Beth Givertz, Michael M. Bloomfield, Daniel M. Dittrich, Howard van der Meer, Peter van Veldhuisen, Dirk J. Hillege, Hans L. Voors, Adriaan A. TI Optimizing clinical use of biomarkers in high-risk acute heart failure patients SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE Acute heart failure; Prognosis; Risk stratification; Multimarker strategy; Time-dependent AUC analysis ID NATRIURETIC PEPTIDE; ACUTE DYSPNEA; SOLUBLE ST2; MORTALITY; HOSPITALIZATION; STRATIFICATION; PREDICTION; OUTCOMES; ROLOFYLLINE; ANTAGONIST AB AimThe clinical value of single biomarkers at single time-points to predict outcomes in patients with acute heart failure (AHF) is limited. We performed a multimarker, multi-time-point analysis of biomarkers for the prediction of post-discharge clinical outcomes in high-risk AHF patients. Methods and resultsA set of 48 circulating biomarkers were measured in the PROTECT trial which enrolled 2033 patients with AHF. Associations between baseline levels of biomarkers and outcomes (30-day all-cause mortality, 30-day death or rehospitalization for renal/cardiovascular causes and 180-day all-cause mortality) were evaluated. Prognostic accuracies of baseline, days 2 or 3, 7, and 14 biomarker measurements were estimated and compared utilizing a time-dependent area under the curve (AUC) analysis. Forty-four biomarkers were significantly associated with outcomes, but 42 had limited prognostic value (C-index<0.70). However, multimarker models combining best-performing biomarkers from different clusters had a much stronger prognostic value. Combining blood urea nitrogen (BUN), chloride, interleukin (IL)-6, cTnI, sST-2 and VEGFR-1 into a clinical model yielded a 11% increase in C-index to 0.84 and 0.78 for 30-day and 180-day all-cause mortality, respectively, and cNRI of 0.86 95% CI [0.55-1.11] and 0.76 95% CI [0.57-0.87]. Prognostic gain was modest for the 30-day death/rehospitalization for cardiovascular or renal causes endpoint. Comparative time-dependent AUC analysis indicated that late measurements provided superior accuracy for the prediction of all-cause mortality over 180days, with few exceptions including BUN and galectin-3. However, the predictive value of most biomarkers showed a diminishing pattern over time irrespective of moment of measurement. ConclusionsMultimarker models significantly improve risk prediction. Subsequent measurements, beyond admission, are needed for majority of biomarkers to maximize prognostic value over time, particularly in the long term. C1 [Demissei, Biniyam G.; Valente, Mattia A. E.; van der Meer, Peter; van Veldhuisen, Dirk J.; Hillege, Hans L.; Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. [Demissei, Biniyam G.; Hillege, Hans L.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands. [Cleland, John G.] Univ London Imperial Coll Sci Technol & Med, London, England. [O'Connor, Christopher M.] Duke Univ, Med Ctr, Durham, NC USA. [Metra, Marco] Univ Brescia, Brescia, Italy. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Cotter, Gad; Davison, Beth] Momentum Res, Durham, NC USA. [Givertz, Michael M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA. [Dittrich, Howard] Univ Iowa, Abboud Cardiovasc Res Ctr, Carver Coll Med, Iowa City, IA 52242 USA. RP Voors, AA (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. EM a.a.voors@umcg.nl RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064 FU NovaCardia, a subsidiary of Merck FX The PROTECT trial was supported by NovaCardia, a subsidiary of Merck. NR 29 TC 10 Z9 10 U1 2 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD MAR PY 2016 VL 18 IS 3 BP 269 EP 280 DI 10.1002/ejhf.443 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DI0BO UT WOS:000373160000007 PM 26634889 ER PT J AU Jaramillo, CA Eapen, BC McGeary, CA McGeary, DD Robinson, J Amuan, M Pugh, MJ AF Jaramillo, Carlos A. Eapen, Blessen C. McGeary, Cindy A. McGeary, Donald D. Robinson, Jedediah Amuan, Megan Pugh, Mary Jo TI A cohort study examining headaches among veterans of Iraq and Afghanistan wars: Associations with traumatic brain injury, PTSD, and depression SO HEADACHE LA English DT Article DE headache; traumatic brain injury; posttraumatic stress disorder; postconcussive symptoms; persistence; veterans ID POSTTRAUMATIC-STRESS-DISORDER; US SOLDIERS; MILITARY PERSONNEL; HEAD-INJURY; CONCUSSION; PREVALENCE; SEVERITY; MIGRAINE; PROGRAM; BLAST AB ObjectivesTo describe the prevalence and persistence of headache and associated conditions in an inception cohort of U.S. veterans of Iraq and Afghanistan wars. BackgroundIraq and Afghanistan war veterans (IAV) suffer from persistent and difficult-to-treat headaches that have been found to co-occur with traumatic brain injury (TBI) and other deployment related comorbidities. MethodsThis longitudinal retrospective cohort study used data from the national Veterans Health Administration (VA) data repository for IAV who first received VA care in 2008 (baseline) and also received care each year in 2009, 2010, and 2011. We used ICD-9-CM codes, to identify those treated for headache each year (2008-2011). Individuals with headache diagnosed each year were classified as having persistent headache. We also identified comorbidities that may be associated with baseline headache using algorithms validated for use with ICD-9-CM codes. Comorbidities included TBI, posttraumatic stress disorder (PTSD), depression, and conditions associated with these diagnoses (anxiety, memory/attention/cognition, neck pain, tinnitus/hyperacusis, photosensitivity/photo blurring, insomnia, malaise/fatigue, and vertigo/dizziness). Multivariable logistic regression analysis was used to determine characteristics associated with baseline headache as well as those associated with persistent headache. ResultsAmong all IAV, 38,426 received their first year of VA care in 2008 and had care each year 2009-2011: 13.7% of these were diagnosed with headache in 2008. Veterans diagnosed with headache in 2008 were more likely than those without a headache diagnosis to also have a diagnosis of TBI alone (adjusted odds ratios [AOR] 6.75; 95% CI 5.79-7.86), TBI+depression (AOR 7.09; 95% CI 5.23-9.66), TBI+PTSD (AOR 10.16; 95% CI 8.96-11.53), TBI+PTSD+depression (AOR 9.40; 95% CI 8.12-10.09), and neck pain (AOR 2.44; 95% CI 2.14-2.77). Among those with headache diagnosis in 2008, 24.3% had a headache diagnosis each of the subsequent years of care (persistent headache). While diagnoses of TBI, PTSD, and/or depression at baseline were not associated with headache persistence, persistence was more likely for individuals with baseline tinnitus/hyperacusis (AOR 1.21; 95% CI 1.02-1.45), insomnia (AOR 1.19; 95% CI 1.02-1.39), and vertigo/dizziness (AOR 1.83; 95% CI 1.30-2.57). ConclusionsOur results indicate that TBI alone is a strong predictor of headache in the first year of VA care among IAV and that comorbid psychiatric comorbidities increase the likelihood of headache among individuals with TBI. However, among those with baseline headache, only tinnitus, insomnia, and vertigo were baseline clinical predictors of headache persistence. These results suggest that attention to other symptoms and conditions early in the diagnosis and treatment of headaches may be important for understanding prognosis. These comorbidities offer potential targets for intervention strategies that may help address postdeployment headaches. C1 [Jaramillo, Carlos A.; Eapen, Blessen C.] South Texas Vet Hlth Care Syst, Polytrauma Rehabil Ctr, San Antonio, TX USA. [Jaramillo, Carlos A.; Eapen, Blessen C.; Robinson, Jedediah] Univ Texas Hlth Sci Ctr San Antonio, Dept Rehabil Med, San Antonio, TX 78229 USA. [McGeary, Cindy A.; McGeary, Donald D.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Amuan, Megan] Edith Nourse Rogers Mem Hosp, CHQOER, Bedford, MA USA. [Pugh, Mary Jo] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. RP Jaramillo, CA (reprint author), South Texas Vet Healthcare Syst ALMD, Polytrauma Rehabil Ctr, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM jaramilloc3@uthscsa.edu OI Pugh, Mary Jo/0000-0003-4196-7763 FU VA Health Services Research and Development [DHI 09-237] FX The study was funded by VA Health Services Research and Development (DHI 09-237). NR 54 TC 1 Z9 1 U1 1 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-8748 EI 1526-4610 J9 HEADACHE JI Headache PD MAR PY 2016 VL 56 IS 3 BP 528 EP 539 DI 10.1111/head.12726 PG 12 WC Clinical Neurology SC Neurosciences & Neurology GA DH6HG UT WOS:000372891000009 PM 26688427 ER PT J AU Cadena, J Thompson, GR Patterson, TF AF Cadena, Jose Thompson, George R., III Patterson, Thomas F. TI Invasive Aspergillosis Current Strategies for Diagnosis and Management SO INFECTIOUS DISEASE CLINICS OF NORTH AMERICA LA English DT Article DE Aspergillosis; Invasive pulmonary aspergillosis; Resistance; Chronic cavitary aspergillosis; Aspergilloma ID STEM-CELL TRANSPLANTATION; CRITICALLY-ILL PATIENTS; CHRONIC PULMONARY ASPERGILLOSIS; RANDOMIZED CONTROLLED-TRIAL; AMPHOTERICIN-B THERAPY; ANTIFUNGAL THERAPY; FUNGAL-INFECTIONS; HEMATOLOGICAL PATIENTS; NEUTROPENIC PATIENTS; SERUM GALACTOMANNAN AB Aspergillosis remains a significant cause of morbidity and mortality in the immunocompromised population. The spectrum of disease is broad, ranging from severe and rapidly fatal infection to noninvasive disease. The diversity of patients and risk factors complicates diagnostic and therapeutic decision-making. Invasive procedures are often precluded by host status; noninvasive diagnostic tests vary in their sensitivity and specificity. Advancements in understanding the pathophysiology of invasive aspergillosis and host genetics in differential risk have also occurred. Future work may assist in therapeutic decision-making and patient prognosis. Voriconazole remains the preferred agent for treatment. Additional alternatives have emerged. C1 [Cadena, Jose; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, 7703 Floyd Curl Dr,MSC 7881, San Antonio, TX 78229 USA. [Cadena, Jose; Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Thompson, George R., III] Univ Calif Davis, Dept Internal Med, Div Infect Dis, 1 Shields Ave,Tupper Hall,Room 3146, Davis, CA 95616 USA. RP Patterson, TF (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, 7703 Floyd Curl Dr,MSC 7881, San Antonio, TX 78229 USA. EM patterson@uthscsa.edu NR 95 TC 3 Z9 4 U1 1 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0891-5520 EI 1557-9824 J9 INFECT DIS CLIN N AM JI Infect. Dis. Clin. North Am. PD MAR PY 2016 VL 30 IS 1 BP 125 EP + DI 10.1016/j.idc.2015.10.015 PG 20 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DH5UJ UT WOS:000372857200008 PM 26897064 ER PT J AU Anesi, JA Baddley, JW AF Anesi, Judith A. Baddley, John W. TI Approach to the Solid Organ Transplant Patient with Suspected Fungal Infection SO INFECTIOUS DISEASE CLINICS OF NORTH AMERICA LA English DT Article DE Solid organ transplant; Invasive fungal infection; Candida; Aspergillus; Endemic fungi; Cryptococcus; Mold ID PNEUMOCYSTIS-CARINII-PNEUMONIA; SURVEILLANCE NETWORK TRANSNET; ORTHOTOPIC LIVER-TRANSPLANTATION; PRIMARY CUTANEOUS CRYPTOCOCCOSIS; CENTRAL-NERVOUS-SYSTEM; OF-THE-LITERATURE; BETA-D-GLUCAN; INVASIVE-ASPERGILLOSIS; RISK-FACTORS; LUNG TRANSPLANTATION AB In solid organ transplant (SOT) recipients, invasive fungal infections (IFIs) are associated with significant morbidity and mortality. Detection of IFIs can be difficult because the signs and symptoms are similar to those of viral or bacterial infections, and diagnostic techniques have limited sensitivity and specificity. Clinicians must rely on knowledge of the patient's risk factors for fungal infection to make a diagnosis. The authors describe their approach to the SOT recipient with suspected fungal infection. The epidemiology of IFIs in the SOT population is reviewed, and a syndromic approach to suspected IFI in SOT recipients is described. C1 [Anesi, Judith A.] Univ Penn, Div Infect Dis, 3400 Spruce St,3 Silverstein,Suite E, Philadelphia, PA 19104 USA. [Baddley, John W.] Univ Alabama Birmingham, Dept Med, 1900 Univ Blvd,229 THT, Birmingham, AL 35294 USA. [Baddley, John W.] Birmingham VA Med Ctr, Med Serv, 700 South 19th St, Birmingham, AL 35233 USA. RP Baddley, JW (reprint author), Univ Alabama Birmingham, Dept Med, 1900 Univ Blvd,229 THT, Birmingham, AL 35294 USA. EM jbaddley@uab.edu OI Anesi, Judith/0000-0001-6671-4557 NR 149 TC 0 Z9 0 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0891-5520 EI 1557-9824 J9 INFECT DIS CLIN N AM JI Infect. Dis. Clin. North Am. PD MAR PY 2016 VL 30 IS 1 BP 277 EP + DI 10.1016/j.idc.2015.10.001 PG 21 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DH5UJ UT WOS:000372857200016 PM 26739603 ER PT J AU Wiederhold, NP Najvar, LK Fothergill, AW Bocanegra, R Olivo, M McCarthy, DI Fukuda, Y Mitsuyama, J Patterson, TF AF Wiederhold, Nathan P. Najvar, Laura K. Fothergill, Annette W. Bocanegra, Rosie Olivo, Marcos McCarthy, Dora I. Fukuda, Yoshiko Mitsuyama, Junichi Patterson, Thomas F. TI The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrata SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article ID FKS MUTATIONS; SUSCEPTIBILITY; CASPOFUNGIN; EFFICACY; ALBICANS AB Candida species are major causes of invasive mycoses in immunocompetent and immunocompromised hosts. Treatment options are limited in the setting of antifungal resistance and increased rates of echinocandin-resistantCandida glabrata have been reported. The novel arylamidine T-2307 demonstrates potentin vitro antifungal activity againstCandida species. Our objective was to evaluate thein vitro andin vivo activity of T-2307 against resistantC. glabrata. In vitro activity was determined against 42 clinicalC. glabrata isolates, including 17 echinocandin-resistant strains. Neutropenic ICR mice were inoculated intravenously with an echinocandin-resistantC. glabrata isolate (T-2307; caspofungin MICs a parts per thousand currency sign0.008 and 0.5 mg/L, respectively). Therapy with vehicle control, T-2307 (0.75, 1.5, 3 or 6 mg/kg subcutaneously once daily) or caspofungin (1 or 10 mg/kg intraperitoneally once daily) began 1 day post-challenge. Kidneys were collected on day 8 and fungal burden was assessed by counting cfu. T-2307 demonstrated potentin vitro activity againstC. glabrata (geometric mean MIC 0.0135 mg/L), which was maintained against echinocandin-resistant isolates (geometric mean MIC 0.0083 mg/L). T-2307 also demonstratedin vivo efficacy in mice infected with echinocandin-resistantC. glabrata. Significant reductions in fungal burden were observed at each dosage level of T-2307 compared with control. Reductions in fungal burden were also observed with high-dose caspofungin. T-2307 demonstrated potentin vitro activity againstC. glabrata, including echinocandin-resistant isolates, which translated intoin vivo efficacy against invasive candidiasis caused by an echinocandin-resistantC. glabrata strain. These results demonstrate the potential for T-2307 as therapy against echinocandin-resistantCandida. C1 [Wiederhold, Nathan P.; Najvar, Laura K.; Fothergill, Annette W.; Bocanegra, Rosie; Olivo, Marcos; McCarthy, Dora I.; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Najvar, Laura K.; Bocanegra, Rosie; Olivo, Marcos; Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Fukuda, Yoshiko; Mitsuyama, Junichi] Toyama Chem Co Ltd, Toyama, Japan. RP Wiederhold, NP (reprint author), Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. EM wiederholdn@uthscsa.edu OI Wiederhold, Nathan/0000-0002-2225-5122 FU National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHS272201000018I, HHSN272201000038I] FX This project utilized preclinical services funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract Nos. HHS272201000018I and HHSN272201000038I-Task Orders A03 and A13, respectively. NR 15 TC 0 Z9 1 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 EI 1460-2091 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD MAR PY 2016 VL 71 IS 3 BP 692 EP 695 DI 10.1093/jac/dkv398 PG 4 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA DH7OS UT WOS:000372984200019 PM 26620102 ER PT J AU Fraenkel, L Lim, J Garcia-Tsao, G Reyna, V Monto, A AF Fraenkel, Liana Lim, Joseph Garcia-Tsao, Guadalupe Reyna, Valerie Monto, Alexander TI Examining Hepatitis C Virus Treatment Preference Heterogeneity Using Segmentation Analysis Treat Now or Defer? SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article DE patient preferences; hepatitis C; treatment deferral ID DISCRETE-CHOICE EXPERIMENT; GENOTYPE 1 INFECTION; FUZZY-TRACE THEORY; RHEUMATOID-ARTHRITIS; INTERFERON THERAPY; KNEE REPLACEMENT; AFRICAN-AMERICAN; HCV; SOFOSBUVIR; RIBAVIRIN AB Objective: To improve our understanding of patients' treatment preferences for chronic hepatitis C (HCV). Methods: Subjects with HCV were recruited from 2 VA medical centers. Preferences were ascertained using conjoint analysis. We used segmentation analysis to examine whether there were groups of respondents with similar preferences that were systematically different from the preferences of others. We then measured the associations between treatment preference with subjects' characteristics and their gist principles related to living with HCV and the burden of therapy. Results: A total of 199 subjects participated in this study. The segmentation analysis demonstrated that subjects could be classified into 2 distinct groups. The larger group [group 1, n=118 (59%)] opted for current treatment and the other [group 2, n=81 (41%)] preferred to defer. Patients with cirrhosis were less likely to belong to group 2 (prefer to defer) compared with those without cirrhosis (40.5% vs. 21.3%), whereas subjects self-identifying as African American were more likely to belong to group 2 than white subjects (51.3% vs. 30.5%). Members of group 1 had a more positive overall gist principles related to HCV compared with members of group 2 [mean (SD) score=28.63 (3.06) vs. 26.46 (2.79), P < 0.0001]. These gist principles mediated the relationship between race and treatment preference (Sobel test statistic=-2.68, 2-tailed P=0.007). Conclusions: Our findings indicate that there are groups of HCV patients with similar preferences that are distinct from other groups' preferences. Patients' gist principles related to the significance of having a chronic viral infection and the burdens of therapy are strongly related to their current treatment decisions. These findings help inform how best to initiate and deliver treatment for patients with HCV. C1 [Fraenkel, Liana; Lim, Joseph; Garcia-Tsao, Guadalupe] Yale Univ, Sch Med, VA Connecticut Hlth Care Syst, New Haven, CT 06520 USA. [Reyna, Valerie] Cornell Univ, Dept Human Dev & Psychol, Ithaca, NY USA. [Monto, Alexander] San Francisco VA Med Ctr, San Francisco, CA USA. [Monto, Alexander] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Fraenkel, L (reprint author), Yale Univ, Rheumatol Sect, Sch Med, 300 Cedar ST,TAC Bldg,RM 525,POB 208031, New Haven, CT 06520 USA. EM liana.fraenkel@yale.edu FU VA Health Services and Research Department [IIR 10-131]; Abbott; Achillion; Bristol-Myers Squibb; Gilead; Janssen; Xerox FX Supported in full by the VA Health Services and Research Department (IIR 10-131). Analyses were performed by Liana Fraenkel. All authors had a substantial role in the design of the study and writing the manuscript.; J.L. has served as a consultant for Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, Janssen, Merck, and has received research funding from Abbott, Achillion, Bristol-Myers Squibb, Gilead, and Janssen (paid to the institution). V.R. has served on including committees of the National Academy of Sciences, Psychonomic Society, and other nonprofits. She has been a paid consultant for Xerox. G.G.-T. has served as a consultant for Abbvie and Fibrogen, is an associate editor for Hepatology and serves on committees of the American Association for the Study of Liver Diseases. The remaining authors declare that they have nothing to disclose. NR 41 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0192-0790 EI 1539-2031 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD MAR PY 2016 VL 50 IS 3 BP 252 EP 257 DI 10.1097/MCG.0000000000000380 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DH5NT UT WOS:000372837100012 PM 26166145 ER PT J AU Fu, LW Wei, CC Powell, PC Bradley, WE Ahmad, S Ferrario, CM Collawn, JF Dell'Italia, LJ AF Fu, Lianwu Wei, Chih-Chang Powell, Pamela C. Bradley, Wayne E. Ahmad, Sarfaraz Ferrario, Carlos M. Collawn, James F. Dell'Italia, Louis J. TI Increased fibroblast chymase production mediates procollagen autophagic digestion in volume overload SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY LA English DT Article DE Volume overload; Cardiac fibroblast; Chymase; Autophagy; Intracellular procollagen ID MAST-CELL CHYMASE; MATRIX-METALLOPROTEINASE ACTIVITY; RENIN-ANGIOTENSIN SYSTEM; EXTRACELLULAR-MATRIX; MITRAL REGURGITATION; NEUTROPHIL ELASTASE; CARDIAC FIBROBLASTS; FORMING PATHWAYS; HEART-FAILURE; HIGH-GLUCOSE AB Background: Previous work has identified mast cells as the major source of chymase largely associated with a profibrotic phenotype. We recently reported increased fibroblast autophagic procollagen degradation in a rat model of pure volume overload (VO). Here we demonstrate a connection between increased fibroblast chymase production and autophagic digestion of procollagen in the pure VO of aortocaval fistula (ACF) in the rat. Methods and results: Isolated LV fibroblasts taken from 4 and 12 week ACF Sprague-Dawley rats have significant increases in chymase mRNA and chymase activity. Increased intracellular chymase protein is documented by immunocytochemistry in the ACF fibroblasts compared to cells obtained from age-matched sham rats. To implicate VO as a stimulus for chymase production, we show that isolated adult rat LV fibroblasts subjected to 24 h of 20% cyclical stretch induces chymase mRNA and protein production. Exogenous chymase treatment of control isolated adult cardiac fibroblasts demonstrates that chymase is internalized through a dynamin-dependent mechanism. Chymase treatment leads to an increased formation of autophagic vacuoles, LC3-II production, autophagic flux, resulting in increased procollagen degradation. Chymase inhibitor treatment reduces cyclical stretch-induced autophagy in isolated cardiac fibroblasts, demonstrating chymase's role in autophagy induction. Conclusion: In a pure VO model, chymase produced in adult cardiac fibroblasts leads to autophagic degradation of newly synthesized intracellular procollagen I, suggesting a new role of chymase in extracellular matrix degradation. Published by Elsevier Ltd. C1 [Fu, Lianwu; Wei, Chih-Chang; Powell, Pamela C.; Dell'Italia, Louis J.] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Wei, Chih-Chang; Bradley, Wayne E.; Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Fu, Lianwu; Collawn, James F.; Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL USA. [Ahmad, Sarfaraz; Ferrario, Carlos M.] Wake Forest Univ, Bowman Gray Sch Med, Div Surg Sci, Winston Salem, NC USA. RP Dell'Italia, LJ (reprint author), Birmingham VA Med Ctr, 700 South 19th St, Birmingham, AL 35233 USA. EM louis.dellitalia@va.gov FU Department of Veteran Affairs for Merit Review [1BX001050-01, 1CX000993-01]; NIH [P01 HL051952] FX This work was supported by grants from Department of Veteran Affairs for Merit Review (Grant 1BX001050-01 to C.C.W. and Grant 1CX000993-01 to L.J.D.) and NIH (Grant P01 HL051952 to CMF and L.J.D.). NR 46 TC 5 Z9 5 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0022-2828 EI 1095-8584 J9 J MOL CELL CARDIOL JI J. Mol. Cell. Cardiol. PD MAR PY 2016 VL 92 BP 1 EP 9 DI 10.1016/j.yjmcc.2016.01.019 PG 9 WC Cardiac & Cardiovascular Systems; Cell Biology SC Cardiovascular System & Cardiology; Cell Biology GA DH9DD UT WOS:000373095700001 PM 26807691 ER PT J AU Veenema, TG Griffin, A Gable, AR MacIntyre, L Simons, RADMN Couig, MP Walsh, JJ Lavin, RP Dobalian, A Larson, E AF Veenema, Tener Goodwin Griffin, Anne Gable, Alicia R. MacIntyre, Linda Simons, R. A. D. M. Nadine Couig, Mary Pat Walsh, John J., Jr. Lavin, Roberta Proffitt Dobalian, Aram Larson, Elaine TI Nurses as Leaders in Disaster Preparedness and ResponseA Call to Action SO JOURNAL OF NURSING SCHOLARSHIP LA English DT Editorial Material DE Competencies; curriculum; disaster; education; nursing; policy; practice; preparedness; public health emergency; research; scope of practice ID VOLUNTEER HEALTH-PROFESSIONALS; PUBLIC-HEALTH; HURRICANE KATRINA; EARTHQUAKE RELIEF; CORE COMPETENCES; EMERGENCIES; EXPERIENCE; MANAGEMENT; KNOWLEDGE; EDUCATION AB PurposeTo develop a vision for the future of disaster nursing, identify barriers and facilitators to achieving the vision, and develop recommendations for nursing practice, education, policy, and research. Design and MethodsA series of semistructured conference calls were conducted with 14 national subject matter experts to generate relevant concepts regarding national nursing workforce preparedness. An invitational daylong workshop hosted by the Veterans Emergency Management Evaluation Center, U.S. Department of Veterans Affairs, was held in December 2014 to expand and refine these concepts. Workshop participants included 70 nurses, emergency managers, and a broad range of public health professionals. Conference call notes and audiotapes of the workshop were transcribed and thematic analysis conducted to outline a vision for the future of nursing in disaster preparedness and response, and to articulate an agenda for nursing practice, education, policy, and research to achieve that vision. FindingsThe group developed a vision for the future of disaster nursing, and identified current barriers and opportunities to advance professional disaster nursing. A broad array of recommendations for nursing practice, education, policy, and research, as well as implementation challenges, are summarized in this article. ConclusionsThis project represents an important step toward enhancing nurses' roles as leaders, educators, responders, policymakers, and researchers in disaster preparedness and response. Nurses and the health and human service organizations that employ them are encouraged to engage in an expansive national dialogue regarding how to best incorporate the vision and recommendations into their individual lives and the organizations for which they work. Clinical RelevanceNurses comprise the largest healthcare workforce, and opportunities exist to strengthen disaster readiness, enhance national surge capacity, and build community resiliency to disasters. C1 [Veenema, Tener Goodwin] Johns Hopkins Univ, Johns Hopkins Sch Nursing, Sch Nursing, Dept Community & Publ Hlth, Baltimore, MD USA. [Veenema, Tener Goodwin] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Refugee & Disaster Response, Baltimore, MD USA. [Griffin, Anne; Gable, Alicia R.; Dobalian, Aram] US Dept Vet Affairs, Vet Hlth Adm, Off Publ Hlth, Vet Emergency Management Evaluat Ctr, North Hills, CA USA. [MacIntyre, Linda] Amer Red Cross, Washington, DC 20006 USA. [Simons, R. A. D. M. Nadine] US Dept Hlth & Human Serv, Off Assistant Secretary Hlth, Reg 9, San Francisco, CA USA. [Couig, Mary Pat] US Dept Vet Affairs, Off Nursing Serv, Special Projects & Publ Hlth Emergency Preparedne, Emergency Preparedness, Washington, DC USA. [Walsh, John J., Jr.] Vanderbilt Univ, Sch Med, Vanderbilt Program Disaster Res & Training, 221 Kirkland Hall, Nashville, TN 37235 USA. [Lavin, Roberta Proffitt] Univ Missouri, Coll Nursing, Acad Programs, St Louis, MO 63121 USA. [Dobalian, Aram] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Dobalian, Aram] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. [Larson, Elaine] Columbia Univ, Sch Nursing, Res, New York, NY USA. [Larson, Elaine] Columbia Univ, Sch Nursing, Nursing Res, New York, NY USA. [Larson, Elaine] Columbia Univ, Mailman Sch Publ Hlth, Epidemiol, New York, NY USA. RP Veenema, TG (reprint author), Johns Hopkins Sch Nursing, 525 N Wolfe St Off,Room 532, Baltimore, MD 21205 USA. EM tveenem1@jhu.edu RI Lavin, Roberta/H-1892-2016 OI Lavin, Roberta/0000-0001-6106-8066 NR 62 TC 2 Z9 2 U1 13 U2 24 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1527-6546 EI 1547-5069 J9 J NURS SCHOLARSHIP JI J. Nurs. Scholarsh. PD MAR PY 2016 VL 48 IS 2 BP 187 EP 200 DI 10.1111/jnu.12198 PG 14 WC Nursing SC Nursing GA DG7MH UT WOS:000372267900010 PM 26869230 ER PT J AU Zhang, YQ Liu, YH Walsh, M Bokov, A Ikeno, Y Jang, YC Perez, VI Van Remmen, H Richardson, A AF Zhang, Yiqiang Liu, Yuhong Walsh, Michael Bokov, Alex Ikeno, Yuji Jang, Young C. Perez, Viviana I. Van Remmen, Holly Richardson, Arlan TI Liver specific expression of Cu/ZnSOD extends the lifespan of Sod1 null mice SO MECHANISMS OF AGEING AND DEVELOPMENT LA English DT Article DE CuZnSOD; Oxidative stress; Lifespan; Liver-specific transgenic mice ID MANGANESE SUPEROXIDE-DISMUTASE; SKELETAL-MUSCLE ATROPHY; OXIDATIVE STRESS; HEPATOCELLULAR-CARCINOMA; HEARING-LOSS; LIPID-PEROXIDATION; DEFICIENT MICE; AGE; CUZNSOD; LEADS AB Genetic ablation of CuZn-superoxide dismutase (Sod1) in mice (Sod1(-/-) mice) leads to shortened lifespan with a dramatic increase in hepatocellular carcinoma and accelerated aging phenotypes, including early onset sarcopenia. To study the tissue specific effects of oxidative stress in the Sod1(-/-) mice, we generated mice that only express the human SOD1 gene specifically in the liver of Sod1(-/-) mice (Sod1(-/-)/hSOD1(alb) mice). Expression of hSOD1 in the liver of Sod1(-/-) mice improved liver function, reduced oxidative damage in liver, and partially restored the expression of several genes involved in tumorigenesis, which are abnormally expressed in the livers of the Sod1(-/-) mice. However, liver specific expression of hSOD1 did not prevent the loss of body weight and muscle mass and alterations in the structure of neuromuscular junctions. The expression of hSOD1 in the liver of Sod1(-/-) mice significantly improved the lifespan of Sod1(-/-) mice; however, the lifespan of the Sod1(-/-)/hSOD1(alb) mice was still significantly shorter than wild type mice. Published by Elsevier Ireland Ltd C1 [Zhang, Yiqiang] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA. [Liu, Yuhong; Walsh, Michael] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular Biol, San Antonio, TX 78229 USA. [Liu, Yuhong; Walsh, Michael] Univ Texas Hlth Sci Ctr San Antonio, Dept Biol Struct, San Antonio, TX 78229 USA. [Bokov, Alex] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol, San Antonio, TX 78229 USA. [Bokov, Alex] Univ Texas Hlth Sci Ctr San Antonio, Dept Biostat, San Antonio, TX 78229 USA. [Ikeno, Yuji] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Ikeno, Yuji] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. [Jang, Young C.] Georgia Inst Technol, Sch Appl Physiol, Atlanta, GA 30332 USA. [Perez, Viviana I.] Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA. [Van Remmen, Holly] Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA. [Van Remmen, Holly; Richardson, Arlan] Oklahoma City VA Med Ctr, Oklahoma City, OK USA. [Richardson, Arlan] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. RP Richardson, A (reprint author), Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. EM LiuY2@uthscsa.edu; walshme125@gmail.com; BOKOV@uthscsa.edu; youngjang@gatech.edu; Viviana.Perez@oregonstate.edu; Holly-VanRemmen@omrf.org; arlan-richardson@ouhsc.edu FU National Institute on Aging [AG-020591]; VA Merit Grants FX This study was funded as part of a program project grant from the National Institute on Aging (AG-020591) and VA Merit Grants to HVR and AR. NR 37 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0047-6374 J9 MECH AGEING DEV JI Mech. Ageing Dev. PD MAR PY 2016 VL 154 BP 1 EP 8 DI 10.1016/j.mad.2016.01.005 PG 8 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA DH6YN UT WOS:000372938100001 PM 26839948 ER PT J AU Hernandez, SE Taylor, L Grembowski, D Reid, RJ Wong, E Nelson, KM Liu, CF Fihn, SD Hebert, PL AF Hernandez, Susan E. Taylor, Leslie Grembowski, David Reid, Robert J. Wong, Edwin Nelson, Karin M. Liu, Chuan-Fen Fihn, Stephan D. Hebert, Paul L. TI A First Look at PCMH Implementation for Minority Veterans Room for Improvement SO MEDICAL CARE LA English DT Article DE primary care; health care delivery; health inequality; disparities; patient-centered care; health disparities; delivery of health care; health service research ID CENTERED MEDICAL HOME; QUALITY-OF-CARE; RACIAL DISPARITIES; NEIGHBORHOOD ENVIRONMENT; HEALTH-CARE; PATIENT SATISFACTION; OLDER-ADULTS; HOSPITALS; MORTALITY; BENEFICIARIES AB Background: Implementation of Patient Aligned Care Teams (PACT), a patient-centered medical home model, has been inconsistent among the > 900 primary care facilities in the Veterans Health Administration. Objective: Estimate if the degree of PACT implementation at a facility varied with the percentage of minority veteran patients at the facility. Research Design: Cross-sectional, facility-level analysis of PACT implementation measures in 2012. Subjects: Veterans Health Administration hospital-based and community-based primary care facilities. Measures: We used a previously validated PACT Implementation Progress Index (Pi(2)) and its 8 domains: access, continuity of care, care coordination, comprehensiveness, self-management support, and patient-centered care and communication, shared decision-making domains, and team functioning. Facilities were categorized as low (< 5.2%, n=208), medium (5.2%-25.8%, n=413), and high (> 25.8%, n=206) percent minority based on the percent of their own veteran population. Results: Most minority veterans received care in high minority (69%) and medium minority facilities (29%). In adjusted analyses, medium and high minority facilities scored 0.773 (P=0.009) and 0.930 (P=0.008) points lower on the Pi(2) score relative to low minority facilities. Relative to low minority facilities, both medium and high minority facilities were less likely of having high Pi(2) scores (>= 2) and more likely of having low Pi(2) scores (<=-2). Both medium and high minority facilities had the same 3 domain scores lower than low minority facilities (care coordination, comprehensiveness, and self-management). Conclusion: Overall PACT implementation varied with respect to the racial/ethnic composition of a facility, with medium and high minority facilities having a lower implementation scores. C1 [Hernandez, Susan E.; Grembowski, David; Wong, Edwin; Liu, Chuan-Fen; Hebert, Paul L.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Hernandez, Susan E.; Taylor, Leslie; Wong, Edwin; Nelson, Karin M.; Liu, Chuan-Fen; Hebert, Paul L.] Seattle Ctr Innovat Vet Ctr & Value Dr Care, Puget Sound Hlth Care Syst, 1660 S Columbian Way S-152, Seattle, WA 98108 USA. [Reid, Robert J.] Trillium Hlth Partners, Inst Better Hlth, Toronto, ON, Canada. [Nelson, Karin M.; Fihn, Stephan D.] VA Puget Sound Hlth Care Syst, Gen Internal Med Serv, Seattle, WA USA. [Nelson, Karin M.; Fihn, Stephan D.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Fihn, Stephan D.] Vet Hlth Adm, Off Analyt & Business Intelligence, Washington, DC USA. RP Hernandez, SE (reprint author), Seattle Ctr Innovat Vet Ctr & Value Dr Care, Puget Sound Hlth Care Syst, 1660 S Columbian Way S-152, Seattle, WA 98108 USA. EM seh315@uw.edu FU Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services [5T32HS013853-7, 5T32HS013853-8, HS023376-01]; VA Health Services Research and Development Career Development Award [CDA 13-024]; VA FX This project was funded under Grant Numbers (5T32HS013853-7, 5T32HS013853-8, and HS023376-01) from the Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services. Data for this project were developed by the national evaluation team at the PACT Demonstration Lab Coordinating Center and the VHA Office of Analytics and Business Intelligence. E.W. is funded by a VA Health Services Research and Development Career Development Award (CDA 13-024).; E.W. has previously owned stock in Tenet Healthcare Corp. in the past 3 years. D.G. received support from VA funding for the evaluation of PACT. L.T., E.W., K.M.N., C.F.-L., S.D.F., P.L.H., and S.E.H. are part of the national PACT evaluation team. The remaining authors declare no conflict of interest. NR 43 TC 1 Z9 1 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD MAR PY 2016 VL 54 IS 3 BP 253 EP 261 DI 10.1097/MLR.0000000000000512 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DH6XM UT WOS:000372935400006 PM 26871643 ER PT J AU Blakeley, JO Coons, SJ Corboy, JR Leidy, NK Mendoza, TR Wefel, JS AF Blakeley, Jaishri O. Coons, Stephen Joel Corboy, John R. Leidy, Nancy Kline Mendoza, Tito R. Wefel, Jeffrey S. TI Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations SO NEURO-ONCOLOGY LA English DT Article DE clinical outcome assessment; clinical trials; endpoints; malignant glioma ID QUALITY-OF-LIFE; NEWLY-DIAGNOSED GLIOBLASTOMA; KARNOFSKY PERFORMANCE STATUS; MODULE EORTC QLQ-BN20; RANDOMIZED PHASE-III; BRAIN-TUMOR MODULE; HIGH-GRADE GLIOMAS; EUROPEAN-ORGANIZATION; NEUROCOGNITIVE FUNCTION; COGNITIVE FUNCTION AB The shared goal of all parties developing therapeutics against malignant gliomas is to positively impact the lives of people affected by these cancers. Clinical outcome assessment (COA) tools, including measures of patient-reported outcome, performance outcome, clinician-reported outcome, and observer-reported outcome, allow patient-focused assessments to complement traditional efficacy measures such as overall survival and radiographic endpoints. This review examines the properties of various COA measures used in malignant glioma clinical trials to date and cross references their content to the priority signs, symptoms, and functional limitations defined through a community survey conducted by the National Brain Tumor Society. The overarching goal of this initiative is to identify COA measures that are feasible and have appropriate psychometric properties for use in this patient population as well as highlight where further development is needed. C1 [Blakeley, Jaishri O.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21287 USA. [Blakeley, Jaishri O.] Johns Hopkins Univ, Dept Neurosurg, Baltimore, MD 21287 USA. [Blakeley, Jaishri O.] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21287 USA. [Coons, Stephen Joel] Crit Path Inst, 1730 E River Rd, Tucson, AZ USA. [Corboy, John R.] Univ Colorado, Sch Med, Denver Vet Affairs Med Ctr, 12631 East 17th Ave B185, Aurora, CO USA. [Leidy, Nancy Kline] Evidera, 7101Wisconsin Ave,Suite 1400, Bethesda, MD USA. [Mendoza, Tito R.; Wefel, Jeffrey S.] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Bld, Houston, TX 77030 USA. RP Blakeley, JO (reprint author), Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21287 USA.; Blakeley, JO (reprint author), Johns Hopkins Univ, Dept Neurosurg, Baltimore, MD 21287 USA.; Blakeley, JO (reprint author), Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21287 USA. EM jblakel3@jhmi.edu NR 57 TC 0 Z9 0 U1 2 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD MAR PY 2016 VL 18 SU 2 BP 13 EP 20 DI 10.1093/neuonc/nov291 PG 8 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA DH9KO UT WOS:000373115200002 ER PT J AU Singh, S Rejai, S Antongiorgi, Z Gonzalez, N Stelzner, M AF Singh, Sumit Rejai, Sepehr Antongiorgi, Zarah Gonzalez, Nestor Stelzner, Matthias TI Misconnections in the Critically Ill: Injection of High-Dose Gadolinium into an External Ventricular Drain SO A & A CASE REPORTS LA English DT Article ID INTRATHECAL GADOLINIUM; GADOPENTETATE DIMEGLUMINE; ENCEPHALOPATHY; CISTERNOGRAPHY AB We report an unfortunate case of accidental administration of intrathecal gadolinium through an external ventricular drain in a postcraniotomy patient during magnetic resonance imaging of the brain. The incident occurred after the venous contrast line was connected mistakenly to the ventricular drainage catheter. The patient subsequently developed confusion, aphasia, and right facial droop with new computed tomography evidence of diffuse cerebral edema and stroke. Review of the magnetic resonance image revealed the inappropriate presence of subarachnoid gadolinium. Despite all interventions, the patient developed irreversible neurologic disability. We address the clinical sequelae, management strategies, and factors contributing to the catheter misconnection that led to this event. C1 [Singh, Sumit; Rejai, Sepehr; Antongiorgi, Zarah] Univ Calif Los Angeles, Med Ctr, Dept Anesthesiol & Perioperat Med, Los Angeles, CA 90024 USA. [Gonzalez, Nestor] Univ Calif Los Angeles, Med Ctr, Neurosurg, Los Angeles, CA 90024 USA. [Stelzner, Matthias] Univ Calif Los Angeles, Med Ctr, VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90024 USA. RP Singh, S (reprint author), Univ Calif Los Angeles, Dept Anesthesiol & Perioperat Med, 757 Westwood Plaza, Los Angeles, CA 90024 USA. EM SPSingh@mednet.ucla.edu OI Gonzalez, Nestor/0000-0002-8277-6317 NR 14 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2325-7237 J9 A A CASE REP JI A A Case Rep. PD MAR 1 PY 2016 VL 6 IS 5 BP 121 EP 123 DI 10.1213/XAA.0000000000000230 PG 3 WC Anesthesiology SC Anesthesiology GA DH2OT UT WOS:000372626400004 PM 26462163 ER PT J AU Beristianos, MH Yaffe, K Cohen, B Byers, AL AF Beristianos, Matthew H. Yaffe, Kristine Cohen, Beth Byers, Amy L. TI PTSD and Risk of Incident Cardiovascular Disease in Aging Veterans SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE PTSD; cardiovascular disease; veterans ID POSTTRAUMATIC-STRESS-DISORDER; CORONARY-HEART-DISEASE; PERIPHERAL ARTERIAL-DISEASE; MENTAL-HEALTH PROBLEMS; VIETNAM VETERANS; US VETERANS; SYMPTOMS; AFGHANISTAN; PREVALENCE; IRAQ AB Objectives: To determine if late-life posttraumatic stress disorder (PTSD) is associated with cardiovascular disease in a sample of older veterans, and whether the association is independent of medical and psychiatric comorbities. Design: Retrospective cohort study conducted using the Department of Veterans Affairs (VA) National Patient Care Database (2000-2011). Setting: VA medical centers in the United States. Participants: A total of 138,341 veterans 55 years and older without cardiovascular disease at study baseline (2000-2003). Measurements: PTSD and cardiovascular disease (as defined by diagnoses of: cerebrovascular disease [CVD], congestive heart failure [CHF], myocardial infarction [MI], and peripheral vascular disease [PVD]) were identified by ICD-9 codes during study baseline (2000-2003) and follow-up (2004-2011), respectively. Results: 3% of veterans (N = 4,041) had a baseline diagnosis of PTSD. Unadjusted increased risk of incidence of CVD was 80%, CHF was 56%, MI was 82%, and PVD was 60% in veterans with PTSD compared with those without PTSD. After adjustment for demographics, medical comorbidities, substance use, and psychiatric comorbidities, veterans with late-life PTSD were at a 45% increased risk for incident CVD, 26% increased risk for incident CHF, 49% increased risk for incident MI, and 35% increased risk for PVD compared with veterans without late-life PTSD. Conclusions: Findings highlight the longitudinal impact of PTSD on increasing the incidence of cardiovascular disease in older adults. This study implies the need for greater monitoring and treatment of PTSD in older persons, particularly older veterans, to assist in preventing adverse outcomes, such as cardiovascular disease, over the long term. C1 [Beristianos, Matthew H.; Yaffe, Kristine; Byers, Amy L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Cohen, Beth] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Beristianos, Matthew H.; Yaffe, Kristine; Cohen, Beth; Byers, Amy L.] San Francisco VA Med Ctr, San Francisco, CA USA. [Beristianos, Matthew H.] Alliant Int Univ, Calif Sch Profess Psychol, San Francisco, CA USA. RP Beristianos, MH (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Psychiat, 4150 Clement St,116H, San Francisco, CA 94121 USA. EM Matthew.Beristianos@ucsf.edu FU U.S. Department of Defense [W81XWH-11-2-0189]; K24 Midcareer Investigator Award from the National Institute on Aging [AG031155]; National Heart, Lung, and Blood Institute [K23 HL 094765-0]; American Heart Association [12CRP11810021]; Takeda, Inc.; National Institute on Aging FX This study was funded by U.S. Department of Defense grant W81XWH-11-2-0189 (principal investigator: Dr. Byers). Dr. Yaffe is supported in part by a K24 Midcareer Investigator Award from the National Institute on Aging (AG031155). Dr. Cohen is supported in part by the National Heart, Lung, and Blood Institute grant K23 HL 094765-0 and grant 12CRP11810021 from the American Heart Association.; Mr. Beristianos, Dr. Cohen, and Dr. Byers report no financial relationships with commercial interests. Dr. Yaffe reports having served as a consultant to Novartis, Inc., and Pfizer for reasons not related to the current project. She serves on DSMB committees for Takeda, Inc., and a National Institute on Aging-sponsored study, and also serves on the Beeson Scientific Advisory Board. The authors have no competing interests, including specific financial interests or relationships or affiliations relevant to the subject of this article. NR 41 TC 7 Z9 7 U1 3 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2016 VL 24 IS 3 BP 192 EP 200 DI 10.1016/j.jagp.2014.12.003 PG 9 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA DG8CF UT WOS:000372309300003 PM 25555625 ER PT J AU Diem, SJ Blackwell, TL Stone, KL Yaffe, K Tranah, G Cauley, JA Ancoli-Israel, S Redline, S Spira, AP Hillier, TA Ensrud, KE AF Diem, Susan J. Blackwell, Terri L. Stone, Katie L. Yaffe, Kristine Tranah, Greg Cauley, Jane A. Ancoli-Israel, Sonia Redline, Susan Spira, Adam P. Hillier, Teresa A. Ensrud, Kristine E. TI Measures of Sleep-Wake Patterns and Risk of Mild Cognitive Impairment or Dementia in Older Women SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE cognitive aging; sleep disorders; older women; dementia; actigraphy ID OSTEOPOROTIC FRACTURES; ALZHEIMERS-DISEASE; DECLINE; ADULTS; FRAGMENTATION; QUESTIONNAIRE; RELIABILITY; ACTIGRAPHY; DURATION; RHYTHMS AB Objective: Sleep disturbances are common in older adults. Little is known about the sleep of cognitively intact older adults and its relationship to subsequent cognitive impairment. The objective of this study was to examine the association between objective sleep-wake measures and risk of incident cognitive impairment. Methods: In this prospective cohort study encompassing four U.S. sites, 1,245 women (mean age: 82.6 years) without dementia participated in the Study of Osteoporotic Fractures and completed actigraphy at the baseline visit and comprehensive cognitive assessment at follow-up. The association between sleep-wake patterns measured by actigraphy and risk of incident mild cognitive impairment (MCI) and dementia was examined. Results: A total of 473 women (38%) developed cognitive impairment during an average (SD) follow-up of 4.9 (0.6) years; 290 (23.3%) developed MCI and 183 (14.7%) developed dementia. After controlling for multiple potential confounders, women in the lowest quartile of average sleep efficiency (<74%) had a 1.5-fold higher odds of developing MCI or dementia compared with women in the highest quartile of sleep efficiency (>86%) (odds ratio: Q1 versus Q4 1.53; 95% CI: 1.07, 2.19; Wald chi(2) [1, N = 1,223] = 5.34 for p for trend = 0.03). Longer average sleep latency, but not total sleep time, was also associated with higher odds of developing cognitive impairment. Greater variability in both sleep efficiency and total sleep time was associated with an increased odds of developing MCI or dementia. Conclusion: Lower average sleep efficiency, longer average sleep latency, and greater variability in sleep efficiency and total sleep time are associated with increased odds of developing cognitive impairment. Further research is needed to explore the mechanisms underlying these associations. C1 [Diem, Susan J.; Ensrud, Kristine E.] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA. [Diem, Susan J.; Ensrud, Kristine E.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55415 USA. [Blackwell, Terri L.; Stone, Katie L.; Tranah, Greg] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA. [Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA. [Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Redline, Susan] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, 75 Francis St, Boston, MA 02115 USA. [Redline, Susan] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA. [Spira, Adam P.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA. [Hillier, Teresa A.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA. [Ensrud, Kristine E.] Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. RP Diem, SJ (reprint author), Univ Minnesota, 1100 Washington Ave S, Minneapolis, MN 55415 USA. EM sdiem@umn.edu RI Cauley, Jane/N-4836-2015 OI Cauley, Jane/0000-0003-0752-4408 FU National Institute on Aging [RO1 AG005407, RO1 AR35582, ROA AR35583, RO1 AR35584, RO1 AG005394, RO1 AG027574, RO1 AG027576, KO1 AG033195] FX The Study of Osteoporotic Fractures is supported by grants RO1 AG005407, RO1 AR35582, ROA AR35583, RO1 AR35584, RO1 AG005394, RO1 AG027574, RO1 AG027576, and KO1 AG033195 from the National Institute on Aging. The funding agencies had no direct role in the conduct of the study; the collection, management, analyses and interpretation of the data; or preparation or approval of the manuscript. All authors have nothing to disclose. NR 49 TC 2 Z9 2 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2016 VL 24 IS 3 BP 248 EP 258 DI 10.1016/j.jagp.2015.12.002 PG 11 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA DG8CF UT WOS:000372309300009 PM 26964485 ER PT J AU Schlosser, RJ Storck, K Cortese, BM Uhde, TW Rudmik, L Soler, ZM AF Schlosser, Rodney J. Storck, Kristina Cortese, Bernadette M. Uhde, Thomas W. Rudmik, Luke Soler, Zachary M. TI Depression in chronic rhinosinusitis: A controlled cohort study SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY LA English DT Article ID ENDOSCOPIC SINUS SURGERY; QUALITY-OF-LIFE; INVENTORY-II; DIABETES-MELLITUS; DISEASE SEVERITY; SYMPTOMS; OUTCOMES; HEALTH; IMPACT; ASSOCIATION AB Background: Depression in patients with chronic rhinosinusitis (CRS) is underdiagnosed but significantly impacts treatment outcomes and health care utilization. Objective: To compare undiagnosed depression in a CRS cohort with a healthy, non-CRS control cohort. Methods: A case-control study of patients with symptomatic CRS and a non-CRS control cohort was performed. Demographic and comorbidity factors were correlated to depression-specific outcomes by using the Beck Depression Inventory II (BDI). Results: We enrolled 42 patients with CRS and 88 control patients with no history of CRS. Physician-diagnosed depression was equivalent in CRS and control patients (6% and 9%, respectively). BDI-detected depression was higher among patients with CRS compared with controls (31% versus 14.8%, respectively; p = 0.031). BDI scores were higher in patients with CRS even when controlling for comorbid asthma, allergy, and aspirin sensitivity. When examined by polyp status, the patients without polyps had more depression than did the controls (38% versus 14.8%; p = 0.048). The somatic subscale scores of the BDI were worse in patients with CRS (p = 0.004), whereas the cognitive subscale trended toward significance (p = 0.081). Conclusion: Depression may be more common in CRS than previously recognized, especially in patients without polyps. Somatic subscale scores of the BDI are increased in CRS and may impact future treatment outcomes. C1 [Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Dept Surg, Charleston, SC USA. [Schlosser, Rodney J.; Storck, Kristina; Soler, Zachary M.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Cortese, Bernadette M.; Uhde, Thomas W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Rudmik, Luke] Univ Calgary, Dept Surg, Div Otolaryngol Head & Neck Surg, Calgary, AB, Canada. RP Schlosser, RJ (reprint author), Med Univ S Carolina, Dept Otolaryngol, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. EM schlossr@musc.edu FU Flight Attendant Medical Research Institute [ID113042_CIA]; National Institute on Deafness and Other Communication Disorders, one of the National Institutes of Health, Bethesda, Maryland [R01 DC005805, R03 DC013651-01]; National Institute of Mental Health [K01 MH090548]; Entellus; IntersectENT; OptiNose FX Supported by a grant from the Flight Attendant Medical Research Institute (ID113042_CIA). Z.M. Soler is also supported by grants from the National Institute on Deafness and Other Communication Disorders, one of the National Institutes of Health, Bethesda, Maryland (R01 DC005805; R03 DC013651-01). B.M. Cortese is supported by a grant from the National Institute of Mental Health (K01 MH090548).; Z.M. Soler is a consultant for Olympus, which is not affiliated with this manuscript, and has grant support from Entellus and IntersectENT. R.J. Schlosser is supported by grants from OptiNose, Entellus, and IntersectENT, which are not associated with this manuscript, and is a consultant for Olympus, Meda, and Arrinex, which are not affiliated with this study. The remaining authors have no conflicts of interest pertaining to this article NR 33 TC 6 Z9 6 U1 1 U2 3 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1945-8924 EI 1945-8932 J9 AM J RHINOL ALLERGY JI Am. J. Rhinol. Allergy PD MAR-APR PY 2016 VL 30 IS 2 BP 128 EP 133 DI 10.2500/ajra.2016.30.4290 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA DG8PL UT WOS:000372346000019 PM 26980393 ER PT J AU Lin, JE Neylan, TC Epel, E O'Donovan, A AF Lin, Joy E. Neylan, Thomas C. Epel, Elissa O'Donovan, Aoife TI Associations of childhood adversity and adulthood trauma with C-reactive protein: A cross-sectional population-based study SO BRAIN BEHAVIOR AND IMMUNITY LA English DT Article DE Childhood adversity; Adulthood trauma; C-reactive protein; Immune system; Inflammation ID POSTTRAUMATIC-STRESS-DISORDER; INTIMATE PARTNER VIOLENCE; EARLY-LIFE STRESS; ELEVATED INFLAMMATION; MENTAL-HEALTH; CARDIOVASCULAR-DISEASE; PSYCHIATRIC-DISORDERS; PSYCHOLOGICAL STRESS; GENE-EXPRESSION; RISK AB Mounting evidence highlights specific forms of psychological stress as risk factors for ill health. Particularly strong evidence indicates that childhood adversity and adulthood trauma exposure increase risk for physical and psychiatric disorders, and there is emerging evidence that inflammation may play a key role in these relationships. In a population-based sample from the Health and Retirement Study (n = 11,198, mean age 69 +/- 10), we examine whether childhood adversity, adulthood trauma, and the interaction between them are associated with elevated levels of the systemic inflammatory marker high sensitivity C-reactive protein (hsCRP). All models were adjusted for age, gender, race, education, and year of data collection, as well as other possible confounds in follow-up sensitivity analyses. In our sample, 67% of individuals had experienced at least one traumatic event during adulthood, and those with childhood adversity were almost three times as likely to have experienced trauma as an adult. Childhood adversities and adulthood traumas were independently associated with elevated levels of hsCRP (beta = 0.03, p = 0.01 and beta = 0.05, p < 0.001, respectively). Those who had experienced both types of stress had higher levels of hsCRP than those with adulthood trauma alone, Estimate = -0.06, 95% CI [-0.003, -0.12], p = 0.04, but not compared to those with childhood adversity alone, Estimate = -0.06, 95% CI [0.03, -0.16], p = 0.19. There was no interaction between childhood and adulthood trauma exposure. To our knowledge, this is the first study to examine adulthood trauma exposure and inflammation in a large population-based sample, and the first to explore the interaction of childhood adversity and adulthood trauma with inflammation. Our study demonstrates the prevalence of trauma-related inflammation in the general population and suggests that childhood adversity and adulthood trauma are independently associated with elevated inflammation. (C) 2015 Elsevier Inc. All rights reserved. C1 [Lin, Joy E.] Univ Calif San Francisco, Sch Med, 500 Parnassus Ave, San Francisco, CA 94143 USA. [Neylan, Thomas C.; Epel, Elissa; O'Donovan, Aoife] Univ Calif San Francisco, Dept Psychiat, 500 Parnassus Ave, San Francisco, CA 94143 USA. [Lin, Joy E.; Neylan, Thomas C.; O'Donovan, Aoife] San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. RP Lin, JE (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, 4150 Clement St 116C-1, San Francisco, CA 94121 USA. EM joy.lin@ucsf.edu; thomas.neylan@ucsf.edu; elissa.epel@ucsf.edu; aoife.odonovan@ucsf.edu FU National Institute on Aging [NIA U01AG009740]; National Center for Advancing Translational Sciences Career Development Award at the University of California, San Francisco [KL2 TR000143]; Society in Science-Branco Weiss Fellowship; UCSF Dean's Office Medical Student Research Program FX The HRS (Health and Retirement Study) is sponsored by the National Institute on Aging (grant number NIA U01AG009740) and was conducted by the University of Michigan. A.O.D. was supported by a National Center for Advancing Translational Sciences Career Development Award at the University of California, San Francisco (KL2 TR000143) and a Society in Science-Branco Weiss Fellowship. J.E.L. was supported by the UCSF Dean's Office Medical Student Research Program. The authors would like to acknowledge Tom Metzler for statistical support in preparation of this manuscript. NR 79 TC 1 Z9 1 U1 4 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0889-1591 EI 1090-2139 J9 BRAIN BEHAV IMMUN JI Brain Behav. Immun. PD MAR PY 2016 VL 53 BP 105 EP 112 DI 10.1016/j.bbi.2015.11.015 PG 8 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA DG9BJ UT WOS:000372377500012 PM 26616398 ER PT J AU Singh, JA Ramachandran, R AF Singh, Jasvinder A. Ramachandran, Rekha TI Sex differences in characteristics, utilization, and outcomes of patient undergoing total elbow arthroplasty: a study of the US nationwide inpatient sample SO CLINICAL RHEUMATOLOGY LA English DT Article DE Discharge; Hospital stay; Mortality; Outcomes; Sex; TEA; Total elbow arthroplasty; Utilization ID SURGEON PROCEDURE VOLUME; TOTAL KNEE ARTHROPLASTY; UNITED-STATES; SHOULDER ARTHROPLASTY; HIP-REPLACEMENT; HOME; ASSOCIATION; DISCHARGE; MORTALITY; SUPPORT AB The aim of this study was to compare patient characteristics, utilization rates, and outcomes after total elbow arthroplasty (TEA) by sex. We used the nationwide inpatient sample from 1998 to 2011 to study sex-related time trends in patient characteristics, comorbidity, and outcomes after TEA. We used chi-squared test, analysis of variance, and the Cochran-Armitage test to assess differences in utilization rates and characteristics over time by sex and logistic regression to compare mortality, discharge disposition, and the length of hospital stay by sex. Overall TEA utilization 0.45 in 1998 to 0.96 per 100,000 in 2011 (p < 0.0001). The utilization rates were significantly higher in females compared to males throughout the study period: 0.62 vs. 0.29 in 1998 (p < 0.0001) and 1.31 vs. 0.70 in 2011 (p < 0.0001). Compared to males, females undergoing TEA were more likely to be white (79.7 vs. 71.4 %; p < 0.0001), have rheumatoid arthritis (16.7 vs. 8.1 %; p < 0.0001), and have Deyo-Charlson index of 2 or more (11.3 vs. 5.9 %; p < 0.0001) and were older (63.5 vs. 51.4 years; p < 0.0001). Compared to males undergoing TEA, females had significantly lower mortality, 0.1 vs. 0.4 % (p = 0.03); lower proportion were discharged to home, 81.9 vs. 89.6 % (p < 0.0001), and fewer had has index hospital stay above the median, 30.0 vs. 33.0 % (p = 0.01); most differences were significant after multivariable adjustment. TEA utilization in the USA more than doubled in the last 14 years, with rates higher in females than males. Females had better outcomes after TEA than men. Preoperative risk communication should be sex-specific based on these data. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.; Ramachandran, Rekha] Univ Alabama Birmingham, Sch Med, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Ramachandran, Rekha] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Sch Med, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM jasvinder.md@gmail.com FU Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs); National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS); National Institute of Aging (NIA); National Cancer Institute (NCI) FX This material is the result of work supported by the resources and use of facilities at the Birmingham VA Medical Center, Alabama, USA. J.A.S. is also supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs), National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS), National Institute of Aging (NIA), and National Cancer Institute (NCI). NR 19 TC 2 Z9 2 U1 0 U2 0 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0770-3198 EI 1434-9949 J9 CLIN RHEUMATOL JI Clin. Rheumatol. PD MAR PY 2016 VL 35 IS 3 BP 723 EP 731 DI 10.1007/s10067-014-2778-9 PG 9 WC Rheumatology SC Rheumatology GA DG9UJ UT WOS:000372429000022 PM 25316506 ER PT J AU Burge, SK Katerndahl, DA Wood, RC Becho, J Ferrer, RL Talamantes, M AF Burge, Sandra K. Katerndahl, David A. Wood, Robert C. Becho, Johanna Ferrer, Robert L. Talamantes, Melissa TI Using Complexity Science to Examine Three Dynamic Patterns of Intimate Partner Violence SO FAMILIES SYSTEMS & HEALTH LA English DT Article DE spouse abuse; battered women; domestic violence; nonlinear dynamics; longitudinal studies ID PRIMARY-CARE; LYAPUNOV EXPONENTS; TIME-SERIES; RELIABILITY; SEVERITY; VALIDITY; SYSTEMS; HEALTH; CHAOS; MOOD AB Introduction: The partner violence literature describes 3 dominant models of dynamics of partner aggression: cycle of violence, family systems theory, and Duluth model (power and control wheel). Complexity science describes 3 patterns of system dynamics: periodic, chaotic, and random. Are these parallel patterns? In this analysis, investigators calculated dynamic patterns (periodic, chaotic, and random) using 84 daily reports of male-to-female aggression and assessed the "fit" between time-series-derived patterns of male partners' violent behaviors and literature-based models of violence dynamics. Method: Participants were 200 women in moderately violent intimate relationships who completed a telephone survey about their relationships every day for 12 weeks. They also completed baseline and end-of-study surveys and maintained telephone contact with the study team weekly. Of 200 participants, 135 women provided enough data to be assigned to period, chaotic, or random groups. Results: Group membership included 16 women in periodic, 40 in chaotic, and 79 in random groups. Consistent with the cycle of violence, periodic women found violence to be predictable and controllable. Consistent with the Duluth model, women in the random group found violence to be unpredictable and out of their control, occurring with high frequency. The chaotic group had the lowest frequency and severity of violence, lowest stress and arguments, and the highest marital satisfaction. Discussion: The most common dynamic pattern in partner violence is random, which exhibits high frequency and unpredictability of aggression. Complexity science suggests interventions in random systems have unpredictable outcomes, posing great challenges for clinicians who work with victims of violence. C1 [Burge, Sandra K.; Katerndahl, David A.; Wood, Robert C.; Becho, Johanna; Ferrer, Robert L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, 7703 Floyd Curl Dr,Mail Code 7795, San Antonio, TX 78229 USA. [Talamantes, Melissa] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Burge, SK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, 7703 Floyd Curl Dr,Mail Code 7795, San Antonio, TX 78229 USA. EM burge@uthscsa.edu FU "Dynamics of Human Behavior" program, National Science Foundation [0525026] FX This study was funded with a grant from the "Dynamics of Human Behavior" program, National Science Foundation, Award 0525026. Automated data collection was provided by the University of Colorado, Department of Family Medicine Information Services group. We thank Stephanie Mitchell, Kelli Giacomini, and Wilson Pace for their invaluable assistance with IVR. We also express appreciation to Norma Cantu and Diandrea Garza for their commitment to screening and enrolling women for this study. NR 39 TC 2 Z9 2 U1 1 U2 5 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1091-7527 EI 1939-0602 J9 FAM SYST HEALTH JI Fam. Syst. Health PD MAR PY 2016 VL 34 IS 1 BP 4 EP 14 DI 10.1037/fsh0000170 PG 11 WC Health Care Sciences & Services; Family Studies; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Family Studies; Public, Environmental & Occupational Health GA DG8WG UT WOS:000372363700002 PM 26618639 ER PT J AU Schulman, JM Oh, DH Sanborn, JZ Pincus, L McCalmont, TH Cho, RJ AF Schulman, Joshua M. Oh, Dennis H. Sanborn, J. Zachary Pincus, Laura McCalmont, Timothy H. Cho, Raymond J. TI Multiple Hereditary Infundibulocystic Basal Cell Carcinoma Syndrome Associated With a Germline SUFU Mutation SO JAMA DERMATOLOGY LA English DT Article ID GORLIN SYNDROME; MEDULLOBLASTOMA AB IMPORTANCE Multiple hereditary infundibulocystic basal cell carcinoma syndrome (MHIBCC) is a rare genodermatosis in which numerous indolent, well-differentiated basal cell carcinomas develop primarily on the face and genitals, without other features characteristic of basal cell nevus syndrome. The cause is unknown. The purpose of the study was to identify a genetic basis for the syndrome and a mechanism by which the associated tumors develop. OBSERVATIONS Whole-exome sequencing of 5 tumors and a normal buccal mucosal sample from a patient with MHIBCC was performed. A conserved splice-site mutation in 1 copy of the suppressor of fused gene (SUFU) was identified in all tumor and normal tissue samples. Additional distinct deletions of the trans SUFU allele were identified in all tumor samples, none of which were present in the normal sample. CONCLUSIONS AND RELEVANCE A germline SUFU mutation was present in a patient with MHIBCC, and additional acquired SUFU mutations underlie the development of infundibulocystic basal cell carcinomas. The downstream location of the SUFU gene within the sonic hedgehog pathway may explain why its loss is associated with relatively well-differentiated tumors and suggests that MHIBCC will not respond to therapeutic strategies, such as smoothened inhibitors, that target upstream components of this pathway. C1 [Schulman, Joshua M.; Oh, Dennis H.; Pincus, Laura; McCalmont, Timothy H.; Cho, Raymond J.] Univ Calif San Francisco, Dept Dermatol, 2340 Sutter St,S431, San Francisco, CA 94115 USA. [Schulman, Joshua M.; Pincus, Laura; McCalmont, Timothy H.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94115 USA. [Oh, Dennis H.] San Francisco VA Med Ctr, Dermatol Res Unit, San Francisco, CA USA. [Sanborn, J. Zachary] NantOmics LLC, Santa Cruz, CA USA. RP Cho, RJ (reprint author), Univ Calif San Francisco, Dept Dermatol, 2340 Sutter St,S431, San Francisco, CA 94115 USA. EM chorj@derm.ucsf.edu FU Well Aging Research Center, Samsung Advanced Institute of Technology; National Cancer Institute, National Institutes of Health [K08 CA169865] FX This study was supported by the Well Aging Research Center, Samsung Advanced Institute of Technology, under the auspices of Sang Chul Park, MD, PhD, and by grant K08 CA169865 from the National Cancer Institute, National Institutes of Health (Dr Cho). NR 15 TC 2 Z9 2 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6068 EI 2168-6084 J9 JAMA DERMATOL JI JAMA Dermatol. PD MAR PY 2016 VL 152 IS 3 BP 323 EP 327 DI 10.1001/jamadermatol.2015.4233 PG 5 WC Dermatology SC Dermatology GA DH0GH UT WOS:000372460300019 PM 26677003 ER PT J AU Morone, NE Greco, CM Moore, CG Rollman, BL Lane, B Morrow, LA Glynn, NW Weiner, DK AF Morone, Natalia E. Greco, Carol M. Moore, Charity G. Rollman, Bruce L. Lane, Bridget Morrow, Lisa A. Glynn, Nancy W. Weiner, Debra K. TI A Mind-Body Program for Older Adults With Chronic Low Back Pain A Randomized Clinical Trial SO JAMA INTERNAL MEDICINE LA English DT Article ID SELF-EFFICACY; PSYCHOMETRIC PROPERTIES; NATIONAL-HEALTH; SCALE; METAANALYSIS; MINDFULNESS; VALIDATION; MEDITATION; DISABILITY; INTENSITY AB IMPORTANCE Treatment of chronic low back pain (LBP) in older adults is limited by the adverse effects of analgesics. Effective nonpharmacologic treatment options are needed. OBJECTIVE To determine the effectiveness of a mind-body program at increasing function and reducing pain in older adults with chronic LBP. DESIGN, SETTING, AND PARTICIPANTS This single-blind, randomized clinical trial compared a mind-body program (n = 140) with a health education program (n = 142). Community-dwelling older adults residing within the Pittsburgh metropolitan area were recruited from February 14, 2011, to June 30, 2014, with 6-month follow-up completed by April 9, 2015. Eligible participants were 65 years or older with functional limitations owing to their chronic LBP (>= 11 points on the Roland and Morris Disability Questionnaire) and chronic pain (duration >= 3 months) of moderate intensity. Data were analyzed from March 1 to July 1, 2015. INTERVENTIONS The intervention and control groups received an 8-week group program followed by 6 monthly sessions. The intervention was modeled on the Mindfulness-Based Stress Reduction program; the control program, on the "10 Keys" to Healthy Aging. MAIN OUTCOMES AND MEASURES Follow-up occurred at program completion and 6 months later. The score on the Roland and Morris Disability Questionnaire was the primary outcome and measured functional limitations owing to LBP. Pain (current, mean, and most severe in the past week) was measured with the Numeric Pain Rating Scale. Secondary outcomes included quality of life, pain self-efficacy, and mindfulness. Intent-to-treat analyses were conducted. RESULTS Of 1160 persons who underwent screening, 282 participants enrolled in the trial (95 men [33.7%] and 187 women [66.3%]; mean [SD] age, 74.5 [6.6] years). The baseline mean (SD) Roland and Morris Disability Questionnaire scores for the intervention and control groups were 15.6 (3.0) and 15.4 (3.0), respectively. Compared with the control group, intervention participants improved an additional -1.1 (mean, 12.1 vs 13.1) points at 8 weeks and -0.04 (mean, 12.2 vs 12.6) points at 6 months (effect sizes, -0.23 and -0.08, respectively) on the Roland and Morris Disability Questionnaire. By 6 months, the intervention participants improved on the Numeric Pain Rating Scale current and most severe pain measures an additional -1.8 points (95% CI, -3.1 to -0.05 points; effect size, -0.33) and -1.0 points (95% CI, -2.1 to 0.2 points; effect size, -0.19), respectively. The changes in Numeric Pain Rating Scale mean pain measure after the intervention were not significant (-0.1 [95% CI, -1.1 to 1.0] at 8 weeks and -1.1 [95% CI, -2.2 to -0.01] at 6 months; effect size, -0.01 and -0.22, respectively). CONCLUSIONS AND RELEVANCE A mind-body program for chronic LBP improved short-term function and long-term current and most severe pain. The functional improvement was not sustained, suggesting that future development of the intervention could focus on durability. C1 [Morone, Natalia E.; Rollman, Bruce L.; Lane, Bridget] Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Div Gen Internal Med, 230 McKee Pl,Ste 600, Pittsburgh, PA 15213 USA. [Morone, Natalia E.; Rollman, Bruce L.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA 15213 USA. [Morone, Natalia E.; Weiner, Debra K.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Greco, Carol M.] Univ Pittsburgh, Sch Med, UPMC, Dept Psychiat,Ctr Integrat Med, Pittsburgh, PA 15213 USA. [Moore, Charity G.] Carolinas HealthCare Syst, Dickson Adv Analyt, Charlotte, NC USA. [Morrow, Lisa A.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA. [Glynn, Nancy W.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15213 USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA 15213 USA. RP Morone, NE (reprint author), Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Div Gen Internal Med, 230 McKee Pl,Ste 600, Pittsburgh, PA 15213 USA. EM moronene@upmc.edu OI Glynn, Nancy/0000-0003-2265-0162; Moore, Charity/0000-0002-0060-0124 FU National Institutes of Health [R01 AG034078] FX This study was supported by grant R01 AG034078 from the National Institutes of Health. NR 29 TC 13 Z9 13 U1 8 U2 18 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAR PY 2016 VL 176 IS 3 BP 329 EP 337 DI 10.1001/jamainternmed.2015.8033 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA DG7ZP UT WOS:000372302500010 PM 26903081 ER PT J AU Auer, R Vittinghoff, E Yaffe, K Kunzi, A Kertesz, SG Levine, DA Albanese, E Whitmer, RA Jacobs, DR Sidney, S Glymour, MM Pletcher, MJ AF Auer, Reto Vittinghoff, Eric Yaffe, Kristine Kuenzi, Arnaud Kertesz, Stefan G. Levine, Deborah A. Albanese, Emiliano Whitmer, Rachel A. Jacobs, David R., Jr. Sidney, Stephen Glymour, M. Maria Pletcher, Mark J. TI Association Between Lifetime Marijuana Use and Cognitive Function in Middle Age The Coronary Artery Risk Development in Young Adults (CARDIA) Study SO JAMA INTERNAL MEDICINE LA English DT Article ID POPULATION-BASED COHORT; HEAVY CANNABIS USERS; SOCIOECONOMIC-STATUS; DRUG-USE; DECLINE; HEALTH; IQ; INTERFERENCE; EXPOSURE; MIDLIFE AB IMPORTANCE Marijuana use is increasingly common in the United States. It is unclear whether it has long-term effects on memory and other domains of cognitive function. OBJECTIVE To study the association between cumulative lifetime exposure to marijuana use and cognitive performance in middle age. DESIGN, SETTING, AND PARTICIPANTS We used data from the Coronary Artery Risk Development in Young Adults (CARDIA) study, a cohort of 5115 black and white men and women aged 18 to 30 years at baseline from March 25, 1985, to June 7, 1986 (year 0), and followed up over 25 years from June 7, 1986, to August 31, 2011, to estimate cumulative years of exposure to marijuana (1 year = 365 days of marijuana use) using repeated measures and to assess associations with cognitive function at year 25. Linear regression was used to adjust for demographic factors, cardiovascular risk factors, tobacco smoking, use of alcohol and illicit drugs, physical activity, depression, and results of the mirror star tracing test (a measure of cognitive function) at year 2. Data analysis was conducted from June 7, 1986, to August 31, 2011. MAIN OUTCOMES AND MEASURES Three domains of cognitive function were assessed at year 25 using the Rey Auditory Verbal Learning Test (verbal memory), the Digit Symbol Substitution Test (processing speed), and the Stroop Interference Test (executive function). RESULTS Among 3385 participants with cognitive function measurements at the year 25 visit, 2852 (84.3%) reported past marijuana use, but only 392 (11.6%) continued to use marijuana into middle age. Current use of marijuana was associated with worse verbal memory and processing speed; cumulative lifetime exposure was associated with worse performance in all 3 domains of cognitive function. After excluding current users and adjusting for potential confounders, cumulative lifetime exposure to marijuana remained significantly associated with worse verbal memory. For each 5 years of past exposure, verbal memory was 0.13 standardized units lower (95% CI, -0.24 to -0.02; P =.02), corresponding to a mean of 1 of 2 participants remembering 1 word fewer from a list of 15 words for every 5 years of use. After adjustment, we found no associations with lower executive function (-0.03 [95% CI, -0.12 to 0.07]; P =.56) or processing speed (-0.04 [95% CI, -0.16 to 0.08]; P =.51). CONCLUSIONS AND RELEVANCE Past exposure to marijuana is associated with worse verbal memory but does not appear to affect other domains of cognitive function. C1 [Auer, Reto; Vittinghoff, Eric; Yaffe, Kristine; Glymour, M. Maria; Pletcher, Mark J.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Auer, Reto; Kuenzi, Arnaud] Univ Lausanne, Dept Ambulatory Care & Community Med, Lausanne, Switzerland. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat & Neurol, San Francisco, CA 94143 USA. [Kertesz, Stefan G.] Birmingham Vet Affairs Med Ctr, Ctr Surg Med & Acute Care Res, Birmingham, AL USA. [Kertesz, Stefan G.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA. [Levine, Deborah A.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA. [Levine, Deborah A.] Vet Affairs Ctr Clin Management Res, Ann Arbor, MI USA. [Levine, Deborah A.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA. [Levine, Deborah A.] Univ Michigan, Dept Neurol, Ann Arbor, MI USA. [Levine, Deborah A.] Univ Michigan, Stroke Program, Ann Arbor, MI 48109 USA. [Albanese, Emiliano] Univ Geneva, Dept Psychiat, Geneva, Switzerland. [Whitmer, Rachel A.; Sidney, Stephen] Kaiser Permanente, Div Res, Oakland, CA USA. [Jacobs, David R., Jr.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA. RP Auer, R (reprint author), Univ Lausanne, Dept Ambulatory Care & Community Med, Rue Bugnon 44, CH-1011 Lausanne, Switzerland. EM reto.auer@hospvd.ch OI Glymour, M. Maria/0000-0001-9644-3081 FU National Heart, Lung, and Blood Institute (NHLBI); University of Alabama at Birmingham [HHSN268201300025C, HHSN268201300026C]; Northwestern University [HHSN268201300027C]; University of Minnesota [HHSN268201300028C]; Kaiser Foundation Research Institute [HHSN268201300029C]; Johns Hopkins University School of Medicine [HHSN268200900041C]; Intramural Research Program of the National Institute on Aging (NIA); NIA [AG0005]; NHLBI [AG0005] FX The Coronary Artery Risk Development in Young Adults (CARDIA) study is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the University of Alabama at Birmingham (grants HHSN268201300025C and HHSN268201300026C), Northwestern University (grant HHSN268201300027C), University of Minnesota (grant HHSN268201300028C), Kaiser Foundation Research Institute (grant HHSN268201300029C), and The Johns Hopkins University School of Medicine (grant HHSN268200900041C). The CARDIA study is also partially supported by the Intramural Research Program of the National Institute on Aging (NIA) and an intra-agency agreement between the NIA and the NHLBI (AG0005). NR 45 TC 13 Z9 13 U1 7 U2 18 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAR PY 2016 VL 176 IS 3 BP 352 EP 361 DI 10.1001/jamainternmed.2015.7841 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA DG7ZP UT WOS:000372302500014 PM 26831916 ER PT J AU Widera, E Talebreza, S AF Widera, Eric Talebreza, Shaida TI Variability in Hospice Care at the Very End of Life SO JAMA INTERNAL MEDICINE LA English DT Editorial Material C1 [Widera, Eric] Univ Calif San Francisco, Dept Internal Med, Div Geriatr, San Francisco, CA 94143 USA. [Widera, Eric] San Francisco VA Med Ctr, 4150 Clement St,Campus Box 181G, San Francisco, CA 94121 USA. [Talebreza, Shaida] Univ Utah, Sch Med, Dept Internal Med, Div Geriatr, Salt Lake City, UT USA. [Talebreza, Shaida] George E Wahlen Salt Lake City Vet Affairs Med Ct, Salt Lake City, UT USA. [Talebreza, Shaida] Inspirat Hosp, Salt Lake City, UT USA. RP Widera, E (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Campus Box 181G, San Francisco, CA 94121 USA. EM eric.widera@ucsf.edu NR 2 TC 2 Z9 2 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAR PY 2016 VL 176 IS 3 BP 370 EP 371 DI 10.1001/jamainternmed.2015.7931 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA DG7ZP UT WOS:000372302500017 PM 26856885 ER PT J AU Kim, TY Schafer, AL AF Kim, Tiffany Y. Schafer, Anne L. TI Variability in DXA Reporting and Other Challenges in Osteoporosis Evaluation SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID PREVENTION; FRACTURE; THERAPY C1 [Kim, Tiffany Y.; Schafer, Anne L.] San Francisco VA Med Ctr, Endocrine Res Unit, 1700 Owens St,Room 367, San Francisco, CA 94158 USA. RP Schafer, AL (reprint author), San Francisco VA Med Ctr, Endocrine Res Unit, 1700 Owens St,Room 367, San Francisco, CA 94158 USA. EM anne.schafer@ucsf.edu FU CSRD VA [IK2 CX000549] NR 7 TC 1 Z9 1 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAR PY 2016 VL 176 IS 3 BP 393 EP 395 DI 10.1001/jamainternmed.2015.7550 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA DG7ZP UT WOS:000372302500025 PM 26746871 ER PT J AU Waltz, P Luciano, J Peitzman, A Zuckerbraun, BS AF Waltz, Paul Luciano, Jason Peitzman, Andrew Zuckerbraun, Brian S. TI Femoral Hernias in Patients Undergoing Total Extraperitoneal Laparoscopic Hernia Repair: Including Routine Evaluation of the Femoral Canal in Approaches to Inguinal Hernia Repair SO JAMA SURGERY LA English DT Letter C1 [Waltz, Paul; Luciano, Jason; Peitzman, Andrew; Zuckerbraun, Brian S.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA. [Zuckerbraun, Brian S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Zuckerbraun, BS (reprint author), Univ Pittsburgh, Dept Surg, VA Pittsburgh Healthcare Syst, F1267 PUH,200 Lothrop St, Pittsburgh, PA 15213 USA. EM zuckerbraunbs@upmc.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD MAR PY 2016 VL 151 IS 3 BP 292 EP 293 DI 10.1001/jamasurg.2015.3402 PG 3 WC Surgery SC Surgery GA DG7TI UT WOS:000372286200024 PM 26558846 ER PT J AU Kansagara, D Chiovaro, JC Kagen, D Jencks, S Rhyne, K O'Neil, M Kondo, K Relevo, R Motu'apuaka, M Freeman, M Englander, H AF Kansagara, Devan Chiovaro, Joseph C. Kagen, David Jencks, Stephen Rhyne, Kerry O'Neil, Maya Kondo, Karli Relevo, Rose Motu'apuaka, Makalapua Freeman, Michele Englander, Honora TI So many options, where do we start? An overview of the care transitions literature SO JOURNAL OF HOSPITAL MEDICINE LA English DT Review ID RANDOMIZED CLINICAL-TRIAL; ACUTE CORONARY SYNDROME; HEART-FAILURE; FOLLOW-UP; HOSPITAL DISCHARGE; SYSTEMATIC REVIEWS; METAANALYSIS; HOME; INTERVENTIONS; READMISSIONS AB BACKGROUNDHealth systems are faced with a large array of transitional care interventions and patient populations to whom such activities might apply. PURPOSETo summarize the health and utilization effects of transitional care interventions, and to identify common themes about intervention types, patient populations, or settings that modify these effects. DATA SOURCESPubMed and Cochrane Database of Systematic Reviews (January 1950-May 2014), reference lists, and technical advisors. STUDY SELECTIONSystematic reviews of transitional care interventions that reported hospital readmission as an outcome. DATA EXTRACTIONWe extracted transitional care procedures, patient populations, settings, readmissions, and health outcomes. We identified commonalities and compiled a narrative synthesis of emerging themes. DATA SYNTHESISAmong 10 reviews of mixed patient populations, there was consistent evidence that enhanced discharge planning and hospital-at-home interventions reduced readmissions. Among 7 reviews in specific patient populations, transitional care interventions reduced readmission in patients with congestive heart failure and general medical populations. In general, interventions that reduced readmission addressed multiple aspects of the care transition, extended beyond hospital stay, and had the flexibility to accommodate individual patient needs. There was insufficient evidence on how caregiver involvement, transition to sites other than home, staffing, patient selection practices, or care settings modified intervention effects. CONCLUSIONSSuccessful interventions are comprehensive, extend beyond hospital stay, and have the flexibility to respond to individual patient needs. The strength of evidence should be considered low because of heterogeneity in the interventions studied, patient populations, clinical settings, and implementation strategies. Journal of Hospital Medicine 2016;11:221-230. (c) 2015 Society of Hospital Medicine. C1 [Kansagara, Devan; Chiovaro, Joseph C.; Kagen, David; Rhyne, Kerry; Freeman, Michele] VA Portland Hlth Care Syst, Dept Med, Portland, OR USA. [Kansagara, Devan; Chiovaro, Joseph C.; Kagen, David; Rhyne, Kerry; Englander, Honora] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Kansagara, Devan; O'Neil, Maya; Kondo, Karli; Relevo, Rose; Motu'apuaka, Makalapua; Freeman, Michele] Portland VA Evidence Based Synth Program, Portland, OR USA. RP Kansagara, D (reprint author), Portland VA Med Ctr, Mailcode RD71,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM kansagar@ohsu.edu FU Department of Veterans Affairs, Veterans Health Administration (VHA) [ESP 05-225, 01-0206]; Quality Enhancement Research Initiative, Department of Veterans Affairs [05-225] FX The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration (VHA) Project ESP 05-225, VA#01-0206. Dr. Jencks' work on this project was supported in part by a grant from the Quality Enhancement Research Initiative (05-225), Department of Veterans Affairs. Dr. Jencks has reported prior consulting work with the following entities: Inovalon, Care Centrix, Affymax, Curaspan, Reinforced Care, Health Services Advisory Group, Delmarva Foundation, Connecticut Peer Review Organization, Maryland Health Services Cost Review Commission, Institute for Healthcare Improvement, American Association for Respiratory Care, Monaghan Medical, Iowa Society for Respiratory Care. NR 38 TC 6 Z9 6 U1 6 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD MAR PY 2016 VL 11 IS 3 BP 221 EP 230 DI 10.1002/jhm.2502 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA DG8JQ UT WOS:000372330500011 PM 26551918 ER PT J AU Lyerly, MJ Wu, TC Mullen, MT Albright, KC Wolff, C Boehme, AK Branas, CC Grotta, JC Savitz, SI Carr, BG AF Lyerly, Michael J. Wu, Tzu-Ching Mullen, Michael T. Albright, Karen C. Wolff, Catherine Boehme, Amelia K. Branas, Charles C. Grotta, James C. Savitz, Sean I. Carr, Brendan G. TI The effects of telemedicine on racial and ethnic disparities in access to acute stroke care SO JOURNAL OF TELEMEDICINE AND TELECARE LA English DT Article DE Teleneurology; tele-stroke; healthcare access; racial minorities; ethnic minorities; telemedicine ID TISSUE-PLASMINOGEN ACTIVATOR; AMERICAN-HEART-ASSOCIATION; ACUTE ISCHEMIC-STROKE; UNITED-STATES; OUTCOMES; CENTERS; TIME; RECOMMENDATIONS; THROMBOLYSIS; TELESTROKE AB Racial and ethnic disparities have been previously reported in acute stroke care. We sought to determine the effect of telemedicine (TM) on access to acute stroke care for racial and ethnic minorities in the state of Texas. Data were collected from the US Census Bureau, The Joint Commission and the American Hospital Association. Access for racial and ethnic minorities was determined by summing the population that could reach a primary stroke centre (PSC) or telemedicine spoke within specified time intervals using validated models. TM extended access to stroke expertise by 1.5 million residents. The odds of providing 60-minute access via TM were similar in Blacks and Whites (prevalence odds ratios (POR) 1.000, 95% CI 1.000-1.000), even after adjustment for urbanization (POR 1.000, 95% CI 1.000-1.001). The odds of providing access via TM were also similar for Hispanics and non-Hispanics (POR 1.000, 95% CI 1.000-1.000), even after adjustment for urbanization (POR 1.000, 95% CI 1.000-1.000). We found that telemedicine increased access to acute stroke care for 1.5 million Texans. While racial and ethnic disparities exist in other components of stroke care, we did not find evidence of disparities in access to the acute stroke expertise afforded by telemedicine. C1 [Lyerly, Michael J.] Univ Alabama Birmingham, Dept Neurol, 1813 6th Ave South,RWUH M226, Birmingham, AL 35294 USA. [Lyerly, Michael J.] Birmingham Vet Affairs Med Ctr, Stroke Program, Birmingham, AL USA. [Wu, Tzu-Ching; Grotta, James C.; Savitz, Sean I.] Univ Texas Houston, Mem Hermann Med Ctr, Dept Neurol, Houston, TX USA. [Mullen, Michael T.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Albright, Karen C.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA. [Albright, Karen C.] Univ Alabama Birmingham, Hlth Serv & Outcomes Res Ctr Outcome & Effectiven, Birmingham, AL 35294 USA. [Albright, Karen C.] Univ Alabama Birmingham, Ctr Excellence Comparat Effectiveness Res Elimina, Minor Hlth & Hlth Dispar Res Ctr MHRC, Birmingham, AL 35294 USA. [Albright, Karen C.] Birmingham Vet Affairs Med Ctr, GRECC, Birmingham, AL USA. [Wolff, Catherine] Duke Univ, Sch Med, Durham, NC USA. [Boehme, Amelia K.] Columbia Univ, Dept Neurol, Gertrude Sergievsky Ctr, New York, NY USA. [Branas, Charles C.] Univ Penn, Dept Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Carr, Brendan G.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA. RP Lyerly, MJ (reprint author), Univ Alabama Birmingham, Dept Neurol, 1813 6th Ave South,RWUH M226, Birmingham, AL 35294 USA. EM mjlyerly@uab.edu OI Lyerly, Michael/0000-0003-4236-1018 FU AHRQ HHS [5 T32 HS013852-10]; NIMHD NIH HHS [P60 MD000502, 3 P60 MD000502-08S1]; None [HS013852] NR 52 TC 3 Z9 3 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1357-633X EI 1758-1109 J9 J TELEMED TELECARE JI J. Telemed. Telecare PD MAR PY 2016 VL 22 IS 2 BP 114 EP 120 DI 10.1177/1357633X15589534 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DG4XG UT WOS:000372075900005 PM 26116854 ER PT J AU Vedire, K Joselow, AL Markham, CM Raugi, GJ AF Vedire, Kirtana Joselow, Andrew L. Markham, Craig M. Raugi, Gregory J. TI Teledermatology-directed surgical care is safe and reduces travel SO JOURNAL OF TELEMEDICINE AND TELECARE LA English DT Article DE Telemedicine; teledermatology; melanoma; severely dysplastic nevi; primary care clinicians ID GENERAL-PRACTITIONERS; MELANOMA; EXCISION; REFERRALS; PROGRAM AB Methods: We conducted a retrospective chart review and identified 186 Veterans in the VA Corporate Data Warehouse as having malignant melanomas or severely dysplastic nevi during the four-year period of observation from 1 July 2009 to 30 June 2013 and met inclusion and exclusion criteria for analysis. Results: Three hundred and sixty-six surgical procedures were performed for diagnosis and treatment of these conditions including biopsy and wide-local excision, of which 189 carefully selected cases were performed by primary care clinicians with 2.0% biopsy complication rate and a 7.7% wide-local excision complication rate. Cases not performed by primary care providers were referred to specialists (e.g. dermatologists, general surgeons or specialty surgeons) who had a 2.5% complication rate in biopsies and wide-local excision complication rate of 13.5% in severely dysplastic nevi and pTis and pT1a lesions and a 10.7% complication rate for lesions pT1b and greater. Discussion: These results show that a significant fraction of surgical procedures for diagnosis and treatment of malignant melanoma and severely dysplastic nevi can be safely performed in rural clinics by trained primary care providers. C1 [Vedire, Kirtana; Joselow, Andrew L.; Markham, Craig M.; Raugi, Gregory J.] VA Puget Sound Hlth Care Syst, Seattle Div, Washington, DC USA. [Joselow, Andrew L.] Tulane Univ, Sch Med, 1430 Tulane Ave, New Orleans, LA 70112 USA. [Raugi, Gregory J.] Univ Washington, Dept Med Dermatol, Seattle, WA 98195 USA. RP Raugi, GJ (reprint author), VISN20 Teledermatol,Fed Off Bldg,Suite 630, Seattle, WA 98104 USA. EM gregory.raugi@va.gov FU US Department of Veterans Affairs; VISN20 Office of Rural Health Services; Office of Rural Health FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: US Department of Veterans Affairs, VISN20 Office of Rural Health Services, and the Office of Rural Health. NR 17 TC 0 Z9 0 U1 0 U2 3 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1357-633X EI 1758-1109 J9 J TELEMED TELECARE JI J. Telemed. Telecare PD MAR PY 2016 VL 22 IS 2 BP 121 EP 126 DI 10.1177/1357633X15589861 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DG4XG UT WOS:000372075900006 PM 26116856 ER PT J AU Moriarty, H Winter, L Piersol, C Vause-Earland, T Robinson, K Newhart, B AF Moriarty, Helene Winter, Laraine Piersol, Catherine Vause-Earland, Tracey Robinson, Keith Newhart, Brian TI Patient-Centered and Family-Centered Outcomes in Intervention Research: Use of Target Outcomes in a Study with Veterans with Traumatic Brain Injury and Their Family Members SO NURSING RESEARCH LA English DT Meeting Abstract C1 [Moriarty, Helene] Villanova Univ, Villanova, PA 19085 USA. [Winter, Laraine; Robinson, Keith; Newhart, Brian] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Piersol, Catherine; Vause-Earland, Tracey] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-6562 EI 1538-9847 J9 NURS RES JI Nurs. Res. PD MAR-APR PY 2016 VL 65 IS 2 BP E71 EP E71 PG 1 WC Nursing SC Nursing GA DG6SA UT WOS:000372215200194 ER PT J AU Moreno, CC Mittal, PK Ghonge, NP Bhargava, P Heller, MT AF Moreno, Courtney Coursey Mittal, Pardeep K. Ghonge, Nitin P. Bhargava, Puneet Heller, Matthew T. TI Imaging Complications of Renal Transplantation SO RADIOLOGIC CLINICS OF NORTH AMERICA LA English DT Article DE Renal transplantation; Complications of renal transplantation; Renal artery stenosis; Renal vein thrombosis; Collecting system injury; Lymphocele; Urinoma; Posttransplant lymphoproliferative disorder ID CHRONIC ALLOGRAFT NEPHROPATHY; DELAYED GRAFT FUNCTION; ARTERY-STENOSIS; RISK-FACTORS; KIDNEY-TRANSPLANTATION; VASCULAR COMPLICATIONS; MULTIVARIATE-ANALYSIS; DOPPLER SONOGRAPHY; RESISTIVE INDEX; ACUTE REJECTION AB Renal transplant complications are categorized as those related to the transplant vasculature, collecting system, perinephric space, renal parenchyma, and miscellaneous complications including posttransplant lymphoproliferative disorder. Many of these renal transplant complications are diagnosed with imaging. Medical complications including rejection, acute tubular necrosis, and drug toxicity also can impair renal function. These medical complications are typically indistinguishable at imaging, and biopsy may be performed to establish a diagnosis. Normal transplant anatomy, imaging techniques, and the appearances of renal transplant complications at ultrasound, computed tomography, and MR imaging are reviewed. C1 [Moreno, Courtney Coursey; Mittal, Pardeep K.] Emory Univ, Sch Med, Dept Radiol & Imaging Sci, 1364 Clifton Rd NE, Atlanta, GA 30322 USA. [Ghonge, Nitin P.] Indraprastha Apollo Hosp, Dept Radiol, Delhi Mathura Rd, New Delhi 110076, India. [Bhargava, Puneet] Univ Washington, Med Ctr, Dept Radiol, VA Puget Sound Hlth Care Syst, 1959 NE Pacific St,Room BB308,Box 357115, Seattle, WA 98195 USA. [Heller, Matthew T.] Univ Pittsburgh, Sch Med, Dept Radiol, 200 Lothrop St,Suite 174E PUH, Pittsburgh, PA 15213 USA. RP Moreno, CC (reprint author), Emory Univ, Sch Med, Dept Radiol & Imaging Sci, 1364 Clifton Rd NE, Atlanta, GA 30322 USA. EM courtney.moreno@emoryhealthcare.org OI Mittal, Pardeep/0000-0002-3302-8590 NR 62 TC 2 Z9 2 U1 1 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0033-8389 EI 1557-8275 J9 RADIOL CLIN N AM JI Radiol. Clin. N. Am. PD MAR PY 2016 VL 54 IS 2 BP 235 EP + DI 10.1016/j.rcl.2015.09.007 PG 17 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DH4QN UT WOS:000372770600005 PM 26896222 ER PT J AU Backhus, LM Mulligan, MS Ha, R Shriki, JE Mohammed, TLH AF Backhus, Leah M. Mulligan, Michael S. Ha, Richard Shriki, Jabi E. Mohammed, Tan-Lucien H. TI Imaging in Lung Transplantation Surgical Considerations of Donor and Recipient SO RADIOLOGIC CLINICS OF NORTH AMERICA LA English DT Article DE Lung transplant; Transplant evaluation; Transplant surgery; Computed tomography ID IDIOPATHIC PULMONARY-FIBROSIS; TRAUMATIC CARDIOPULMONARY ARREST; VOLUME REDUCTION SURGERY; INTERNATIONAL-SOCIETY; CYSTIC-FIBROSIS; ORGAN DONATION; FLEISCHNER-SOCIETY; SIZE MISMATCH; BRAIN-DEATH; MANAGEMENT AB Modifications in recipient and donor criteria and innovations in donor management hold promise for increasing rates of lung transplantation, yet availability of donors remains a limiting resource. Imaging is critical in the work-up of donor and recipient including identification of conditions that may portend to poor posttransplant outcomes or necessitate modifications in surgical technique. This article describes the radiologic principles that guide selection of patients and surgical procedures in lung transplantation. C1 [Backhus, Leah M.; Ha, Richard] Stanford Univ, Dept Cardiothorac Surg, 300 Pasteur Dr,Falk Bldg, Stanford, CA 94304 USA. [Mulligan, Michael S.] Univ Washington, Dept Surg, Div Cardiothorac Surg, Seattle, WA 98195 USA. [Shriki, Jabi E.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Shriki, Jabi E.] VA Puget Sound Hlth Care Syst, Diagnost Imaging Serv, Seattle, WA USA. [Mohammed, Tan-Lucien H.] Univ Florida, Coll Med, Dept Radiol, Gainesville, FL 32610 USA. RP Backhus, LM (reprint author), Stanford Univ, Dept Cardiothorac Surg, 300 Pasteur Dr,Falk Bldg, Stanford, CA 94304 USA. EM lbackhus@stanford.edu NR 67 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0033-8389 EI 1557-8275 J9 RADIOL CLIN N AM JI Radiol. Clin. N. Am. PD MAR PY 2016 VL 54 IS 2 BP 339 EP + DI 10.1016/j.rcl.2015.09.013 PG 16 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DH4QN UT WOS:000372770600011 PM 26896228 ER PT J AU Bahney, CS Jacobs, L Tamai, R Hu, D Luan, TF Wang, MQ Reddy, S Park, M Limburg, S Kim, HT Marcucio, R Kuo, AC AF Bahney, Chelsea S. Jacobs, Linsey Tamai, Robert Hu, Diane Luan, Tammy F. Wang, Miqi Reddy, Sanjay Park, Michelle Limburg, Sonja Kim, Hubert T. Marcucio, Ralph Kuo, Alfred C. TI Promoting Endochondral Bone Repair Using Human Osteoarthritic Articular Chondrocytes SO TISSUE ENGINEERING PART A LA English DT Article ID MESENCHYMAL STEM-CELLS; IN-VIVO; CARTILAGE REPAIR; GENE-EXPRESSION; OSSIFICATION; HYDROGELS; DEFECTS; CULTURE AB Introduction: Current tissue engineering strategies to heal critical-size bone defects through direct bone formation are limited by incomplete integration of grafts with host bone and incomplete graft vascularization. An alternative strategy for bone regeneration is the use of cartilage grafts that form bone through endochondral ossification. Endochondral cartilages stimulate angiogenesis and are remodeled into bone, but are found in very small quantities in growth plates and healing fractures. We sought to develop engineered endochondral cartilage grafts using osteoarthritic (OA) articular chondrocytes as a cell source. Such chondrocytes often undergo hypertrophy, which is a characteristic of endochondral cartilages. Materials and Methods: We compared the ability of unmodified human OA (hOA) cartilage and cartilage grafts formed in vitro from hOA chondrocytes to undergo endochondral ossification in mice. Scaffold-free engineered chondrocyte grafts were generated by pelleting chondrocytes, followed by culture with transforming growth factor-beta 1 (TGF-beta 1) and bone morphogenetic protein 4. Samples derived from either primary or passaged chondrocytes were implanted subcutaneously into immunocompromised mice. Grafts derived from passaged chondrocytes from three patients were implanted into critical-size tibial defects in mice. Bone formation was assessed with histology after 4 weeks of implantation. The composition of tibial repair tissue was quantified with histomorphometry. Results: Engineered cartilage grafts generated from passaged OA chondrocytes underwent endochondral ossification after implantation either subcutaneously or in bone. Cartilage grafts integrated with host bone at 15 out of 16 junctions. Grafts variably remodeled into woven bone, with the proportion of bony repair tissue in tibial defects ranging from 22% to 85% (average 48%). Bony repair tissue bridged the tibial defects in half of the animals. In contrast, unmodified OA cartilage and engineered grafts formed from primary chondrocytes did not undergo endochondral ossification in vivo. Conclusions: hOA chondrocytes can adopt an endochondral phenotype after passaging and TGF-beta superfamily treatment. Engineered endochondral cartilage grafts can integrate with host bone, undergo ossification, and heal critical-size long-bone defects in a mouse model. However, additional methods to further enhance ossification of these grafts are required before the clinical translation of this approach. C1 [Bahney, Chelsea S.; Hu, Diane; Marcucio, Ralph] Univ Calif San Francisco, Orthopaed Trauma Inst, San Francisco Gen Hosp, San Francisco, CA 94121 USA. [Jacobs, Linsey; Tamai, Robert; Luan, Tammy F.; Wang, Miqi; Reddy, Sanjay; Park, Michelle; Limburg, Sonja; Kim, Hubert T.; Kuo, Alfred C.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, 4150 Clement St,Box 112, San Francisco, CA 94121 USA. RP Kuo, AC (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, 4150 Clement St,Box 112, San Francisco, CA 94121 USA. EM kuoac@orthosurg.ucsf.edu FU National Institute of Arthritis and Musculoskeletal and Skin Disease (NIAMS) of the National Institutes of Health (NIH) [5F32AR062469]; Musculoskeletal Transplant Foundation; UCSF Graduate Education in Medical Sciences (GEMS); UCSF Department of Orthopaedic Surgery; San Francisco Veterans Affairs Medical Center FX Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Disease (NIAMS) of the National Institutes of Health (NIH) under the following award numbers: CSB (#5F32AR062469). Additional research support was provided by the Musculoskeletal Transplant Foundation (CSB: MTF Junior Investigator Award), the UCSF Graduate Education in Medical Sciences (GEMS), the UCSF Department of Orthopaedic Surgery, and the San Francisco Veterans Affairs Medical Center. NR 31 TC 0 Z9 1 U1 3 U2 8 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1937-3341 EI 1937-335X J9 TISSUE ENG PT A JI Tissue Eng. Part A PD MAR 1 PY 2016 VL 22 IS 5-6 BP 427 EP 435 DI 10.1089/ten.tea.2014.0705 PG 9 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology SC Cell Biology; Biotechnology & Applied Microbiology GA DH0FL UT WOS:000372457800005 PM 26830207 ER PT J AU Allott, EH Howard, LE Aronson, WJ Terris, MK Kane, CJ Amling, CL Cooperberg, MR Freedland, SJ AF Allott, Emma H. Howard, Lauren E. Aronson, William J. Terris, Martha K. Kane, Christopher J. Amling, Christopher L. Cooperberg, Matthew R. Freedland, Stephen J. TI Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID AFRICAN-AMERICAN; RISK; MEN; COHORT; ATHEROSCLEROSIS; MORTALITY; IMPACT; GRADE; CELLS AB Background: Black men are disproportionately affected by both cardiovascular disease and prostate cancer. Epidemiologic evidence linking dyslipidemia, an established cardiovascular risk factor, and prostate cancer progression is mixed. As existing studies were conducted in predominantly non-black populations, research on black men is lacking. Methods: We identified 628 black and 1,020 non-black men who underwent radical prostatectomy and never used statins before surgery in the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Median follow-up was 2.9 years. The impact of preoperative hypercholesterolemia on risk of biochemical recurrence was examined using multivariable, race-stratified proportional hazards. In secondary analysis, we examined associations with low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides, overall and among men with dyslipidemia. Results: High cholesterol was associated with increased risk of recurrence in black [HRper10 (mg/dL) 1.06; 95% confidence interval (CI), 1.02-1.11] but not non-black men (HRper10 mg/dL 0.99; 95% CI, 0.95-1.03; P-interaction = 0.011). Elevated triglycerides were associated with increased risk in both black and non-black men (HRper10 mg/dL 1.02; 95% CI, 1.00-1.03 and 1.02; 95% CI, 1.00-1.02, respectively; P-interaction = 0.458). There were no significant associations between LDL or HDL and recurrence risk in either race. Associations with cholesterol, LDL, and triglycerides were similar among men with dyslipidemia, but low HDL was associated with increased risk of recurrence in black, but not non-black men with dyslipidemia (P-interaction = 0.047). Conclusion: Elevated cholesterol was a risk factor for recurrence in black but not non-black men, whereas high triglycerides were associated with increased risk regardless of race. Impact: Significantly contrasting associations by race may provide insight into prostate cancer racial disparities. (C) 2016 AACR. C1 [Allott, Emma H.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Allott, Emma H.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Howard, Lauren E.] Duke Univ, Sch Med, Dept Biostat & Bioinformat, Durham, NC USA. [Aronson, William J.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA. [Aronson, William J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. [Terris, Martha K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA. [Terris, Martha K.] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA. [Kane, Christopher J.] Univ Calif San Diego Hlth Syst, Dept Urol, San Diego, CA USA. [Amling, Christopher L.] Oregon Hlth & Sci Univ, Div Urol, Portland, OR 97201 USA. [Cooperberg, Matthew R.] UCSF Helen Diller Family Comprehens Canc Ctr, Dept Urol, San Francisco, CA USA. [Freedland, Stephen J.] Cedars Sinai Med Ctr, 8635 West 3rd St,Suite 1070W, Los Angeles, CA 90048 USA. [Freedland, Stephen J.] Vet Affairs Med Ctr, Div Urol, Durham, NC USA. RP Freedland, SJ (reprint author), Cedars Sinai Med Ctr, 8635 West 3rd St,Suite 1070W, Los Angeles, CA 90048 USA. EM stephen.freedland@cshs.org FU NIH [1K24CA160653, P50CA92131]; University Cancer Research Fund of North Carolina FX This study was supported by grants from NIH [1K24CA160653 (to S.J. Freedland) and P50CA92131 (to W.J. Aronson)] and by the University Cancer Research Fund of North Carolina (to E.H. Allott). NR 32 TC 0 Z9 0 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD MAR PY 2016 VL 25 IS 3 BP 547 EP 554 DI 10.1158/1055-9965.EPI-15-0876 PG 8 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA DG6EA UT WOS:000372173900015 PM 26809276 ER PT J AU Mackin, RS Vigil, O Insel, P Kivowitz, A Kupferman, E Hough, CM Fekri, S Crothers, R Bickford, D Delucchi, KL Mathews, CA AF Mackin, R. Scott Vigil, Ofilio Insel, Philip Kivowitz, Alana Kupferman, Eve Hough, Christina M. Fekri, Shiva Crothers, Ross Bickford, David Delucchi, Kevin L. Mathews, Carol A. TI PATTERNS OF CLINICALLY SIGNIFICANT COGNITIVE IMPAIRMENT IN HOARDING DISORDER SO DEPRESSION AND ANXIETY LA English DT Article DE hoarding disorder; cognitive impairment; executive dysfunction; categorization; information processing speed; memory; attention ID OBSESSIVE-COMPULSIVE DISORDER; SYMPTOM DIMENSIONS; OLDER-ADULTS; EXECUTIVE FUNCTION; DECISION-MAKING; DEPRESSION; INVENTORY; ATTENTION; VALIDITY; THERAPY AB ObjectivesThe cognitive characteristics of individuals with hoarding disorder (HD) are not well understood. Existing studies are relatively few and somewhat inconsistent but suggest that individuals with HD may have specific dysfunction in the cognitive domains of categorization, speed of information processing, and decision making. However, there have been no studies evaluating the degree to which cognitive dysfunction in these domains reflects clinically significant cognitive impairment (CI). MethodsParticipants included 78 individuals who met DSM-V criteria for HD and 70 age- and education-matched controls. Cognitive performance on measures of memory, attention, information processing speed, abstract reasoning, visuospatial processing, decision making, and categorization ability was evaluated for each participant. Rates of clinical impairment for each measure were compared, as were age- and education-corrected raw scores for each cognitive test. ResultsHD participants showed greater incidence of CI on measures of visual memory, visual detection, and visual categorization relative to controls. Raw-score comparisons between groups showed similar results with HD participants showing lower raw-score performance on each of these measures. In addition, in raw-score comparisons HD participants also demonstrated relative strengths compared to control participants on measures of verbal and visual abstract reasoning. ConclusionsThese results suggest that HD is associated with a pattern of clinically significant CI in some visually mediated neurocognitive processes including visual memory, visual detection, and visual categorization. Additionally, these results suggest HD individuals may also exhibit relative strengths, perhaps compensatory, in abstract reasoning in both verbal and visual domains. C1 [Mackin, R. Scott; Vigil, Ofilio; Kivowitz, Alana; Kupferman, Eve; Hough, Christina M.; Crothers, Ross; Bickford, David; Delucchi, Kevin L.; Mathews, Carol A.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Mackin, R. Scott; Insel, Philip] San Francisco VA Med Ctr, San Francisco, CA USA. [Fekri, Shiva] Univ Colorado, Dept Psychol, Denver, CO 80202 USA. RP Mackin, RS (reprint author), Univ Calif San Francisco, Langley Porter Psychiat Inst, Dept Psychiat, 401 Parnassus Ave,Box F-0984, San Francisco, CA 94143 USA. EM Scott.Mackin@ucsf.edu RI Hough, Christina/K-2416-2016 OI Hough, Christina/0000-0002-8864-5262 FU NIMH [R21 MH087748, K08 MH081065, R01 0977669]; Patient-Centered Outcomes Research Institute (PCORI) Award [6000] FX Contract grant sponsor: NIMH; Grant numbers: R21 MH087748, K08 MH081065, R01 0977669. The Althea Foundation and a Patient-Centered Outcomes Research Institute (PCORI) Award; Contract number: 6000. NR 46 TC 3 Z9 3 U1 6 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 EI 1520-6394 J9 DEPRESS ANXIETY JI Depress. Anxiety PD MAR PY 2016 VL 33 IS 3 BP 211 EP 218 DI 10.1002/da.22439 PG 8 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA DG6FY UT WOS:000372179800005 PM 26474146 ER PT J AU Achuko, O Walker, RJ Campbell, JA Dawson, AZ Egede, LE AF Achuko, Obinna Walker, Rebekah J. Campbell, Jennifer A. Dawson, Aprill Z. Egede, Leonard E. TI Pathways Between Discrimination and Quality of Life in Patients with Type 2 Diabetes SO DIABETES TECHNOLOGY & THERAPEUTICS LA English DT Article ID REPORTED RACIAL-DISCRIMINATION; RANDOMIZED CONTROLLED-TRIAL; PERCEIVED DISCRIMINATION; SOCIAL DETERMINANTS; AFRICAN-AMERICAN; GLYCEMIC CONTROL; HEALTH-CARE; EVERYDAY DISCRIMINATION; PSYCHOLOGICAL DISTRESS; WEIGHT DISCRIMINATION AB Background: Discrimination is a social determinant that has been linked to poor physical and mental health outcomes. This study aimed to examine the pathway whereby discrimination influences quality of life in patients with type 2 diabetes. Subjects and Methods: Six hundred fifteen patients were recruited from two adult primary care clinics in the southeastern United States. Measures included perceived discrimination, perceived stress, social support, and social cohesion and were based on a theoretical model for the pathways by which perceived discrimination influences mental and physical health. Quality of life was measured using the SF-12 questionnaire. Results: The final model [chi(2)(106) = 157.35, P = 0.009, R-2 = 0.99, root mean square error of approximation = 0.03, comparative fit index = 0.99] indicates direct effects of higher perceived stress (r = -1.02, P < 0.05) and lower social support (r = 0.36, P < 0.001) significantly related to decreased mental health component score (MCS) of quality of life. Discrimination and social cohesion were not significantly directly related to MCS. However, higher discrimination (r = 0.47, P < 0.001), higher social cohesion (r = 0.14, P < 0.05), and lower social support (r = -0.43, P < 0.001) were significantly directly related to increased stress. No significant paths were found for the physical component score of quality of life. Conclusions: Perceived discrimination was significantly associated with stress and served as a pathway to influence the mental health component of quality of life (MCS). Social support had a direct and an indirect effect on MCS through a negative association with stress. These results suggest that future interventions should be developed to decrease stress and increase social support surrounding discrimination to improve the MCS of quality of life in patients with diabetes. C1 [Achuko, Obinna; Walker, Rebekah J.; Campbell, Jennifer A.; Dawson, Aprill Z.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280, Charleston, SC 29425 USA. [Walker, Rebekah J.; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Charleston VA Hlth Serv Res & Dev COIN, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA. [Walker, Rebekah J.; Egede, Leonard E.] Med Univ S Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280, Charleston, SC 29425 USA. EM egedel@musc.edu FU National Institute of Diabetes and Digestive and Kidney Disease [K24DK093699-01] FX This study was supported by grant K24DK093699-01 from the National Institute of Diabetes and Digestive and Kidney Disease (Principal Investigator: L.E.E.). NR 58 TC 1 Z9 1 U1 2 U2 4 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1520-9156 EI 1557-8593 J9 DIABETES TECHNOL THE JI Diabetes Technol. Ther. PD MAR 1 PY 2016 VL 18 IS 3 BP 151 EP 158 DI 10.1089/dia.2015.0305 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DG6HE UT WOS:000372183700008 PM 26866351 ER PT J AU McGinley, KF Sun, XZ Howard, LE Aronson, WJ Terris, MK Kane, CJ Amling, CL Cooperberg, MR Freedland, SJ AF McGinley, Kathleen F. Sun, Xizi Howard, Lauren E. Aronson, William J. Terris, Martha K. Kane, Christopher J. Amling, Christopher L. Cooperberg, Matthew R. Freedland, Stephen J. TI Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database SO INTERNATIONAL JOURNAL OF UROLOGY LA English DT Article DE lymph node excision; prostatectomy; prostatic neoplasms; quality of health care; robotic surgical procedures ID MEN; UPDATE AB ObjectiveTo evaluate performance of pelvic lymph node dissection during radical prostatectomy within an equal access care setting over a period of time, and stratified by prostate cancer risk group and surgical technique. MethodsWe identified men in the Shared Equal Access Regional Cancer Hospital database who had open or robotic-assisted radical prostatectomy from 2006 to 2013. Univariable logistic regression was used to test the association between age, race, body mass index, total biopsy cores, number of positive biopsy cores, risk group, year, center, surgical volume and surgical technique on pelvic lymph node dissection use. Multivariable logistic analysis was used to examine surgical technique and pelvic lymph node dissection performance. Spearman's correlation examined temporal changes in pelvic lymph node dissection utilization stratified by risk group and surgical technique. ResultsA total of 1425 men met inclusion criteria; 67% of them underwent pelvic lymph node dissection. On multivariable analysis, robotic-assisted radical prostatectomy was associated with an 92% decreased use of pelvic lymph node dissection in low-risk, 84% decreased in intermediate-risk and 91% decreased in high-risk men (all P < 0.001). In robotic-assisted radical prostatectomy, there was a trend for increased pelvic lymph node dissection utilization over time in high-risk men (Spearman; P = 0.077) reaching similar to 85% in 2012-2013, which was accompanied by increased use in low-risk men (P = 0.016). For open radical prostatectomy, fewer pelvic lymph node dissections were carried out in low-risk men over time, decreasing to similar to 35% (P = 0.047) in 2012-2013, whereas rates remained high for high-risk men throughout (similar to 95%; P = 0.621). ConclusionRegardless of risk group, pelvic lymph node dissection is carried out significantly less during robotic-assisted radical prostatectomy. For robotic-assisted radical prostatectomy, pelvic lymph node dissection utilization increased over time for high-risk men, but rates also increased for low-risk men. Further attention to the discrepancy between provided and guideline recommended pelvic lymph node dissection performance is required to improve prostate cancer care. C1 [McGinley, Kathleen F.] Duke Univ, Dept Surg, Div Urol, Durham, NC USA. [McGinley, Kathleen F.; Sun, Xizi; Howard, Lauren E.; Freedland, Stephen J.] Vet Affairs Med Ctr, Dept Surg, Div Urol, Durham, NC USA. [Sun, Xizi; Howard, Lauren E.] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA. [Aronson, William J.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA. [Aronson, William J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. [Terris, Martha K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA. [Terris, Martha K.] Georgia Regents Univ, Dept Urol, Augusta, GA USA. [Kane, Christopher J.] Univ Calif San Diego Hlth Syst, Dept Urol, San Diego, CA USA. [Amling, Christopher L.] Oregon Hlth & Sci Univ, Dept Urol, Portland, OR 97201 USA. [Cooperberg, Matthew R.] UCSF Helen Diller Family Comprehens Canc Ctr, Dept Urol, San Francisco, CA USA. [Freedland, Stephen J.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Ctr, Dept Surg, Div Urol, Los Angeles, CA 90048 USA. RP Freedland, SJ (reprint author), Cedars Sinai Med Ctr, 8635 West 3rd St,Suite 1070W, Los Angeles, CA 90048 USA. EM stephen.freedland@cshs.org NR 21 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0919-8172 EI 1442-2042 J9 INT J UROL JI Int. J. Urol. PD MAR PY 2016 VL 23 IS 3 BP 241 EP 246 DI 10.1111/iju.13027 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA DG5YH UT WOS:000372157100011 PM 26667212 ER PT J AU Harwood, NMK Golden-Mason, L Cheng, LL Rosen, HR Mengshol, JA AF Harwood, Noah M. K. Golden-Mason, Lucy Cheng, Linling Rosen, Hugo R. Mengshol, John A. TI HCV-infected cells and differentiation increase monocyte immunoregulatory galectin-9 production SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE JFH-1; non-classical monocyte; exosome ID HEPATITIS-C VIRUS; NATURAL-KILLER-CELLS; IN-VITRO; HEPATOCELLULAR-CARCINOMA; GLYCAN INTERACTIONS; SIGNALING PATHWAY; TIM-3 EXPRESSION; STRANDED-RNA; IMMUNITY; REPLICATION AB The lectin galectin-9 may help establish and maintain chronic hepatitis C virus infection. Galectin-9 is elevated in the liver and sera of hepatitis C virus patients, induces apoptosis of hepatitis C virus-specific T cells, and increases inhibitory regulatory T cells. Kupffer cells stain strongly for galectin-9 protein in hepatitis C virus patients. In the current study, we determined stimuli that induce galectin-9 production by monocytes and macrophages in hepatitis C virus infection. With the use of real-time PCR and flow cytometry, we analyzed galectin-9 mRNA and protein from human monocytes cocultured with hepatitis C virus-infected cells or noninfectious hepatitis C virus subgenomic replicon cells. We focused on finding the stimuli for galectin-9 production. Additionally, we measured galectin-9 during monocyte-to-macrophage maturation. Finally, we examined galectin-9 in peripheral monocytes from hepatitis C virus patients using flow cytometry. Galectin-9 mRNA increased 8-fold when primary monocytes were exposed to hepatitis C virus-infected cells. Maximum induction required proximity or contact and did not require IFN-gamma or hepatitis C virus virions. Coculture of monocytes with subgenomic replicon cells increased galectin-9 5-fold, and purified exosomes from infected cells stimulated galectin-9 production. Stimulation of monocyte TLR3, -7, and -8 increased galectin-9 production. Differentiation of monocytes to macrophages increased galectin-9, and nonclassic monocytes from hepatitis C virus patients had the highest levels of galectin-9. Hepatitis C virus-infected cells stimulated monocytes to produce galectin-9 in close proximity, possibly, in part, as a result of exosomes and endosomal TLRs. Differentiation of monocytes to macrophages increased galectin-9. Nonclassic monocytes from hepatitis C virus patients express the highest galectin-9 levels, suggesting they may contribute to elevated galectin-9 and adaptive immune inhibition in hepatitis C virus infection. C1 [Harwood, Noah M. K.; Golden-Mason, Lucy; Cheng, Linling; Rosen, Hugo R.; Mengshol, John A.] Univ Colorado, Sch Med, Denver VA Med Ctr, Div Gastroenterol & Hepatol, Denver, CO 80220 USA. RP Mengshol, JA (reprint author), Univ Colorado, Sch Med, Div Gastroenterol & Hepatol, 1055 Clermont St,Box 111E, Denver, CO 80220 USA. EM andy.mengshol@ucdenver.edu FU Denver Research Institute; Liver Scholar Award from American Association for the Study of Liver Disease; U.S. National Institutes of Health National Institute of Allergy and Infectious Diseases [R21-AI103361]; American Liver Foundation; VA Merit Review Grant FX J.A.M. is supported by the Denver Research Institute and a Liver Scholar Award from the American Association for the Study of Liver Disease and the American Liver Foundation. H.R.R. is funded by U.S. National Institutes of Health National Institute of Allergy and Infectious Diseases Grant R21-AI103361 and a VA Merit Review Grant. The authors thank our leukocyte donors for their generous contribution and Diana Ir and Katelyn Leahy for tissue-culture work. Additionally, the authors thank Harsh Pratap for flow cytometry assistance and Ron Bouchard for immunofluorescence guidance. Amy Stone provided valuable advice regarding TLR stimulation. NR 52 TC 1 Z9 1 U1 1 U2 3 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 EI 1938-3673 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD MAR PY 2016 VL 99 IS 3 BP 495 EP 503 DI 10.1189/jlb.5A1214-582R PG 9 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA DG2IO UT WOS:000371890800012 PM 26475932 ER PT J AU Tang, Y Chang, CCH Lave, JR Gellad, WF Huskamp, HA Donohue, JM AF Tang, Yan Chang, Chung-Chou H. Lave, Judith R. Gellad, Walid F. Huskamp, Haiden A. Donohue, Julie M. TI Patient, Physician and Organizational Influences on Variation in Antipsychotic Prescribing Behavior SO JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS LA English DT Article ID CARE; RECOMMENDATIONS; ANTIDEPRESSANT; SCHIZOPHRENIA; INFORMATION; PERFORMANCE; MORTALITY; DIFFUSION; OUTCOMES; IMPACT AB Background: Physicians face the choice of multiple ingredients when prescribing drugs in many therapeutic categories. For conditions with considerable patient heterogeneity in treatment response, customizing treatment to individual patient needs and preferences may improve outcomes. Aims of the Study: To assess variation. in the diversity of antipsychotic prescribing for mental health conditions, a necessary although not sufficient condition for personalizing treatment. To identify patient caseload, physician, and organizational factors associated with the diversity of antipsychotic prescribing. Methods: Using 2011 data from Pennsylvania's Medicaid program, IMS Health's HCOS (TM) database, and the AMA Masterfile, we identified 764 psychiatrists who prescribed antipsychotics to >= 10 patients. We constructed three physician level measures of diversity/concentration of antipsychotic prescribing: number of ingredients prescribed, share of prescriptions for most preferred ingredient, and Herfindahl-Hirschman index (HHI). We used multiple membership linear mixed models to examine patient caseload, physician, and healthcare organizational predictors of physician concentration of antipsychotic prescribing. Results: There was substantial variability in antipsychotic prescribing concentration among psychiatrists, with number of ingredients ranging from 2-17, share for most preferred ingredient from 16%-85%, and HHI from 1,088-7,270. On average, psychiatrist prescribing behavior was relatively diversified; however, 11% of psychiatrists wrote an average of 55% of their prescriptions for their most preferred ingredient. Female prescribers and those with smaller shares of disabled or serious mental illness patients had more concentrated prescribing behavior on average. Discussion: Antipsychotic prescribing by individual psychiatrists in a large state Medicaid program varied substantially across psychiatrists. Our findings illustrate the importance of understanding physicians' prescribing behavior and indicate that even among specialties regularly prescribing a therapeutic category, some physicians rely heavily on a small number of agents. Implications for Health Policies, Health Care Provision and Use: Health systems may need to offer educational interventions to clinicians in order to improve their ability to tailor treatment decisions to the needs of individual patients. Implications for Future Research: Future studies should examine the impact of the diversity of antipsychotic prescribing to determine whether more diversified prescribing improves patient adherence and outcomes. C1 [Tang, Yan; Gellad, Walid F.; Donohue, Julie M.] Univ Pittsburgh, Hlth Policy Inst, Ctr Pharmaceut Policy & Prescribing CP3, Pittsburgh, PA 15261 USA. [Tang, Yan; Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 130 DeSoto St,Crabtree Hall A645, Pittsburgh, PA 15261 USA. [Chang, Chung-Chou H.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Lave, Judith R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15261 USA. [Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gellad, Walid F.] Univ Pittsburgh, Div Gen Med, Pittsburgh, PA 15261 USA. [Huskamp, Haiden A.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Cambridge, MA 02138 USA. RP Tang, Y (reprint author), Univ Pittsburgh, Hlth Policy Inst, Ctr Pharmaceut Policy & Prescribing CP3, Pittsburgh, PA 15261 USA.; Tang, Y (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 130 DeSoto St,Crabtree Hall A645, Pittsburgh, PA 15261 USA. EM yan.tang@pitt.edu FU National Institute of Mental Health [R01MH093359]; Pennsylvania Department of Human Services; University of Pittsburgh FX This work was supported in part by grant R01MH093359 from the National Institute of Mental Health (Drs. Donohue and Huskamp), and by an inter -governmental agreement between the Pennsylvania Department of Human Services and the University of Pittsburgh. Dr. Huskamp serves on the Academic Advisory Committee for the Health Services Research Network at IMS Health Inc. (uncompensated). The other authors report no conflict of interest. Some of the findings were presented at the International Society of Pharmacoeconomics and Outcomes Research 20th Annual International Meeting, May 16-20, 2015, Philadelphia, PA, USA. NR 40 TC 0 Z9 0 U1 0 U2 0 PU INT CTR MENTAL HEALTH POLICY & ECONOMICS-ICMPE PI MILANO PA VIA DANIELE CRESPI 7, MILANO, 20123, ITALY SN 1091-4358 J9 J MENT HEALTH POLICY JI J. Ment. Health Policy Econ. PD MAR PY 2016 VL 19 IS 1 BP 45 EP 59 PG 15 WC Health Policy & Services; Psychiatry SC Health Care Sciences & Services; Psychiatry GA DG6QP UT WOS:000372211500005 PM 27084793 ER PT J AU Bunpin, JJD Chapman, S Blegen, M Spetz, J AF Bunpin, Jose J. Dy, III Chapman, Susan Blegen, Mary Spetz, Joanne TI Differences in Innovative Behavior Among Hospital-Based Registered Nurses SO JOURNAL OF NURSING ADMINISTRATION LA English DT Article ID CARE; EMPOWERMENT; AUTONOMY AB BACKGROUND: The 2010 Institute of Medicine report, 'The Future of Nursing: Leading Change, Advancing Health', advocated for nurses to innovate in their practice, research, and education. However, little is known about the innovative behavior of registered nurses or whether there are differences in innovative behavior among registered nurses. OBJECTIVE: The purpose of this article is to describe the innovative behavior of hospital-based registered nurses and understand the differences in innovative behavior when registered nurses are categorized into various demographic groups. METHODS: A survey of 251 hospital-based registered nurses from 9 hospitals in California was administered to assess demographic characteristics and innovative behavior, measured through Scott and Bruce's Individual Innovative Behavior Scale. RESULTS: Hospital-based registered nurses, on average, reported moderate levels of innovative behavior. There were statistically significant differences in innovative behavior when registered nurses were categorized according to specialty certification, role, level of education, hospital size, and hospital innovativeness. CONCLUSIONS: To support innovative behavior, organizations should provide opportunities for specialty certification and increasing levels of education. C1 [Bunpin, Jose J. Dy, III] San Francisco VA Med Ctr, Surg & Procedural Care, San Francisco, CA 94121 USA. [Chapman, Susan] Univ Calif San Francisco, Sch Nursing, Dept Social & Behav Sci, San Francisco, CA 94143 USA. [Blegen, Mary] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. [Spetz, Joanne] Univ Calif San Francisco, Sch Med, Inst Hlth Policy Studies, San Francisco, CA 94143 USA. RP Bunpin, JJD (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM jose.dybunpin@va.gov NR 33 TC 0 Z9 0 U1 7 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0002-0443 EI 1539-0721 J9 J NURS ADMIN JI J. Nurs. Adm. PD MAR PY 2016 VL 46 IS 3 BP 122 EP 127 DI 10.1097/NNA.0000000000000310 PG 6 WC Nursing SC Nursing GA DF8BZ UT WOS:000371583200006 ER PT J AU Ikizler, HO Zelnick, L Ruzinski, J Curtin, L Utzschneider, KM Kestenbaum, B Himmelfarb, J de Boer, IH AF Ikizler, Halil O. Zelnick, Leila Ruzinski, John Curtin, Laura Utzschneider, Kristina M. Kestenbaum, Bryan Himmelfarb, Jonathan de Boer, Ian H. TI Dietary Acid Load is Associated With Serum Bicarbonate but not Insulin Sensitivity in Chronic Kidney Disease SO JOURNAL OF RENAL NUTRITION LA English DT Article ID GLOMERULAR-FILTRATION-RATE; METABOLIC-ACIDOSIS; AFRICAN-AMERICANS; HYPERTENSIVE NEPHROPATHY; UNITED-STATES; OLDER-ADULTS; RESISTANCE; RISK; PROGRESSION; HUMANS AB Objective: In chronic kidney disease (CKD), dietary acid may promote metabolic acidosis and insulin resistance, which in turn may contribute to adverse clinical health outcomes. We examined associations between dietary acid load, serum bicarbonate, and insulin sensitivity in CKD. Design: In a cross-sectional study, we collected 3-day prospective food diaries to quantify dietary acid load as net endogenous acid production (NEAP, the nonvolatile acid load produced by the diet's acid balance) and potential renal acid load (PRAL). We measured urine net acid excretion (NAE) in 24-hour urine samples. Insulin sensitivity was measured by hyperinsulinemic euglycemic clamp. Subjects: Forty-two patients with CKD Stages 3 to 5 attending nephrology clinics in the Pacific Northwest and 21 control subjects (estimated glomerular filtration rate [eGFR] >= 60 mL/minute/1.73 m(2)). Main Outcome Measures: Serum bicarbonate and insulin sensitivity (SIclamp). Results: Mean age was 60.8 +/- 13.6 years, and 54% of participants were men. Mean eGFR and serum bicarbonate concentrations were 34.4 +/- 13.1 mL/minute/1.73 m(2) and 24.1 +/- 2.9 mEq/L for participants with CKD and 88.6 +/- 14.5 mL/minute/1.73 m(2) and 26.3 +/- 1.8 mEq/L for control subjects, respectively. Mean NEAP, PRAL, and NAE were 58.2 +/- 24.3, 9.7 +/- 18.4, and 32.1 +/- 19.8 mEq/day, respectively. Considering all participants, dietary acid load was significantly, inversely associated with serum bicarbonate, adjusting for age, gender, race, eGFR, body mass index, and diuretic use: -1.2 mEq/L per standard deviation (SD) NEAP (95% confidence interval [CI] -1.8 to -0.6, P<.0001); -0.9 mEq/L bicarbonate per SD PRAL (95% CI -1.5 to -0.4, P=.0005); -0.7 mEq/L bicarbonate per SD NAE (95% CI -1.2 to -0.1, P=.01). These associations were similar in participants with and without CKD. However, neither NEAP and PRAL nor NAE was significantly associated with SIclamp. Serum bicarbonate was also not significantly associated with SIclamp. Conclusions: In CKD, dietary acid load is associated with serum bicarbonate, suggesting that acidosis may be improved by dietary changes, but not with insulin sensitivity. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. C1 [Ikizler, Halil O.] Univ Vermont, Coll Med, Burlington, VT USA. [Ikizler, Halil O.; Zelnick, Leila; Ruzinski, John; Curtin, Laura; Kestenbaum, Bryan; Himmelfarb, Jonathan; de Boer, Ian H.] Univ Washington, Kidney Res Inst, Box 359606,325 9th Ave, Seattle, WA 98104 USA. [Utzschneider, Kristina M.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Utzschneider, Kristina M.] Univ Washington, Seattle, WA 98195 USA. [Kestenbaum, Bryan; Himmelfarb, Jonathan; de Boer, Ian H.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA. [Kestenbaum, Bryan; de Boer, Ian H.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP de Boer, IH (reprint author), Univ Washington, Kidney Res Inst, Box 359606,325 9th Ave, Seattle, WA 98104 USA. EM deboer@u.washington.edu FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [T32DK007247]; NIDDK [DK087726, DK007247, DK017047]; University of Washington Diabetes Research Center [P30 DK01704]; University of Washington Institute of Translational Health Sciences [UL1TR000423]; Department of Veterans Affairs FX H.O.I. was supported by grant T32DK007247 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The SUGAR study was supported by NIDDK grants DK087726, DK007247, and DK017047. Support was also provided by the University of Washington Diabetes Research Center (P30 DK01704), the University of Washington Institute of Translational Health Sciences (UL1TR000423), and the Department of Veterans Affairs. The funding sources had no role in study design, analysis or interpretation of data, writing of the report, or the decision to submit this article for publication. NR 44 TC 4 Z9 4 U1 3 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1051-2276 EI 1532-8503 J9 J RENAL NUTR JI J. Renal Nutr. PD MAR PY 2016 VL 26 IS 2 BP 93 EP 102 DI 10.1053/j.jrn.2015.08.008 PG 10 WC Nutrition & Dietetics; Urology & Nephrology SC Nutrition & Dietetics; Urology & Nephrology GA DG4AA UT WOS:000372011100007 PM 26508542 ER PT J AU Molfino, A Kaysen, GA Chertow, GM Doyle, J Delgado, C Dwyer, T Laviano, A Fanelli, FR Johansen, KL AF Molfino, Alessio Kaysen, George A. Chertow, Glenn M. Doyle, Julie Delgado, Cynthia Dwyer, Tjien Laviano, Alessandro Fanelli, Filippo Rossi Johansen, Kirsten L. TI Validating Appetite Assessment Tools Among Patients Receiving Hemodialysis SO JOURNAL OF RENAL NUTRITION LA English DT Article ID CHRONIC KIDNEY-DISEASE; HOSPITALIZED-PATIENTS; NUTRITIONAL-STATUS; ANOREXIA; LEPTIN; INFLAMMATION; ADIPONECTIN; MORTALITY; CACHEXIA; DEATH AB Objective: To test the performance of appetite assessment tools among patients receiving hemodialysis (HD). Design: Cross-sectional. Subjects: Two hundred twenty-one patients receiving HD enrolled in seven dialysis facilities in Northern California. Intervention: We assessed 5 appetite assessment tools (self-assessment of appetite, subjective assessment of appetite, visual analog scale [VAS], Functional Assessment of Anorexia/Cachexia Therapy [FAACT] score, and the Anorexia Questionnaire [AQ]). Main Outcome Measures: Reported food intake, normalized protein catabolic rate, and change in body weight were used as criterion measures, and we assessed associations among the appetite tools and biomarkers associated with nutrition and inflammation. Patients were asked to report their appetite and the percentage of food eaten (from 0% to 100%) during the last meal compared to usual intake. Results: Fifty-eight (26%) patients reported food intake <= 50% (defined as poor appetite). The prevalence of anorexia was 12% by self-assessment of appetite, 6% by subjective assessment of appetite, 24% by VAS, 17% by FAACT score, and 12% by AQ. All the tools were significantly associated with food intake <= 50% (P<.001), except self-assessment of appetite. The FAACT score and the VAS had the strongest association with food intake <= 50% (C-statistic 0.80 and 0.76). Patients with food intake <= 50% reported weight loss more frequently than patients without low intake (36% vs 22%) and weight gain less frequently (19% vs 35%; P = .03). Normalized protein catabolic rate was lower among anorexic patients based on the VAS (1.1 +/- 0.3 vs 1.2 +/- 0.3, P=.03). Ln interleukin-6 correlated inversely with food intake (P = .03), but neither interleukin-6 nor C-reactive protein correlated with any of the appetite tools. Furthermore, only the self-assessment of appetite was significantly associated with serum albumin (P = .02), prealbumin (P = .02) and adiponectin concentrations (P = .03). Conclusions: Alternative appetite assessment tools yielded widely different estimates of the prevalence of anorexia in HD. When considering self-reported food intake as the criterion standard for anorexia, the FAACT score and VAS discriminated patients reasonably well. (C) 2016 by the National Kidney Foundation, Inc. All rights reserved. C1 [Molfino, Alessio; Kaysen, George A.; Dwyer, Tjien] Univ Calif Davis, Dept Internal Med, Div Nephrol, Davis, CA 95616 USA. [Molfino, Alessio; Laviano, Alessandro; Fanelli, Filippo Rossi] Univ Roma La Sapienza, Dept Clin Med, Viale Univ 37, I-00185 Rome, Italy. [Chertow, Glenn M.] Stanford Univ, Sch Med, Dept Med, Div Nephrol, Palo Alto, CA 94304 USA. [Doyle, Julie; Delgado, Cynthia; Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Doyle, Julie; Delgado, Cynthia; Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA USA. RP Molfino, A (reprint author), Univ Roma La Sapienza, Dept Clin Med, Viale Univ 37, I-00185 Rome, Italy. EM alessio.molfino@uniroma1.it FU National Institute of Diabetes and Digestive and Kidney Diseases [N01-DK-7-005, N01-DK-7-5004]; NIDDK [K24DK085153]; Department of Veterans Affairs, Clinical Science Research and Development Program [1IK2CX000527-01A2]; National Center for Research Resources; National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant [UL1 RR024131] FX This work was supported by contracts N01-DK-7-005 and N01-DK-7-5004 from the National Institute of Diabetes and Digestive and Kidney Diseases. K.L.J.'s effort was supported in part by K24DK085153 from NIDDK. C.D.'s work was supported by the Department of Veterans Affairs, Clinical Science Research and Development Program under Career Development Award 1IK2CX000527-01A2. Her contribution is the result of work supported with the resources and the use of facilities at the San Francisco VA Medical Center. This publication was also supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant number UL1 RR024131. NR 28 TC 1 Z9 1 U1 1 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1051-2276 EI 1532-8503 J9 J RENAL NUTR JI J. Renal Nutr. PD MAR PY 2016 VL 26 IS 2 BP 103 EP 110 DI 10.1053/j.jrn.2015.09.002 PG 8 WC Nutrition & Dietetics; Urology & Nephrology SC Nutrition & Dietetics; Urology & Nephrology GA DG4AA UT WOS:000372011100008 PM 26522141 ER PT J AU Mysore, VS Szablowski, J Dervan, PB Frost, PJ AF Mysore, Veena S. Szablowski, Jerzy Dervan, Peter B. Frost, Patrick J. TI A DNA-binding Molecule Targeting the Adaptive Hypoxic Response in Multiple Myeloma Has Potent Antitumor Activity SO MOLECULAR CANCER RESEARCH LA English DT Article ID BONE-MARROW ANGIOGENESIS; IN-VIVO; ACTIVATED PRODRUG; INDUCIBLE FACTOR; CELLS; CANCER; TUMOR; EXPRESSION; TRANSLATION; INHIBITION AB Multiple myeloma is incurable and invariably becomes resistant to chemotherapy. Although the mechanisms remain unclear, hypoxic conditions in the bone marrow have been implicated in contributing to multiple myeloma progression, angiogenesis, and resistance to chemotherapy. These effects occur via adaptive cellular responses mediated by hypoxia-inducible transcription factors (HIF), and targeting HIFs can have anticancer effects in both solid and hematologic malignancies. Here, it was found that in most myeloma cell lines tested, HIF1 alpha, but not HIF2 alpha expression was oxygen dependent, and this could be explained by the differential expression of the regulatory prolyl hydroxylase isoforms. The anti-multiple myeloma effects of a sequence-specific DNA-binding pyrrole-imidazole (Py-Im) polyamide (HIF-PA), which disrupts the HIF heterodimer from binding to its cognate DNA sequences, were also investigated. HIF-PA is cell permeable, localizes to the nuclei, and binds specific regions of DNA with an affinity comparable with that of HIFs. Most of the multiple myeloma cells were resistant to hypoxia-mediated apoptosis, and HIF-PA treatment could overcome this resistance in vitro. Using xenograft models, it was determined that HIF-PA significantly decreased tumor volume and increased hypoxic and apoptotic regions within solid tumor nodules and the growth of myeloma cells engrafted in the bone marrow. This provides a rationale for targeting the adaptive cellular hypoxic response of the O-2-dependent activation of HIF alpha using polyamides. C1 [Mysore, Veena S.; Frost, Patrick J.] Greater Los Angeles Vet Adm Healthcare Syst, 11301Wilshire Blvd,Bldg 114,Room 113, Los Angeles, CA 90073 USA. [Mysore, Veena S.; Frost, Patrick J.] Univ Calif Los Angeles, Los Angeles, CA USA. [Szablowski, Jerzy; Dervan, Peter B.] CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA. RP Frost, PJ (reprint author), Greater Los Angeles Vet Adm Healthcare Syst, 11301Wilshire Blvd,Bldg 114,Room 113, Los Angeles, CA 90073 USA. EM pfrost@ucla.edu FU MERIT from the United States Department of Veterans Affairs Biomedical Laboratory Research and Development Service [1I01BX001532]; NIH [GM051747] FX This work was supported by a MERIT grant 1I01BX001532 (to P.J. Frost) from the United States Department of Veterans Affairs Biomedical Laboratory Research and Development Service and a NIH GM051747 grant (to P.B. Dervan). NR 50 TC 0 Z9 0 U1 4 U2 7 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1541-7786 EI 1557-3125 J9 MOL CANCER RES JI Mol. Cancer Res. PD MAR PY 2016 VL 14 IS 3 BP 253 EP 266 DI 10.1158/1541-7786.MCR-15-0361 PG 14 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DG3XM UT WOS:000372004400002 PM 26801054 ER PT J AU Li, H Wheeler, S Park, Y Ju, ZL Thomas, SM Fichera, M Egloff, AM Lui, VW Duvvuri, U Bauman, JE Mills, GB Grandis, JR AF Li, Hua Wheeler, Sarah Park, Yongseok Ju, Zhenlin Thomas, Sufi M. Fichera, Michele Egloff, Ann M. Lui, Vivian W. Duvvuri, Umamaheswar Bauman, Julie E. Mills, Gordon B. Grandis, Jennifer R. TI Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts SO MOLECULAR CANCER RESEARCH LA English DT Article ID SQUAMOUS-CELL CARCINOMA; PHASE PROTEIN ARRAY; DRUG DEVELOPMENT; PANCREATIC-CANCER; GENOMIC CHARACTERIZATION; PREDICTIVE BIOMARKERS; TUMOR XENOGRAFTS; IN-VITRO; MODELS; MOUSE AB Despite advances in treatment approaches for head and neck squamous cell carcinoma (HNSCC), survival rates have remained stagnant due to the paucity of preclinical models that accurately reflect the human tumor. Patient-derived xeno-grafts (PDX) are an emerging model system where patient tumors are implanted directly into mice. Increased understanding of the application and limitations of PDXs will facilitate their rational use. Studies to date have not reported protein profiles of PDXs. Therefore, we developed a large cohort of HNSCC PDXs and found that tumor take rate was not influenced by the clinical, pathologic, or processing features. Protein expression profiles, from a subset of the PDXs, were characterized by reverse-phase protein array and the data was compared with The Cancer Genome Atlas HNSCC data. Cluster analysis revealed that HNSCC PDXs were more similar to primary HNSCC than to any other tumor type. Interestingly, while a significant fraction of proteins were expressed similarly in both primary HNSCC and PDXs, a subset of proteins/phosphoproteins were expressed at higher (or lower) levels in PDXs compared with primary HNSCC. These findings indicate that the proteome is generally conserved in PDXs, but mechanisms for both positive and negative model selection and/or differences in the stromal components exist. C1 [Li, Hua; Egloff, Ann M.; Duvvuri, Umamaheswar; Grandis, Jennifer R.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA. [Wheeler, Sarah; Fichera, Michele; Grandis, Jennifer R.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA. [Park, Yongseok] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA. [Ju, Zhenlin; Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA. [Thomas, Sufi M.] Univ Kansas, Med Ctr, Dept Otolaryngol, Kansas City, KS 66103 USA. [Thomas, Sufi M.] Univ Kansas, Med Ctr, Dept Canc Biol, Kansas City, KS 66103 USA. [Lui, Vivian W.] Univ Hong Kong, Dept Pharmacol & Pharm, Hong Kong, Hong Kong, Peoples R China. [Duvvuri, Umamaheswar] Vet Affairs Pittsburgh Healthcare Syst, Univ Dr Campus, Pittsburgh, PA USA. [Bauman, Julie E.] Univ Pittsburgh, Dept Internal Med Hematol Oncol, Pittsburgh, PA USA. [Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA. [Grandis, Jennifer R.] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94158 USA. RP Grandis, JR (reprint author), Univ Calif San Francisco, 1450 3rd St,Room HD200, San Francisco, CA 94158 USA. EM jennifer.grandis@ucsf.edu RI Lui, Vivian/I-5458-2016 FU NIH [P50CA097190, K07 CA137140]; American Cancer Society; Department of Veterans Affairs BLRD; NCI [CA16672] FX This work was supported by grants NIH P50CA097190 and the American Cancer Society (to J.R. Grandis), NIH K07 CA137140 (to A.M. Egloff), Department of Veterans Affairs BLR&D (to U. Duvvuri). RPPA work was performed in the MDACC CCSG supported core NCI CA16672. NR 40 TC 4 Z9 5 U1 1 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1541-7786 EI 1557-3125 J9 MOL CANCER RES JI Mol. Cancer Res. PD MAR PY 2016 VL 14 IS 3 BP 278 EP 286 DI 10.1158/1541-7786.MCR-15-0354 PG 9 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DG3XM UT WOS:000372004400004 PM 26685214 ER PT J AU Martinez-Martin, P Leentjens, AFG de Pedro-Cuesta, J Chaudhuri, KR Schrag, AE Weintraub, D AF Martinez-Martin, Pablo Leentjens, Albert F. G. de Pedro-Cuesta, Jesus Chaudhuri, Kallol Ray Schrag, Anette E. Weintraub, Daniel TI Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease SO MOVEMENT DISORDERS LA English DT Review DE Parkinson's disease; neuropsychiatric symptoms; screening; instruments; accuracy ID GERIATRIC DEPRESSION SCALE; IMPULSIVE-COMPULSIVE DISORDERS; DRUG-INDUCED PSYCHOSIS; ANXIETY RATING-SCALES; QUALITY-OF-LIFE; NONMOTOR SYMPTOMS; HOSPITAL ANXIETY; RECOGNIZING DEPRESSION; COGNITIVE IMPAIRMENT; REPETITIVE BEHAVIORS AB Parkinson's disease includes neuropsychiatric manifestations, such as depression, anxiety, apathy, psychosis, and impulse control disorders, which often are unreported by patients and caregivers or undetected by doctors. Given their substantial impact on patients and caregivers as well as the existence of effective therapies for some of these disorders, screening for neuropsychiatric symptoms is important. Instruments for screening have a particular methodology for validation, and their performance is expressed in terms of accuracy compared with formal diagnostic criteria. The present study reviews the attributes of the screening instruments applied for detection of the aforementioned major neuropsychiatric symptoms in Parkinson's disease. A quasi-systematic review (including predefined selection criteria, but not evaluating the quality of the reviewed studies) was carried out on the basis of previous systematic reviews (commissioned by the American Academy of Neurology and the Movement Disorder Society) and made current by conducting a literature search (2005-2014). For depression, 11 scales and questionnaires were shown to be valid for Parkinson's disease screening. The recently developed Parkinson Anxiety Scale and the Geriatric Anxiety Inventory demonstrate satisfactory properties as screening instruments for anxiety, and the Lille Apathy Rating Scale for detection of apathy. No scale adequately screens for psychosis, so a specific psychosis instrument should be developed. The Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (Questionnaire and Rating Scale) are valid for comprehensive screening of impulse control disorders, and the Parkinson's Disease-Sexual Addiction Screening Test for hypersexuality specifically. (c) 2015 International Parkinson and Movement Disorder Society C1 [Martinez-Martin, Pablo; de Pedro-Cuesta, Jesus] Carlos III Inst Hlth, Natl Ctr Epidemiol, Avda Monforte de Lemos 5, Madrid 28029, Spain. [Martinez-Martin, Pablo; de Pedro-Cuesta, Jesus] Carlos III Inst Hlth, CIBERNED, Madrid 28029, Spain. [Leentjens, Albert F. G.] Maastricht Univ, Med Ctr, Dept Psychiat, NL-6200 MD Maastricht, Netherlands. [Chaudhuri, Kallol Ray] Kings Coll London, Natl Parkinson Fdn Int Ctr Excellence, London WC2R 2LS, England. [Chaudhuri, Kallol Ray] South London & Maudsley NHS Fdn Trust, Natl Inst Hlth Res, Mental Hlth Biomed Res Ctr, London, England. [Chaudhuri, Kallol Ray] South London & Maudsley NHS Fdn Trust, Dementia Unit, London, England. [Chaudhuri, Kallol Ray] Kings Coll London, London WC2R 2LS, England. [Schrag, Anette E.] UCL, Inst Neurol, Royal Free Campus, London, England. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Martinez-Martin, P (reprint author), Carlos III Inst Hlth, Natl Ctr Epidemiol, Avda Monforte de Lemos 5, Madrid 28029, Spain. EM pmartinez@isciii.es NR 97 TC 6 Z9 6 U1 5 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD MAR PY 2016 VL 31 IS 3 BP 270 EP 279 DI 10.1002/mds.26522 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA DG7SR UT WOS:000372284500003 PM 26695691 ER PT J AU Moelter, ST Weintraub, D Mace, L Cary, M Sullo, E Xie, SX Karlawish, J AF Moelter, Stephen T. Weintraub, Daniel Mace, Lauren Cary, Mark Sullo, Elizabeth Xie, Sharon X. Karlawish, Jason TI Research consent capacity varies with executive function and memory in Parkinson's disease SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; decision making; capacity; cognitive impairment; informed consent ID MILD COGNITIVE IMPAIRMENT; DEMENTIA; TRIAL AB BackgroundWe examined the association between cognitive domains and research consent capacity in PD. Our hypothesis was that research consent capacity is best predicted by executive function. MethodsA cohort of 90 PD patients and 30 healthy older adults were administered the MacArthur Competence Assessment Tool for Clinical Research, Dementia Rating Scale-2, and the MoCA. Experts classified patients as either capable or not capable of providing informed consent to participate in two clinical trials. ResultsMacArthur Competence Assessment Tool for Clinical Research Reasoning scores for both clinical trial types were most associated with executive functions and delayed recall. As scores on these domains improved, the odds of an expert rating of capable of consent increased. ConclusionsThese results extend our previous findings by demonstrating that memory and executive abilities appear closely associated with capacity when evaluated using either a structured interview or expert judgment of that interview. (c) 2016 International Parkinson and Movement Disorder Society C1 [Moelter, Stephen T.; Mace, Lauren] Univ Sci, Dept Behav & Social Sci, 600 South 43rd St, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Geriatr Psychiat Sect, Perelman Sch Med, Philadelphia, PA 19104 USA. [Cary, Mark; Xie, Sharon X.] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Sullo, Elizabeth; Karlawish, Jason] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Karlawish, Jason] Univ Penn, Dept Med Eth & Hlth Policy, Perelman Sch Med, Philadelphia, PA 19104 USA. [Karlawish, Jason] Univ Penn, Leonard Davis Inst Hlth Econ, Perelman Sch Med, Philadelphia, PA 19104 USA. [Karlawish, Jason] Univ Penn, Alzheimers Dis Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Moelter, ST (reprint author), Univ Sci, Dept Behav & Social Sci, 600 South 43rd St, Philadelphia, PA 19104 USA. EM s.moelte@usciences.edu FU National Institute of Neurological Disorders and Stroke [R01NS65087]; Morris K. Udall Center for Parkinson's Disease Research [P50 NS053488, NS062684]; National Institute on Aging [AG10124] FX This work was supported by the National Institute of Neurological Disorders and Stroke (R01NS65087), Morris K. Udall Center for Parkinson's Disease Research (P50 NS053488 and NS062684), and the National Institute on Aging (AG10124). NR 15 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD MAR PY 2016 VL 31 IS 3 BP 414 EP 417 DI 10.1002/mds.26469 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA DG7SR UT WOS:000372284500026 PM 26861463 ER PT J AU Brawner, BM Alexander, KA Fannin, EF Baker, JL Davis, ZM AF Brawner, Bridgette M. Alexander, Kamila A. Fannin, Ehriel F. Baker, Jillian L. Davis, Zupenda M. TI The Role of Sexual Health Professionals in Developing a Shared Concept of Risky Sexual Behavior as it Relates to HIV Transmission SO PUBLIC HEALTH NURSING LA English DT Article DE disease prevention; diversity; health promotion; HIV; AIDS; patient education; prevention; programme planning; public health systems; sexual behavior ID INTIMATE PARTNER VIOLENCE; YOUNG-ADULTS; RELATIONSHIP POWER; DOMESTIC VIOLENCE; ADOLESCENT GIRLS; UNITED-STATES; SELF-EFFICACY; SOUTH-AFRICA; CONDOM USE; PREVENTION AB Risky sexual behavior accounts for the majority of new HIV infections regardless of gender, age, geographic location, or ethnicity. The phrase, however, refers to a relatively nebulous concept that hampers development of effective sexual health communication strategies. The purpose of this paper was to propose development of a shared conceptual understanding of risky sexual behavior. We reviewed multidisciplinary HIV/AIDS literature to identify definitions of risky sexual behavior. Both the linguistic components and the social mechanisms that contribute to the concept of risky sexual behaviors were noted. Risky sexual behavior was often defined in a subjective manner in the literature, even in the scientific research. We urge a paradigm shift to focus on explicit behaviors and the social context of those behaviors in determining HIV risk. We also propose a new definition that reduces individual biases and promotes a broader discussion of the degree of sexual risk across a diversity of behavioral contexts. Sexual health professionals can strengthen practice and research initiatives by operating from a concise working definition of risky sexual behavior that is broadly transferable and expands beyond a traditional focus on identity-based groups. C1 [Brawner, Bridgette M.] Univ Penn, Sch Nursing, Dept Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. [Brawner, Bridgette M.; Fannin, Ehriel F.] Univ Penn, Sch Nursing, Ctr Global Womens Hlth, 418 Curie Blvd,Room 419, Philadelphia, PA 19036 USA. [Alexander, Kamila A.] Johns Hopkins Sch Nursing, Dept Community Publ Hlth, Baltimore, MD USA. [Fannin, Ehriel F.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, 418 Curie Blvd,Room 419, Philadelphia, PA 19036 USA. [Baker, Jillian L.; Davis, Zupenda M.] La Salle Univ, Sch Nursing & Hlth Sci, Dept Urban Publ Hlth & Nutr, Philadelphia, PA 19141 USA. RP Brawner, BM (reprint author), Univ Penn, Sch Nursing, Ctr Global Womens Hlth, 418 Curie Blvd,Room 419, Philadelphia, PA 19036 USA.; Brawner, BM (reprint author), Univ Penn, Sch Nursing, Ctr Hlth Equ Res, 418 Curie Blvd,Room 419, Philadelphia, PA 19036 USA. EM brawnerb@nursing.upenn.edu FU Centers for Disease Control and Prevention [CDC U01PS003304]; National Institute of Mental Health [NIH/NIMH R25MH087217]; Substance Abuse and Mental Health Services Administration at American Nurses Association Minority Fellowship Program [5SM058566-02]; Hampton-Penn Center for Health Disparities Research [NINR P20NR008361]; Distinguished Postdoctoral Fellowship; Fontaine Society Fellowship at University of Pennsylvania; Individual Ruth L. Kirschstein NRSA Predoctoral Fellowship [F31NR013121]; Ruth L. Kirschstein NRSA Postdoctoral Fellowship; Ruth L. Kirschstein NRSA Predoctoral Fellowship [5T32NR007100-13]; National Institute of Child Health & Human Development Diversity Research Supplement Award [5R01HD061061-03] FX This article was supported by funding to Dr. Brawner from the Centers for Disease Control and Prevention (CDC U01PS003304), the National Institute of Mental Health (NIH/NIMH R25MH087217; PI: B. Guthrie, J.), the Substance Abuse and Mental Health Services Administration at the American Nurses Association Minority Fellowship Program (5SM058566-02), the Hampton-Penn Center for Health Disparities Research (NINR P20NR008361), and the Distinguished Postdoctoral Fellowship and the Fontaine Society Fellowship at the University of Pennsylvania. The article was also supported by the Individual Ruth L. Kirschstein NRSA Predoctoral Fellowship (F31NR013121) and the Ruth L. Kirschstein NRSA Postdoctoral Fellowship (T32HDO64428; PI: Campbell) awarded to Dr. Alexander; the Ruth L. Kirschstein NRSA Predoctoral Fellowship (5T32NR007100-13; PI: Sommers) awarded to Ms. Ehriel Fannin; and funding from a National Institute of Child Health & Human Development Diversity Research Supplement Award (5R01HD061061-03; PI: Jemmott) to Dr. Baker. NR 74 TC 1 Z9 1 U1 5 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0737-1209 EI 1525-1446 J9 PUBLIC HEALTH NURS JI Public Health Nurs. PD MAR-APR PY 2016 VL 33 IS 2 BP 139 EP 150 DI 10.1111/phn.12216 PG 12 WC Public, Environmental & Occupational Health; Nursing SC Public, Environmental & Occupational Health; Nursing GA DG2PW UT WOS:000371910700007 PM 26184496 ER PT J AU Pang, CE Sarraf, D Freund, KB AF Pang, Claudine E. Sarraf, David Freund, K. Bailey TI An Atypical Presentation of Bartonella Neuroretinitis Reply SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Letter ID MYOPIA C1 [Pang, Claudine E.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA. [Pang, Claudine E.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY USA. [Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90024 USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA. RP Pang, CE (reprint author), Vitreous Retina Macula Consultants New York, New York, NY USA.; Pang, CE (reprint author), Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0275-004X EI 1539-2864 J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PD MAR PY 2016 VL 36 IS 3 BP e24 EP e24 DI 10.1097/IAE.0000000000000990 PG 1 WC Ophthalmology SC Ophthalmology GA DG1MX UT WOS:000371833300008 PM 26849457 ER PT J AU Weisbord, SD AF Weisbord, Steven D. TI Patient-Centered Dialysis Care: Depression, Pain, and Quality of Life SO SEMINARS IN DIALYSIS LA English DT Article ID STAGE RENAL-DISEASE; RECEIVING CHRONIC-HEMODIALYSIS; MAINTENANCE HEMODIALYSIS; PSYCHOSOCIAL FACTORS; TRANSPLANT PATIENTS; MORTALITY RISK; SYMPTOMS; PREVALENCE; ADHERENCE; HOSPITALIZATION AB Remarkable advancements have been made in the provision of chronic dialysis therapy since its inception decades ago. A series of studies inform current dialysis dosing recommendations, while advancements in strategies to treat mineral and bone disease, acid-base and electrolyte disturbances, and anemia have facilitated the management of these well-recognized complications of ESRD. The collective result has been a model of chronic dialysis care focused principally on the achievement of metabolic and dialysis-related targets. In fact, guidelines such as the Kidney Disease Outcomes Quality Initiative put forth by the National Kidney Foundation recommend metrics that characterize successful dialysis care, including the attainment of specific solute clearance targets; maintenance of hemoglobin, calcium, phosphorous, and parathyroid hormone levels within target ranges; and the preferred use of primary arteriovenous fistulae for vascular access. This focus on serologic and dialysis-specific outcomes has helped renal providers manage the biochemical effects related to the loss of kidney function and has reduced ESRD-related morbidity and mortality. Yet, absent from this model of care is an emphasis on the treatment of bothersome symptoms and the impact of such treatment on quality of life (QOL). Among the many symptoms that affect patients on chronic dialysis, depression and pain are particularly common, strongly associated with decrements in QOL, and potentially treatable. This review discusses key research findings and unanswered questions pertaining to the prevalence, significance, and treatment of depression and pain and the effect of such treatment on QOL in patients dependent on chronic dialysis, with the broad goal of incorporating symptom management strategies into a paradigm of patient-centered dialysis care. C1 [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Med Serv Line, Renal Sect, Pittsburgh, PA USA. [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Weisbord, Steven D.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA. RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, 7E Room 120,111F U, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu NR 47 TC 2 Z9 2 U1 3 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-0959 EI 1525-139X J9 SEMIN DIALYSIS JI Semin. Dial. PD MAR PY 2016 VL 29 IS 2 BP 158 EP 164 DI 10.1111/sdi.12464 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA DG7SC UT WOS:000372283000010 PM 26748494 ER PT J AU Saby, A Miller, LS AF Saby, Adam Miller, Lawrence S. TI Functional Assessment in End-Stage Renal Disease: Enhancing Quality of Life SO SEMINARS IN DIALYSIS LA English DT Article ID DIALYSIS PATIENTS; HEMODIALYSIS; MORTALITY; HEALTH; FACILITIES; DISABILITY; CAPACITY; OUTCOMES; FALLS; RISK AB Why do functional assessments in patients with end-stage renal disease (ESRD) matter? Multiple studies show that new dialysis patients undergo a substantial decline among activities of daily living. Moreover, poor functional status in ESRD patients is associated with early morality. That is why CMS has developed new criteria to assess ESRD patients in regards to their functional, psychologic, and cognitive capabilities. Functional assessments by health providers have been used in field of Rehabilitation Medicine for over 50 years; rehabilitation physicians have found them effective in establishing goals and monitoring improvement. Assessments can provide guidance by identifying the needs and types of intervention most suited for patients. Impairments can be addressed with referrals to physical therapy for gross motor issues, occupational therapy for self-care problems, psychiatry for mental disorders, and neurology for cognitive deficits. The more accurate the assessments over time, the more targeted and effective the therapies become. We believe that the new CMS goals to assess functionality will improve ESRD patient's quality of life, longevity, and long-term healthcare costs. C1 [Saby, Adam] Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles Vet Adm Hlth Care Syst, Dept Phys Med & Rehabil, Los Angeles, CA 90095 USA. [Miller, Lawrence S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Saby, A (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles Vet Adm Hlth Care Syst, Dept Phys Med & Rehabil, Los Angeles, CA 90095 USA.; Saby, A (reprint author), Dept Phys Med & Rehabil 117, 11301 Wilshire blvd, Los Angeles, CA 90073 USA. EM asaby@ucla.edu NR 21 TC 0 Z9 0 U1 2 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-0959 EI 1525-139X J9 SEMIN DIALYSIS JI Semin. Dial. PD MAR PY 2016 VL 29 IS 2 BP 170 EP 172 DI 10.1111/sdi.12466 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA DG7SC UT WOS:000372283000012 PM 26756940 ER PT J AU Sarmiento, K Rossettie, J Stepnowsky, C Atwood, C Calvitti, A AF Sarmiento, Kathleen Rossettie, John Stepnowsky, Carl Atwood, Charles Calvitti, Alan CA VA Sleep Network TI The state of Veterans Affairs sleep medicine programs: 2012 inventory results SO SLEEP AND BREATHING LA English DT Article DE Access to health care; Health services; Sleep disorders; Veterans AB The Veterans Health Administration (VHA) represents one of the largest integrated health-care systems in the country. In 2012, the Veterans Affairs Sleep Network (VASN) sought to identify available sleep resources at VA medical centers (VAMCs) across the country through a national sleep inventory. The sleep inventory was administered at the annual 2012 VA Sleep Practitioners meeting and by email to sleep contacts at each VAMC. National prosthetics contacts were used to identify personnel at VAMCs without established sleep programs. Follow-up emails and telephone calls were made through March 2013. One hundred eleven VA medical centers were included for analysis. Thirty-nine programs did not respond, and 10 were considered "satellites," referring all sleep services to a larger neighboring VAMC. Sleep programs were stratified based on extent of services offered (i.e., in-lab and home testing, sleep specialty clinics, cognitive behavioral therapy for insomnia (CBT-i)): 28 % were complex sleep programs (CSPs), 46 % were intermediate (ISPs), 9 % were standard (SSPs), and 17 % offered no formal sleep services. Overall, 138,175 clinic visits and 90,904 sleep testing encounters were provided in fiscal year 2011 by 112.1 physicians and clinical psychologists, 100.4 sleep technologists, and 115.3 respiratory therapists. More than half of all programs had home testing and CBT-i programs, and 26 % utilized sleep telehealth. The 2012 VA sleep inventory suggests considerable variability in sleep services within the VA. Demand for sleep services is high, with programs using home testing, sleep telehealth, and a growing number of mid-level providers to improve access to care. C1 [Sarmiento, Kathleen; Rossettie, John; Stepnowsky, Carl; Calvitti, Alan] VA San Diego Healthcare Syst, 3350 Jolla Village Dr,111J, San Diego, CA 92161 USA. [Sarmiento, Kathleen] Univ Calif San Diego, Dept Pulm & Crit Care Med, La Jolla, CA 92093 USA. [Rossettie, John; Stepnowsky, Carl] Univ Calif San Diego, Dept Med, La Jolla, CA 92103 USA. [Atwood, Charles] VA Pittsburgh Healthcare Syst, Univ Dr, Pittsburgh, PA 15240 USA. [Atwood, Charles] UPMC Montefiore, PACCM, Pittsburgh, PA 15213 USA. RP Sarmiento, K (reprint author), VA San Diego Healthcare Syst, 3350 Jolla Village Dr,111J, San Diego, CA 92161 USA.; Sarmiento, K (reprint author), Univ Calif San Diego, Dept Pulm & Crit Care Med, La Jolla, CA 92093 USA. EM kfsarmiento@ucsd.edu NR 1 TC 4 Z9 4 U1 0 U2 0 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1520-9512 EI 1522-1709 J9 SLEEP BREATH JI Sleep Breath. PD MAR PY 2016 VL 20 IS 1 BP 379 EP 382 DI 10.1007/s11325-015-1184-0 PG 4 WC Clinical Neurology; Respiratory System SC Neurosciences & Neurology; Respiratory System GA DG5ZJ UT WOS:000372160800058 PM 25924933 ER PT J AU Becker, WC Gordon, K Edelman, EJ Kerns, RD Crystal, S Dziura, JD Fiellin, LE Gordon, AJ Goulet, JL Justice, AC Fiellin, DA AF Becker, William C. Gordon, Kirsha Edelman, E. Jennifer Kerns, Robert D. Crystal, Stephen Dziura, James D. Fiellin, Lynn E. Gordon, Adam J. Goulet, Joseph L. Justice, Amy C. Fiellin, David A. TI Trends in Any and High-Dose Opioid Analgesic Receipt Among Aging Patients With and Without HIV SO AIDS AND BEHAVIOR LA English DT Article DE Analgesics; Opioids; Aging; Pain; Chronic; Human immunodeficiency virus ID HUMAN-IMMUNODEFICIENCY-VIRUS; CORONARY-HEART-DISEASE; CHRONIC NONCANCER PAIN; HEALTH-CARE-SYSTEM; UNINFECTED PATIENTS; INFECTED ADULTS; DRUG-DEPENDENCE; UNITED-STATES; RISK-FACTORS; BACK-PAIN AB Harms of opioid analgesics, especially high-dose therapy among individuals with comorbidities and older age, are increasingly recognized. However, trends in opioid receipt among HIV-infected patients are not well characterized. We examined trends, from 1999 to 2010, in any and high-dose (a parts per thousand yen120 mg/day) opioid receipt among patients with and without HIV, by age strata, controlling for demographic and clinical correlates. Of 127,216 patients, 64 % received at least one opioid prescription. Opioid receipt increased substantially among HIV-infected and uninfected patients over the study; high-dose therapy was more prevalent among HIV-infected patients. Trends in high-dose receipt stratified by three age groups revealed an increasing trend in each age strata, higher among HIV-infected patients. Correlates of any opioid receipt included HIV, PTSD and major depression. Correlates of high-dose receipt included HIV, PTSD, major depression and drug use disorders. These findings suggest a need for appropriate balance of risks and benefits, especially as these populations age. C1 [Becker, William C.; Gordon, Kirsha; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven VA Med Ctr, Internal Med, Mail Stop 151B,950 Campbell Ave, West Haven, CT 06516 USA. [Kerns, Robert D.; Goulet, Joseph L.] VA Connecticut Healthcare Syst, Psychol, West Haven, CT 06516 USA. [Becker, William C.; Edelman, E. Jennifer; Dziura, James D.; Fiellin, Lynn E.; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Med, Internal Med, New Haven, CT USA. [Kerns, Robert D.; Goulet, Joseph L.] Yale Univ, Sch Med, Psychol, New Haven, CT USA. [Crystal, Stephen] Rutgers State Univ, Ctr Hlth Serv Res, New Brunswick, NJ 08903 USA. [Gordon, Adam J.] Univ Pittsburgh, Pittsburgh, PA USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Becker, WC (reprint author), VA Connecticut Healthcare Syst, West Haven VA Med Ctr, Internal Med, Mail Stop 151B,950 Campbell Ave, West Haven, CT 06516 USA.; Becker, WC (reprint author), Yale Univ, Sch Med, Internal Med, New Haven, CT USA. EM william.becker@yale.edu OI Edelman, E. Jennifer/0000-0002-9375-0489; Fiellin, David/0000-0002-4006-010X; Justice, Amy/0000-0003-0139-5502; Goulet, Joseph/0000-0002-0842-804X FU Veterans Health Administration Health Services Research & Development Career Development Award [08-276]; VA Health Services Research and Development Center of Innovation [CIN 13-047]; Society of General Internal Medicine's Lawrence Linn Award; Robert Wood Johnson Foundation Clinical Scholars Program; Veterans Aging Cohort study; National Institute on Alcohol Abuse and Alcoholism [U10 AA 13566] FX This work was supported by a Veterans Health Administration Health Services Research & Development Career Development Award (08-276); other VA support came from VA Health Services Research and Development Center of Innovation (CIN 13-047). This work was also supported by the Society of General Internal Medicine's Lawrence Linn Award, the Robert Wood Johnson Foundation Clinical Scholars Program, and the Veterans Aging Cohort study, funded by the National Institute on Alcohol Abuse and Alcoholism (U10 AA 13566). This work was presented at the Northeast Regional Society of General Internal Medicine Meeting, New Haven, CT, March 8, 2013 and the Society of General Internal Medicine National Meeting, Denver, CO, April 25, 2013. The authors would like to thank Dr. Eugenia Buta for input on statistical analyses. NR 60 TC 5 Z9 5 U1 2 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD MAR PY 2016 VL 20 IS 3 BP 679 EP 686 DI 10.1007/s10461-015-1197-5 PG 8 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA DF8JA UT WOS:000371602700020 PM 26384973 ER PT J AU Merlin, JS Tamhane, A Starrels, JL Kertesz, S Saag, M Cropsey, K AF Merlin, Jessica S. Tamhane, Ashutosh Starrels, Joanna L. Kertesz, Stefan Saag, Michael Cropsey, Karen TI Factors Associated with Prescription of Opioids and Co-prescription of Sedating Medications in Individuals with HIV SO AIDS AND BEHAVIOR LA English DT Article DE HIV; Chronic pain; Opioid; Benzodiazepine; Muscle relaxant ID QUALITY-OF-LIFE; OVERDOSE DEATHS; UNITED-STATES; PRESCRIBING PRACTICES; NONMALIGNANT PAIN; INFECTED PATIENTS; SCREENING-TEST; MENTAL-HEALTH; BENZODIAZEPINES; DISORDERS AB Opioids are often prescribed for chronic pain, and opioid risks such as overdose and death are heightened when opioids are co-prescribed with other sedating medications. We investigated factors associated with chronic opioid prescription, alone and in combination with benzodiazepines and muscle relaxants, in a clinical cohort of individuals with HIV. We used multivariable logistic regression models to determine participant clinical and demographic characteristics that are associated with chronic prescription of opioids or chronic co-prescription of opioids with sedating medications. Among 1474 participants, chronic prescription of opioids occurred in 253 individuals (17.2 %), and chronic co-prescription occurred in 90 individuals (6.1 %). Age > 50, public insurance as compared to private insurance, and symptoms of depression and anxiety were significantly associated with chronic opioid prescription and chronic co-prescription. Our findings raise concern that opioid prescription and co-prescription of sedating medications occurs disproportionately in patients for whom use is riskier. C1 [Merlin, Jessica S.; Tamhane, Ashutosh; Saag, Michael] Univ Alabama Birmingham, Dept Med, Div Infect Dis, BBRB 222,1530 3rd Ave S, Birmingham, AL 35294 USA. [Merlin, Jessica S.] Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA. [Starrels, Joanna L.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [Kertesz, Stefan] Birmingham VA Med Ctr, Birmingham, AL USA. [Kertesz, Stefan] Univ Alabama Birmingham, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA. [Cropsey, Karen] Univ Alabama Birmingham, Dept Psychiat, Birmingham, AL 35294 USA. RP Merlin, JS (reprint author), Univ Alabama Birmingham, Dept Med, Div Infect Dis, BBRB 222,1530 3rd Ave S, Birmingham, AL 35294 USA.; Merlin, JS (reprint author), Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA. EM jmerlin@uab.edu OI Tamhane, Ashutosh/0000-0002-4475-2760; Kertesz, Stefan/0000-0001-6101-8421 FU University of Alabama at Birmingham (UAB) Center for AIDS Research, an NIH [P30 A1027767]; NIAID; NCI; NICHD; NHLBI; NIDA; NIMH; NIA; FIC; OAR; AHRQ [1K12HS02169401]; NIDA [K23DA027719]; Mary Fisher CARE Fund at UAB FX This research was supported by the University of Alabama at Birmingham (UAB) Center for AIDS Research, an NIH funded program (P30 A1027767) that was made possible by the following institutes: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, FIC, and OAR. JSM was supported by 1K12HS02169401 (AHRQ). JLS was supported by K23DA027719 (NIDA). Funding was also provided by the Mary Fisher CARE Fund at UAB. NR 52 TC 2 Z9 2 U1 0 U2 0 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD MAR PY 2016 VL 20 IS 3 BP 687 EP 698 DI 10.1007/s10461-015-1178-8 PG 12 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA DF8JA UT WOS:000371602700021 PM 26487298 ER PT J AU Korom-Djakovic, D Canamucio, A Lempa, M Yano, EM Long, JA AF Korom-Djakovic, Danijela Canamucio, Anne Lempa, Michele Yano, Elizabeth M. Long, Judith A. TI Organization Complexity and Primary Care Providers' Perceptions of Quality Improvement Culture Within the Veterans Health Administration SO AMERICAN JOURNAL OF MEDICAL QUALITY LA English DT Article DE quality improvement; culture; organizational complexity; primary care; Veterans Affairs ID MEDICAL GROUP PRACTICES; IMPLEMENTATION; DELIVERY; STAFF; HOME AB This study examined how aspects of quality improvement (QI) culture changed during the introduction of the Veterans Health Administration (VHA) patient-centered medical home initiative and how they were influenced by existing organizational factors, including VHA facility complexity and practice location. A voluntary survey, measuring primary care providers' (PCPs') perspectives on QI culture at their primary care clinics, was administered in 2010 and 2012. Participants were 320 PCPs from hospital- and community-based primary care practices in Pennsylvania, West Virginia, Delaware, New Jersey, New York, and Ohio. PCPs in community-based outpatient clinics reported an improvement in established processes for QI, and communication and cooperation from 2010 to 2012. However, their peers in hospital-based clinics did not report any significant improvements in QI culture. In both years, compared with high-complexity facilities, medium- and low-complexity facilities had better scores on the scales assessing established processes for QI, and communication and cooperation. C1 [Korom-Djakovic, Danijela; Canamucio, Anne; Lempa, Michele; Long, Judith A.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Korom-Djakovic, Danijela; Long, Judith A.] Univ Penn, Philadelphia, PA 19104 USA. [Yano, Elizabeth M.] VA Greater Angeles Healthcare Syst, Sepulveda, CA USA. [Yano, Elizabeth M.] UCLA Fielding Sch Publ Hlth, Los Angeles, CA USA. RP Long, JA (reprint author), Univ Penn, Perelman Sch Med, 1201 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM jalong@mail.med.upenn.edu FU VA Office of Patient Care Services FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was undertaken as part of the Veterans Affairs (VA) Patient Aligned Care Team (PACT) Demonstration Laboratory initiative, supporting and evaluating VA's transition to a patient-centered medical home. Funding for the PACT Demonstration Laboratory initiative is provided by the VA Office of Patient Care Services. NR 25 TC 2 Z9 2 U1 2 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1062-8606 EI 1555-824X J9 AM J MED QUAL JI Am. J. Med. Qual. PD MAR-APR PY 2016 VL 31 IS 2 BP 139 EP 146 DI 10.1177/1062860614559743 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DF8VL UT WOS:000371638300007 PM 25414376 ER PT J AU Tanner, NT Kanodra, NM Gebregziabher, M Payne, E Halbert, CH Warren, GW Egede, LE Silvestri, GA AF Tanner, Nichole T. Kanodra, Neeti M. Gebregziabher, Mulugeta Payne, Elizabeth Halbert, Chanita Hughes Warren, Graham W. Egede, Leonard E. Silvestri, Gerard A. TI The Association between Smoking Abstinence and Mortality in the National Lung Screening Trial SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE smoking cessation; lung neoplasms; early detection of cancer; tobacco ID UNITED-STATES; COST-EFFECTIVENESS; CLINICAL-PRACTICE; CANCER-PATIENTS; PUBLIC-HEALTH; TOBACCO USE; CESSATION; PARTICIPANTS; GUIDELINE; DIAGNOSIS AB Rationale: Smoking is the largest contributor to lung cancer risk, and those who continue to smoke after diagnosis have a worse survival. Screening for lung cancer with low-dose computed tomography (LDCT) reduces mortality in high-risk individuals. Smoking cessation is an essential component of a high-quality screening program. Objectives: To quantify the effects of smoking history and abstinence on mortality in high-risk individuals who participated in the NLST (National Lung Screening Trial). Methods: This is a secondary analysis of a randomized controlled trial (NLST). Measurements and Main Results: Measurements included self-reported demographics, medical and smoking history, and lung cancer-specific and all-cause mortality. Cox regression was used to study the association of mortality with smoking status and pack-years. Kaplan-Meier survival curves were examined for differences in survival based on trial arm and smoking status. Current smokers had an increased lung cancer-specific (hazard ratio [HR], 2.14-2.29) and all-cause mortality (HR, 1.79-1.85) compared with former smokers irrespective of screening arm. Former smokers in the control arm abstinent for 7 years had a 20% mortality reduction comparable with the benefit reported with LDCT screening in the NLST. The maximum benefit was seen with the combination of smoking abstinence at 15 years and LDCT screening, which resulted in a 38% reduction in lung cancer-specific mortality (HR, 0.62; 95% confidence interval, 0.51-0.76). Conclusions: Seven years of smoking abstinence reduced lung cancer-specific mortality at a magnitude comparable with LDCT screening. This reduction was greater when abstinence was combined with screening, highlighting the importance of smoking cessation efforts-in screening programs. C1 [Tanner, Nichole T.; Kanodra, Neeti M.; Silvestri, Gerard A.] Med Univ S Carolina, Div Pulm Crit Care & Sleep Med, Charleston, SC 29425 USA. [Tanner, Nichole T.; Gebregziabher, Mulugeta; Halbert, Chanita Hughes; Egede, Leonard E.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Gebregziabher, Mulugeta; Payne, Elizabeth] Med Univ S Carolina, Dept Psychiat & Behav Sci, Hollings Canc Ctr, 171 Ashley Ave, Charleston, SC 29425 USA. [Halbert, Chanita Hughes] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA. [Warren, Graham W.] Med Univ S Carolina, Dept Cell & Mol Pharmacol, Charleston, SC 29425 USA. [Warren, Graham W.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson Vet Affairs Hosp, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA. RP Tanner, NT (reprint author), 96 Jonathan Lucas St, Charleston, SC 29425 USA. EM tripici@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU OneBreath Foundation FX Supported by OneBreath Foundation. NR 33 TC 12 Z9 12 U1 2 U2 6 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD MAR 1 PY 2016 VL 193 IS 5 BP 534 EP 541 DI 10.1164/rccm.201507-1420OC PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DG0KI UT WOS:000371753300014 PM 26502000 ER PT J AU Clark, DJ Neptune, RR Behrman, AL Kautz, SA AF Clark, David J. Neptune, Richard R. Behrman, Andrea L. Kautz, Steven A. TI Locomotor Adaptability Task Promotes Intense and Task-Appropriate Output From the Paretic Leg During Walking SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Electromyography; Rehabilitation; Stroke; Walking ID COORDINATION; HEMIPARESIS; PERFORMANCE; POSTSTROKE; LENGTH; STROKE AB Objective: To test the hypothesis that participants with stroke will exhibit appropriate increase in muscle activation of the paretic leg when taking a long step with the nonparetic leg compared to during steady-state walking, with a consequent increase in biomechanical output and symmetry during the stance phase of the modified gait cycle. Design: Single-session observational study. Setting: Clinical research center in an outpatient hospital setting. Participants: Adults with chronic poststroke hemiparesis (N=15). Interventions: Participants walked on an instrumented treadmill while kinetic, kinematic, and electromyogram data were recorded. Participants performed steady-state walking and a separate trial of the long-step adaptability task in which they were instructed to intermittently take a longer step with the nonparetic leg. Main Outcome Measures: Forward progression, propulsive force, and neuromuscular activation during walking. Results: Participants performed the adaptability task successfully and demonstrated greater neuromuscular activation in appropriate paretic leg muscles, particularly increased activity in paretic plantarflexor muscles. Propulsion and forward progression by the paretic leg were also increased. Conclusions: These findings support the assertion that the nonparetic long-step task may be effective for use in poststroke locomotor rehabilitation to engage the paretic leg and promote recovery of walking. (C) 2016 by the American Congress of Rehabilitation Medicine C1 [Clark, David J.] Malcom Randall Vet Affairs Med Ctr, Brain Rehabil Res Ctr, Gainesville, FL 32608 USA. [Clark, David J.] Univ Florida, Dept Aging & Geriatr Res, Gainesville, FL USA. [Neptune, Richard R.] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA. [Behrman, Andrea L.] Univ Louisville, Dept Neurol Surg, Louisville, KY 40292 USA. [Kautz, Steven A.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Kautz, Steven A.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Kautz, Steven A.] Med Univ S Carolina, Dept Hlth Profess, Div Phys Therapy, Charleston, SC 29425 USA. RP Clark, DJ (reprint author), Malcom Randall Vet Affairs Med Ctr, Brain Rehabil Res Ctr 151A, 1601 SW Archer Rd, Gainesville, FL 32608 USA. EM davidclark@ufl.edu FU National Institutes of Health [HD-46820, GM-109040]; U.S. Department of Veterans Affairs Rehabilitation Research and Development Service [B3983R, B4888M, B7176W] FX Supported by the National Institutes of Health (grant nos. HD-46820 and GM-109040) and the U.S. Department of Veterans Affairs Rehabilitation Research and Development Service (Merit Review B3983R and Career Development Awards B4888M and B7176W). The contents do not represent the views of the U.S Department of Veterans Affairs or the U.S. government. NR 10 TC 2 Z9 2 U1 5 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAR PY 2016 VL 97 IS 3 BP 493 EP 496 DI 10.1016/j.apmr.2015.10.081 PG 4 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA DG1TJ UT WOS:000371850100018 PM 26525528 ER PT J AU Placzek, AN Molfese, DL Khatiwada, S Di Prisco, GV Huang, W Sidrauski, C Krnjevic, K Amos, CL Ray, R Dani, JA Walter, P Salas, R Costa-Mattioli, M AF Placzek, Andon N. Molfese, David L. Khatiwada, Sanjeev Di Prisco, Gonzalo Viana Huang, Wei Sidrauski, Carmela Krnjevic, Kresimir Amos, Christopher L. Ray, Russell Dani, John A. Walter, Peter Salas, Ramiro Costa-Mattioli, Mauro TI Translational control of nicotine -evoked synaptic potentiation in mice and neuronal responses in human smokers by elF2 alpha SO ELIFE LA English DT Article ID LONG-TERM POTENTIATION; DOPAMINE NEURONS; BINDING-PROTEIN; IN-VIVO; HOMEOSTASIS; EXPOSURE; SMOKING; REWARD; DEPRESSION; WITHDRAWAL AB Adolescents are particularly vulnerable to nicotine, the principal addictive component driving tobacco smoking. In a companion study, we found that reduced activity of the translation initiation factor eIF2 alpha underlies the hypersensitivity of adolescent mice to the effects of cocaine. Here we report that nicotine potentiates excitatory synaptic transmission in ventral tegmental area dopaminergic neurons more readily in adolescent mice compared to adults. Adult mice with genetic or pharmacological reduction in p-eIF2 alpha-mediated translation are more susceptible to nicotine's synaptic effects, like adolescents. When we investigated the influence of allelic variability of the Eif2s1 gene (encoding eIF2 alpha) on reward -related neuronal responses in human smokers, we found that a single nucleotide polymorphism in the Eif2s1 gene modulates mesolimbic neuronal reward responses in human smokers. These findings suggest that p-eIF2 alpha regulates synaptic actions of nicotine in both mice and humans, and that reduced p-eIF2 alpha may enhance susceptibility to nicotine (and other drugs of abuse) during adolescence. C1 [Placzek, Andon N.; Khatiwada, Sanjeev; Di Prisco, Gonzalo Viana; Huang, Wei; Ray, Russell; Salas, Ramiro; Costa-Mattioli, Mauro] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA. [Placzek, Andon N.; Khatiwada, Sanjeev; Di Prisco, Gonzalo Viana; Huang, Wei; Ray, Russell; Costa-Mattioli, Mauro] Baylor Coll Med, Memory & Brain Res Ctr, Houston, TX 77030 USA. [Molfese, David L.; Salas, Ramiro] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Molfese, David L.; Salas, Ramiro] Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA. [Khatiwada, Sanjeev] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA. [Sidrauski, Carmela; Walter, Peter] Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA USA. [Krnjevic, Kresimir] McGill Univ, Dept Physiol, Montreal, PQ, Canada. [Amos, Christopher L.] Dartmouth Coll, Geisel Sch Med, Dept Community & Family Med, Ctr Genom Med, 1 Med Ctr Dr, Lebanon, NH 03756 USA. [Dani, John A.] Perelman Sch Med, Mahoney Inst Neurosci, Dept Neurosci, Philadelphia, PA USA. [Placzek, Andon N.] Mercer Univ, Sch Med, Div Basic Med Sci, Macon, GA 31207 USA. [Sidrauski, Carmela] Calico LLC, San Francisco, CA USA. RP Costa-Mattioli, M (reprint author), Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA.; Costa-Mattioli, M (reprint author), Baylor Coll Med, Memory & Brain Res Ctr, Houston, TX 77030 USA. EM costamat@bcm.edu FU National Institute of Mental Health [MH096816]; National Institute of Neurological Disorders and Stroke [NS076708, NS21229]; National Institute on Drug Abuse [DA09411, DA026539, DA09167]; Howard Hughes Medical Institute; U.S. Department of Veterans Affairs [VHA5101CX000994] FX National Institute of Mental Health MH096816 Mauro Costa-Mattioli; National Institute of Neurological Disorders and Stroke NS076708, NS21229 John A Dani Mauro Costa-Mattioli; National Institute on Drug Abuse DA09411, DA026539, DA09167 John A Dani Ramiro Salas; Howard Hughes Medical Institute PW Peter Walter; U.S. Department of Veterans Affairs VHA5101CX000994 Ramiro Salas NR 32 TC 3 Z9 3 U1 1 U2 2 PU ELIFE SCIENCES PUBLICATIONS LTD PI CAMBRIDGE PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND SN 2050-084X J9 ELIFE JI eLife PD MAR 1 PY 2016 VL 5 AR e12056 DI 10.7554/eLife.12056 PG 11 WC Biology SC Life Sciences & Biomedicine - Other Topics GA DG2IA UT WOS:000371889400001 ER PT J AU Liu, M Blanco-Centurion, C Konadhode, RR Luan, LJ Shiromani, PJ AF Liu, Meng Blanco-Centurion, Carlos Konadhode, Roda Rani Luan, Liju Shiromani, Priyattam J. TI Orexin gene transfer into the amygdala suppresses both spontaneous and emotion-induced cataplexy in orexin-knockout mice SO EUROPEAN JOURNAL OF NEUROSCIENCE LA English DT Article DE amygdala; emotion; narcolepsy; orexin; predator odour; sleep ID HUMAN NARCOLEPSY; NEURONS; SLEEP; RAT; MUTATION; BEHAVIOR; RECEPTOR; MODELS; BRAIN; ONSET AB Narcolepsy is a chronic sleep disorder linked to the loss of orexin-producing neurons in the hypothalamus. Cataplexy, a sudden loss of muscle tone during waking, is an important distinguishing symptom of narcolepsy and it is often triggered by strong emotions. The neural circuit underlying cataplexy attacks is not known, but is likely to involve the amygdala, a region implicated in regulating emotions. In mice models of narcolepsy, transfer of the orexin gene into surrogate neurons has been successful in ameliorating narcoleptic symptoms. However, it is not known whether this method also blocks cataplexy triggered by strong emotions. To examine this possibility, the gene encoding mouse prepro-orexin was transferred into amygdala neurons of orexin-knockout (KO) mice (rAAV-orexin; n=8). Orexin-KO mice that did not receive gene transfer (no-rAAV; n=7) or received only the reporter gene (rAAV-GFP; n=7) served as controls. Three weeks later, the animal's sleep and behaviour were recorded at night (no-odour control night), followed by another recording at night in the presence of predator odour (odour night). Orexin-KO mice given the orexin gene transfer into surrogate amygdala neurons had significantly less spontaneous bouts of cataplexy, and predator odour did not induce cataplexy compared with control mice. Moreover, the mice with orexin gene transfer were awake more during the odour night. These results demonstrate that orexin gene transfer into amygdala neurons can suppress both spontaneous and emotion-induced cataplexy attacks in narcoleptic mice. It suggests that manipulating amygdala pathways is a potential strategy for treating cataplexy in narcolepsy. C1 [Liu, Meng; Blanco-Centurion, Carlos; Konadhode, Roda Rani; Luan, Liju; Shiromani, Priyattam J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA. [Shiromani, Priyattam J.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. RP Liu, M (reprint author), Med Univ S Carolina, Charleston, SC 29425 USA.; Shiromani, PJ (reprint author), Ralph H Johnson VA Med Ctr, Charleston, SC USA. EM liumen@musc.edu; shiroman@musc.edu FU Medical Research Service of the Department of Veterans Affairs [I01 BX000798]; NIH [1K01AG041520, NS052287, NS084477, NS079940, HL091363] FX This study was supported by Medical Research Service of the Department of Veterans Affairs (I01 BX000798) and NIH grants 1K01AG041520, NS052287, NS084477, NS079940 and HL091363. We thank Dr Patrick K. Randall for support with the SPSS statistical analysis program. NR 34 TC 1 Z9 1 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0953-816X EI 1460-9568 J9 EUR J NEUROSCI JI Eur. J. Neurosci. PD MAR PY 2016 VL 43 IS 5 BP 681 EP 688 DI 10.1111/ejn.13158 PG 8 WC Neurosciences SC Neurosciences & Neurology GA DG2PN UT WOS:000371909800009 PM 26741960 ER PT J AU Burke, RE Johnson-Koenke, R Nowels, C Silveira, MJ Jones, J Bekelman, DB AF Burke, Robert E. Johnson-Koenke, Rachel Nowels, Carolyn Silveira, Maria J. Jones, Jacqueline Bekelman, David B. TI Can we engage caregiver spouses of patients with heart failure with a low-intensity, symptom-guided intervention? SO HEART & LUNG LA English DT Article DE Symptom management; Heart failure; Caregiver; Palliative care; Quality of life ID QUALITY-OF-LIFE; INFORMAL CAREGIVERS; PALLIATIVE CARE; TRANSITIONAL CARE; FAMILY CAREGIVERS; SELF-MANAGEMENT; OLDER-ADULTS; TRIAL; SUPPORT; METAANALYSIS AB Objective: Evaluate a pilot intervention to engage caregivers in management of heart failure (HF) patient symptoms. Background: HF impairs quality of life; caregivers provide an important role in HF management. Methods: We developed modules to help patients report and caregivers alleviate symptoms of depression, pain, dyspnea, and fatigue. Semi-structured interviews followed by a mixed inductive and deductive, team based analysis were used to evaluate acceptability and feasibility in patients with HF and their caregivers. Results: Participants (n = 22) expressed significant interest but few used the modules in follow-up. We identified three barriers to acceptability and feasibility: the quality of dyadic relationship, the timing and structure of the intervention, and the patient's perceived control over their illness. Conclusions: Future interventions should evaluate dyadic relationship dynamics, match the timing and content of the intervention to the patient population, and enroll patients with perceived control over their illness to maximize intervention acceptability and feasibility. Published by Elsevier Inc. C1 [Burke, Robert E.; Johnson-Koenke, Rachel; Bekelman, David B.] Denver VA Med Ctr, Dept Med, Denver, CO USA. [Burke, Robert E.; Nowels, Carolyn; Bekelman, David B.] Univ Colorado, Denver Sch Med, Dept Med, Div Gen Internal Med, Anschutz Med Campus, Aurora, CO USA. [Silveira, Maria J.] Ann Arbor Vet Affairs Med Ctr, Ctr Clin Management Res, Ann Arbor, MI USA. [Silveira, Maria J.] Univ Michigan, Dept Internal Med, Div Gen Med, Ann Arbor, MI 48109 USA. [Jones, Jacqueline] Univ Colorado, Coll Nursing, Aurora, CO USA. RP Burke, RE (reprint author), Denver VA Med Ctr, 1055 Clermont St, Denver, CO 80220 USA. EM Robert.Burke5@va.gov FU VA Chronic Heart Failure Quality Enhancement Research Initiative (QUERI) Locally Initiated Project award; VA [IIR 08-0309]; VA Career Development Award [08-022] FX The study was supported by a VA Chronic Heart Failure Quality Enhancement Research Initiative (QUERI) Locally Initiated Project award to Drs. Burke and Bekelman. Dr. Silveira was supported by VA IIR 08-0309. Dr. Bekelman was supported by a VA Career Development Award (08-022). These funding sources had no role in the design, interpretation, or presentation of results. This report represents the views of the authors and not necessarily those of the U.S. Department of Veterans Affairs. NR 57 TC 0 Z9 0 U1 6 U2 9 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0147-9563 EI 1527-3288 J9 HEART LUNG JI Heart Lung PD MAR-APR PY 2016 VL 45 IS 2 BP 114 EP 120 DI 10.1016/j.hrtlng.2015.12.006 PG 7 WC Cardiac & Cardiovascular Systems; Nursing; Respiratory System SC Cardiovascular System & Cardiology; Nursing; Respiratory System GA DG1SL UT WOS:000371847700006 PM 26831372 ER PT J AU Choi, J Tate, JA Rogers, MA Donahoe, MP Hoffman, LA AF Choi, JiYeon Tate, Judith A. Rogers, Mary Alana Donahoe, Michael P. Hoffman, Leslie A. TI Depressive symptoms and anxiety in intensive care unit (ICU) survivors after ICU discharge SO HEART & LUNG LA English DT Article DE Post intensive care unit; Intensive care unit survivors; Depressive symptoms; Anxiety; Recovery ID QUALITY-OF-LIFE; PROLONGED MECHANICAL VENTILATION; RESPIRATORY-DISTRESS-SYNDROME; LONG-TERM OUTCOMES; RANDOMIZED CONTROLLED-TRIAL; CRITICALLY-ILL PATIENTS; ACUTE LUNG INJURY; CRITICAL ILLNESS; POSTTRAUMATIC-STRESS; HEALTH AB Background: The association between intensive care unit (ICU) survivors' psychological sequelae, individual care needs, and discharge disposition has not been evaluated. Objective: To describe depressive symptoms and anxiety in ICU survivors and explore these symptoms based on individual care needs and discharge disposition for 4 months post-ICU discharge. Methods: We analyzed data from 39 ICU survivors who self-reported measures of depressive symptoms (Center for Epidemiologic Studies-Depression 10 items [CESD-10]) and anxiety (Shortened Profile of Mood States-Anxiety subscale [POMS-A]). Results: A majority of patients reported CESD-10 scores above the cut off (>= 8) indicating risk for clinical depression. POMS-A scores were highest within 2 weeks post-ICU discharge and decreased subsequently. Data trends suggest worse depressive symptoms and anxiety when patients had moderate to high care needs and/or were unable to return home. Conclusion: ICU survivors who need caregiver assistance and extended institutional care reported trends of worse depressive symptoms and anxiety. (C) 2016 Elsevier Inc. All rights reserved. C1 [Choi, JiYeon; Hoffman, Leslie A.] Univ Pittsburgh, Sch Nursing, Dept Acute & Tertiary Care, Pittsburgh, PA 15261 USA. [Donahoe, Michael P.] Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA. [Tate, Judith A.] Ohio State Univ, Coll Nursing, Columbus, OH 43210 USA. [Rogers, Mary Alana] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Hoffman, Leslie A.] Clin & Translat Sci Inst, San Francisco, CA USA. RP Choi, J (reprint author), Univ Pittsburgh, Sch Nursing, 336 Victoria Bldg,3500 Victoria St, Pittsburgh, PA 15261 USA. EM jic11@pitt.edu FU NIH, National Institute of Nursing Research, U.S. Public Health Service [F32 NR 011271, T32 NR 008857]; Rehabilitation Nursing Foundation [FEL-0905]; Undergraduate Research Mentorship Program, University of Pittsburgh School of Nursing FX Funding was provided by the NIH, National Institute of Nursing Research, U.S. Public Health Service (F32 NR 011271 and T32 NR 008857) and Rehabilitation Nursing Foundation, Fellow Research Award (FEL-0905). Work from Ms. Mary Alana Rogers was supported by the Undergraduate Research Mentorship Program, University of Pittsburgh School of Nursing. The authors declare no conflicts of interest. NR 54 TC 1 Z9 1 U1 3 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0147-9563 EI 1527-3288 J9 HEART LUNG JI Heart Lung PD MAR-APR PY 2016 VL 45 IS 2 BP 140 EP 146 DI 10.1016/j.hrtlng.2015.12.002 PG 7 WC Cardiac & Cardiovascular Systems; Nursing; Respiratory System SC Cardiovascular System & Cardiology; Nursing; Respiratory System GA DG1SL UT WOS:000371847700010 PM 26791248 ER PT J AU Blosnich, JR Bossarte, RM AF Blosnich, John R. Bossarte, Robert M. TI Childhood Abuse and Military Experience-Important Information to Better Serve Those Who Have Served SO JAMA PSYCHIATRY LA English DT Editorial Material C1 [Blosnich, John R.] US Dept Vet Affairs, VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Blosnich, John R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA. [Bossarte, Robert M.] US Dept Vet Affairs, Off Publ Hlth, Washington, DC USA. [Bossarte, Robert M.] Univ Rochester, Dept Psychiat, Rochester, NY USA. [Bossarte, Robert M.] Univ Rochester, Dept Publ Hlth Sci, Rochester, NY USA. RP Blosnich, JR (reprint author), VA Pittsburgh Healthcare Syst, Dept Vet Affairs, Ctr Hlth Equ Res & Promot, Univ Dr C 151C-U,Bldg 30, Pittsburgh, PA 15240 USA. EM john.blosnich@va.gov NR 8 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD MAR PY 2016 VL 73 IS 3 BP 195 EP 196 DI 10.1001/jamapsychiatry.2015.2736 PG 2 WC Psychiatry SC Psychiatry GA DF8NC UT WOS:000371613500005 PM 26817448 ER PT J AU Carter, SP DiMauro, J Renshaw, KD Curby, TW Babson, KA Bonn-Miller, MO AF Carter, Sarah P. DiMauro, Jennifer Renshaw, Keith D. Curby, Timothy W. Babson, Kimberly A. Bonn-Miller, Marcel O. TI Longitudinal associations of friend-based social support and PTSD symptomatology during a cannabis cessation attempt SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE PTSD; Social support; Substance use; Longitudinal study; Military ID POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE USE DISORDERS; PSYCHOLOGICAL DISTRESS; CAREGIVER BURDEN; MENTAL-ILLNESS; VETERANS; SYMPTOMS; PARTNERS; ABUSE; METAANALYSIS AB Research supports bidirectional associations between social support and posttraumatic stress disorder (PTSD), whereby social support may buffer against PTSD, and individuals with PTSD may experience decreasing support over time. Research examining contexts that may affect these relations is needed. This study examined the longitudinal associations between PTSD and social support from friends over a 6-month period in 116 veterans with cannabis dependence who had recently initiated an attempt to quit cannabis use. A cross-lagged autoregressive model revealed a significant, negative relation between earlier PTSD symptoms and later support. An exploratory multigroup analysis comparing those with and without a relapse in the first month after their quit attempt revealed that the significant negative association between PTSD and future support was present only in those who relapsed. Although this analysis was limited by a small sample size, results suggest that substance use may be an influential contextual variable that impacts the longitudinal associations between PTSD and support. (c) 2016 Elsevier Ltd. All rights reserved. C1 [Carter, Sarah P.; DiMauro, Jennifer; Renshaw, Keith D.; Curby, Timothy W.] George Mason Univ, Dept Psychol, 4400 Univ Dr,3F5, Fairfax, VA 22030 USA. [Babson, Kimberly A.; Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, 795 Willow Rd, Menlo Pk, CA 94025 USA. [Babson, Kimberly A.; Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd, Menlo Pk, CA 94025 USA. [Bonn-Miller, Marcel O.] Philadelphia VA Med Ctr, Ctr Excellence Subst Abuse Treatment & Educ, 3900 Woodland Ave, Philadelphia, PA 19104 USA. [Bonn-Miller, Marcel O.] Univ Penn, Perelman Sch Med, Dept Psychiat, 3440 Market St,Suite 370, Philadelphia, PA 19104 USA. RP Carter, SP (reprint author), George Mason Univ, Dept Psychol, 4400 Univ Dr,3F5, Fairfax, VA 22030 USA. EM scarte18@gmu.edu FU VA Clinical Science Research and Development (CSR&D) Career Development Award [CDA-2, 1IK2CX1023-01A1] FX This work was supported, in part, by a VA Clinical Science Research and Development (CSR&D) Career Development Award (CDA-2; 1IK2CX1023-01A1) awarded to Dr. Babson. Data for the parent study were collected as part of VA CSR&D CDA-2 awarded to Dr. Bonn-Miller. NR 43 TC 0 Z9 0 U1 3 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 EI 1873-7897 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD MAR PY 2016 VL 38 BP 62 EP 67 DI 10.1016/j.janxdis.2016.01.008 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DF6EQ UT WOS:000371449100008 PM 26836369 ER PT J AU Korte, KJ Allan, NP Gros, DF Acierno, R AF Korte, Kristina J. Allan, Nicholas P. Gros, Daniel F. Acierno, Ron TI Differential treatment response trajectories in individuals with subclinical and clinical PTSD SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE PTSD; Posttraumatic stress disorder; Subclinical; Subthreshold; Military; Veterans; Growth curve modeling ID POSTTRAUMATIC-STRESS-DISORDER; COVARIANCE STRUCTURE-ANALYSIS; COGNITIVE PROCESSING THERAPY; CONFIRMATORY FACTOR-ANALYSIS; RANDOMIZED CONTROLLED-TRIAL; SUBTHRESHOLD PTSD; PRIMARY-CARE; BEHAVIORAL ACTIVATION; PROLONGED EXPOSURE; MILITARY VETERANS AB Subclinical presentations of posttraumatic stress disorder (PTSD), wherein patients are one or two symptom criteria short of the full disorder, are prevalent and associated with levels of distress and impaired functioning approximating that of full PTSD. Nonetheless, research examining treatment efficacy for this group is in the nascent stage. The purpose of the present study was to examine whether the sub clinical PTSD group would: (1) show a greater reduction in PTSD symptoms at pre and post treatment in response to an exposure based treatment and (2) show a greater rate of change over the course of treatment, when compared to the full criteria PTSD group. We also examined whether differences would emerge when examining PTSD symptom clusters. Consistent with predictions, the subclinical PTSD group demonstrated a greater reduction in PTSD symptoms at post-treatment (29%) than those with a PTSD diagnosis (14%). Further, the groups had different treatment trajectories, with the subclinical PTSD group showing a marginally greater rate of change during the course of treatment. Findings also varied by symptom cluster with the subclinical group showing a greater rate of change in the intrusions, hyper vigilance, and avoidance symptom clusters. There was not a significant between group difference in the numbing symptom cluster. This study provides preliminary evidence that treating PTSD symptoms at the subclinical level may result in a larger, and more rapid symptom reduction, and thus has implications supporting treatment earlier in the developmental trajectory of the disorder. Published by Elsevier Ltd. C1 [Korte, Kristina J.; Allan, Nicholas P.; Gros, Daniel F.; Acierno, Ron] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Korte, Kristina J.; Allan, Nicholas P.; Gros, Daniel F.; Acierno, Ron] Med Univ S Carolina, Charleston, SC 29425 USA. RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM kortek@musc.edu; grosd@musc.edu FU CSRD VA [IK2 CX000845]; NIAAA NIH HHS [T32 AA007474] NR 49 TC 0 Z9 0 U1 4 U2 13 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 EI 1873-7897 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD MAR PY 2016 VL 38 BP 95 EP 101 DI 10.1016/j.janxdis.2016.01.006 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DF6EQ UT WOS:000371449100012 PM 26874291 ER PT J AU Krigbaum, H Takemoto, S Kim, HT Kuo, AC AF Krigbaum, Henry Takemoto, Steven Kim, Hubert T. Kuo, Alfred C. TI Costs and Complications of Short Versus Long Cephalomedullary Nailing of OTA 31-A2 Proximal Femur Fractures in U.S. Veterans SO JOURNAL OF ORTHOPAEDIC TRAUMA LA English DT Article DE cephalomedullary nail; intertrochanteric femur fracture ID INTERTROCHANTERIC HIP-FRACTURES; INTRAMEDULLARY NAILS; GAMMA-NAIL; A2 AB Objectives: In fractures without subtrochanteric extension, the indications for the use of short versus long cephalomedullary nails (CMNs) for intertrochanteric femur fractures are unclear. We hypothesized that long nails would be associated with higher costs and similar complication rates. Design: Retrospective comparative study. Setting: United States Department of Veterans Affairs Medical Centers. Participants: Patients receiving CMNs for OTA 31-A2 pertrochanteric fractures from 2001 to 2010. Interventions: Short versus long cephalomedullary nailing. Main Outcome Measurements: Costs, perioperative complications, readmissions, surgical failures, and mortality. Results: We identified 262 patients with OTA 31-A2 pertrochanteric fractures (125 treated with short CMNs and 137 treated with long CMNs). The 2 cohorts had similar demographic and medical characteristics. There were no significant differences in perioperative complications, readmissions within 30 days, surgical failures within one year, or death within 30 days or one year. The average cost of hospitalization was significantly higher for the cohort treated with long nails (greater than $7000 in actual costs, and greater than $3000 when statistically adjusted for differences in postoperative lengths of stay). Multivariable analyses showed no significant differences in the rates of development of at least one complication, readmission, or death. Conclusions: In a cohort of patients with similar characteristics and fracture patterns, the use of long CMNs was associated with similar rates of complications, readmission, and reoperations, but significantly higher costs than with the use of short nails. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence. C1 [Kuo, Alfred C.] San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Kuo, AC (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM kuoac@orthosurg.ucsf.edu FU James O. Johnston resident research grant FX Supported by the James O. Johnston resident research grant to H. Krigbaum. NR 14 TC 2 Z9 2 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0890-5339 EI 1531-2291 J9 J ORTHOP TRAUMA JI J. Orthop. Trauma PD MAR PY 2016 VL 30 IS 3 BP 125 EP 129 DI 10.1097/BOT.0000000000000521 PG 5 WC Orthopedics; Sport Sciences SC Orthopedics; Sport Sciences GA DF5IK UT WOS:000371384900005 PM 26894639 ER PT J AU Suhasini, AN Wang, L Holder, KN Lin, AP Bhatnagar, H Kim, SW Moritz, AW Aguiar, RCT AF Suhasini, A. N. Wang, L. Holder, K. N. Lin, A-P Bhatnagar, H. Kim, S-W Moritz, A. W. Aguiar, R. C. T. TI A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma SO LEUKEMIA LA English DT Article ID NON-HODGKIN-LYMPHOMA; MICROVESSEL DENSITY; GENE-EXPRESSION; CYCLIC-AMP; MURINE LYMPHOMAS; PDE4 INHIBITORS; PROLIFERATION; CANCER; VEGF; CHEMOTHERAPY AB Angiogenesis associates with poor outcome in diffuse large B-cell lymphoma (DLBCL), but the contribution of the lymphoma cells to this process remains unclear. Addressing this knowledge gap may uncover unsuspecting proangiogenic signaling nodes and highlight alternative antiangiogenic therapies. Here, we identify the second messenger cyclic-AMP (cAMP) and the enzyme that terminates its activity, phosphodiesterase 4B (PDE4B), as regulators of B-cell lymphoma angiogenesis. We first show that cAMP, in a PDE4B-dependent manner, suppresses PI3K/AKT signals to downmodulate vascular endothelial growth factor (VEGF) secretion and vessel formation in vitro. Next, we create a novel mouse model that combines the lymphomagenic Myc transgene with germline deletion of Pde4b. We show that lymphomas developing in a Pde4b-null background display significantly lower microvessel density (MVD) in association with lower VEGF levels and PI3K/AKT activity. We recapitulate these observations by treating lymphoma-bearing mice with the FDA-approved PDE4 inhibitor, Roflumilast. Lastly, we show that primary human DLBCLs with high PDE4B expression display significantly higher MVD. Here, we defined an unsuspected signaling circuitry in which the cAMP generated in lymphoma cells downmodulates PI3K/AKT and VEGF secretion to negatively influence vessel development in the microenvironment. These data identify PDE4 as an actionable antiangiogenic target in DLBCL. C1 [Suhasini, A. N.; Wang, L.; Lin, A-P; Bhatnagar, H.; Kim, S-W; Aguiar, R. C. T.] Univ Texas Hlth Sci Ctr San Antonio, Div Hematol & Med Oncol, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Holder, K. N.; Moritz, A. W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Aguiar, R. C. T.] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA. [Aguiar, R. C. T.] Audie Murphy VA Hosp, South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Aguiar, RCT (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Hematol & Med Oncol, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM aguiarr@uthscsa.edu FU CPRIT [RP110200, RP150277]; William and Ella Owens Medical Research Foundation; Cancer Center support grant [P30 CA054174] FX We thank the Cancer Therapy and Research Center at UTHSCSA Core Pathology Tissue Bank for procurement of the primary DLBCL samples. We acknowledge Patricia Dahia for insightful suggestions during the execution of this project. This work was supported by CPRIT awards RP110200 and RP150277 (to RCTA), a grant from the William and Ella Owens Medical Research Foundation (to RCTA), and a Cancer Center support grant P30 CA054174. NR 48 TC 4 Z9 4 U1 0 U2 7 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 EI 1476-5551 J9 LEUKEMIA JI Leukemia PD MAR PY 2016 VL 30 IS 3 BP 617 EP 626 DI 10.1038/leu.2015.302 PG 10 WC Oncology; Hematology SC Oncology; Hematology GA DF9NR UT WOS:000371688500011 PM 26503641 ER PT J AU Cote, AJ McLeod, CM Farrell, MJ McClanahan, PD Dunagin, MC Raj, A Mauck, RL AF Cote, Allison J. McLeod, Claire M. Farrell, Megan J. McClanahan, Patrick D. Dunagin, Margaret C. Raj, Arjun Mauck, Robert L. TI Single-cell differences in matrix gene expression do not predict matrix deposition SO NATURE COMMUNICATIONS LA English DT Article ID MESENCHYMAL STEM-CELLS; MARROW STROMAL CELLS; HUMAN ARTICULAR CHONDROCYTES; BONE-MARROW; IN-VITRO; CHONDROGENIC DIFFERENTIATION; LINEAGE COMMITMENT; HETEROGENEITY; CARTILAGE; CULTURE AB Mesenchymal stem cells (MSCs) display substantial cell-to-cell heterogeneity, complicating their use in regenerative medicine. However, conventional bulk assays mask this variability. Here we show that both chondrocytes and chondrogenically induced MSCs exhibit substantial mRNA expression heterogeneity. Single-molecule RNA FISH to measure mRNA expression of differentiation markers in single cells reveals that sister cell pairs have high levels of mRNA variability, suggesting that marker expression is not heritable. Surprisingly, this variability does not correlate with cell-to-cell differences in cartilage-like matrix production. Transcriptome-wide analysis suggests that no combination of markers can predict functional potential. De-differentiating chondrocytes also show a disconnect between mRNA expression of the cartilage marker aggrecan and cartilage-like matrix accumulation. Altogether, these quantitative analyses suggest that sorting subpopulations based on these markers would only marginally enrich the progenitor population for ' superior' MSCs. Our results suggest that instantaneous mRNA abundance of canonical markers is tenuously linked to the chondrogenic phenotype at the single-cell level. C1 [Cote, Allison J.; McLeod, Claire M.; Farrell, Megan J.; McClanahan, Patrick D.; Dunagin, Margaret C.; Raj, Arjun; Mauck, Robert L.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA. [McLeod, Claire M.; Farrell, Megan J.; Mauck, Robert L.] Univ Penn, Perelman Sch Med, McKay Orthopaed Res Lab, Dept Orthopaed Surg, Philadelphia, PA 19104 USA. [McLeod, Claire M.; Mauck, Robert L.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA 19104 USA. RP Raj, A; Mauck, RL (reprint author), Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA.; Mauck, RL (reprint author), Univ Penn, Perelman Sch Med, McKay Orthopaed Res Lab, Dept Orthopaed Surg, Philadelphia, PA 19104 USA.; Mauck, RL (reprint author), Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA 19104 USA. EM arjunrajlab@gmail.com; lemauck@mail.med.upenn.edu OI Raj, Arjun/0000-0002-2915-6960 FU NSF CAREER award [1350601]; NIH New Innovator [1DP2OD008514]; Penn Center for Musculoskeletal Disorders [P30 AR050950]; NIH [R01 EB008722, R01 EB02425]; NIH training grant [T32 GM-07229, T32 HL007954]; NSF Graduate Research Fellowship [DGE-0822] FX A.R. acknowledges support from an NSF CAREER award (Grant Number 1350601), NIH New Innovator 1DP2OD008514, and a pilot grant from the Penn Center for Musculoskeletal Disorders P30 AR050950. R.L.M. acknowledges support from NIH grants R01 EB008722 and R01 EB02425. A.J.C. was supported by NIH training grant T32 GM-07229. C.M.M. was supported by NSF Graduate Research Fellowship DGE-0822 and by NIH training grant T32 HL007954. NR 70 TC 5 Z9 5 U1 2 U2 18 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD MAR PY 2016 VL 7 AR 10865 DI 10.1038/ncomms10865 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DF9WG UT WOS:000371712300001 PM 26936319 ER PT J AU O'Hare, AM Rodriguez, RA Bowling, CB AF O'Hare, Ann M. Rodriguez, Rudolph A. Bowling, Christopher Barrett TI Caring for patients with kidney disease: shifting the paradigm from evidence-based medicine to patient-centered care SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Review DE evidence-based medicine; patient-centered care; kidney disease; older adults; paradigm ID MULTIPLE CHRONIC CONDITIONS; SHARED DECISION-MAKING; QUALITY-OF-CARE; CLINICAL-PRACTICE GUIDELINES; STAGE RENAL-DISEASE; OLDER-ADULTS; UNITED-STATES; HEALTH-CARE; BLOOD-PRESSURE; TRIALS AB The last several decades have witnessed the emergence of evidence-based medicine as the dominant paradigm for medical teaching, research and practice. Under an evidence-based approach, populations rather than individuals become the primary focus of investigation. Treatment priorities are largely shaped by the availability, relevance and quality of evidence and study outcomes and results are assumed to have more or less universal significance based on their implications at the population level. However, population-level treatment goals do not always align with what matters the most to individual patients-who may weigh the risks, benefits and harms of recommended treatments quite differently. In this article we describe the rise of evidence-based medicine in historical context. We discuss limitations of this approach for supporting real-world treatment decisions-especially in older adults with confluent comorbidity, functional impairment and/or limited life expectancy-and we describe the emergence of more patient-centered paradigms to address these limitations. We explain how the principles of evidence-based medicine have helped to shape contemporary approaches to defining, classifying and managing patients with chronic kidney disease. We discuss the limitations of this approach and the potential value of a more patient-centered paradigm, with a particular focus on the care of older adults with this condition. We conclude by outlining ways in which the evidence-base might be reconfigured to better support real-world treatment decisions in individual patients and summarize relevant ongoing initiatives. C1 [O'Hare, Ann M.; Rodriguez, Rudolph A.] VA Puget Sound Hlth Care Syst, Hosp & Specialty Med Serv, Seattle, WA USA. [O'Hare, Ann M.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Innovat, Seattle, WA USA. [O'Hare, Ann M.; Rodriguez, Rudolph A.] Univ Washington, Dept Med, Seattle, WA USA. [Bowling, Christopher Barrett] Atlanta VA Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Decatur, GA USA. [Bowling, Christopher Barrett] Emory Univ, Dept Med, Atlanta, GA 30322 USA. RP O'Hare, AM (reprint author), VA Puget Sound Hlth Care Syst, Hosp & Specialty Med Serv, Seattle, WA USA.; O'Hare, AM (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Innovat, Seattle, WA USA.; O'Hare, AM (reprint author), Univ Washington, Dept Med, Seattle, WA USA. EM ann.ohare@va.gov FU NIH [1U01DK102150-01]; US Department of Veterans Affairs [1I01HX000961-01, 1IK2CX000856-01A1]; CDC [IAA 14FED1405094-0001]; National Institute on Aging [R03AG042336-01]; T. Franklin Williams Scholarship Award (Atlantic Philanthropies, Inc.); T. Franklin Williams Scholarship Award (John A. Hartford Foundation); T. Franklin Williams Scholarship Award (Association of Specialty Professors); T. Franklin Williams Scholarship Award (American Society of Nephrology); T. Franklin Williams Scholarship Award (American Geriatrics Society) FX A.M.O. receives research funding from the NIH (1U01DK102150-01), the US Department of Veterans Affairs (1I01HX000961-01) and the CDC (IAA 14FED1405094-0001). She receives an honorarium from UpToDate. C.B.B. receives funding from the National Institute on Aging (R03AG042336-01) and the T. Franklin Williams Scholarship Award (funding provided by Atlantic Philanthropies, Inc., the John A. Hartford Foundation, the Association of Specialty Professors, the American Society of Nephrology and the American Geriatrics Society) and the US Department of Veterans Affairs (1IK2CX000856-01A1). NR 89 TC 3 Z9 3 U1 6 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 EI 1460-2385 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD MAR PY 2016 VL 31 IS 3 BP 368 EP 375 DI 10.1093/ndt/gfv003 PG 8 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA DF7EU UT WOS:000371521400007 PM 25637639 ER PT J AU Barnett, PG Jeffers, A Smith, MW Chow, BK McFall, M Saxon, AJ AF Barnett, Paul G. Jeffers, Abra Smith, Mark W. Chow, Bruce K. McFall, Miles Saxon, Andrew J. TI Cost-Effectiveness of Integrating Tobacco Cessation Into Post-Traumatic Stress Disorder Treatment SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID QUALITY-OF-LIFE; SMOKING-CESSATION; VIETNAM VETERANS; ECONOMIC EVALUATIONS; CIGARETTE-SMOKING; MENTAL-ILLNESS; FORMER SMOKERS; HEALTH-CARE; MORTALITY; POPULATION AB We examined the cost-effectiveness of smoking cessation integrated with treatment for post-traumatic stress disorder (PTSD). Smoking veterans receiving care for PTSD (N = 943) were randomized to care integrated with smoking cessation versus referral to a smoking cessation clinic. Smoking cessation services, health care cost and utilization, quality of life, and biochemically-verified abstinence from cigarettes were assessed over 18-months of follow-up. Clinical outcomes were combined with literature on changes in smoking status and the effect of smoking on health care cost, mortality, and quality of life in a Markov model of cost-effectiveness over a lifetime horizon. We discounted cost and outcomes at 3% per year and report costs in 2010 US dollars. The mean of smoking cessation services cost was $1286 in those randomized to integrated care and $551 in those receiving standard care (P < .001). There were no significant differences in the cost of mental health services or other care. After 12 months, prolonged biochemically verified abstinence was observed in 8.9% of those randomized to integrated care and 4.5% of those randomized to standard care (P = .004). The model projected that Integrated Care added $836 in lifetime cost and generated 0.0259 quality adjusted life years (QALYs), an incremental cost-effectiveness ratio of $32 257 per QALY. It was 86.0% likely to be cost-effective compared to a threshold of $100 000/QALY. Smoking cessation integrated with treatment for PTSD was cost-effective, within a broad confidence region, but less cost-effective than most other smoking cessation programs reported in the literature. C1 [Barnett, Paul G.] Vet Affairs Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, 795 Willow Rd 152 MPD, Menlo Pk, CA 94025 USA. [Barnett, Paul G.] Univ Calif San Francisco, Dept Psychiat, Treatment Res Ctr, San Francisco, CA 94143 USA. [Jeffers, Abra] Stanford Univ, Dept Management Sci & Engn, Stanford, CA 94305 USA. [Smith, Mark W.] Truven Hlth Analyt, Bethesda, MD USA. [Chow, Bruce K.] Vet Affairs Cooperat Studies Program Coordinating, Palo Alto, CA USA. [McFall, Miles; Saxon, Andrew J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [McFall, Miles; Saxon, Andrew J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Barnett, PG (reprint author), Vet Affairs Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, 795 Willow Rd 152 MPD, Menlo Pk, CA 94025 USA. EM paul.barnett@va.gov FU Cooperative Studies Program; National Institute on Drug Abuse [P50 DA09253] FX This research was supported by the Cooperative Studies Program and grant P50 DA09253 from the National Institute on Drug Abuse. Trial registration: http://ClinicalTrials.gov identifier: NCT00118534. NR 49 TC 0 Z9 0 U1 3 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD MAR PY 2016 VL 18 IS 3 BP 267 EP 274 DI 10.1093/ntr/ntv094 PG 8 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA DF8HP UT WOS:000371598600006 PM 25943761 ER PT J AU Katzman, WB Vittinghoff, E Kado, DM Schafer, AL Wong, SS Gladin, A Lane, NE AF Katzman, Wendy B. Vittinghoff, Eric Kado, Deborah M. Schafer, Anne L. Wong, Shirley S. Gladin, Amy Lane, Nancy E. TI Study of Hyperkyphosis, Exercise and Function (SHEAF) Protocol of a Randomized Controlled Trial of Multimodal Spine-Strengthening Exercise in Older Adults With Hyperkyphosis SO PHYSICAL THERAPY LA English DT Article ID COMMUNITY-DWELLING MEN; OSTEOPOROTIC FRACTURES; PHYSICAL PERFORMANCE; RANCHO-BERNARDO; THORACIC KYPHOSIS; WOMEN; POSTURE; TRUNK; VALIDATION; GUIDELINES AB Background. Hyperkyphosis negatively affects health status, physical mobility, and quality of life, but there is no standard protocol for treating people with hyperkyphosis. Treatment options include targeted exercise. Objectives. This single-site randomized controlled trial (RCT) will determine the efficacy of a targeted multimodal spine-strengthening exercise program, compared with no exercise intervention, among community-dwelling men and women aged >= 60 years, with thoracic kyphosis >= 40 Design. The RCT is a parallel-group design, with 1:1 randomization to exercise and attentional control groups. Setting. The study will be conducted at one primary site (one academic medical center partnered with one local community medical center). Participants. One hundred men and women, aged years, with thoracic kyphosis degrees will be randomized. Intervention. The targeted multimodal spine-strengthening exercise intervention includes exercise and postural training delivered by a physical therapist in a group of 10 participants, 3 times a week for 6 months. Controls receive monthly health education meetings in a group of 10 participants and monthly calls from the study. coordinator to monitor physical activity and any adverse events. Measurements. The primary outcome is change in Cobb angle of kyphosis measured from lateral spine radiographs at baseline and 6 months. Secondary outcomes include change in physical function (assessed with the modified Physical Performance Test, Timed "Up & Go" Test, timed loaded standing, 4-m walk, and Six-Minute Walk Test) and health-related quality of life (assessed with the modified Scoliosis Research Society instrument [SRS-30] self-image domain and Patient Reported Outcomes Measurement Information System [PROMIS] global health and physical function indexes). Additional secondary outcomes include pain, physical activity level, spinal flexion and extension muscle strength, paraspinal extensor muscle density, and adverse events. Limitations. Blinding of the participants and instructors providing the intervention is not possible. Conclusions. The efficacy of a high-quality, adequately powered exercise intervention in men and women with kyphosis degrees will be evaluated to determine whether targeted multimodal spine-strengthening exercise reduces hyperkyphosis in older adults and improves important secondary outcomes of physical function and health-related quality of life. C1 [Katzman, Wendy B.; Wong, Shirley S.] Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, UCSF Box 0625, San Francisco, CA 94143 USA. [Vittinghoff, Eric; Schafer, Anne L.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Kado, Deborah M.] Univ Calif San Diego, Dept Family Med, San Diego, CA 92103 USA. [Kado, Deborah M.] Univ Calif San Diego, Dept Publ Hlth, San Diego, CA 92103 USA. [Kado, Deborah M.] Univ Calif San Diego, Dept Internal Med, San Diego, CA 92103 USA. [Schafer, Anne L.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Schafer, Anne L.] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA. [Gladin, Amy] Kaiser Permanente No Calif, San Francisco Med Ctr, San Francisco, CA USA. [Lane, Nancy E.] Univ Calif Davis, Dept Internal Med, Davis, CA 95616 USA. RP Katzman, WB (reprint author), Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, UCSF Box 0625, San Francisco, CA 94143 USA. EM wendy.katzman@ucsf.edu FU National Institute of Aging [R01-AG028]; US Department of Veterans Affairs, Veterans Health Administration, Office of Clinical Science Research and Development [5 IK2 CX000549] FX The study was funded by National Institute of Aging grant R01-AG028. Additional support was provided by the US Department of Veterans Affairs, Veterans Health Administration, Office of Clinical Science Research and Development, under grant 5 IK2 CX000549 (to Dr Schafer). NR 36 TC 1 Z9 1 U1 4 U2 5 PU AMER PHYSICAL THERAPY ASSOC PI ALEXANDRIA PA 1111 N FAIRFAX ST, ALEXANDRIA, VA 22314 USA SN 0031-9023 EI 1538-6724 J9 PHYS THER JI Phys. Ther. PD MAR PY 2016 VL 96 IS 3 BP 371 EP 381 DI 10.2522/ptj.20150171 PG 11 WC Orthopedics; Rehabilitation SC Orthopedics; Rehabilitation GA DF6FV UT WOS:000371452200013 PM 26251480 ER PT J AU Jain, S Keys, D Martin, S Edelstein, CL Jani, A AF Jain, Swati Keys, Daniel Martin, Sandra Edelstein, Charles L. Jani, Alkesh TI Protection From Apoptotic Cell Death During Cold Storage Followed by Rewarming in 13-Lined Ground Squirrel Tubular Cells: The Role of Prosurvival Factors X-Linked Inhibitor of Apoptosis and PhosphoAkt SO TRANSPLANTATION LA English DT Article ID POLYCYSTIC KIDNEY-DISEASE; AKT PHOSPHORYLATION; EPITHELIAL-CELLS; HIBERNATION; INJURY; ISCHEMIA; MITOCHONDRIA; REPERFUSION; PROGRESSION; METABOLISM AB Background. Hibernators, such as the 13-lined ground squirrel, endure severe hypothermia during torpor followed by periodic rewarming (REW) during interbout arousal (IBA), proapoptotic conditions that are lethal to nonhibernatingmammals. We have previously shown that 13-lined ground squirrel tubular cells are protected from apoptotic cell death during IBA. To understand the mechanism of protection, we developed an in vitro model of prolonged cold storage (CS) followed by REW, which is akin to the in vivo changes of hypothermia followed by REW observed during IBA. We hypothesized that renal tubular epithelial cells (RTECs) isolated from hibernating ground squirrels would be protected against apoptosis during CS/REW versus nonhibernating mouse RTECs. Methods. Isolated hibernating ground squirrel and mouse RTECs were subjected to CS at 4 degrees C for 24 hours followed by REW to 37 degrees C for 24 hours (CS/REW). Results. Ground squirrel RTECs had significantly less apoptosis compared to mouse RTECs when subjected to CS/REW. Next, we hypothesized that the mechanism of protection was related to the antiapoptotic proteins X-linked inhibitor of apoptosis (XIAP), phospho-Akt (pAkt), and phospho-BAD. There was a significantly increased pAkt and pBAD expression in ground squirrel versus mouse RTECs subjected to CS/REW. The XIAP expression was maintained in ground squirrel RTECs but was significantly decreased in mouse RTECs after CS/REW. Ground squirrel RTECs in which gene expression of Akt1 and XIAP was silenced lost their protection and demonstrated increased apoptosis and cleaved caspase-3 expression after CS/REW. Conclusions. Our findings suggest that ground squirrel RTECs are protected against apoptosis during prolonged CS/REW by the "prosurvival" factors XIAP and pAkt. C1 [Jain, Swati; Keys, Daniel; Martin, Sandra; Edelstein, Charles L.; Jani, Alkesh] Univ Colorado, Denver, CO 80202 USA. [Edelstein, Charles L.; Jani, Alkesh] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Jani, A (reprint author), Univ Colorado Denver, Div Renal Dis & Hypertens, 12700 East 19th Ave,C281, Aurora, CO 80045 USA. EM Alkesh.jani@ucdenver.edu FU NIH [1 R03 DK96151-01]; VA Merit Award [1I01BX001737] FX This work was supported by NIH 1 R03 DK96151-01 and a VA Merit Award 1I01BX001737. NR 33 TC 0 Z9 0 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD MAR PY 2016 VL 100 IS 3 BP 538 EP 545 DI 10.1097/TP.0000000000000937 PG 8 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA DF8BR UT WOS:000371582400025 PM 26457601 ER PT J AU Treuting, PM Snyder, JM Ikeno, Y Schofield, PN Ward, JM Sundberg, JP AF Treuting, P. M. Snyder, J. M. Ikeno, Y. Schofield, P. N. Ward, J. M. Sundberg, J. P. TI The Vital Role of Pathology in Improving Reproducibility and Translational Relevance of Aging Studies in Rodents SO VETERINARY PATHOLOGY LA English DT Article DE aging; pathology; health span; life span; longevity; necropsy; histopathology; rodent; mouse model; animal model; cause of death ID GENETICALLY HETEROGENEOUS MICE; OF-DEATH ASSIGNMENT; EXTENDS LIFE-SPAN; CHRONIC DISEASE; INTERIM-REPORT; ANIMAL-MODELS; MOUSE MODELS; DATA-CAPTURE; RAPAMYCIN; LONGEVITY AB Pathology is a discipline of medicine that adds great benefit to aging studies of rodents by integrating in vivo, biochemical, and molecular data. It is not possible to diagnose systemic illness, comorbidities, and proximate causes of death in aging studies without the morphologic context provided by histopathology. To date, many rodent aging studies do not utilize end points supported by systematic necropsy and histopathology, which leaves studies incomplete, contradictory, and difficult to interpret. As in traditional toxicity studies, if the effect of a drug, dietary treatment, or altered gene expression on aging is to be studied, systematic pathology analysis must be included to determine the causes of age-related illness, moribundity, and death. In this Commentary, the authors discuss the factors that should be considered in the design of aging studies in mice, with the inclusion of robust pathology practices modified after those developed by toxicologic and discovery research pathologists. Investigators in the field of aging must consider the use of histopathology in their rodent aging studies in this era of integrative and preclinical geriatric science (geroscience). C1 [Treuting, P. M.; Snyder, J. M.] Univ Washington, Sch Med, Dept Comparat Med, Seattle, WA 98195 USA. [Ikeno, Y.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst, San Antonio, TX 78229 USA. [Ikeno, Y.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Ikeno, Y.] South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA. [Ikeno, Y.] South Texas Vet Hlth Care Syst, Audie L Murphy VA Hosp, Geriatr Res & Educ Clin Ctr, San Antonio, TX USA. [Schofield, P. N.] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge, England. [Schofield, P. N.; Sundberg, J. P.] Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA. [Ward, J. M.] Global VetPathol, Montgomery Village, MD USA. RP Treuting, PM (reprint author), Univ Washington, Comparat Pathol, Dept Comparat Med & Histol & Imaging Core, Sch Med, 1-458,Box 357340, Seattle, WA 98195 USA. EM treuting@uw.edu FU BLRD VA [I01 BX001023]; NCI NIH HHS [CA34196, P30 CA034196]; NIA NIH HHS [AG13319, AG25707, P01 AG001751, P01AG01751, P30 AG013280, P30 AG013319, P30 AG025707, P30AG013280]; NIH HHS [R25 OD010450, R25OD010450] NR 81 TC 3 Z9 3 U1 4 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0300-9858 EI 1544-2217 J9 VET PATHOL JI Vet. Pathol. PD MAR PY 2016 VL 53 IS 2 BP 244 EP 249 DI 10.1177/0300985815620629 PG 6 WC Pathology; Veterinary Sciences SC Pathology; Veterinary Sciences GA DF8PO UT WOS:000371620500003 PM 26792843 ER PT J AU Jarlenski, M Baller, J Borrero, S Bennett, WL AF Jarlenski, Marian Baller, Julia Borrero, Sonya Bennett, Wendy L. TI Trends in Disparities in Low-Income Children's Health Insurance Coverage and Access to Care by Family Immigration Status SO ACADEMIC PEDIATRICS LA English DT Article DE access to care; disparities; health insurance; immigrant ID UNINSURED CHILDREN; UNITED-STATES; EXPANSIONS; MEDICAID; PARENTS; IMPACT AB OBJECTIVE: To examine time trends in disparities in low-income children's health insurance coverage and access to care by family immigration status. METHODS: We used data from the National Survey of Children's Health in 2003 to 2011-2012, including 83,612 children aged 0 to 17 years with family incomes <200% of the federal poverty level. We examined 3 immigration status categories: citizen children with nonimmigrant parents; citizen children with immigrant parents; and immigrant children. We used multivariable regression analyses to obtain adjusted trends in health insurance coverage and access to care.. RESULTS: All low-income children experienced gains in health insurance coverage and access to care from 2003 to 2011-2012, regardless of family immigration status. Relative to citizen children with nonimmigrant parents, citizen children with immigrant parents had a 5 percentage point greater increase in health insurance coverage (P = .06), a 9 percentage point greater increase in having a personal doctor or nurse (P < .01), and an 11 percentage point greater increase in having no unmet medical need (P < .01). Immigrant children had significantly lower health insurance coverage than other groups. However, the group had a 14 percentage point greater increase in having a personal doctor or nurse (P < .01) and a 26 percentage point greater increase in having no unmet medical need (P < .01) relative to citizen children with nonimmigrant parents. CONCLUSIONS: Some disparities in access to care related to family immigration status have lessened over time among children in low-income families, although large disparities still exist. Policy efforts are needed to ensure that children of immigrant parents and immigrant children are able to access health insurance and health care. C1 [Jarlenski, Marian] Univ Pittsburgh, Dept Hlth Policy & Management, Grad Sch Publ Hlth, 130 DeSoto St,A647, Pittsburgh, PA 15261 USA. [Jarlenski, Marian; Borrero, Sonya] Univ Pittsburgh, Ctr Womens Hlth Res & Innovat, Pittsburgh, PA USA. [Baller, Julia] Math Policy Res, Washington, DC USA. [Borrero, Sonya] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Borrero, Sonya] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Bennett, Wendy L.] Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD USA. [Bennett, Wendy L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Baltimore, MD USA. RP Jarlenski, M (reprint author), Univ Pittsburgh, Dept Hlth Policy & Management, Grad Sch Publ Hlth, 130 DeSoto St,A647, Pittsburgh, PA 15261 USA. EM marian.jarlenski@pitt.edu OI Jarlenski, Marian/0000-0001-6907-5447 NR 37 TC 1 Z9 1 U1 2 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1876-2859 EI 1876-2867 J9 ACAD PEDIATR JI Acad. Pediatr. PD MAR PY 2016 VL 16 IS 2 BP 208 EP 215 PG 8 WC Pediatrics SC Pediatrics GA DF5AK UT WOS:000371364000016 PM 26329016 ER PT J AU Kranzler, HR Armeli, S Wetherill, R Feinn, R Tennen, H Gelernter, J Covault, J Pond, T AF Kranzler, Henry R. Armeli, Stephen Wetherill, Reagan Feinn, Richard Tennen, Howard Gelernter, Joel Covault, Jonathan Pond, Timothy TI Self-efficacy mediates the effects of topiramate and GRIK1 genotype on drinking SO ADDICTION BIOLOGY LA English DT Article DE GRIK1; mediated moderation; personalized treatment; pharmacogenetics; self-efficacy; topiramate ID ALCOHOL DEPENDENCE; 12-STEP; EXPECTATIONS; MODERATION; DRINKERS; PROGRAMS; OUTCOMES AB Previous studies indicate that topiramate reduces alcohol use among problem drinkers, with one study showing that the effect was moderated by a polymorphism (rs2832407) in GRIK1, the gene encoding the GluK1 kainate subunit. We examined whether the interactive effect of medication and genotype (1) altered the association between daily self-efficacy and later-day drinking; and (2) had an indirect effect on drinking via self-efficacy. In a 12-week, placebo-controlled trial of topiramate, we used daily interactive voice response technology to measure self-efficacy (i.e. confidence in avoiding heavy drinking later in the day) and drinking behavior in 122 European-American heavy drinkers. Topiramate's effects on both self-efficacy and drinking level were moderated by rs2832407. C-allele homozygotes treated with topiramate showed higher levels of self-efficacy and lower levels of nighttime drinking across the 12-week trial. Further, the interactive effect of topiramate and genotype on mean nighttime drinking levels was mediated by mean levels of self-efficacy. By modeling topiramate's effects on nighttime drinking across multiple levels of analysis, we found that self-efficacy, a key psychologic construct, mediated the effect of topiramate, which was moderated by rs2832407 genotype. Thus, it may be possible to use an individualized assessment (i.e. genotype) to select treatment to optimize the reduction in heavy drinking and thereby provide a personalized treatment approach. C1 [Kranzler, Henry R.; Wetherill, Reagan; Pond, Timothy] Univ Penn, Dept Psychiat, Ctr Studies Addict, Perelman Sch Med, 3900 Chestnut St, Philadelphia, PA 19104 USA. [Kranzler, Henry R.] Philadelphia VA Med Ctr, MIRECC VISN4, Philadelphia, PA USA. [Armeli, Stephen] Fairleigh Dickinson Univ, Dept Psychol, Teaneck, NJ USA. [Feinn, Richard] Quinnipiac Univ, Frank Netter Sch Med, Dept Med Sci, Hamden, CT USA. [Tennen, Howard] Univ Connecticut, Sch Med, Dept Community Med & Healthcare, Farmington, CT USA. [Covault, Jonathan] Univ Connecticut, Dept Psychiat, Sch Med, Alcohol Res Ctr, Farmington, CT 06107 USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Gelernter, Joel] Vet Affairs Connecticut Healthcare Ctr, West Haven, CT USA. RP Kranzler, HR (reprint author), Univ Penn, Dept Psychiat, Ctr Studies Addict, Perelman Sch Med, 3900 Chestnut St, Philadelphia, PA 19104 USA. EM kranzler@mail.med.upenn.edu FU National Institutes of Health [P60 AA03510, K24 AA13736] FX Supported by National Institutes of Health grants P60 AA03510 and K24 AA13736. Staff members of the Clinical Research and Evaluation Unit of the University of Connecticut Alcohol Research Center and the Center for Studies of Addiction of the University of Pennsylvania Perelman School of Medicine were instrumental in the conduct of the study. NR 31 TC 7 Z9 9 U1 4 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1355-6215 EI 1369-1600 J9 ADDICT BIOL JI Addict. Biol. PD MAR PY 2016 VL 21 IS 2 BP 450 EP 459 DI 10.1111/adb.12207 PG 10 WC Biochemistry & Molecular Biology; Substance Abuse SC Biochemistry & Molecular Biology; Substance Abuse GA DF2CW UT WOS:000371148700020 PM 25496338 ER PT J AU Clarke, TK Smith, AH Gelernter, J Kranzler, HR Farrer, LA Hall, LS Fernandez-Pujals, AM MacIntyre, DJ Smith, BH Hocking, LJ Padmanabhan, S Hayward, C Thomson, PA Porteous, DJ Deary, IJ McIntosh, AM AF Clarke, Toni-Kim Smith, Andrew H. Gelernter, Joel Kranzler, Henry R. Farrer, Lindsay A. Hall, Lynsey S. Fernandez-Pujals, Ana M. MacIntyre, Donald J. Smith, Blair H. Hocking, Lynne J. Padmanabhan, Sandosh Hayward, Caroline Thomson, Pippa A. Porteous, David J. Deary, Ian J. McIntosh, Andrew M. TI Polygenic risk for alcohol dependence associates with alcohol consumption, cognitive function and social deprivation in a population-based cohort SO ADDICTION BIOLOGY LA English DT Article DE Alcohol dependence; cognition; environment; genetics; polygenic; social deprivation ID EXECUTIVE FUNCTIONS; FAMILY HEALTH; OLD-AGE; CHILDREN; INTELLIGENCE; ADOLESCENCE; CHILDHOOD; EDUCATION; CORTEX; ABUSE AB Alcohol dependence is frequently co-morbid with cognitive impairment. The relationship between these traits is complex as cognitive dysfunction may arise as a consequence of heavy drinking or exist prior to the onset of dependence. In the present study, we tested the genetic overlap between cognitive abilities and alcohol dependence using polygenic risk scores (PGRS). We created two independent PGRS derived from two recent genome-wide association studies (GWAS) of alcohol dependence (SAGE GWAS: n=2750; Yale-Penn GWAS: n=2377) in a population-based cohort, Generation Scotland: Scottish Family Health Study (GS:SFHS) (n=9863). Data on alcohol consumption and four tests of cognitive function [Mill Hill Vocabulary (MHV), digit symbol coding, phonemic verbal fluency (VF) and logical memory] were available. PGRS for alcohol dependence were negatively associated with two measures of cognitive function: MHV (SAGE: P=0.009, =-0.027; Yale-Penn: P=0.001, =-0.034) and VF (SAGE: P=0.0008, =-0.036; Yale-Penn: P=0.00005, =-0.044). VF remained robustly associated after adjustment for education and social deprivation; however, the association with MHV was substantially attenuated. Shared genetic variants may account for some of the phenotypic association between cognitive ability and alcohol dependence. A significant negative association between PGRS and social deprivation was found (SAGE: P=5.2x10(-7), =-0.054; Yale-Penn: P=0.000012, =-0.047). Individuals living in socially deprived regions were found to carry more alcohol dependence risk alleles which may contribute to the increased prevalence of problem drinking in regions of deprivation. Future work to identify genes which affect both cognitive impairment and alcohol dependence will help elucidate biological processes common to both disorders. C1 [Clarke, Toni-Kim; Hall, Lynsey S.; Fernandez-Pujals, Ana M.; MacIntyre, Donald J.; McIntosh, Andrew M.] Univ Edinburgh, Div Psychiat, Edinburgh EH10 5HF, Midlothian, Scotland. [Hayward, Caroline; Thomson, Pippa A.] Univ Edinburgh, Western Gen Hosp, Ctr Genom & Expt Med, Inst Genet & Mol Med, Edinburgh EH10 5HF, Midlothian, Scotland. [Hayward, Caroline; Porteous, David J.] Univ Edinburgh, MRC Human Genet, MRC IGMM, Edinburgh EH10 5HF, Midlothian, Scotland. [Thomson, Pippa A.; Porteous, David J.; Deary, Ian J.; McIntosh, Andrew M.] Univ Edinburgh, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh EH10 5HF, Midlothian, Scotland. [Deary, Ian J.] Univ Edinburgh, Dept Psychol, Edinburgh EH10 5HF, Midlothian, Scotland. [Smith, Andrew H.; Gelernter, Joel] Yale Univ, Sch Med, Dept Psychiat, Div Human Genet, West Haven, CT 06516 USA. [Smith, Andrew H.; Gelernter, Joel] VA CT Healthcare Ctr, West Haven, CT USA. [Smith, Andrew H.] Yale Univ, Sch Med, Med Scientist Training Program, West Haven, CT 06516 USA. [Smith, Andrew H.] Yale Univ, Sch Med, Interdept Neurosci Program, West Haven, CT 06516 USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Genet & Neurobiol, West Haven, CT 06516 USA. [Kranzler, Henry R.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Kranzler, Henry R.] Philadelphia VA Med Ctr, MIRECC VISN4, Philadelphia, PA USA. [Farrer, Lindsay A.] Boston Univ, Sch Med & Publ Hlth, Dept Med, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Dept Neurol, Sch Med & Publ Hlth, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Dept Ophthalmol, Sch Med & Publ Hlth, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Dept Biomed Genet, Sch Med & Publ Hlth, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Dept Epidemiol, Sch Med & Publ Hlth, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Dept Biostat, Sch Med & Publ Hlth, Boston, MA 02215 USA. [Smith, Blair H.] Univ Dundee, Populat Hlth Sci, Dundee DD1 4HN, Scotland. [Hocking, Lynne J.] Univ Aberdeen, Div Appl Hlth Sci, Aberdeen AB9 1FX, Scotland. [Padmanabhan, Sandosh] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow G12 8QQ, Lanark, Scotland. RP Clarke, TK (reprint author), Univ Edinburgh, Royal Edinburgh Hosp, Div Psychiat, Kennedy Tower, Edinburgh EH10 5HF, Midlothian, Scotland. EM toni.clarke@ed.ac.uk RI ; Padmanabhan, Sandosh/S-3963-2016 OI Smith, Blair/0000-0002-5362-9430; McIntosh, Andrew/0000-0002-0198-4588; MacIntyre, Donald J/0000-0001-6963-1335; Clarke, Toni-Kim/0000-0002-7745-6351; Farrer, Lindsay/0000-0001-5533-4225; Hocking, Lynne J/0000-0002-2414-2826; Padmanabhan, Sandosh/0000-0003-3869-5808 FU Chief Scientist Office of the Scottish Government; Scottish Funding Council; Scottish Government Health Department, Chief Scientist Office [CZD/16/6]; National Institutes of Health [N01-HG-65403, RC2 DA028909, R01 DA12690, R01 DA12849, R01 DA18432, R01 AA11330, R01 AA017535, P50 AA12870, MSTP T32GM07205, CTSA 8UL1TR000142]; Study of Addiction: Genetics and Environment (SAGE) was provided through the NIH Genes, Environment and Health Initiative [GEI] [U01 HG004422]; GENEVA Coordinating [U01 HG004446]; Collaborative Study on the Genetics of Alcoholism (COGA) [U10 AA008401]; Collaborative Genetic Study of Nicotine Dependence (COGEND) [P01 CA089392]; Family Study of Cocaine Dependence (FSCD) [R01 DA013423]; Johns Hopkins University Center for Inherited Disease Research; NIH GEI [U01HG004438]; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; NIH [HHSN268200782096C]; Dr Mortimer and Theresa Sackler Foundation; Biotechnology and Biological Sciences Research Council (BBSRC); Medical Research Council (MRC); Wellcome Trust [104036/Z/14/Z] FX The Chief Scientist Office of the Scottish Government and the Scottish Funding Council provided core support for Generation Scotland. GS:SFHS was funded by a grant from the Scottish Government Health Department, Chief Scientist Office (No. CZD/16/6). Genotyping services for a part of the Yale GWAS study were provided by the Center for Inherited Disease Research (CIDR) and Yale University (Center for Genome Analysis). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University (Contract No. N01-HG-65403). The publicly available datasets used for the analyses described in this manuscript were obtained from dbGaP at http://www.ncbi.nlmnih.gov/projects/gap/cgi-bin/studycgi?study_id=phs000 092.vl.p1 through dbGaP accession number phs000092.vl.p. Funding support for the Study of Addiction: Genetics and Environment (SAGE) was provided through the NIH Genes, Environment and Health Initiative [GEI] (U01 HG004422). SAGE is one of the genome-wide association studies funded as part of the Gene Environment Association Studies (GENEVA) under GEL Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by the GENEVA Coordinating Center (U01 HG004446). Assistance with data cleaning was provided by the National Center for Biotechnology Information. Support for collection of datasets and samples was provided by the Collaborative Study on the Genetics of Alcoholism (COGA; U10 AA008401), the Collaborative Genetic Study of Nicotine Dependence (COGEND; P01 CA089392) and the Family Study of Cocaine Dependence (FSCD: R01 DA013423). Funding support for genotyping, which was performed at the Johns Hopkins University Center for Inherited Disease Research, was provided by the NIH GEI (U01HG004438), the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Drug Abuse, and the NIH contract 'High throughput genotyping for studying the genetic contributions to human disease' (HHSN268200782096C). The authors TKC and AN NI acknowledge with gratitude the financial support received for this work from the Dr Mortimer and Theresa Sackler Foundation. PAT, DTP, IJD and AMM are members of Hie University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative (MR/K026992/1). Funding from the Biotechnology and Biological Sciences Research Council (BBSRC) and Medical Research Council (MRC) is gratefully acknowledged, supported in part by National Institutes of Health grants RC2 DA028909, R01 DA12690, R01 DA12849, R01 DA18432, R01 AA11330, R01 AA017535, P50 AA12870, MSTP T32GM07205 and CTSA 8UL1TR000142. This work is supported by the Wellcome Trust through a Strategic Award, reference 104036/Z/14/Z. NR 47 TC 3 Z9 5 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1355-6215 EI 1369-1600 J9 ADDICT BIOL JI Addict. Biol. PD MAR PY 2016 VL 21 IS 2 BP 469 EP 480 DI 10.1111/adb.12245 PG 12 WC Biochemistry & Molecular Biology; Substance Abuse SC Biochemistry & Molecular Biology; Substance Abuse GA DF2CW UT WOS:000371148700022 PM 25865819 ER PT J AU Heath, B Bernhardt, J Michalski, TJ Crnich, CJ Moehring, R Schmader, KE Olds, D Higgins, PA Jump, RLP AF Heath, Barbara Bernhardt, Jaime Michalski, Thomas J. Crnich, Christopher J. Moehring, Rebekah Schmader, Kenneth E. Olds, Danielle Higgins, Patricia A. Jump, Robin L. P. TI Results of a Veterans Affairs employee education program on antimicrobial stewardship for older adults SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Antimicrobial stewardship; Professional education; Nursing home; Registered nurses; Asymptomatic bacteriuria; Aged ID CARE FACILITIES; NURSES AB We describe a course in the Veterans Affairs (VA) Employee Education System designed to engage nursing staff working in VA long-term care facilities as partners in antimicrobial stewardship. We found that the course addressed an important knowledge gap. Our outcomes suggest opportunities to engage nursing staff in advancing antimicrobial stewardship, particularly in the long-term care setting. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Heath, Barbara; Higgins, Patricia A.; Jump, Robin L. P.] Geriatr Res Educ & Clin Ctr, Cleveland, OH USA. [Bernhardt, Jaime; Michalski, Thomas J.] Louis Stokes Cleveland Vet Affairs Med Ctr, Employee Educ Syst, Cleveland, OH USA. [Crnich, Christopher J.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Crnich, Christopher J.] Univ Wisconsin, Madison, WI USA. [Moehring, Rebekah; Schmader, Kenneth E.] Durham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA. [Moehring, Rebekah; Schmader, Kenneth E.] Duke Univ, Durham, NC USA. [Olds, Danielle] Louis Stokes Cleveland Vet Affairs Med Ctr, Qual Scholars Program, Cleveland, OH USA. [Higgins, Patricia A.] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA. [Jump, Robin L. P.] Case Western Reserve Univ, Dept Med, Div Infect Dis & HIV Med, Cleveland, OH 44106 USA. [Jump, Robin L. P.] Louis Stokes Cleveland Vet Affairs Med Ctr, Div Med, Infect Dis Sect, Cleveland, OH USA. RP Jump, RLP (reprint author), Louis Stokes Cleveland VA Med Ctr, GRECC 111C W,10701 East Blvd, Cleveland, OH 44106 USA. EM robin.jump@va.gov FU AHRQ HHS [K08 HS023866] NR 10 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD MAR 1 PY 2016 VL 44 IS 3 BP 349 EP 351 DI 10.1016/j.ajic.2015.09.026 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA DF4CS UT WOS:000371295500024 PM 26553404 ER PT J AU Safdar, N Codispoti, N Purvis, S Knobloch, MJ AF Safdar, Nasia Codispoti, Nicolette Purvis, Suzanne Knobloch, Mary Jo TI Patient perspectives on indwelling urinary catheter use in the hospital SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Patient perspectives; Catheter-associated urinary tract infections ID TRACT-INFECTIONS AB Urinary tract infections are one of the most common hospital-acquired infections, with 70%-80% resulting from catheter-associated urinary tract infections (CAUTIs). We undertook a qualitative study to assess patient perspectives of indwelling urinary catheters using a semistructured interview. We found that patient awareness and patient engagement regarding indwelling urinary catheters and their consequences could be improved in the hospital setting. Implementing educational programs incorporating patient preferences for both health care workers and patients is likely to increase the involvement of patients in decision-making regarding urinary catheters and may lead to a decline in CAUTIs. Published by Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Safdar, Nasia; Knobloch, Mary Jo] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Safdar, Nasia] Univ Wisconsin, Sch Med & Publ Hlth, Infect Dis, Dept Med, Madison, WI USA. [Codispoti, Nicolette] Univ Wisconsin, Madison, WI USA. [Purvis, Suzanne] Univ Wisconsin Hosp & Clin, Geriatr, Madison, WI 53792 USA. RP Safdar, N (reprint author), MFCB 5221,1685 Highland Ave, Madison, WI 53705 USA. EM ns2@medicine.wisc.edu OI Purvis, Suzanne/0000-0001-5977-5984 FU Agency for Healthcare Research and Quality [R03HS023791] FX Supported by the Agency for Healthcare Research and Quality (grant no. R03HS023791). NR 11 TC 2 Z9 2 U1 1 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD MAR 1 PY 2016 VL 44 IS 3 BP E23 EP E24 DI 10.1016/j.ajic.2015.10.011 PG 2 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA DF4CS UT WOS:000371295500003 PM 26698670 ER PT J AU Nair, BG Horibe, M Neradilek, MB Newman, SF Peterson, GN AF Nair, Bala G. Horibe, Mayumi Neradilek, Moni B. Newman, Shu-Fang Peterson, Gene N. TI The Effect of Intraoperative Blood Glucose Management on Postoperative Blood Glucose Levels in Noncardiac Surgery Patients SO ANESTHESIA AND ANALGESIA LA English DT Article ID INDEPENDENT RISK-FACTOR; VASCULAR-SURGERY; PERIOPERATIVE PERIOD; COLORECTAL SURGERY; INSULIN INFUSION; GLYCEMIC CONTROL; CARDIAC-SURGERY; SITE INFECTION; HYPERGLYCEMIA; OUTCOMES AB BACKGROUND: Postoperative hyperglycemia has been associated with poor surgical outcome. The effect of intraoperative glucose management on postoperative glucose levels and the optimal glycemic threshold for initiating insulin are currently unknown. METHODS: We performed a retrospective cohort study of surgery patients who required intraoperative glucose management with data extracted from electronic medical records. In patients who required glucose management, intraoperative glucose levels and insulin therapy were compared against postoperative glucose levels during 3 periods: first postoperative level within 1 hour, within the first 12 hours, and 24 hours of the postoperative period. Logistic regression models that adjusted for patient and surgical factors were used to determine the association between intraoperative glucose management and postoperative glucose levels. RESULTS: In 2440 patients who required intraoperative glucose management, an increase in mean intraoperative glucose level by 10 mg/dL was associated with an increase in postoperative glucose levels by 4.7 mg/dL (confidence interval [CI], 4.1-5.3; P < 0.001) for the first postoperative glucose measurement, 2.6 mg/dL (CI, 2.1-3.1; P < 0.001) for the mean first 12-hour postoperative glucose, and 2.4 mg/dL (CI, 2.0-2.9; P < 0.001) for the mean first 24-hour postoperative glucose levels (univariate analysis). Multivariate analysis showed that these effects depended on (interacted with) body mass index and diabetes status of the patient. Both diabetes status (regression coefficient = 12.2; P < 0.001) and intraoperative steroid use (regression coefficient = 10.2; P < 0.001) had a positive effect on elevated postoperative glucose levels. Intraoperative hyperglycemia (> 180 mg/dL) was associated with postoperative hyperglycemia during the first 12 hours and the first 24 hours. However, interaction with procedure duration meant that this association was stronger for shorter surgeries. When compared with starting insulin for an intraoperative glucose threshold of 140 mg/dL thus avoiding hyperglycemia, initiation of insulin for a hyperglycemia threshold of 180 mg/dL was associated with an increase in postoperative glucose level (7 mg/dL; P < 0.001) and postoperative hyperglycemia incidence (odds ratio = 1.53; P = 0.01). CONCLUSIONS: A higher intraoperative glucose level is associated with a higher postoperative glucose level. Intraoperative hyperglycemia increases the odds for postoperative hyperglycemia. Adequate intraoperative glucose management by initiating insulin infusion when glucose level exceeds 140 mg/dL to prevent hyperglycemia is associated with lower postoperative glucose levels and fewer incidences of postoperative hyperglycemia. However, patient- and procedure-specific variable interactions make the relationship between intraoperative and postoperative glucose levels complicated. C1 [Nair, Bala G.; Newman, Shu-Fang; Peterson, Gene N.] Univ Washington, Dept Anesthesiol & Pain Med, BB 1469 Hlth Sci Bldg,Mail Box 356540, Seattle, WA 98195 USA. [Horibe, Mayumi] VA Puget Sound Hlth Care Syst, Dept Anesthesiol, Seattle, WA USA. [Neradilek, Moni B.] Mt Whisper Light Stat LLC, Seattle, WA USA. [Peterson, Gene N.] Virginia Commonwealth Univ, Dept Anesthesiol, Richmond, VA USA. RP Nair, BG (reprint author), Univ Washington, Dept Anesthesiol & Pain Med, BB 1469 Hlth Sci Bldg,Mail Box 356540, Seattle, WA 98195 USA. EM nairbg@uw.edu FU Patient Safety Innovation Program Grant by the University of Washington FX This research was partly supported by a Patient Safety Innovation Program Grant provided by the University of Washington. NR 25 TC 1 Z9 1 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD MAR PY 2016 VL 122 IS 3 BP 893 EP 902 DI 10.1213/ANE.0000000000001100 PG 10 WC Anesthesiology SC Anesthesiology GA DE2FL UT WOS:000370441900010 PM 26599793 ER PT J AU Grubaugh, AL Clapp, JD Frueh, BC Tuerk, PW Knapp, RG Egede, LE AF Grubaugh, Anouk L. Clapp, Joshua D. Frueh, B. Christopher Tuerk, Peter W. Knapp, Rebecca G. Egede, Leonard E. TI Open trial of exposure therapy for PTSD among patients with severe and persistent mental illness SO BEHAVIOUR RESEARCH AND THERAPY LA English DT Article DE Severe mental illness (SMI); Posttraumatic stress disorder (PTSD); Trauma; Exposure therapy; Prolonged exposure ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIORAL TREATMENT; QUALITY-OF-LIFE; SCHIZOAFFECTIVE DISORDER; PSYCHOMETRIC PROPERTIES; DSM-IV; SCHIZOPHRENIA; TRAUMA; VETERANS; ADULTS AB Objective: There are few empirical data regarding effective treatment of trauma-related symptoms among individuals with severe mental illness (SMI; e.g., bipolar disorder, schizophrenia). This under examined clinical issue is significant because rates of trauma and PTSD are higher among individuals with SMI relative to the general population, and there are sufficient data to suggest that PTSD symptoms exacerbate the overall course and prognosis of SMI. Method: 34 veterans with SMI received prolonged exposure (PE) for PTSD using an open trial study design. Results: Data suggest that PE is feasible to implement, well-tolerated, and results in clinically significant decreases in PTSD severity in patients with SMI. Mean CAPS scores improved 27.2 points from baseline to immediate post [95% CI for mean change: -44.3, - 10.1; p = 0.002, paired t-test, and treatment gains were maintained at 6 months [mean change from baseline to 6-months, W-16.1; 95% CI: -31.0, -1.2; p = 0.034, paired t-test]. Conclusions: The current data support the use of exposure-based interventions for PTSD among individuals with SMI and highlight the need for rigorous randomized efficacy trials investigating frontline PTSD interventions in this patient population. (C) 2015 Published by Elsevier Ltd. C1 [Grubaugh, Anouk L.; Tuerk, Peter W.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, 109 Bee St, Charleston, SC 29401 USA. [Grubaugh, Anouk L.; Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 109 Bee St, Charleston, SC 29401 USA. [Clapp, Joshua D.] Univ Wyoming, Dept Psychol, 1000 E Univ Ave, Laramie, WY 82071 USA. [Frueh, B. Christopher] Menninger Clin, Houston, TX USA. [Frueh, B. Christopher] Univ Hawaii, Dept Psychol, 200 W Kawili St, Hilo, HI 96720 USA. [Knapp, Rebecca G.] Med Univ S Carolina, Dept Publ Hlth Sci, 135 Cannon St, Charleston, SC 29403 USA. [Egede, Leonard E.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, 135 Rutledge Ave,POB 250593, Charleston, SC 29425 USA. [Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, 135 Rutledge Ave,POB 250593, Charleston, SC 29425 USA. RP Grubaugh, AL (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, POB 250861, Charleston, SC 29425 USA. EM grubaugh@musc.edu NR 58 TC 1 Z9 1 U1 6 U2 14 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0005-7967 EI 1873-622X J9 BEHAV RES THER JI Behav. Res. Ther. PD MAR PY 2016 VL 78 BP 1 EP 12 DI 10.1016/j.brat.2015.12.006 PG 12 WC Psychology, Clinical SC Psychology GA DF5DX UT WOS:000371373100001 PM 26797658 ER PT J AU Jordan, TH Talarico, RH Schuberth, JM AF Jordan, Thomas H. Talarico, Ross H. Schuberth, John M. TI Letter Regarding: The Fate of the Fixed Syndesmosis Over Time SO FOOT & ANKLE INTERNATIONAL LA English DT Letter C1 [Jordan, Thomas H.] Kaiser Permanente Med Grp, Santa Rosa, CA USA. [Talarico, Ross H.] Podiat Surg Sect, San Francisco, CA USA. [Talarico, Ross H.] San Francisco VA Med Ctr, San Francisco, CA USA. [Schuberth, John M.] Kaiser Fdn Hosp, Dept Orthoped Surg, Foot & Ankle Surg, San Francisco, CA USA. RP Schuberth, JM (reprint author), Kaiser Fdn Hosp, Dept Orthoped Surg, Foot & Ankle Surg, San Francisco, CA USA. EM jmfoot@aol.com NR 2 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1071-1007 EI 1944-7876 J9 FOOT ANKLE INT JI Foot Ankle Int. PD MAR PY 2016 VL 37 IS 3 BP 344 EP 344 DI 10.1177/1071100715627352 PG 1 WC Orthopedics SC Orthopedics GA DF4JS UT WOS:000371314500015 PM 26921312 ER PT J AU Klingaman, EA Hoerster, KD Aakre, JM Viverito, KM Medoff, DR Goldberg, RW AF Klingaman, Elizabeth A. Hoerster, Katherine D. Aakre, Jennifer M. Viverito, Kristen M. Medoff, Deborah R. Goldberg, Richard W. TI Veterans with PTSD report more weight loss barriers than Veterans with no mental health disorders SO GENERAL HOSPITAL PSYCHIATRY LA English DT Article DE Veterans; Post-traumatic stress disorder; Weight management; MOVE ID POSTTRAUMATIC-STRESS-DISORDER; PHYSICAL-ACTIVITY; SELF-EFFICACY; BEHAVIORAL ACTIVATION; ANXIETY DISORDERS; MILITARY SERVICE; HEART-DISEASE; RISK-FACTOR; DEPRESSION; MORTALITY AB Objective: This study characterized and compared Veterans of the United States Armed Forces with posttraumatic stress disorder ( PTSD) to Veterans with no mental health disorders on self-reported measures of factors that influence success in weight management programs. Method: We examined the relation of PTSD diagnosis with weight loss plan, reasons for overweight/obesity and barriers to dieting and physical exercise among 171,884 Veterans. Statistically significant variables in chi-square tests (P<.05) with at least a small effect size were then compared via multivariate logistic regression analyses. Results: Both groups reported high ratings of importance and confidence regarding changing weight loss behaviors and were preparing or actively engaging in efforts to manage their weight. Compared to Veterans without mental health disorders, more Veterans with PTSD endorsed 27 of the 28 barriers to changing eating and physical habits. Conclusions: The results of this study help to explain the lower rates of success of Veterans with PTSD in weight loss programs. Results suggest that a comprehensive, integrated approach to promoting weight loss in Veterans with PTSD is needed. Published by Elsevier Inc. C1 [Klingaman, Elizabeth A.; Aakre, Jennifer M.; Medoff, Deborah R.; Goldberg, Richard W.] US Dept Vet Affairs, Capitol Healthcare Network, Mental Illness Res Educ & Clin Ctr, 10 North Greene St,Annex Suite 720, Baltimore, MD 21201 USA. [Klingaman, Elizabeth A.; Aakre, Jennifer M.; Medoff, Deborah R.; Goldberg, Richard W.] Univ Maryland, Sch Med, Dept Psychiat, 737 West Lombard St, Baltimore, MD 21201 USA. [Hoerster, Katherine D.] VA Puget Sound Healthcare Syst, Seattle Div, Mental Hlth Serv, 1660 South Columbian Way S-116, Seattle, WA 98108 USA. [Hoerster, Katherine D.] Univ Washington, Dept Psychiat & Behav Sci, 1959 Northeast Pacific St,Box 356560,Room BB1644, Seattle, WA 98195 USA. [Viverito, Kristen M.] Cent Arkansas Vet Healthcare Syst, Hlth Serv Res & Dev Serv, Mental Healthcare & Outcomes Res, North Little Rock, AR 72114 USA. [Viverito, Kristen M.] Univ Arkansas Med Sci, Inst Psychiat Res, Div Hlth Serv Res, 4301 West Markham,554, Little Rock, AR 72205 USA. RP Klingaman, EA (reprint author), Baltimore VA Med Ctr, VA Maryland Healthcare Syst, 10 North Greene St,Annex Suite 720, Baltimore, MD 21201 USA. EM elizabeth.klingaman@va.gov; Katherine.hoerster@va.gov; jennifer.aakre@va.gov; Kristen.viverito@va.gov; dmedoff@psych.umaryland.edu; richard.goldberg@va.gov FU Department of Veterans Affairs (VA) Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment; VA Health Services Research and Development Fellowship; VA Career Development Award (HSRD) [CDA 12-263]; VA Capitol Healthcare Network Mental Illness Research, Education and Clinical Center; Central Arkansas Veterans Healthcare System Center for Mental Healthcare and Outcomes Research FX This research is supported by the Department of Veterans Affairs (VA) Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment and the VA Health Services Research and Development Fellowship. Dr. Hoerster is supported by VA Career Development Award (HSR&D CDA 12-263). It is the result of work supported with resources and the use of facilities at the VA Capitol Healthcare Network Mental Illness Research, Education and Clinical Center and the Central Arkansas Veterans Healthcare System Center for Mental Healthcare and Outcomes Research. Special thanks to Susan Raffa, Ken Jones and Tony Rogers for their contributions to this manuscript. NR 51 TC 4 Z9 4 U1 2 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 EI 1873-7714 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD MAR-APR PY 2016 VL 39 BP 1 EP 7 DI 10.1016/j.genhosppsych.2015.11.003 PG 7 WC Psychiatry SC Psychiatry GA DF3KY UT WOS:000371244000001 PM 26719103 ER PT J AU Swenson, ER AF Swenson, Erik R. TI Reply to Drs. Teppema and Berendsen SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Letter ID CARBONIC-ANHYDRASE INHIBITION; VENTILATORY RESPONSES; AMMONIUM-CHLORIDE; ACETAZOLAMIDE; HYPOXIA; HUMANS; ACIDOSIS C1 [Swenson, Erik R.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Swenson, ER (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. EM erik.swenson@va.gov NR 10 TC 0 Z9 0 U1 2 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 EI 1522-1601 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD MAR 1 PY 2016 VL 120 IS 5 BP 565 EP 565 DI 10.1152/japplphysiol.00872.2015 PG 1 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA DF6CN UT WOS:000371442900011 PM 26933003 ER PT J AU Urayama, A Grubb, JH Sly, WS Banks, WA AF Urayama, Akihiko Grubb, Jeffrey H. Sly, William S. Banks, William A. TI Pharmacologic manipulation of lysosomal enzyme transport across the blood-brain barrier SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE Blood-brain barrier; beta-glucuronidase; enzyme replacement therapy; brain uptake; mannose 6-phosphate receptor ID MANNOSE 6-PHOSPHATE RECEPTOR; MUCOPOLYSACCHARIDOSIS TYPE-VII; ALPHA-MANNOSIDOSIS MICE; REPLACEMENT-THERAPY; MEDIATED TRANSPORT; BETA-GLUCURONIDASE; MOUSE MODEL; LIGAND INTERACTIONS; INSULIN TRANSPORT; PERMEABILITY AB The adult blood-brain barrier, unlike the neonatal blood-brain barrier, does not transport lysosomal enzymes into brain, making enzyme replacement therapy ineffective in treating the central nervous system symptoms of lysosomal storage diseases. However, enzyme transport can be re-induced with alpha-adrenergics. Here, we examined agents that are known to alter the blood-brain barrier transport of large molecules or to induce lysosomal enzyme transport across the blood-brain barrier ((+/-)epinephrine, insulin, retinoic acid, and lipopolysaccharide) in 2-week-old and adult mice. In 2-week-old adolescent mice, all these pharmacologic agents increased brain and heart uptake of phosphorylated human beta-glucuronidase. In 8-week-old adult mice, manipulations with (+/-)epinephrine, insulin, and retinoic acid were significantly effective on uptake by brain and heart. The increased uptake of phosphorylated human b-glucuronidase was inhibited by mannose 6-phosphate for the agents (+/-)epinephrine and retinoic acid and by L-NG-nitroarginine methyl ester for the agent lipopolysaccharide in neonatal and adult mice. An in situ brain perfusion study revealed that retinoic acid directly modulated the transport of phosphorylated human beta-glucuronidase across the blood-brain barrier. The present study indicates that there are multiple opportunities to at least transiently induce phosphorylated human beta-glucuronidase transport at the adult blood-brain barrier. C1 [Urayama, Akihiko] Univ Texas Med Sch Houston, Dept Neurol, Houston, TX USA. [Grubb, Jeffrey H.] Ultragenyx Pharmaceut Inc, Lysosomal Res, Novato, CA USA. [Grubb, Jeffrey H.; Sly, William S.] St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO USA. [Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Banks, William A.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. RP Urayama, A (reprint author), Univ Texas Med Sch Houston, Dept Neurol, Houston, TX USA. EM Akihiko.Urayama@uth.tmc.edu FU Sanfilippo Syndrome Medical Research Foundation; Veterans Affairs Merit Review; National Institutes of Health [NS050547, AG029839]; National Institutes of Health Grant [GM34182] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by The Sanfilippo Syndrome Medical Research Foundation (WAB and WSS), Veterans Affairs Merit Review (WAB), National Institutes of Health Grants NS050547 and AG029839 (to WAB), and National Institutes of Health Grant GM34182 (to WSS). NR 40 TC 1 Z9 1 U1 1 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0271-678X EI 1559-7016 J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD MAR PY 2016 VL 36 IS 3 BP 476 EP 486 DI 10.1177/0271678X15614589 PG 11 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA DF4ER UT WOS:000371301100004 PM 26661222 ER PT J AU Winchester, RJ Williams, JS Wolfman, TE Egede, LE AF Winchester, Rhonda J. Williams, Joni S. Wolfman, Tamara E. Egede, Leonard E. TI Depressive symptoms, serious psychological distress, diabetes distress and cardiovascular risk factor control in patients with type 2 diabetes SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Article DE Diabetes; Diabetes distress; Depressive symptoms; Serious psychological distress; Cardiovascular disease risk factor ID CLINICAL DEPRESSION; GENERAL-POPULATION; GLYCEMIC CONTROL; SCREENING SCALE; MENTAL-ILLNESS; MORTALITY; HEALTH; ADULTS; K6 AB Objective: This study examined the association between cardiovascular disease (CVD) risk factor control and elevated depressive symptoms (EDS), serious psychological distress (SPD), and diabetes distress (DD) in patients with type 2 diabetes (T2DM). Methods: This was a cross-sectional study of adults seen at an academic medical center and Veterans Affairs Medical Center in the southeastern US. Linear regression models were computed using CVD risk factors as clinically meaningful outcomes (glycosylated hemoglobin A1c (HbA1c); systolic (SBP) and diastolic (DBP) blood pressure; and low-density lipoprotein cholesterol (LDL-C)); EDS, SPD, and DD were primary independent variables. Covariates included sociodemographics and comorbidities. Results: The sample consisted of 361 adults. Correlation analyses showed significant relationships between DD and HbA1c, DBP, and LDL-C. Adjusted linear regression models showed DD to be significantly associated with HbA1c and LDL-C, and SPD to be significantly associated only with LDL-C. In the fully adjusted model, DD remained significantly associated with HbA1c ((beta = 4349; 95% CI (-0.649, 2.222)). Conclusions: In this sample of adults with T2DM, DD and SPD were significantly associated with CVD risk factors; however, after controlling for covariates, only DD was shown to be significantly associated with poor glycemic control. Practice implications: Strategies are warranted to examine the relationship between DD and CVD risk factor control in patients with T2DM. Published by Elsevier Inc. C1 [Winchester, Rhonda J.; Williams, Joni S.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,POB 250593, Charleston, SC 29425 USA. [Williams, Joni S.; Wolfman, Tamara E.; Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Dept Med, 96 Jonathan Lucas St,Suite 803,MSC 623, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr, 109 Beet St, Charleston, SC 29401 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, Hlth Equ & Rural Outreach Innovat Ctr, 135 Rutledge Ave,Room 280G,POB 250593, Charleston, SC 29425 USA. EM runwithjane@gmail.com; stromjl@musc.edu; wolfmant@musc.edu; egedel@musc.edu FU National Institute of Diabetes and Digestive and Kidney Disease [K24DK093699] FX Funding Source: This study was supported by Grant K24DK093699 from The National Institute of Diabetes and Digestive and Kidney Disease (PI: Leonard Egede). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 30 TC 0 Z9 0 U1 9 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 EI 1873-460X J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD MAR PY 2016 VL 30 IS 2 BP 312 EP 317 DI 10.1016/j.jdiacomp.2015.11.010 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DF2SW UT WOS:000371195100022 PM 26657725 ER EF